<SEC-DOCUMENT>0001437749-22-002516.txt : 20220204
<SEC-HEADER>0001437749-22-002516.hdr.sgml : 20220204
<ACCEPTANCE-DATETIME>20220204170214
ACCESSION NUMBER:		0001437749-22-002516
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		101
FILED AS OF DATE:		20220204
DATE AS OF CHANGE:		20220204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-262541
		FILM NUMBER:		22594360

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			GA
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			GA
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>govx-20210930.htm
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:govx="http://geovax.com/20210930" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>govx20220202_s1.htm</title>
  <!-- Generated by ThunderDome Portal - 2/3/2022 8:27:19 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0000832489</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">GeoVax Labs, Inc.</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
<ix:nonFraction id="c80220915" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c80220916" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c80220863" contextRef="i_2021-09-30" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c80220864" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c80220867" contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c80220868" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c80220865" contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction>
<ix:nonFraction id="c80220866" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction>
<ix:nonFraction id="c80220869" contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c80220871" contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c80220870" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction>
<ix:nonFraction id="c80220872" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction>
<ix:nonFraction id="c80220873" contextRef="i_2021-09-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c80220874" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c80220875" contextRef="i_2021-09-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">600,000,000</ix:nonFraction>
<ix:nonFraction id="c80220876" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">600,000,000</ix:nonFraction>
<ix:nonFraction id="c80220877" contextRef="i_2021-09-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">6,381,541</ix:nonFraction>
<ix:nonFraction id="c80220879" contextRef="i_2021-09-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">6,381,541</ix:nonFraction>
<ix:nonFraction id="c80220878" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834,095</ix:nonFraction>
<ix:nonFraction id="c80220880" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834,095</ix:nonFraction>
<ix:nonNumeric contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember" name="us-gaap:DebtInstrumentTerm" id="c80220395" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c80220397" contextRef="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">5</ix:nonFraction>
<ix:nonFraction id="c80220447" contextRef="d_2021-01-01_2021-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantToPnpMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c80220462" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c80220914" contextRef="d_2020-01-01_2020-09-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c80220491" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncomeTaxesPaid" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c80220933" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c80220934" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c80220917" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c80220918" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c80220919" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c80220920" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c80220921" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction>
<ix:nonFraction id="c80220923" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction>
<ix:nonFraction id="c80220922" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">2,486</ix:nonFraction>
<ix:nonFraction id="c80220924" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,486</ix:nonFraction>
<ix:nonFraction id="c80220925" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c80220926" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c80220927" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">600,000,000</ix:nonFraction>
<ix:nonFraction id="c80220928" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">600,000,000</ix:nonFraction>
<ix:nonFraction id="c80220929" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834,095</ix:nonFraction>
<ix:nonFraction id="c80220931" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834,095</ix:nonFraction>
<ix:nonFraction id="c80220930" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">14,992</ix:nonFraction>
<ix:nonFraction id="c80220932" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">14,992</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c80220527" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c80220528" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember" name="us-gaap:DebtInstrumentTerm" id="c80220569" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c80220587" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="Pure" name="govx:NumberOfInstitutionalInvestors" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c80220590" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,200,000</ix:nonFraction>
<ix:nonNumeric contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c80220591" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" name="us-gaap:DebtInstrumentTerm" id="c80220597" format="ixt-sec:durmonth">12</ix:nonNumeric>
<ix:nonFraction id="c80220611" contextRef="i_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheOneMember" unitRef="Share" name="govx:NumberOfCommonStockSecuritiesCalledByEachUnit" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220612" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220614" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheTwoMember" unitRef="Share" name="govx:NumberOfWarrantsCalledByEachUnit" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220615" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220616" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220619" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c80220621" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c80220646" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c80220735" contextRef="i_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember" unitRef="Share" name="govx:NumberOfCommonStockSecuritiesCalledByEachUnit" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220736" contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220738" contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220739" contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220741" contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c80220743" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c80220749" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c80220755" contextRef="i_2020-09-29" unitRef="Share" name="govx:NumberOfCommonStockSecuritiesCalledByEachUnit" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c80220756" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember" unitRef="Share" name="govx:NumberOfWarrantsCalledByEachUnit" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c80220773" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c80220774" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c80220778" contextRef="d_2019-01-01_2019-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c80220791" format="ixt-sec:duryear">5</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="govx-20210930.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2021-01-01_2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">govx:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">govx:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_TitleOfIndividualAxis-ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">govx:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_TitleOfIndividualAxis-ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">govx:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-21</xbrli:startDate><xbrli:endDate>2020-01-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:EquipmentAndFurnishingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:EquipmentAndFurnishingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-28</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-05-01_2021-05-31_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-07_2021-06-07_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-07</xbrli:startDate><xbrli:endDate>2021-06-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-11_2021-02-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-11_2021-02-11_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-02-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_PlanNameAxis-StockIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">govx:StockIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsFirstIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsSecondIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-01_2021-02-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsFirstIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsSecondIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-08-01_2021-08-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantToPnpMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantToPnpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-09-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_ProductOrServiceAxis-NIHGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_ProductOrServiceAxis-NIHGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_ProductOrServiceAxis-NIHGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_ProductOrServiceAxis-NIHGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_ProductOrServiceAxis-LeidosIncResearchCollaborativeAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:LeidosIncResearchCollaborativeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_ProductOrServiceAxis-LeidosIncResearchCollaborativeAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:LeidosIncResearchCollaborativeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">govx:CityOfHopeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_ProductOrServiceAxis-LicenseFirstAnniversaryPaymentMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">govx:CityOfHopeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:LicenseFirstAnniversaryPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_ProductOrServiceAxis-LicenseSecondAnniversaryPaymentMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">govx:CityOfHopeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:LicenseSecondAnniversaryPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OtherFurnitureFixturesAndEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:OtherFurnitureFixturesAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-OtherFurnitureFixturesAndEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:OtherFurnitureFixturesAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-26</xbrli:startDate><xbrli:endDate>2020-06-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:ConversionUnitsTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:ConversionUnitsTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:ConversionUnitsTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:ConversionUnitsTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-06-26_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-26</xbrli:startDate><xbrli:endDate>2020-06-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesHConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesHConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesIConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesIConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementClassOfStockAxis-SeriesCConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesCPreferredStockIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementClassOfStockAxis-SeriesEConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-01_2019-02-28_StatementClassOfStockAxis-SeriesFConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesFPreferredStockIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesFPreferredStockIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementClassOfStockAxis-SeriesFConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-01_2019-02-28_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-25_2019-02-25_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-25</xbrli:startDate><xbrli:endDate>2019-02-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-26_2019-02-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-26</xbrli:startDate><xbrli:endDate>2019-02-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-26_2019-04-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-26</xbrli:startDate><xbrli:endDate>2019-04-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-26_2019-04-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-26</xbrli:startDate><xbrli:endDate>2019-04-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-07-31_StatementClassOfStockAxis-SeriesGConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementClassOfStockAxis-SeriesGConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesHConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHPreferredStockIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHPreferredStockIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesIConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesIPreferredStockIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesIPreferredStockIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-01-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesJConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesJPreferredStockIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesJPreferredStockIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesJConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-30_2019-04-30_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-30</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-24_2020-09-24_ClassOfWarrantOrRightAxis-ConversionWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-24</xbrli:startDate><xbrli:endDate>2020-09-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-24_2020-09-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-24</xbrli:startDate><xbrli:endDate>2020-09-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-24_2020-09-24_StatementEquityComponentsAxis-CapitalUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-24</xbrli:startDate><xbrli:endDate>2020-09-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-24_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CapitalUnitsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-24</xbrli:startDate><xbrli:endDate>2020-09-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CapitalUnitsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-24_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheTwoMember_StatementEquityComponentsAxis-CapitalUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CapitalUnitsTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-24</xbrli:startDate><xbrli:endDate>2020-09-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-24_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-24_StatementEquityComponentsAxis-CapitalUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-24_StatementClassOfStockAxis-UnitsIncludingPrefundedWarrantsMember_StatementEquityComponentsAxis-CapitalUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:UnitsIncludingPrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-09-24_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-24</xbrli:startDate><xbrli:endDate>2020-09-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ManagementWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PlanNameAxis-StockIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">govx:StockIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:SeriesIWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-June2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-UnitConversionAndManagementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitConversionAndManagementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_RangeAxis-WeightedAverageMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-OutstandingWarrantsExcludingPreFundedWarrantsMember_RangeAxis-WeightedAverageMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:OutstandingWarrantsExcludingPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-07-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:SeriesIWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NIHGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-NIHGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ResearchAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:ResearchAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ResearchAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:ResearchAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-01-31_ProductOrServiceAxis-SBIRGrantMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:SBIRGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:SeriesIWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-UnitWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-CommonStockWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
   &#xa0;
  </div>
  <div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>As filed with the Securities and Exchange Commission on February 4, 2022</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration No. 333-</b></p>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2021-01-01_2021-09-30">S-1</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REGISTRATION STATEMENT</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>UNDER THE SECURITIES ACT OF 1933</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2021-01-01_2021-09-30">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2834</b></p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2021-01-01_2021-09-30">87-0455038</ix:nonNumeric></b></p> </td></tr>
<tr><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">incorporation or organization)</p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Primary Standard Industrial</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Classification Code Number)</p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification Number)</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2021-01-01_2021-09-30">1900 Lake Park Drive, Suite 380</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2021-01-01_2021-09-30">Smyrna</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2021-01-01_2021-09-30">Georgia</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2021-01-01_2021-09-30">30080</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Tel: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2021-01-01_2021-09-30">678</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2021-01-01_2021-09-30">384-7220</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address, including zip code, and telephone number, including area code, of registrant&#x2019;s principal executive offices)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>David A. Dodd</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>President &amp; Chief Executive Officer</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GeoVax Labs, Inc.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>1900 Lake Park Drive, Suite 380</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Smyrna, Georgia 30080</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Tel: (678) 384-7220</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>Copies to:</i></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>F. Reid Avett, Esq.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Womble Bond Dickinson (US) LLP</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2001 K Street, NW, Suite 400 South</b><br /> <b>Washington, D.C. 20006</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Tel: (202) 857-4425</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Approximate date of commencement of proposed sale to the public</b>: As soon as practicable after this registration statement is declared effective.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: &#x2612;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer</p> </td><td style="vertical-align:middle;width:auto;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2610;</p> </td><td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer</p> </td><td style="vertical-align:middle;width:auto;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2610;</p> </td></tr>
<tr><td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2021-01-01_2021-09-30">Non-accelerated filer</ix:nonNumeric></p> </td><td style="vertical-align:middle;width:auto;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2612;</p> </td><td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-09-30">&#x2612;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:top;width:auto;">&#xa0;</td><td style="vertical-align:top;width:auto;">&#xa0;</td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-09-30">&#x2610;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CALCULATION OF REGISTRATION FEE</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Title of Each Class of </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Security Being Registered</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Being </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Registered(1)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Proposed Maximum Offering Price per Security(2)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Proposed </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Maximum </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Offering </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Price(2)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Registration </b><br /> <b>Fee</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common Stock, $0.001 par value per share (3)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,134,968</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,509,199.32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,345.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>6,134,968</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>2.365</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>14,509,199.32</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>1,345.01</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1) This registration statement also includes an indeterminate number of securities that may become offered, issuable or sold to prevent dilution resulting from stock splits, stock dividends and similar transactions, which are included pursuant to Rule 416 under the Securities Act of 1933, as amended.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under the Securities Act of 1933, as amended, based upon the average of the high and low prices of the common stock as reported on the Nasdaq Capital Market on January 31, 2022.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(3) Consists of (i) 707,484 shares of common stock issued in a private placement in January 2022 (the &#x201c;Private Placement&#x201d;), (ii) 2,360,000 shares of common stock issuable upon the exercise of pre-funded warrants issued in the Private Placement and (iii) 3,067,484 shares of common stock issuable upon the exercise of warrants issued in the Private Placement at an exercise price of $3.26 per share.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="color:#ff0000;">The information in this preliminary prospectus is not complete and may be changed. The selling stockholder may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ff0000;"><b>SUBJECT TO COMPLETION, DATED February 4, 2022</b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ff0000;"><b>PRELIMINARY PROSPECTUS</b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="govx20220202_s1img001.gif" src="govx20220202_s1img001.gif" style="width:359;height:106;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>6,134,968 Shares of Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus relates to the resale, by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &#x201c;Selling Stockholder&#x201d;), of up to an aggregate of 6,134,968 shares of our common stock, par value $0.001 per share, consisting of (i) 707,484 shares of common stock (the &#x201c;Common Shares&#x201d;) issued in a private placement in January 2022 (the &#x201c;Private Placement&#x201d;), (ii) 2,360,000 shares of common stock issuable upon the exercise of pre-funded warrants issued in the Private Placement (the &#x201c;Pre-Funded Warrant&#x201d;) and (iii) 3,067,484 shares of common stock issuable upon the exercise of warrants issued in the Private Placement at an exercise price of $3.26 per share (the &#x201c;Common Warrant&#x201d; and together with the Pre-Funded Warrant, the &#x201c;Warrants,&#x201d; and the Warrants, collectively with the Common Shares, the &#x201c;Securities&#x201d;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus by the Selling Stockholder. All net proceeds from the sale of the shares of common stock covered by this prospectus will go to the Selling Stockholder. However, we may receive the proceeds from any exercise of the Common Warrant. See &#x201c;Use of Proceeds.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Stockholder may sell all or a portion of the shares of common stock covered by this prospectus from time to time in market transactions through any market on which our shares of common stock are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of sale. See &#x201c;Plan of Distribution.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our common stock and the warrants we issued to investors in a September 2020 public offering (the &#x201c;September 2020 Warrants&#x201d;) are listed on the Nasdaq Capital Market under the symbols &#x201c;GOVX&#x201d; and &#x201c;GOVXW,&#x201d; respectively. On January 31, 2022, the last reported sale price of our common stock was $2.42 per share and the last reported sale price of the September 2020 Warrants was $0.9298 per warrant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Investing in our shares of common stock involves a high degree of risk. The risks are described in the </b>&#x201c;<b>Risk Factors</b>&#x201d;<b> section beginning on page 6</b><b>&#xa0;of this prospectus. You should also consider the risk factors described or referred to in any applicable prospectus supplement before investing in these securities.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Neither the Securities and Exchange Commission (</b>&#x201c;<b>SEC</b>&#x201d;<b>) nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">The date of this prospectus is&#xa0; &#xa0; &#xa0; &#xa0; , 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ABOUT THIS PROSPECTUS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">i</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PROSPECTUS SUMMARY</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">RISK FACTORS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">15</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">USE OF PROCEEDS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">16</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DETERMINATION OF OFFERING PRICE</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">16</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DIVIDEND POLICY</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">16</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CAPITALIZATION</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">17</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BUSINESS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">18</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">35</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MANAGEMENT</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">45</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EXECUTIVE COMPENSATION</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">48</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">52</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS, DIRECTORS AND OFFICERS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">53</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SELLING STOCKHOLDER</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">54</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DESCRIPTION OF CAPITAL STOCK</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">55</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PLAN OF DISTRIBUTION</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">59</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LEGAL MATTERS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">61</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EXPERTS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">61</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">WHERE YOU CAN FIND MORE INFORMATION</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">61</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">INDEX TO FINANCIAL STATEMENTS</p> </td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">F-1</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;">&#xa0;</td>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ABOUT THIS PROSPECTUS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus is part of a registration statement that we filed with the SEC. As permitted by the rules and regulations of the SEC, the registration statement filed by us includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC&#x2019;s website described below under the heading &#x201c;Where You Can Find More Information.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Neither we nor the Selling Stockholder have authorized anyone to provide you with information different from that contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectus prepared by us or on our behalf. Neither we nor the Selling Stockholder take any responsibility for, or can provide any assurance as to the reliability of, any information other than the information contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectus prepared by us or on our behalf. We and the Selling Stockholder are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. You should assume that the information appearing in this prospectus or in any free writing prospectus prepared by us is accurate only as of their respective dates or on the date or dates which are specified in such documents. Our business, financial condition, results of operations and prospects may have changed since those dates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Neither we nor the Selling Stockholder are offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities as to distribution of the prospectus outside of the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Unless the context otherwise requires, references to &#x201c;GeoVax,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us&#x201d; or the &#x201c;Company&#x201d; in this prospectus mean GeoVax Labs, Inc. and its consolidated subsidiaries. Solely for convenience, trademarks and tradenames referred to in this prospectus may appear without the &#xae; or &#x2122; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      i
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 9pt;"><b>PROSPECTUS SUMMARY</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:28pt;"><i>The following summary highlights certain information contained elsewhere in this prospectus. Because this is only a summary, however, it does not contain all the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you make an investment decision, you should read this entire prospectus carefully, including the risks of investing in our securities discussed under the section of this prospectus entitled </i>&#x201c;<i>Risk Factors.</i>&#x201d;<i> You should also carefully read the exhibits to the registration statement of which this prospectus is a part.</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Overview</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GeoVax is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax&#x2019;s product pipeline includes ongoing human clinical trials in COVID-19, head and neck cancer, and HIV. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. Our portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 70 granted or pending patent applications spread over 20 patent families.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Product Development Pipeline</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are currently developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The table below summarizes the status of our product development programs, which are discussed in greater detail under the heading &#x201c;Business&#x201d; below.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Indication</span></b></p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Product Candidate</span></b></p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Current Status</span></b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Coronavirus Vaccines</span></b></p> </td>
      <td style="vertical-align:top;width:11.9%;">&#xa0;</td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">COVID-19 (Booster to mRNA)</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-CM04S1</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 2</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">COVID-19 (Primary vaccine for immunocompromised patients)</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-CM04S1</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 2</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pan Coronavirus</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-CM02</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Preclinical/IND-Enabling</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Cancer Immunotherapy</span></b></p> </td>
      <td style="vertical-align:top;width:11.9%;">&#xa0;</td>
      <td style="vertical-align:top;width:15.2%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Solid Tumors (Advanced Head and Neck Cancer)*</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Gedeptin</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 1/2</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Solid Tumors (MUC1)</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">MVA-VLP-MUC1</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Preclinical/IND-Enabling</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Other Infectious Disease Vaccines</span></b></p> </td>
      <td style="vertical-align:top;width:11.9%;">&#xa0;</td>
      <td style="vertical-align:top;width:15.2%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">HIV (preventive)</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GOVX-B11</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 2a completed</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">HIV (immunotherapy)</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GOVX-B01</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 1</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Zika**</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-ZM02</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Preclinical/IND-Enabling</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Ebola, Marburg, Sudan**</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-EM01</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Preclinical/IND-Enabling</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Lassa Fever**</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-LM01</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Exploratory</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:top;width:27.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Malaria**</p> </td>
      <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-MM02</p> </td>
      <td style="vertical-align:top;width:15.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Exploratory</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>---------------</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>* Orphan Drug status granted</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>** Indication within FDA Priority Review Voucher program</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our corporate strategy is to advance, protect and exploit our differentiated vaccine/immunotherapy technologies leading to the successful development of preventive and therapeutic vaccines and immunotherapies against infectious diseases and various cancers. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have not generated any revenues from the sale of the products we are developing, and we do not expect to generate any such revenues for at least the next several years. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Recent Developments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>GEO-CM04S1 License</i> -- In November 2021, GeoVax entered into a license agreement with City of Hope (the &#x201c;COH License&#x201d;), granting GeoVax exclusive rights to further develop and commercialize GEO-CM04S1 (formerly referred to as COH04S1). GEO-CM04S1, a synthetic, attenuated modified vaccinia Ankara (sMVA) vector expressing Spike and Nucleocapsid antigens of the SARS-CoV-2 virus, was initially developed at COH for immunocompromised patients.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GEO-CM0461 is being studied in an ongoing Phase 2 clinical trial to evaluate its safety and immunogenicity, compared to the Pfizer mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy. GEO-CM0461 is the only COVID-19 vaccine that includes both SARS-CoV-2 spike and nucleocapsid proteins to advance to a Phase 2 trial in cancer patients. Such vaccines also tend to produce an immune response quickly &#x2013; in less than 14 days &#x2013; with only mild side effects. The trial is also the first to compare an investigational multi-antigenic COVID-19 vaccine to the current Food and Drug Administration (FDA)-approved mRNA vaccine from Pfizer/BioNTech in people who are immunocompromised. Such patients have often shown a weak antibody response after receiving currently available COVID-19 vaccines.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In December 2021, patient enrollment began for the Phase 2 portion of a Phase 1/2 trial of GEO-CM0461, to study its use as a universal booster vaccine to current FDA-approved vaccines. GeoVax believes that the GEO-CM0461 vaccine, when administered as a heterologous booster, will provide additional recognition elements to the immune system over a homologous boost from mRNA vaccines such as those developed by Moderna or Pfizer, which are directed only toward SARS-CoV-2 Spike protein. The COH04S1 vaccine&#x2019;s MVA backbone may be more effective at inducing COVID-19 immunity since MVA strongly induces T cell responses even in a background of immunosuppression. In addition, GEO-CM0461 targeting of both Spike and Nucleocapsid antigens, may offer greater protection against the significant sequence variation observed with the Spike antigen.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Gedeptin</i>&#xae;<i> License</i> -- In September 2021, GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc. (the &#x201c;Gedeptin License), whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#xae;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase 1/2 clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and no curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#x2019;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but not limited to, cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Private Placement</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On January 14, 2022, we entered into a Securities Purchase Agreement with the Selling Stockholder providing for the issuance and sale to the Selling Stockholder of 707,484 shares of common stock, 2,360,000 shares of common stock issuable upon the exercise of the Pre-Funded Warrant and 3,067,484 shares of common stock issuable upon the exercise of the Common Warrant for gross proceeds to the Company of approximately $10.0 million. The Warrants are exercisable immediately and contain price adjustment provisions which may, under certain circumstances, reduce the applicable exercise price; the Pre-Funded Warrant shall terminate when fully exercised and the Common Warrant shall terminate on the fifth anniversary of the effective date of the registration statement of which this prospectus is a part (the &#x201c;Resale Registration Statement&#x201d;). The Private Placement closed on January 20, 2022. We paid the placement agent, Maxim Group LLC, a cash fee of $700,000 at closing.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In connection with the Purchase Agreement, we entered in a registration rights agreement with the Selling Stockholder in which we agreed to file by February 3, 2022 the Resale Registration Statement with the SEC covering all shares of common stock sold to investors and the shares of common stock issuable upon exercise of the Warrants, and to cause the Resale Registration Statement to become effective by February 28, 2022 (or, in the event of a &#x201c;full review&#x201d; by the SEC of the Resale Registration Statement, by March 15, 2022).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Risk Factors</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our business is subject to numerous risks and uncertainties, discussed in more detail in the following section. These risks include, among others, the following key risks:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Risks Related to Our Business and Capital Requirements</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have a history of operating losses, and we expect losses to continue for the foreseeable future.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business will require continued funding. If we do not receive adequate funding, we may not be able to continue our operations.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant disruptions of information technology systems or breaches of information security systems could adversely affect our business.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business could be adversely affected by widespread public health epidemics or other catastrophic events beyond our control.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Risks Related to Development and Commercialization of Product Candidates and Dependence on Third Parties</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our products are still being developed and are unproven. These products may not be successful.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We depend upon key personnel who may terminate their employment with us at any time. If we were to lose the services of any of these individuals, our business and operations may be adversely affected.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Regulatory and legal uncertainties could result in significant costs or otherwise harm our business.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face intense competition and rapid technological change that could result in products that are superior to the products we will be commercializing or developing.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our product candidates are based on new medical technology and, consequently, are inherently risky. Concerns about the safety and efficacy of our products could limit our future success.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may experience delays in our clinical trials that could adversely affect our financial results and our commercial prospects.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Failure to obtain timely regulatory approvals required to exploit the commercial potential of our products could increase our future development costs or impair our future sales.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">State pharmaceutical marketing compliance and reporting requirements may expose us to regulatory and legal action by state governments or other government authorities.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may not be successful in establishing collaborations for product candidates we seek to commercialize, which could adversely affect our ability to discover, develop, and commercialize products.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not have manufacturing, sales or marketing experience.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our products under development may not gain market acceptance.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may be required to defend lawsuits or pay damages for product liability claims.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that they will be widely used.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Risks Related to Our Intellectual Property</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We could lose our license rights to our important intellectual property if we do not fulfill our contractual obligations to our licensors.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other parties may claim that we infringe their intellectual property or proprietary rights, which could cause us to incur significant expenses or prevent us from selling products.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any inability to protect intellectual property rights in the United States and foreign countries could limit our ability to manufacture or sell products.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Risks Related to Our Common Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The market price of our common stock is highly volatile.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The sale or issuance of additional shares of our common stock or other equity securities could result in additional dilution to our stockholders.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain provisions of our certificate of incorporation which authorize the issuance of shares of preferred stock may make it more difficult for a third party to effect a change in control.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have never paid dividends and have no plans to do so.&#xa0;</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Public company compliance may make it more difficult for us to attract and retain officers and directors.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Certificate of Incorporation and Bylaws may be amended by the affirmative vote of a majority of our stockholders.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Broker-dealers may be discouraged from effecting transactions in shares of our common stock if we are considered to be a penny stock and thus subject to the penny stock rules.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Corporate Information</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We are incorporated under the laws of the State of Delaware. Our principal corporate offices are located at 1900 Lake Park Drive, Suite 380, Smyrna, Georgia 30080 (metropolitan Atlanta). Our telephone number is (678) 384-7220. The address of our website is www.geovax.com. Information contained on our website does not form a part of this prospectus.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:28pt;">&#xa0;</p>
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
    4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    &#xa0;
   </div>
  </div>
  <div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>The Offering</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">
    <tbody>
     <tr>
      <td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Shares offered</b></p> </td>
      <td style="vertical-align: top; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">6,134,968 shares of our common stock, consisting of 707,484 shares of common stock held by the Selling Stockholder, 2,360,000 shares of common stock issuable upon the exercise of the Pre-Funded Warrant and 3,067,484 shares of common stock issuable upon the exercise of the Common Warrant.</p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 30%;">&#xa0;</td>
      <td style="vertical-align: top; width: 70%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Shares of common stock outstanding prior to this offering</b></p> </td>
      <td style="vertical-align: top; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7,089,025 shares of common stock.</p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 30%;">&#xa0;</td>
      <td style="vertical-align: top; width: 70%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of proceeds</b></p> </td>
      <td style="vertical-align: top; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We will not receive any proceeds from the sale of the shares of common stock by the Selling Stockholder. All net proceeds from the sale of the shares of common stock covered by this prospectus will go to the Selling Stockholder. However, we may receive the proceeds from any exercise of the Common Warrant. See &#x201c;Use of Proceeds.&#x201d;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 30%;">&#xa0;</td>
      <td style="vertical-align: top; width: 70%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Nasdaq Capital Markets symbols</b></p> </td>
      <td style="vertical-align: top; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our common stock and the warrants we issued to investors in a September 2020 public offering (the &#x201c;September 2020 Warrants&#x201d;) are listed on the Nasdaq Capital Market under the symbols &#x201c;GOVX&#x201d;&#xa0;and &#x201c;GOVXW,&#x201d;&#xa0;respectively.</p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 30%;">&#xa0;</td>
      <td style="vertical-align: top; width: 70%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risk factors</b></p> </td>
      <td style="vertical-align: top; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Investment in our common stock involves a high degree of risk and could result in a loss of your entire investment. Before investing in our common stock, you should carefully read and consider the &#x201c;Risk Factors&#x201d;&#xa0;beginning on page 6 of this prospectus.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Unless otherwise indicated, the number of shares of our common stock outstanding prior to this offering is based on 7,089,025 shares of common stock outstanding as of February 3, 2022, and exclude as of such date:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width:36pt;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2,360,000 shares of common stock issuable upon the exercise of the Pre-Funded Warrants with an exercise price of $0.0001 per share;</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width: 36pt; text-align: justify;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4,064,149 shares of common stock issuable upon the exercise of other outstanding warrants with a weighted average exercise price of $3.88 per share; and</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
    <tbody>
     <tr>
      <td style="width: 36pt; text-align: justify;">&#xa0;</td>
      <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
      <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1,500,000 shares of common stock which are reserved for issuance under our 2020 Stock Incentive Plan, of which 962,300 shares of common stock are issuable upon exercise of outstanding options at an average exercise price of $3.18 per share.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RISK FACTORS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>An investment in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the following risk factors as well as other information we include in this prospectus. The risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Business and Capital Requirements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have a history of operating losses, and we expect losses to continue for the foreseeable future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a research and development-focused company, we have had no product revenue to date and revenues from our government grants and other collaborations have not generated sufficient cash flows to cover operating expenses. Since our inception, we have incurred operating losses each year due to costs incurred in connection with research and development activities and general and administrative expenses associated with our operations. We incurred a net loss of $3.0 million, $2.4 million, $4.8 million and $1.6 million for the years ended December 31, 2020 and 2019 and the nine months ended September 30, 2021 and 2020, respectively. We expect to incur additional operating losses and expect cumulative losses to increase as our research and development, preclinical, clinical, and manufacturing efforts expand. Our ability to generate revenue and achieve profitability depends on our ability to successfully complete the development of our product candidates, conduct preclinical tests and clinical trials, obtain the necessary regulatory approvals, and manufacture and market or otherwise commercialize our products. Unless we are able to successfully meet these challenges, we will not be profitable and may not remain in business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business will require continued funding. If we do not receive adequate funding, we may not be able to continue our operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To date, we have financed our operations principally through the sale of our equity securities and through government grants and clinical trial support. We will require substantial additional financing at various intervals for our operations, including clinical trials, operating expenses, intellectual property protection and enforcement, for pursuit of regulatory approvals, and for establishing or contracting out manufacturing, marketing and sales functions. There is no assurance that such additional funding will be available on terms acceptable to us or at all. If we are not able to secure the significant funding that is required to maintain and continue our operations at current levels, or at levels that may be required in the future, we may be required to delay clinical studies or clinical trials, curtail operations, or obtain funds through collaborative arrangements that may require us to relinquish rights to some of our products or potential markets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We may pursue additional support from the federal government for our vaccine and immunotherapy development programs; however, as we progress to the later stages of our development activities, government financial support may be more difficult to obtain, or may not be available at all. Therefore, it will be necessary for us to look to other sources of funding to finance our development activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We expect that our current working capital will be sufficient to support our planned level of operations into early 2023. We will need to raise additional funds to significantly advance our vaccine development programs and to continue our operations. In order to meet our operating cash flow needs we plan to seek sources of non-dilutive capital through government grant programs and clinical trial support. We may also plan additional offerings of our equity securities, debt, or convertible debt instruments. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, the consequences could have a material adverse effect on our business, operating results, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Significant disruptions of information technology systems or breaches of information security systems could adversely affect our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We rely upon a combination of information technology systems and traditional recordkeeping to operate our business. In the ordinary course of business, we collect, store, and transmit confidential information (including, but not limited to, personal information and intellectual property). We have also outsourced elements of our operations to third parties, including elements of our information technology systems and, as a result, we manage a number of independent vendor relationships with third parties who may or could have access to our confidential information. Our information technology and information security systems and records are potentially vulnerable to security breaches, service interruptions, or data loss from inadvertent or intentional actions by our employees or vendors. Our information technology and information security systems and records are also potentially vulnerable to malicious attacks by third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of expertise and motives (including, but not limited to, financial crime, industrial espionage, and market manipulation).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">While we have invested, and continue to invest, a portion of our limited funds in our information technology and information security systems, there can be no assurance that our efforts will prevent security breaches, service interruptions, or data losses. Any security breaches, service interruptions, or data losses could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business, and reputational harm to us or allow third parties to gain material, inside information that they may use to trade in our securities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business could be adversely affected by widespread public health epidemics or other catastrophic events beyond our control.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to our reliance on our own employees and facilities, we depend on our collaborators, laboratories and other facilities for the continued operation of our business. Despite any precautions we take, public health epidemics, such as COVID-19, or other catastrophic events, such as natural disasters, terrorist attacks, hurricanes, fire, floods and ice and snowstorms, may result in interruptions in our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In response to the COVID-19 pandemic, we have curtailed non-essential travel for our employees and are canceling or postponing in-person attendance at industry events. Currently, as a result of the work and travel restrictions related to the ongoing pandemic, several of our business activities are being conducted remotely which might be less effective than in-person meetings or in-office work. Despite these precautions, the necessary work within our laboratory and of our collaborators has continued without significant interruption. Although we continue to monitor the situation and may adjust our current policies as more information and guidance become available, temporarily suspending travel and limitations on doing business in-person has and could continue to negatively impact our business development efforts and create operational or other challenges, any of which could harm our business, financial condition and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, the COVID-19 pandemic could disrupt our operations due to absenteeism by infected or ill members of management or other employees because of our limited staffing. COVID-19 related illness could also impact members of our Board of Directors resulting in absenteeism from meetings of the directors or committees of directors, and making it more difficult to convene the quorums of the full Board of Directors or its committees needed to conduct meetings for the management of our affairs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Development and Commercialization of Product Candidates and Dependence on Third Parties</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our products are still being developed and are unproven. These products may not be successful.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To become profitable, we must generate revenue through sales of our products. However, our products are in varying stages of development and testing. Our products have not been proven in human clinical trials and have not been approved by any government agency for sale. If we cannot successfully develop and prove our products and processes, or if we do not develop other sources of revenue, we will not become profitable and at some point, we would discontinue operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We depend upon key personnel who may terminate their employment with us at any time. If we were to lose the services of any of these individuals, our business and operations may be adversely affected.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers. Competition for qualified personnel is intense among companies, academic institutions and other organizations. The ability to attract and retain personnel is adversely affected by our financial challenges. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Regulatory and legal uncertainties could result in significant costs or otherwise harm our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To manufacture and sell our products, we must comply with extensive domestic and international regulation. In order to sell our products in the United States, approval from the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) is required. Satisfaction of regulatory requirements, including FDA requirements, typically takes many years, and if approval is obtained at all, it is dependent upon the type, complexity and novelty of the product, and requires the expenditure of substantial resources. We cannot predict whether our products will be approved by the FDA. Even if they are approved, we cannot predict the time frame for approval. Foreign regulatory requirements differ from jurisdiction to jurisdiction and may, in some cases, be more stringent or difficult to meet than FDA requirements. As with the FDA, we cannot predict if or when we may obtain these regulatory approvals. If we cannot demonstrate that our products can be used safely and successfully in a broad segment of the patient population on a long-term basis, our products would likely be denied approval by the FDA and the regulatory agencies of foreign governments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We face intense competition and rapid technological change that could result in products that are superior to the products we will be commercializing or developing.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The market for vaccines that protect against or treat human infectious diseases is intensely competitive and is subject to rapid and significant technological change. We have numerous competitors in the United States and abroad, including, among others, large companies with substantially greater resources than us. If any of our competitors develop products with efficacy or safety profiles significantly better than our products, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive or result in treatments or cures superior to ours.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our product candidates are based on new medical technology and, consequently, are inherently risky. Concerns about the safety and efficacy of our products could limit our future success.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are subject to the risks of failure inherent in the development of product candidates based on new medical technologies. These risks include the possibility that the products we create will not be effective, that our product candidates will be unsafe or otherwise fail to receive the necessary regulatory approvals, and that our product candidates will be difficult to manufacture on a large scale or will be uneconomical to market.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Many pharmaceutical products cause multiple potential complications and side effects, not all of which can be predicted with accuracy and many of which may vary from patient to patient. Long term follow-up data may reveal previously unidentified complications associated with our products. The responses of potential physicians and others to information about complications could materially adversely affect the market acceptance of our products, which in turn would materially harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may experience delays in our clinical trials that could adversely affect our financial results and our commercial prospects.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We do not know whether planned pre-clinical and clinical trials will begin on time or whether we will complete any of our trials on schedule, if at all. Product development costs will increase if we have delays in testing or approvals, or if we need to perform more or larger clinical trials than planned. Significant delays may adversely affect our financial results and the commercial prospects for our products and delay our ability to become profitable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We rely heavily on independent clinical investigators, vaccine manufacturers, and other third-party service providers for successful execution of our clinical trials, but do not control many aspects of their activities. We are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The failure of these third parties to carry out their obligations could delay or prevent the development, approval and commercialization of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Failure to obtain timely regulatory approvals required to exploit the commercial potential of our products could increase our future development costs or impair our future sales.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">None of our vaccines are approved by the FDA for sale in the United States or by other regulatory authorities for sale in foreign countries. To exploit the commercial potential of our technologies, we are conducting and planning to conduct additional pre-clinical studies and clinical trials. This process is expensive and can require a significant amount of time. Failure can occur at any stage of testing, even if the results are favorable. Failure to adequately demonstrate safety and efficacy in clinical trials could delay or preclude regulatory approval and restrict our ability to commercialize our technology or products. Any such failure may severely harm our business. In addition, any approvals we obtain may not cover all of the clinical indications for which approval is sought or may contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use, or in the form of onerous risk management plans, restrictions on distribution, or post-approval study requirements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>State pharmaceutical marketing compliance and reporting requirements may expose us to regulatory and legal action by state governments or other government authorities.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs and file periodic reports on sales, marketing, pricing and other activities. Similar legislation is being considered in other states. Many of these requirements are new and uncertain, and available guidance is limited. Unless we are in full compliance with these laws, we could face enforcement action, fines, and other penalties and could receive adverse publicity, all of which could harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the United States and foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States and elsewhere, including in the European Union, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#x201c;Affordable Care Act&#x201d;), substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act includes a number of provisions that are intended to lower healthcare costs, including provisions relating to prescription drug prices and government spending on medical products.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Since its enactment, there have also been judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as efforts by the former Trump administration to repeal or replace certain aspects of the statute. We continue to evaluate the effect that the Affordable Care Act and subsequent changes to the statute has on our business. It is uncertain the extent to which any such changes may impact our business or financial condition.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There has also been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products. There have been several Congressional inquiries and proposed bills, as well as state efforts, designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. In June 2017, the FDA issued a Drug Competition Action plan intended to lower prescription drug prices by encouraging competition from generic versions of existing products. In July 2018, the FDA issued a Biosimilar Action Plan, intended to similarly promote competition to prescription biologics from biosimilars.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. For example, in September 2017, the California State Assembly approved SB17, which requires pharmaceutical companies to notify health insurers and government health plans at least 60 days before any scheduled increases in the prices of their products if they exceed 16% over a two-year period, and further requiring pharmaceutical companies to explain the reasons for such increase. Effective in 2016, Vermont passed a law requiring certain manufacturers identified by the state to justify their price increases.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We expect that these, and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be successful in establishing collaborations for product candidates we seek to commercialize, which could adversely affect our ability to discover, develop, and commercialize products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We expect to seek collaborations for the development and commercialization of product candidates in the future. The timing and terms of any collaboration will depend on the evaluation by prospective collaborators of the clinical trial results and other aspects of a product&#x2019;s safety and efficacy profile. If we are unable to reach agreements with suitable collaborators for any product candidate, we will be forced to fund the entire development and commercialization of such product candidates, ourselves, and we may not have the resources to do so. If resource constraints require us to enter into a collaboration agreement early in the development of a product candidate, we may be forced to accept a more limited share of any revenues the product may eventually generate. We face significant competition in seeking appropriate collaborators. Moreover, these collaboration arrangements are complex and time-consuming to negotiate and document. We may not be successful in our efforts to establish collaborations or other alternative arrangements for any product candidate. Even if we are successful in establishing collaborations, we may not be able to ensure fulfillment by collaborators of their obligations or our expectations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We do not have manufacturing, sales or marketing experience.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We do not have experience in manufacturing, selling, or marketing. To obtain the expertise necessary to successfully manufacture, market, and sell our products, we must develop our own commercial infrastructure and/or collaborative commercial arrangements and partnerships. Our ability to execute our current operating plan is dependent on numerous factors, including, the performance of third-party collaborators with whom we may contract.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our products under development may not gain market acceptance.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our products may not gain market acceptance among physicians, patients, healthcare payers and the medical community. Significant factors in determining whether we will be able to compete successfully include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the efficacy and safety of our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the time and scope of regulatory approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reimbursement coverage from insurance companies and others;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the price and cost-effectiveness of our products, especially as compared to any competitive products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability to maintain patent protection.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be required to defend lawsuits or pay damages for product liability claims.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Product liability is a major risk in testing and marketing biotechnology and pharmaceutical products. We may face substantial product liability exposure in human clinical trials and for products that we sell after regulatory approval. We carry product liability insurance and we expect to continue such policies. However, product liability claims, regardless of their merits, could exceed policy limits, divert management&#x2019;s attention, and adversely affect our reputation and demand for our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that they will be widely used.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Market acceptance of products we develop, if approved, will depend on reimbursement policies and may be affected by, among other things, future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will cover and establish payment levels. We cannot be certain that reimbursement will be available for any products that we may develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for our products. If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize products that we develop.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We could lose our license rights to our important intellectual property if we do not fulfill our contractual obligations to our licensors.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our rights to significant parts of the technology we use in our products are licensed from third parties and are subject to termination if we do not fulfill our contractual obligations to our licensors. Termination of intellectual property rights under any of our license agreements could adversely impact our ability to produce or protect our products. Our obligations under our license agreements include requirements that we make milestone payments to our licensors upon the achievement of clinical development and regulatory approval milestones, royalties as we sell commercial products, and reimbursement of patent filing and maintenance expenses. Should we become bankrupt or otherwise unable to fulfill our contractual obligations, our licensors could terminate our rights to critical technology that we rely upon.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Other parties may claim that we infringe their intellectual property or proprietary rights, which could cause us to incur significant expenses or prevent us from selling products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our success will depend in part on our ability to operate without infringing the patents and proprietary rights of third parties. The manufacture, use and sale of new products have been subject to substantial patent rights litigation in the pharmaceutical industry. These lawsuits generally relate to the validity and infringement of patents or proprietary rights of third parties. Infringement litigation is prevalent with respect to generic versions of products for which the patent covering the brand name product is expiring, particularly since many companies that market generic products focus their development efforts on products with expiring patents. Pharmaceutical companies, biotechnology companies, universities, research institutions or other third parties may have filed patent applications or may have been granted patents that cover aspects of our products or our licensors&#x2019; products, product candidates or other technologies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Future or existing patents issued to third parties may contain patent claims that conflict with those of our products. We expect to be subject to infringement claims from time to time in the ordinary course of business, and third parties could assert infringement claims against us in the future with respect to our current products or with respect to products that we may develop or license. Litigation or interference proceedings could force us to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">stop or delay selling, manufacturing or using products that incorporate, or are made using the challenged intellectual property;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">pay damages; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">enter into licensing or royalty agreements that may not be available on acceptable terms, if at all.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any litigation or interference proceedings, regardless of their outcome, would likely delay the regulatory approval process, be costly and require significant time and attention of our key management and technical personnel.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Any inability to protect intellectual property rights in the United States and foreign countries could limit our ability to manufacture or sell products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will rely on trade secrets, unpatented proprietary know-how, continuing technological innovation and, in some cases, patent protection to preserve our competitive position. Our patents and licensed patent rights may be challenged, invalidated, infringed or circumvented, and the rights granted in those patents may not provide proprietary protection or competitive advantages to us. We and our licensors may not be able to develop patentable products with acceptable patent protection. Even if patent claims are allowed, the claims may not issue, or in the event of issuance, may not be sufficient to protect the technology owned by or licensed to us. If patents containing competitive or conflicting claims are issued to third parties, we may be prevented from commercializing the products covered by such patents or may be required to obtain or develop alternate technology. In addition, other parties may duplicate, design around or independently develop similar or alternative technologies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We may not be able to prevent third parties from infringing or using our intellectual property, and the parties from whom we may license intellectual property may not be able to prevent third parties from infringing or using the licensed intellectual property. We generally attempt to control and limit access to, and the distribution of, our product documentation and other proprietary information. Despite efforts to protect this proprietary information, unauthorized parties may obtain and use information that we may regard as proprietary. Other parties may independently develop similar know-how or may even obtain access to these technologies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Neither the U.S. Patent and Trademark Office nor the courts have established a consistent policy regarding the breadth of claims allowed in pharmaceutical patents. The allowance of broader claims may increase the incidence and cost of patent interference proceedings and the risk of infringement litigation. On the other hand, the allowance of narrower claims may limit the value of our proprietary rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The market price of our common stock is highly volatile.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The market price of our common stock has been, and is expected to continue to be, highly volatile. Certain factors, including announcements of new developments by us or other companies, regulatory matters, new or existing medicines or procedures, concerns about our financial position, operating results, litigation, government regulation, developments or disputes relating to agreements, patents or proprietary rights, may have a significant impact on the market price of our stock. In addition, potential dilutive effects of future sales of shares of common stock by us, and subsequent sales of common stock by the holders of our options and warrants could have an adverse effect on the market price of our shares.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, the securities markets from time-to-time experience significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The sale or issuance of additional shares of our common stock or other equity securities could result in additional dilution to our stockholders.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In order to meet our operating cash flow needs, we may plan additional offerings of our equity securities, debt, or convertible debt instruments. The sale of additional equity securities could result in significant additional dilution to our stockholders. The incurrence of indebtedness could result in debt service obligations and operating and financing covenants that would restrict our operations. We cannot assure investors that financing will be available in amounts or on terms acceptable to us, if at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are obligated to issue additional shares of our common stock in connection with our outstanding warrants if the warrant holders choose to exercise them. There are outstanding Pre-Funded warrants exercisable for 2,360,000 shares at a nominal exercise price, and other outstanding warrants are exercisable for 4,064,149 shares at exercise prices ranging from $3.26 to $13.00 per share. The exercise of these warrants will cause us to issue additional shares of our common stock and will dilute the percentage ownership of our shareholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Certain provisions of our certificate of incorporation which authorize the issuance of shares of preferred stock may make it more difficult for a third party to effect a change in control.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our certificate of incorporation authorizes our Board of Directors to issue up to 10,000,000 shares of preferred stock. The shares of preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our Board of Directors without further action by the stockholders. These terms may include voting rights, including the right to vote as a series on particular matters, preferences as to dividends and liquidation, conversion rights, redemption rights and sinking fund provisions. The issuance of any newly issued preferred stock could diminish the rights of holders of our common stock, and therefore could reduce the value of our common stock. In addition, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell assets to, a third party. The ability of our Board of Directors to issue preferred stock could make it more difficult, delay, discourage, prevent or make it costlier to acquire or effect a change-in-control, which in turn could prevent the stockholders from recognizing a gain in the event that a favorable offer is extended and could materially and negatively affect the market price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have never paid dividends and have no plans to do so.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Holders of shares of our common stock are entitled to receive such dividends as may be declared by our Board of Directors. To date, we have paid no cash dividends on our shares of common stock and we do not expect to pay cash dividends on our common stock in the foreseeable future. We intend to retain future earnings, if any, to provide funds for operations of our business. Therefore, any potential return investors may have in our common stock will be in the form of appreciation, if any, in the market value of their shares of common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Public company compliance may make it more difficult for us to attract and retain officers and directors.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Sarbanes-Oxley Act, the Dodd-Frank Act, the JOBS Act, the FAST Act, and rules subsequently implemented by the SEC have required changes in corporate governance practices of public companies. As a public company, we expect these rules and regulations, and amendments to them, to contribute to our compliance costs and to make certain activities more time consuming and costly. As a public company, we also expect that these rules and regulations may make it difficult and expensive for us to obtain director and officer liability insurance and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our Certificate of Incorporation and Bylaws may be amended by the affirmative vote of a majority of our stockholders. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the Delaware General Corporation Law, a corporation&#x2019;s certificate of incorporation may be amended by the affirmative vote of the holders of a majority of the outstanding shares entitled to vote, and a majority of the outstanding shares of each class entitled to vote as a class, unless the articles require the vote of a larger percentage of shares. Our Certificate of Incorporation, as amended, does not require the vote of a larger percentage of shares. As permitted under the Delaware General Corporation Law, our Bylaws give our board of directors the power to adopt, amend, or repeal our Bylaws. Our stockholders entitled to vote have concurrent power to adopt, amend, or repeal our Bylaws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Broker-dealers may be discouraged from effecting transactions in shares of our common stock if we are considered to be a penny stock and thus subject to the penny stock rules.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The SEC has adopted a number of rules to regulate &#x201c;penny stocks&#x201d; that restrict transactions involving stock which is deemed to be penny stock. Such rules include Rules 3a51-1, 15g-1, 15g-2, 15g-3, 15g-4, 15g-5, 15g-6, 15g-7, and 15g-9 under the Exchange Act. These rules may have the effect of reducing the liquidity of penny stocks. &#x201c;Penny stocks&#x201d; generally are equity securities with a price of less than $5.00 per share (other than securities registered on certain national securities exchanges or quoted on Nasdaq if current price and volume information with respect to transactions in such securities is provided by the exchange or system). Our securities have in the past constituted, and may again in the future, if we are delisted from Nasdaq, constitute, &#x201c;penny stock&#x201d; within the meaning of the rules. The additional sales practice and disclosure requirements imposed upon U.S. broker-dealers may discourage broker-dealers from effecting transactions in shares of our common stock, which could severely limit the market liquidity of such shares and impede their sale in the secondary market.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A U.S. broker-dealer selling penny stock to anyone other than an established customer or &#x201c;accredited investor&#x201d; (generally, an individual with net worth in excess of $1,000,000 (exclusive of personal residence) or an annual income exceeding $200,000, or $300,000 together with his or her spouse) must make a special suitability determination for the purchaser and must receive the purchaser&#x2019;s written consent to the transaction prior to sale, unless the broker-dealer or the transaction is otherwise exempt. In addition, the &#x201c;penny stock&#x201d; regulations require the U.S. broker-dealer to deliver, prior to any transaction involving a &#x201c;penny stock&#x201d;, a disclosure schedule prepared in accordance with SEC standards relating to the &#x201c;penny stock&#x201d; market, unless the broker-dealer or the transaction is otherwise exempt. A U.S. broker-dealer is also required to disclose commissions payable to the U.S. broker-dealer and the registered representative and current quotations for the securities. Finally, a U.S. broker-dealer is required to submit monthly statements disclosing recent price information with respect to the &#x201c;penny stock&#x201d; held in a customer&#x2019;s account and information with respect to the limited market in &#x201c;penny stocks&#x201d;.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Stockholders should be aware that, according to the SEC, the market for &#x201c;penny stocks&#x201d; has suffered in recent years from patterns of fraud and abuse. Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (iii) &#x201c;boiler room&#x201d; practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (iv) excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and (v) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, resulting in investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market. Although we do not expect to be in a position to dictate the behavior of the market or of broker-dealers who participate in the market, management will strive within the confines of practical limitations to prevent the described patterns from being established with respect to our securities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Some of the statements in this prospectus contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our ability to control or predict and that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by forward-looking statements. These factors include but are not limited to those described under &#x201c;Risk Factors&#x201d; herein, as well as the other information contained in this prospectus. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this prospectus. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In some cases, you can identify forward-looking statements by terminology such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;expects,&#x201d; &#x201c;intends,&#x201d; &#x201c;plans,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue&#x201d; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Our forward-looking statements may include, among other things, statements about:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to continue as a going concern and our history of losses;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to obtain additional financing;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our use of the net proceeds from this offering;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to prosecute, maintain or enforce our intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the accuracy of our estimates regarding expenses, future revenues and capital requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the implementation of our business model and strategic plans for our business and technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the successful development and regulatory approval of our technologies and products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the potential markets for our products and our ability to serve those markets;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the rate and degree of market acceptance of our products and any future products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to retain key management personnel; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory developments and our compliance with applicable laws.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>USE OF PROCEEDS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will not receive any proceeds from the sale of the shares of common stock by the Selling Stockholder. All net proceeds from the sale of the shares of common stock covered by this prospectus will go to the Selling Stockholder. We expect that the Selling Stockholder will sell their shares of common stock as described under &#x201c;Plan of Distribution.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We may receive proceeds from the exercise of the Common Warrant and related issuance of shares of common stock. The Common Warrant, however, is exercisable on a cashless basis only under certain circumstances. If the Common Warrant is exercised for cash in full, the gross proceeds would be approximately $10.0 million. We intend to use the net proceeds from the exercise of the Common Warrant, if any, for general corporate purposes and working capital.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pending any use, as described above, we intend to invest the net proceeds in high-quality, short-term, interest-bearing securities. We can make no assurances that the Common Warrant will be exercised, or if exercised, that it will be exercised for cash, the quantity which will be exercised or in the period in which it will be exercised.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DETERMINATION OF OFFERING PRICE</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Stockholder will determine at what price it may sell the securities offered by this prospectus, and such sales may be made at fixed prices, prevailing market prices at the time of the sale, varying prices determined at the time of sale, or negotiated prices. For more information, see &#x201c;Plan of Distribution.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIVIDEND POLICY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To date, we have paid no cash dividends on our shares of common stock and we do not expect to pay cash dividends on our common stock in the foreseeable future. We intend to retain future earnings, if any, to provide funds for operations of our business. Therefore, any potential return investors may have in our common stock will be in the form of appreciation, if any, in the market value of their shares of common stock. We are not subject to any legal restrictions respecting the payment of dividends, except that we may not pay dividends if the payment would render us insolvent. Any future determination as to the payment of cash dividends on our common stock will be at the discretion of our Board of Directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CAPITALIZATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table sets forth our capitalization as of September 30, 2021:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">on an actual basis; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">on an as adjusted basis to give effect to (i) the issuance and sale by us of 707,484 shares of common stock in the Private Placement, (ii) the issuance of 2,360,000 shares of common stock upon the exercise of the Pre-Funded Warrant, (iii) the issuance of 3,067,484 shares of common stock issuable upon the exercise of the Common Warrant at a price of $3.26 per share and (iv) receipt of the gross proceeds from the Private Placement after deducting commissions and offering expenses payable by us and the use of proceeds therefrom.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">You should read this table together with our financial statements and the related notes, and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of September 30, 2021</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(unaudited)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Actual</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As Adjusted</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,107,019</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">37,337,229</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">335,650</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">335,650</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stockholder&#x2019;s equity:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Common stock</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,382</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12,517</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Additional paid-in capital</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">68,630,363</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">87,854,438</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Accumulated deficit</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(50,632,895</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(50,632,895</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total stockholders&#x2019; equity</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,003,850</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">37,234,060</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The table and discussion above are based on 6,381,541 shares of common stock outstanding as of September 30, 2021, and 12,516,509 shares as adjusted, and do not include, as of that date:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2,816,631 shares of common stock issuable upon the exercise of other outstanding warrants with a weighted average exercise price of $5.35 per share; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1,500,000 shares of common stock which are reserved for issuance under our 2020 Stock Incentive Plan, of which 602,000 shares of common stock are issuable upon exercise of outstanding options at an average exercise price of $2.79 per share.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BUSINESS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GeoVax is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax&#x2019;s product pipeline includes ongoing human clinical trials in COVID-19, head and neck cancer, and HIV. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. Our portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 70 granted or pending patent applications spread over 20 patent families.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Product Development Pipeline</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are currently developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The table below summarizes the status of our product development programs, which are discussed in greater detail in the following pages.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Indication</span></b></p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Product Candidate</span></b></p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Current Status</span></b></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Coronavirus Vaccines</span></b></p> </td>
     <td style="vertical-align:top;width:13.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">COVID-19 (Booster to mRNA)</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-CM04S1</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 2</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">COVID-19 (Primary vaccine for immunocompromised patients)</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-CM04S1</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 2</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pan Coronavirus</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-CM02</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Preclinical/IND-Enabling</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Cancer Immunotherapy</span></b></p> </td>
     <td style="vertical-align:top;width:13.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:14.3%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Solid Tumors (Advanced Head and Neck Cancer)*</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Gedeptin&#xae;</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 1/2</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Solid Tumors (MUC1)</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">MVA-VLP-MUC1</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Preclinical/IND-Enabling</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Other Infectious Disease Vaccines</span></b></p> </td>
     <td style="vertical-align:top;width:13.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:14.3%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">HIV (preventive)</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GOVX-B11</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 2a completed</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">HIV (immunotherapy)</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GOVX-B01</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Clinical - Phase 1</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Zika**</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-ZM02</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Preclinical/IND-Enabling</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Ebola, Marburg, Sudan**</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-EM01</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Preclinical/IND-Enabling</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Lassa Fever**</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-LM01</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Exploratory</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Malaria**</p> </td>
     <td style="vertical-align:top;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GEO-MM02</p> </td>
     <td style="vertical-align:top;width:14.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Exploratory</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>---------------</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>* Orphan Drug status granted</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>** Indication within FDA Priority Review Voucher program</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Coronavirus Vaccine Programs</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">COVID-19, caused by SARS-CoV-2, has rapidly swept throughout the world. The World Health Organization (WHO) declared COVID-19 a public health emergency of international concern, and in late January 2022 has reported more than 350 million cases and nearly 6 million deaths worldwide. A proportion of patients recovering from COVID-19 continue shedding virus for days, and asymptomatic carriers may also transmit SARS-CoV-2, indicating a risk of a continuous and long-term pandemic.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There are currently twenty-four vaccines are authorized for use in one or more countries around the world, including three in the United States. These vaccines are based on the S protein of SARS-CoV-2 but rely on different mechanisms for presentation or expression of the S antigen, including recombinant proteins, whole inactivated virus, defective adenovirus vectors (three different types) or mRNA. Antiviral drugs and mAbs currently have limited availability and effectiveness. According to the U.S. Centers for Disease Control and Prevention (CDC), estimates of COVID-19 mRNA vaccine effectiveness have declined in recent months because of waning vaccine induced immunity over time, possible increased immune evasion by SARS-CoV-2 variants, or a combination of these and other factors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">SARS-CoV-2 is an enveloped, single-stranded, positive-sense RNA virus belonging to the family <i>Coronavidae</i>&#xa0;within the genus b-coronavirus. The genome of SARS-CoV-2 encodes one large Spike (&#x201c;S&#x201d;) protein that plays a pivotal role during viral attachment to the host receptor, angiotensin converting enzyme 2 (&#x201c;ACE2&#x201d;), and entry into host cells. The S protein is the major principal antigen target for vaccines against human coronavirus, including SARS-CoV-2. Neutralizing antibodies targeting the receptor binding domain (&#x201c;RBD&#x201d;) subunit of the S protein block the virus from binding to host cells. Over 90% of all neutralizing antibodies produced in response to infection are directed to the RBD subunit, and mAbs that have shown therapeutic activity target epitopes on the RBD.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>GEO-CM04S1 for Immunocompromised Patients </b>&#x2013;<b> </b>The CDC lists immunocompromised patients, including patients who have received therapeutic procedures for hematologic malignancy, as high risk for SARS-CoV-2 disease. SARS-CoV-2 infection is expected to be very serious in this vulnerable population of hematology patients, including autologous (auto) and allogeneic (allo) hematopoietic cell transplant (HCT), and recipients of chimeric antigen receptor (CAR)-T cell therapies. Given the serious impact of other respiratory viruses in this vulnerable patient population, it is anticipated that hematology recipients of cell therapy may develop severe clinical disease, profoundly impacting the therapy outcomes, such as morbidity and survival. There is very limited data and multiple critical gaps in our knowledge of the epidemiology and clinical manifestations of COVID 19 in hematology patients as no clinical trial of a COVID-19 vaccine has enrolled immunocompromised patients. Thus, the efficacy and safety of a SARS-CoV-2 vaccine has not been established in the different immunocompromised patient populations and it is possible that candidate SARS-CoV-2 vaccines may differ in their efficacy and safety for these patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our vaccine candidate, GEO-CM04S1 (formerly referred to as COH04S1), is based on a synthetic, attenuated Modified Vaccinia Ankara (sMVA) vector expressing both spike (S) and nucleocapsid (N) antigens of the SARS-CoV-2 virus and was initially developed at City of Hope (COH) for immunocompromised patients. In a placebo-controlled Phase 1 clinical trial of healthy adults conducted by COH, GEO-CM04S1 was shown to be safe and immunogenic. In November 2021, GeoVax entered into a license agreement with COH, granting GeoVax exclusive worldwide rights to further develop and commercialize the vaccine.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GEO-CM04S1 is being studied in an ongoing Phase 2 clinical trial (NCT04977024) to evaluate its safety and immunogenicity, compared to the Pfizer/BioNTech mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy. GEO-CM04S1 is the only COVID-19 vaccine that includes both SARS-CoV-2 spike and nucleocapsid proteins to advance to a Phase 2 trial in cancer patients. Such vaccines tend to produce an immune response quickly &#x2013; in less than 14 days &#x2013; with only mild side effects. The trial is also the first to compare an investigational multi-antigenic COVID-19 vaccine to the current Food and Drug Administration (FDA)-approved mRNA vaccine from Pfizer/BioNTech in people who are immunocompromised. Such patients have often shown a weak antibody response after receiving currently available COVID-19 vaccines.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>GEO-CM04S1 as a Booster Vaccine</b> &#x2013; In December 2021, patient enrollment began for the Phase 2 portion of a Phase 1/2 trial (NCT04639466) of GEO-CM0461, evaluating its use as a universal booster vaccine to current FDA-approved two-shot mRNA vaccines from Pfizer/BioNTech and Moderna. The clinical trial, titled &#x201c;Phase 1/2 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers&#x201d; is being conducted at COH.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GEO-CM04S1 is a synthetic, non-replicating MVA vaccine vector, developed as a double recombinant vectored vaccine to stimulate potent humoral and cellular immune responses against both the S and N proteins of SARS-CoV-2. Upon immunization, the vaccine vector infects cells at the local injection site, leading to the expression of the SARS-CoV-2 antigens that are visible to the immune system. GeoVax believes GEO-CM04S1 will provide additional recognition elements to the immune system over a homologous boost from mRNA vaccines alone, such as those developed by Moderna or Pfizer/BioNTech, which are directed only toward the S protein. The GEO-CM0461 vaccine&#x2019;s MVA backbone may also be more effective at inducing COVID-19 immunity since MVA is known to strongly induce T cell responses even in a background of immunosuppression. In addition, GEO-CM04S1 targeting of both S and N antigens, may offer greater protection and durability against the significant sequence variation observed with the S antigen.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Phase 1 portion of the trial was designed as a dose-escalation safety study in healthy individuals between the ages of 18 to 55, who had not been previously infected with SARS-CoV-2. The primary objectives were to evaluate the safety, tolerability and immunogenicity of the COH04S1 vaccine in healthy volunteers who were administered the vaccine at three different dose levels by intramuscular (IM) injection. Follow-up studies of the volunteers are continuing in order to better assess duration of immune responses. Scientific presentations and publications of the Phase 1 trial results are planned for early 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Phase 2 booster study, for which vaccination is ongoing, will include 60 healthy individuals, 18 years of age and older, who were previously vaccinated with the two-dose regimen of one of the FDA-approved SARS-CoV-2 mRNA vaccines, manufactured by either Pfizer/BioNtech or Moderna. The study is designed as a dose-escalation trial to specifically evaluate the safety profile and immunogenicity of COH04S1 as a booster. The immunological responses measured throughout the study will include the level of SARS-CoV-2 neutralizing antibodies against SARS-CoV-2 variants of concern (VOC), including the newly identified Omicron VOC, as well as specific T-cell responses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>GEO-CM02 as a Pan-Coronavirus Vaccine</b> &#x2013; First-generation SARS-CoV-2 vaccines were rapidly developed and have proven highly efficacious in the human population. These first-generation vaccines were designed to encode the S protein of the SARS-CoV-2 virus with the goal of inducing high levels of neutralizing antibodies. However, potential limitations of narrowly focusing on the S protein are becoming apparent with emerging variants capable of partially escaping neutralization by vaccine induced antibodies, as has been seen with the Omicron variant initially discovered in South Africa but now rapidly spreading globally. Thus, the effectiveness of these vaccines against new SARS-CoV-2 variants and future coronavirus spillover events remains of immense concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Using its novel Modified Virus Ankara - Virus Like Particle (GV-MVA-VLP<sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup>) platform, GeoVax has developed a design strategy for vaccines expected to induce broader immunity through inclusion of multiple, genetically conserved structural and nonstructural proteins from the target pathogen. The GV-MVA-VLP<sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup> platform is known to induce a balanced humoral (antibody) and cellular (T-cells) response against the multiple encoded immunogens, potentially limiting immune escape by emerging variants. Expression of the SARS-CoV-2 spike (S), membrane (M) and envelope (E) proteins by MVA supports the <i>in vivo</i> formation of virus like particles (VLPs), which induce both antibody and T-cell responses. Incorporation of sequence-conserved structural and nonstructural proteins can provide targets for T-cell responses to increase the breadth and function of vaccine-induced immune responses. This strategy provides the basis for generating a universal vaccine with augmented potential to alleviate the burden of disease caused by circulating coronaviruses. Unique compared to other vaccines approved or under development, the GeoVax vaccine candidates are therefore specifically designed to provide a broader and more long-lived level of protective immunity against SARS-CoV-2 which should protect against emerging variants while avoiding the potential side effects that can limit vaccine utility and acceptance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GeoVax&#x2019;s lead vaccine candidate (GEO-CM02) encodes the S protein as the antibody target and the M and E proteins as T-cell targets. The combination of S, M and E protein expression supports <i>in vivo</i> VLP formation and optimal immunogenicity. In small animal studies, the Company measured functional immune responses after a single dose that mediated protection from infection and pathogenesis, including protection against the more virulent Beta variant</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In January 2021, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded the GeoVax a Small Business Innovative Research (SBIR) grant in support of the Company&#x2019;s vaccine development efforts. The Phase 1 grant, titled, &#x201c;<i>Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,</i>&#x201d; is supporting the ongoing design, construction and preclinical testing of our vaccine candidate&#x2019;s evaluation, in preparation for human clinical trials. Scientific presentations and publications of the experimental results were delivered at multiple international vaccine conferences during 2021 and publication is planned for early 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Cancer Immunotherapy Programs</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Gedeptin</b>&#xae;<b> </b>&#x2013; Gedeptin is a novel patented product/technology for the treatment of solid tumors through a gene therapy strategy known as Gene-Directed Enzyme Prodrug Therapy (GDEPT). In September 2021, GeoVax entered into an assignment and license agreement with PNP Therapeutics, Inc. (&#x201c;PNP&#x201d;), granting GeoVax exclusive rights to develop and commercialize Gedeptin. The Gedeptin technology was developed with funding support from the National Cancer Institute (NCI), part of the NIH. GeoVax&#x2019;s license to Gedeptin includes the rights to expand the use of Gedeptin to all human diseases and/or conditions including, but not limited to, other cancers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a very toxic antitumor compound, <i>in situ</i>. A cycle of Gedeptin<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>therapy consists of three intra-tumoral injections of Gedeptin over a two-day period followed by infusion of a prodrug, fludarabine phosphate, once a day for three days. A Phase 1 dose ranging study, evaluating the safety of a single cycle of Gedeptin therapy, found the therapy to be well tolerated, with evidence of a reduction in tumor size in patients with solid tumors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A Phase 1/2 trial (NCT03754933), evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumor(s) accessible for injection and no curable treatment options, is currently enrolling at Stanford University in collaboration with Emory University. The trial design involves repeat administration using Gedeptin followed by systemic fludarabine, as a way to gain additional information prior to expansion towards a larger patient trial. The initial stage of the study is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. The FDA has also granted Gedeptin<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>orphan drug status for the intra-tumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities. In January 2022, we engaged CATO SMS, a global provider of clinical research solutions, to manage the ongoing Phase 1/2 trial, and to assist with the expansion of clinical sites and acceleration of patient enrollment and evaluation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>MUC1-based Immunotherapy</b> &#x2013; Tumors hijack the body&#x2019;s natural immune checkpoints by over expressing immune checkpoint ligands (proteins that bind to and activate the inhibitory activity of immune checkpoints), as a mechanism of immune resistance, especially against the T cells that are specific for tumor antigens and can kill cancer cells. The field of immuno-oncology has received new momentum with the discovery and commercial launch of immune checkpoint inhibitors (ICIs), a type of monoclonal antibodies (Mabs). ICIs block the interaction of immune checkpoints with their ligands on tumor cells, allowing otherwise poorly functional T cells to resume proliferation, cytokine production and killing of tumor cells.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Unlike conventional therapies (e.g. radiation, chemotherapy, antibody, etc.), therapeutic cancer vaccines have the potential to induce responses that not only result in the control and even clearance of tumors but also establish immunological memory that can suppress and prevent tumor recurrence. Convenience, safety, and low toxicity of cancer vaccines could make them invaluable tools to be included in future immunotherapy approaches for treating tumors. Currently, there are only a few vectored cancer vaccines being tested in combination with ICIs, all of which are in early clinical stages.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are developing our GV-MVA-VLP&#x2122; vaccine platform that is based on the abnormal, aberrantly glycosylated forms of the cell surface-associated MUC1 protein that is expressed on a wide range of cancers, including breast, colon, ovarian, prostate, pancreatic, and lung, with the goal of raising therapeutic anti-tumor antibodies and T cell responses in cancer patients. We previously collaborated with Dr. Olivera Finn, a leading expert in cancer immunotherapy at the University of Pittsburgh, who was one of the first to show that many tumors express an abnormal form of MUC1 that is recognized by the immune system as foreign. Our collaboration with Dr. Finn has shown that a combination of our MVA-VLP-MUC1 vaccine candidate with a MUC1 synthetic peptide was capable of breaking tolerance to human MUC1 in transgenic mice and inducing immune responses with efficacy against challenge in a lymphoma tumor model. In 2022 we will further these animal studies in collaboration to define the optimal course and schedule of vaccination to define a protocol that can be evaluated in a Phase 1 clinical trial.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have also collaborated with ViaMune, Inc., which has developed a fully synthetic MUC1 vaccine candidate (MTI), with the goal of developing a MUC1-based vaccine that can produce a broad spectrum of anti-tumor antibody and T cell responses. The resulting MUC1 vaccine could be combined with ICIs as a novel vaccination strategy for cancer patients with advanced MUC1+ tumors. We have produced a MVA-VLP-MUC1 vaccine candidate, demonstrated VLP production by electron microscopy using MUC1 immunogold staining, and showed that the VLPs express a hypo-glycosylated form of MUC1 in human cell lines. Preclinical studies of the combined MTI and MVA-VLP-MUC1 vaccines conducted by Dr. Pinku Mukherjee at the University of North Carolina at Charlotte have shown the combination of our vaccine with MTI and ICI have significantly reduced the tumor burden in a mouse model for colorectal cancer.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our HIV/AIDS Vaccine Programs</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>GOVX-B11 as a Preventive HIV Vaccine. </i></b>&#x2013;GOVX-B11 is designed to protect against the clade B subtype of the HIV virus prevalent in the Americas, Western Europe, Japan and Australia. GOVX-B11 consists of a recombinant DNA vaccine used to prime immune responses and a recombinant MVA vaccine (MVA62B) used to boost the primed responses. Both the DNA and MVA vaccines induce the production of non-infectious VLPs by the cells of the vaccinated person.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Phase 1 and Phase 2a human clinical trials of GOVX-B11 were conducted by the HIV Vaccine Trials Network (HVTN). The HVTN is the largest worldwide clinical trials network dedicated to the development and testing of HIV/AIDS vaccines. Support for the HVTN comes from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). In these trials, totaling approximately 500 participants, GOVX-B11 was tested at various doses and regimens. GOVX-B11 was demonstrated to be safe, well-tolerated and immunogenic, inducing both antibody and cellular immune responses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In January 2017 HVTN began the next human clinical trial (HVTN 114) of GOVX-B11, which enrolled individuals who previously participated in the Phase 2a trial (HVTN 205). HVTN 114 tested the ability of late booster vaccines (additional vaccinations) to increase the antibody responses elicited by the GOVX B11 vaccine regimen. Following completion of HVTN 114, the HVTN began planning an additional Phase 1 trial (HVTN 132) to further assess the safety, tolerability and immunogenicity (elicited antibody responses) of a prime-boost regimen of GOVX-B11, in combination with gp120 booster vaccines. The initiation of HVTN 132 has been delayed due to clinical sites and clinical operations resources being transferred to support COVID-19 vaccine clinical development trials. The Company awaits further information from NIAID and HVTN on when the trial may commence.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>GOVX-B01 for HIV Immunotherapy </i></b>&#x2013; We are participating in a collaborate effort lead by researchers at the University of California, San Francisco (UCSF) to develop a combinational therapy aimed at inducing remission in HIV-positive individuals (a &#x201c;functional cure&#x201d;). The studies are being conducted with funding from amfAR, The Foundation for AIDS Research. The clinical trial is intended to enroll 20 HIV-infected adults who are on stable and effective antiretroviral therapy (ART). The therapeutic regimen involves a combination of vaccines, drugs and biologics. GeoVax is providing its GOVX-B01 vaccine for use in the studies. The primary objectives of the trial are to assess the safety and tolerability of the combinational therapy and to determine the viral load &#x201c;set-point&#x201d; during ART interruption. Secondary objectives will be to assess immune responses and changes in viral reservoir status. Patient enrollment for the clinical trial commenced in August 2020 but, similar to HVTN 132, this trial has been affected by the COVID-19 pandemic, and we await further information regarding the status of patient enrollment and trial results.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Hemorrhagic Fever Virus Vaccines (Ebola, Sudan, Marburg and Lassa) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Ebola (EBOV, formerly designated as Zaire ebolavirus), Sudan (SUDV), and Marburg viruses (MARV) are the most virulent species of the <i>Filoviridae</i> family, causing hemorrhagic fever illnesses with up to a 90% fatality rate in humans. Lassa fever virus (LASV), a member of the <i>Arenaviridae</i> family, also causes severe and often fatal hemorrhagic illnesses in an overlapping region with Ebola. In December 2019, FDA approved the first live recombinant Ebola vaccine for prevention of Ebola disease by Zaire virus. This rVSV-ZEBOV showed safety concerns in Phase 1 trials and by virtue of being replication competent could pose threats to immunocompromised individuals, such as those infected with HIV living in West Africa where recent Ebola epidemics started.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To address the unmet need for a product that can respond to future hemorrhagic fever outbreaks, we are developing vaccines utilizing our GV-MVA-VLP&#x2122; platform. The MVA vector itself is considered safe, having originally been developed for use in immunocompromised individuals as a smallpox vaccine. We expect our vaccines may not only protect at-risk individuals against EBOV, SUDV, MARV and LASV, but also potentially reduce or modify the severity of other re-emerging pathogens such as Bundibugyo, Ivory Coast, and Reston viruses, based on antigenic cross reactivity and the elicitation of T cells to the more conserved matrix proteins (e.g. VP40 or Z) in addition to standard GP proteins used by us and other manufacturers. Thus, the GeoVax GV-MVA-VLP&#x2122; approach could offer a unique combination of advantages to achieve breadth and safety of a pan-filo vaccine. In addition to protecting people in Africa, it is intended to prevent the spread of disease to the US, and for preparedness against terrorist release of any of bio-threat pathogens.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our initial preclinical studies in rodents and nonhuman primates for our MVA-VLP-EBOV vaccine candidate have shown 100% protection against a lethal dose of EBOV upon a single immunization. Recent studies in lethal challenge guinea pig models demonstrated that GeoVax vaccines MVA-VLP-SUDV and MVA-VLP-MARV conferred 100% protection from death. These vaccines were subsequently evaluated in a rigorous cynomolgus macaque infectious challenge model. Vaccination protected nonhuman primates from viremia, weight loss and death following challenge with a dose of Sudan or Marburg virus that is lethal in nonvaccinated animals. Evaluation of immune responses following vaccination demonstrated presence of both neutralizing antibodies and functional T cells, indicating a breadth of responses that combine for optimal protection. Likewise, our initial preclinical studies in rodents for our LASV vaccine candidate have shown 100% single-dose protection against a lethal dose of LASV challenge composed of multiple strains delivered directly into the brain. The nonhuman primate studies are ongoing in collaboration with NIAID and DoD and clinical development programs will be defined based on efficacy data and global priorities as potentially dangerous outbreaks occur.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Other Infectious Disease Programs</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>GEO-ZM02 for Zika</b> &#x2013; Zika disease is an emerging infectious disease caused by the Zika virus (ZIKV) and has been linked to an increase in microcephaly in infants and Guillain-Barre syndrome (a neurodegenerative disease) in adults. ZIKV is a member of the <i>Flaviviridae</i> family, which includes medically important pathogens such as dengue fever, yellow fever, Japanese encephalitis, tick-borne encephalitis, and West Nile viruses. Public health officials recommend avoiding exposure to ZIKV, delaying pregnancy, and following basic supportive care (fluids, rest, and acetaminophen) after infection.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To address the unmet need for a ZIKV vaccine, we are developing novel vaccine candidates constructed using our GV-MVA-VLP platform. MVA has an outstanding safety record, which is particularly important given the need to include women of child-bearing age and newborns among those being vaccinated. Our Zika vaccine is designed based on the NS1 gene product to eliminate the risk of Antibody Dependent Enhancement (ADE), which is a serious side effect observed when a vaccinated individual doesn&#x2019;t have a fully protective immune response which actually causes a more virulent reaction if infected.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our initial preclinical studies in rodents using our GEO-ZM02 vaccine candidate demonstrated 100% single-dose protection against a lethal dose of ZIKV delivered directly into the brain. In rhesus macaques, vaccination with GEO-ZM02 induced immune responses that effectively controlled the virus replication despite the fact the vaccine is not designed to induce ZIKV neutralizing antibodies. Further development of our ZIKV vaccine will be dependent upon partnering support.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>GEO-MM02 for Malaria</b> &#x2013; Globally, malaria causes 228 million infections and 405,000 deaths annually. Despite decades of vaccine research, vaccine candidates have failed to induce substantial protection (e.g. &gt;50%). Most of these vaccines are based on individual proteins that induce immune responses targeting only one stage of the malaria parasite&#x2019;s life cycle. GeoVax&#x2019;s MVA-VLP malaria vaccine candidates incorporate antigens derived from multiple stages of the parasite&#x2019;s life cycle and are designed to induce an immune response with durable functional antibodies and CD4+ and CD8+ T cell responses, all hallmarks of an ideal vaccine-induced immune response.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have collaborated with the Burnet Institute, a leading infectious diseases research institute in Australia, for the development of a vaccine to prevent malaria infection. The project included the design, construction, and characterization of multiple malaria vaccine candidates using GeoVax&#x2019;s GV-MVA-VLP&#x2122; vaccine platform combined with malaria <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> sequences identified by the Burnet Institute. The vaccine design, construction, and characterization were performed at GeoVax with immunogenicity and challenge studies in animal models conducted at Burnet Institute using their unique functional assays. This program is currently inactive, pending additional funding support via federal grants or other sources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our GV-MVA-VLP</b>&#x2122;<b> Platform</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GeoVax&#x2019;s GV-MVA-VLP&#x2122; vaccine platform utilizes Modified Vaccinia Ankara (MVA), a large virus capable of carrying several vaccine antigens, that expresses proteins that assemble into virus-like particles (VLP) immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic the virus production that occurs in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Vaccines typically contain agents (antigens) that resemble disease-causing microorganisms. Traditional vaccines are often made from weakened or killed forms of the virus or from its surface proteins. Some newer vaccines use recombinant DNA (deoxyribonucleic acid) technology to generate vaccine antigens in bacteria or cultured cells from specific portions of the DNA sequence of the target pathogen. The generated antigens are then purified and formulated for use in a vaccine. We believe the most successful of these purified antigens have been non-infectious virus-like particles (VLPs) as exemplified by vaccines for hepatitis B (Merck&#x2019;s Recombivax&#xae; and GSK&#x2019;s Engerix&#xae;) and Papilloma viruses (GSK&#x2019;s Cervarix&#xae;, and Merck&#x2019;s Gardasil&#xae;). Our approach uses recombinant DNA and/or recombinant MVA to produce VLPs in the person being vaccinated (in vivo) reducing complexity and costs of manufacturing. In human clinical trials of our HIV vaccines, we believe we have demonstrated that our VLPs, expressed from within the cells of the person being vaccinated, can be safe, yet elicit both strong and durable humoral and cellular immune response.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">VLPs mimic authentic viruses in form but are not infectious or capable of replicating and can cause the body&#x2019;s immune system to recognize and kill targeted viruses to prevent an infection. VLPs can also train the immune system to recognize and kill virus-infected cells to control infection and reduce the length and severity of disease. One of the biggest challenges with VLP-based vaccines is to design the vaccines in such a way that the VLPs will be recognized by the immune system in the same way as the authentic virus would be. We design our vaccines such that, when VLPs for enveloped viruses like HIV, Ebola, Marburg or Lassa fever are produced <i>in vivo</i> (in the cells of the recipient), they include not only the protein antigens, but also an envelope consisting of membranes from the vaccinated individual&#x2019;s cells. In this way, they are highly similar to the virus generated in a person&#x2019;s body during a natural infection. VLPs produced <i>in vitro</i> (in a pharmaceutical plant), by contrast, have no envelope; or, envelopes from the cultured cells (typically hamster or insect cells) used to produce them. We believe our technology therefore provides distinct advantages by producing VLPs that more closely resemble the authentic viruses. We believe this feature of our immunogens allows the body&#x2019;s immune system to more readily recognize the virus. By producing VLPs <i>in vivo</i>, we believe we also avoid potential purification issues associated with <i>in vitro</i> production of VLPs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Figure 1 below shows examples of thin section electron micrographs of actual viruses and VLPs for these viruses expressed by GeoVax MVA-VLP vaccines.</p>
  <p style="text-align:justify;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="govx20220202_s1img002.gif" src="govx20220202_s1img002.gif" style="width:644;height:340;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Figure 1. Comparison of MVA-VLPs and native virus structures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the MVA-VLP platform, we take advantage of MVA&#x2019;s large &#x201c;coding capacity&#x201d; to insert genes that encode multiple proteins, the combination of which is adequate to support the generation of VLPs by the MVA infected cells. Utility has been demonstrated for multiple vaccine candidates wherein the MVA-encoded viral matrix proteins and glycoproteins assemble into VLPs. MVA was originally developed as a safer smallpox vaccine for use in immune-compromised individuals. It was developed by attenuating the standard smallpox vaccine by passaging it (over 500 passages) in chicken embryos or chicken embryo fibroblasts, resulting in a virus with limited ability to replicate in human cells (thus safe) but with high replication capability in avian cells (thus cost effective for manufacturing). The deletions also resulted in the loss of immune evasion genes which assist the spread of wild type smallpox infections, even in the presence of human immune responses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We collaborated with the laboratory of Dr. Bernard Moss at NIH/NIAID on four different generations of MVA vectors, spanning over 15 years of collaboration, to effectively express vaccine proteins that assemble into VLPs. These efforts led to the development of different shuttle vectors and the identification of multiple insertion sites for introducing foreign genes encoding the vaccine target proteins into MVA in a manner that optimizes each product for manufacturing stability. Each MVA-VLP vaccine has up to two expression cassettes, each encoding one or more antigens selected from pathogens of interest. At a minimum, each vaccine expresses two antigens required for VLP formation; in the case of HIV and hemorrhagic fever vaccines for example, a viral matrix protein and an envelope glycoprotein. We use a synthetic early late promoter that provides high, yet not lethal, levels of insert expression, which is initiated immediately after infection in cells of the vaccinated individual.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our GV-MVA-VLP&#x2122; vaccine platform affords other advantages:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Safety:</i></b><b>&#xa0;</b>Our HIV vaccines have demonstrated outstanding safety in multiple human clinical trials. Safety for MVA, generally, has been shown in more than 120,000 subjects in Europe, including immunocompromised individuals during the initial development of MVA and more recently with the development of MVA as a safer vaccine against smallpox.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Durability:</i></b><b>&#xa0;</b>Our technology raises highly durable (long-lasting) vaccine responses, the most durable in the field of vectored HIV vaccines. We hypothesize that elicitation of durable vaccine responses is conferred on responding B cells by the vaccinia parent of MVA, which raises highly durable responses for smallpox.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Limited pre-existing immunity to vector</i></b><b>: </b>Following the eradication of smallpox in 1980, smallpox vaccinations subsequently ended, leaving all but those born before 1980 and selected populations (such as vaccinated laboratory workers and first responders) unvaccinated and without pre-existing immunity to MVA-derived vaccines. A potential interference of pre-existing immunity to a vector may be more problematic with those vectors related to parent viruses used in routine vaccinations (e.g. measles) or constitute common viruses that infect people of all ages (e.g. cytomegalovirus).</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Repeated use of the platform for different vaccines used in sequence</i></b><i>. </i>In mouse experiments, we have shown that two of our vaccines (e.g. GV-MVA-VLP-Zika followed by GV-MVA-VLP-Ebola) can be given at <span style="text-decoration: underline; ">&lt;</span>4 week intervals without any negative impact on their immunogenicity (lack of vector immunity).</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>No need for adjuvants:</i></b><b>&#xa0;</b>MVA generally stimulates strong innate immune responses and does not require the use of adjuvants.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Thermal stability:</i></b><b>&#xa0;</b>MVA is stable in both liquid and lyophilized formats (&gt; 6 years of storage).</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Genetic stability and manufacturability:</i></b><b>&#xa0;</b>If appropriately engineered, MVA is genetically stable and can reliably be manufactured in either the established Chick Embryo Fibroblast cell substrate, or novel continuous cell lines that support scalability as well as greater process consistency and efficiency.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Licenses and Collaboration Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">From time to time, we may enter into research collaborations, licensing and/or commercialization agreements when they align with our mission, some of which we may consider to be part of our ordinary course of business and not material for full disclosure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>City of Hope License Agreement</b> &#x2013; On November 9, 2021, we entered into an Exclusive License Agreement (COH License) with City of Hope (COH), a California nonprofit public benefit corporation, under which the Company obtained exclusive worldwide rights to further develop and commercialize COH04S1, a multi-antigenic SARS-CoV-2 vaccine currently undergoing Phase 2 human clinical trials. The COH License grants GeoVax exclusive rights to key patents, know-how, regulatory filings and clinical materials for use against COVID-19. The terms of the COH License, include an upfront fee consisting of an initial payment to COH of $5,000,000 within 30 days of the effective date of the COH License, and additional payments of $3,000,000 and $2,000,000 on the first and second anniversaries, respectively, of the effective date of the COH License. The terms also include milestone payments due upon the achievement of selected development, regulatory and sales events. The Company will also pay COH an annual royalty on net sales of products covered by the patents licensed from COH on a country-by-country and licensed product-by-licensed product basis, subject to specified reductions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Gedeptin License</b> &#x2013; On September 28, 2021, we entered into an Assignment and License Agreement (the &#x201c;Gedeptin License&#x201d;) with PNP Therapeutics, Inc. (&#x201c;PNP&#x201d;) under which the Company obtained exclusive worldwide rights to key intellectual property, including Gedeptin patents, know-how, regulatory filings, clinical materials, and trademarks. The Gedeptin patent portfolio was originally licensed from the University of Alabama at Birmingham (&#x201c;UAB&#x201d;) and Southern Research Institute (&#x201c;SRI&#x201d;) by PNP. Under the terms of the Gedeptin License, the Company is the successor to PNP under the Exclusive License Agreement between UAB, SRI and PNP, and has acquired the exclusive rights to develop and commercialize Gedeptin, a novel patented product for the treatment of solid tumors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The terms of the Gedeptin License, include (i) an upfront payment at closing, (ii) milestone payments due upon the achievement of selected development and regulatory events, and (iii) quarterly support payments for the lesser period of three years or the Company&#x2019;s filing for FDA approval of its Biologics License Application on the use of Gedeptin for the treatment of head and neck cancer in humans. The Company will also pay tiered percentage annual royalties in the low-to-mid teens on Net Sales (as defined in the Gedeptin License) of products covered under the Gedeptin License on a country-by-country and product-by-product basis, subject to specified reductions. The Company also issued a warrant to PNP, exercisable at any time following March 28, 2022, and prior to September 28, 2026, for up to 100,000 shares of the Company&#x2019;s common stock at an exercise price of $13.00 per share. The Gedeptin License will remain in effect during the original term, which concludes upon FDA approval of a generic or biosimilar product, and then will automatically renew for 5-year additional terms, subject to customary termination rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>NIH Licenses </b>&#x2013;<b> </b>On November 25, 2020, the Company entered into a Patent and Biological Materials License Agreement for Internal Research Use (the &#x201c;Research License&#x201d;) with the U.S. Department of Health and Human Services (HHS), as represented by NIAID, in support of the Company&#x2019;s non-clinical development of vaccines against numerous pathogens. The Research License allows GeoVax to use these materials and patent rights owned by agencies of the HHS in combination with the Company&#x2019;s proprietary technology for the creation of preventive and/or therapeutic Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccines against Ebola-Zaire virus, Ebola-Sudan virus, Lassa virus, Marburg virus, Zika virus and malaria. The agreement also extends to the Company&#x2019;s research and development efforts in certain oncology areas. The agreement provides GeoVax with nonexclusive rights for the nonclinical development and manufacturing of its vaccine and immunotherapy candidates using HHS patents and materials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On October 22, 2020, the Company entered into a Patent and Biological Materials License Agreement (the &#x201c;COVID License&#x201d;) with HHS, as represented by NIAID, in support of the Company&#x2019;s development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The COVID License allows GeoVax to use these materials and patent rights owned by agencies of the HHS in combination with the Company&#x2019;s proprietary technology for the creation of a preventive Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccine that primes and/or boosts the immune system against COVID-19. The COVID License provides GeoVax with nonexclusive rights to develop, manufacture and commercialize its COVID-19 vaccine and includes access to NIAID&#x2019;s patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Support from the United States Government</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Grants and Contracts.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have been the recipient of multiple federal grants and contracts in support of our vaccine development programs. Our most recent awards are as follows:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Lassa DoD Grant. In September 2018, the U.S. Department of Defense (DoD) awarded us a $2,442,307 cooperative agreement in support of our LASV vaccine development program. The grant was awarded by the U.S. Army Medical Research Acquisition Activity pursuant to the Peer Reviewed Medical Research Program (PRMRP), part of the Congressionally Directed Medical Research Programs (CDMRP). In addition to the grant funds provided directly to GeoVax, DoD also funded testing of our vaccine by U.S. Army scientists under a separate subaward. The award, entitled &#x201c;<i>Advanced Preclinical Development and Production of Master Seed Virus of GEO-LM01, a Novel MVA-VLP Vaccine Against Lassa Fev</i>er&#x201d;, supports generation of immunogenicity and efficacy data for our vaccine candidate in both rodent and nonhuman primate models, as well as manufacturing process development and cGMP production of vaccine seed stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">COVID-19 SBIR Grant. In January 2021, NIAID awarded us a $299,927 Phase I SBIR grant in support of our development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The grant, titled, &#x201c;<i>Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,</i>&#x201d; has supported the ongoing design, construction and preclinical testing of our vaccine candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Federal Support</i>.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have been the recipient of additional in-kind federal support through collaborative and intramural arrangements with CDC for our Zika vaccine program, the Rocky Mountain Laboratory facility of NIAID for our hemorrhagic fever virus vaccine program, and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for our hemorrhagic fever virus vaccine program. This support generally has been for the conduct or support of preclinical animal studies on our behalf. All our human clinical trials for our preventive HIV vaccines have been conducted by the HVTN and funded by NIAID. This financial support has been provided by NIAID directly to the HVTN.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Government Regulation</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Regulation by governmental authorities in the United States and other countries is a significant factor in our ongoing research and development activities and in the manufacture of our products. Complying with these regulations involves considerable expertise, time and expense.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the United States, drugs and biologics are subject to rigorous federal and state regulation. Our products are regulated under the Federal Food, Drug and Cosmetic Act (FD&amp;C Act), the Public Health Service Act, and the regulations promulgated under these statutes, and other federal and state statutes and regulations. These laws govern, among other things, the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of medications and medical devices. Product development and approval within this regulatory framework is difficult to predict, takes several years and involves great expense. The steps required before a human vaccine may be marketed in the United States include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Preclinical laboratory tests, in vivo preclinical studies and formulation studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Manufacturing and testing of the product under strict compliance with current Good Manufacturing Practice (cGMP) regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Submission to the FDA of an Investigational New Drug application for human clinical testing which must become effective before human clinical trials can commence;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Adequate and well-controlled human clinical trials to establish the safety and efficacy of the product;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The submission of a Biologics License Application to the FDA, along with the required user fees; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDA approval of the BLA prior to any commercial sale or shipment of the product</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Before marketing any drug or biologic for human use in the United States, the product sponsor must obtain FDA approval. In addition, each manufacturing establishment must be registered with the FDA and must pass a pre-approval inspection before introducing any new drug or biologic into commercial distribution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Emergency Use Authorization (EUA) authority granted to the FDA allows the FDA to help strengthen the nation&#x2019;s public health protections against certain threats by facilitating the availability and use of medical countermeasures needed during public health emergencies. Under section 564 of the FD&amp;C Act, the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by threat agents when there are no adequate, approved, and available alternatives. This potentially may provide a faster pathway to market for our COVID-19 or other infectious disease vaccine candidates. This was the approval pathway followed by Pfizer-BioNTech and Moderna for their respective COVID-19 vaccines.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Because GeoVax does not manufacture vaccines for human use within our own facilities, we must ensure compliance both in our own operations and in the outsourced manufacturing operations. All FDA-regulated manufacturing establishments (both domestic establishments and foreign establishments that export products to the United States) are subject to inspections by the FDA and must comply with the FDA&#x2019;s cGMP regulations for products, drugs and devices.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The FDA determines compliance with applicable statutes and regulations through documentation review, investigations, and inspections. Several enforcement mechanisms are available to the FDA, ranging from a simple demand to correct a minor deficiency to mandatory recalls, closure of facilities, and even criminal charges for the most serious violations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Even if FDA regulatory clearances are obtained, a marketed product is subject to continual review, and later discovery of previously unknown problems or failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Whether or not the FDA has approved the drug, approval of a product by regulatory authorities in foreign countries must be obtained prior to the commencement of commercial sales of the drug in such countries. The requirements governing the conduct of clinical trials and drug approvals vary widely from country to country, and the time required for approval may be longer or shorter than that required for FDA approval.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We also are subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances used in connection with our research. The extent of government regulation that might result from any future legislation or administrative action cannot be accurately predicted.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>FDA Tropical Disease Priority Review Voucher Program</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Section 524 of the FD&amp;C Act authorizes the FDA to award priority review vouchers (PRVs) to sponsors of approved tropical disease product applications that meet certain criteria. To qualify for a PRV, a sponsor&#x2019;s application must be for a drug or biological product for the prevention or treatment of a &#x201c;tropical disease,&#x201d; must otherwise qualify for priority review, and must contain no active ingredient (including any salt or ester of an active ingredient) that has been approved in any other application under Section 505(b)(1) of the FD&amp;C Act or section 351 of the Public Health Services Act. Priority review means that the FDA aims to render a decision in 6 months.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The PRV may be sold. For example, a small company might win a voucher for developing a drug for a neglected disease and sell the voucher to a large company for use on a commercial disease. The price of the voucher depends on supply and demand. The voucher&#x2019;s value derives from three factors: shifting sales earlier, longer effective patent life due to earlier entry, and competitive benefits from earlier entry relative to competitors. Top-selling treatments can yield billions in sales each year, so being approved months earlier can be worth hundreds of millions of dollars to the voucher. Since the first voucher sale in 2014, the price of the vouchers has ranged from $68 million to $350 million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GeoVax believes that its vaccine programs in Ebola, Sudan, Marburg, Lassa Fever, Malaria and Zika may each be eligible for a PRV and we intend to apply for a PRV at the appropriate time. There can be no assurance, however, that we will qualify or be approved for a PRV.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Manufacturing</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To be successful, our products must be manufactured in commercial quantities in compliance with regulatory requirements and at an acceptable cost. To date, we have not commercialized any products, nor have we demonstrated that we can manufacture commercial quantities of our product candidates in accordance with regulatory requirements. If we cannot manufacture products in suitable quantities and in accordance with regulatory standards, either on our own or through contracts with third parties, it may delay clinical trials, regulatory approvals and marketing efforts for such products. Such delays could adversely affect our competitive position and our chances of achieving profitability. We cannot be sure that we can manufacture, either on our own or through contracts with third parties, such products at a cost or in quantities that are commercially viable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We do not currently have the facilities or internal expertise to manufacture any of the clinical or commercial supplies of any of our product. Rather, our strategy is to rely on third-party contract manufacturers to produce vaccines needed for research and clinical trials. We have arrangements with third party manufacturers for the supply of our DNA and MVA vaccines for use in our planned clinical trials. These suppliers operate under the FDA&#x2019;s Good Manufacturing Practices and (in the case of European manufacturers) similar regulations of the European Medicines Agency. We anticipate that these suppliers will be able to provide sufficient vaccine supplies to complete our currently planned clinical trials. Various contractors are generally available in the United States and Europe for manufacture of vaccines for clinical trial evaluation, however, it may be difficult to replace existing contractors for certain manufacturing and testing activities and costs for contracted services may increase substantially if we switch to other contractors. Furthermore, there is currently a shortage of vaccine manufacturing capability due to demand for potential COVID-19 vaccines, which could affect our ability to have our vaccine candidates manufactured.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The MVA component of our vaccine is currently manufactured in cells that are cultured from embryonated eggs. We are exploring a number of approaches to growing MVA in continuous cell lines that can be grown in bioreactors more suitable for commercial-scale manufacturing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The raw materials and other supplies that are used in the production process for our vaccines and that we use in our research activities are generally available from a number of commercial suppliers and we believe we will be able to obtain sufficient quantities of such materials and supplies for all foreseeable clinical investigations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Competition</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our product candidates face, and will continue to face, intense competition from large pharmaceutical companies, specialty pharmaceutical and biotechnology companies as well as academic and research institutions. We compete in an industry that is characterized by rapid technological change; evolving industry standards; emerging competition; and new product introductions. Competitors have existing products and technologies that will compete with our pipeline candidates and technologies and may develop and commercialize additional products and technologies that will compete with our pipeline candidates and technologies. Because competing companies and institutions may have greater financial resources than us, they may be able to provide broader services and product lines; and make greater investments in research and development. Competitors may also have greater development capabilities than we do and have substantially greater experience in undertaking nonclinical and clinical testing of products, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products. They may also have greater name recognition and better access to customers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We face general market competition from several subsectors of the vaccine development field, including large, multinational pharmaceutical companies including Sanofi, GSK, Merck, Janssen, Mitsubishi Tanabe, Takeda, and Pfizer, Inc.; mid-size pharmaceutical companies and emerging biotechnology companies including Dynavax, Novavax Inc., Moderna, BioNTech, and Hookipa; and academic and not-for-profit vaccine researchers and developers including the NIH. The industry is typified by extensive collaboration, licensing, and merger and acquisition activity despite the intense competition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">More than twenty COVID-19 vaccines are currently authorized for use in one or more countries around the world, including three in the United States (from Pfizer/BioNTech, Moderna, and Janssen). All these vaccines are based on the S protein of the SARS-CoV-2 virus, but rely on different mechanisms for presentation or expression of the S antigen, including whole, inactivated virus, defective adenovirus vectors (three different types) or mRNA. Key companies in the space with late-stage clinical or pre-approval vaccine candidates include, Novavax, Inc., AstraZeneca PLC, CureVac N.V., Medicago Inc., GSK, Sanofi S.A., Dynavax, and Valneva SE.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A number of companies are developing various types of therapeutic vaccines or other immunotherapy approaches to treat cancer including Advaxis, Immune Design, Oncothyreon, Bavarian Nordic, Roche Pharmaceuticals, Merck &amp; Co, Bristol Myers Squibb, and AstraZeneca plc.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There are currently no FDA licensed and commercialized HIV vaccines, Zika vaccines, or hemorrhagic fever virus vaccines (other than for Ebola) available in the world market. We are aware of several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are actively engaged in vaccine research and development in these areas. For hemorrhagic fever viruses, these include NewLink Genetics and Merck, Johnson &amp; Johnson, Novavax, Inovio and GlaxoSmithKline. For HIV, these include Sanofi, GlaxoSmithKline, and Johnson &amp; Johnson. Other HIV vaccines are in varying stages of research, testing and clinical trials including those supported by the NIH Vaccine Research Center, the U.S. Military, IAVI, the European Vaccine Initiative, and the South African AIDS Vaccine Initiative. For Zika, these include NewLink Genetics, Inovio, Merck, Butantan Institute and NIH (NIAID). In December 2019, the FDA approved the first vaccine (ERVEBO&#xae;) for prevention of Ebola, developed by Merck.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There are numerous FDA-approved treatments for HIV, primarily antiretroviral therapies, marketed by large pharmaceutical companies. Currently, there are no approved therapies for the eradication of HIV. We expect that major pharmaceutical companies that currently market antiretroviral therapy products or other companies that are developing HIV product candidates may seek to develop products for the eradication of HIV.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There are currently no commercialized vaccines to prevent malaria infection. A first-generation infection-blocking malaria vaccine, RTS, S, is under regulatory review. It requires 4 doses and has been recommended by the WHO for pilot implementation studies. Since this vaccine is based on a single antigen and has modest efficacy (30-40%, depending on the age of subjects), the WHO has defined a Road Map for developing and licensing of next generation malaria vaccines. These vaccines are expected to contain multiple antigens designed to block both infection and transmission of malaria with at least a 75% efficacy rate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our vaccines, including our Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) based vaccines, and methods of treatment using our vaccines.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We seek patent protection on each of our product and developmental candidates and, where applicable, on combinations with other therapeutic and/or antigenic agents and dosing schedules. Our success also depends on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. patent applications and, where appropriate, foreign patent applications covering our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. Additionally, we expect to benefit, where appropriate, from statutory frameworks in the United States, Europe, and other countries that provide a period of clinical data exclusivity to compensate for the time required for regulatory approval of our vaccine candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We continually assess and refine our intellectual property strategies as we develop new technologies and product candidates. We plan to file additional patent applications based on our intellectual property strategies where appropriate, including where we seek to improve our basic technology, adapt to competition, or to improve business opportunities. Further, we plan to file patent applications, as we consider appropriate under the circumstances, to protect new technologies that we develop. Our patent filing strategy typically includes seeking patent protection in the United States and, wherein appropriate, in additional countries where we believe such protection is likely to be useful.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2020, our owned and in-licensed patent estate, on a worldwide basis, includes 14 granted U.S. patents, 16 pending U.S. patent applications; 43 granted foreign patents, 13 pending foreign patent applications, and 1 Patent Cooperation Treaty (PCT) application spread over 19 patent families. The term of individual patents depends upon the laws of the countries in which they are obtained. In the countries in which we currently file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application which serves as a priority application. In addition, we plan to seek patent term adjustments, restorations, and/or patent term extensions where applicable in the United States and other jurisdictions. For example, depending upon the timing, duration, and specifics of FDA approval of our vaccine products, some of our U.S. patents may be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the &#x201c;Hatch-Waxman Amendments,&#x201d; and codified as 35 U.S.C. &#xa7; 156. 35 U.S.C. &#xa7; 156 permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally one half the time between the effective date of an IND and the submission date of a Biologics License Application (BLA), plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved vaccine product is eligible for such an extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. A similar kind of patent extension, referred to as a Supplementary Protection Certificate, is available in Europe. Legal frameworks are also available in certain other jurisdictions to extend the term of a patent. We currently intend to seek patent term extensions on any of our, or our exclusively licensed, issued patents in any jurisdiction where we have a qualifying patent and the extension is available; however, there is no guarantee that the applicable regulatory authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. Further, even if our patent is extended, the patent, including the extended portion of the patent, may be held invalid or unenforceable by a court of final jurisdiction in the United States or a foreign country.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our current patent portfolio includes 5 patent families directed to various aspects of our DNA and MVA-based HIV vaccines, their genetic inserts expressing multiple HIV protein components, composition, structure, claim of immunization against multiple subtypes of HIV, routes of administration, safety and other related factors and methods of therapeutic and prophylactic use thereof including administration regimes. We have in-licensed patents from Emory University and the U.S. National Institutes of Health (NIH) relevant to our HIV-vaccine program. These patents will expire between 2022 and 2028, exclusive of any patent term adjustments or extensions. We wholly own one patent family directed to specific vaccine administration methods which, if issued, valid, and enforceable, will expire in 2037, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We wholly own one U.S. patent application directed to preventive vaccines against hemorrhagic fever viruses (Ebola, Sudan, Marburg and Lassa), and uses thereof. This application, if issued, valid, and enforceable, will expire in 2036, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We wholly own one U.S. patent application directed to preventive vaccines against Zika virus, and uses thereof. This application, if issued, valid, and enforceable, will expire in 2037, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We co-own one patent family with Georgia State University directed to preventive vaccines against human papilloma virus (HPV), and uses thereof. These applications, if issued, valid, and enforceable, will expire in 2037, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We wholly own one U.S. patent application directed to preventive vaccines against malaria, and use thereof. This application, if issued, valid, and enforceable, will expire in 2038, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We wholly own 3 patent families directed to our immuno-oncology vaccine compositions and methods of use thereof. The patent applications of these families, if issued, valid, and enforceable, will expire between 2037-2040, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have a pending U.S. application directed to our virus-like particle (VLP) platform technology. This patent application, if issued, valid, and enforceable, will expire in 2037, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We wholly own one pending patent family directed to various MVA-based vaccines for the treatment of SARS CoV-2. The patent applications in this family, if issued, valid, and enforceable, will expire in 2041, exclusive of any patent term adjustments or extensions. We have non-exclusively in-licensed from the U.S. National Institutes of Health (NIH) 3 patent families directed to certain aspects of our MVA-viral backbone used in our SARS-CoV2 vaccine, which will expire between 2023 and 2032, exclusive of any patent term adjustments or extensions. We have non-exclusively in-licensed from the NIH 2 patent families relating to coronavirus spike protein compositions relevant to our MVA SARS-CoV2 vaccine candidates. The patent applications for these families, if issued, valid, and enforceable, will expire between 2037 and 2041, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are the exclusive, worldwide licensee of several patents and patent applications, which we refer to as the Emory Technology, owned, licensed or otherwise controlled by Emory University for HIV or smallpox vaccines pursuant to a license agreement originally entered into on August 23, 2002 and restated on June 23, 2004 (the &#x201c;Emory License&#x201d;). The in-licensed Emory University patents will expire between 2022 and 2028, exclusive of any patent term extensions. Through the Emory License we are also a non-exclusive licensee of four issued United States patents owned by the NIH related to the ability of our MVA vector vaccine to operate as a vehicle to deliver HIV virus antigens, and to induce an immune response in humans. These in-licensed NIH patents will expire in 2023, exclusive of any patent term extensions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The MVA backbone that we have been using in our vaccines was provided to us by the laboratory of Dr. Bernard Moss of the NIAID, Laboratory of Viral Diseases (LVD). We have a non-exclusive commercial license to the NIH MVA backbone for our SARS CoV-2 vaccine with the NIAID of the National Institutes of Health NIH on behalf of the United States, which includes the use of certain patents and patent applications arising from the Moss laboratory and the provided materials. We also have a non-exclusive research and development license to use the MVA backbone for our other vaccine candidates. If we later decide to commercialize vaccine candidates that are under the research and development license, we will need to negotiate appropriate commercialization licenses. These in-licensed NIH patents and patent applications, if and where issued, valid, and enforceable, will expire between 2023 and 2032, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We cannot be certain that any of the current pending patent applications we have or have licensed, or any new patent applications we may file or license, will ever be issued in the United States or any other country. Even if issued, there can be no assurance that those patents will be sufficiently broad to prevent others from using our products or processes. Furthermore, our patents, as well as those we have licensed or may license in the future, may be held invalid or unenforceable by a court, or third parties could obtain patents that we would need to either license or to design around, which we may be unable to do. Current and future competitors may have licensed or filed patent applications or received patents and may acquire additional patents or proprietary rights relating to products or processes competitive to ours. In addition, any claims relating to the infringement of third-party proprietary rights, or earlier date of invention, even if not meritorious, could result in costly litigation, lengthy governmental proceedings, divert management&#x2019;s attention and resources and require us to enter royalty or license agreements which are not advantageous to us, if available at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We also expect to benefit, where appropriate, from statutory frameworks in the United States, Europe, and other countries that provide a period of regulatory exclusivity to compensate for the time and cost required in securing regulatory approval of our vaccine products. For example, in 2010, the United States enacted the Biologics Price Competition and Innovation Act (BPCIA). Under the BPCIA, innovator manufacturers of vaccine products may be granted 12 years of exclusive use before biosimilar versions of such products can be licensed for marketing in the U.S. This means that the FDA may not approve an application for a biosimilar version of our vaccine product until 12 years after the date our vaccine product is approved for sale (with a potential six-month extension of exclusivity if certain pediatric studies are conducted and the results accepted by the FDA), although a biosimilar application may be submitted four years after the date we receive approval from the FDA to sell our vaccine product. Additionally, the BPCIA establishes procedures by which potentially relevant patents may be shared and litigation over patents may proceed in advance of approval. The BPCIA also provides incentives to biosimilar applicants by providing a period of exclusivity to the first biosimilar of a product approved by the FDA. The 12-year data exclusivity provision of the BPCIA does not prevent a competitor from seeking marketing approval of one of our vaccine products, or a product similar thereto, by submitting its own, original Biologics License Application (BLA).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We intend to benefit, where applicable, from additional market exclusivity provisions in various jurisdictions that reward the treatments of rare diseases. For example, in the United States under the Orphan Drug Act of 1983, the FDA may grant orphan designation to a vaccine product intended to prevent or treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication; in the latter case, because health care professionals are free to prescribe products for off-label uses, the competitor&#x2019;s product could be used for the orphan indication despite our orphan exclusivity.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are not a party to any litigation, opposition, interference, or other potentially adverse proceeding with regard to our patent positions. However, if we become involved in litigation, interference proceedings, oppositions or other intellectual property proceedings, for example as a result of an alleged infringement or a third-party alleging an earlier date of invention, we may have to spend significant amounts of money and time and, in the event of an adverse ruling, we could be subject to liability for damages, invalidation of our intellectual property and injunctive relief that could prevent us from using technologies or developing products, any of which could have a significant adverse effect on our business, financial conditions or results of operations. In addition, any claims relating to the infringement of third-party proprietary rights, or earlier date of invention, even if not meritorious, could result in costly litigation, lengthy governmental proceedings, divert management&#x2019;s attention and resources and require us to enter royalty or license agreements which are not advantageous if available at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to patents, we rely upon unpatented, proprietary trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees, and consultants, and invention assignment agreements with our employees. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Research and Development</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our expenditures for research and development activities were $2.44 million, $1.91 million, $2.66 million and $1.69 million during the years ended December 31, 2020 and 2019 and the nine months ended September 30, 2021 and 2020, respectively. As our vaccines continue to go through the process to obtain regulatory approval, we expect our research and development costs to increase. We have not yet formulated any plans for marketing and sales of any vaccine candidate we may successfully develop. Compliance with environmental protection laws and regulations has not had a material effect on our capital expenditures, earnings or competitive position to date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Scientific Advisors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We seek advice from our Scientific Advisory Board, which consists of a number of leading scientists, on scientific and medical matters. The current members of our Scientific Advisory Board are:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 25%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name</b></p> </td>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td style="vertical-align: top; width: 73%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Position/Institutional Affiliation</b></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 25%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Harriet L. Robinson, PhD.</p> </td>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td style="vertical-align: top; width: 73%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Scientific Officer Emeritus, GeoVax</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 25%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stanley A. Plotkin, MD</p> </td>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td style="vertical-align: top; width: 73%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Professor Emeritus, University of Pennsylvania, Adjunct Professor, Johns Hopkins University</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 25%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Barney S. Graham, MD, PhD</p> </td>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td style="vertical-align: top; width: 73%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Senior Investigator, Vaccine Research Center, NIAID</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 25%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Scott C. Weaver, PhD</p> </td>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td style="vertical-align: top; width: 73%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, University of Texas Medical Branch Institute for Human Infections and Immunity</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 25%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Olivera J. Finn, PhD</p> </td>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td style="vertical-align: top; width: 73%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Distinguished Professor of Immunology and Surgery, University of Pittsburgh</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Properties</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our principal executive offices are located in Smyrna, Georgia, where we lease approximately 8,400 square feet of office and laboratory space. Our lease for the premises is currently scheduled to terminate on December 31, 2022. We do not currently own any real property. We believe that our current facilities are adequate to meet our immediate needs and believe that we should be able to renew our lease without an adverse impact on our operations. In addition, we believe that if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Human Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We currently have nine full-time and one part-time employees. None of our employees are covered by collective bargaining agreements and we believe that our employee relations are good. We also engage consultants and independent contractors to fulfill key roles and/or provide expert services on both an ongoing and short-term basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive compensation, opportunity for equity ownership, and a robust employment package that promotes wellness across all aspects of their lives, including healthcare, retirement planning, and paid time off.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate Background</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our primary business is conducted by our wholly owned subsidiary, GeoVax, Inc., which was incorporated under the laws of Georgia in June 2001. Our address is 1900 Lake Park Drive, Smyrna, Georgia 30080, and our telephone number at that address is 678-384-7220. The predecessor of our parent company, GeoVax Labs, Inc. (the reporting entity) was originally incorporated in June 1988 under the laws of Illinois as Dauphin Technology, Inc. (&#x201c;Dauphin&#x201d;). In September 2006, Dauphin completed a merger with GeoVax, Inc. As a result of the merger, GeoVax, Inc. became a wholly owned subsidiary of Dauphin, and Dauphin changed its name to GeoVax Labs, Inc. In June 2008, the Company was reincorporated under the laws of Delaware. We currently do not conduct any business other than GeoVax, Inc.&#x2019;s business of developing new products for the treatment or prevention of human diseases. Our principal offices are in Smyrna, Georgia (metropolitan Atlanta).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MANAGEMENT</b>&#x2019;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes included in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties because they are based on current expectations and relate to future events and our future financial performance. Our actual results may differ materially from those anticipated in these forward-looking statements because of many important factors, including those set forth under </i>&#x201c;<i>Risk Factors</i>&#x201d;<i> and elsewhere in this prospectus.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview and Recent Developments</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GeoVax is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax&#x2019;s product pipeline includes ongoing human clinical trials in COVID-19 and head and neck cancer. Additional research and development programs include preventive vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for solid tumors. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>GEO-CM04S1 License</i> -- In November 2021, GeoVax entered into a license agreement with City of Hope (the &#x201c;COH License&#x201d;), granting GeoVax exclusive rights to further develop and commercialize GEO-CM04S1 (formerly referred to as COH04S1). GEO-CM04S1, a synthetic, attenuated modified vaccinia Ankara (sMVA) vector expressing Spike and Nucleocapsid antigens of the SARS-CoV-2 virus, was initially developed at COH for immunocompromised patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GEO-CM0461 is being studied in an ongoing Phase 2 clinical trial to evaluate its safety and immunogenicity, compared to the Pfizer mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy. GEO-CM0461 is the only COVID-19 vaccine that includes both SARS-CoV-2 spike and nucleocapsid proteins to advance to a Phase 2 trial in cancer patients. Such vaccines also tend to produce an immune response quickly &#x2013; in less than 14 days &#x2013; with only mild side effects. The trial is also the first to compare an investigational multi-antigenic COVID-19 vaccine to the current Food and Drug Administration (FDA)-approved mRNA vaccine from Pfizer/BioNTech in people who are immunocompromised. Such patients have often shown a weak antibody response after receiving currently available COVID-19 vaccines.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In December 2021, patient enrollment began for the Phase 2 portion of a Phase 1/2 trial of GEO-CM0461, to study its use as a universal booster vaccine to current FDA-approved vaccines. GeoVax believes that the GEO-CM0461 vaccine, when administered as a heterologous booster, will provide additional recognition elements to the immune system over a homologous boost from mRNA vaccines such as those developed by Moderna or Pfizer, which are directed only toward SARS-CoV-2 Spike protein. The COH04S1 vaccine&#x2019;s MVA backbone may be more effective at inducing COVID-19 immunity since MVA strongly induces T cell responses even in a background of immunosuppression. In addition, GEO-CM0461 targeting of both Spike and Nucleocapsid antigens, may offer greater protection against the significant sequence variation observed with the Spike antigen.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Gedeptin</i>&#xae;<i> License</i> -- In September 2021, GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc. (the &#x201c;Gedeptin License), whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#xae;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase 1/2 clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and no curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#x2019;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but not limited to, cancers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 14, 2022, we entered into a Securities Purchase Agreement with the Selling Stockholder providing for the issuance and sale to the Selling Stockholder of 707,484 shares of common stock, 2,360,000 shares of common stock issuable upon the exercise of the Pre-Funded Warrant and 3,067,484 shares of common stock issuable upon the exercise of the Common Warrant for gross proceeds to the Company of approximately $10.0 million. The Warrants are exercisable immediately and contain price adjustment provisions which may, under certain circumstances, reduce the applicable exercise price; the Pre-Funded Warrant shall terminate when fully exercised and the Common Warrant shall terminate on the fifth anniversary of the effective date of the Resale Registration Statement. The Private Placement closed on January 20, 2022. We paid the placement agent, Maxim Group LLC, a cash fee of $700,000 at closing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our corporate strategy is to advance, protect and exploit our differentiated vaccine/immunotherapy technologies leading to the successful development of preventive and therapeutic vaccines and immunotherapies against infectious diseases and various cancers. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have not generated any revenues from the sale of the products we are developing, and we do not expect to generate any such revenues for at least the next several years. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our operating results typically fluctuate due to the timing of activities and related costs associated with our research and development activities and our general and administrative costs, as described below. The following tables summarize our results of operations for the years ended December 31, 2020 and 2019 and the nine-month periods ended September 30, 2021 and 2020:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Year Ended December 31,</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Change</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Grant and collaboration revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,823,658</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,175,896</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">647,762</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,444,459</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,910,715</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">533,744</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,196,014</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,637,674</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">558,340</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,640,473</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,548,389</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,092,084</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2,816,815</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2,372,493</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(444,322</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total other income (expense)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(141,253</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,864</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(143,117</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,958,068</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,370,629</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(587,439</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Nine Months Ended September 30,</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Change</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Grant and collaboration revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">220,539</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,572,037</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,351,498</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,659,980</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,687,113</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">972,867</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,562,641</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,364,650</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,197,991</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,222,621</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,051,763</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,170,858</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5,002,082</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,479,726</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,522,356</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total other income (expense)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">174,768</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(141,820</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">316,588</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,827,314</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,621,546</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,205,768</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Grant and Collaboration Revenues</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our grant revenues relate to grants and contracts from agencies of the U.S. government in support of our vaccine development activities. During the years ended December 31, 2020 and 2019, we also recorded revenues associated with several research collaborations with third parties. Detail concerning our grant and collaboration revenues during the years ended December 31, 2020 and 2019, the nine-month periods ended September 30, 2021 and 2020, and the remaining funds available for use as of September 30, 2021 is presented in the table below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Revenues Recorded During the Periods:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Unused Funds</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Year Ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Nine Months Ended September 30,</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Available at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30,</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lassa Fever &#x2013; U.S. Army Grant</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,438,465</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">674,179</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,186,844</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">165,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Covid-19 &#x2013; NIH SBIR Grant</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">147,042</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">220,539</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">79,388</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Zika &#x2013; NIH SBIR Grant</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">162,461</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Collaboration Revenues</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">385,193</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">192,214</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">385,193</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,823,658</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,175,896</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">220,539</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,572,037</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">244,888</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Grant and collaboration revenues increased by $647,762 (55%) for the year ended December 31, 2020 compared to the year ended December 31, 2019, and decreased by $1,351,498 (86%) for the nine-month period ended September 30, 2021 compared to the nine-month period ended September 30, 2020, attributable to the differing mix of active grants and collaborations as shown in the table above, as well as the timing of expenditures related to such grants and collaborations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our research and development expenses can fluctuate considerably on a period-to-period basis, depending on the timing of expenditures related to our government grants and other research projects, and other factors. We do not disclose our research and development expenses by project, since our employees&#x2019; time is spread across multiple programs and our laboratory facility is used for multiple vaccine candidates. We track the direct cost of research and development expenses related to government grant revenue by the percentage of assigned employees&#x2019; time spent on each grant and other direct costs associated with each grant. Indirect costs associated with grants are not tracked separately but are applied based on a contracted overhead rate negotiated with the NIH. Therefore, the recorded revenues associated with government grants approximate the costs incurred.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the nine-month period ended September 30, 2021, research and development expenses increased by $972,867 (58%) versus the 2020 period. Of this increase, $459,825 relates to upfront license fees (inclusive of $209,825 of stock-based expense) associated with our in-license of Gedeptin in September 2021. Research and development expense for the nine-month period ended September 30, 2021 includes stock-based compensation expense of $64,404 associated with employee stock options; no stock-based compensation expense was allocated to research and development expense for the comparable period in 2020 (see discussion under &#x201c;Stock-Based Compensation Expense&#x201d; below). The remaining increase of $448,638 for the nine-month period ended September 30, 2021 relates primarily due to expenditures related to our COVID-19 vaccine program, manufacturing process development, and a generally higher level of activity, offset in part by lower external expenditures related to our government grants.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our research and development expenses were $2,444,459 and $1,910,715 for the years ended December 31, 2020 and 2019, respectively. Research and development expense for these periods includes stock-based compensation expense of $7,156 and $43,801 for 2020 and 2019, respectively (see discussion under &#x201c;Stock-Based Compensation Expense&#x201d; below). Research and development expenses increased by $533,744, or 28% from 2019 to 2020. The fluctuation is primarily due to the timing of expenditures related to our government grants. Our research and development costs do not include costs incurred by the HVTN in conducting clinical trials of our preventive HIV vaccines; those costs are funded directly to the HVTN by NIAID.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>General and Administrative Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the nine-month period ended September 30, 2021, general and administrative expenses increased by $1,197,991 (88%). General and administrative expense for the nine-month period ended September 30, 2021 included stock-based compensation expense of $184,899 as compared to $24,000 for the comparable period of 2020 (see discussion under &#x201c;Stock-Based Compensation Expense&#x201d; below). A significant portion of the increase during each period is attributable to higher Delaware franchise taxes, with the remainder primarily due to higher legal, accounting and patent costs; insurance costs; consulting fees; Nasdaq listing fees; investor relations costs; and personnel costs.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our general and administrative expenses were $2,196,014 and $1,637,674 for the years ended December 31, 2020 and 2019, respectively. General and administrative costs include officers&#x2019; salaries, legal and accounting costs, patent costs, and other general corporate expenses. General and administrative expense includes stock-based compensation expense of $57,307 and $283,699 for 2020 and 2019, respectively (see discussion under &#x201c;Stock-Based Compensation Expense&#x201d; below). Excluding stock-based compensation expense, general and administrative expenses were $2,138,707 and $1,353,975 for 2020 and 2019, respectively, representing an increase of $784,732 or 58%. The increase from 2019 to 2020 is primarily related to higher legal fees, patent costs, investor relations consulting, and personnel costs. We expect that our general and administrative costs will increase in the future in support of expanded research and development activities and other general corporate activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The table below shows the components of stock-based compensation expense for the years ended December 31, 2020 and 2019 and nine-month periods ended September 30, 2021 and 2020. In general, stock-based compensation expense is allocated to research and development expense or general and administrative expense according to the classification of cash compensation paid to the employee, consultant or director to whom the stock compensation was granted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Year Ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Nine Months Ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30,</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock option expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,730</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">104,420</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">168,570</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock issued for consulting services</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45,733</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">223,080</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80,733</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,463</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">327,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">249,303</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a result of the reverse stock splits enacted in April 2019 and in January 2020, we made adjustments and retroactive restatements to all of our outstanding stock options such that the balances in January 2020 were negligible. We therefore recorded no stock-based compensation expense related to our stock option plan for the majority of 2020. We re-initiated employee stock option grants in December 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Income (Expense)</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Interest income for the nine-month period ended September 30, 2021 was $3,998 as compared to $902 for the comparable period of 2020. Interest income was $2,271 and $6,359 for the years ended December 31, 2020 and 2019, respectively. The variance between periods is primarily attributable to cash available for investment and interest rate fluctuations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Interest expense for the nine-month period ended September 30, 2021 was $1,286 as compared to $142,772 for the comparable period of 2020. Interest expense for the 2021 period relates to the GRA Note (as defined below) and PPP Loan (as defined below), and for the 2020 period relates to the GRA Note, PPP Loan, financing costs associated with insurance premiums, and Convertible Debentures (as defined below) which were retired during 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Interest expense was $143,524 and $4,495 for the years ended December 31, 2020 and 2019, respectively. Interest expense relates to the Convertible Debentures, GRA Note, PPP Loan, and financing costs associated with insurance premiums. For 2020, interest expense included $14,667 of accrued interest payable and $124,185 of amortized debt discount related to the Convertible Debentures. Subsequent to the full conversion of the Convertible Debentures into our equity securities on September 29, 2020, there will be no more interest expense associated with the Convertible Debentures, and we expect other interest expense will be minimal.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the nine-month period ended September 30, 2021, we recorded a $172,056 gain on debt extinguishment associated with the forgiveness of the PPP Loan principal and accrued interest.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">From inception through September 30, 2021, we have accumulated net losses of approximately $50.6 million and we expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. We have funded our operations to date primarily from sales of our equity securities and from government grants and clinical trial assistance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following tables summarize our liquidity and capital resources as of September 30, 2021 and December 31, 2020 and 2019, and our cash flows for the years ended December 31, 2020 and 2019 nine-month periods ended September 30, 2021 and 2020:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liquidity and Capital Resources</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2019</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,107,019</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,883,796</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">283,341</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Working Capital</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,824,187</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,424,839</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,568,929</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Year Ended December 31,</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash Flow Data</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash provided by (used in):</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2,750,570</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,398,497</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Investing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(156,791</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(7,606</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Financing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,507,816</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,429,743</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,600,455</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">23,640</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Nine Months Ended September 30,</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash Flow Data</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash provided by (used in):</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,513,271</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,208,619</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Investing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(47,718</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2,470</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Financing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,784,212</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,508,342</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,223,223</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,297,253</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Operating Activities</i> &#x2013; Net cash used in operating activities of $4,513,271 for the nine months ended September 30, 2021, was primarily due to our net loss of $4,827,314, offset by non-cash items such as depreciation expense, stock-based compensation expense and the gain recognized on extinguishment of our PPP loan, and by changes in our working capital accounts. Net cash used in operating activities of $1,208,619 for the nine months ended September 30, 2020, was primarily due to our net loss of $1,621,546, offset by non-cash charges such as depreciation and stock-based compensation expense, and by changes in our working capital accounts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash used in operating activities was $2,750,570 and $1,398,497 for the years ended December&#xa0;31, 2020 and 2019, respectively. Generally, the variances between periods are due to fluctuations in our net losses, offset by non-cash charges such as depreciation and stock-based compensation expense, and by net changes in our assets and liabilities. Our net losses generally fluctuate based on expenditures for our research activities, partially offset by government grant revenues. See &#x201c;Results of Operations&#x2013;Grant and Collaboration Revenues&#x201d; above for additional details concerning our government grants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Investing Activities</i> &#x2013; Net cash used in investing activities was $47,718 and $2,470 for the nine-month periods ended September&#xa0;30, 2021 and 2020, respectively, and relates to purchases of property and equipment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash used in investing activities was $156,791 and $7,606 for the years ended December 31, 2020 and 2019, respectively, and consisted predominantly of capital expenditures for laboratory equipment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Financing Activities</i> &#x2013; Net cash provided by financing activities was $12,784,212 for the nine-month period ended September&#xa0;30, 2021, consisting primarily of (i) net proceeds of $9,408,920 from a public offering of our common stock, (ii) $3,404,156 of net proceeds from the exercise of warrants, (iii) $1,000 expended for the repurchase of outstanding convertible preferred stock, and (iv) $27,864 in principal repayments toward a note payable to the Georgia Research Alliance, Inc. (the &#x201c;GRA Note&#x201d;); the GRA Note has now been fully repaid. Additionally, during May 2021, our PPP Loan of $170,200, together with $1,856 of accrued interest, was forgiven by the lender and extinguished.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash provided by financing activities was $12,508,342 for the nine-month period ended September&#xa0;30, 2020, consisting of (i) net proceeds of $11,158,496 from a public offering of our common stock and warrants, (ii) net proceeds of $300,000 from the sale of our convertible preferred stock, (iii) $170,200 of PPP Loan proceeds, (iv) $888,500 of net proceeds from issuance of a note payable, and (v) $8,854 in principal repayments toward the GRA Note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash provided by financing activities was $12,507,816 and $1,429,743 for the years ended December 31, 2020 and 2019, respectively. Net cash provided by financing activities during 2020 relates to (i) the sale in January 2020 of shares of our Series J Preferred Stock for net proceeds of $300,000, (ii) $170,200 of PPP Loan proceeds received in April 2020, (iii) $888,500 of net proceeds received in June 2020 from our issuance of Convertible Debentures, (iv) net proceeds of approximately $11.2 million received in September 2020 from the public offering of our equity securities, (v) $2,500 of net proceeds from the exercise of warrants and (vi) $11,880 in principal repayments toward the GRA Note. Net cash provided by financing activities during 2019 relates to the sale of shares of our Series G and Series I convertible preferred stock for aggregate net proceeds of $1,440,000 and $10,257 in principal repayments toward the GRA Note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>PPP Loan.</i> On April 17, 2020, we received a $170,200 bank loan backed by the United States Small Business Administration pursuant to the Paycheck Protection Program (PPP) provisions of the CARES Act (the &#x201c;PPP Loan&#x201d;). The loan bears an annual interest rate of one percent and is due April 17, 2022. In October 2020, we applied to the lender to have the loan forgiven, based upon our submission of qualifying information regarding eligible expenses; during May 2021, our PPP Loan of $170,200, together with $1,856 of accrued interest, was forgiven by the lender and extinguished.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Issuance of Convertible Debenture and Subsequent Conversion to Equity.</i> On June 26, 2020, we entered into a securities purchase agreement with two institutional investors, pursuant to which we received gross proceeds of $1,050,000 in exchange for the issuance of: (i) 5% Original Issue Discount Senior Secured Convertible Debentures (the &#x201c;Convertible Debentures&#x201d;) in the aggregate principal amount of $1,200,000; and (ii) five-year warrants (the &#x201c;June 2020 Warrants&#x201d;) to purchase an aggregate of 120,000 shares of our common stock at an initial exercise price of $10.00 per share. Net proceeds after deducting the original issue discount, finder&#x2019;s fee and other debt issuance costs were $888,500.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Convertible Debentures were mandatorily convertible upon our consummation of a public offering of common stock with gross proceeds of $6,000,000 or more, and which resulted in the listing of our common stock on a national securities exchange (a &#x201c;Qualified Offering&#x201d;). The conversion price upon the occurrence of a Qualified Offering was equal to the lower of (i) $10.00 per share or (ii) 80% of the offering price. The conversion provisions of the Convertible Debentures were subject to a &#x201c;conversion blocker&#x201d; such that each of the purchasers could not convert the Convertible Debentures to the extent that the conversion would result in the purchaser and its affiliates holding more than 4.99% of our outstanding common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Upon our consummation of the public offering discussed below, the $1,200,000 maturity value of the Convertible Debentures and $14,667 of accrued interest were automatically converted at $4.00, the Qualified Offering discounted price, resulting in the issuance of 303,668 conversion units. Of the 303,668 conversion units: (a) 177,626 consisted of one share of common stock and a warrant to purchase one share of common stock (a &#x201c;Conversion Warrant&#x201d;), and (b) 126,042 consisted of one pre-funded warrant to purchase one share of common stock and a Conversion Warrant. The pre-funded warrants provided the holder the right to purchase one share of Common Stock at an exercise price of $0.01 per share and were exercised in full in January 2021. The Conversion Warrants provide the holder the right to purchase one share of common stock, are immediately exercisable at an exercise price of $5.00 per share and expire five years after the issuance date. As a result of the public offering in September 2020, the exercise price of the June 2020 Warrants was reduced to $5.00.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Public Offerings </i>&#x2013;<i> </i>On September 29, 2020, we closed an underwritten public offering of an aggregate of 2,560,000 units of our equity securities (the &#x201c;Units&#x201d;), with gross proceeds to us of approximately $12.8 million (the &#x201c;September Offering&#x201d;). Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $11.2 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Of the 2,560,000 Units sold in the September Offering: (a) 2,310,000 Units consisting of one share of our common stock, and a Warrant to purchase one share of common stock (each, a &#x201c;Unit Warrant&#x201d;); and (b) 250,000 Units consisting of a pre-funded warrant to purchase one share of common stock and a Unit Warrant. The pre-funded warrants provided the holder the right to purchase one share of common stock at an exercise price of $0.01 per share and were exercised in full during October 2020. The Unit Warrants provide the holder the right to purchase one share of common stock, are immediately exercisable at an exercise price of $5.00 per share and expire five years after the issuance date. The public offering price was $5.00 per Unit ($4.99 for each Unit including a pre-funded warrant).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On February 11, 2021, we closed an underwritten bought deal public offering of 1,644,000 shares of our common stock, including 204,000 shares sold pursuant to the full exercise of the underwriter&#x2019;s option to purchase additional shares, at a price to the public of $6.25 per share. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $9.4 million</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Conversion of Deferred Compensation to Equity </i>&#x2013;<i> </i>From 2016 through August 2020, to help conserve the Company&#x2019;s cash resources, our executive officers and non-employee directors agreed to defer receipt of all or a portion (at varying levels) of their respective cash compensation. On September 29, 2020, upon our consummation of the public offering, $1,500,000 of the accumulated deferrals were converted at the $5.00 offering price, resulting in the issuance of 300,001 units substantially similar to the units sold in the public offering, with each unit consisting of one share of our common stock and one warrant substantially similar to a Unit Warrant (a &#x201c;Management Warrant&#x201d;). The Company also paid the executive officers and non-employee directors $525,198 of the deferred compensation in cash.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Funding Requirements and Sources of Capital</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our primary uses of capital are for salaries and related expenses for personnel, manufacturing costs for preclinical and clinical materials, third-party research services, laboratory and related supplies, legal and other regulatory expenses, and general overhead costs. We expect these costs will continue to be the primary operating capital requirements for the near future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe our existing cash and cash equivalents will be sufficient to meet our anticipated cash requirements into early 2023. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties and is based on assumptions that may prove to be wrong; actual results could vary materially. We may need to obtain additional funds sooner than planned or in greater amounts than we currently anticipate. The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These factors include the progress of our research activities; the number and scope of our research programs; the progress and success of our pre-clinical and clinical development activities; the progress of the development efforts of parties with whom we have entered into research and development agreements; the costs of manufacturing our product candidates, and the progress of efforts with parties with whom we may enter into commercial manufacturing agreements; our ability to maintain current research and development programs and to establish new research and development and licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; the impact of any natural disasters or public health crises, such as the COVID-19 pandemic; the costs associated with any products or technologies that we may in-license or acquire; and the costs and timing of regulatory approvals.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will need to continue to raise additional capital to support our future operating activities, including progression of our development programs, preparation for commercialization, and other operating costs. Financing strategies we may pursue include, but are not limited to, the public or private sale of equity, debt financings or funds from other capital sources, such as government funding, collaborations, strategic alliances or licensing arrangements with third parties. There can be no assurances additional capital will be available to secure additional financing, or if available, that it will be sufficient to meet our needs on favorable terms. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We expect our research and development costs to increase as we continue development of our various programs and as we move toward later stages of development, especially with regard to clinical trials. Our expenditures during 2022 and beyond will increase significantly as a result of the license fees and development costs we assumed related to the Gedeptin and COH04S1 clinical programs. We do not provide forward-looking estimates of costs and time to complete our research programs due to the many uncertainties associated with biotechnology research and development. Due to these uncertainties, our future expenditures are likely to be highly volatile in future periods depending on the outcomes of the trials and studies. As we obtain data from pre-clinical studies and clinical trials, we may elect to discontinue or delay certain development programs to focus our resources on more promising product candidates. Completion of preclinical studies and human clinical trials may take several years or more, but the length of time can vary substantially depending upon several factors. The duration and the cost of future clinical trials may vary significantly over the life of the project because of differences arising during development of the human clinical trial protocols, including the length of time required to enroll suitable patient subjects, the number of patients that ultimately participate in the clinical trial, the duration of patient follow-up, and the number of clinical sites included in the clinical trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We expect, for the remainder of 2021, our general and administrative expenses to remain reasonably consistent with that of the third quarter of 2021. We expect that our general and administrative costs will increase during 2022 in support of expanded research and development activities and other general corporate activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Grant Funding</i> &#x2013; We have ongoing government support for our COVID-19 vaccine program through a Small Business Innovative Research (SBIR) grant from NIAID and for our Lassa Fever vaccine program via a grant from the U.S. Department of Defense. As of September 30, 2021, there is $244,888 in approved grant funds remaining and available for use through mid-2022. Additionally, our Sudan ebolavirus and Marburg virus vaccine candidates are being developed in collaboration with researchers at the University of Texas Medical Branch (UTMB) and Battelle Memorial Institute utilizing the suite of preclinical services from NIAID. We are currently seeking sources of capital through additional government and quasi-government grant programs and clinical trial support, although there can be no assurance any such funds will be obtained.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Clinical Trial Support</i>&#xa0;&#x2013; NIAID has funded the costs of conducting all of our human clinical trials (Phase 1 and Phase 2a) to date for our preventive HIV vaccines, with GeoVax incurring certain costs associated with manufacturing the clinical vaccine supplies and other study support. We expect that NIAID will also fund the cost of the planned Phase 1 trial (HVTN 132) to further evaluate the safety and immunogenicity of adding &#x201c;protein boost&#x201d; components to our vaccine, GOVX-B11. The start of HVTN 132 has been delayed due to COVID-19, and we await further information from NIAID and HVTN on when the trial may commence. Additionally, we are party to a collaboration with a consortium led by researchers at the University of California, San Francisco (UCSF), using our vaccine as part of a combinational therapy to induce remission in HIV-positive individuals; this program is currently undergoing clinical trials. Similar to HVTN 132, this trial has been affected by the pandemic, so we await further information regarding the status of patient enrollment and trial results. Our prior collaboration with American Gene Technologies International, Inc. (AGT) was recently discontinued due to AGT&#x2019;s remodeling of their clinical trial plans. Gedeptin is in a Phase 1/2 trial, being conducted at Stanford University in collaboration with Emory University; the initial stage of the study (10 patients) is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Equity Funding</i> &#x2013; During February 2021, we closed an underwritten public offering of our common stock for net proceeds of $9,408,920. During January, February and August 2021, certain of our outstanding stock purchase warrants were exercised, resulting in net proceeds to us of $3,404,156. As of September 30, 2021, there are 2,816,631 stock purchase warrants outstanding, including 1,819,966 publicly-traded warrants (Nasdaq: GOVXW) exercisable for cash at $5.00 per share and expiring on September 29, 2025. Should these warrants be exercised in full, we would receive approximately $9.1 million in gross proceeds.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Off-Balance Sheet Arrangements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have no off-balance sheet arrangements that are likely or reasonably likely to have a material effect on our financial condition or results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of United States interest rates, particularly because a significant portion of our investments are in institutional money market funds. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income received without significantly increasing risk. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We do not have any derivative financial instruments or foreign currency instruments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Accounting Policies and Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates and adjusts them as necessary. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our significant accounting policies are summarized in Note&#xa0;2 to our consolidated financial statements for the year ended December 31, 2020. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue Recognition</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We recognize revenue in accordance with FASB Accounting Standards Update 2014-09, <i>Revenue from Contracts with Customers</i> (ASU 2014-09), which created a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Grant revenue</i> &#x2013; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Research collaborations</i> &#x2013; From time to time, we may enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive third-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU 2014-09 and revenue is recognized accordingly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Stock-Based Compensation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#x2019;s fair value as calculated by using the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 8 to our consolidated financial statements for the year ended December 31, 2020 for additional stock-based compensation information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MANAGEMENT</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table sets forth certain information with respect to our directors and executive officers as of the date hereof:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:16.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:3.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Age</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:36%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Current Position</b></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:16.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">David A. Dodd</p> </td>
     <td style="vertical-align:top;width:3.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">72</p> </td>
     <td style="vertical-align:top;width:36%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board of Directors, President and Chief Executive Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:16.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mark W. Reynolds, CPA</p> </td>
     <td style="vertical-align:top;width:3.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">60</p> </td>
     <td style="vertical-align:top;width:36%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer and Corporate Secretary</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:16.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mark J. Newman, Ph.D.</p> </td>
     <td style="vertical-align:top;width:3.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">66</p> </td>
     <td style="vertical-align:top;width:36%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Scientific Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:16.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Kelly T. McKee, M.D.</p> </td>
     <td style="vertical-align:top;width:3.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">71</p> </td>
     <td style="vertical-align:top;width:36%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Medical Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:16.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert T. McNally Ph.D.(1)(2)</p> </td>
     <td style="vertical-align:top;width:3.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">73</p> </td>
     <td style="vertical-align:top;width:36%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:16.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Randal D. Chase, Ph.D. (1)(2)(3)</p> </td>
     <td style="vertical-align:top;width:3.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">72</p> </td>
     <td style="vertical-align:top;width:36%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Independent Director</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:16.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dean G. Kollintzas (2)(3)</p> </td>
     <td style="vertical-align:top;width:3.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">48</p> </td>
     <td style="vertical-align:top;width:36%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Independent Director</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:16.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John N. Spencer, Jr. (1)(3)</p> </td>
     <td style="vertical-align:top;width:3.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">81</p> </td>
     <td style="vertical-align:top;width:36%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Independent Director</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Member of the Compensation Committee of the Board of Directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Member of the Nominating and Governance Committee of the Board of Directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Member of the Audit Committee of the Board of Directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>David A. Dodd</i></b>. Mr. Dodd joined the Board of Directors in March 2010, becoming Chairman of our Board of Directors on January 1, 2011. Effective September 5, 2018, Mr. Dodd became our President and Chief Executive Officer, following Dr. McNally&#x2019;s retirement. His executive management experience in the pharmaceutical and biotechnology industries spans more than 40 years. From September 2017 to April 2018, he served as Chief Executive Officer, and as a member of the Board of Directors of Medizone International, Inc. (&#x201c;Medizone&#x201d;), a developer and manufacturer of disinfectant systems. On April 20, 2018, Medizone announced that certain of its creditors had commenced an involuntary bankruptcy proceeding under Chapter 11 of the United States Bankruptcy Code against Medizone. The creditors included Medizone&#x2019;s former Chairman and Chief Executive Officer and its former Director of Operations. From April 2013 to July 2017, Mr. Dodd served as President and Chief Executive Officer, and as a member of the Board of Directors, of Aeterna Zentaris Inc., a drug development company. He was Chairman of the Board of Directors of Aeterna Zentaris, Inc. from May 2014 to May 2016, and continued to serve as a member of its Board of Directors until May 2018. From December 2007 to June 2009, Mr. Dodd was President, Chief Executive officer and Chairman of BioReliance Corporation, a leading provider of biological safety and related testing services. From October 2006 to April 2009, he served as non-executive Chairman of Stem Cell Sciences Plc., where he oversaw the development and implementation of a strategic growth plan, implementation of an experienced executive team, and the sale of the company to Stem Cells, Inc. in April 2009. Before that, Mr. Dodd served as President, Chief Executive Officer and Director of Serologicals Corporation before it was sold to Millipore Corporation in July 2006 for $1.5 billion. For five years prior to his employment by Serologicals Corporation, Mr. Dodd served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and Chairman of its subsidiary Unimed Pharmaceuticals, Inc. He is also the Chief Executive Officer of RiversEdge BioVentures, an investment and advisory firm focused on the life sciences and pharmaceuticals industries, which he founded in 2009. The Board of Directors has concluded that Mr. Dodd should serve on the Board of Directors due to his experience in the pharmaceutical industry and his involvement as an officer and director of the Company, as well as his background in general management, business transformation, corporate partnering, and mergers and acquisitions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Mark W. Reynolds, CPA.</i></b> Mr. Reynolds joined the Company in October 2006 as Chief Financial Officer and Corporate Secretary. From 2004 to 2008, Mr. Reynolds served as Chief Financial Officer for HealthWatchSystems, Inc. a privately-held company in the consumer healthcare industry. From 2004 to 2006, he served as Chief Financial Officer for Duska Therapeutics, Inc., a publicly-held biotechnology company. From 1988 to 2002, Mr. Reynolds worked for CytRx Corporation, a publicly-held biopharmaceutical company, where he first served as Controller and then as Chief Financial Officer. Mr. Reynolds began his career as an auditor with Arthur Andersen &amp; Co. from 1985 to 1988. He is a certified public accountant and earned a Master of Accountancy degree from the University of Georgia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Mark J. Newman,</i></b> <b><i>Ph.D</i></b>. Dr. Newman became employed as our Chief Scientific Officer on August 25, 2020. Dr. Newman, who previously served the Company as vice president of research and development from 2010 to 2013, works for the Company on a half-time basis. The other portion of his working time is devoted primarily to his work at NewMark Diagnostics LLC, a diagnostics development company, which he founded in 2016. Prior, he served senior management positions at PaxVax, Pharmexa A/S, Epimmune, Vaxcel, Apollon, and Cambridge Biotech. During his 30-year career he shepherded the development of experimental vaccine and adjuvant products through preclinical research and into Phase 1 &amp; 2 clinical testing. He is widely published in peer review publications and holds 10 U.S. patents. He holds a dual B.Sc/M.Sc. degree in Agriculture and Pre-Veterinary Medicine from the Ohio State University and earned his Ph.D. in Immunology at the John Curtin School for Medical Research, The Australian National University, Canberra.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Kelly T. McKee,</i></b>&#xa0;<b><i>M.D</i></b>. Dr. McKee was appointed as our Chief Medical Officer effective January 6, 2022 and serves in that role on a part-time basis pursuant to a consulting agreement. Dr. McKee has over 30 years of experience in research and development, with specific expertise in vaccines, emerging diseases, biodefense, and respiratory viral infections. His progressive clinical research experience began in 1981 at Fort Detrick, Frederick, MD., United States, where he held a variety of leadership positions in virology, immunology, preventive medicine, and clinical research and development with the U.S. Army, retiring as a Colonel in 2001. Dr. McKee subsequently served as State Epidemiologist in North Carolina, and as Senior Director of Clinical Research at DynPort Vaccine Company. He then held multiple leadership roles, including Vice President and Managing Director of Public Health and Government Services, and Vice President for Vaccines and Public Health in the Infectious Diseases and Vaccines Center of Excellence, at Quintiles/QuintilesIMS (now IQVIA) for more than 10 years. Since 2017 he has provided contract clinical development and medical advisory services to biopharmaceutical industry in infectious diseases and related areas. Dr. McKee earned an M.D. from the University of Virginia School of Medicine, and a Master of Public Health degree from Johns Hopkins University School of Hygiene and Public Health in Baltimore, MD. Over the course of a successful military and private-sector career, he has also earned multiple board and advisory appointments, certifications, grants, civilian honors, and inductions and fellowships to some of the world&#x2019;s most prestigious medical associations. He has authored or co-authored more than 100 peer-reviewed publications and book chapters.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Robert T. McNally,</i></b> <b><i>Ph.D</i></b>. Dr. McNally joined the Board of Directors in December 2006 and was appointed as our President and Chief Executive Officer effective April 1, 2008, a position he held until his retirement in September 2018. From 2000 to March 2008, Dr. McNally served as Chief Executive Officer of Cell Dynamics LLC, a cGMP laboratory services company. Previously, Dr. McNally was a co-founder and Senior Vice President of Clinical Research for CryoLife, Inc., a pioneering company in transplantable human tissues. He has over 35 years of experience in academic and corporate clinical investigations, management, research, business, quality and regulatory affairs. Dr. McNally is a Fellow of the American Institute for Medical and Biological Engineering, served on the advisory boards of the Petit Institute for Bioengineering and Dupree College of Management at the Georgia Institute of Technology, and is a former Chairman of Georgia Bio, a state trade association. Dr. McNally graduated with a Ph.D. in biomedical engineering from the University of Pennsylvania. The Board of Directors has concluded that Dr. McNally should serve on its Board of Directors by virtue of his prior business and scientific experience, including his experience as Chief Executive Officer of Cell Dynamics, LLC and as Senior Vice President of Clinical Research for CryoLife, Inc., and due to his involvement with the Company as its former President and Chief Executive Officer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Randal D. Chase, Ph.D.</i></b> Dr. Chase joined the Board of Directors in March 2015. Dr. Chase is an experienced pharmaceutical and biotechnology executive who currently serves as a business advisor and consultant to companies in the life science sector. He also serves as a director for Mirexus Biotechnologies, Inc., a biomaterials company, and as Chairman of the Board for Glysantis, Inc. a biotechnology company. From February 2017 to April 2018, Dr. Chase was President and Chief Executive Officer of Advanced Proteome Therapeutics Corporation, a publicly-held biopharmaceutical company; he served as a member of that company&#x2019;s board of directors from 2015 to April 2018. He served as Chairman of the Board for Medicago, Inc. until its sale to Mitsubishi Tanabe Pharma Corporation in 2013. From 2006 to 2011, he served as President and Chief Executive Officer of Immunovaccine, Inc., a clinical-stage biotechnology company developing vaccines against cancer and infectious diseases. Dr. Chase is also a former president of Shire Biologics, North American Vaccine, Pasteur Merieux Connaught, and Quadra Logic Technologies, Inc. His early career was at Bristol Myers and Glaxo Pharmaceuticals. Dr. Chase attended the Senior Executive Program of the London Business School in the United Kingdom, holds a Bachelor of Sciences degree in biochemistry from Bishop&#x2019;s University and a Ph.D. in biochemistry from the University of British Columbia. Dr. Chase completed a post-doctoral fellowship at the McArdle Cancer Institute of the University of Wisconsin. The Board of Directors has concluded that Dr. Chase should serve on the Board of Directors due to his extensive leadership experience in the pharmaceutical industry, and the vaccine industry in particular.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Dean G. Kollintzas.</i></b> Mr. Kollintzas joined the Board of Directors in September 2006. Since 2001 Mr. Kollintzas has been an intellectual property attorney specializing in biotechnology and pharmaceutical licensing, FDA regulation, and corporate/international transactions. He is a member of the Wisconsin and American Bar Associations. Since 2004, Mr. Kollintzas has been in private practice. In 2014, he founded Procare Clinical, LLC, a clinical trial management company headquartered in Naperville, IL. Mr. Kollintzas received a microbiology degree from the University of Illinois and a J.D. from the University of New Hampshire School of Law. The Board of Directors has concluded that Mr. Kollintzas should serve on the Board of Directors by virtue of his experience with intellectual property matters, biotechnology and pharmaceutical licensing, and FDA regulation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><b><i>John N. (Jack) Spencer,</i></b> <b><i>Jr., CPA. </i></b>Mr. Spencer joined the Board of Directors in September 2006. Mr. Spencer is a certified public accountant and was a partner of Ernst &amp; Young LLP where he spent more than 38 years until he retired in 2000. Mr. Spencer received a Bachelor of Science degree from Syracuse University, and he earned an M.B.A. degree from Babson College. He also attended the Harvard Business School Advanced Management Program. The Board of Directors has concluded that Mr. Spencer should serve on the Board of Directors by virtue of his experience at Ernst &amp; Young LLP where he was the partner in charge of that firm&#x2019;s life sciences practice for the southeastern United States, and his clients included a large number of publicly-owned and privately-held medical technology companies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Family Relationships</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There are no family relationships among any of our directors or executive officers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Director Independence</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Board of Directors has determined that Messrs. Chase, Kollintzas, and Spencer are the members of our Board of Directors who are &#x201c;independent,&#x201d; as that term is defined by Section 301(3)(B) of the Sarbanes-Oxley Act of 2002. The Board of Directors has also determined that these individuals meet the definition of &#x201c;independent director&#x201d; set forth in Rule 5605(a)(2) of the Nasdaq Listing Rules and that Mr. Spencer is the qualified &#x201c;financial expert&#x201d; on the Audit Committee. As independent directors, Messrs. Chase, Kollintzas and Spencer serve as the members of our Audit Committee, our Compensation Committee, and our Nominating and Governance Committee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>EXECUTIVE COMPENSATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary Compensation Table</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table sets forth all compensation awarded or earned for employment services during 2021 and 2020 by (i) each person who served as our chief executive officer during 2021, and (ii) our two other most highly compensated executive officers (collectively referred to as the &#x201c;Named Executive Officers&#x201d;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 24%; border-width: 1px; border-style: solid; border-color: black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Name and</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Principal Position</b></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Year</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Salary</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Bonus</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Option</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Awards (1)</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>All Other</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Compensation</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 24%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">David A. Dodd</p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">125,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">295,610</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">(3)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,500</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">(9)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">677,110</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 24%; padding-left: 9pt; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;"><i>President and CEO</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%; text-align: center; border-bottom: 1px solid black;">2020</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">250,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">162,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">305,760</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">(6)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">8,483</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">(9)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">726,743</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 24%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Mark W. Reynolds</p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">234,392</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">94,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">138,334</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">(4)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,600</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">(9)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">478,326</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 24%; padding-left: 9pt; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;"><i>Chief Financial Officer</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%; text-align: center; border-bottom: 1px solid black;">2020</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">234,392</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">117,196</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">143,360</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">(7)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">5,803</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">(9)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">500,751</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 24%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Mark J. Newman, PhD (2)</p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">125,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,759</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">(5)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">248,759</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 24%; padding-left: 9pt; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;"><i>Chief Scientific Officer</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%; text-align: center; border-bottom: 1px solid black;">2020</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">41,667</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">18,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">39,200</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">(8)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">-</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">99,617</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the grant date fair value of the stock options for financial statement reporting purposes. See footnotes 2 and 7 to our consolidated financial statements for the year ended December 31, 2021 for a discussion of the assumptions made and methods used for determining stock compensation values.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Dr. Newman became our Chief Scientific Officer effective August 25, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the grant date fair value for stock options granted on December 7, 2021 for 103,000 shares with an exercise price of $3.82 per share, vesting over a three-year period.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(4)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the grant date fair value for stock options granted on December 7, 2021 for 48,200 shares with an exercise price of $3.82 per share, vesting over a three-year period</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(5)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the grant date fair value for stock options granted on December 7, 2021 for 25,700 shares with an exercise price of $3.82 per share, vesting over a three-year period.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(6)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the grant date fair value for stock options granted on December 2, 2020 for 273,000 shares with an exercise price of $2.79 per share, vesting over a three-year period.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(7)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the grant date fair value for stock options granted on December 2, 2020 for 128,000 shares with an exercise price of $2.79 per share, vesting over a three-year period.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(8)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the grant date fair value for stock options granted on December 2, 2020 for 35,000 shares with an exercise price of $2.79 per share, vesting over a three-year period.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(9)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Represents employer matching contributions to the Company&#x2019;s 401(k) retirement plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>David A. Dodd</i></b><b>. </b>Mr. Dodd serves as our President and Chief Executive Officer under an employment agreement dated September 1, 2018. The employment agreement has no specified term. The employment agreement provides for an initial annual salary of $250,000 to Mr. Dodd, subject to periodic increases as determined by the Board. Mr. Dodd is also eligible for an annual bonus, as determined by the Board. Mr. Dodd is eligible for annual grants of additional awards from our equity incentives plans as determined by the Board. Mr. Dodd also is eligible for health insurance and 401(k) benefits at the same level and subject to the same conditions as provided to all other employees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our employment agreement with Mr. Dodd provides that we will pay severance compensation to Mr. Dodd in the event his employment is terminated by the Company without cause or by Mr. Dodd with good reason (as defined in the agreement). If we terminate Mr. Dodd&#x2019;s employment not for cause or he resigns for good reason, then we would pay (a) an amount in cash equal to three times his then base salary and target annual bonus and (b) all stock option grants held by Mr. Dodd will be fully vested. The agreement also addresses his compensation upon termination if there is a change in control (as defined). If we terminate Mr. Dodd&#x2019;s employment not for cause or he resigns for good reason at any time during the three month period which immediately precedes a change in control (as defined) or during the one year period following a change in control, then we would also pay Mr. Dodd an amount in cash equal to (x) three times the cost to provide 401(k) or other deferred compensation or health and welfare benefits to him, and (y) a tax gross-up payment (if an excise tax is imposed by &#xa7; 4999 of the Internal Revenue Code or any related interest or penalties are incurred by him).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Mark W. Reynolds.</i></b> Mr. Reynolds serves as our Chief Financial Officer under an employment agreement dated January 1, 2010 and amended on October 22, 2013. The employment agreement has no specified term. The employment agreement, as amended, provides for an initial annual salary of $212,600 to Mr. Reynolds, subject to periodic increases as determined by the Compensation Committee. The Board of Directors may also approve the payment of a discretionary bonus annually. Mr. Reynolds is eligible for annual grants of additional awards from our equity incentives plans as determined by the Board. Mr. Reynolds is eligible for health insurance and 401(k) benefits at the same level and subject to the same conditions as provided to all other employees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our employment agreement with Mr. Reynolds provides that, if we terminate his employment without cause, we will pay a severance payment in the form of monthly payments of base salary for a period equal to one week for each full year of service. Additionally if we terminate Mr. Reynolds&#x2019; employment at any time during the three month period which immediately precedes a change in control (as defined in the amended employment agreement) or during the one year period following a change in control, then we would pay an amount in cash equal to (a) two times his then base salary and target annual bonus, (b) two times the cost to provide 401(k) or other deferred compensation or health and welfare benefits to him, (c) full, complete vesting of all stock options, restricted stock grants or other equity or equity-type grants, and (d) a tax gross-up payment (if an excise tax is imposed by &#xa7;4999 of the Internal Revenue Code or any related interest or penalties are incurred by him). The change of control provision also provides for full and complete vesting of all stock option grants held by him.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Mark J. Newman, PhD</i></b><b>. </b>Dr. Newman serves as our Chief Scientific Officer under an employment agreement dated August 25, 2020. The employment agreement has no specified term. The employment agreement provides for an initial annual salary of $250,000 on a full-time annualized basis, or $125,000 per year on a 50% prorated basis to Dr. Newman, subject to periodic increases as determined by the Compensation Committee. The Board of Directors may also approve the payment of a discretionary bonus annually. Dr. Newman is eligible for grants of awards from our equity incentive plans at the same level and subject to the same conditions as provided to all other employees. Dr. Newman is not eligible for health insurance and 401(k) benefits due to his part-time employment status. Our employment agreement with Dr. Newman provides that, if we terminate his employment without cause, we will pay a severance payment in the form of monthly payments of base salary for a period equal to one week for each full year of service.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
    49
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Outstanding Equity Awards</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GeoVax has awarded stock options to its senior management and other employees, pursuant to the GeoVax Labs, Inc. 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;). The 2020 Plan was adopted by the Board on June 19, 2020 to provide equity-based and/or incentive awards to selected employees, directors, and independent contractors of the Company or its affiliates. The terms of these awards typically provide for vesting over a defined period of time and the options expire if not exercised within ten years from the date of grant. The Company does not have a formula for determining stock option awards. Awards are generally based on the subjective judgment of the President and Chief Executive Officer and on the Compensation Committee&#x2019;s subjective judgment. The following table sets forth certain information with respect to unexercised options previously awarded to our Named Executive Officers that were outstanding as of December 31, 2021. The table also includes warrants, if any, granted to our Named Executive Officers upon payment of deferred compensation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td colspan="14" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 84%; border-width: 1px; border-style: solid; border-color: black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Option Awards</b></p> </td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 31%; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 19%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Securities</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Underlying Unexercised Options</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 2%; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid black;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%; border-bottom: 1px solid black;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-right: 1px solid black;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 16%; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 31%; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Name</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(#) Exercisable</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 2%; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(#) Unexercisable</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 2%; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Option Exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Price ($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Option Expiration</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 31%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">David Dodd</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">103,000</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">(1)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.82</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 16%; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/7/31</p> </td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="width: 31%; border-left: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 14%; text-align: right;">91,000</td>
     <td style="width: 2%; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 14%; text-align: right;">182,000</td>
     <td style="width: 2%; margin-left: 0pt; border-right: 1px solid black;">(2)</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 14%; text-align: right;">2.79</td>
     <td style="width: 1%; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="text-align: center; width: 16%; border-right: 1px solid black;">12/2/30</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="width: 31%; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; text-align: right; border-bottom: 1px solid black;">81,870</td>
     <td style="width: 2%; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">(3)</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; text-align: right; border-bottom: 1px solid black;">-</td>
     <td style="width: 2%; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; text-align: right; border-bottom: 1px solid black;">5.00</td>
     <td style="width: 1%; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="text-align: center; width: 16%; border-bottom: 1px solid black; border-right: 1px solid black;">9/29/25</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 31%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Mark Reynolds</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">48,200</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">(1)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.82</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 16%; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/7/31</p> </td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="width: 31%; border-left: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 14%; text-align: right;">42,666</td>
     <td style="width: 2%; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 14%; text-align: right;">85,334</td>
     <td style="width: 2%; margin-left: 0pt; border-right: 1px solid black;">(2)</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 14%; text-align: right;">2.79</td>
     <td style="width: 1%; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="text-align: center; width: 16%; border-right: 1px solid black;">12/2/30</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="width: 31%; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; text-align: right; border-bottom: 1px solid black;">60,184</td>
     <td style="width: 2%; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">(3)</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; text-align: right; border-bottom: 1px solid black;">-</td>
     <td style="width: 2%; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; text-align: right; border-bottom: 1px solid black;">5.00</td>
     <td style="width: 1%; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="text-align: center; width: 16%; border-bottom: 1px solid black; border-right: 1px solid black;">9/29/25</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 31%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Mark Newman, PhD</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25,700</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">(1)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.82</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-right: 1px solid black;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 16%; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1287/31</p> </td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="width: 31%; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; text-align: right; border-bottom: 1px solid black;">11,666</td>
     <td style="width: 2%; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; text-align: right; border-bottom: 1px solid black;">23,334</td>
     <td style="width: 2%; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">(2)</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; text-align: right; border-bottom: 1px solid black;">2.79</td>
     <td style="width: 1%; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="text-align: center; width: 16%; border-bottom: 1px solid black; border-right: 1px solid black;">12/2/30</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The unexercisable portion of these stock options vest and become exercisable in equal installments on December 7, 2022, 2023 and 2024.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The unexercisable portion of these stock options vest and become exercisable in equal installments on December 2, 2022 and 2023.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Warrants granted as partial payment of deferred compensation occurring on September 29, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The 2020 Plan contains provisions that could lead to an accelerated vesting of options or other awards. In the event of certain change-in-control transactions described in the 2020 Plan, (i) outstanding options or other awards may be assumed, converted or replaced; (ii) the successor corporation may substitute equivalent options or other awards or provide substantially similar consideration to 2020 Plan participants as were provided to stockholders (after taking into account the existing provisions of the options or other awards); or (iii) the successor corporation may replace options or awards with substantially similar shares or other property. In the event the successor corporation (if any) refuses to assume or substitute options or other awards as described (i) the vesting of any or all options or awards granted pursuant to the 2020 Plan will accelerate upon the change-in-control transaction, and (ii) any or all options granted pursuant to the Plans will become exercisable in full prior to the consummation of the change-in-control transaction at such time and on such conditions as the Compensation Committee determines. If the options are not exercised prior to the consummation of the change-in-control transaction, they shall terminate at such time as determined by the Compensation Committee. Subject to any greater rights granted to 2020 Plan participants under the 2020 Plan, in the event of the occurrence of a change-in-control transaction any outstanding options or other awards will be treated as provided in the applicable agreement or plan of merger, consolidation, dissolution, liquidation, or sale of assets. If the Company had experienced a change-in-control event as described in the 2020 Plan on December&#xa0;31, 2021, the value of accelerated options the Named Executive Officers, based on the difference between the closing price of our common stock on the Nasdaq Stock Market on December&#xa0;31, 2021, and, if lower, the exercise price per share of each option for which vesting would be accelerated for each Named Executive Officer, would be an aggregate of $241,254.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director Compensation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table sets forth information concerning the compensation earned for service on our Board of Directors during the fiscal year ending December 31, 2021 by each individual who served as a director at any time during the fiscal year.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 28%; border-width: 1px; border-style: solid; border-color: black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Name</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fees</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Earned or </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Paid in Cash</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Option</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Awards</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>($) (2)(3)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Non-Equity</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Incentive</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Plan</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Compensation</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Non-qualified</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Deferred</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Compensation </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Earnings</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>All</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Other</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Compensation</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Randal D. Chase</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">41,650</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">71,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">113,400</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">David A. Dodd (1)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dean G. Kollintzas</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">35,975</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">71,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">107,725</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Robert T. McNally</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">27,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">71,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">98,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">John N. Spencer, Jr.</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">47,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">71,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">118,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">As discussed below under &#x201c;Director Compensation Plan&#x201d;&#xa0;directors who are employees of the Company receive no compensation for their service as directors. As President and CEO, Mr. Dodd therefore receives no compensation for his service as a director; his compensation for service as President and CEO is shown in the &#x201c;Summary Compensation&#x201d;&#xa0;table above.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Represents the grant date fair value of&#xa0;stock options granted on December 7, 2021 to each non-employee director for 25,000 shares with an exercise price of $3.82 per share, vesting over a one-year period.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The table below shows the aggregate numbers of warrants and option awards outstanding for each non-employee director as of December&#xa0;31, 2021. The table includes warrants granted to our directors upon payment of deferred compensation occurring on September 29, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 18pt;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%; border-width: 1px; border-style: solid; border-color: black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Name</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate Option Awards</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Outstanding</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">as of December 31, 2021</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(#)</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-right: 1px solid black; border-top: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Randal D. Chase</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">66,613</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dean G. Kollintzas</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">61,987</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Robert T. McNally</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">103,925</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">John N. Spencer, Jr.</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
     <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">71,024</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid black; border-bottom: 1px solid black;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Director Compensation Plan.</i></b><b> </b>In December 2020, the Board of Directors approved a recommendation from the Compensation Committee for director compensation, which we refer to as the &#x201c;Director Compensation Plan.&#x201d; The Director Compensation Plan applies only to non-employee directors. Directors who are employees of the Company receive no compensation for their service as directors or as members of committees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Cash Fees </i>&#x2013;<i> </i>For 2021, each non-employee director earned an annual retainer (paid quarterly) of $10,000 ($30,000 for a non-employee Chairperson) for service as a member of the Board, $5,000 ($9,000 for the Chairperson) for service as a member of the Audit Committee. and $3,300 ($6,000 for the Chairperson) for service as a member of the Compensation Committee or the Nominating and Corporate Governance Committee. Non-employee directors also earned fees for each Board of Directors or Committee meeting attended as follows: $3,000 for in person Board of Directors meetings ($1,500 for telephonic meetings), $1,000 for in person Committee meeting chaired ($750 for telephonic meetings), and $500 for in person Committee meeting attended as a non-chair member ($400 for telephonic meetings).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In December 2021, the Board of Directors approved a recommendation from the Compensation Committee to amend the Director Compensation Plan, effective January 1, 2022, such that each non-employee director will receive an annual retainer (paid quarterly) of $25,000 ($50,000 for a non-employee Chairperson) for service as a member of the Board. In the absence of a non-employee Chairperson of the Board, a non-employee director designated as the Lead Director shall receive an annual cash retainer of $35,000. Each non-employee director will also receive an annual retainer of $7,500 ($15,000 for the Chairperson) for service as a member of the Audit Committee, $5,000 ($10,000 for the Chairperson) for service as a member of the Compensation Committee, and $5,000 ($7,500 for the Chairperson) for service as a member of the Nominating and Corporate Governance Committee. No additional fees will be paid for meetings attended.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Stock Option Grants </i>&#x2013;We currently do not have a formula for determining stock option grants to directors (upon their election to the Board of Directors, or otherwise). Such option grants are currently determined by the Board of Directors, upon recommendation by the Compensation Committee based on the Compensation Committee&#x2019;s annual deliberations and review of the director compensation structure of similar companies. At its meeting in December 2021, upon a recommendation of the Compensation Committee, the Board of Directors approved an annual stock option grant of 25,000 shares to each of its non-employee members for ongoing service as members of the Board of Directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expense Reimbursement </i>&#x2013;<i> </i>All directors are reimbursed for expenses incurred in connection with attending meetings of the Board of Directors and committees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Other than compensation arrangements for our Named Executive Officers and directors, we describe below each transaction since January 1, 2021, to which we were a party or will be a party, in which the amount exceeds $120,000 and in which any &#x201c;related person&#x201d; (as defined in paragraph (a) of Item 404 of Regulation S-K) had or will have a direct or indirect material interest. Compensation arrangements for our named executive officers and directors are described above under &#x201c;Executive Compensation.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Series I Warrants</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On February 25, 2019, we entered into a Securities Purchase Agreement with the Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (collectively, &#x201c;Sabby&#x201d;) providing for the issuance and sale to Sabby of an aggregate of up to 1,000 shares of our Series G Convertible Preferred Stock and related warrants (&#x201c;Series I Warrants&#x201d;) for gross proceeds of up to $1.0 million. In January 2021, all of the remaining Series I Warrants were converted into 20,196 shares of our common stock pursuant to the cashless exercise provisions of the warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>June 2020 Bridge Financing</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On June 26, 2020, we entered into a Securities Purchase Agreement with Cavalry Fund I LP and Cavalry Special Ops Fund, LLC, pursuant to which the Company received aggregate gross proceeds of $1,050,000 in exchange for the issuance of 5% Original Issue Senior Secured Convertible Debentures in the aggregate principal amount of $1,200,000 and five-year warrants to purchase an aggregate of 2,400,000 shares of our common stock at an exercise price of $0.50 per share, subject to adjustment. On September 29, 2020, the June 26, 2020 5% Original Issue Senior Secured Convertible Debentures mandatorily converted into 303,667 conversion units, of which 177,625 include shares of common stock and 126,042 include pre-funded warrants (the &#x201c;Conversion Units&#x201d;). The Conversion Units provide substantially the same terms as the Units issued in September 2020. The pre-funded warrants provide the holder the right to purchase one share of common stock at an exercise price of $0.01 per share, are immediately exercisable and will not expire until exercised in full. These pre-funded warrants were exercised on January 13, 2021. The Company also issued these investors five-year warrants to acquire an additional 303,668 shares of common stock, in the aggregate, at $5.00 per share.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SECURITY OWNERSHIP OF</b><br /> <b>PRINCIPAL STOCKHOLDERS, DIRECTORS AND OFFICERS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Based solely upon information made available to us, the following table sets forth information with respect to the beneficial ownership of our common stock as of February 3, 2022 by (i) each director; (ii) each of the executive officers named in the summary compensation table; and (iii) all executive officers and directors as a group. Other than the Selling Stockholder, we do not know of any person who beneficially owns more than 5% of our common stock as of February 3, 2022. Except as otherwise indicated in footnotes to this table or, where applicable, to the extent authority is shared by spouses under community property laws, to our knowledge, the holders listed below have sole voting and investment power with respect to all shares of common stock beneficially owned by them.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Name of Beneficial Owner</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount and Nature of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Beneficial Ownership</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percent of</b><br /> <b>Class (1)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Directors and Executive Officers: (2)</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Randal Chase (3)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">41,559</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">David A. Dodd (4)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,740</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.5</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Dean G. Kollintzas (5)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,307</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Robert T. McNally (6)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">116,183</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.6</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Kelly T. McKee</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Mark J. Newman (7)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,666</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Mark W. Reynolds (8)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">163,034</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.3</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">John N. Spencer, Jr. (9)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">50,381</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">All executive officers and directors as a group (8 persons) (10)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">669,870</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8.9</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>* </b>Less than 1%</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">This table is based upon information supplied by officers and directors, and with respect to principal stockholders, any Schedules 13D and 13G filed with the SEC. Beneficial ownership is determined in accordance with the rules of the SEC. Applicable percentage ownership is based on 7,089,025 shares of Common Stock outstanding as of February 3, 2022. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of Common Stock subject to options or warrants currently exercisable, or exercisable within 60 days after February 3, 2022 (subject to specified limits), at any time at the option of the holder, are deemed outstanding.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Except as otherwise indicated, the business address of each director and executive officer listed is c/o GeoVax Labs, Inc., 1900 Lake Park Drive, Suite 380, Smyrna, Georgia 30080.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes 16,613 shares of Common Stock and stock options/warrants to purchase 24,946 shares of common stock exercisable within 60 days.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(4)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes 81,870 shares of Common Stock and stock options/warrants to purchase 172,870 shares of common stock exercisable within 60 days.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(5)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes 11,987 shares of Common Stock and stock options/warrants to purchase 20,320 shares of common stock exercisable within 60 days.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(6)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes 53,925 shares of Common Stock and stock options/warrants to purchase 62,258 shares of common stock exercisable within 60 days.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(7)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes stock options to purchase 11,666 shares of common stock exercisable within 60 days.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(8)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes 60,184 shares of Common Stock and stock options/warrants to purchase 102,850 shares of common stock exercisable within 60 days.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(9)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes 21,024 shares of Common Stock and stock options/warrants to purchase 29,357 shares of common stock exercisable within 60 days.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(10)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes 245,603 shares of Common Stock and stock options/warrants to purchase 424,267 shares of common stock exercisable within 60 days.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
    53
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SELLING STOCKHOLDER</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The common stock being offered by the Selling Stockholder are those previously issued to the Selling Stockholder, and those issuable to the Selling Stockholder, upon exercise of the Warrants. For additional information regarding the issuances of those shares of common stock and the Warrants, see &#x201c;Prospectus Summary&#x2013;Recent Developments&#x2013;Private Placement&#x201d; above. We are registering the shares of common stock in order to permit the Selling Stockholder to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the Warrants, the Selling Stockholder has not had any material relationship with us within the past three years.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The table below lists the Selling Stockholder and other information regarding the beneficial ownership of the shares of common stock by the Selling Stockholder. The second column lists the number of shares of common stock beneficially owned by the Selling Stockholder, based on its ownership of the shares of common stock and the Warrants, as of February 3, 2022, assuming exercise of the Warrants held by the Selling Stockholder on that date, without regard to any limitations on exercises. The third column lists the shares of common stock being offered by this prospectus by the Selling Stockholder.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In accordance with the terms of a registration rights agreement with the Selling Stockholder, this prospectus generally covers the resale of the sum of (i) the number of shares of common stock issued to the Selling Stockholder as described in &#x201c;Prospectus Summary&#x2013;Recent Developments&#x2013;Private Placement&#x201d; and (ii) the maximum number of shares of common stock issuable upon exercise of the Warrants, determined as if the outstanding Warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the registration right agreement, without regard to any limitations on the exercise of the Warrants. The fourth column assumes the sale of all of the shares offered by the Selling Stockholder pursuant to this prospectus.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the terms of the Warrants, the Selling Stockholder may not exercise the Warrants to the extent such exercise would cause the Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such Warrants which have not been exercised. The number of shares in the second and fourth columns do not reflect this limitation. The Selling Stockholder may sell all, some or none of their shares in this offering. See &#x201c;Plan of Distribution.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 45%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Selling</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Stockholder</b></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of Shares of Common Stock Owned Prior to Offering</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Shares of Common Stock Owned After the Offering</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Armistice Capital Master Fund Ltd. <sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;">&#xa0;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,134,968</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,134,968</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2013;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;The shares are directly held by the Selling Stockholder and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (&#x201c;Armistice Capital&#x201d;), as the investment manager of the Selling Stockholder; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. The number of shares beneficially owned prior to this offering includes: (i) 2,360,000 shares of common stock issuable upon exercise of the Pre-Funded Warrants, which are subject to beneficial ownership limitations that prohibit the Selling Stockholder from exercising any portion of a warrant if such exercise would result in the Selling Stockholder owning a percentage of our outstanding common stock exceeding the 9.99% ownership limitation after giving effect to the issuance of common stock in connection with the Selling Stockholder&#x2019;s exercise of the Pre-Funded Warrant; (ii) 3,067,484 shares of common stock issuable upon the exercise of Common Warrants, which are subject to beneficial ownership limitations that prohibit the Master Fund from exercising any portion of a warrant if such exercise would result in the Selling Stockholder owning a percentage of our outstanding common stock exceeding the 4.99% ownership limitation after giving effect to the issuance of common stock in connection with the Selling Stockholder&#x2019;s exercise of the Common Warrants. The percentage of shares owned after offering assumes the exercise of all Warrants held by the Selling Stockholder, notwithstanding the existence of beneficial ownership limitations described above. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>&#xa0;Floor, New York, NY 10022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DESCRIPTION OF CAPITAL STOCK</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Capital Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following description of our capital stock is summarized from, and qualified in its entirety by reference to, our certificate of incorporation, as amended, including the certificates of designation, as amended, setting forth the terms of our preferred stock. This summary is not intended to give full effect to provisions of statutory or common law. We urge you to review the following documents because they, and not this summary, define the rights of a holder of shares of common stock and preferred stock:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the General Corporation Law of the State of Delaware, or the &#x201c;DGCL&#x201d;, as it may be amended from time to time;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our certificate of incorporation, as it may be amended or restated from time to time; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our bylaws, as they may be amended or restated from time to time.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>General</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our authorized capital stock currently consists of 610,000,000 shares, which are divided into two classes consisting of 600,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of February 3, 2022, there were 7,089,025 shares of common stock outstanding and no shares of preferred stock outstanding. As of February 3, 2022, there were 2,360,000 Pre-Funded Warrants with an exercise price of $0.0001 per share and other outstanding warrants to purchase 4,064,149 shares of common stock issuable upon the exercise of such warrants with a weighted average exercise price of $3.88 per share. An additional 1,500,000 shares of common stock are reserved for issuance under our 2020 Stock Incentive Plan, of which 962,300 shares of common stock are issuable upon exercise of outstanding options at an average exercise price of $3.18 per share.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our common stock is listed and traded on the Nasdaq Capital Market under the symbol &#x201c;GOVX.&#x201d; Holders of our common stock are entitled to one vote for each share held in the election of directors and in all other matters to be voted on by the stockholders. There is no cumulative voting in the election of directors. Holders of common stock are entitled to receive dividends as may be declared from time to time by our Board of Directors out of funds legally available therefor, and subject to the rights of holders of our Series B Preferred Stock. In the event of liquidation, dissolution or winding up of the Company, holders of common stock are to share in all assets remaining after the payment of liabilities, and satisfaction of the liquidation preference of our outstanding Series B Preferred Stock. Holders of common stock have no pre-emptive or conversion rights and are not subject to further calls or assessments. There are no redemption or sinking fund provisions applicable to the common stock. The rights of the holders of the common stock are subject to any rights that may be fixed in the future for holders of preferred stock. All of the outstanding shares of common stock are fully paid and non-assessable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Undesignated Preferred Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our Board of Directors has the authority to issue up to 10,000,000 shares of preferred stock in one or more series and fix the number of shares constituting any such series, the voting powers, designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof, including the dividend rights, dividend rate, terms of redemption (including sinking fund provisions), redemption price or prices, conversion rights and liquidation preferences of the shares constituting any series, without any further vote or action by the stockholders. For example, the Board of Directors is authorized to issue preferred stock that would have the right to vote, separately or with any other stockholder of preferred stock, on any proposed amendment to our certificate of incorporation, or on any other proposed corporate action, including business combinations and other transactions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We will not offer preferred stock unless the offering is approved by a majority of our independent directors. The independent directors will have access, at our expense, to our counsel or independent counsel.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Delaware Anti-Takeover Law</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have elected not to be subject to certain provisions of Delaware law that could make it more difficult to acquire us by means of a tender offer, a proxy contest, open market purchases, removal of incumbent directors and otherwise. These provisions, summarized below, are expected to discourage types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in various &#x201c;business combination&#x201d; transactions with any interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the transaction is approved by the corporation&#x2019;s board of directors prior to the date the interested stockholder obtained interested stockholder status;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">upon consummation of the transaction that resulted in the stockholder&#x2019;s becoming an interested stockholder, the stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned by (a) persons who are directors and also officers and (b) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">on or subsequent to the date the business combination is approved by the corporation&#x2019;s board of directors and authorized at an annual or special meeting of stockholders by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A &#x201c;business combination&#x201d; is defined to include mergers, asset sales and other transactions resulting in financial benefit to a stockholder. In general, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns or within three years, did own, 15% or more of a corporation&#x2019;s voting stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Section 203 applies to Delaware corporations that have a class of voting stock that is listed on a national securities exchange or held of record by more than 2,000 stockholders; provided, however, the restrictions of this statute will not apply to a corporation if:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the corporation&#x2019;s original charter contains a provision expressly electing not to be governed by the statute;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the corporation&#x2019;s board of directors adopts an amendment to the corporation&#x2019;s bylaws within 90 days of the effective date of the statute expressly electing not to be governed by it;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the stockholders of the corporation adopt an amendment to its charter or bylaws expressly electing not to be governed by the statute (so long as such amendment is approved by the affirmative vote of a majority of the shares entitled to vote);</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a stockholder becomes an interested stockholder inadvertently and as soon as practicable divests himself of ownership of a sufficient number of shares so that he ceases to be an interested stockholder, and during the three-year period immediately prior to a business combination, would not have been an interested stockholder but for the inadvertent acquisition;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the business combination is proposed prior to the consummation or abandonment of a merger or consolidation, a sale, lease, exchange, mortgage, pledge, transfer or other disposition of assets of the corporation or a proposed tender or exchange offer for 50% or more of the outstanding voting shares of the corporation; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the business combination is with an interested stockholder who became an interested stockholder at a time when the restrictions contained in the statutes did not apply.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our certificate of incorporation includes a provision electing not to be governed by Section 203 of the DCGL. Accordingly, our board of directors does not have the power to reject certain business combinations with interested stockholders based on Section 203 of the DCGL.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Indemnification</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#x2019; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our bylaws provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#x2019; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#x2019;s conduct was unlawful. Our bylaws also provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#x2019; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under our bylaws, expenses (including attorneys&#x2019; fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company. Such expenses (including attorneys&#x2019; fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any, as we deem appropriate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The indemnification and advancement of expenses provided by our bylaws is not exclusive, both as to action in such person&#x2019;s official capacity and as to action in another capacity while holding such office.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our bylaws also provide that we may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#x2019;s status as such, whether or not the Company would have the power to indemnify such person against such liability under our bylaws. The Company maintains an insurance policy providing for indemnification of its officers, directors and certain other persons against liabilities and expenses incurred by any of them in certain stated proceedings and under certain stated conditions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In October 2006, GeoVax and our subsidiary, GeoVax, Inc. entered into indemnification agreements with Messrs. McNally, Reynolds, Kollintzas and Spencer. Pursuant to these agreements, we have agreed to hold harmless and indemnify these directors and officers to the full extent authorized or permitted by applicable Illinois and Georgia law against certain expenses and other liabilities actually and reasonably incurred by these individuals in connection with certain proceedings if they acted in a manner they believed in good faith to be in or not opposed to the best interests of the Company and, with respect to any criminal proceeding, had no reasonable cause to believe that such conduct was unlawful. The agreements also provide for the advancement of expenses to these individuals subject to specified conditions. Under these agreements, we will not indemnify these individuals for expenses or other amounts for which applicable Illinois and Georgia law prohibit indemnification. The obligations under these agreements continue during the period in which these individuals are our directors or officers and continue thereafter so long as these individuals shall be subject to any proceeding by reason of their service to the Company, whether or not they are serving in any such capacity at the time the liability or expense incurred for which indemnification can be provided under the agreements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the event that a claims for indemnification against such liabilities (other than our payment of expenses incurred or paid by a director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Transfer Agent, Warrant Agent and Registrar</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The transfer agent and registrar for our common stock and warrant agent for our September Warrants is American Stock Transfer &amp; Trust Company, LLC, 6201 15th Avenue, Brooklyn, NY 11219, telephone (718) 921-8200.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Listing</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our common stock is listed on The Nasdaq Capital Market under the symbol &#x201c;GOVX.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PLAN OF DISTRIBUTION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Selling Stockholder and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the Nasdaq or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. The Selling Stockholder may use any one or more of the following methods when selling securities:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">an exchange distribution in accordance with the rules of the applicable exchange;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">privately negotiated transactions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">settlement of short sales;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">in transactions through broker-dealers that agree with the Selling Stockholder to sell a specified number of such securities at a stipulated price per security;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a combination of any such methods of sale; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other method permitted pursuant to applicable law.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Selling Stockholder may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Broker-dealers engaged by the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the sale of the securities or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholder may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Selling Stockholder and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#x201c;underwriters&#x201d; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are required to pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholder without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for us to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholder or any other person. We will make copies of this prospectus available to the Selling Stockholder and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>LEGAL MATTERS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The validity of the shares of Common Stock offered hereby will be passed upon for us by Womble Bond Dickinson (US) LLP. If the securities are distributed in an underwritten offering, certain legal matters will be passed upon for the underwriters by counsel identified in the applicable prospectus supplement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXPERTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our consolidated financial statements as of and for the years ended December 31, 2020 and 2019 included in this prospectus and elsewhere in the registration statement have been audited by Wipfli LLP, an independent registered public accounting firm, as indicated in their report with respect thereto, and are included herein in reliance upon the authority of said firm as experts in auditing and accounting in giving said report.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WHERE YOU CAN FIND MORE INFORMATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have filed with the SEC, under the Securities Act, a registration statement on Form S-1 relating to the securities offered hereby. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. For further information with respect to our company and the securities we are offering by this prospectus you should refer to the registration statement, including the exhibits and schedules thereto. The SEC also maintains an Internet site that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The SEC&#x2019;s website address is http://www.sec.gov.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We file periodic reports, proxy statements and other information with the SEC in accordance with requirements of the Exchange Act. These periodic reports, proxy statements and other information are available at the SEC&#x2019;s website address referred to above. In addition, you may request a copy of any of our periodic reports filed with the SEC at no cost, by writing or telephoning us at the following address:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">GeoVax Labs, Inc.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1900 Lake Park Drive, Suite 380</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Smyrna, Georgia 30080</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Tel: (678) 384-7220</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Attention: Mark W. Reynolds, Chief Financial Officer</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Information contained on our website is not a prospectus and does not constitute a part of this prospectus.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">You should rely only on the information contained in or incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume the information in this prospectus is accurate as of any date other than the date on the front of this prospectus.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>INDEX TO FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Condensed Consolidated Financial Statements</span></b>:</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="text-decoration: underline; ">Page</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-2</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Condensed Consolidated Statements of Operations for the three-month and nine-month periods ended September 30, 2021 and 2020 (unaudited)</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-3</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Condensed Consolidated Statements of Changes in Stockholders&#x2019;&#xa0;Equity (Deficiency) for the three-month and nine-month periods ended September 30, 2021 and 2020 (unaudited)</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-4</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Condensed Consolidated Statements of Cash Flows for the three-month and nine-month periods ended September 30, 2021 and 2020 (unaudited)</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-6</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Notes to Condensed Consolidated Financial Statements (unaudited)</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-8</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:85.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.6%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">2020 Consolidated Financial Statements</span></b>:</p> </td>
     <td style="vertical-align:top;width:15.6%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Report of Independent Registered Public Accounting Firm</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-13</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Consolidated Balance Sheets as of December 31, 2020 and 2019</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-15</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Consolidated Statements of Operations for the years ended December 31, 2020 and 2019</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-16</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Consolidated Statements of Stockholders&#x2019;&#xa0;Equity (Deficiency) for the years ended December 31, 2020 and 2019</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-17</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-18</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Notes to Consolidated Financial Statements</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-19</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Financial Statement Schedule:</p> </td>
     <td style="vertical-align:top;width:15.6%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:85.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;">Schedule II &#x2013;&#xa0;Valuation and Qualifying Accounts for the years ended December 31, 2020 and 2019</p> </td>
     <td style="vertical-align:top;width:15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-31</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0; &#xa0;&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Part I -- FINANCIAL INFORMATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 1</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b><span style="text-decoration: underline; ">Financial Statements</span></b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td colspan="7" style="vertical-align:top;width:102.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p> </td>
    </tr>

    <tr>
     <td colspan="7" style="vertical-align:top;width:102.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONDENSED CONSOLIDATED BALANCE SHEETS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(unaudited)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASSETS</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219557" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">18,107,019</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219558" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">9,883,796</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Grant funds and other receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219559" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:GrantsReceivable" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219560" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:GrantsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF">182,663</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219561" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">52,818</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219562" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">168,689</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219563" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">18,159,837</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219564" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">10,235,148</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219565" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">168,653</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219566" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">147,741</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deposits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219567" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:DepositsAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">11,010</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219568" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DepositsAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">11,010</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219569" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">18,339,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219570" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">10,393,899</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219571" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">289,438</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219572" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">267,702</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219573" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">46,212</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219574" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">359,281</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Current portion of notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219575" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219576" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">183,326</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219577" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">335,650</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219578" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">810,309</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219579" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LongTermNotesPayable" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219580" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">14,738</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219581" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">335,650</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219582" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">825,047</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Commitments (Note 8)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c80220915">&#xa0;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c80220916">&#xa0;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stockholders&#x2019; equity:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Preferred Stock, $<span style="-sec-ix-hidden:c80220863"><span style="-sec-ix-hidden:c80220864">.01</span></span> par value:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Authorized shares &#x2013; <span style="-sec-ix-hidden:c80220867"><span style="-sec-ix-hidden:c80220868">10,000,000</span></span> Series B convertible preferred stock, $<span style="-sec-ix-hidden:c80220865"><span style="-sec-ix-hidden:c80220866">1,000</span></span> stated value; -<span style="-sec-ix-hidden:c80220869"><span style="-sec-ix-hidden:c80220871">0</span></span>- and <span style="-sec-ix-hidden:c80220870"><span style="-sec-ix-hidden:c80220872">100</span></span> shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219583" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219584" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Common stock, $<span style="-sec-ix-hidden:c80220873"><span style="-sec-ix-hidden:c80220874">.001</span></span> par value:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Authorized shares &#x2013; <span style="-sec-ix-hidden:c80220875"><span style="-sec-ix-hidden:c80220876">600,000,000</span></span> Issued and outstanding shares &#x2013; <span style="-sec-ix-hidden:c80220877"><span style="-sec-ix-hidden:c80220879">6,381,541</span></span> and <span style="-sec-ix-hidden:c80220878"><span style="-sec-ix-hidden:c80220880">3,834,095</span></span> at September 30, 2021 and December 31, 2020, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219585" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">6,382</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219586" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219587" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">68,630,363</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219588" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">55,294,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219589" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">50,632,895</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219590" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">45,805,581</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders&#x2019; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219591" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">18,003,850</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219592" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">9,568,852</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities and stockholders&#x2019; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80219593" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">18,339,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80219594" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">10,393,899</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Three Months Ended September 30,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Nine Months Ended September 30,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Grant and collaboration revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219603" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">30,414</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219604" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">415,458</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219605" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">220,539</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219606" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,572,037</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46.3%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219607" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,224,362</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219608" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">416,756</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219609" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,659,980</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219610" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,687,113</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219611" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">757,432</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219612" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">435,013</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219613" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,562,641</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219614" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,364,650</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total operating expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219615" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">1,981,794</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219616" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">851,769</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219617" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">5,222,621</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219618" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">3,051,763</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219619" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,951,380</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219620" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">436,311</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219621" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,002,082</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219622" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,479,726</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income (expense):</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219623" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">877</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219624" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">90</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219625" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">3,998</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219626" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">902</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219627" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219628" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">134,427</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219629" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,286</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219630" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">142,722</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Gain on debt extinguishment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219631" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219632" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219633" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">172,056</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219634" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total other income (expense)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219635" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">877</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80219636" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">134,337</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219637" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">174,768</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80219638" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">141,820</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219639" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,950,503</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219640" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">570,648</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219641" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,827,314</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219642" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,621,546</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss per common share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219643" contextRef="d_2021-07-01_2021-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.31</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219644" contextRef="d_2020-07-01_2020-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.73</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219645" contextRef="d_2021-01-01_2021-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.80</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219646" contextRef="d_2020-01-01_2020-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2.85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219647" contextRef="d_2021-07-01_2021-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">6,349,297</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219648" contextRef="d_2020-07-01_2020-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">782,978</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219649" contextRef="d_2021-01-01_2021-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">6,005,032</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219650" contextRef="d_2020-01-01_2020-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">569,955</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS</b>&#x2019;<b> EQUITY (DEFICIENCY)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="26" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Three-Month and Nine-Month Periods Ended September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Preferred Stock</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Additional</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stockholders&#x2019;</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Paid-in Capital</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deficit</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219654" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219655" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219656" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219657" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219658" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">55,294,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219659" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">45,805,581</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219660" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">9,568,852</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Sale of common stock for cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219661" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219662" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219663" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,644,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219664" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,644</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219665" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">9,407,276</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219666" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219667" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">9,408,920</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common stock upon warrant exercise</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219668" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219669" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219670" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">835,900</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219671" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">836</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219672" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">3,173,320</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219673" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219674" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">3,174,156</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common stock for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219675" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219676" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219677" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">1,472</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219678" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219679" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">5,999</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219680" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219681" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">6,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219686" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">56,190</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 72pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219688" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">56,190</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss for the three months ended March 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219694" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,562,778</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219695" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,562,778</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at March 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219696" contextRef="i_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219697" contextRef="i_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219698" contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">6,315,467</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219699" contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">6,315</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219700" contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">67,937,289</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219701" contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">47,368,359</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219702" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">20,651,340</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Repurchase of preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219703" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219704" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219705" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219706" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219707" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">75,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219708" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219709" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common stock for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219710" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219711" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219712" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">12,235</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219713" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">13</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219714" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">65,828</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219715" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219716" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">65,841</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219718" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219720" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219721" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">56,190</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 72pt; text-align: right;"><ix:nonFraction id="c80219722" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219723" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">56,190</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss for the three months ended June 30, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219725" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219727" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219728" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219729" contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,314,033</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219730" contextRef="d_2021-04-01_2021-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,314,033</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219731" contextRef="i_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219732" contextRef="i_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219733" contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">6,327,702</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219734" contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">6,328</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219735" contextRef="i_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">68,134,402</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219736" contextRef="i_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">48,682,392</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219737" contextRef="i_2021-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">19,458,338</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common stock upon warrant exercise</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219738" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219739" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219740" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">53,839</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219741" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">54</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219742" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">229,946</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219743" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219744" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">230,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219746" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219748" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219749" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">56,190</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219750" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219751" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">56,190</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of warrant for technology license</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219753" contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219755" contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219756" contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">209,825</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219757" contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219758" contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">209,825</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss for the three months ended September 30, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219760" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219762" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219763" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219764" contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,950,503</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219765" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,950,503</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at September 30, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219766" contextRef="i_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219767" contextRef="i_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219768" contextRef="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">6,381,541</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219769" contextRef="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">6,382</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219770" contextRef="i_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">68,630,363</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219771" contextRef="i_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">50,632,895</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219772" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">18,003,850</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
    F-4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS</b>&#x2019;<b> EQUITY (DEFICIENCY)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="26" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Three-Month and Nine-Month Periods Ended September 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Preferred Stock</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Additional</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stockholders&#x2019;</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Paid-in Capital</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deficit</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity (Deficiency)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219773" contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219774" contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">1,932,433</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219775" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">14,992</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219776" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">15</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219777" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">39,340,509</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219778" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">42,847,513</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219779" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,574,556</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Sale of convertible preferred stock for cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219780" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" format="ixt:numdotdecimal" decimals="INF">300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219781" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219786" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Conversion of preferred stock to common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219787" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,386</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219788" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,856,338</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219789" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">674,067</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219790" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">674</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219791" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,855,664</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock issued for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219794" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219795" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219796" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">521</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219797" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219798" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">5,999</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219799" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219800" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">6,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss for the three months ended March 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219806" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">595,694</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219807" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">595,694</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at March 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219808" contextRef="i_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">400</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219809" contextRef="i_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">376,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219810" contextRef="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">689,580</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219811" contextRef="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">690</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219812" contextRef="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">41,202,172</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219813" contextRef="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">43,443,207</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219814" contextRef="i_2020-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,864,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock issued for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219815" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219816" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219817" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">2,124</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219818" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219819" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">11,998</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219820" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219821" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">12,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrants issued in bridge financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219823" contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219825" contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219826" contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">457,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 72pt; text-align: right;"><ix:nonFraction id="c80219827" contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219828" contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">457,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss for the three months ended June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219830" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219832" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219833" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80219834" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">455,204</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80219835" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">455,204</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219836" contextRef="i_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">400</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219837" contextRef="i_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">376,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219838" contextRef="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">691,704</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219839" contextRef="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">692</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219840" contextRef="i_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">41,672,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219841" contextRef="i_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">43,898,411</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219842" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,849,621</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Conversion of preferred stock to common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219843" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219844" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219845" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">42,723</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219846" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">43</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219847" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">299,957</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219848" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219849" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrants exercised for common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219850" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219851" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219852" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">36,902</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219853" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80219854" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219855" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219856" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock issued upon debenture conversion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219857" contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219858" contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219859" contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">177,626</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219860" contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219861" contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">569,340</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219862" contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219863" contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">569,517</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock issued upon cancellation of accrued compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219864" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219865" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219866" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">300,001</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219867" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219868" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">1,499,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219869" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219870" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">1,500,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Sale of common stock for cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219871" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219872" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219873" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,310,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219874" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,310</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219875" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">11,156,186</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219876" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219877" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">11,158,496</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock issued for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219878" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219879" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219880" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">517</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219881" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt; text-align: right;"><ix:nonFraction id="c80219882" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">6,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219883" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219884" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">6,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss for the three months ended September 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219886" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219888" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219889" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219890" contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">570,648</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219891" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">570,648</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at September 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219892" contextRef="i_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219893" contextRef="i_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219894" contextRef="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,559,473</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219895" contextRef="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">3,559</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219896" contextRef="i_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">55,203,149</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219897" contextRef="i_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">44,469,059</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219898" contextRef="i_2020-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">10,813,744</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td colspan="9" style="vertical-align:top;width:101.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Nine Months Ended September 30,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash flows from operating activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c80219899" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,827,314</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c80219900" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,621,546</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-indent: -9pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219901" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">26,806</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219902" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">2,983</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-indent: -9pt;">Stock-based compensation for employees and directors</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219903" contextRef="d_2021-01-01_2021-09-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">168,570</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219904" contextRef="d_2020-01-01_2020-09-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-indent: -9pt;">Stock-based compensation for consultants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219905" contextRef="d_2021-01-01_2021-09-30_TitleOfIndividualAxis-ConsultantsMember" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">80,733</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219906" contextRef="d_2020-01-01_2020-09-30_TitleOfIndividualAxis-ConsultantsMember" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">24,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-indent: -9pt;">Warrant issued for technology license fee</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219907" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" format="ixt:numdotdecimal" decimals="INF">209,825</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219908" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-indent: -9pt;">Gain on debt extinguishment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c80219909" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">172,056</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219910" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-indent: -9pt;">Changes in assets and liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 63pt; text-indent: -9pt;">Grant funds and other receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219911" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">182,663</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c80219912" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" format="ixt:numdotdecimal" decimals="INF">72,551</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 63pt; text-indent: -9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219913" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">106,979</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219914" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">82,274</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 63pt; text-indent: -9pt;">Amortization of debt discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219915" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219916" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" format="ixt:numdotdecimal" decimals="INF">124,185</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 63pt; text-indent: -9pt;">Accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80219917" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">289,477</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219918" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">252,036</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 63pt; text-indent: -9pt;">Total adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219919" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">314,043</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219920" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">412,927</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net cash used in operating activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c80219921" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,513,271</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c80219922" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,208,619</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash flows from investing activities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Purchase of property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80219923" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">47,718</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80219924" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">2,470</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Net cash used in investing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c80219925" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">47,718</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c80219926" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,470</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash flows from financing activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Net proceeds from sale of common stock and warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219927" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="govx:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">9,408,920</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219928" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="govx:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">11,158,496</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Net proceeds from sale of preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219929" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219930" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Net proceeds from warrant exercises</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219931" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:numdotdecimal" decimals="INF">3,404,156</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219932" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Net proceeds from bridge financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219933" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219934" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">888,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Net proceeds from issuance of note payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219935" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219936" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">170,200</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Repurchase of preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c80219937" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219938" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Principal repayment of note payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80219939" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:RepaymentsOfNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">27,864</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80219940" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:RepaymentsOfNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">8,854</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Net cash provided by financing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219941" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">12,784,212</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219942" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">12,508,342</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219943" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">8,223,223</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80219944" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">11,297,253</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219945" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">9,883,796</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219946" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">283,341</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at end of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80219947" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">18,107,019</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80219948" contextRef="i_2020-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">11,580,594</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Supplemental disclosure of non-cash financing activities:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the nine months ended September 30, 2021:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:9pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">149,705 shares of common stock were issued upon the cashless exercise of stock purchase warrants</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:9pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$172,056 of principal and accrued interest related to a note payable was extinguished upon the loan&#x2019;s forgiveness</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the nine months ended September 30, 2020:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:9pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">716,790 shares of common stock were issued upon conversion of convertible preferred stock</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:9pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">36,902 shares of common stock were issued upon the cashless exercise of stock purchase warrants</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:9pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">300,001 shares of common stock and 300,001 stock purchase warrants were issued in exchange for cancellation of $1,500,000 owed to current and former employees and directors</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:9pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">177,626 shares of common stock, 126,042 pre-funded stock purchase warrants and 303,668 stock purchase warrants were issued upon conversion of $1,200,000 convertible debentures and $14,667 of related accrued interest</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC. </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>September 30, 2021</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:NatureOfOperations" id="c2016481" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Description of Business </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax&#x2019;s Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) based platform utilizes MVA, a large virus capable of carrying several vaccine antigens, to express proteins that assemble into highly effective virus-like particle (VLP) immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax&#x2019;s MVA-VLP development programs are focused primarily on preventive vaccines against the SARS-CoV-<em style="font: inherit;">2</em> virus (COVID-<em style="font: inherit;">19</em>) and immunotherapies for solid tumor cancers. Other development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), Human Immunodeficiency Virus (HIV), and malaria. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 28, 2021, </em>GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc., whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#xae;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase <em style="font: inherit;">1/2</em> clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and <em style="font: inherit;">no</em> curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#x2019;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but <em style="font: inherit;">not</em> limited to, cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:BasisOfAccounting" id="c2016482" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Basis of Presentation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying condensed consolidated financial statements at <em style="font: inherit;"> September 30, 2021 </em>and for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020</em> are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2020. </em>We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results in future periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We enacted reverse stock splits of our common stock on <em style="font: inherit;"> September 25, 2020 (</em><em style="font: inherit;">1</em>-for-<ix:nonFraction id="c80220371" contextRef="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:numdotdecimal" decimals="INF">20</ix:nonFraction>) and on <em style="font: inherit;"> January 21, 2020 (</em><em style="font: inherit;">1</em>-for-<ix:nonFraction id="c80220373" contextRef="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:numdotdecimal" decimals="INF">2,000</ix:nonFraction>). The accompanying financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for at least the <em style="font: inherit;">twelve</em>-month period following the issue date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We <em style="font: inherit;"> may </em>never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we <em style="font: inherit;"> may </em>seek additional capital through arrangements with strategic partners or from other sources. There can be <em style="font: inherit;">no</em> assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#xa0;</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2016483" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Significant Accounting Policies and Recent Accounting Pronouncements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We disclosed in Note <em style="font: inherit;">2</em> to our consolidated financial statements included in our Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2020 </em>those accounting policies that we consider significant in determining our results of operations and financial position. During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>there have been <em style="font: inherit;">no</em> material changes to, or in the application of, the accounting policies previously identified and described in the Form <em style="font: inherit;">10</em>-K, and there have been <em style="font: inherit;">no</em> other recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:EarningsPerShareTextBlock" id="c2016484" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Basic and Diluted Loss Per Common Share</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share totaled <ix:nonFraction id="c80220384" contextRef="d_2021-07-01_2021-09-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">2,965,451</ix:nonFraction> and <ix:nonFraction id="c80220385" contextRef="d_2021-01-01_2021-09-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">2,550,184</ix:nonFraction> shares for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>respectively, as compared to <ix:nonFraction id="c80220388" contextRef="d_2020-07-01_2020-09-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">204,553</ix:nonFraction> and <ix:nonFraction id="c80220389" contextRef="d_2020-01-01_2020-09-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">78,754</ix:nonFraction> shares for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2020, </em>respectively.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2016485" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;"> December 31, 2020:</em></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2016486" escape="true">
    <table class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and furnishings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220207" contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">591,554</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220208" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">543,836</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220209" contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">115,605</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220210" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">115,605</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220211" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">707,159</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220212" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">659,441</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220213" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">538,506</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220214" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">511,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220215" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">168,653</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220216" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">147,741</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="c2016487" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Accrued Expenses</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;"> December 31, 2020:</em></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c2016488" escape="true">
    <table class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220217" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccruedSalariesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">11,212</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220218" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedSalariesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">279,696</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220219" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">35,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220220" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">79,585</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220221" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">46,212</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220222" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">359,281</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:DebtDisclosureTextBlock" id="c2016489" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GRA Note</i> &#x2013; On <em style="font: inherit;"> February 28, 2018, </em>we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a <span style="-sec-ix-hidden:c80220395">five</span>-year Senior Promissory Note (the &#x201c;GRA Note&#x201d;) to GRA in exchange for $<ix:nonFraction id="c80220396" contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction>. The GRA Note bore an annual interest rate of <span style="-sec-ix-hidden:c80220397">five</span> percent. Interest expense related to the GRA Note for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021 </em>was $-<ix:nonFraction id="c80220400" contextRef="d_2021-07-01_2021-09-30_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>- and $<ix:nonFraction id="c80220401" contextRef="d_2021-01-01_2021-09-30_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">633</ix:nonFraction>, respectively, as compared to $<ix:nonFraction id="c80220402" contextRef="d_2020-07-01_2020-09-30_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">411</ix:nonFraction> and $<ix:nonFraction id="c80220403" contextRef="d_2020-01-01_2020-09-30_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">1,344</ix:nonFraction>, respectively, for the same periods of <em style="font: inherit;">2020.</em> During <em style="font: inherit;"> May 2021, </em>we repaid the remaining principal balance of $<ix:nonFraction id="c80220405" contextRef="d_2021-05-01_2021-05-31_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:RepaymentsOfNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">22,737</ix:nonFraction> and retired the GRA Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>CARES Act Paycheck Protection Program Loan </i>&#x2013;<i> </i>On <em style="font: inherit;"> April 17, 2020, </em>we received a $<ix:nonFraction id="c80220406" contextRef="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">170,200</ix:nonFraction> bank loan backed by the United States Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bore an annual interest rate of <em style="font: inherit;">one</em> percent. We recorded accrued interest expense related to the PPP Loan of $-<ix:nonFraction id="c80220408" contextRef="d_2021-07-01_2021-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>- and $<ix:nonFraction id="c80220409" contextRef="d_2021-01-01_2021-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">653</ix:nonFraction> for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>respectively, as compared to $<ix:nonFraction id="c80220412" contextRef="d_2020-07-01_2020-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">429</ix:nonFraction> and $<ix:nonFraction id="c80220413" contextRef="d_2020-01-01_2020-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">774</ix:nonFraction>, respectively, for the same periods of <em style="font: inherit;">2020.</em> During <em style="font: inherit;"> May 2021, </em>upon receiving payment from the SBA, the lender forgave the full principal balance of $<ix:nonFraction id="c80220415" contextRef="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:ExtinguishmentOfDebtAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">170,200</ix:nonFraction> together with $<ix:nonFraction id="c80220416" contextRef="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="govx:GainLossFromInterestForgiven" scale="0" format="ixt:numdotdecimal" decimals="INF">1,856</ix:nonFraction> of accrued interest and extinguished the PPP Loan.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:CommitmentsDisclosureTextBlock" id="c2016490" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We lease approximately <ix:nonFraction id="c80220418" contextRef="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:numdotdecimal" decimals="INF">8,400</ix:nonFraction> square feet of office and laboratory space pursuant to an operating lease which expires on <em style="font: inherit;"> December 31, 2022. </em>Rent expense for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021 </em>was $<ix:nonFraction id="c80220421" contextRef="d_2021-07-01_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">42,803</ix:nonFraction> and $<ix:nonFraction id="c80220422" contextRef="d_2021-01-01_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">128,410</ix:nonFraction>, respectively, as compared to $<ix:nonFraction id="c80220423" contextRef="d_2020-07-01_2020-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">41,539</ix:nonFraction> and $<ix:nonFraction id="c80220424" contextRef="d_2020-01-01_2020-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">124,617</ix:nonFraction>, respectively, for the same periods of <em style="font: inherit;">2020.</em> Future minimum lease payments total $<ix:nonFraction id="c80220426" contextRef="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" format="ixt:numdotdecimal" decimals="INF">42,803</ix:nonFraction> for the remainder of <em style="font: inherit;">2021</em> and $<ix:nonFraction id="c80220428" contextRef="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" format="ixt:numdotdecimal" decimals="INF">176,356</ix:nonFraction> in <em style="font: inherit;">2022,</em> although the lease <em style="font: inherit;"> may </em>be terminated at any time by either party with <em style="font: inherit;">ninety</em> days&#x2019; written notice.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of <em style="font: inherit;"> September 30, 2021, </em>there are approximately $<ix:nonFraction id="c80220431" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">607,000</ix:nonFraction> of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in <em style="font: inherit;">2021.</em></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:PreferredStockTextBlock" id="c2016491" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Stockholders</b>&#x2019;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Preferred Stock </i>&#x2013;<i> </i>On <em style="font: inherit;"> June 7, 2021, </em>we repurchased the remaining <ix:nonFraction id="c80220434" contextRef="d_2021-06-07_2021-06-07_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction> shares of our Series B Convertible Preferred Stock for a total price of $<ix:nonFraction id="c80220435" contextRef="d_2021-06-07_2021-06-07_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction>. As of <em style="font: inherit;"> September 30, 2021, </em>there are <ix:nonFraction id="c80220436" contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of our preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Public Offering </i>&#x2013;<i> </i>On <em style="font: inherit;"> February 11, 2021, </em>we closed an underwritten public offering of <ix:nonFraction id="c80220437" contextRef="d_2021-02-11_2021-02-11" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,644,000</ix:nonFraction> shares of our common stock, including <ix:nonFraction id="c80220438" contextRef="d_2021-02-11_2021-02-11_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">204,000</ix:nonFraction> shares sold pursuant to the full exercise of the underwriter&#x2019;s option to purchase additional shares, at a price to the public of $<ix:nonFraction id="c80220439" contextRef="i_2021-02-11" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">6.25</ix:nonFraction> per share. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $<ix:nonFraction id="c80220440" contextRef="d_2021-02-11_2021-02-11" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">9.4</ix:nonFraction> million. Additionally, we issued to the underwriter, as a portion of the underwriting compensation, warrants to purchase <ix:nonFraction id="c80220441" contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">72,000</ix:nonFraction> shares of our common stock at an exercise price of $<ix:nonFraction id="c80220442" contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">6.875</ix:nonFraction> per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Options </i>&#x2013;<i> </i>We have a stock-based incentive plan (the <em style="font: inherit;">&#x201c;2020</em> Plan&#x201d;) pursuant to which our Board of Directors <em style="font: inherit;"> may </em>grant stock options and other stock-based awards to our employees, directors and consultants. A total of <ix:nonFraction id="c80220444" contextRef="i_2021-09-30_PlanNameAxis-StockIncentivePlan2020Member" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">1,500,000</ix:nonFraction> shares of our common stock are reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan. During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>there were <span style="-sec-ix-hidden:c80220447">no</span> stock option transactions related to the <em style="font: inherit;">2020</em> Plan. As of <em style="font: inherit;"> September 30, 2021, </em>there were <ix:nonFraction id="c80220449" contextRef="i_2021-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">602,000</ix:nonFraction> stock options outstanding, with a weighted-average exercise price of $<ix:nonFraction id="c80220450" contextRef="i_2021-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.79</ix:nonFraction> per share and a weighted-average remaining term of <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c80220451" format="ixt-sec:duryear">9.2</ix:nonNumeric> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Purchase Warrants </i>&#x2013;<i> </i>During <em style="font: inherit;"> January </em>and <em style="font: inherit;"> February 2021, </em><ix:nonFraction id="c80220452" contextRef="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">188,688</ix:nonFraction> stock purchase warrants were exercised on a cashless basis, resulting in the issuance of <ix:nonFraction id="c80220453" contextRef="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">145,866</ix:nonFraction> shares of our common stock, and <ix:nonFraction id="c80220454" contextRef="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">690,034</ix:nonFraction> stock purchase warrants were exercised for cash, resulting in the issuance of <ix:nonFraction id="c80220455" contextRef="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">690,034</ix:nonFraction> shares of our common stock for net proceeds to us of $<ix:nonFraction id="c80220456" contextRef="d_2021-02-01_2021-02-28" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:numdotdecimal" decimals="INF">3,174,156</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During <em style="font: inherit;"> August 2021, </em><ix:nonFraction id="c80220457" contextRef="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">27,004</ix:nonFraction> stock purchase warrants were exercised on a cashless basis, resulting in the issuance of <ix:nonFraction id="c80220458" contextRef="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">3,839</ix:nonFraction> shares of our common stock, and <ix:nonFraction id="c80220459" contextRef="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction> stock purchase warrants were exercised for cash, resulting in the issuance of <ix:nonFraction id="c80220460" contextRef="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction> shares of our common stock for net proceeds to us of $<ix:nonFraction id="c80220461" contextRef="d_2021-08-01_2021-08-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:numdotdecimal" decimals="INF">230,000</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 28, 2021, </em>in connection with our entering into an Assignment and License Agreement with PNP Therapeutics, Inc. (PNP) we issued a <span style="-sec-ix-hidden:c80220462">five</span>-year stock purchase warrant to PNP for <ix:nonFraction id="c80220463" contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantToPnpMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction> shares of our common stock at an exercise price of $<ix:nonFraction id="c80220464" contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantToPnpMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">13.00</ix:nonFraction> per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> September 30, 2021, </em>there are <ix:nonFraction id="c80220465" contextRef="i_2021-09-30_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,816,631</ix:nonFraction> stock purchase warrants outstanding, with a weighted-average exercise price of $<ix:nonFraction id="c80220466" contextRef="i_2021-09-30_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.35</ix:nonFraction> per share and a weighted-average remaining term of <ix:nonNumeric contextRef="i_2021-09-30_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c80220467" format="ixt-sec:duryear">3.9</ix:nonNumeric> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Common Stock Transactions</i> &#x2013; During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>we issued <ix:nonFraction id="c80220469" contextRef="d_2021-01-01_2021-09-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">13,707</ix:nonFraction> shares of our common stock pursuant to consulting agreements.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
    F-9
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2016492" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Stock-Based Expense</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock-based compensation expense related to employee and director stock options was $<ix:nonFraction id="c80220471" contextRef="d_2021-07-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">56,190</ix:nonFraction> and $<ix:nonFraction id="c80220472" contextRef="d_2021-01-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">168,570</ix:nonFraction> during the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>respectively; there was <ix:nonFraction id="c80220475" contextRef="d_2020-07-01_2020-09-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> stock-based compensation expense related to employee stock options during the comparable periods of <em style="font: inherit;">2020.</em> Stock-based compensation expense related to stock options is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the related employee classification. As of <em style="font: inherit;"> September&#xa0;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2021,</em> there is $<ix:nonFraction id="c80220479" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">486,940</ix:nonFraction> of unrecognized compensation expense that we expect to recognize over a weighted-average period of <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c80220480" format="ixt-sec:duryear">2.2</ix:nonNumeric> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>we recorded stock-based compensation expense of $<ix:nonFraction id="c80220483" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">29,560</ix:nonFraction> and $<ix:nonFraction id="c80220484" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">80,733</ix:nonFraction>, respectively, associated with common stock issued for consulting services, as compared to $<ix:nonFraction id="c80220485" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">6,000</ix:nonFraction> and $<ix:nonFraction id="c80220486" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">24,000</ix:nonFraction>, respectively, during the comparable periods of <em style="font: inherit;">2020.</em> As of <em style="font: inherit;"> September 30, 2021, </em>there is $<ix:nonFraction id="c80220488" contextRef="i_2021-09-30" unitRef="USD" name="govx:PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">39,773</ix:nonFraction> recorded as a prepaid expense for these arrangements, which will be recognized as expense over the remaining terms of the related agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During <em style="font: inherit;"> September 2021, </em>we recorded $<ix:nonFraction id="c80220489" contextRef="d_2021-09-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="govx:WarrantIssuanceExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">209,825</ix:nonFraction> of expense associated with the issuance of a stock purchase warrant to PNP in connection with our entering into a technology licensing agreement; such amount was recorded as research and development expense.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2016493" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because of our historically significant net operating losses, we have <span style="-sec-ix-hidden:c80220491">not</span> paid income taxes since inception. We maintain deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets are comprised primarily of net operating loss carryforwards and also include amounts relating to nonqualified stock options and research and development credits. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of our future profitability and our ability to utilize the deferred tax assets. Utilization of operating losses and credits will be subject to substantial annual limitations due to ownership change provisions of Section <em style="font: inherit;">382</em> of the Internal Revenue Code. The annual limitation <em style="font: inherit;"> may </em>result in the expiration of net operating losses and credits before utilization.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="govx:GovernmentGrantsandContractsTextBlock" id="c2016494" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Grants and Collaboration Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>we recorded $<ix:nonFraction id="c80220496" contextRef="d_2021-07-01_2021-09-30_ProductOrServiceAxis-NIHGrantsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">30,414</ix:nonFraction> and $<ix:nonFraction id="c80220497" contextRef="d_2021-01-01_2021-09-30_ProductOrServiceAxis-NIHGrantsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">220,539</ix:nonFraction>, respectively, of revenues associated with these grants, as compared to $<ix:nonFraction id="c80220498" contextRef="d_2020-07-01_2020-09-30_ProductOrServiceAxis-NIHGrantsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">231,330</ix:nonFraction> and $<ix:nonFraction id="c80220499" contextRef="d_2020-01-01_2020-09-30_ProductOrServiceAxis-NIHGrantsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,186,844</ix:nonFraction>, respectively, for the comparable periods of <em style="font: inherit;">2020.</em> During the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2020, </em>we also recorded $<ix:nonFraction id="c80220503" contextRef="d_2020-07-01_2020-09-30_ProductOrServiceAxis-LeidosIncResearchCollaborativeAgreementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">184,128</ix:nonFraction> and $<ix:nonFraction id="c80220504" contextRef="d_2020-01-01_2020-09-30_ProductOrServiceAxis-LeidosIncResearchCollaborativeAgreementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">385,193</ix:nonFraction>, respectively, of revenues associated with research collaboration agreements with <em style="font: inherit;">third</em> parties. As of <em style="font: inherit;"> September 30, 2021, </em>there is an aggregate of $<ix:nonFraction id="c80220506" contextRef="i_2021-09-30" unitRef="USD" name="govx:UnusedGrantFunds" scale="0" format="ixt:numdotdecimal" decimals="INF">244,888</ix:nonFraction> in approved grant funds available for use through mid-<em style="font: inherit;">2022.</em></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:SubsequentEventsTextBlock" id="c2016495" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">13.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Subsequent Event</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> November 9, 2021, </em>we entered into an Exclusive License Agreement the (&#x201c;License Agreement&#x201d;) with City of Hope (&#x201c;COH&#x201d;) under which we obtained exclusive worldwide rights to key patents, know-how, regulatory filings and clinical materials related to COH&#x2019;s COVID-<em style="font: inherit;">19</em> vaccine program, currently undergoing human clinical trials. We will pay an upfront fee to COH of $<ix:nonFraction id="c80220510" contextRef="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="govx:UpfrontFee" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction> within <em style="font: inherit;">30</em> days of the effective date of the License Agreement and are obligated to pay additional fees of $<ix:nonFraction id="c80220512" contextRef="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_ProductOrServiceAxis-LicenseFirstAnniversaryPaymentMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="govx:LicenseFees" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000,000</ix:nonFraction> and $<ix:nonFraction id="c80220513" contextRef="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_ProductOrServiceAxis-LicenseSecondAnniversaryPaymentMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="govx:LicenseFees" scale="0" format="ixt:numdotdecimal" decimals="INF">2,000,000</ix:nonFraction> on the <em style="font: inherit;">first</em> and <em style="font: inherit;">second</em> anniversaries, respectively, of the effective date of the License Agreement. We will also pay COH milestone fees based on achievement of success-based development and regulatory milestones, and annual royalties on net sales of products covered by the License Agreement.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
   <tbody>
    <tr>
     <td style="width: 55%;">
      <div>
       <img alt="a03.jpg" src="a03.jpg" /></div> </td>
     <td style="width: 45%; vertical-align: top;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">235 Peachtree Street NE&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 404 588 4200</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Suite 1800&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; wipfli.com</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Atlanta, GA 30303</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">To the Stockholders and the Board of Directors of GeoVax Labs, Inc.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Opinion on the Consolidated Financial Statements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We have audited the accompanying consolidated balance sheets of GeoVax Labs, Inc. and subsidiary (the &#x201c;Company&#x201d;) as of December 31, 2020 and 2019, and the related consolidated statements of operations, stockholders&#x2019; equity (deficiency) and cash flows for the years then ended and the related notes to the consolidated financial statements and schedule (collectively, the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Basis for Opinion</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Critical Audit Matter</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Equity Transactions</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As described in Notes 6 and 8 to the consolidated financial statements, the Company has multiple equity instruments with various levels of complexity and volumes including convertible debentures, convertible preferred stock, preferred stock, warrants and stock options.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The principal considerations for our determination that the complexity of the Company&#x2019;s equity structure should be a critical audit matter were based on the accounting for certain equity instruments including convertible debentures, convertible preferred stock and stock options requiring significant judgment and estimates as well as the volume of equity transactions, including conversions to common stock, common stock issuance activity and warrant activity making it challenging to ensure adequate disclosure of all equity transactions. Auditing such estimates and activity required extensive audit effort due to the volume and complexity of these transactions and a high degree of auditor judgment when performing the requisite audit procedures and evaluating the results of those procedures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The primary audit procedures we performed to address this critical audit matter included:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We evaluated the design effectiveness of controls over the Company&#x2019;s process for accounting for and recording equity transactions</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We evaluated management&#x2019;s judgments related to the application of U.S. GAAP by reviewing management&#x2019;s accounting analysis for convertible debentures and convertible preferred stock</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We tested the assumptions used within the Black-Scholes model calculation to estimate the value of stock options granted, which included key assumptions such as the estimated life of the stock options and volatility of the Company&#x2019;s stock price</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <img alt="a02.jpg" src="a02.jpg" /></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have served as the Company&#x2019;s auditor since 2005.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Atlanta, Georgia</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">March 23, 2021</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>GEOVAX LABS, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASSETS</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219954" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">9,883,796</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219955" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">283,341</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Grant funds and other receivables</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219956" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:GrantsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF">182,663</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219957" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:GrantsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF">68,603</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219958" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">168,689</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219959" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">95,320</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219960" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">10,235,148</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219961" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">447,264</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net (Note 3)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219962" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">147,741</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219963" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">10,606</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219964" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DepositsAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">11,010</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219965" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DepositsAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">11,010</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219966" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">10,393,899</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219967" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">468,880</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY (DEFICIENCY)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219968" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">267,702</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219969" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">152,653</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses (Note 4)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219970" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">359,281</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219971" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,851,040</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Current portion of notes payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219972" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">183,326</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80219973" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">12,500</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219974" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">810,309</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219975" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,016,193</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note payable, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219976" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">14,738</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219977" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LongTermNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">27,243</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219978" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">825,047</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219979" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,043,436</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Commitments (Note 7)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;<span style="-sec-ix-hidden:c80220933">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;<span style="-sec-ix-hidden:c80220934">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stockholders&#x2019; equity (deficiency):</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Preferred stock, $<span style="-sec-ix-hidden:c80220917"><span style="-sec-ix-hidden:c80220918">.01</span></span> par value (Note 8):</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Authorized shares &#x2013; <span style="-sec-ix-hidden:c80220919"><span style="-sec-ix-hidden:c80220920">10,000,000</span></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Issued and outstanding shares &#x2013; <span style="-sec-ix-hidden:c80220921"><span style="-sec-ix-hidden:c80220923">100</span></span> and <span style="-sec-ix-hidden:c80220922"><span style="-sec-ix-hidden:c80220924">2,486</span></span> at December 31, 2020 and 2019, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219980" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219981" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,932,433</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Common stock, $<span style="-sec-ix-hidden:c80220925"><span style="-sec-ix-hidden:c80220926">.001</span></span> par value:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Authorized shares &#x2013; <span style="-sec-ix-hidden:c80220927"><span style="-sec-ix-hidden:c80220928">600,000,000</span></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Issued and outstanding shares &#x2013; <span style="-sec-ix-hidden:c80220929"><span style="-sec-ix-hidden:c80220931">3,834,095</span></span> and <span style="-sec-ix-hidden:c80220930"><span style="-sec-ix-hidden:c80220932">14,992</span></span> at December 31, 2020 and 2019, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219982" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219983" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">15</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219984" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">55,294,504</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80219985" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">39,340,509</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219986" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">45,805,581</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219987" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">42,847,513</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders&#x2019; equity (deficiency)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80219988" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">9,568,852</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80219989" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,574,556</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities and stockholders&#x2019; equity (deficiency)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80219990" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">10,393,899</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80219991" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">468,880</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>GEOVAX LABS. INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years Ended December 31,</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Grant and collaboration revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220002" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,823,658</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220003" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,175,896</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating expenses:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220004" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,444,459</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220005" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,910,715</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220006" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,196,014</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220007" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,637,674</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220008" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">4,640,473</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220009" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">3,548,389</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220010" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,816,815</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220011" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,372,493</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income (expense):</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220012" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">2,271</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220013" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">6,359</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80220014" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">143,524</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80220015" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">4,495</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total other income (expense)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80220016" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">141,253</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220017" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,864</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80220018" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,958,068</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80220019" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,370,629</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Loss per common share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220020" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2.14</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220021" contextRef="d_2019-01-01_2019-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">781.87</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Weighted average shares outstanding</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220022" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">1,383,829</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220023" contextRef="d_2019-01-01_2019-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">3,032</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS</b>&#x2019;<b> EQUITY (DEFICIENCY)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;" cellspacing="0" cellpadding="0"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 34%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 34%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Preferred Stock (Note 8)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Common Stock</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: thin solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Additional</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Accumulated</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Stockholders&#x2019;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 34%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Paid-in Capital</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Deficit</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Equity (Deficiency)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220027" contextRef="i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,450</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220028" contextRef="i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">1,971,333</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220029" contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">11</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220030" contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220031" contextRef="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">37,483,204</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c80220032" contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">40,476,884</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c80220033" contextRef="i_2018-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,022,347</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 18pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Sale of convertible preferred stock for cash and cancellation of note payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220034" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" format="ixt:numdotdecimal" decimals="INF">1,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220035" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:numdotdecimal" decimals="INF">1,542,950</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220036" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220037" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220038" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:numdotdecimal" decimals="INF">147,050</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220039" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220040" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:numdotdecimal" decimals="INF">1,690,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 18pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Conversion of preferred stock to common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c80220041" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,664</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c80220042" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,581,850</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220043" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">14,819</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220044" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">15</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220045" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,581,835</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220046" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220047" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Issuance of common stock for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220048" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220049" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220050" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">162</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220051" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220052" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">24,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220053" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220054" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">24,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220056" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220058" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220059" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">104,420</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220060" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220061" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">104,420</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Net loss for the year ended December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220063" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220065" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220066" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220067" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,370,629</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220068" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,370,629</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220069" contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220070" contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">1,932,433</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220071" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">14,992</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220072" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">15</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220073" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">39,340,509</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c80220074" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">42,847,513</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c80220075" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,574,556</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Sale of convertible preferred stock for cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220076" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" format="ixt:numdotdecimal" decimals="INF">300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220077" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220078" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220079" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220080" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220081" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220082" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Conversion of preferred stock to common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c80220083" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,686</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c80220084" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,156,338</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220085" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">716,790</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220086" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">717</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220087" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,155,621</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220088" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220089" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Warrants issued in bridge financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220091" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220093" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220094" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">457,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220095" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220096" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">457,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 18pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common stock upon warrant exercise</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220097" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220098" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220099" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">286,902</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220100" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">287</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220101" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">2,213</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220102" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220103" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">2,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 18pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common stock upon debenture conversion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220104" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesDebentureConversion" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220105" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220106" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesDebentureConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">177,626</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220107" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220108" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">569,340</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220109" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220110" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">569,517</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 18pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common stock upon cancellation of accrued compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220111" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220112" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220113" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">300,001</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220114" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220115" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">1,499,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220116" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220117" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">1,500,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Sale of common stock for cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220118" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220119" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220120" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,310,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220121" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,310</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220122" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">11,156,186</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220123" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220124" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">11,158,496</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Issuance of common stock for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220125" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220126" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220127" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">26,581</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220128" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">27</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220129" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">94,373</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220130" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220131" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">94,400</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220133" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220135" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220136" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">18,730</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220137" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220138" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">18,730</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 18pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Roundup of shares following reverse stock split</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220139" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220140" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" format="ixt:zerodash" decimals="0">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220141" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" format="ixt:numdotdecimal" decimals="INF">1,203</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220142" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" format="ixt:numdotdecimal" decimals="0">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c80220143" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220144" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" format="ixt:zerodash" decimals="0">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c80220145" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" format="ixt:zerodash" decimals="0">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 18pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Net loss for the year ended December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220147" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220149" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220150" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220151" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,958,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220152" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,958,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220153" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220154" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220155" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220156" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220157" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">55,294,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c80220158" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">45,805,581</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220159" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">9,568,852</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 58pt;text-indent:-58pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
   &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>GEOVAX LABS. INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years Ended December 31,</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash flows from operating activities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220160" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,958,068</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220161" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,370,629</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 9pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220162" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">19,656</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220163" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">8,350</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 70%; padding-left: 36pt;">Amortization of debt discount</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220164" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" format="ixt:numdotdecimal" decimals="INF">124,185</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220165" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220166" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">64,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220167" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">327,500</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 9pt;">Changes in assets and liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 9pt;">Grant funds and other receivables</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220168" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" format="ixt:numdotdecimal" decimals="INF">114,060</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220169" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">53,211</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220170" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">24,702</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220171" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">56,211</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 9pt;">Accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220172" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">137,956</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220173" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">639,282</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: 9pt;">Total adjustments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220174" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">207,498</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220175" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">972,132</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net cash used in operating activities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220176" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,750,570</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220177" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,398,497</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash flows from investing activities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Purchase of property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220178" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">156,791</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220179" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">7,606</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net cash used in investing activities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220180" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">156,791</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220181" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">7,606</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash flows from financing activities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net proceeds from sale of preferred stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220182" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220183" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" format="ixt:numdotdecimal" decimals="INF">1,440,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net proceeds from issuance of note payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220184" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">170,200</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220185" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net proceeds from bridge financing</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220186" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">888,500</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220187" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net proceeds from sale of common stock and warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220188" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">11,158,496</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220189" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="govx:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net proceeds from warrant exercises</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220190" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:numdotdecimal" decimals="INF">2,500</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220191" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Principal repayment of notes payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220192" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RepaymentsOfNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">11,880</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220193" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:RepaymentsOfNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">10,257</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net cash provided by financing activities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220194" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">12,507,816</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220195" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,429,743</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net increase in cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220196" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">9,600,455</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220197" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">23,640</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash and cash equivalents at beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220198" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">283,341</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220199" contextRef="i_2018-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">259,701</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 70%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash and cash equivalents at end of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220200" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">9,883,796</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220201" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">283,341</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&#xa0;</p>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">Supplemental disclosure of non-cash financing activities:</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">During the year ended December 31, 2020, 2,686 shares of preferred stock were converted into 716,790 shares of common stock and 36,902 shares of common stock were issued upon the &#x201c;cashless&#x201d;&#xa0;exercise of stock purchase warrants.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">During the year ended December 31, 2019, 2,664 shares of preferred stock were converted into 14,819 shares of common stock and $250,000 of notes payable were cancelled in exchange for shares of our preferred stock.</p>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC. </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Years Ended December 31, 2020 and 2019</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:NatureOfOperations" id="c2016496" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">1.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Description of Business</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or &#x201c;GV-MVA-VLP<sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup>&#x201d;). In this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into highly effective VLP immunogens in the person being vaccinated. The MVA-VLP virus replicates to high titers in approved avian cells for manufacturing but cannot productively replicate in mammalian cells. Therefore, the MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live attenuated virus, while providing the safety characteristics of a replication-defective vector.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current development programs are focused on preventive vaccines against novel coronavirus (COVID-<em style="font: inherit;">19</em>), Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as immunotherapies for HIV and solid tumor cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our corporate strategy is to advance, protect and exploit our differentiated vaccine immunotherapy platform leading to the successful development of preventive and therapeutic vaccines against infectious diseases and various cancers. With our design and development capabilities, we are progressing and validating an array of cancer and infectious disease immunotherapy and vaccine product candidates. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage <em style="font: inherit;">third</em> party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <em style="font: inherit;"> may </em>take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with <em style="font: inherit;">one</em> or more potential strategic partners.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2016497" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Summary of Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ConsolidationPolicyTextBlock" id="c80222139" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c80222140" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note <em style="font: inherit;">8.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the <em style="font: inherit;">twelve</em>-month period following the issue date of these consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">17</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from government grants and clinical trial assistance, corporate and academic collaborations, and from sales of our equity securities. We believe that our existing cash resources together with current government funding commitments, will be sufficient to continue our planned operations into <em style="font: inherit;">2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We <em style="font: inherit;"> may </em>never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we <em style="font: inherit;"> may </em>seek additional capital through arrangements with strategic partners or from other sources. There can be <em style="font: inherit;">no</em> assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:UseOfEstimates" id="c80222141" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c80222142" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consider all highly liquid investments with a maturity of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c80222143" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fair Value of Financial Instruments and Concentration of Credit Risk</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c80222144" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:c80220527">three</span> to <span style="-sec-ix-hidden:c80220528">five</span> years. We amortize leasehold improvements using the straight-line method over the term of the related lease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases</i> (ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em>), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or <em style="font: inherit;">not</em> the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than <em style="font: inherit;">12</em> months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than <em style="font: inherit;">12</em> months, we made an accounting policy election to <em style="font: inherit;">not</em> recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c80222145" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Impairment of Long-Lived Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be<b> </b>recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      F-
     <em style="font: inherit;">18</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="govx:AccruedLiabilitiesPolicyTextBlock" id="c80222146" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Accrued Expenses</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have <em style="font: inherit;">not</em> yet been billed by our <em style="font: inherit;">third</em>-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c80222147" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Net Loss Per Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled <ix:nonFraction id="c80220542" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,001,948</ix:nonFraction> and <ix:nonFraction id="c80220543" contextRef="d_2019-01-01_2019-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">558</ix:nonFraction> shares at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="c80222150" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize revenue in accordance with FASB Accounting Standards Update <em style="font: inherit;">2014</em>-<em style="font: inherit;">09,</em> <i>Revenue from Contracts with Customers</i> (ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em>), which created a new Topic, Accounting Standards Codification Topic <em style="font: inherit;">606.</em> The standard is principle-based and provides a <em style="font: inherit;">five</em>-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grant revenue</i> &#x2013; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research collaborations</i> &#x2013; From time to time, we <em style="font: inherit;"> may </em>enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive <em style="font: inherit;">third</em>-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em> and revenue is recognized accordingly.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c80222151" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expense</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to <em style="font: inherit;">third</em>-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c80222152" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Patent Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.<b> </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="c80222153" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Period-to-Period Comparisons</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results for future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c80222154" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c80222155" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#x2019;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note <em style="font: inherit;">8</em> for additional stock-based compensation information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c80222156" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Except as discussed above, there have been <em style="font: inherit;">no</em> recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standards if currently adopted would have a material effect on our financial statements.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2016498" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2016499" escape="true">
    <table class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220223" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">532,100</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220224" contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">534,577</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220225" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">115,605</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220226" contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">115,605</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other furniture, fixtures &amp; equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220227" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OtherFurnitureFixturesAndEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">11,736</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220228" contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-OtherFurnitureFixturesAndEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">11,736</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220229" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">659,441</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220230" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">661,918</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220231" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">511,700</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80220232" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">651,312</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220233" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">147,741</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220234" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">10,606</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation expense was $<ix:nonFraction id="c80220563" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">19,656</ix:nonFraction>&#xa0;and $<ix:nonFraction id="c80220564" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">8,350</ix:nonFraction> during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="c2016500" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Accrued Expenses</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c2016501" escape="true">
    <table class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries and directors&#x2019; fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220235" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedSalariesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">279,696</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220236" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccruedSalariesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,732,702</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220237" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">79,585</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220238" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">118,338</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220239" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">359,281</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220240" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,851,040</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:DebtDisclosureTextBlock" id="c2016502" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GRA Note</i> &#x2013; On <em style="font: inherit;"> February 28, 2018, </em>we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a <span style="-sec-ix-hidden:c80220569">five</span>-year Senior Promissory Note (the &#x201c;GRA Note&#x201d;) to GRA in exchange for $<ix:nonFraction id="c80220570" contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction>. The GRA Note bears an annual interest rate of <ix:nonFraction id="c80220571" contextRef="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">5</ix:nonFraction>%, payable monthly, with principal repayments beginning in the <em style="font: inherit;">second</em> year. Future principal repayments are expected to be $<ix:nonFraction id="c80220573" contextRef="i_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" format="ixt:numdotdecimal" decimals="INF">12,487</ix:nonFraction> in <em style="font: inherit;">2021,</em> $<ix:nonFraction id="c80220575" contextRef="i_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" format="ixt:numdotdecimal" decimals="INF">13,126</ix:nonFraction> <em style="font: inherit;">in2022,</em> and $<ix:nonFraction id="c80220577" contextRef="i_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" format="ixt:numdotdecimal" decimals="INF">2,252</ix:nonFraction> in <em style="font: inherit;">2023.</em> Interest expense related to the GRA Note was $<ix:nonFraction id="c80220579" contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,727</ix:nonFraction> and $<ix:nonFraction id="c80220580" contextRef="d_2019-01-01_2019-12-31_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,097</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>CARES Act Paycheck Protection Program Loan </i>&#x2013;<i> </i>On <em style="font: inherit;"> April 17, 2020, </em>we received a $<ix:nonFraction id="c80220582" contextRef="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">170,200</ix:nonFraction> bank loan backed by the United States Small Business Administration pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bears an annual interest rate of <em style="font: inherit;">one</em> percent and is due <em style="font: inherit;"> April 17, 2022. </em>We have accrued interest expense associated with the PPP Loan of $<ix:nonFraction id="c80220584" contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">1,203</ix:nonFraction>. In <em style="font: inherit;"> October 2020, </em>we applied to the lender to have the loan forgiven, based upon our submission of qualifying information regarding eligible expenses; as of the date of this report our forgiveness application has <em style="font: inherit;">not</em> been processed.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ShortTermDebtTextBlock" id="c2016503" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Convertible Debentures</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> June 26 2020, </em>we entered into a Securities Purchase Agreement with <span style="-sec-ix-hidden:c80220587">two</span> institutional investors, pursuant to which we received gross proceeds of $<ix:nonFraction id="c80220588" contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="govx:ProceedsFromConvertibleDebtGross" scale="0" format="ixt:numdotdecimal" decimals="INF">1,050,000</ix:nonFraction> in exchange for the issuance of: (i) <ix:nonFraction id="c80220589" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">5</ix:nonFraction>% Original Issue Discount Senior Secured Convertible Debentures (the &#x201c;Convertible Debentures&#x201d;) in the aggregate principal amount of <span style="-sec-ix-hidden:c80220590">$1,200,000;</span> and (ii) <span style="-sec-ix-hidden:c80220591">five</span>-year warrants (the <em style="font: inherit;"> &#x201c;June 2020 </em>Warrants&#x201d;) to purchase an aggregate of <ix:nonFraction id="c80220592" contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000</ix:nonFraction> shares of our common stock at an exercise price of $<ix:nonFraction id="c80220593" contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">10.00</ix:nonFraction> per share. Net proceeds after deducting the original issue discount, finder&#x2019;s fee and other debt issuance costs were $<ix:nonFraction id="c80220594" contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">888,500</ix:nonFraction>. As a result of the public offering of our securities described in Note <em style="font: inherit;">8,</em> on <em style="font: inherit;"> September 29, 2020 </em>the exercise price of the <em style="font: inherit;"> June 2020 </em>Warrants was reduced to $<ix:nonFraction id="c80220596" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction>. The Convertible Debentures had an original maturity of <span style="-sec-ix-hidden:c80220597">twelve</span> months, bore interest at a rate of <ix:nonFraction id="c80220598" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">5</ix:nonFraction>% per annum, and were secured by substantially all of the Company&#x2019;s assets until such time as they were paid or converted in full.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Convertible Debentures were mandatorily convertible upon our consummation of a public offering of common stock with gross proceeds of $<ix:nonFraction id="c80220599" contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="govx:GrossProceedsFromIssuanceOfCommonStockPublicOffering" scale="0" format="ixt:numdotdecimal" decimals="INF">6,000,000</ix:nonFraction> or more, and which resulted in the listing of our common stock on a national securities exchange (a &#x201c;Qualified Offering&#x201d;). The conversion price upon the occurrence of a Qualified Offering was equal to the lower of (i) $<ix:nonFraction id="c80220600" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">10.00</ix:nonFraction> per share or (ii) <ix:nonFraction id="c80220601" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="Pure" name="govx:PercentageOfOfferingPrice" scale="-2" format="ixt:numdotdecimal" decimals="1">80</ix:nonFraction>% of the offering price. The conversion provisions of the Convertible Debentures were subject to a &#x201c;conversion blocker&#x201d; such that each of the purchasers could <em style="font: inherit;">not</em> convert the Convertible Debentures to the extent that the conversion would result in the purchaser and its affiliates holding more than <ix:nonFraction id="c80220603" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="Pure" name="govx:DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">4.99</ix:nonFraction>% of our outstanding common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 29, 2020, </em>upon our consummation of the public offering discussed in Note <em style="font: inherit;">8,</em> the $<ix:nonFraction id="c80220605" contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" format="ixt:numdotdecimal" decimals="INF">1,200,000</ix:nonFraction> maturity value of the Convertible Debentures and $<ix:nonFraction id="c80220606" contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="USD" name="govx:DebtConversionAccruedInterestAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">14,667</ix:nonFraction> of accrued interest were automatically converted at $<ix:nonFraction id="c80220607" contextRef="i_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.00</ix:nonFraction>, the Qualified Offering discounted price, resulting in the issuance of <ix:nonFraction id="c80220608" contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">303,668</ix:nonFraction> conversion units. Of the <em style="font: inherit;">303,668</em> conversion units: (a) <ix:nonFraction id="c80220610" contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheOneMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">177,626</ix:nonFraction> consist of <span style="-sec-ix-hidden:c80220611">one</span> share of common stock and a warrant to purchase <span style="-sec-ix-hidden:c80220612">one</span> share of common stock (a &#x201c;Conversion Warrant&#x201d;), and (b) <ix:nonFraction id="c80220613" contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheTwoMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">126,042</ix:nonFraction> consist of <span style="-sec-ix-hidden:c80220614">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c80220615">one</span> share of common stock (a &#x201c;Pre-Funded Warrant&#x201d;) and a Conversion Warrant. The Pre-Funded Warrants provide the holder the right to purchase <span style="-sec-ix-hidden:c80220616">one</span> share of Common Stock at an exercise price of $<ix:nonFraction id="c80220617" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction> per share, are immediately exercisable and will <em style="font: inherit;">not</em> expire until exercised in full. The Conversion Warrants provide the holder the right to purchase <span style="-sec-ix-hidden:c80220619">one</span> share of common stock, are immediately exercisable at an exercise price of $<ix:nonFraction id="c80220620" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction> per share and expire <span style="-sec-ix-hidden:c80220621">five</span> years after the issuance date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon the issuance of the Convertible Debentures, we recorded a debt discount of $<ix:nonFraction id="c80220622" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" format="ixt:numdotdecimal" decimals="INF">769,334</ix:nonFraction>, including the $<ix:nonFraction id="c80220623" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="govx:DebtConversionOriginalDebtDiscount" scale="0" format="ixt:numdotdecimal" decimals="INF">150,000</ix:nonFraction> original issue discount, $<ix:nonFraction id="c80220624" contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">457,833</ix:nonFraction> of fair value allocated to the warrants (recorded as Additional Paid-in Capital), and $<ix:nonFraction id="c80220625" contextRef="d_2020-06-26_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="USD" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">161,500</ix:nonFraction> of direct transaction costs incurred. The debt discount was amortized to interest expense over the <em style="font: inherit;">12</em>-month term of the Debentures using the effective interest rate method, up to the date of conversion. As a result of the mandatory conversion of the Convertible Debentures on <em style="font: inherit;"> September 29, 2020, </em>the remaining unamortized debt discount ($<ix:nonFraction id="c80220627" contextRef="i_2020-09-29_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" format="ixt:numdotdecimal" decimals="INF">645,150</ix:nonFraction>) was recorded as Additional Paid-in Capital. Interest expense associated with the Convertible Debentures recorded during <em style="font: inherit;">2020</em> was $<ix:nonFraction id="c80220629" contextRef="d_2020-01-01_2020-12-31_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">138,851</ix:nonFraction>, including $<ix:nonFraction id="c80220630" contextRef="d_2020-01-01_2020-12-31_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" format="ixt:numdotdecimal" decimals="INF">124,185</ix:nonFraction> of debt discount amortization.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:CommitmentsDisclosureTextBlock" id="c2016504" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We lease approximately <ix:nonFraction id="c80220632" contextRef="i_2020-12-31" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:numdotdecimal" decimals="INF">8,400</ix:nonFraction> square feet of office and laboratory space pursuant to an operating lease which expires on <em style="font: inherit;"> December 31, 2022. </em>Rent expense for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $<ix:nonFraction id="c80220634" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:LeaseAndRentalExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">166,577</ix:nonFraction> and $<ix:nonFraction id="c80220635" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:LeaseAndRentalExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">161,673</ix:nonFraction>, respectively. Future minimum lease payments total $<ix:nonFraction id="c80220636" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" format="ixt:numdotdecimal" decimals="INF">171,213</ix:nonFraction> in <em style="font: inherit;">2021</em> and $<ix:nonFraction id="c80220638" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" format="ixt:numdotdecimal" decimals="INF">176,356</ix:nonFraction> in <em style="font: inherit;">2022,</em> although the lease <em style="font: inherit;"> may </em>be terminated at any time by either party with <em style="font: inherit;">ninety</em> days written notice.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of <em style="font: inherit;"> December 31, 2020, </em>we had approximately $<ix:nonFraction id="c80220641" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">190,000</ix:nonFraction> of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in <em style="font: inherit;">2021.</em> We expect $<ix:nonFraction id="c80220643" contextRef="i_2020-12-31" unitRef="USD" name="govx:UnrecordedUnconditionalPurchaseObligationReimbursableAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">165,500</ix:nonFraction> of this amount to be reimbursable to us pursuant to currently outstanding government grants.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
    F-21
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PreferredStockTextBlock" id="c2016505" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Stockholders</b>&#x2019;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Convertible Preferred Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are authorized to issue up to <ix:nonFraction id="c80220645" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction> shares of our Preferred Stock, <span style="-sec-ix-hidden:c80220646">$.01</span> par value, which <em style="font: inherit;"> may </em>be issued in <em style="font: inherit;">one</em> or more series. The table below presents our issued and outstanding series of preferred stock as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019.</em> Each series of our outstanding preferred stock has a stated value of $<ix:nonFraction id="c80220649" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction> per share. Further details concerning each series of preferred stock, and the changes in each series during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> are discussed in the sections that follow the table.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="govx:ScheduleOfPreferredStockTableTextBlock" id="c2016506" escape="true">
    <table class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Carrying</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Carrying</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series B Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220241" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220242" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220243" contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220244" contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series H Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220245" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80220246" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220247" contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">1,686</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220248" contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,156,338</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series I Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220249" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220250" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220251" contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">700</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220252" contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">700,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220253" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220254" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220255" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,486</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c80220256" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,932,433</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series B Convertible Preferred Stock </i>&#x2013;<i> </i>Our Series B Convertible Preferred Stock, $<ix:nonFraction id="c80220651" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction> stated value (&#x201c;Series B Preferred Stock&#x201d;), has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series B Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. As of <em style="font: inherit;"> December 31, 2020, </em>there were <ix:nonFraction id="c80220654" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction> shares of Series B Preferred Stock outstanding, convertible at any time at the option of the holder into shares of common stock at a fixed conversion price of $<ix:nonFraction id="c80220655" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USDPerShare" name="govx:ConvertiblePreferredStockConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">7,000,000</ix:nonFraction> per common share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series C Convertible Preferred Stock </i>&#x2013;<i> </i>Our Series C Convertible Preferred Stock, $<ix:nonFraction id="c80220656" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesCConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction> stated value (&#x201c;Series C Preferred Stock&#x201d;), has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series C Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> <ix:nonFraction id="c80220660" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">587</ix:nonFraction> shares of our Series C Preferred Stock were converted into <ix:nonFraction id="c80220661" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction> shares of our common stock and the remaining <ix:nonFraction id="c80220662" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">1,563</ix:nonFraction> shares of Series C Preferred Stock were exchanged for Series F Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were <ix:nonFraction id="c80220663" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesCConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of Series C Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series E Convertible Preferred Stock </i>&#x2013; Our Series E Convertible Preferred Stock, $<ix:nonFraction id="c80220664" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesEConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction> stated value, (&#x201c;Series E Preferred Stock&#x201d;) has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series E Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> all outstanding shares of Series E Preferred Stock (<ix:nonFraction id="c80220668" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">1,200</ix:nonFraction> shares) were exchanged for Series F Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were <ix:nonFraction id="c80220669" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesEConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of Series E Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series F Preferred Stock </i>&#x2013;<i> </i>In <em style="font: inherit;"> February 2019, </em>we entered into Exchange Agreements with holders of our Series C and Series E Preferred Stock, pursuant to which the holders exchanged all shares of Series C and Series E Preferred Stock held by them for an aggregate of <ix:nonFraction id="c80220670" contextRef="d_2019-02-01_2019-02-28_StatementClassOfStockAxis-SeriesFConvertiblePreferredStockMember" unitRef="Share" name="govx:NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" scale="0" format="ixt:numdotdecimal" decimals="INF">2,763</ix:nonFraction> shares of Series F Convertible Preferred Stock (&#x201c;Series F Preferred Stock&#x201d;). Our Series F Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series F Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> <ix:nonFraction id="c80220674" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesFPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">507</ix:nonFraction> shares of Series F Preferred Stock were converted into <ix:nonFraction id="c80220675" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesFPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">9</ix:nonFraction> shares of our common stock and all remaining outstanding shares of Series F Preferred Stock (<ix:nonFraction id="c80220676" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">2,256</ix:nonFraction> shares) were exchanged for Series H Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were <ix:nonFraction id="c80220677" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesFConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of Series F Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series G Preferred Stock </i>&#x2013;<i> </i>In <em style="font: inherit;"> February 2019, </em>we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#x201c;Purchasers&#x201d;) providing for sale to the Purchasers of an aggregate of up to <ix:nonFraction id="c80220678" contextRef="d_2019-02-01_2019-02-28_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" unitRef="Share" name="govx:ConvertiblePreferredStockAndRelatedWarrantsAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction> shares of our Series G Convertible Preferred Stock (&#x201c;Series G Preferred Stock&#x201d;) and related warrants for gross proceeds of up to $<ix:nonFraction id="c80220679" contextRef="d_2019-02-25_2019-02-25_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" unitRef="USD" name="govx:ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" scale="6" format="ixt:numdotdecimal" decimals="-6">1.0</ix:nonFraction> million, which was funded at <em style="font: inherit;">three</em> different closings. Our Series G Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series G Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. At the <em style="font: inherit;">first</em> closing, which occurred in <em style="font: inherit;"> February 2019, </em>we issued <ix:nonFraction id="c80220684" contextRef="d_2019-02-01_2019-02-28_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" unitRef="Share" name="govx:ConvertiblePreferredStockAndRelatedWarrantsIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">500</ix:nonFraction> shares of Series G Preferred Stock in exchange for the payment by the Purchasers of $<ix:nonFraction id="c80220685" contextRef="d_2019-02-26_2019-02-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" unitRef="USD" name="govx:ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" scale="0" format="ixt:numdotdecimal" decimals="INF">250,000</ix:nonFraction> in the aggregate, plus the cancellation of Term Notes held by the Purchasers in the amount of <em style="font: inherit;">$250,000.</em> At the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> closings, which occurred in <em style="font: inherit;"> April </em>and <em style="font: inherit;"> June 2019, </em>we issued an aggregate of <ix:nonFraction id="c80220689" contextRef="d_2019-04-26_2019-04-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" unitRef="Share" name="govx:ConvertiblePreferredStockAndRelatedWarrantsIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">500</ix:nonFraction> additional shares of Series G Preferred Stock in exchange for the payment by the Purchasers of a total of $<ix:nonFraction id="c80220690" contextRef="d_2019-04-26_2019-04-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockMember" unitRef="USD" name="govx:ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" scale="0" format="ixt:numdotdecimal" decimals="INF">500,000</ix:nonFraction>. During <em style="font: inherit;"> July 2019, </em>all outstanding shares of Series G Preferred Stock (<ix:nonFraction id="c80220691" contextRef="i_2019-07-31_StatementClassOfStockAxis-SeriesGConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction> shares) were exchanged for Series H Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were <ix:nonFraction id="c80220692" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesGConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of Series G Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">22</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series H Preferred Stock </i>&#x2013;<i> </i>In <em style="font: inherit;"> July 2019, </em>we entered into Exchange Agreements with holders of our Series F and Series G Preferred Stock, pursuant to which the holders exchanged all shares of Series F and Series G Preferred Stock held by them for an aggregate of <ix:nonFraction id="c80220694" contextRef="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">3,256</ix:nonFraction> shares of Series H Convertible Preferred Stock (&#x201c;Series H Preferred Stock&#x201d;). Our Series H Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series H Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> <ix:nonFraction id="c80220698" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">1,570</ix:nonFraction> shares of Series H Preferred Stock were converted into <ix:nonFraction id="c80220699" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">14,808</ix:nonFraction> shares of our common stock. During <em style="font: inherit;">2020,</em> <ix:nonFraction id="c80220701" contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">1,686</ix:nonFraction> shares of our Series H Convertible Preferred Stock were converted into <ix:nonFraction id="c80220702" contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">469,697</ix:nonFraction> shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were <ix:nonFraction id="c80220703" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of Series H Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series I Preferred Stock </i>&#x2013;<i> </i>In <em style="font: inherit;"> July 2019, </em>we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#x201c;Purchasers&#x201d;) providing for sale to the Purchasers of an aggregate of <ix:nonFraction id="c80220704" contextRef="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">700</ix:nonFraction> shares of our Series I Convertible Preferred Stock (&#x201c;Series I Preferred Stock&#x201d;) for gross proceeds of $<ix:nonFraction id="c80220705" contextRef="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="0" format="ixt:numdotdecimal" decimals="INF">700,000</ix:nonFraction>. Our Series I Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series I Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2020,</em> <ix:nonFraction id="c80220709" contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesIPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">700</ix:nonFraction> shares of our Series I Convertible Preferred Stock were converted into <ix:nonFraction id="c80220710" contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesIPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">204,371</ix:nonFraction> shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were <ix:nonFraction id="c80220711" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of Series I Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series J Preferred Stock </i>&#x2013;<i> </i>In <em style="font: inherit;"> January 2020, </em>we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#x201c;Purchasers&#x201d;) providing for sale to the Purchasers of an aggregate of <ix:nonFraction id="c80220712" contextRef="d_2020-01-01_2020-01-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">300</ix:nonFraction> shares of our Series J Convertible Preferred Stock (&#x201c;Series J Preferred Stock&#x201d;) for gross proceeds of $<ix:nonFraction id="c80220713" contextRef="d_2020-01-01_2020-01-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction>. Our Series J Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series J Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2020,</em> <ix:nonFraction id="c80220717" contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesJPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">300</ix:nonFraction> shares of Series J Preferred Stock were converted into <ix:nonFraction id="c80220718" contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesJPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">42,723</ix:nonFraction> shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were <ix:nonFraction id="c80220719" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of Series J Preferred Stock outstanding</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Common Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Reverse Stock Splits </i>&#x2013; On <em style="font: inherit;"> April 30, 2019, </em>we effected a <em style="font: inherit;">1</em>-for-<ix:nonFraction id="c80220721" contextRef="d_2019-04-30_2019-04-30_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:numdotdecimal" decimals="INF">500</ix:nonFraction> reverse stock split of our common stock, on <em style="font: inherit;"> January 21, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-<ix:nonFraction id="c80220723" contextRef="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:numdotdecimal" decimals="INF">2000</ix:nonFraction> reverse split of our common stock and on <em style="font: inherit;"> September 25, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-<ix:nonFraction id="c80220725" contextRef="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:numdotdecimal" decimals="INF">20</ix:nonFraction> reverse split of our common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Conversions of Preferred Stock</i> &#x2013; During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> we issued an aggregate of <ix:nonFraction id="c80220728" contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">716,790</ix:nonFraction> and <ix:nonFraction id="c80220729" contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">14,819</ix:nonFraction> shares of our common stock, respectively, pursuant to the conversion of several series of our convertible preferred stock as discussed above.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Public Offering </i>&#x2013;<i> </i>On <em style="font: inherit;"> September 24, 2020, </em>we entered into an Underwriting Agreement (the &#x201c;Underwriting Agreement&#x201d;) with Maxim Group LLC, as representative of the underwriters (the &#x201c;Representative&#x201d;), for an underwritten public offering (the &#x201c;Offering&#x201d;) of an aggregate of <ix:nonFraction id="c80220730" contextRef="d_2020-09-24_2020-09-24_ClassOfWarrantOrRightAxis-ConversionWarrantsMember" unitRef="Share" name="govx:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">2,560,000</ix:nonFraction> units of our equity securities (the &#x201c;Units&#x201d;). The Offering closed on <em style="font: inherit;"> September 29, 2020, </em>with gross proceeds to us of approximately $<ix:nonFraction id="c80220731" contextRef="d_2020-09-24_2020-09-24" unitRef="USD" name="govx:ProceedsFromIssuanceOrSaleOfEquityGross" scale="6" format="ixt:numdotdecimal" decimals="-5">12.8</ix:nonFraction> million; net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $<ix:nonFraction id="c80220732" contextRef="d_2020-09-24_2020-09-24" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-5">11.2</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Of the <ix:nonFraction id="c80220733" contextRef="d_2020-09-24_2020-09-24_StatementEquityComponentsAxis-CapitalUnitsMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,560,000</ix:nonFraction> Units sold in the Offering: (a) <ix:nonFraction id="c80220734" contextRef="d_2020-09-24_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,310,000</ix:nonFraction> Units consist of <span style="-sec-ix-hidden:c80220735">one</span> share of our common stock, and a Warrant to purchase <span style="-sec-ix-hidden:c80220736">one</span> share of common stock (each, a &#x201c;Unit Warrant&#x201d;); and (b) <ix:nonFraction id="c80220737" contextRef="d_2020-09-24_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheTwoMember_StatementEquityComponentsAxis-CapitalUnitsMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">250,000</ix:nonFraction> Units consisting of a Pre-Funded Warrant to purchase <span style="-sec-ix-hidden:c80220738">one</span> share of common stock and a Unit Warrant. The Pre-Funded Warrants provided the holder the right to purchase <span style="-sec-ix-hidden:c80220739">one</span> share of common stock at an exercise price of $<ix:nonFraction id="c80220740" contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction> per share and were exercised in full during <em style="font: inherit;"> October 2020. </em>The Unit Warrants provide the holder the right to purchase <span style="-sec-ix-hidden:c80220741">one</span> share of common stock, are immediately exercisable at an exercise price of $<ix:nonFraction id="c80220742" contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction> per share and expire <span style="-sec-ix-hidden:c80220743">five</span> years after the issuance date. The public offering price was $<ix:nonFraction id="c80220744" contextRef="i_2020-09-24_StatementEquityComponentsAxis-CapitalUnitsMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction> per Unit ($<ix:nonFraction id="c80220745" contextRef="i_2020-09-24_StatementClassOfStockAxis-UnitsIncludingPrefundedWarrantsMember_StatementEquityComponentsAxis-CapitalUnitsMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">4.99</ix:nonFraction> for each Unit including a Pre-Funded Warrant).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the Underwriting Agreement, we issued to the Representative, as a portion of the underwriting compensation, warrants to purchase up to a total of <ix:nonFraction id="c80220746" contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">128,000</ix:nonFraction> shares of common stock (the &#x201c;Representative Warrants&#x201d;). The Representative Warrants have an exercise price of $<ix:nonFraction id="c80220747" contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.50</ix:nonFraction> per share, are initially exercisable <ix:nonNumeric contextRef="d_2020-09-24_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember" name="govx:ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" id="c80220748" format="ixt-sec:durday">180</ix:nonNumeric> days after the effective date of the Offering and have a term of <span style="-sec-ix-hidden:c80220749">three</span> years from their initial exercise date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">23</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Conversion of Deferred Compensation to Equity </i>&#x2013;<i> </i>From <em style="font: inherit;">2016</em> through <em style="font: inherit;"> August 2020, </em>to help conserve the Company&#x2019;s cash resources, our executive officers and non-employee directors agreed to defer receipt of all or a portion (at varying levels) of their respective cash compensation. On <em style="font: inherit;"> September 29, 2020, </em>upon our consummation of the Offering, $<ix:nonFraction id="c80220752" contextRef="d_2020-09-29_2020-09-29" unitRef="USD" name="govx:DeferredCompensationLiabilityConversionToEquityAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,500,000</ix:nonFraction> of the accumulated deferrals were converted at the $<ix:nonFraction id="c80220753" contextRef="i_2020-09-29" unitRef="USDPerShare" name="govx:DeferredCompensationLiabilityConversionToEquityConversionPrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction> offering price, resulting in the issuance of <ix:nonFraction id="c80220754" contextRef="d_2020-09-29_2020-09-29" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">300,001</ix:nonFraction> units substantially similar to the units sold in the public offering, with each unit consisting of <span style="-sec-ix-hidden:c80220755">one</span> share of our common stock and <span style="-sec-ix-hidden:c80220756">one</span> warrant substantially similar to a Unit Warrant (a &#x201c;Management Warrant&#x201d;).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Conversion of Convertible Debentures to Equity</i> &#x2013; As discussed in Note <em style="font: inherit;">6,</em> upon our consummation of the Offering, we issued an aggregate of <ix:nonFraction id="c80220758" contextRef="d_2020-09-29_2020-09-29" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">177,626</ix:nonFraction> shares of our common stock, <ix:nonFraction id="c80220759" contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">126,042</ix:nonFraction> Pre-Funded Warrants and <ix:nonFraction id="c80220760" contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">303,668</ix:nonFraction> Conversion Warrants upon the mandatory conversion of $<ix:nonFraction id="c80220761" contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="USD" name="govx:DebtConversionConvertedInstrumentPrincipalAndInterestAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,214,667</ix:nonFraction> of Convertible Debentures and accrued interest.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Common Stock Transactions</i> &#x2013; During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> we issued <ix:nonFraction id="c80220764" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">26,581</ix:nonFraction> and <ix:nonFraction id="c80220765" contextRef="d_2019-01-01_2019-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">162</ix:nonFraction> shares, respectively, of our common stock pursuant to consulting agreements. During <em style="font: inherit;">2020,</em> certain warrants were exercised using the &#x201c;cashless&#x201d; exercise feature of the warrants, resulting in the issuance of an aggregate of <ix:nonFraction id="c80220767" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">36,902</ix:nonFraction> shares of our common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Options</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have a stock-based incentive plan (the <em style="font: inherit;">&#x201c;2020</em> Plan&#x201d;) pursuant to which our Board of Directors <em style="font: inherit;"> may </em>grant stock options to our employees. A total of <ix:nonFraction id="c80220769" contextRef="i_2020-12-31_PlanNameAxis-StockIncentivePlan2020Member" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000,000</ix:nonFraction> shares of our common stock are reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan. The exercise price for any option granted <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be less than fair value (<ix:nonFraction id="c80220772" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" format="ixt:numdotdecimal" decimals="1">110</ix:nonFraction>% of fair value for ISO&#x2019;s granted to certain employees). Options have a maximum <span style="-sec-ix-hidden:c80220773">ten</span>-year term and generally vest over <span style="-sec-ix-hidden:c80220774">three</span> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2016507" escape="true">
    <table class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220257" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">0.69</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220259" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of option (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c80220261" format="ixt-sec:duryear">7.0</ix:nonNumeric></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220263" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="4">38.16</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of stock option activity under the <em style="font: inherit;">2020</em> Plan as of <em style="font: inherit;"> December 31, 2020, </em>and changes during the year then ended is presented below.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2016508" escape="true">
    <table class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Term (yrs)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220265" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220266" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220269" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">602,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220270" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.79</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220273" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220274" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220277" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220278" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220281" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">602,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220282" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.79</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c80220283" format="ixt-sec:duryear">9.9</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220284" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="INF">355,180</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-<ix:nonFraction id="c80220285" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220286" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220288" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted-average grant date fair value of options granted during <em style="font: inherit;">2020</em> was $<ix:nonFraction id="c80220777" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.12</ix:nonFraction>. <span style="-sec-ix-hidden:c80220778">No</span> stock options were granted during <em style="font: inherit;">2019.</em> Total employee and director stock-based compensation expense recognized in the consolidated statement of operations for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $<ix:nonFraction id="c80220781" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">18,730</ix:nonFraction> and $<ix:nonFraction id="c80220782" contextRef="d_2019-01-01_2019-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">104,420</ix:nonFraction>, respectively. As of <em style="font: inherit;"> December 31, 2020, </em>there is $<ix:nonFraction id="c80220783" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" format="ixt:numdotdecimal" decimals="INF">655,510</ix:nonFraction> of unrecognized compensation expense related to employee and director stock-based compensation arrangements that will be recognized over a weighted-average period of <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c80220784" format="ixt-sec:duryear">2.9</ix:nonNumeric> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      F-
     <em style="font: inherit;">24</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Purchase Warrants</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Summary of Warrants Outstanding </i>&#x2013; The table below presents summary information about our warrants outstanding as of <em style="font: inherit;"> December 31, 2020. </em>Additional information concerning the warrants follows the table.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c2016509" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55.6%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant Description</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expiration</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series I Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220289" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">62,626</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220290" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Oct-Dec 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">June 2020 Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220292" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220293" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Jun 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Pre-Funded Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220295" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">126,042</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220296" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="2">0.01</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Perpetual</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unit, Conversion and Management Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220298" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-UnitConversionAndManagementWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,163,669</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220299" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-UnitConversionAndManagementWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="0">5.00</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220301" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">128,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220302" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="1">5.50</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Mar 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Warrants Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220304" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,600,337</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Exercise Price</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220307" contextRef="i_2020-12-31_RangeAxis-WeightedAverageMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.84</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"><ix:nonNumeric contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-OutstandingWarrantsExcludingPreFundedWarrantsMember_RangeAxis-WeightedAverageMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c80220310" format="ixt-sec:duryear">4.7</ix:nonNumeric></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series I Warrants</i> &#x2013; During <em style="font: inherit;"> July 2020, </em>Series I Warrants were exercised using the &#x201c;cashless&#x201d; exercise feature of the warrants, resulting in the issuance of <ix:nonFraction id="c80220786" contextRef="d_2020-07-01_2020-07-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">29,755</ix:nonFraction> shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were <ix:nonFraction id="c80220787" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">62,626</ix:nonFraction> Series I Warrants outstanding, with an exercise price of $<ix:nonFraction id="c80220788" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction> per share, reflective of anti-dilution adjustments resulting from the Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;"> June 2020 </em>Warrants</i> &#x2013; As discussed in Note <em style="font: inherit;">6,</em> on <em style="font: inherit;"> June 26, 2020, </em>in connection with the issuance of the Convertible Debentures, we issued warrants to purchase <ix:nonFraction id="c80220790" contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000</ix:nonFraction> shares of common stock, with a <span style="-sec-ix-hidden:c80220791">five</span>-year term and an exercise price of $<ix:nonFraction id="c80220792" contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">10.00</ix:nonFraction>. As a result of the Offering, on <em style="font: inherit;"> September 29, 2020 </em>the exercise price was reduced to $<ix:nonFraction id="c80220793" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrants Issued Upon Conversion of Convertible Debentures</i> &#x2013; As discussed in Note <em style="font: inherit;">6,</em> on <em style="font: inherit;"> September 29, 2020, </em>upon the conversion of the Convertible Debentures into our equity securities, we issued <ix:nonFraction id="c80220795" contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">126,042</ix:nonFraction> Pre-Funded Warrants and <ix:nonFraction id="c80220796" contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">303,668</ix:nonFraction> Conversion Warrants to purchase our common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrants Issued Upon Conversion of Deferred Compensation</i> &#x2013; As discussed above under &#x201c;<i>Common Stock </i>&#x2013;<i> Conversion of Deferred Compensation to Equity</i>&#x201d;, on <em style="font: inherit;"> September&#xa0;</em><em style="font: inherit;">29,</em> <em style="font: inherit;">2020,</em> upon the conversion of amounts owed to current and former executive officers and directors, we issued Management Warrants to purchase <ix:nonFraction id="c80220799" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">300,001</ix:nonFraction> shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrants Issued in Connection with Public Offering</i> &#x2013; As discussed above under &#x201c;<i>Common Stock </i>&#x2013;<i> Public Offering</i>&#x201d;, on <em style="font: inherit;"> September 29, 2020, </em>in connection with the Offering, we issued Unit Warrants to purchase <ix:nonFraction id="c80220800" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">2,560,000</ix:nonFraction> shares of common stock, Pre-Funded Warrants to purchase <ix:nonFraction id="c80220801" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">250,000</ix:nonFraction> shares of common stock (fully exercised in <em style="font: inherit;"> October 2020), </em>and Representative Warrants to purchase <ix:nonFraction id="c80220802" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">128,000</ix:nonFraction> shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Additional Stock-Based Compensation Expense</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to stock-based compensation expense related to the <em style="font: inherit;">2020</em> Plan (see <i>Stock Options</i> above), during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> we recognized $<ix:nonFraction id="c80220805" contextRef="d_2020-01-01_2020-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">45,733</ix:nonFraction> and $<ix:nonFraction id="c80220806" contextRef="d_2019-01-01_2019-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">223,080</ix:nonFraction>, respectively, of expense related to the issuance of our common stock pursuant to consulting and investment banking agreements. As of <em style="font: inherit;"> December 31, 2020, </em>there is $<ix:nonFraction id="c80220807" contextRef="i_2020-12-31" unitRef="USD" name="govx:PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">48,667</ix:nonFraction> recorded as a prepaid expense for <em style="font: inherit;">one</em> of these arrangements, which will be recognized as expense during <em style="font: inherit;">2021</em> over the term of the related agreement.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="c2016510" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; <b>Retirement Plan</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We participate in a multi-employer defined contribution retirement plan (the <em style="font: inherit;">&#x201c;401k</em> Plan&#x201d;) administered by a <em style="font: inherit;">third</em>-party service provider, and the Company contributes to the <em style="font: inherit;">401k</em> Plan on behalf of its employees based upon a matching formula. During the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> our contributions to the <em style="font: inherit;">401k</em> Plan were $<ix:nonFraction id="c80220816" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">27,511</ix:nonFraction> and $<ix:nonFraction id="c80220817" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">25,876</ix:nonFraction>, respectively.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2016511" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At <em style="font: inherit;"> December 31, 2020, </em>we have a consolidated federal net operating loss (&#x201c;NOL&#x201d;) carryforward of approximately $<ix:nonFraction id="c80220819" contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">61.8</ix:nonFraction> million available to offset against future taxable income of which approximately $<ix:nonFraction id="c80220820" contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="govx:OperatingLossCarryforwardsSubjectToExpiration" scale="6" format="ixt:numdotdecimal" decimals="-5">53.6</ix:nonFraction> million expires in varying amounts in <em style="font: inherit;">2021</em> through <em style="font: inherit;">2037.</em> Additionally, we have approximately $<ix:nonFraction id="c80220823" contextRef="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">1.2</ix:nonFraction> million in research and development (&#x201c;R&amp;D&#x201d;) tax credits that expire in <em style="font: inherit;">2022</em> through <em style="font: inherit;">2040</em> unless utilized earlier. <ix:nonFraction id="c80220826" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaid" scale="0" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> income taxes have been paid to date. Section <em style="font: inherit;">382</em> of the Internal Revenue Code contains provisions that <em style="font: inherit;"> may </em>limit our utilization of our NOL and R&amp;D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or <em style="font: inherit;"> may </em>occur in future periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2016512" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 64.1%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220313" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">14,737,240</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220314" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">15,328,336</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research and development tax credit carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220315" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" format="ixt:numdotdecimal" decimals="INF">1,189,110</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220316" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" format="ixt:numdotdecimal" decimals="INF">1,122,536</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220317" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:numdotdecimal" decimals="INF">4,870</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220318" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:numdotdecimal" decimals="INF">1,877,284</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued salaries and directors&#x2019; fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220319" contextRef="i_2020-12-31" unitRef="USD" name="govx:DeferredTaxAssetsAccruedSalariesAndDirectorsFees" scale="0" format="ixt:numdotdecimal" decimals="INF">72,721</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220320" contextRef="i_2019-12-31" unitRef="USD" name="govx:DeferredTaxAssetsAccruedSalariesAndDirectorsFees" scale="0" format="ixt:numdotdecimal" decimals="INF">450,503</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220321" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220322" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">8,571</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220323" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">16,003,941</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220324" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">18,787,230</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Deferred tax liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220325" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">28,274</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80220326" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220327" contextRef="i_2020-12-31" unitRef="USD" name="govx:DeferredTaxAssetsBeforeValuationAllowanceNet" scale="0" format="ixt:numdotdecimal" decimals="INF">15,975,667</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220328" contextRef="i_2019-12-31" unitRef="USD" name="govx:DeferredTaxAssetsBeforeValuationAllowanceNet" scale="0" format="ixt:numdotdecimal" decimals="INF">18,787,230</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80220329" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">15,975,667</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c80220330" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">18,787,230</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset after reduction for valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-<ix:nonFraction id="c80220331" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-<ix:nonFraction id="c80220332" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2016513" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. federal statutory rate applied to pretax loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220335" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">621,194</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220336" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">497,833</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220337" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">65</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220338" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220339" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="0" format="ixt:numdotdecimal" decimals="INF">66,574</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220340" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="0" format="ixt:numdotdecimal" decimals="INF">47,053</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance, net of expired items and other adjustments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220341" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">687,703</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c80220342" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">544,308</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reported income tax expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-<ix:nonFraction id="c80220343" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-<ix:nonFraction id="c80220344" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="govx:GovernmentGrantsandContractsTextBlock" id="c2016514" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Grants and Collaboration Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> we recorded $<ix:nonFraction id="c80220832" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NIHGrantsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,438,465</ix:nonFraction> and $<ix:nonFraction id="c80220833" contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-NIHGrantsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">983,682</ix:nonFraction>, respectively, of revenue associated with these grants. As of <em style="font: inherit;"> December 31, 2020, </em>there is an aggregate of $<ix:nonFraction id="c80220834" contextRef="i_2020-12-31" unitRef="USD" name="govx:UnusedGrantFunds" scale="0" format="ixt:numdotdecimal" decimals="INF">165,500</ix:nonFraction> in remaining grant funds available for use during <em style="font: inherit;">2021.</em> During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> we recorded $<ix:nonFraction id="c80220838" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ResearchAgreementsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">385,193</ix:nonFraction> and $<ix:nonFraction id="c80220839" contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ResearchAgreementsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">192,214</ix:nonFraction>, respectively, of revenues associated with research collaboration agreements with several <em style="font: inherit;">third</em> parties.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2016515" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em></b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>SBIR Grant</i> &#x2013; In <em style="font: inherit;"> January 2021, </em>NIAID awarded us a Small Business Innovative Research (SBIR) grant in support of our development of a vaccine against SARS-CoV-<em style="font: inherit;">2,</em> the virus that causes COVID-<em style="font: inherit;">19.</em> The $<ix:nonFraction id="c80220844" contextRef="d_2021-01-01_2021-01-31_ProductOrServiceAxis-SBIRGrantMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">299,927</ix:nonFraction> Phase <em style="font: inherit;">1</em> grant, titled, &#x201c;<i>Preclinical Development of GV-MVA-VLP Vaccines Against COVID-<em style="font: inherit;">19,</em></i>&#x201d; will support the ongoing design, construction and preclinical testing of our vaccine candidates in preparation for human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Warrant Exercises</i> &#x2013; During <em style="font: inherit;"> January </em>and <em style="font: inherit;"> February 2021, </em>holders of our warrants exercised <ix:nonFraction id="c80220847" contextRef="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">62,626</ix:nonFraction> Series I Warrants, <ix:nonFraction id="c80220848" contextRef="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">126,042</ix:nonFraction> Pre-Funded Warrants and <ix:nonFraction id="c80220849" contextRef="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-UnitWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">690,034</ix:nonFraction> Unit Warrants, resulting in the issuance of <ix:nonFraction id="c80220850" contextRef="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-CommonStockWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">835,900</ix:nonFraction> shares of our common stock for aggregate net proceeds to us of $<ix:nonFraction id="c80220851" contextRef="d_2021-01-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:numdotdecimal" decimals="INF">3,174,156</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Bought Deal Public Offering -- </i>On <em style="font: inherit;"> February 11, 2021, </em>we closed an underwritten bought deal public offering of <ix:nonFraction id="c80220852" contextRef="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,644,000</ix:nonFraction> shares of our common stock, including <ix:nonFraction id="c80220853" contextRef="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">204,000</ix:nonFraction> shares sold pursuant to the full exercise of the underwriter&#x2019;s option to purchase additional shares, at a price to the public of $<ix:nonFraction id="c80220854" contextRef="i_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">6.25</ix:nonFraction> per share. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $<ix:nonFraction id="c80220855" contextRef="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">9.4</ix:nonFraction> million.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
    F-26
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="c2016516" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SCHEDULE II </b>&#x2013;<b> VALUATION AND QUALIFYING ACCOUNTS</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the Years Ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="c2016517" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Additions (Reductions)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Description</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Costs and</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expenses</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Other</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accounts</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deductions</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for Deferred Tax Assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220345" contextRef="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" format="ixt:numdotdecimal" decimals="INF">18,787,230</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220346" contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,811,563</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-<ix:nonFraction id="c80220347" contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-<ix:nonFraction id="c80220348" contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220349" contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" format="ixt:numdotdecimal" decimals="INF">15,975,667</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220350" contextRef="i_2018-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" format="ixt:numdotdecimal" decimals="INF">19,879,954</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c80220351" contextRef="d_2019-01-01_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,092,724</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-<ix:nonFraction id="c80220352" contextRef="d_2019-01-01_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-<ix:nonFraction id="c80220353" contextRef="d_2019-01-01_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c80220354" contextRef="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" format="ixt:numdotdecimal" decimals="INF">18,787,230</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      F-27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0; &#xa0;&#xa0;</p>
  <div>
   &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="govx20220202_s1img005.gif" src="govx20220202_s1img005.gif" style="width:359;height:106;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>6,134,968 Shares of Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 13. Other Expenses of Issuance and Distribution.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table sets forth the fees and expenses payable in connection with the registration of the securities hereunder. All amounts are estimates except the SEC registration fee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Item</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount to be paid</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">SEC registration fee</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,345</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Legal fees and expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounting fees and expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Miscellaneous fees and expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,845</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 14. Indemnification of Directors and Officers.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#x2019; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our bylaws provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#x2019; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#x2019;s conduct was unlawful. Our bylaws also provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#x2019; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      II-1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under our bylaws, expenses (including attorneys&#x2019; fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company. Such expenses (including attorneys&#x2019; fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any, as we deem appropriate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The indemnification and advancement of expenses provided by our bylaws is not exclusive, both as to action in such person&#x2019;s official capacity and as to action in another capacity while holding such office.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our bylaws also provide that we may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#x2019;s status as such, whether or not the Company would have the power to indemnify such person against such liability under our bylaws. The Company maintains an insurance policy providing for indemnification of its officers, directors and certain other persons against liabilities and expenses incurred by any of them in certain stated proceedings and under certain stated conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In October 2006, GeoVax and our subsidiary, GeoVax, Inc. entered into indemnification agreements with Messrs. McNally, Reynolds, Kollintzas and Spencer. Pursuant to these agreements, we have agreed to hold harmless and indemnify these directors and officers to the full extent authorized or permitted by applicable Illinois and Georgia law against certain expenses and other liabilities actually and reasonably incurred by these individuals in connection with certain proceedings if they acted in a manner they believed in good faith to be in or not opposed to the best interests of the Company and, with respect to any criminal proceeding, had no reasonable cause to believe that such conduct was unlawful. The agreements also provide for the advancement of expenses to these individuals subject to specified conditions. Under these agreements, we will not indemnify these individuals for expenses or other amounts for which applicable Illinois and Georgia law prohibit indemnification. The obligations under these agreements continue during the period in which these individuals are our directors or officers and continue thereafter so long as these individuals shall be subject to any proceeding by reason of their service to the Company, whether or not they are serving in any such capacity at the time the liability or expense incurred for which indemnification can be provided under the agreements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 15. Recent Sales of Unregistered Securities.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information provided below has been updated as noted to retroactively reflect the effect of the Company&#x2019;s 1:500, 1:2000, and 1:20 reverse stock splits effected in April 2019, January 2020 and September 2020, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On February 18, 2019, we entered into Exchange Agreements with the Purchasers pursuant to which the Purchasers exchanged an aggregate of 1,563.146 shares of our Series C Convertible Preferred Stock and 1,200 shares of our Series E Preferred Shares, held by them for an aggregate of 2,763.146 shares of our Series F Convertible Preferred Stock. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D. The accredited investors acquired the shares for investment for their own accounts in a transaction that did not involve a general solicitation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On February 25, 2019, we entered into a Securities Purchase Agreement with the Purchasers providing for the issuance and sale to the Purchasers of an aggregate of up to 1,000 shares of our Series G Convertible Preferred Stock (the &#x201c;Series G Preferred Shares&#x201d;) and Series I Warrants to purchase up to 16,666,666 shares (16.67 shares post-split) of our common stock at $0.015 per share ($15,000 per share post-split) at an initial aggregate exercise price of $250,000 for gross proceeds of up to $1.0 million, to be funded at up to three different closings. At the first closing on February 25, 2019, we issued 500 Series G Preferred Shares and Series I Warrants to purchase up to 16,666,666, shares (16.67 shares post-split) of our common stock in exchange for the payment by the Purchasers of $250,000 in the aggregate, plus the cancellation by them of Term Notes due to them from the Company in the aggregate amount of $250,000. At the second and third closings, which occurred on April 26 and June 19, 2019, we issued an aggregate of 500 additional shares of Series G Preferred Stock and Series I Warrants to purchase up to 33,333,333 shares (33.33 shares post-split) in exchange for the payment by the Purchasers of a total of $500,000. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D. The accredited investors acquired the shares for investment for their own accounts in a transaction that did not involve a general solicitation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      II-2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On July 17, 2019, we entered into Exchange Agreements with the Purchasers pursuant to which the Purchasers exchanged an aggregate of 2,256.5338 Series F Preferred Shares and 1,000 Series G Preferred Shares held by them for an aggregate of 3,256.5338 shares of our Series H Convertible Preferred Stock, for aggregate gross proceeds of $3,256,534. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D. The accredited investors acquired the shares for investment for their own accounts in a transaction that did not involve a general solicitation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On July 24, 2019, we entered into a Securities Purchase Agreement with the Purchasers providing for the issuance and sale to the Purchasers of an aggregate of 700 shares of our Series I Convertible Preferred Stock for gross proceeds of $700,000. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D. The accredited investors acquired the shares for investment for their own accounts in a transaction that did not involve a general solicitation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 24, 2020, we entered into a Securities Purchase Agreement (the &#x201c;January Securities Purchase Agreement&#x201d;) with the Purchasers providing for the issuance and sale to the Purchasers of an aggregate of 300 shares of our Series J Convertible Preferred Stock for gross proceeds of $300,000. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D. The accredited investors acquired the shares for investment for their own accounts in a transaction that did not involve a general solicitation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Effective as of May 1, 2020, we entered into a Customer Agreement and Subscription Agreement with Content Carnivores, LLC, pursuant to which the Company receives services related to the management of our social media accounts in exchange for the issuance of shares of our common stock. As of the date hereof, we have issued 7,391 shares of our common stock to Content Carnivores, LLC at an aggregate value of $36,000 pursuant to this agreement. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On June 26, 2020, we entered into a Securities Purchase Agreement with Cavalry Fund I LP and Cavalry Special Ops Fund, LLC, pursuant to which the Company received aggregate gross proceeds of $1,050,000 in exchange for the issuance of 5% Original Issue Senior Secured Convertible Debentures in the aggregate principal amount of $1,200,000 and five-year warrants to purchase an aggregate of 2,400,000 shares of our common stock at an exercise price of $0.50 per share, subject to adjustment. On September 29, 2020, the June 26, 2020 5% Original Issue Senior Secured Convertible Debentures mandatorily converted into 303,667 conversion units, of which 177,625 include shares of common stock and 126,042 include pre-funded warrants (the &#x201c;Conversion Units&#x201d;). The Conversion Units provide substantially the same terms as the units issued in our public offering in September 2020. The pre-funded warrants provide the holder the right to purchase one share of common stock at an exercise price of $0.01 per share, are immediately exercisable and will not expire until exercised in full. These pre-funded warrants were fully exercised on January 13, 2021. The Company also issued warrants to purchase 303,668 shares of common stock to the investors who provided us with bridge financing in June 2020 on terms which are substantially the same as the September 2020 Warrants. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D. The accredited investors acquired the shares for investment for their own accounts in a transaction that did not involve a general solicitation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On September 29, 2020, the underwriters who conducted our public offering in September 2020 received warrants granted to them to purchase 128,000 shares of common (equal to five percent (5%) of the total number of shares of common stock sold in that offering) at an exercise price equal to $5.50 (110% of the public offering price in that offering), as a portion of the underwriting compensation payable to the underwriters in connection with this offering (the &#x201c;Underwriters Warrants&#x201d;). The Underwriters Warrants are initially exercisable March 29, 2021, and have a term of three years from their initial exercise date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      II-3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Effective as of November 1, 2020, we entered into a Marketing and Consulting Agreement and Subscription Agreement with CorProminence, LLC, pursuant to which the Company is receiving services related to shareholder information and relations. In November 2020, we issued 20,000 shares of our common stock to CorProminence, LLC as a restricted stock award under our 2020 Stock Incentive Plan with a value at that date of $58,400. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a) (2) thereof and Rule 506 of Regulation D.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On February 11, 2021, the Company issued to the Maxim Group LLC, as a portion of the underwriting compensation, warrants to purchase up to a total of 72,000 shares (equal to five percent (5%) of the shares of common stock sold in that offering) of common stock (the &#x201c;Underwriter&#x2019;s Warrant Agreement&#x201d;). The shares subject to the Underwriter&#x2019;s Warrant Agreement are exercisable at $6.875 per share, are initially exercisable August 10, 2021, and have a term of three years from their initial exercise date. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Effective as of May 1, 2021, we renewed our agreement with Content Carnivores, LLC for an additional one-year period. In connection with the renewal, in May 2021, we issued 11,000 shares of our common stock to Content Carnivores, LLC as a restricted stock award under our 2020 Stock Incentive Plan with a value at that date of $59,840. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a) (2) thereof and Rule 506 of Regulation D.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On September 28, 2021, in connection with entering into an assignment and license agreement, the Company issued warrants to PNP Therapeutics, Inc. (&#x201c;PNP&#x201d;), exercisable at any time following March 28, 2022, and prior to September 28, 2026, for up to 100,000 shares of the Company&#x2019;s common stock at an exercise price of $13.00 per share. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 14, 2022, we entered into a Securities Purchase Agreement with the Selling Stockholder providing for the issuance and sale to the Selling Stockholder of 707,484 shares of common stock, 2,360,000 shares of common stock issuable upon the exercise of the Pre-Funded Warrant and 3,067,484 shares of common stock issuable upon the exercise of the Common Warrant. The Warrants are exercisable immediately and contain price adjustment provisions which may, under certain circumstances, reduce the applicable exercise price; the Pre-Funded Warrant shall terminate when fully exercised and the Common Warrant shall terminate on the fifth anniversary of the effective date of the Resale Registration Statement. The Private Placement closed on January 20, 2022. The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof and Rule 506 of Regulation D. The Selling Stockholder acquired the shares for investment for its own account in a transaction that did not involve a general solicitation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 16. Exhibits and Financial Statement Schedules.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;"><b>(a) </b><b><i>Exhibit Index</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095014408005004/g13992exv3w1.htm" style="-sec-extract:exhibit;">Certificate of Incorporation (3)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1.1</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095012310034714/c99234exv3w1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed April 13, 2010 (5)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1.2</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095012310039442/c99794exv3w1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed April 27, 2010 (6)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1.3</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774913009821/ex3-1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed August 2, 2013 (7)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1.4</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774915010019/ex3-1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed May 13, 2015 (8)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1.5</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774916033922/ex3-1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed June 14, 2016 (11)</a></td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      II-4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1.6</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774917013827/ex3-1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed August 4, 2017 (12)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1.7</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774919008334/ex_141886.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed April 30, 2019 (15)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1.8</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920000912/ex_169967.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed January 21, 2020 (17)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.1.9</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920020279/ex_205103.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed September 24, 2020 (24)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">3.2</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095014408005004/g13992exv3w2.htm" style="-sec-extract:exhibit;">Bylaws (3)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920018705/ex_201544.htm" style="-sec-extract:exhibit;">Form of Stock Certificate representing the Company&#x2019;s Common Stock, par value $0.001 per share (21)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1.1</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920020061/ex_204703.htm" style="-sec-extract:exhibit;">Form of Common Stock Purchase Warrant (23)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1.2</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920019373/ex_203004.htm" style="-sec-extract:exhibit;">Form of Representative&#x2019;s Warrant Agreement (22)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1.3</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920019373/ex_203036.htm" style="-sec-extract:exhibit;">Form of Warrant Agent Agreement (22)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1.4</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920019373/ex_203037.htm" style="-sec-extract:exhibit;">Form of Warrant issued to certain Management Creditors (22)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1.5</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920014012/ex_191614.htm" style="-sec-extract:exhibit;">Form of Common Stock Purchase Warrant, dated June 26, 2020 (20)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1.6</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921002520/ex_225848.htm" style="-sec-extract:exhibit;">Form of Underwriters Warrant Agreement dated February 11, 2021 (27)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1.7</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921022842/ex_287396.htm" style="-sec-extract:exhibit;">Form of Common Stock Purchase Warrant, dated September 28, 2021 (29)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1.8</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774922001326/ex_325631.htm" style="-sec-extract:exhibit;">Form of Pre-Funded Warrant Agreement (31)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">4.1.9</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774922001326/ex_325632.htm" style="-sec-extract:exhibit;">Form of Common Warrant (31)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">5.1*</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="ex_331601.htm" style="-sec-extract:exhibit;">Opinion of Womble Bond Dickinson (US) LLP</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.1 **</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774918016713/ex_123550.htm" style="-sec-extract:exhibit;">Employment Agreement between GeoVax Labs, Inc. and David A. Dodd (13)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.2 **</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095012310022136/g22401exv10w2.htm" style="-sec-extract:exhibit;">Employment Agreement between GeoVax, Inc. and Mark W. Reynolds (4)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.2.1 **</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774913013257/ex10-3.htm" style="-sec-extract:exhibit;">Amendment No. 1 to Employment Agreement between GeoVax Labs, Inc. and Mark W. Reynolds (8)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.5 **</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921026298/ex_303773.htm" style="-sec-extract:exhibit;">GeoVax Labs, Inc. 2020 Stock Incentive Plan, as amended and restated August 11, 2021 (19)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.5.1 **</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921006906/ex_234779.htm" style="-sec-extract:exhibit;">Form of Non-Qualified Stock Option Agreement (28)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.6</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000109690606001179/geovax8k100106ex10-2.htm" style="-sec-extract:exhibit;">License Agreement (as amended and restated) between GeoVax, Inc. and Emory University (2)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.7</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920021652/ex_208661.htm" style="-sec-extract:exhibit;">Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases, dated October 22, 2020 (25)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.8</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920024573/ex_215829.htm" style="-sec-extract:exhibit;">Patent and Biological Materials License Agreement for Internal Research Use with the National Institute of Allergy and Infectious Diseases, dated November 25, 2020 (26)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.9</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920006029/ex_178175.htm" style="-sec-extract:exhibit;">Office and Laboratory Lease between UCB, Inc. and GeoVax, Inc. (18)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.10</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921006906/ex_234780.htm" style="-sec-extract:exhibit;">Summary of the GeoVax Labs, Inc. Director Compensation Plan (28)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.11</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921022842/ex_287401.htm" style="-sec-extract:exhibit;">Assignment and License Agreement by and between GeoVax, Inc. and PNP Therapeutics, Inc. dated September 28, 2021 (29)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.12</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921026180/govx20211109_8k.htm" style="-sec-extract:exhibit;">Exclusive License Agreement by and between GeoVax, Inc. and City of Hope, dated November 9, 2021 (30)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.13</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774922001326/ex_325629.htm" style="-sec-extract:exhibit;">Securities Purchase Agreement, dated January 14, 2022 (31)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">10.14</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774922001326/ex_325630.htm" style="-sec-extract:exhibit;">Registration Rights Agreement, dated January 14, 2022 (31)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">21.1</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774919021977/ex_162624.htm" style="-sec-extract:exhibit;">Subsidiaries of the Registrant (16)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">23.1 *</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="ex_331664.htm" style="-sec-extract:exhibit;">Consent of Wipfli LLP</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">23.2 *</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="ex_331601.htm" style="-sec-extract:exhibit;">Consent of Womble Bond Dickinson (US) LLP (included in Exhibit 5.1)</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">24.1</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="#poa" style="-sec-extract:exhibit;">Power of Attorney (included in the signature page to this Registration Statement).</a></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">101.INS</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;">Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data Files because its XBRL tags are embedded with the Inline XBRL Document) (1)</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">101.SCH</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;">Inline XBRL Taxonomy Extension Schema Document (1)</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">101.CAL</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;">Inline XBRL Taxonomy Extension Calculation Linkbase Document (1)</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">101.DEF</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;">Inline XBRL Taxonomy Extension Definition Linkbase Document (1)</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">101.LAB</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;">Inline XBRL Taxonomy Extension Label Linkbase Document (1)</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">101.PRE</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;">Inline XBRL Taxonomy Extension Presentation Linkbase Document (1)</td>
    </tr>

    <tr>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif;">107*</td>
     <td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif;"><a href="ex_331720.htm" style="-sec-extract:exhibit;">Filing fee table</a></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; font-size: 10pt;">*</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-size: 10pt;">Filed herewith.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">**</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Indicates a management contract or compensatory plan or arrangement.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">These interactive data files shall not be deemed filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under these sections.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed October 4, 2006.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      II-5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed June 23, 2008.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(4)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Annual Report on Form 10-K filed March 8, 2010.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(5)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed April 14, 2010.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(6)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed April 28, 2010.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(7)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed August 2, 2013.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(8)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed October 23, 2013.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(9)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">[Not Used]</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(10)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed May 14, 2015.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(11)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed June 16, 2016.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(12)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed August 4, 2017.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(13)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed September 7, 2018.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(14)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Annual Report on Form 10-K filed March 26, 2019.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(15)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed April 30, 2019</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(16)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Quarterly Report on Form 10-Q filed November 7, 2019.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(17)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed January 21, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(18)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Annual Report on Form 10-K filed March 24, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(19)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Quarterly Report on Form 10-Q filed November 12, 2021.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(20)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed June 26, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(21)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the Amendment No. 2 to registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-239958) filed August 26, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(22)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the Amendment No. 3 to registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-239958) filed September 8, 2020</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(23)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the Amendment No. 4 to registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-239958) filed September 23, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(24)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed September 25, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(25)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed October 26, 2020. Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as the Company has determined (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to the Company if publicly disclosed.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(26)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed November 30, 2020. Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as the Company has determined (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to the Company if publicly disclosed.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(27)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed February 11, 2021.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(28)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Annual Report on Form 10-K filed March 23, 2021.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(29)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed September 29, 2021. Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as (i) the Company has determined the omitted information is not material and (ii) the Company customarily and actually treats the omitted information as private or confidential.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(30)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed November 10, 2021. Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as (i) the Company has determined the omitted information is not material and (ii) the Company customarily and actually treats the omitted information as private or confidential.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(31)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed January 20, 2022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 17. Undertakings</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(a)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The undersigned Registrant hereby undertakes:</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      II-6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post- effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#x201c;Calculation of Registration Fee&#x201d;&#xa0;table in the effective registration statement;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(iii)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt;">Provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">That for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and this offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(4)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(i)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) (&#xa7;&#xa0;230.424(b)(3) of this chapter) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(ii)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(5)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(i)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(ii)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      II-7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(iii)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(iv)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(b)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#x2019;s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#x2019;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(c)</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      II-8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Smyrna, State of Georgia, on February 4, 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>GEOVAX LABS, INC.</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: top; width: 9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p> </td>
     <td style="vertical-align: top; width: 89%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ David A. Dodd</i></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name:</p> </td>
     <td style="vertical-align: top; width: 89%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">David A. Dodd</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 2%;">&#xa0;</td>
     <td style="vertical-align: top; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:</p> </td>
     <td style="vertical-align: top; width: 89%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="poa" title="poa" href="#"></a>POWER OF ATTORNEY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>KNOW ALL MEN BY THESE PRESENT</b>, that each person whose signature appears below constitutes and appoints David A. Dodd and Mark W. Reynolds and each of them, any of whom may act without the joinder of the other, his true and lawful attorneys-in-fact and agents with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that said attorneys-in-fact and agents or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Position</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ David A. Dodd</i></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">President and Chief Executive Officer</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 4, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">David A. Dodd</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Executive Officer)</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Mark W. Reynolds</i></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Financial Officer</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 4, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mark W. Reynolds</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Financial and Accounting Officer)</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Randal D. Chase</i></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 4, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Randal D. Chase</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Dean G. Kollintzas</i></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 4, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dean G. Kollintzas</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Robert T. McNally</i></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 4, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert T. McNally</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ John N. Spencer, Jr.</i></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">February 4, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 27%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John N. Spencer, Jr.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 51%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">II-9</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      &#xa0;
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex_331601.htm
<TEXT>
<html><head>
	<title>ex_331601.htm</title>

	<!-- Generated by ThunderDome Portal - 2/3/2022 5:07:05 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 5.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%; vertical-align: top;">
			<div><img alt="image01.jpg" src="image01.jpg"></div>
			</td>
			<td style="width: 50%;">
			<div style="text-align: right;"><img alt="image02.jpg" src="image02.jpg"></div>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 4, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc.<br>
1900 Lake Park Dr. Suite 380<br>
Smyrna, Georgia 30080</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Registration Statement on Form S-1</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;text-indent:-18pt;">Ladies and Gentlemen:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have acted as counsel to GeoVax Labs, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with the preparation of the Company&#8217;s registration statement on Form S-1 (the &#8220;Registration Statement&#8221;), under the Securities Act of 1933, as amended (the &#8220;Act&#8221;), filed by the Company with the Securities and Exchange Commission (the &#8220;Commission&#8221;). The Registration Statement relates to up to 6,134,968 shares of common stock, $0.001 par value, of the Company (the &#8220;Common Stock&#8221;) that may be sold from time to time by the selling stockholders named in the Registration Statement, including (i) 707,484 shares of Common Stock (the &#8220;Common Shares,&#8221; and collectively with the Warrant Shares (as defined below), the &#8220;Shares&#8221;), issued in a private placement in January 2022 (the &#8220;Private Placement&#8221;), (ii) 2,360,000 shares of Common Stock (the &#8220;Pre-Funded Warrant Shares&#8221;) issuable upon the exercise of pre-funded warrants issued in the Private Placement (the &#8220;Pre-Funded Warrant&#8221;) and (iii) 3,067,484 shares of Common Stock (the &#8220;Common Warrant Shares, &#8221; and collectively with the Pre-Funded Warrant Shares, the &#8220;Warrant Shares&#8221;) issuable upon the exercise of warrants issued in the Private Placement at an exercise price of $3.26 per share (the &#8220;Common Warrant&#8221; and together with the Pre-Funded Warrant, the &#8220;Warrants&#8221;). This opinion is delivered to you pursuant to Item 16(a) of Form S-1 and Item 601(b)(5) of Regulation&nbsp;S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, the prospectus or any prospectus supplement other than as expressly stated herein with respect to the issuance of the Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As the Company&#8217;s counsel, we have examined originals or copies, certified or otherwise identified to our satisfaction, of the Company&#8217;s certificate of incorporation and bylaws, each as amended to date, and minutes and records of the corporate proceedings of the Company relating to the filing of the Registration Statement and the issuance of the Shares, as provided to us by the Company, certificates of public officials and of representatives of the Company, and statutes and other instruments and documents, as a basis for the opinions hereinafter expressed. In rendering this opinion, we have relied upon certificates of public officials and representatives of the Company with respect to the accuracy of the factual matters contained in such certificates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">GeoVax Labs, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">February 4, 2022</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In connection with such examination, we have assumed (a) the genuineness of all signatures and the legal capacity of all signatories; (b) the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as certified or photostatic copies; (c) that the Warrants constitute the enforceable obligation of the parties thereto other than the Company; and (d) the proper issuance and accuracy of certificates of public officials and representatives of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Based on and subject to the foregoing, and having regard for such legal considerations as we deem relevant, it is our opinion that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Common Shares have been duly authorized by all necessary corporate action on the part of the Company and are validly issued, fully paid and non-assessable; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Warrant Shares, when issued and delivered against payment therefor in accordance with the terms of the Pre-Funded Warrant or the Common Warrant, as applicable, such Warrant Shares will be validly issued, fully paid and nonassessable.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This opinion is limited to (1) the Delaware General Corporation Law (the &#8220;DGCL&#8221;) and applicable provisions of the Delaware Constitution, in each case as currently in effect, and reported judicial decisions as of the date of this opinion that interpret the DGCL and such provisions of the Delaware Constitution, and (2) as to the Warrants, the laws of the State of New York as currently in effect, and we are expressing no opinion as to the effect of the laws of any other jurisdiction.&nbsp;This opinion is rendered as of the date hereof, and we undertake no obligation to advise you of any changes in applicable law or any other matters that may come to our attention after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This opinion is furnished to you in connection with the filing of the Registration Statement and is not to be used, circulated, quoted or otherwise relied upon for any other purpose except that purchasers of the Shares offered pursuant to the Registration Statement may rely on this opinion to the same extent as if it were addressed to them.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to any reference to the name of our firm in the Registration Statement. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the 1933 Act or the rules and regulations of the Commission thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">GeoVax Labs, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">February 4, 2022</p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 50%;">Very truly yours,</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>/s/ Womble Bond Dickinson (US) LLP</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 180pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 180pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">JPD</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">FRA</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex_331664.htm
<TEXT>
<html><head>
	<title>ex_331664.htm</title>

	<!-- Generated by ThunderDome Portal - 2/3/2022 5:11:23 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We consent to the use in this Registration Statement on Form S-1 of GeoVax Labs, Inc. of our report dated March 23, 2021, relating to the 2020 consolidated financial statements of GeoVax Labs, Inc. which report expresses an unqualified opinion, appearing in the Prospectus, which is part of this Registration Statement, and of our report dated March 23, 2021 relating to the financial statement schedule appearing elsewhere in this Registration Statement. We also consent to the reference to our firm under the heading &#8220;Experts&#8221; in such Prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div><img alt="sig01.jpg" src="sig01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Atlanta, Georgia</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">February 4, 2022</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; margin: 0pt;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%; margin: 0pt;">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We consent to the use in this Registration Statement on Form S-1 of GeoVax Labs, Inc. of our report dated March 23, 2021, relating to the 2020 consolidated financial statements of GeoVax Labs, Inc. which report expresses an unqualified opinion, appearing in the Prospectus, which is part of this Registration Statement, and of our report dated March 23, 2021 relating to the financial statement schedule appearing elsewhere in this Registration Statement. We also consent to the reference to our firm under the heading &#8220;Experts&#8221; in such Prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Wipfli LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Atlanta, Georgia</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">February 4, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ex_331720.htm
<TEXT>
<html><head>
	<title>ex_331720.htm</title>

	<!-- Generated by ThunderDome Portal - 2/3/2022 5:20:12 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 107</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Calculation of Filing Fee Table</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 34.4%; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form S-1</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:34.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Form Type</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:34.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 34.4%; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GeoVax Labs, Inc.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:34.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in its Charter</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:34.4%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Table 1: Newly Registered Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%; margin-left: 7.5%; margin-right: 7.5%;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Security</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Type</p>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Security</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Class Title</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fee Calculation or Carry Forward Rule</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Registered (1)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Proposed</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Maximum</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Offering</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Price Per Unit (2)</p>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Maximum</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Aggregate</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Offering Price (2)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fee Rate</p>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amount of</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Registration Fee</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fees to be Paid</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Equity</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Common Stock, $0.001 par value per share (3)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">457(c)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6,134,968</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">$2.365</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">$14,509,199.32</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">0.0000927</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">$1,345.01</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 31%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Total Offering Amounts</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">$14,509,199.32</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">$1,345.01</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 31%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Total Fees Previously Paid</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 31%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Total Fee Offsets</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 31%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Net Fee Due</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">$1,345.01</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1) This registration statement also includes an indeterminate number of securities that may become offered, issuable or sold to prevent dilution resulting from stock splits, stock dividends and similar transactions, which are included pursuant to Rule 416 under the Securities Act of 1933, as amended.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under the Securities Act of 1933, as amended, based upon the average of the high and low prices of the common stock as reported on the Nasdaq Capital Market on January 31, 2022.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3) Consists of (i) 707,484 shares of common stock issued in a private placement in January 2022 (the &#8220;Private Placement&#8221;), (ii) 2,360,000 shares of common stock issuable upon the exercise of pre-funded warrants issued in the Private Placement and (iii) 3,067,484 shares of common stock issuable upon the exercise of warrants issued in the Private Placement at an exercise price of $3.26 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Table 2: Fee Offset Claims and Sources</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Table 3: Combined Prospectuses</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>a02.jpg
<TEXT>
begin 644 a02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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MX5)"C."6=RJ(H9F8*": .^HKXK^,?Q<^/'P8^/'P)N-<\9: K?%3Q\OAZY\
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%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>a03.jpg
<TEXT>
begin 644 a03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M23#, .22AXHYD%F14444P+VC?\M/P_K11HW_ "T_#^M%<=7XF;1V/3/V^/\
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(J_$S:.Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>govx20220202_s1img001.gif
<TEXT>
begin 644 govx20220202_s1img001.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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>/47K,S6CP!B4P1FD0?>KP1O$P1S4P1WDP:,("  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>govx20220202_s1img002.gif
<TEXT>
begin 644 govx20220202_s1img002.gif
M1TE&.#EAA )4 ?<         ,P  9@  F0  S   _P K   K,P K9@ KF0 K
MS  K_P!5  !5,P!59@!5F0!5S !5_P"   " ,P" 9@" F0" S " _P"J  "J
M,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5S #5_P#_  #_,P#_9@#_F0#_
MS #__S,  #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5
M,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J
MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M#C=F#VACL^:UKX%X'5=R:-O_$&+26@X08F"%NY;A:=5SEN!"E,D&IT$;@C<
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MC<9F2^US2SW,[TG1AFJ..LL2O1)(?AF.D#'D%),TNI9H$]P1M8:A7M<J+OF
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M]KF(W!0%C,C9N-DE#EE$2CE)S,T93HAC)I@&A'W5]5S/5T6;NS;$M3W$/@)
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MCYZ&=\2J8&="5X1H3XIQ,(#-7'K3T82W7JY(;IDD#-" 'M8#+ ()&M3G(W"
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M R2'#++.$\T>@T\N!*+(BWCVDV813(@!:J<T5"0:$W2/3F_KF1A*A(DPIR]
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MQ#J&9/14M+#JFTSU=1('9"XW=+Q1.M;N?=@[D$)# UT'7&RLB%:G?1R#,&X
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M&QTDB)WG.U'&>1;A=YFPF+]I)_=2(^2F+\>&05G((S_)5Q/G)B:Q#&2YD0"
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M7900UB1[]7$W+?DXHF$R#Z<6[V4R?VDB^'.?$N$0E2)Q:M2DOM$>:@A1YG$
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M2OD2,6Z3%1S.B1Y0D=VT[I@4ZV3E8E?)ST%5U+N?T.JC?#-1Q-13K;\(1AF
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MH"1@4U"'8\C$4C 6X%#8+&I7)KR!\'1.#\V<HY0&4V3,PTS,N+T@23 $:.!
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MRX<YO[7T?OE3_YYY;EGUC0IN27C,4N2@O_FW__)TOVV\Y8DT'X!N_^YG,;T
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M+O-Y-FW0+/3%<%;EQJ>PCO0U""F%1NR:>D?%YB;I!LBL4'+K<HQ_6FTS!2B
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M$ 7H3&M26\@X=)ZR"4QO:MW64]PXR<Z^^E>>5JG<^C:DZ08971*D/#$3N8:
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M2*F/:G0.3VFWNYN(]%^TNPE,"F.;-\(O8FAP74N>Q]*<W!0F'%E>SG[WO*5
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MZ)I*K(^Q$:7$L!TQ', $?C =(1]%@NR5.$>]%+G42N8XXZ6-+VC)N0BG;RG
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M_AD@5C4Q(5;)8^9.T1HYM:I&\Z)Q4]@9)#L=]K*J^E,@F0EAV%=G<8%Q82N
M"1F2>2'HD@DW4S2J95FN!U!)5([Y*BU&)$,P%$5!!EBPM!#O-KNP[1\-4:_+
M@<3SE(%S*2O5*<G81U?(&[D[<Q1O4"?FI5)29X3NAS.98&B&D4>C!+W1.V"3
M&&"FQM'B*^=[FLQ5-Y0G92G+B"E8-[,V)W$X]]U* ET*?S,>EQ8CI!96\9U'
M(V.2B(8 SZ;K]^BF1DI6IYM)9W)U+G6I5G5)T9(5--CG_!MX/>I WT**=.^K
MP8MW;B=O,&@[+Z['Z&V]SD&9U$^1>[1%@4;C_SPTX(QBFK!+=6.-LT7;YU'
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M4'U;=%+)-(S>#*5Y,FC0D3(S3:K7<F5@8J"&*2,Z"<TD3&/%X##[\V_?AL-
M5;Z<3)-FA8J/NN6Y<*[5&& 7IQ$3IFE5J5*MPE5X-6O/3&DR)0LJ,K=EF<F4
M%<Z=J9Y+XL6-'T>>7/ERYLV=N]0D>9(DVS_=^+1YDR;1R4+Y:CXL\O=X@RC_
MR6=$7UX]^89\)_W$R7WD)[Z:]F:7:1GX2667TX\W+Z&5#(*.((\JBH8>: IZ
MR2!-T(AA,30RR:@@@BRZ<$&0E%$0H64J0DC! P_2)\0+/_SPH8<4)(:K&]*@
MR,1Z.@HIHP QTN=""V<LJ"*/E)E$)NHH1(D8E?8!A;B81)J)&/AP<FJAZOZJ
M2:B:)D$*A@!B8 HIR,@J"PVP;G#-*Z^D? HJLF[ 02<PH0H#,DEPDD0LV9**
M 8 8MCRSSH4:D5 QZDR*:2:;:@KJIV62<4D\F0KSZZ:J< C#M<7@.\FPR_0K
M3R^Q=-JBM2C%,(DJ4W^B"@>HT.+**S*EG!,-J<R,_^I4(@'4C3]B<"-R$FB>
M S9888<EEAC;AI',)DS?.RD[G&:RK]F3-@/N/X<"O'8]&]$SCZ_LHGL/)[YV
MA70[1$_"+:/PBK36P0'I<:DA:);1\$>($()()+0HG<0B:":ZT"$+!0+1QX-^
M+&C>BA)&J$2'Z2W(0F*@6D$,@Q*4J*+_*@**&/-JS#BBB3@V-+>4]M%GF$8U
M*92HFA+[BRK1%K-I&&(BS2\-U0[0$H:H5#L*3L@><VW5K6+E2K4S65/K,RD5
M$S1-I  P(  #5% J!AP6$P.3MWJ"FN:3\IO)Y68U^8VX(*F5-M&_>!JZJCFA
M;M;D\8B,.=4QJY*5[[#HGO^.-3*U<LU%N5&+L[05O-2*YH;H@]QD8N@#A3^1
MAB,V<^9R:Y3"\8@3J;N#-"_NRI]>;CFOR6#V*=+[*%NR/5P#E'TC];#M-J'X
M7LYN+[+] MZPFG#5EMOUCE3FUY5 B5$@%0DJD</RTHJAWPUSS#=@[?.%*,&.
M(CIPWA(]&E]%B#Q:$)H6F;K!//(]'._'WV(>B;P#4T18HY#8-4BFE01;R6;.
M-91HV210/WF44"(EB:/X#"ML0HIJ0B4#U<1)-:(RE=\>0[3&/65Q7;&48FCS
MEZL<0 4FS%,,#@ 6NOPE;('JG;F"A)>1+.,3Q,D$?;;SFV15B35AD1!01)*?
M(AG_YBR0"8,,"B<5KLV,.G=*VF/B) 8NW  -J'F3"F.PA3/]1'8QV0M]B <D
MY9'.C,69V"16L@P&!N4&#W&)0K1B%3B>D2AI0."SI!4IU6''4(<Q%TU\DQ'/
M90MW&-'8>;!UK==-XDHV@=1E=+B=]M#G,,P[S^S24Y$C-21>#UE&CF9$/OU=
MRU1HZQ&*TI.]'2D,?JQ4$<%"";$+)2@CK;*8]E(DO?283H@.T1"]%(2>A0',
MD$F"B$M@0L.@-$E:^&D9M"8C0J@< "M*TUHVI0*9.6[0*61B8FIPP$56X>E,
MC</)J: D&SWIJ30TP\Z3%".4D]"G/M,:!B74UZA)>*M*_WNY#S6M(J>?*&-)
M_=$,;M!F$W'&*32NF80;6&45,'EE:(YYS9V.0JL(B0$HX,E$Y612'C'B[8PG
M)0XTJO(0?2R$C6(@!G&&L9"&3.(&D] '1%"2N4?J<7<)1-9V\'//^Q#E9F@C
MER8-:;S<K:=VB'DD#<&HP_STY7CE25?Q_M,>P2@CIP$T2/3N92\3.80[#O&>
M1CB$2(S,Z$($JQ?&WD>B@WU(8>DK2":^PA"#U,LA&*G1S;I#$V)HC$8Z.A%%
M:)3(WQP)@/M 5*&&(CP"_DZR!/28=JHB Q@LI2O6#%53P/)#J52J*ULBK5HJ
M>L$1ZL0M(Z%>EY@BFMK,*1,F2?_6N("B0V_9)# X[*W-(&G)D1BE*JH1PUO2
M0#9J =2209GH6S)(PJNLZDU<= VEC&*:K8RI-&:2&TT0XQ\C955V-:TC2L]H
MTYAF0@8M8:^2I+*29%1/7U5Y;+#<TQ?MU*UN?NFGZHPJK9A4;KR9S-:V%ME4
M!!OJ)M$AH'_KAE2M:NN\MSL9]\ :HH$X+WK;2K#&5 DPYW5(([;\T$ 81" .
MT0A[X%.EQ%!S$@V);)?E^1%CCVJS\J H1^#[UU^U1QX*H>Q(^X!&V8P8K69R
M)W41'J*RGG+"=F9E5ML,BU42AQ4  ,!GK5&+F2H*F0D5]S4Q<]-5*$4;QM#%
M+)"D)W__7^9(9*&MCM"82[CRXK%<B60Z<6)3E/Z""70-CT*<N<FK1#.HR=BI
M514%H5>V0"DFBM!.;6G@TP"$&_H(T#+* $_EU*M>9>! $M&81!@>DFID!A L
M4+H!VA;BY_0"JR8E>=9^FY4KWF5'PJ_;BR(MC&!A+])&E&46G.OCEV"GAW_6
M,K8FAD.@E: D>O>3GL2(C1 +J?5>UTYL+,U'D&#RZ& )"B60+134@/6(F#$2
MLK4ZXLJ"F0A!\BO/D1@U&/'ZMS=!>91\_GDV:34P #!P9S>Y.=H7BC-+!P]
MPKO2I1A444VB\8EC%C.HL%E%$F^ FF(DU(AX>B<O )YF-![+_Q.Q+*8W0IF?
M8BCX3KG!9C)[V510\/CH,'R-S6D E&P&EQ7":85P?-.)S"B%1!4FUR1$24E2
M41(M'L)KU&=41E6(T?.54"6F+AF&JM BG)9*Y229"PIUDB4NDP^X4&Q'70RK
M16RF"AO$&(:J?(*$P)=EAG9X3_!3AXV\.J*2W*,<2+KGYSGW\7+$&K.70\[G
MH6LC1$,0B=ZU40PBKR*DD,]KZX9"TNV->"1BX@NEN>EUXT36Y']*8G:<:W)9
M@%>)*"9)5&I4>,(O1ZE22IP9U)BV^ZII*4O6!&%:;E!%I),P#!*2D@M%6)V&
MBZ4D)S>4N !\FAJJ;(U]PR]0[,P?%_\^A8)A04V=YF*279?KMI^I=,L'+9JT
MH 4J8D_B5^*698^CAC0W4#L["PZ'H)!A@#H*R81HN+J3RH3GNP'!F 0<\#Y7
MRR7,V0<G&3MBJ9*0DXF"ZJV!\YB@PHLGFX]=6:K:,3;<23 0,Y*;,1*<>9G?
MP"1C [Q,8K!A4$"O^B3P@3%>LI!?RJ31$SWIF:4.$9&&2;>$F9$4*8@/XYZU
M2@_2$S&-*":O2JQ[^Y?)BQZW\A%N,R;_V8<)7"9E\[=FP0YI>8LQ<#15V3UK
MLA0IXIN-^XNOT2(8. #/B@$[S$.B [/DLZTK.@VJP*W^2B?%J O_4S]F:;++
MBA7<F@25(P[_KM@)/.(5J.,+VX@-I)L3U)B09-N-*\&HJ>B)J4!$+.JFU-B*
M&S@_\'.13U$(.ZF4,6 _E$B7%VR(A7H[JUM TB&&S[ Z!F(\: @[25@&T*F?
M5#NR8.FID3 49\*+8$- \7,[(GHJR"D>%5Q!!4N(\? - ?2UD3J,W&D(RP$Q
M\KI&@QJ0PFNWY)FK3K&<C\"?3>J\\CF8<SL0%5N0>SP(O^(PD$@D][DQ(@2)
M?QDQ@<0VM[*K%%M"7MH0UX,LEU"YRKHLHRH99DP,G:B4+6":T+HXM+"@K;BB
MGV @&% !/;'#$WH@&> HZN$2K'BS<%&_%G(6-*N3#"H)>-(.;\DS_\FP,Y?0
M!PBA+=5Y,I^0*#1) TP8%)DDO]Q#13(S%:X1$[%C%5DA,S>9M T2%4LAH0R:
M"G'I-,OH1O48&U';Q3-" RY  Y>PJ='RJ*T;@Z\:#*ZLM>?0M:%P&SXB+*B"
MJEUKF[/1#S%JC[]3*KK#1JVZ&3H;'@',*FV40?+@%*>Z' V[P+YR*](C0'%Q
M",;:$-L9L11)R+F2I?09$><9)2\<IOTRGI&APHD8'T3:QUA*0MC\,>"9'WUS
MB7I@F6>2R,G22>Z@0RVZ@=#2BDF;-%H)%54A$^Y"@T8@BP, @(/+$Y_Y/\.!
M"@.H,JT9H6E*Q)N0CUC)LU'AFVE2%E^;%O_A>*RD8SN]&"D_PS6<*(DH@<J=
M:#\S<PRV? ^9*9P?$H-0P2^928V/5+JJ$"&!*K-;Z8_S2JA;1):Y+$MA^8TR
M&@]JB0AB*".(S(T*=8ZOBJIF(L^U*33$,"@B0AO]T QRJ1O#,"C?$+S4'$P;
M+#8FZ0X><PAS-(_/&S9B([P"R1<+"9$4<1L[PY"+T)B!":OD:<*PXC""0;?.
M@RL/N3=VG C/0T_#(R8O+*L:B4T509$@FZ5..3./>KV5T(=GE##=3+:Y8 3=
M"S.R8,/3HI4/*@O66!P'4JVG0"XU60$ 6!RE@)/DTLT8W4"?H N62SK1N#XO
M^JG!RH1%<0DVPL3_RD+1):D)1KL)JA@M.X&:8VD9D9N4,PDGM.!*_;0B#8H;
MZ!/$K_%//PVP_ADIQI-!0,JO!I757=3)_G(2R9*,$/6/PY#0RA"@7!F*,0H\
MNW.V%?R\AF >OA!0!&2/3[B[<P11X@F*'(1+.VLE?/.\*^(QSE.L78+'PXM2
M(^S!\5G24>+!&/L>("$5-0R/#>'6?W&>>BP8#-&0A#F0'2% C5(CEKA-"'NF
MRR)$_QPZY.L2)0JSELPFGT&^/1S8%5"3LA@SC80*JL%#J9A%9HRG3:2.0.%8
M.Y&9MPBP9-$.17FLG!"J<2P/O1O95+$*D!6;^D&S->M#_G.*2YNHBT(#_Y;C
MFD&AF8=RJ,FHQ1TZ#TGEG%DUV@6,JFG:,04"([PQJ/'ZM/(:Q\FY18-P5O;8
MJA.\._YI"-SXMU>D)!2]L*6ZG; <#_]PE\DL$,GSQ[<2"49  R"UJR4$D1^;
M5X&I$!XTMX.I,2&EJX!!"&+PFD_1A"K,3!3)L70+"<^LB'^YB!RIL8DHBK+@
MNF1:B8B4C-H3"I^@)J_XH*M1"CX%B^/S&9/$"A1BBN=4B]Z;%&PR(6MZC(>C
M4\B8$FFI6=9@OD5#,[^QE?%TDL%RDFB80""YK8):*)S3M9"5&3M!&A>2EG0"
M2<.YE.6%OM:%DY"<DNMCQF9AV;8D+,JQF4@U+P(0%?^.HS5?]7(/MQ$OUSD4
M"EF2]C.,KC62^7G!&F1,NK,[RZG:A?(+FB$*X>F?^UT/M#6/=C62 2DCM!F1
M&PLR@\(O_2F8#C.F(,U;(U41)<R1'H57"48D6P(2NMG,*6S@=B'"+ R8#,8W
M@[&I;G(L92J@,I4._,R*UUV!UX58K( XXZNH$ZI8+<+."8E=+O.9T5(AA8V@
M2^&OK<1*6AE51Q,5T%B=J&(6/?HMM0Q)O2@TWH JL5'6#,H@2]M<):Y>,6B$
MZ^!*-\O***F3I*0S--R;/9+4$B6@:/4/7SG?.S:CJ.*. 1NL&3HJ\$ JA>*,
M78%9^AW6!1M6NR-1JB4*LX'_F7/)#0$4HVP,QXPHL-KI*EW\&"M$7(P(NS#H
M)]:L1W)CW-=4*PR!J\1R*UOJMBS=$+Z0T>AQS=.C92C,3!Z595ZZEU>>2I70
MAZ_;!Y5[%LN:8A*:%3'+DJOA&8>E(!R@LI[AF0="BFA.N#4Q#3?)D]#=DG":
M&JQQ6(^:#$I0XJN T^7SICK-V62CIV6IH7V#B'2N#0("*<E"EK7#U-!(52Z6
ME/A;"*G@5.9=C+8P&M?PO\CH#M=:.O9#*B(!)+N1T,C$XX@>%G\U$CUZWM^5
MK+T,ULR8JA<4*O%X-JS-1F*%,)2XC+S 5:G:XUT9GJ9J#[3]#=[28B.9-G6T
M//G)_Y[IT8HBS1!\=3R#V<R\78:"2"MWHQ=4MCRW?;==TDP2CCP+EIY$LC=3
M0@O;6(D;XK>?,J*1<$2CF#1(6UASDHW4?2#JH9C0W4,_E(VE.#@]*9-I7HU+
MP2V!S9)(&SJR]HJ>R\F1%4_Q2L;3.2MZ[J_^6M8K&I7E%5F/53OJ#3G#QD^*
MBM/4L-BM? ^T*(TIR8W)$4#A04$[ENC/IDM%%2S\B#,CF>,O<AF!:U4$8S!B
MM;!D* H%2F(7L@T\.IU,292H'6F6!AY$(<!T+) JS#$)SKH&" .TV5++!!BW
MFN"*"!"'6:M[ZU'TJ<<;"SU:"B8*CIAP@S=OU1!TX[R/&/\&_Z.9, UFP,;5
M/),0;)J:%#IFU4(*/&R*L:"4(H:XZU3%Y%)3O/;4/%Q82UE>P=G3+6$?I. B
M+O&L+J&M,RPY E*CQ\+$WS$HBYS#YQ6A12.:.)$99K&/#GPBGQ-0L;EP0?2;
M@283&= @CQ(A,X&A=4$)+8;: BM?T*;QY0 %MENV?WIAOMC+ ]3H[=WC N.4
MPG#10S:D,E66L&$YN-5GQ!"B(NE&KQ7+WA#R0J'6'>RP++=E98"0,"@D=QNK
M*F7(&PEAP(*\YR&ETHO<(57-@02FS(0WANP1%=N8^9&9.CF2"62)]$3#4G$M
M2./328$T:8ZT-;N*U U=/.0N-NS_&7<ZZ[9V[\+Y&N^R)CHU.K*HLL712LX5
MS]M^Q G4!^SP%H"[;<Q2ED^9A#?P$XKJW; I5+!X/@;/H(_CU*N$BDF[U*>X
M(J]A+;$Q**H%3,83GG3Q[!HW=N.HDIK9U$8:FW_2CZG5#K)Y5:EUE%[=VO^H
MC0EQC]'8BMOE1$;P(J$M) HS"+3UKV"#E&I+X#B?8(? DC8A-Y%1;G?U$#ZS
M'XV B'0ED;;BTA'9O._NJV**Q^UN98K &%U*I!P#F!:9$-L0@Q9>HQCBCNG
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MB4L@V[]YDO.\A+^ HZ?-(*J%X\IE3ZU8G:V<G4VHUY[ICNL@1[;09G%L 0Y
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M[K8"8>:J8SJ"VDRC*)1A,S!%37"MY(Q&2-KBXF:-:@!0.<J-DWSB@!8K@<0
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M)5#/D0[7TD(>I[ DP4W1 $:1]3'*<?/^ZJDV!. F[S1 ;A:]@JKP119/Q;2
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3@]24FL"!5Z0/_O"+?_S^# @ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>govx20220202_s1img005.gif
<TEXT>
begin 644 govx20220202_s1img005.gif
M1TE&.#EA9P%J /<         ,P  9@  F0  S   _P K   K,P K9@ KF0 K
MS  K_P!5  !5,P!59@!5F0!5S !5_P"   " ,P" 9@" F0" S " _P"J  "J
M,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5S #5_P#_  #_,P#_9@#_F0#_
MS #__S,  #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5
M,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J
MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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>/47K,S6CP!B4P1FD0?>KP1O$P1S4P1WDP:,("  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image02.jpg
<TEXT>
begin 644 image02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M]<Y]:]GK&MRWBHN^A=.^MPHHHK T"BBB@ HHHH **** "BBB@ HHHH ****
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M2IQCCTXH>*.1D,B*Q1MREAG:?4>AYI\[NF'*<C/;IXA\878C)CM-#@:)9(L
MFZD7D@^J1D#ZN:YOPY8)<VO@.W%_=;6L+EF:.;:Z_)'\@8<J![<^]>I1Q1Q;
MO*14W,6;:H&2>I/O4%MIME9 ?8[."##,P\J)5P6^\>.YQS3]II87+J8GA&YD
MO/!Q.I7,D_ERW,#32-EBB2N@)/<[0.:YRPGDT2#1=,M-7L-:T:ZE6ULWA4+>
M6P*G:ZD$JVT=3@$#DUZ+'%'$NV)%1<DX48&2<DU4M]&TRTO'N[73K2&Y?.Z:
M.!5=L]<D#-)36H<K//O"HF_L/P9IMOJMVEO=1SM<".4!CL0$)D#*@'TY]ZMZ
M;J.LW^H+="=H[A=5>"6.6^58A$LI4Q^3_>V#<#]XG!S@UW5OIMC9_P#'I9V\
M'SL_[N)5^9NIX'4]S2'2[ ZA]O-E;F\QC[1Y2^9C_>QFFZB8<K.&T_4=;O[[
M[6LK1W2ZHT#PRWZK$L2R%3%Y/KL&X'[Q.#G!Q6AX,-KIDFOM=:DWSZU+&%N9
MEP&) 7'3EB<>_%=2=+L#J OS96YO ,"X,2^8!_O8S4=QHFFW,KR2V</F221R
MR.J -(R'*;B.N"!UI.:>@<K1S'CC2H-:\2>&;&X9H]\ERT<L9P\3K%E74^H(
M!KGY4O?$WB75-$U6/RM6M] >%W5<)(XF#13)[$@''8Y':O4VB1Y$=T5G3.QB
M.5SUP>U'E1^=YVQ?,V[=^WYL=<9]*<:EE8'&[/)3XA8VA^(L:.#(#IP0@\KY
M6 ,?]?(Q^->D^&]+&B>&=/T[^*W@57/]Y\98_BQ)J]]DM_($(@B\H-N$>P;0
M<YSCUSS]:FI2GS*R&HV"BBBLR@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH XCQ7J-Y9^(MNI7VJ:9HHME,5WIT D'G9.[S3M8J -
MN. #SS6WI6N0RW5EIBW7]HR2V'VL7R!0DRA@N<#C)SGCBGZGINM37YGTG7%M
M(W0(T$]H)D!&?F7E2#SW)' K,M/!4NDMISZ)JAMY+2U>UD::W$GFJ[^86 !
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MW,,LD1Q(D<@8H?<#I7GFA:+)INJ>&[B\T=C/%I4]NKM;EC'*'4QJS '9\H8
MG  S3=#ANK+6=+U1[&2)(-/N3?QPZ;]F$+85A%DXW\@X))Z9SS0Z:Z,.9GHE
M[>V^G6,UY>RK#;P(9))&Z*H')K'M/$\US<6_G:!J=M:73!8;F1%(YZ%T5BR
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MON;B.+8%7R95W$9.!E@*GEC<=W8FM?&EM=7=O_H-U'I]W.;>UU%POE329(
M!W $@@$C!_$4Z#QE:7TVH1:397VH/82)'(((U&_<&^9"[*&4;2,^O3-<Y:07
ML_AW0O"S:==Q7FGW=O\ :9FA80I' X;S%DQM;=M& #GYN0,5NQI>:;XC\4ZD
MMC-,C6ULULB+_KV1'RJ^^2!^--QBA)LT-$\0QZW<7T"V-Y9RV,BQS+<J@^8K
MNP"K,#P1GTR*V*QO"NE2Z1X?ABO#NO9V:XO'_O3.=S_@"<#V K9K.5KZ%J]M
M0HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4C*&4JP!!&"#WI:* # '2BBB@ Q1110 4444 %%%% !1110 8HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL";Q=;0>*;S
M19+6Z+6EFMVTJ0.X8'=E0 O/"^O).!R*W8I!+"DBA@'4, P(//J#TIM-;BNF
M.HHKE8O%LUSXVBTRWMXSI;1SK]K8G<\L6S>%[;1OP3Z@^E"BWL#=CJJ*XNU\
M5:PUK8:Y<PV?]BZA<I"D2*WG11R-LCD+9VG)*Y7 P&ZG%6M1\6SP>,-.TFPM
MHYK62Y^S7ERQ/[N0Q-(J+CJ0$R?3<*KD8N9'545S?B?7+W3+_3[.TELK*.Z$
MA>_OP3%&5QA, K\S9.,D<*>M5]-UKQ!K&@1WUG_9<!225)9IUD,4RHV%ECP0
M0I )YS]>]'([7#F5['645R6D:GXIU[P[8WT TNS:X\R1I)(Y'!CW?NRJ9!^9
M?FR6XR.*N:/K&IZ]X22^LTM(;YG>,&3<T#E)"A9<<E2%)'U%#BT',=#17#_\
M)?K-@-<;4H+"Y33!%#&UIO427,A $9W$\#<F3_M>U6I/$VH^'[FX@\4_9)@M
MA+?12V2,@(BQOC(8GGYEP<\^@H]G(.9'745R=IKVM6-_IR^)$L5M]4C<H;96
M!MG5#)L8DG>-H;YACD=.:@LO$^M-%I6K7\%FNDZM.D44,8;SK<2?ZIF8G#9X
M!  QN[XHY&',CLZ***@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#G;JPU2W\83ZMI]O;W$4VG+;[9)C&4D1G9?X3D'>!G
MMCO701%S"AF4+(5&Y5.0#W -5+K5K.TU&VL9I&^TW63%&D;,2!C+' ^4<CDX
M'-715-M[B0V6,2PO&2RAU*DJ<$9]#7&6_P /DT_Q!H]Q9:E?M8Z?%,C0371;
M[VS"@8^Z=IW>O%=K5%]8T]-:CTAKJ,:A)"9EM\_,4!P6^E$926P-)[G+6OAK
M6EL=/\/W M!I&GW,<JW2R$R311OOCC\O;A3D*"<]%XZT7?P\4:EID^G:IJ"1
M6^H->3I)=DCYE?)7C[Q9AU[$UOP>*M&N-6_LV&]5KG>T8^1@C.OWD5\;2PP<
M@'/!JW=:QI]CJ-G875U'%=7I86\+'YI"HR<?05?--,FT3G]<TC5]4FTV^FT^
MQO/LIF$NF3SGRGW$!) Q4@L .A'\1Q4,'A?5O^$+N-&::WMOMUT3)%$[%+2V
M=AOBC..?ER!P!\QZ8KHM6U[3M$6+^T9RCSDB*..-I'D(ZX502<=^.*K2>+=$
MCTN#4/MRO;W#F.'RT9WD<9RH0#=D8.1CC'-"<K*R"RN4/%>E:]?6MKIWA_[)
M%INW;=HT[PR.@X$:LJMM4CJ1SC@8K0L$U6TT^TMETVPMUCA=3'#<-LBVC$:K
M\@R#WX&/>@^+-$&D+J?VY3;-+Y*X1BYD_N;,;MW^SC-3V7B#3-0TV:_M+G?!
M;EA-E&#1%1DAD(W X[8I/FM9H>E]S&'A"5O ;Z1+<I_:,S?:I;K;D-=;Q)N/
M<KN 'T%0S>'-2\375Q-XDBM[)/[/EL8HK:8R\RXWR%BHQ]U<#ZYK6L/&&A:G
MJ,=C97XDNI59DB,3H6"C)(W =*MIKNF27][9+?0_:+!!)=)NQY*D$@L>@X!H
MYIKH*T68-MHNMZI?:;_PD<5G';Z6CC-O*7-U(T9CW8*C8-K,<9)R?:H++P[K
MAM](T6_%J-,TB>.5;J.0F2Y6+_5*4VX4@[2QR?N\=:WM)\3Z1KD[0Z;=&214
M\P*\3QETSC>NX#<ON,BDT_Q5HVJ:@;*QO1)/\Q3Y&59=IPVQB,/COM)IWEV"
MR-BBBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** .+U:PM'^(TES?75S;P#1)3*ZW3QHB[P">#@<$GZC/45V%MY?V6+R7
MWQ[!L?=NW#'!SW^M.=%<$.H8$8((SD>E*H 4 # '0"J<KB2L-E9UB=HTWN%)
M5<XW'L,]J\TT^#6;;QSHLFI:1)%J%Y'>/<W/VB-E)(B'&#PB   =>_7->G4A
M R#CD=*<9<MQ.-SS&SN[6;P3X=T*&1#K<&H6Z26P/[V*6.7=,[+U P'.>AW>
M])J,>LQ>,-&U#4]$<W<^L%4D6YC*K"L,P2-><@8)<DXR<^U>F"")9C,L2"5A
M@N%&XCZT\@'&0#CI[5?M/(7*<-XIU&WGUW0KC3=6M].=Q<(NKR;7A51M#0X)
MVEF([D8V'Z5SUO=(NGZ0\-Y%970U>[3^WY,-!(Q!+R8/RD2?= R "IP>!GU9
MK:"2'R7AC:,G.PH"OY4K00O#Y+Q(T6,;"H*X^E)5$E:P.-V>4"Z1=+1EO8A=
M+XA8?\)%QY!D,7,N/NX*_NMN=N>]=+X*U&VCOM7CN=0@O;B:_5!J2,%2]<Q
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>sig01.jpg
<TEXT>
begin 644 sig01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>govx-20210930.xsd
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:53PM UTC 2022-02-04--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:govx="http://geovax.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://geovax.com/20210930">
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://geovax.com/20210930/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-unaudited" roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited" roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited" roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://geovax.com/20210930/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-deficiency-" roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Statement - Consolidated Statements of Stockholders' Equity (Deficiency)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-parentheticals" roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Statement - Consolidated Statements of Cash Flows (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-business-" roleURI="http://geovax.com/20210930/role/statement-note-1-description-of-business-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 1 - Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-presentation" roleURI="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 2 - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-" roleURI="http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-basic-and-diluted-loss-per-common-share" roleURI="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 4 - Basic and Diluted Loss Per Common Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment" roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 5 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-expenses-" roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 6 - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-notes-payable" roleURI="http://geovax.com/20210930/role/statement-note-7-notes-payable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 7 - Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-commitments" roleURI="http://geovax.com/20210930/role/statement-note-8-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 8 - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity" roleURI="http://geovax.com/20210930/role/statement-note-9-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 9 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-expense" roleURI="http://geovax.com/20210930/role/statement-note-10-stockbased-expense">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 10 - Stock-based Expense</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes" roleURI="http://geovax.com/20210930/role/statement-note-11-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 11 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-grants-and-collaboration-revenue" roleURI="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 12 - Grants and Collaboration Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-subsequent-event" roleURI="http://geovax.com/20210930/role/statement-note-13-subsequent-event">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 13 - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF" roleURI="http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 1 - Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-property-and-equipment" roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 3 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accrued-expenses-" roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 4 - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-notes-payable" roleURI="http://geovax.com/20210930/role/statement-note-5-notes-payable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 5 - Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-convertible-debentures-" roleURI="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 6 - Convertible Debentures</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments" roleURI="http://geovax.com/20210930/role/statement-note-7-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 7 - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity" roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 8 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-retirement-plan" roleURI="http://geovax.com/20210930/role/statement-note-9-retirement-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 9 - Retirement Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-taxes" roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 10 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-grants-and-collaboration-revenue" roleURI="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 11 - Grants and Collaboration Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-subsequent-events-" roleURI="http://geovax.com/20210930/role/statement-note-12-subsequent-events-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 12 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-schedule-ii-valuation-and-qualifying-accounts" roleURI="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://geovax.com/20210930/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-tables" roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 5 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-expenses-tables" roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 6 - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-property-and-equipment-tables" roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 3 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accrued-expenses-tables" roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 4 - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity-tables" roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 8 - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-taxes-tables" roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 10 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-schedule-ii-valuation-and-qualifying-accounts-tables" roleURI="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-presentation-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 2 - Basis of Presentation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-basic-and-diluted-loss-per-common-share-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 4 - Basic and Diluted Loss Per Common Share (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-notes-payable-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 7 - Notes Payable (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-commitments-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-8-commitments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 8 - Commitments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-expense-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 10 - Stock-based Expense (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 11 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-grants-and-collaboration-revenue-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note 12 - Grants and Collaboration Revenue (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-subsequent-event-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note 13 - Subsequent Event (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-property-and-equipment-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note 3 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">060 - Disclosure - Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">061 - Disclosure - Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-notes-payable-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">062 - Disclosure - Note 5 - Notes Payable (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-convertible-debentures-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">063 - Disclosure - Note 6 - Convertible Debentures (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-7-commitments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">064 - Disclosure - Note 7 - Commitments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">065 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity-preferred-stock-summary-details" roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">066 - Disclosure - Note 8 - Stockholders' Equity - Preferred Stock Summary (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">067 - Disclosure - Note 8 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity-stock-option-activity-details" roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">068 - Disclosure - Note 8 - Stockholders' Equity- Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity-summary-of-warrants-details" roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">069 - Disclosure - Note 8 - Stockholders' Equity - Summary of Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-retirement-plan-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">070 - Disclosure - Note 9 - Retirement Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-taxes-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">071 - Disclosure - Note 10 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">072 - Disclosure - Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">073 - Disclosure - Note 10 - Income Taxes - Reconciliation of Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-grants-and-collaboration-revenue-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">074 - Disclosure - Note 11 - Grants and Collaboration Revenue (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-subsequent-events-details-textual" roleURI="http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">075 - Disclosure - Note 12 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-schedule-ii-valuation-and-qualifying-accounts-details" roleURI="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">076 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="govx_AccruedLiabilitiesPolicyTextBlock" name="AccruedLiabilitiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_CapitalUnitsTrancheOneMember" name="CapitalUnitsTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_CapitalUnitsTrancheTwoMember" name="CapitalUnitsTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_CityOfHopeMember" name="CityOfHopeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" name="ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConsultantsMember" name="ConsultantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" name="ConversionFromConvertibleDebenturesToConversionUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" name="ConversionFromNotesPayableToConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" name="ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfPreferredStockIntoCommonStockMember" name="ConversionOfPreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" name="ConversionOfSeriesCPreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" name="ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" name="ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" name="ConversionOfSeriesFPreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" name="ConversionOfSeriesHPreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" name="ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" name="ConversionOfSeriesIPreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" name="ConversionOfSeriesJPreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionUnitsTrancheOneMember" name="ConversionUnitsTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionUnitsTrancheTwoMember" name="ConversionUnitsTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionWarrantMember" name="ConversionWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionWarrantsMember" name="ConversionWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConvertibleDebenturesMember" name="ConvertibleDebenturesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized" name="ConvertiblePreferredStockAndRelatedWarrantsAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued" name="ConvertiblePreferredStockAndRelatedWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ConvertiblePreferredStockConversionPrice1" name="ConvertiblePreferredStockConversionPrice1" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="govx_DebtConversionAccruedInterestAmount" name="DebtConversionAccruedInterestAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" name="DebtConversionConvertedInstrumentPrincipalAndInterestAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_DebtConversionOriginalDebtDiscount" name="DebtConversionOriginalDebtDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" name="DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="govx_DeferredCompensationLiabilityConversionToEquityAmount" name="DeferredCompensationLiabilityConversionToEquityAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" name="DeferredCompensationLiabilityConversionToEquityConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" name="DeferredTaxAssetsAccruedSalariesAndDirectorsFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" name="DeferredTaxAssetsBeforeValuationAllowanceNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_EquipmentAndFurnishingsMember" name="EquipmentAndFurnishingsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" name="ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ExtinguishmentOfDebtIncludingInterestAmount" name="ExtinguishmentOfDebtIncludingInterestAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_GainLossFromInterestForgiven" name="GainLossFromInterestForgiven" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_GovernmentGrantsandContractsTextBlock" name="GovernmentGrantsandContractsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering" name="GrossProceedsFromIssuanceOfCommonStockPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_June2020WarrantsMember" name="June2020WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_LeidosIncResearchCollaborativeAgreementMember" name="LeidosIncResearchCollaborativeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_LicenseFees" name="LicenseFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_LicenseFirstAnniversaryPaymentMember" name="LicenseFirstAnniversaryPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_LicenseSecondAnniversaryPaymentMember" name="LicenseSecondAnniversaryPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ManagementWarrantMember" name="ManagementWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_NIHGrantsMember" name="NIHGrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" name="NumberOfCommonStockSecuritiesCalledByEachUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="govx_NumberOfInstitutionalInvestors" name="NumberOfInstitutionalInvestors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" name="NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_NumberOfWarrantsCalledByEachUnit" name="NumberOfWarrantsCalledByEachUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_OfficeAndLaboratoryLeaseAgreementMember" name="OfficeAndLaboratoryLeaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_OperatingLossCarryforwardsSubjectToExpiration" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_OtherFurnitureFixturesAndEquipmentMember" name="OtherFurnitureFixturesAndEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" name="OutstandingWarrantsExcludingPreFundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_PaycheckProtectionProgramCaresActMember" name="PaycheckProtectionProgramCaresActMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_PercentageOfOfferingPrice" name="PercentageOfOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" name="PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_ProceedsFromConvertibleDebtGross" name="ProceedsFromConvertibleDebtGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" name="ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_ProceedsFromIssuanceOrSaleOfEquityGross" name="ProceedsFromIssuanceOrSaleOfEquityGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_RepresentativeWarrantsMember" name="RepresentativeWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ResearchAgreementsMember" name="ResearchAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_SBIRGrantMember" name="SBIRGrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ScheduleOfPreferredStockTableTextBlock" name="ScheduleOfPreferredStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesEConvertiblePreferredStockMember" name="SeriesEConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesFConvertiblePreferredStockMember" name="SeriesFConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" name="SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesGConvertiblePreferredStockMember" name="SeriesGConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesHConvertiblePreferredStockMember" name="SeriesHConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesIConvertiblePreferredStockMember" name="SeriesIConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesIWarrantsMember" name="SeriesIWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesJConvertiblePreferredStockMember" name="SeriesJConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_StockIncentivePlan2020Member" name="StockIncentivePlan2020Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" name="StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodSharesDebentureConversion" name="StockIssuedDuringPeriodSharesDebentureConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" name="StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueDebentureConversion" name="StockIssuedDuringPeriodValueDebentureConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" name="StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueReverseStockSplits" name="StockIssuedDuringPeriodValueReverseStockSplits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueWarrantExercise" name="StockIssuedDuringPeriodValueWarrantExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_StockPurchaseWarrantToPnpMember" name="StockPurchaseWarrantToPnpMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_StockPurchaseWarrantsFirstIssuanceMember" name="StockPurchaseWarrantsFirstIssuanceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_StockPurchaseWarrantsMember" name="StockPurchaseWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_StockPurchaseWarrantsSecondIssuanceMember" name="StockPurchaseWarrantsSecondIssuanceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_UnitConversionAndManagementWarrantsMember" name="UnitConversionAndManagementWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_UnitWarrantMember" name="UnitWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_UnitWarrantsMember" name="UnitWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_UnitsIncludingPrefundedWarrantsMember" name="UnitsIncludingPrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount" name="UnrecordedUnconditionalPurchaseObligationReimbursableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_UnusedGrantFunds" name="UnusedGrantFunds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_UpfrontFee" name="UpfrontFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_WarrantIssuanceExpense" name="WarrantIssuanceExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_WarrantIssuedForTechnologyLicenseMember" name="WarrantIssuedForTechnologyLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_WarrantsIssued" name="WarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_WarrantsIssuedInBridgeFinancingMember" name="WarrantsIssuedInBridgeFinancingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" name="statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-10-income-taxes-tables" name="statement-statement-note-10-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" name="statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-3-property-and-equipment-tables" name="statement-statement-note-3-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" name="statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-4-accrued-expenses-tables" name="statement-statement-note-4-accrued-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" name="statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-5-property-and-equipment-tables" name="statement-statement-note-5-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" name="statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-6-accrued-expenses-tables" name="statement-statement-note-6-accrued-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details" name="statement-statement-note-8-stockholders-equity-preferred-stock-summary-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" name="statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details" name="statement-statement-note-8-stockholders-equity-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details" name="statement-statement-note-8-stockholders-equity-summary-of-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-8-stockholders-equity-tables" name="statement-statement-note-8-stockholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" name="statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" name="statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>govx-20210930_def.xml
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:53PM UTC 2022-02-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:href="govx-20210930.xsd#statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-" xlink:href="govx-20210930.xsd#statement-note-4-accrued-expenses-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF" xlink:href="govx-20210930.xsd#statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-" xlink:href="govx-20210930.xsd#statement-note-6-accrued-expenses-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment" xlink:href="govx-20210930.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-" xlink:href="govx-20210930.xsd#statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-1-description-of-business-" xlink:href="govx-20210930.xsd#statement-note-1-description-of-business-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-1-description-of-business-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-document-and-entity-information" xlink:href="govx-20210930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionAccruedInterestAmount" xlink:label="govx_DebtConversionAccruedInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantsIssued" xlink:label="govx_WarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_WarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionAccruedInterestAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="govx-20210930.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" xlink:label="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation" xlink:href="govx-20210930.xsd#statement-note-2-basis-of-presentation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share" xlink:href="govx-20210930.xsd#statement-note-4-basic-and-diluted-loss-per-common-share" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-7-notes-payable" xlink:href="govx-20210930.xsd#statement-note-7-notes-payable" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-7-notes-payable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-commitments" xlink:href="govx-20210930.xsd#statement-note-8-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-8-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-9-stockholders-equity" xlink:href="govx-20210930.xsd#statement-note-9-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-9-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantToPnpMember" xlink:label="govx_StockPurchaseWarrantToPnpMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:label="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantToPnpMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PreferredStockTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-stockbased-expense" xlink:href="govx-20210930.xsd#statement-note-10-stockbased-expense" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-10-stockbased-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-11-income-taxes" xlink:href="govx-20210930.xsd#statement-note-11-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-11-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue" xlink:href="govx-20210930.xsd#statement-note-12-grants-and-collaboration-revenue" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GovernmentGrantsandContractsTextBlock" xlink:label="govx_GovernmentGrantsandContractsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LeidosIncResearchCollaborativeAgreementMember" xlink:label="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="govx_GovernmentGrantsandContractsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-13-subsequent-event" xlink:href="govx-20210930.xsd#statement-note-13-subsequent-event" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-13-subsequent-event" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CityOfHopeMember" xlink:label="govx_CityOfHopeMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseFirstAnniversaryPaymentMember" xlink:label="govx_LicenseFirstAnniversaryPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseSecondAnniversaryPaymentMember" xlink:label="govx_LicenseSecondAnniversaryPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="govx_CityOfHopeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_LicenseFirstAnniversaryPaymentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_LicenseSecondAnniversaryPaymentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="govx-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment" xlink:href="govx-20210930.xsd#statement-note-3-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-3-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-notes-payable" xlink:href="govx-20210930.xsd#statement-note-5-notes-payable" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-5-notes-payable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-" xlink:href="govx-20210930.xsd#statement-note-6-convertible-debentures-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheOneMember" xlink:label="govx_ConversionUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheTwoMember" xlink:label="govx_ConversionUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantMember" xlink:label="govx_ConversionWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="govx_ConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_ConversionUnitsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ConversionWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_ConversionUnitsTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-7-commitments" xlink:href="govx-20210930.xsd#statement-note-7-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-7-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheTwoMember" xlink:label="govx_CapitalUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:label="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesCConvertiblePreferredStockMember" xlink:label="govx_SeriesCConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesEConvertiblePreferredStockMember" xlink:label="govx_SeriesEConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesFConvertiblePreferredStockMember" xlink:label="govx_SeriesFConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:label="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockMember" xlink:label="govx_SeriesGConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesHConvertiblePreferredStockMember" xlink:label="govx_SeriesHConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIConvertiblePreferredStockMember" xlink:label="govx_SeriesIConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesJConvertiblePreferredStockMember" xlink:label="govx_SeriesJConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitsIncludingPrefundedWarrantsMember" xlink:label="govx_UnitsIncludingPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesCConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesEConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesFConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="govx_SeriesGConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesGConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesHConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesIConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesJConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ConversionWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CapitalUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_CapitalUnitsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_CapitalUnitsTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_UnitsIncludingPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ManagementWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PreferredStockTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-9-retirement-plan" xlink:href="govx-20210930.xsd#statement-note-9-retirement-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-9-retirement-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue" xlink:href="govx-20210930.xsd#statement-note-11-grants-and-collaboration-revenue" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GovernmentGrantsandContractsTextBlock" xlink:label="govx_GovernmentGrantsandContractsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_ResearchAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="govx_GovernmentGrantsandContractsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-12-subsequent-events-" xlink:href="govx-20210930.xsd#statement-note-12-subsequent-events-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-12-subsequent-events-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CommonStockWarrantsMember" xlink:label="govx_CommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SBIRGrantMember" xlink:label="govx_SBIRGrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_SBIRGrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_CommonStockWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-significant-accounting-policies-policies" xlink:href="govx-20210930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_AccruedLiabilitiesPolicyTextBlock" xlink:label="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables" xlink:href="govx-20210930.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables" xlink:href="govx-20210930.xsd#statement-note-6-accrued-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables" xlink:href="govx-20210930.xsd#statement-note-3-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables" xlink:href="govx-20210930.xsd#statement-note-4-accrued-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ScheduleOfPreferredStockTableTextBlock" xlink:label="govx_ScheduleOfPreferredStockTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="govx_ScheduleOfPreferredStockTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-tables" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:href="govx-20210930.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual" xlink:href="govx-20210930.xsd#statement-note-2-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual" xlink:href="govx-20210930.xsd#statement-note-4-basic-and-diluted-loss-per-common-share-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual" xlink:href="govx-20210930.xsd#statement-note-7-notes-payable-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GainLossFromInterestForgiven" xlink:label="govx_GainLossFromInterestForgiven" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_GainLossFromInterestForgiven" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-commitments-details-textual" xlink:href="govx-20210930.xsd#statement-note-8-commitments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-8-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual" xlink:href="govx-20210930.xsd#statement-note-9-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantToPnpMember" xlink:label="govx_StockPurchaseWarrantToPnpMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:label="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantToPnpMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual" xlink:href="govx-20210930.xsd#statement-note-10-stockbased-expense-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" xlink:label="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantIssuanceExpense" xlink:label="govx_WarrantIssuanceExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_WarrantIssuanceExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual" xlink:href="govx-20210930.xsd#statement-note-11-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual" xlink:href="govx-20210930.xsd#statement-note-12-grants-and-collaboration-revenue-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LeidosIncResearchCollaborativeAgreementMember" xlink:label="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnusedGrantFunds" xlink:label="govx_UnusedGrantFunds" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UnusedGrantFunds" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual" xlink:href="govx-20210930.xsd#statement-note-13-subsequent-event-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CityOfHopeMember" xlink:label="govx_CityOfHopeMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseFees" xlink:label="govx_LicenseFees" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseFirstAnniversaryPaymentMember" xlink:label="govx_LicenseFirstAnniversaryPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseSecondAnniversaryPaymentMember" xlink:label="govx_LicenseSecondAnniversaryPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UpfrontFee" xlink:label="govx_UpfrontFee" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="govx_CityOfHopeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_LicenseFirstAnniversaryPaymentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_LicenseSecondAnniversaryPaymentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UpfrontFee" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicenseFees" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="govx-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual" xlink:href="govx-20210930.xsd#statement-note-3-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual" xlink:href="govx-20210930.xsd#statement-note-5-notes-payable-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual" xlink:href="govx-20210930.xsd#statement-note-6-convertible-debentures-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheOneMember" xlink:label="govx_ConversionUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheTwoMember" xlink:label="govx_ConversionUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantMember" xlink:label="govx_ConversionWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionAccruedInterestAmount" xlink:label="govx_DebtConversionAccruedInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionOriginalDebtDiscount" xlink:label="govx_DebtConversionOriginalDebtDiscount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" xlink:label="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering" xlink:label="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfInstitutionalInvestors" xlink:label="govx_NumberOfInstitutionalInvestors" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfWarrantsCalledByEachUnit" xlink:label="govx_NumberOfWarrantsCalledByEachUnit" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PercentageOfOfferingPrice" xlink:label="govx_PercentageOfOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromConvertibleDebtGross" xlink:label="govx_ProceedsFromConvertibleDebtGross" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="govx_ConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_ConversionUnitsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ConversionWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_ConversionUnitsTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfInstitutionalInvestors" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromConvertibleDebtGross" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_PercentageOfOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionAccruedInterestAmount" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfWarrantsCalledByEachUnit" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionOriginalDebtDiscount" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-7-commitments-details-textual" xlink:href="govx-20210930.xsd#statement-note-7-commitments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-7-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount" xlink:label="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheTwoMember" xlink:label="govx_CapitalUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" xlink:label="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:label="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized" xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertiblePreferredStockAndRelatedWarrantsIssued" xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertiblePreferredStockConversionPrice1" xlink:label="govx_ConvertiblePreferredStockConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" xlink:label="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfWarrantsCalledByEachUnit" xlink:label="govx_NumberOfWarrantsCalledByEachUnit" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" xlink:label="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesCConvertiblePreferredStockMember" xlink:label="govx_SeriesCConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesEConvertiblePreferredStockMember" xlink:label="govx_SeriesEConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesFConvertiblePreferredStockMember" xlink:label="govx_SeriesFConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:label="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockMember" xlink:label="govx_SeriesGConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesHConvertiblePreferredStockMember" xlink:label="govx_SeriesHConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIConvertiblePreferredStockMember" xlink:label="govx_SeriesIConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesJConvertiblePreferredStockMember" xlink:label="govx_SeriesJConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitsIncludingPrefundedWarrantsMember" xlink:label="govx_UnitsIncludingPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesCConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesEConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesFConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="govx_SeriesGConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesGConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesHConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesIConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesJConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ConversionWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CapitalUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_CapitalUnitsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_CapitalUnitsTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_UnitsIncludingPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ManagementWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ConvertiblePreferredStockConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfWarrantsCalledByEachUnit" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="42" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="43" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual" xlink:href="govx-20210930.xsd#statement-note-9-retirement-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual" xlink:href="govx-20210930.xsd#statement-note-11-grants-and-collaboration-revenue-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnusedGrantFunds" xlink:label="govx_UnusedGrantFunds" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_ResearchAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UnusedGrantFunds" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual" xlink:href="govx-20210930.xsd#statement-note-12-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CommonStockWarrantsMember" xlink:label="govx_CommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SBIRGrantMember" xlink:label="govx_SBIRGrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_SBIRGrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_CommonStockWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="govx-20210930.xsd#statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_EquipmentAndFurnishingsMember" xlink:label="govx_EquipmentAndFurnishingsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="govx_EquipmentAndFurnishingsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="govx-20210930.xsd#statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="govx-20210930.xsd#statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LaboratoryEquipmentMember" xlink:label="govx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OtherFurnitureFixturesAndEquipmentMember" xlink:label="govx_OtherFurnitureFixturesAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="govx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="govx_OtherFurnitureFixturesAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="govx-20210930.xsd#statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" xlink:label="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitConversionAndManagementWarrantsMember" xlink:label="govx_UnitConversionAndManagementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitConversionAndManagementWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConsultantsMember" xlink:label="govx_ConsultantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_EmployeesAndDirectorsMember" xlink:label="govx_EmployeesAndDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="govx_EmployeesAndDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="govx_ConsultantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-balance-sheets" xlink:href="govx-20210930.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssets" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-operations" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:label="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssets" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-stockholders-equity-deficiency-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-" xlink:type="extended">
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesHConvertiblePreferredStockMember" xlink:label="govx_SeriesHConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIConvertiblePreferredStockMember" xlink:label="govx_SeriesIConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesHConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesIConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited" xlink:type="extended">
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantIssuedForTechnologyLicenseMember" xlink:label="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantsIssuedInBridgeFinancingMember" xlink:label="govx_WarrantsIssuedInBridgeFinancingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_WarrantsIssuedInBridgeFinancingMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:href="govx-20210930.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>govx-20210930_lab.xml
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:53PM UTC 2022-02-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="govx-20210930.xsd#govx_DocumentAndEntityInformation" xlink:label="govx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="govx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DocumentAndEntityInformation" xlink:to="govx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherIncomeAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="govx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="govx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-significant-accounting-policies-policies" xlink:label="govx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-significant-accounting-policies-policies" xlink:to="govx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-5-property-and-equipment-tables" xlink:label="govx_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-5-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-5-property-and-equipment-tables" xlink:to="govx_statement-statement-note-5-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. federal statutory rate applied to pretax loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-6-accrued-expenses-tables" xlink:label="govx_statement-statement-note-6-accrued-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-6-accrued-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Accrued Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-6-accrued-expenses-tables" xlink:to="govx_statement-statement-note-6-accrued-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average risk-free interest rates</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-3-property-and-equipment-tables" xlink:label="govx_statement-statement-note-3-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-3-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-3-property-and-equipment-tables" xlink:to="govx_statement-statement-note-3-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GrantsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant funds and other receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-4-accrued-expenses-tables" xlink:label="govx_statement-statement-note-4-accrued-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-4-accrued-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Accrued Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-4-accrued-expenses-tables" xlink:to="govx_statement-statement-note-4-accrued-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-tables" xlink:label="govx_statement-statement-note-8-stockholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-8-stockholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stockholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-8-stockholders-equity-tables" xlink:to="govx_statement-statement-note-8-stockholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ScheduleOfPreferredStockTableTextBlock" xlink:label="govx_ScheduleOfPreferredStockTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="govx_ScheduleOfPreferredStockTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Preferred Stock [Table Text Block]</link:label>
    <link:label xlink:label="govx_ScheduleOfPreferredStockTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ScheduleOfPreferredStockTableTextBlock" xlink:to="govx_ScheduleOfPreferredStockTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-10-income-taxes-tables" xlink:label="govx_statement-statement-note-10-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-10-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-10-income-taxes-tables" xlink:to="govx_statement-statement-note-10-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:to="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:label="govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:to="govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon debenture conversion (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued during the period as a result of debenture conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:to="govx_StockIssuedDuringPeriodSharesDebentureConversion-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:label="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:to="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:label="govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stockholders' Equity - Preferred Stock Summary (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:to="govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:label="govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:to="govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details" xlink:label="govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stockholders' Equity- Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details" xlink:to="govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:label="govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stockholders' Equity - Summary of Warrants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:to="govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life of option (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:label="govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Income Taxes - Reconciliation of Income Tax Benefit (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:to="govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:to="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon debenture conversion</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross value of stock issued during the period upon Debenture Conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:to="govx_StockIssuedDuringPeriodValueDebentureConversion-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatements" xlink:label="govx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="govx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NotesToFinancialStatements" xlink:to="govx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="govx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="govx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesHConvertiblePreferredStockMember" xlink:label="govx_SeriesHConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesHConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series H Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_SeriesHConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Series H Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesHConvertiblePreferredStockMember" xlink:to="govx_SeriesHConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIConvertiblePreferredStockMember" xlink:label="govx_SeriesIConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesIConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series I Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_SeriesIConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Series I Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesIConvertiblePreferredStockMember" xlink:to="govx_SeriesIConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series H Preferred Stock Into Common Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about conversion of series H preferred stock into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:to="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roundup of shares following reverse stock split</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in value of shares as a result of reverse stock split.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="govx_StockIssuedDuringPeriodValueReverseStockSplits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount" xlink:label="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount" xlink:type="locator"/>
    <link:label xlink:label="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount</link:label>
    <link:label xlink:label="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation Reimbursable, Amount</link:label>
    <link:label xlink:label="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents amount of reimbursable purchase obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount" xlink:to="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited or expired, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses (Note 4)</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Related To Consulting And Investment Banking Agreements [Member]</link:label>
    <link:label xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of expense related to consulting and investment banking agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited or expired, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued salaries</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LaboratoryEquipmentMember" xlink:label="govx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="govx_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LaboratoryEquipmentMember" xlink:to="govx_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OtherFurnitureFixturesAndEquipmentMember" xlink:label="govx_OtherFurnitureFixturesAndEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="govx_OtherFurnitureFixturesAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Furniture Fixtures And Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_OtherFurnitureFixturesAndEquipmentMember" xlink:to="govx_OtherFurnitureFixturesAndEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GovernmentGrantsandContractsTextBlock" xlink:label="govx_GovernmentGrantsandContractsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="govx_GovernmentGrantsandContractsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants and Contracts [Text Block]</link:label>
    <link:label xlink:label="govx_GovernmentGrantsandContractsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_GovernmentGrantsandContractsTextBlock" xlink:to="govx_GovernmentGrantsandContractsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_NIHGrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NIH Grants [Member]</link:label>
    <link:label xlink:label="govx_NIHGrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grants from the National Institutes of Health (NIH).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NIHGrantsMember" xlink:to="govx_NIHGrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositsAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:label="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:type="locator"/>
    <link:label xlink:label="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees</link:label>
    <link:label xlink:label="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued salaries and directors&#8217; fees</link:label>
    <link:label xlink:label="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued salaries and directors' fees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:to="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesEConvertiblePreferredStockMember" xlink:label="govx_SeriesEConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesEConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_SeriesEConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Series E Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesEConvertiblePreferredStockMember" xlink:to="govx_SeriesEConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GainLossFromInterestForgiven" xlink:label="govx_GainLossFromInterestForgiven" xlink:type="locator"/>
    <link:label xlink:label="govx_GainLossFromInterestForgiven-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_GainLossFromInterestForgiven</link:label>
    <link:label xlink:label="govx_GainLossFromInterestForgiven-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) from Interest Forgiven</link:label>
    <link:label xlink:label="govx_GainLossFromInterestForgiven-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents gain (loss) from interest forgiven.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_GainLossFromInterestForgiven" xlink:to="govx_GainLossFromInterestForgiven-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="locator"/>
    <link:label xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of debt</link:label>
    <link:label xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents amount extinguishment of debt including interest amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:to="govx_ExtinguishmentOfDebtIncludingInterestAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net (Note 3)</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:label xlink:label="govx_PaycheckProtectionProgramCaresActMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paycheck Protection Program CARES Act [Member]</link:label>
    <link:label xlink:label="govx_PaycheckProtectionProgramCaresActMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents loan designed to provide funds for small businesses to keep their employees on the payroll.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PaycheckProtectionProgramCaresActMember" xlink:to="govx_PaycheckProtectionProgramCaresActMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_June2020WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June 2020 Warrants [Member]</link:label>
    <link:label xlink:label="govx_June2020WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to June 2020 warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_June2020WarrantsMember" xlink:to="govx_June2020WarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to a conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debentures [Member]</link:label>
    <link:label xlink:label="govx_ConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to convertible debenture.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConvertibleDebenturesMember" xlink:to="govx_ConvertibleDebenturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PercentageOfOfferingPrice" xlink:label="govx_PercentageOfOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="govx_PercentageOfOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_PercentageOfOfferingPrice</link:label>
    <link:label xlink:label="govx_PercentageOfOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Offering Price</link:label>
    <link:label xlink:label="govx_PercentageOfOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of offering price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PercentageOfOfferingPrice" xlink:to="govx_PercentageOfOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to a conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:to="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total adjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionOriginalDebtDiscount" xlink:label="govx_DebtConversionOriginalDebtDiscount" xlink:type="locator"/>
    <link:label xlink:label="govx_DebtConversionOriginalDebtDiscount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_DebtConversionOriginalDebtDiscount</link:label>
    <link:label xlink:label="govx_DebtConversionOriginalDebtDiscount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt Discount</link:label>
    <link:label xlink:label="govx_DebtConversionOriginalDebtDiscount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents original debt discount of debt conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DebtConversionOriginalDebtDiscount" xlink:to="govx_DebtConversionOriginalDebtDiscount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfInstitutionalInvestors" xlink:label="govx_NumberOfInstitutionalInvestors" xlink:type="locator"/>
    <link:label xlink:label="govx_NumberOfInstitutionalInvestors-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_NumberOfInstitutionalInvestors</link:label>
    <link:label xlink:label="govx_NumberOfInstitutionalInvestors-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Institutional Investors</link:label>
    <link:label xlink:label="govx_NumberOfInstitutionalInvestors-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to number of institutional investors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NumberOfInstitutionalInvestors" xlink:to="govx_NumberOfInstitutionalInvestors-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ExtinguishmentOfDebtAmount</link:label>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="locator"/>
    <link:label xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_DeferredTaxAssetsBeforeValuationAllowanceNet</link:label>
    <link:label xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before allocation of valuation allowances and after deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:to="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Reported income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseAndRentalExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LeaseAndRentalExpense</link:label>
    <link:label xlink:label="us-gaap_LeaseAndRentalExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIncentivePlan2020Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2020 [Member]</link:label>
    <link:label xlink:label="govx_StockIncentivePlan2020Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to 2020 stock incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIncentivePlan2020Member" xlink:to="govx_StockIncentivePlan2020Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleConversionPrice1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" xlink:label="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value Expensed During the Period, Issued for Services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" xlink:to="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" xlink:label="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" xlink:type="locator"/>
    <link:label xlink:label="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock</link:label>
    <link:label xlink:label="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock (in shares)</link:label>
    <link:label xlink:label="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of series C and series E preferred stock exchanged for series F convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" xlink:to="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesFConvertiblePreferredStockMember" xlink:label="govx_SeriesFConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesFConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series F Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_SeriesFConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about Series F Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesFConvertiblePreferredStockMember" xlink:to="govx_SeriesFConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series F Preferred Stock Into Common Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about conversion of series F preferred stock into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:to="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Member]</link:label>
    <link:label xlink:label="govx_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The conversion of a reverse stock split where there is a reduction in the shares outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ReverseStockSplitMember" xlink:to="govx_ReverseStockSplitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockMember" xlink:label="govx_SeriesGConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesGConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series G Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_SeriesGConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Series G Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesGConvertiblePreferredStockMember" xlink:to="govx_SeriesGConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesIWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series I Warrants [Member]</link:label>
    <link:label xlink:label="govx_SeriesIWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Series I Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesIWarrantsMember" xlink:to="govx_SeriesIWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" xlink:label="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" xlink:type="locator"/>
    <link:label xlink:label="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum</link:label>
    <link:label xlink:label="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum</link:label>
    <link:label xlink:label="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum amount of proceeds from issuance of convertible preferred stock and related warrants during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" xlink:to="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:label="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series G Convertible Preferred Stock and Related Warrants [Member]</link:label>
    <link:label xlink:label="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about series G convertible preferred stock and related warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:to="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertiblePreferredStockAndRelatedWarrantsIssued" xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued" xlink:type="locator"/>
    <link:label xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ConvertiblePreferredStockAndRelatedWarrantsIssued</link:label>
    <link:label xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock and Related Warrants Issued (in shares)</link:label>
    <link:label xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of convertible preferred stock and related warrants issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued" xlink:to="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized" xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized" xlink:type="locator"/>
    <link:label xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized</link:label>
    <link:label xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock and Related Warrants, Authorized (in shares)</link:label>
    <link:label xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of convertible preferred stock and related warrants authorized for issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized" xlink:to="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roundup of shares following reverse stock split (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromConvertibleDebtGross" xlink:label="govx_ProceedsFromConvertibleDebtGross" xlink:type="locator"/>
    <link:label xlink:label="govx_ProceedsFromConvertibleDebtGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ProceedsFromConvertibleDebtGross</link:label>
    <link:label xlink:label="govx_ProceedsFromConvertibleDebtGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt, Gross</link:label>
    <link:label xlink:label="govx_ProceedsFromConvertibleDebtGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to gross proceeds from convertible debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ProceedsFromConvertibleDebtGross" xlink:to="govx_ProceedsFromConvertibleDebtGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering" xlink:label="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering" xlink:type="locator"/>
    <link:label xlink:label="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering</link:label>
    <link:label xlink:label="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Proceeds from Issuance of Common Stock, Public Offering</link:label>
    <link:label xlink:label="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents gross proceeds from issuance of common stock for public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering" xlink:to="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccounting-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Issued During Period (in shares)</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="govx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on debt extinguishment</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on debt extinguishment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod</link:label>
    <link:label xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Value of Stock Issued for Services During Period</link:label>
    <link:label xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the value of stock issued for services during period recorded as prepaid expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:to="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfExpenseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnusedGrantFunds" xlink:label="govx_UnusedGrantFunds" xlink:type="locator"/>
    <link:label xlink:label="govx_UnusedGrantFunds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_UnusedGrantFunds</link:label>
    <link:label xlink:label="govx_UnusedGrantFunds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused Grant Funds</link:label>
    <link:label xlink:label="govx_UnusedGrantFunds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of grant funds available for use.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UnusedGrantFunds" xlink:to="govx_UnusedGrantFunds-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ResearchAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Agreements [Member]</link:label>
    <link:label xlink:label="govx_ResearchAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Agreements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ResearchAgreementsMember" xlink:to="govx_ResearchAgreementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Grant funds and other receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued in bridge financing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationAndAmortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockRepurchasedDuringPeriodShares</link:label>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of preferred stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesBConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_SeriesBConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Series B Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesBConvertiblePreferredStockMember" xlink:to="govx_SeriesBConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SBIRGrantMember" xlink:label="govx_SBIRGrantMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SBIRGrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SBIR Grant [Member]</link:label>
    <link:label xlink:label="govx_SBIRGrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Small Business Innovative Research (SBIR) grant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SBIRGrantMember" xlink:to="govx_SBIRGrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockRepurchasedDuringPeriodValue</link:label>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of convertible preferred stock for cash and cancellation of note payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of convertible preferred stock for cash and cancellation of note payable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new shares of common stock issued during the period upon exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) (Year)</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock for cash (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficiency)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock for cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Total</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebt</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Preferred Stock into Common Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the conversion of preferred stock into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfPreferredStockIntoCommonStockMember" xlink:to="govx_ConversionOfPreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-funded stock purchase warrants (in shares)</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant issued for technology license fee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion (in shares)</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesJConvertiblePreferredStockMember" xlink:label="govx_SeriesJConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesJConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series J Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_SeriesJConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Series J Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesJConvertiblePreferredStockMember" xlink:to="govx_SeriesJConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_AccruedLiabilitiesPolicyTextBlock" xlink:label="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="govx_AccruedLiabilitiesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Policy Text Block]</link:label>
    <link:label xlink:label="govx_AccruedLiabilitiesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy regarding accrued liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_AccruedLiabilitiesPolicyTextBlock" xlink:to="govx_AccruedLiabilitiesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series I Preferred Stock Into Common Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about conversion of series I preferred stock into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:to="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible debentures</link:label>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CommonStockWarrantsMember" xlink:label="govx_CommonStockWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_CommonStockWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:label xlink:label="govx_CommonStockWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrants to purchase common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CommonStockWarrantsMember" xlink:to="govx_CommonStockWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_EmployeesAndDirectorsMember" xlink:label="govx_EmployeesAndDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_EmployeesAndDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label xlink:label="govx_EmployeesAndDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents employees and directors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_EmployeesAndDirectorsMember" xlink:to="govx_EmployeesAndDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesCConvertiblePreferredStockMember" xlink:label="govx_SeriesCConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesCConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_SeriesCConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents series C convertible stock as per the securities purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesCConvertiblePreferredStockMember" xlink:to="govx_SeriesCConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConsultantsMember" xlink:label="govx_ConsultantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConsultantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultants [Member]</link:label>
    <link:label xlink:label="govx_ConsultantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents consultants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConsultantsMember" xlink:to="govx_ConsultantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock converted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_EquipmentAndFurnishingsMember" xlink:label="govx_EquipmentAndFurnishingsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_EquipmentAndFurnishingsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings [Member]</link:label>
    <link:label xlink:label="govx_EquipmentAndFurnishingsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents equipment and furnishings.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_EquipmentAndFurnishingsMember" xlink:to="govx_EquipmentAndFurnishingsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator"/>
    <link:label xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_OperatingLossCarryforwardsSubjectToExpiration</link:label>
    <link:label xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="govx_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantIssuanceExpense" xlink:label="govx_WarrantIssuanceExpense" xlink:type="locator"/>
    <link:label xlink:label="govx_WarrantIssuanceExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_WarrantIssuanceExpense</link:label>
    <link:label xlink:label="govx_WarrantIssuanceExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Issuance Expense</link:label>
    <link:label xlink:label="govx_WarrantIssuanceExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs associated with the issuance of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_WarrantIssuanceExpense" xlink:to="govx_WarrantIssuanceExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CityOfHopeMember" xlink:label="govx_CityOfHopeMember" xlink:type="locator"/>
    <link:label xlink:label="govx_CityOfHopeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City of Hope [Member]</link:label>
    <link:label xlink:label="govx_CityOfHopeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents City of Hope.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CityOfHopeMember" xlink:to="govx_CityOfHopeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $.001 par value: Authorized shares &#8211; 600,000,000 Issued and outstanding shares &#8211; 3,834,095 and 14,992 at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeniorNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UpfrontFee" xlink:label="govx_UpfrontFee" xlink:type="locator"/>
    <link:label xlink:label="govx_UpfrontFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_UpfrontFee</link:label>
    <link:label xlink:label="govx_UpfrontFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Fee</link:label>
    <link:label xlink:label="govx_UpfrontFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of fee paid at the beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UpfrontFee" xlink:to="govx_UpfrontFee-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseFees" xlink:label="govx_LicenseFees" xlink:type="locator"/>
    <link:label xlink:label="govx_LicenseFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_LicenseFees</link:label>
    <link:label xlink:label="govx_LicenseFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fees</link:label>
    <link:label xlink:label="govx_LicenseFees-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of expense associated with license.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LicenseFees" xlink:to="govx_LicenseFees-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantIssuedForTechnologyLicenseMember" xlink:label="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="locator"/>
    <link:label xlink:label="govx_WarrantIssuedForTechnologyLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Issued for Technology License[Member]</link:label>
    <link:label xlink:label="govx_WarrantIssuedForTechnologyLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrant issued for technology license.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_WarrantIssuedForTechnologyLicenseMember" xlink:to="govx_WarrantIssuedForTechnologyLicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantToPnpMember" xlink:label="govx_StockPurchaseWarrantToPnpMember" xlink:type="locator"/>
    <link:label xlink:label="govx_StockPurchaseWarrantToPnpMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Warrant to PNP [Member]</link:label>
    <link:label xlink:label="govx_StockPurchaseWarrantToPnpMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock purchase warrant to PNP.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockPurchaseWarrantToPnpMember" xlink:to="govx_StockPurchaseWarrantToPnpMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:label xlink:label="srt_WeightedAverageMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantsIssuedInBridgeFinancingMember" xlink:label="govx_WarrantsIssuedInBridgeFinancingMember" xlink:type="locator"/>
    <link:label xlink:label="govx_WarrantsIssuedInBridgeFinancingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Bridge Financing [Member]</link:label>
    <link:label xlink:label="govx_WarrantsIssuedInBridgeFinancingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrants issued in bridge financing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_WarrantsIssuedInBridgeFinancingMember" xlink:to="govx_WarrantsIssuedInBridgeFinancingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseFirstAnniversaryPaymentMember" xlink:label="govx_LicenseFirstAnniversaryPaymentMember" xlink:type="locator"/>
    <link:label xlink:label="govx_LicenseFirstAnniversaryPaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License First Anniversary Payment [Member]</link:label>
    <link:label xlink:label="govx_LicenseFirstAnniversaryPaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents first anniversary payment for license.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LicenseFirstAnniversaryPaymentMember" xlink:to="govx_LicenseFirstAnniversaryPaymentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:label xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Warrants First Issuance [Member]</link:label>
    <link:label xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to stock purchase warrants, first issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseSecondAnniversaryPaymentMember" xlink:label="govx_LicenseSecondAnniversaryPaymentMember" xlink:type="locator"/>
    <link:label xlink:label="govx_LicenseSecondAnniversaryPaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Second Anniversary Payment [Member]</link:label>
    <link:label xlink:label="govx_LicenseSecondAnniversaryPaymentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents second anniversary payment for license.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LicenseSecondAnniversaryPaymentMember" xlink:to="govx_LicenseSecondAnniversaryPaymentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:label="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:type="locator"/>
    <link:label xlink:label="govx_StockPurchaseWarrantsSecondIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Warrants Second Issuance [Member]</link:label>
    <link:label xlink:label="govx_StockPurchaseWarrantsSecondIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to stock purchase warrants second issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:to="govx_StockPurchaseWarrantsSecondIssuanceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $.01 par value (Note 8): Authorized shares &#8211; 10,000,000 Issued and outstanding shares &#8211; 100 and 2,486 at December 31, 2020 and 2019, respectively</link:label>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office and Laboratory Lease Agreement [Member]</link:label>
    <link:label xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to office and laboratory lease agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset after reduction for valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxesPaid</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxesPaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_StockPurchaseWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Warrants [Member]</link:label>
    <link:label xlink:label="govx_StockPurchaseWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to stock purchase warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockPurchaseWarrantsMember" xlink:to="govx_StockPurchaseWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant and collaboration revenue</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LeidosIncResearchCollaborativeAgreementMember" xlink:label="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="govx_LeidosIncResearchCollaborativeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leidos, Inc. Research Collaborative Agreement [Member]</link:label>
    <link:label xlink:label="govx_LeidosIncResearchCollaborativeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Leidos research collaborative agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:to="govx_LeidosIncResearchCollaborativeAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity (deficiency):</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development tax credit carryforward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series C Preferred Stock Into Common Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the conversion of series C preferred stock into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertiblePreferredStockConversionPrice1" xlink:label="govx_ConvertiblePreferredStockConversionPrice1" xlink:type="locator"/>
    <link:label xlink:label="govx_ConvertiblePreferredStockConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ConvertiblePreferredStockConversionPrice1</link:label>
    <link:label xlink:label="govx_ConvertiblePreferredStockConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price1 (in dollars per share)</link:label>
    <link:label xlink:label="govx_ConvertiblePreferredStockConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion price related to convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConvertiblePreferredStockConversionPrice1" xlink:to="govx_ConvertiblePreferredStockConversionPrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OverAllotmentOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments (Note 7)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" xlink:label="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion from Notes Payable to Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents conversion of notes payable to convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" xlink:to="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:label="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion from Series F Preferred Stock to Series H Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the conversion from Series F Preferred Stock to Series H Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:to="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon warrant exercise</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross value of stock issued during the period upon the exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:to="govx_StockIssuedDuringPeriodValueWarrantExercise-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock</link:label>
    <link:label xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from warrant exercises</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfCommonStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Units [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsMember" xlink:to="us-gaap_CapitalUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfDebtIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentUnamortizedDiscount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" xlink:label="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" xlink:type="locator"/>
    <link:label xlink:label="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage</link:label>
    <link:label xlink:label="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Maximum Allowed Ownership of Common Stock Outstanding, Percentage</link:label>
    <link:label xlink:label="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum ownership percentage of common stock outstanding allowed for the conversion feature embedded in the debt instrument to become effective.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" xlink:to="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Warrants [Member]</link:label>
    <link:label xlink:label="govx_ConversionWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionWarrantsMember" xlink:to="govx_ConversionWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheTwoMember" xlink:label="govx_ConversionUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionUnitsTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Units Tranche Two [Member]</link:label>
    <link:label xlink:label="govx_ConversionUnitsTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the tranche two conversion units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionUnitsTrancheTwoMember" xlink:to="govx_ConversionUnitsTrancheTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionAccruedInterestAmount" xlink:label="govx_DebtConversionAccruedInterestAmount" xlink:type="locator"/>
    <link:label xlink:label="govx_DebtConversionAccruedInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related accrued interest</link:label>
    <link:label xlink:label="govx_DebtConversionAccruedInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Accrued Interest Amount</link:label>
    <link:label xlink:label="govx_DebtConversionAccruedInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of the debt accrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DebtConversionAccruedInterestAmount" xlink:to="govx_DebtConversionAccruedInterestAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion from Convertible Debentures to Conversion Units [Member]</link:label>
    <link:label xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of convertible debentures to conversion units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from bridge financing</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheOneMember" xlink:label="govx_ConversionUnitsTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionUnitsTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Units Tranche One [Member]</link:label>
    <link:label xlink:label="govx_ConversionUnitsTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the tranche one conversion units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionUnitsTrancheOneMember" xlink:to="govx_ConversionUnitsTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitConversionAndManagementWarrantsMember" xlink:label="govx_UnitConversionAndManagementWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_UnitConversionAndManagementWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unit, Conversion and Management Warrants [Member]</link:label>
    <link:label xlink:label="govx_UnitConversionAndManagementWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the unit, conversion and management warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UnitConversionAndManagementWarrantsMember" xlink:to="govx_UnitConversionAndManagementWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesBalance</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at Beginning Of Period</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at End Of Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_PreFundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label xlink:label="govx_PreFundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the pre-funded warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PreFundedWarrantsMember" xlink:to="govx_PreFundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_UnitWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unit Warrants [Member]</link:label>
    <link:label xlink:label="govx_UnitWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the unit warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UnitWarrantsMember" xlink:to="govx_UnitWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions Charged to Costs and Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions Charged to Other Accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesDeductions</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:type="locator"/>
    <link:label xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ProceedsFromIssuanceOrSaleOfEquityGross</link:label>
    <link:label xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Gross</link:label>
    <link:label xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:to="govx_ProceedsFromIssuanceOrSaleOfEquityGross-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="govx_CapitalUnitsTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Units Tranche One [Member]</link:label>
    <link:label xlink:label="govx_CapitalUnitsTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the tranche one capital units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CapitalUnitsTrancheOneMember" xlink:to="govx_CapitalUnitsTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:type="locator"/>
    <link:label xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_NumberOfCommonStockSecuritiesCalledByEachUnit</link:label>
    <link:label xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Common Stock Securities Called by Each Unit (in shares)</link:label>
    <link:label xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of common stock securities into which each unit may be converted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:to="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfWarrantsCalledByEachUnit" xlink:label="govx_NumberOfWarrantsCalledByEachUnit" xlink:type="locator"/>
    <link:label xlink:label="govx_NumberOfWarrantsCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_NumberOfWarrantsCalledByEachUnit</link:label>
    <link:label xlink:label="govx_NumberOfWarrantsCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants Called by Each Unit (in shares)</link:label>
    <link:label xlink:label="govx_NumberOfWarrantsCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants into which each unit may be converted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NumberOfWarrantsCalledByEachUnit" xlink:to="govx_NumberOfWarrantsCalledByEachUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_RepresentativeWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Representative Warrants [Member]</link:label>
    <link:label xlink:label="govx_RepresentativeWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the representative warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_RepresentativeWarrantsMember" xlink:to="govx_RepresentativeWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" xlink:label="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Warrants Excluding Pre-Funded Warrants [Member]</link:label>
    <link:label xlink:label="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to outstanding warrants excluding pre-funded warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" xlink:to="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series J Preferred Stock into Common Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about conversion of series J preferred stock into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:to="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about conversion of series H, Series I, and Series J preferred stock into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitsIncludingPrefundedWarrantsMember" xlink:label="govx_UnitsIncludingPrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_UnitsIncludingPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Units Including Pre-Funded Warrants [Member]</link:label>
    <link:label xlink:label="govx_UnitsIncludingPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the capital units that include pre-funded warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UnitsIncludingPrefundedWarrantsMember" xlink:to="govx_UnitsIncludingPrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="govx_UnitWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unit Warrant [Member]</link:label>
    <link:label xlink:label="govx_UnitWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the unit warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UnitWarrantMember" xlink:to="govx_UnitWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheTwoMember" xlink:label="govx_CapitalUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:label xlink:label="govx_CapitalUnitsTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Units Tranche Two [Member]</link:label>
    <link:label xlink:label="govx_CapitalUnitsTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the tranche two capital units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CapitalUnitsTrancheTwoMember" xlink:to="govx_CapitalUnitsTrancheTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:type="locator"/>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_DeferredCompensationLiabilityConversionToEquityConversionPrice</link:label>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share)</link:label>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The price per share for the conversion of deferred compensation liability to equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" xlink:label="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" xlink:type="locator"/>
    <link:label xlink:label="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Period for Warrants or Rights Exercisable (Day)</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of time for warrants to be exercisable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" xlink:to="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="locator"/>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred compensation</link:label>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability Conversion to Equity, Amount</link:label>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of deferred compensation liability being converted into equity in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfNotesPayable</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfNotesPayable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal repayment of note payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of note payable</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ManagementWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management Warrant [Member]</link:label>
    <link:label xlink:label="govx_ManagementWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the management warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ManagementWarrantMember" xlink:to="govx_ManagementWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of common stock and warrants</link:label>
    <link:label xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from issuance of common stock and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantsIssued" xlink:label="govx_WarrantsIssued" xlink:type="locator"/>
    <link:label xlink:label="govx_WarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant issued (in shares)</link:label>
    <link:label xlink:label="govx_WarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants issued in noncash financing activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_WarrantsIssued" xlink:to="govx_WarrantsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants exercised for common stock</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="govx_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantMember" xlink:label="govx_ConversionWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Warrant [Member]</link:label>
    <link:label xlink:label="govx_ConversionWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionWarrantMember" xlink:to="govx_ConversionWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:type="locator"/>
    <link:label xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount</link:label>
    <link:label xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Principal and Interest, Amount</link:label>
    <link:label xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of the financial instrument(s) that the original debt and interest is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:to="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance, net of expired items and other adjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for cancellation of accrued compensation (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new stock issued during the period for the cancellation of accrued compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</link:label>
    <link:label xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon cancellation of accrued compensation</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued in lieu of cancellation of accrued compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:to="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficiency)</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note payable, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="govx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>govx-20210930_pre.xml
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:53PM UTC 2022-02-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:href="govx-20210930.xsd#statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-" xlink:href="govx-20210930.xsd#statement-note-4-accrued-expenses-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF" xlink:href="govx-20210930.xsd#statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-" xlink:href="govx-20210930.xsd#statement-note-6-accrued-expenses-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment" xlink:href="govx-20210930.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-" xlink:href="govx-20210930.xsd#statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-1-description-of-business-" xlink:href="govx-20210930.xsd#statement-note-1-description-of-business-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-1-description-of-business-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-document-and-entity-information" xlink:href="govx-20210930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionAccruedInterestAmount" xlink:label="govx_DebtConversionAccruedInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantsIssued" xlink:label="govx_WarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_WarrantsIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionAccruedInterestAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="govx-20210930.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" xlink:label="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromNotesPayableToConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation" xlink:href="govx-20210930.xsd#statement-note-2-basis-of-presentation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share" xlink:href="govx-20210930.xsd#statement-note-4-basic-and-diluted-loss-per-common-share" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-7-notes-payable" xlink:href="govx-20210930.xsd#statement-note-7-notes-payable" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-7-notes-payable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-commitments" xlink:href="govx-20210930.xsd#statement-note-8-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-8-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-9-stockholders-equity" xlink:href="govx-20210930.xsd#statement-note-9-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-9-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantToPnpMember" xlink:label="govx_StockPurchaseWarrantToPnpMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:label="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantToPnpMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PreferredStockTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-stockbased-expense" xlink:href="govx-20210930.xsd#statement-note-10-stockbased-expense" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-10-stockbased-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-11-income-taxes" xlink:href="govx-20210930.xsd#statement-note-11-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-11-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue" xlink:href="govx-20210930.xsd#statement-note-12-grants-and-collaboration-revenue" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GovernmentGrantsandContractsTextBlock" xlink:label="govx_GovernmentGrantsandContractsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LeidosIncResearchCollaborativeAgreementMember" xlink:label="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="govx_GovernmentGrantsandContractsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-13-subsequent-event" xlink:href="govx-20210930.xsd#statement-note-13-subsequent-event" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-13-subsequent-event" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CityOfHopeMember" xlink:label="govx_CityOfHopeMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseFirstAnniversaryPaymentMember" xlink:label="govx_LicenseFirstAnniversaryPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseSecondAnniversaryPaymentMember" xlink:label="govx_LicenseSecondAnniversaryPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="govx_CityOfHopeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_LicenseFirstAnniversaryPaymentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_LicenseSecondAnniversaryPaymentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="govx-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment" xlink:href="govx-20210930.xsd#statement-note-3-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-3-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-notes-payable" xlink:href="govx-20210930.xsd#statement-note-5-notes-payable" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-5-notes-payable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-" xlink:href="govx-20210930.xsd#statement-note-6-convertible-debentures-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheOneMember" xlink:label="govx_ConversionUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheTwoMember" xlink:label="govx_ConversionUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantMember" xlink:label="govx_ConversionWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="govx_ConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_ConversionUnitsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ConversionWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_ConversionUnitsTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-7-commitments" xlink:href="govx-20210930.xsd#statement-note-7-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-7-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheTwoMember" xlink:label="govx_CapitalUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:label="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesCConvertiblePreferredStockMember" xlink:label="govx_SeriesCConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesEConvertiblePreferredStockMember" xlink:label="govx_SeriesEConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesFConvertiblePreferredStockMember" xlink:label="govx_SeriesFConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:label="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockMember" xlink:label="govx_SeriesGConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesHConvertiblePreferredStockMember" xlink:label="govx_SeriesHConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIConvertiblePreferredStockMember" xlink:label="govx_SeriesIConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesJConvertiblePreferredStockMember" xlink:label="govx_SeriesJConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitsIncludingPrefundedWarrantsMember" xlink:label="govx_UnitsIncludingPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesCConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesEConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesFConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="govx_SeriesGConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesGConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesHConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesIConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesJConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ConversionWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CapitalUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_CapitalUnitsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_CapitalUnitsTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_UnitsIncludingPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ManagementWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PreferredStockTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-9-retirement-plan" xlink:href="govx-20210930.xsd#statement-note-9-retirement-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-9-retirement-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue" xlink:href="govx-20210930.xsd#statement-note-11-grants-and-collaboration-revenue" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GovernmentGrantsandContractsTextBlock" xlink:label="govx_GovernmentGrantsandContractsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_ResearchAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="govx_GovernmentGrantsandContractsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-12-subsequent-events-" xlink:href="govx-20210930.xsd#statement-note-12-subsequent-events-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-12-subsequent-events-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CommonStockWarrantsMember" xlink:label="govx_CommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SBIRGrantMember" xlink:label="govx_SBIRGrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_SBIRGrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_CommonStockWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-significant-accounting-policies-policies" xlink:href="govx-20210930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_AccruedLiabilitiesPolicyTextBlock" xlink:label="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-significant-accounting-policies-policies" xlink:label="govx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables" xlink:href="govx-20210930.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-5-property-and-equipment-tables" xlink:label="govx_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-5-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables" xlink:href="govx-20210930.xsd#statement-note-6-accrued-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-6-accrued-expenses-tables" xlink:label="govx_statement-statement-note-6-accrued-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-6-accrued-expenses-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables" xlink:href="govx-20210930.xsd#statement-note-3-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-3-property-and-equipment-tables" xlink:label="govx_statement-statement-note-3-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-3-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables" xlink:href="govx-20210930.xsd#statement-note-4-accrued-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-4-accrued-expenses-tables" xlink:label="govx_statement-statement-note-4-accrued-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-4-accrued-expenses-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ScheduleOfPreferredStockTableTextBlock" xlink:label="govx_ScheduleOfPreferredStockTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-tables" xlink:label="govx_statement-statement-note-8-stockholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-8-stockholders-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="govx_ScheduleOfPreferredStockTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-tables" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-10-income-taxes-tables" xlink:label="govx_statement-statement-note-10-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-10-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:href="govx-20210930.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual" xlink:href="govx-20210930.xsd#statement-note-2-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual" xlink:href="govx-20210930.xsd#statement-note-4-basic-and-diluted-loss-per-common-share-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual" xlink:href="govx-20210930.xsd#statement-note-7-notes-payable-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GainLossFromInterestForgiven" xlink:label="govx_GainLossFromInterestForgiven-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_GainLossFromInterestForgiven-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-commitments-details-textual" xlink:href="govx-20210930.xsd#statement-note-8-commitments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-8-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual" xlink:href="govx-20210930.xsd#statement-note-9-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantToPnpMember" xlink:label="govx_StockPurchaseWarrantToPnpMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:label="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsSecondIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantToPnpMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual" xlink:href="govx-20210930.xsd#statement-note-10-stockbased-expense-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices" xlink:label="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantIssuanceExpense" xlink:label="govx_WarrantIssuanceExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_WarrantIssuanceExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual" xlink:href="govx-20210930.xsd#statement-note-11-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxesPaid-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual" xlink:href="govx-20210930.xsd#statement-note-12-grants-and-collaboration-revenue-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LeidosIncResearchCollaborativeAgreementMember" xlink:label="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnusedGrantFunds" xlink:label="govx_UnusedGrantFunds-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_LeidosIncResearchCollaborativeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UnusedGrantFunds-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual" xlink:href="govx-20210930.xsd#statement-note-13-subsequent-event-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CityOfHopeMember" xlink:label="govx_CityOfHopeMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseFees" xlink:label="govx_LicenseFees-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseFirstAnniversaryPaymentMember" xlink:label="govx_LicenseFirstAnniversaryPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LicenseSecondAnniversaryPaymentMember" xlink:label="govx_LicenseSecondAnniversaryPaymentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UpfrontFee" xlink:label="govx_UpfrontFee-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="govx_CityOfHopeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_LicenseFirstAnniversaryPaymentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_LicenseSecondAnniversaryPaymentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UpfrontFee-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicenseFees-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="govx-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual" xlink:href="govx-20210930.xsd#statement-note-3-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual" xlink:href="govx-20210930.xsd#statement-note-5-notes-payable-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual" xlink:href="govx-20210930.xsd#statement-note-6-convertible-debentures-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheOneMember" xlink:label="govx_ConversionUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionUnitsTrancheTwoMember" xlink:label="govx_ConversionUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantMember" xlink:label="govx_ConversionWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionAccruedInterestAmount" xlink:label="govx_DebtConversionAccruedInterestAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionOriginalDebtDiscount" xlink:label="govx_DebtConversionOriginalDebtDiscount-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage" xlink:label="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering" xlink:label="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfInstitutionalInvestors" xlink:label="govx_NumberOfInstitutionalInvestors-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfWarrantsCalledByEachUnit" xlink:label="govx_NumberOfWarrantsCalledByEachUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PercentageOfOfferingPrice" xlink:label="govx_PercentageOfOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromConvertibleDebtGross" xlink:label="govx_ProceedsFromConvertibleDebtGross-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="govx_ConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_ConversionUnitsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ConversionWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_ConversionUnitsTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfInstitutionalInvestors-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromConvertibleDebtGross-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_PercentageOfOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionAccruedInterestAmount-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfWarrantsCalledByEachUnit-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionOriginalDebtDiscount-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-7-commitments-details-textual" xlink:href="govx-20210930.xsd#statement-note-7-commitments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-7-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount" xlink:label="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CapitalUnitsTrancheTwoMember" xlink:label="govx_CapitalUnitsTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable" xlink:label="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:label="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:label="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized" xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertiblePreferredStockAndRelatedWarrantsIssued" xlink:label="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConvertiblePreferredStockConversionPrice1" xlink:label="govx_ConvertiblePreferredStockConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock" xlink:label="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NumberOfWarrantsCalledByEachUnit" xlink:label="govx_NumberOfWarrantsCalledByEachUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum" xlink:label="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesCConvertiblePreferredStockMember" xlink:label="govx_SeriesCConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesEConvertiblePreferredStockMember" xlink:label="govx_SeriesEConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesFConvertiblePreferredStockMember" xlink:label="govx_SeriesFConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:label="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesGConvertiblePreferredStockMember" xlink:label="govx_SeriesGConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesHConvertiblePreferredStockMember" xlink:label="govx_SeriesHConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIConvertiblePreferredStockMember" xlink:label="govx_SeriesIConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesJConvertiblePreferredStockMember" xlink:label="govx_SeriesJConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitsIncludingPrefundedWarrantsMember" xlink:label="govx_UnitsIncludingPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesCConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesEConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesFConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="govx_SeriesGConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesGConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesHConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesIConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesJConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ConversionWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CapitalUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_CapitalUnitsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_CapitalUnitsTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_UnitsIncludingPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ManagementWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ConvertiblePreferredStockConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ConvertiblePreferredStockAndRelatedWarrantsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromIssuanceOrSaleOfEquityGross-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfWarrantsCalledByEachUnit-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual" xlink:href="govx-20210930.xsd#statement-note-9-retirement-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_OperatingLossCarryforwardsSubjectToExpiration-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxesPaid-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual" xlink:href="govx-20210930.xsd#statement-note-11-grants-and-collaboration-revenue-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnusedGrantFunds" xlink:label="govx_UnusedGrantFunds-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_ResearchAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UnusedGrantFunds-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual" xlink:href="govx-20210930.xsd#statement-note-12-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_CommonStockWarrantsMember" xlink:label="govx_CommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SBIRGrantMember" xlink:label="govx_SBIRGrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_SBIRGrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_CommonStockWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="govx-20210930.xsd#statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_EquipmentAndFurnishingsMember" xlink:label="govx_EquipmentAndFurnishingsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="govx_EquipmentAndFurnishingsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="govx-20210930.xsd#statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:label="govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="govx-20210930.xsd#statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_LaboratoryEquipmentMember" xlink:label="govx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OtherFurnitureFixturesAndEquipmentMember" xlink:label="govx_OtherFurnitureFixturesAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="govx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="govx_OtherFurnitureFixturesAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="govx-20210930.xsd#statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:label="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:label="govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details" xlink:label="govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" xlink:label="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_RepresentativeWarrantsMember" xlink:label="govx_RepresentativeWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIWarrantsMember" xlink:label="govx_SeriesIWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_UnitConversionAndManagementWarrantsMember" xlink:label="govx_UnitConversionAndManagementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:label="govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_SeriesIWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitConversionAndManagementWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_OutstandingWarrantsExcludingPreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:label="govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ConsultantsMember" xlink:label="govx_ConsultantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_EmployeesAndDirectorsMember" xlink:label="govx_EmployeesAndDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="govx_EmployeesAndDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="govx_ConsultantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-balance-sheets" xlink:href="govx-20210930.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssets" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-operations" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:label="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-3" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssets" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-stockholders-equity-deficiency-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-" xlink:type="extended">
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:href="govx-20210930.xsd#statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesHConvertiblePreferredStockMember" xlink:label="govx_SeriesHConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_SeriesIConvertiblePreferredStockMember" xlink:label="govx_SeriesIConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:label="govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesHConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesIConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited" xlink:type="extended">
    <link:loc xlink:href="govx-20210930.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantIssuedForTechnologyLicenseMember" xlink:label="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_WarrantsIssuedInBridgeFinancingMember" xlink:label="govx_WarrantsIssuedInBridgeFinancingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_WarrantsIssuedInBridgeFinancingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:href="govx-20210930.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions-n9" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>govx-20210930_cal.xml
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:53PM UTC 2022-02-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="govx-20210930.xsd#statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="govx-20210930.xsd#statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="govx-20210930.xsd#statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="govx-20210930.xsd#statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-balance-sheets" xlink:href="govx-20210930.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="govx-20210930.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-consolidated-statements-of-operations" xlink:href="govx-20210930.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="govx-20210930.xsd#statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:label="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:type="locator"/>
    <link:loc xlink:href="govx-20210930.xsd#govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="govx-20210930.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428133121608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000832489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GeoVax Labs, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0455038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1900 Lake Park Drive, Suite 380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Smyrna<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-7220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428130547672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 18,107,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,883,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant funds and other receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">52,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,159,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,235,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net (Note 3)</a></td>
<td class="nump">168,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Deposits</a></td>
<td class="nump">11,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">18,339,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,393,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">289,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (Note 4)</a></td>
<td class="nump">46,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,851,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">335,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,016,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">335,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,043,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficiency):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value (Note 8): Authorized shares &#8211; 10,000,000 Issued and outstanding shares &#8211; 100 and 2,486 at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,932,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value: Authorized shares &#8211; 600,000,000 Issued and outstanding shares &#8211; 3,834,095 and 14,992 at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">6,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">68,630,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,340,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(50,632,895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,847,513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficiency)</a></td>
<td class="nump">18,003,850<span></span>
</td>
<td class="nump">$ 19,458,338<span></span>
</td>
<td class="nump">$ 20,651,340<span></span>
</td>
<td class="nump">9,568,852<span></span>
</td>
<td class="nump">$ 10,813,744<span></span>
</td>
<td class="num">$ (1,849,621)<span></span>
</td>
<td class="num">$ (1,864,250)<span></span>
</td>
<td class="num">(1,574,556)<span></span>
</td>
<td class="num">$ (1,022,347)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficiency)</a></td>
<td class="nump">$ 18,339,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,393,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428220404616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">6,381,541<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">6,381,541<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428129234952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Grant and collaboration revenue</a></td>
<td class="nump">$ 30,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,539<span></span>
</td>
<td class="nump">$ 1,572,037<span></span>
</td>
<td class="nump">$ 1,823,658<span></span>
</td>
<td class="nump">$ 1,175,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,224,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,659,980<span></span>
</td>
<td class="nump">1,687,113<span></span>
</td>
<td class="nump">2,444,459<span></span>
</td>
<td class="nump">1,910,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">757,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,562,641<span></span>
</td>
<td class="nump">1,364,650<span></span>
</td>
<td class="nump">2,196,014<span></span>
</td>
<td class="nump">1,637,674<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,981,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,222,621<span></span>
</td>
<td class="nump">3,051,763<span></span>
</td>
<td class="nump">4,640,473<span></span>
</td>
<td class="nump">3,548,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,951,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(436,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,002,082)<span></span>
</td>
<td class="num">(1,479,726)<span></span>
</td>
<td class="num">(2,816,815)<span></span>
</td>
<td class="num">(2,372,493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,998<span></span>
</td>
<td class="nump">902<span></span>
</td>
<td class="nump">2,271<span></span>
</td>
<td class="nump">6,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
<td class="num">(142,722)<span></span>
</td>
<td class="num">(143,524)<span></span>
</td>
<td class="num">(4,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,056<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,768<span></span>
</td>
<td class="num">(141,820)<span></span>
</td>
<td class="num">(141,253)<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,950,503)<span></span>
</td>
<td class="num">$ (1,314,033)<span></span>
</td>
<td class="num">$ (1,562,778)<span></span>
</td>
<td class="num">$ (570,648)<span></span>
</td>
<td class="num">$ (455,204)<span></span>
</td>
<td class="num">$ (595,694)<span></span>
</td>
<td class="num">$ (4,827,314)<span></span>
</td>
<td class="num">$ (1,621,546)<span></span>
</td>
<td class="num">$ (2,958,068)<span></span>
</td>
<td class="num">$ (2,370,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (2.85)<span></span>
</td>
<td class="num">$ (2.14)<span></span>
</td>
<td class="num">$ (781.87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">6,349,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,005,032<span></span>
</td>
<td class="nump">569,955<span></span>
</td>
<td class="nump">1,383,829<span></span>
</td>
<td class="nump">3,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428118329688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Warrants Issued in Bridge Financing [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Warrants Issued in Bridge Financing [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Warrants Issued in Bridge Financing [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Warrants Issued in Bridge Financing [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Warrants Issued in Bridge Financing [Member]</div></th>
<th class="th">
<div>Warrant Issued for Technology License[Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Warrant Issued for Technology License[Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Warrant Issued for Technology License[Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Warrant Issued for Technology License[Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Warrant Issued for Technology License[Member]</div></th>
<th class="th">
<div>Conversion from Convertible Debentures to Conversion Units [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Conversion from Convertible Debentures to Conversion Units [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Conversion from Convertible Debentures to Conversion Units [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Conversion from Convertible Debentures to Conversion Units [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Conversion from Convertible Debentures to Conversion Units [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,971,333<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 37,483,204<span></span>
</td>
<td class="num">$ (40,476,884)<span></span>
</td>
<td class="num">$ (1,022,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,420<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,370,629)<span></span>
</td>
<td class="num">(2,370,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,542,950<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">147,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,690,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,664)<span></span>
</td>
<td class="nump">14,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,581,850)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">1,581,835<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,932,433<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">39,340,509<span></span>
</td>
<td class="num">(42,847,513)<span></span>
</td>
<td class="num">(1,574,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(595,694)<span></span>
</td>
<td class="num">(595,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,386)<span></span>
</td>
<td class="nump">674,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,856,338)<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">1,855,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">689,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,095<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">41,202,172<span></span>
</td>
<td class="num">(43,443,207)<span></span>
</td>
<td class="num">(1,864,250)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,932,433<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">39,340,509<span></span>
</td>
<td class="num">(42,847,513)<span></span>
</td>
<td class="num">(1,574,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,621,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,559,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,559<span></span>
</td>
<td class="nump">55,203,149<span></span>
</td>
<td class="num">(44,469,059)<span></span>
</td>
<td class="nump">10,813,744<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,932,433<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">39,340,509<span></span>
</td>
<td class="num">(42,847,513)<span></span>
</td>
<td class="num">(1,574,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="nump">11,156,186<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 11,158,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">286,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock upon warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">94,373<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 94,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,958,068)<span></span>
</td>
<td class="num">(2,958,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in bridge financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">457,833<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">457,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,686)<span></span>
</td>
<td class="nump">716,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,156,338)<span></span>
</td>
<td class="nump">$ 717<span></span>
</td>
<td class="nump">2,155,621<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation', window );">Common stock issued for cancellation of accrued compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation', window );">Issuance of common stock upon cancellation of accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">1,499,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,834<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
<td class="nump">9,568,852<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">689,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,095<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">41,202,172<span></span>
</td>
<td class="num">(43,443,207)<span></span>
</td>
<td class="num">(1,864,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">11,998<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(455,204)<span></span>
</td>
<td class="num">(455,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in bridge financing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 457,833<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 457,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">691,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,095<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">41,672,003<span></span>
</td>
<td class="num">(43,898,411)<span></span>
</td>
<td class="num">(1,849,621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="nump">11,156,186<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,158,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(570,648)<span></span>
</td>
<td class="num">(570,648)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">177,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="nump">42,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 569,340<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 569,517<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">299,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation', window );">Common stock issued for cancellation of accrued compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation', window );">Issuance of common stock upon cancellation of accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">1,499,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,559,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,559<span></span>
</td>
<td class="nump">55,203,149<span></span>
</td>
<td class="num">(44,469,059)<span></span>
</td>
<td class="nump">10,813,744<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,834<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
<td class="nump">9,568,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,644<span></span>
</td>
<td class="nump">9,407,276<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,408,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">835,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock upon warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">3,173,320<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,174,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,562,778)<span></span>
</td>
<td class="num">(1,562,778)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">6,315,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 6,315<span></span>
</td>
<td class="nump">67,937,289<span></span>
</td>
<td class="num">(47,368,359)<span></span>
</td>
<td class="nump">20,651,340<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,834<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
<td class="nump">$ 9,568,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,827,314)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,381,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,382<span></span>
</td>
<td class="nump">68,630,363<span></span>
</td>
<td class="num">(50,632,895)<span></span>
</td>
<td class="nump">18,003,850<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">6,315,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 6,315<span></span>
</td>
<td class="nump">67,937,289<span></span>
</td>
<td class="num">(47,368,359)<span></span>
</td>
<td class="nump">20,651,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">65,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,314,033)<span></span>
</td>
<td class="num">(1,314,033)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76,095)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">75,095<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,327,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,328<span></span>
</td>
<td class="nump">68,134,402<span></span>
</td>
<td class="num">(48,682,392)<span></span>
</td>
<td class="nump">19,458,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock upon warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">229,946<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,950,503)<span></span>
</td>
<td class="num">(1,950,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in bridge financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 209,825<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 209,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,381,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,382<span></span>
</td>
<td class="nump">$ 68,630,363<span></span>
</td>
<td class="num">$ (50,632,895)<span></span>
</td>
<td class="nump">$ 18,003,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period for the cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428118299688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,827,314)<span></span>
</td>
<td class="num">$ (1,621,546)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">26,806<span></span>
</td>
<td class="nump">2,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Warrant issued for technology license fee</a></td>
<td class="nump">209,825<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="num">(172,056)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Grant funds and other receivables</a></td>
<td class="nump">182,663<span></span>
</td>
<td class="num">(72,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">106,979<span></span>
</td>
<td class="nump">82,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">124,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(289,477)<span></span>
</td>
<td class="nump">252,036<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">314,043<span></span>
</td>
<td class="nump">412,927<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,513,271)<span></span>
</td>
<td class="num">(1,208,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(47,718)<span></span>
</td>
<td class="num">(2,470)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(47,718)<span></span>
</td>
<td class="num">(2,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from sale of common stock and warrants</a></td>
<td class="nump">9,408,920<span></span>
</td>
<td class="nump">11,158,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from sale of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from warrant exercises</a></td>
<td class="nump">3,404,156<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from bridge financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">888,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Net proceeds from issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">170,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock', window );">Repurchase of preferred stock</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal repayment of note payable</a></td>
<td class="num">(27,864)<span></span>
</td>
<td class="num">(8,854)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,784,212<span></span>
</td>
<td class="nump">12,508,342<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">8,223,223<span></span>
</td>
<td class="nump">11,297,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">9,883,796<span></span>
</td>
<td class="nump">283,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">18,107,019<span></span>
</td>
<td class="nump">11,580,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=govx_EmployeesAndDirectorsMember', window );">Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">168,570<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=govx_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 80,733<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=govx_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=govx_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=govx_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=govx_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428128760360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2020</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation', window );">Common stock issued for cancellation of accrued compensation (in shares)</a></td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredCompensationLiabilityConversionToEquityAmount', window );">Deferred compensation</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember', window );">Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion (in shares)</a></td>
<td class="nump">303,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Convertible debentures</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DebtConversionAccruedInterestAmount', window );">Related accrued interest</a></td>
<td class="nump">$ 14,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsFirstIssuanceMember', window );">Stock Purchase Warrants First Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,839<span></span>
</td>
<td class="nump">145,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Pre-funded stock purchase warrants (in shares)</a></td>
<td class="nump">126,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DebtConversionAccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the debt accrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DebtConversionAccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredCompensationLiabilityConversionToEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred compensation liability being converted into equity in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredCompensationLiabilityConversionToEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period for the cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsFirstIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsFirstIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428130586920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 18,107,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,883,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant funds and other receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">52,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,159,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,235,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net (Note 3)</a></td>
<td class="nump">168,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Deposits</a></td>
<td class="nump">11,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">18,339,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,393,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">289,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (Note 4)</a></td>
<td class="nump">46,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,851,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">335,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,016,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">335,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,043,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficiency):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value (Note 8): Authorized shares &#8211; 10,000,000 Issued and outstanding shares &#8211; 100 and 2,486 at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,932,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value: Authorized shares &#8211; 600,000,000 Issued and outstanding shares &#8211; 3,834,095 and 14,992 at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">6,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">68,630,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,340,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(50,632,895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,847,513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficiency)</a></td>
<td class="nump">18,003,850<span></span>
</td>
<td class="nump">$ 19,458,338<span></span>
</td>
<td class="nump">$ 20,651,340<span></span>
</td>
<td class="nump">9,568,852<span></span>
</td>
<td class="nump">$ 10,813,744<span></span>
</td>
<td class="num">$ (1,849,621)<span></span>
</td>
<td class="num">$ (1,864,250)<span></span>
</td>
<td class="num">(1,574,556)<span></span>
</td>
<td class="num">$ (1,022,347)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficiency)</a></td>
<td class="nump">$ 18,339,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,393,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428130550296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">6,381,541<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">6,381,541<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428128412744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Grant and collaboration revenue</a></td>
<td class="nump">$ 30,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,539<span></span>
</td>
<td class="nump">$ 1,572,037<span></span>
</td>
<td class="nump">$ 1,823,658<span></span>
</td>
<td class="nump">$ 1,175,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,224,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,659,980<span></span>
</td>
<td class="nump">1,687,113<span></span>
</td>
<td class="nump">2,444,459<span></span>
</td>
<td class="nump">1,910,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">757,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,562,641<span></span>
</td>
<td class="nump">1,364,650<span></span>
</td>
<td class="nump">2,196,014<span></span>
</td>
<td class="nump">1,637,674<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,981,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,222,621<span></span>
</td>
<td class="nump">3,051,763<span></span>
</td>
<td class="nump">4,640,473<span></span>
</td>
<td class="nump">3,548,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,951,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(436,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,002,082)<span></span>
</td>
<td class="num">(1,479,726)<span></span>
</td>
<td class="num">(2,816,815)<span></span>
</td>
<td class="num">(2,372,493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,998<span></span>
</td>
<td class="nump">902<span></span>
</td>
<td class="nump">2,271<span></span>
</td>
<td class="nump">6,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
<td class="num">(142,722)<span></span>
</td>
<td class="num">(143,524)<span></span>
</td>
<td class="num">(4,495)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,768<span></span>
</td>
<td class="num">(141,820)<span></span>
</td>
<td class="num">(141,253)<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,950,503)<span></span>
</td>
<td class="num">$ (1,314,033)<span></span>
</td>
<td class="num">$ (1,562,778)<span></span>
</td>
<td class="num">$ (570,648)<span></span>
</td>
<td class="num">$ (455,204)<span></span>
</td>
<td class="num">$ (595,694)<span></span>
</td>
<td class="num">$ (4,827,314)<span></span>
</td>
<td class="num">$ (1,621,546)<span></span>
</td>
<td class="num">$ (2,958,068)<span></span>
</td>
<td class="num">$ (2,370,629)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (2.85)<span></span>
</td>
<td class="num">$ (2.14)<span></span>
</td>
<td class="num">$ (781.87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">6,349,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,005,032<span></span>
</td>
<td class="nump">569,955<span></span>
</td>
<td class="nump">1,383,829<span></span>
</td>
<td class="nump">3,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428117285848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficiency) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,971,333<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 37,483,204<span></span>
</td>
<td class="num">$ (40,476,884)<span></span>
</td>
<td class="num">$ (1,022,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable (in shares)</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable</a></td>
<td class="nump">$ 1,542,950<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">147,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,690,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(2,664)<span></span>
</td>
<td class="nump">14,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (1,581,850)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">1,581,835<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,420<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,370,629)<span></span>
</td>
<td class="num">(2,370,629)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,932,433<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">39,340,509<span></span>
</td>
<td class="num">(42,847,513)<span></span>
</td>
<td class="num">(1,574,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable (in shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(2,386)<span></span>
</td>
<td class="nump">674,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (1,856,338)<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">1,855,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(595,694)<span></span>
</td>
<td class="num">(595,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">689,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 376,095<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">41,202,172<span></span>
</td>
<td class="num">(43,443,207)<span></span>
</td>
<td class="num">(1,864,250)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,932,433<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">39,340,509<span></span>
</td>
<td class="num">(42,847,513)<span></span>
</td>
<td class="num">(1,574,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,621,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,559,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,559<span></span>
</td>
<td class="nump">55,203,149<span></span>
</td>
<td class="num">(44,469,059)<span></span>
</td>
<td class="nump">10,813,744<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,932,433<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">39,340,509<span></span>
</td>
<td class="num">(42,847,513)<span></span>
</td>
<td class="num">(1,574,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable (in shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of convertible preferred stock for cash and cancellation of note payable</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(2,686)<span></span>
</td>
<td class="nump">716,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (2,156,338)<span></span>
</td>
<td class="nump">$ 717<span></span>
</td>
<td class="nump">2,155,621<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">94,373<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 94,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,958,068)<span></span>
</td>
<td class="num">(2,958,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in bridge financing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">457,833<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 457,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">286,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock upon warrant exercise</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesDebentureConversion', window );">Issuance of common stock upon debenture conversion (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">177,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueDebentureConversion', window );">Issuance of common stock upon debenture conversion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">569,340<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">569,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation', window );">Common stock issued for cancellation of accrued compensation (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation', window );">Issuance of common stock upon cancellation of accrued compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">1,499,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="nump">11,156,186<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,158,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Roundup of shares following reverse stock split (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueReverseStockSplits', window );">Roundup of shares following reverse stock split</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,834<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
<td class="nump">9,568,852<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">689,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 376,095<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">41,202,172<span></span>
</td>
<td class="num">(43,443,207)<span></span>
</td>
<td class="num">(1,864,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">11,998<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(455,204)<span></span>
</td>
<td class="num">(455,204)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">691,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 376,095<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">41,672,003<span></span>
</td>
<td class="num">(43,898,411)<span></span>
</td>
<td class="num">(1,849,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(300)<span></span>
</td>
<td class="nump">42,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">299,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(570,648)<span></span>
</td>
<td class="num">(570,648)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation', window );">Common stock issued for cancellation of accrued compensation (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation', window );">Issuance of common stock upon cancellation of accrued compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">1,499,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="nump">11,156,186<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,158,496<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,559,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,559<span></span>
</td>
<td class="nump">55,203,149<span></span>
</td>
<td class="num">(44,469,059)<span></span>
</td>
<td class="nump">10,813,744<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,834<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
<td class="nump">9,568,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,562,778)<span></span>
</td>
<td class="num">(1,562,778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">835,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock upon warrant exercise</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">3,173,320<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,174,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,644<span></span>
</td>
<td class="nump">9,407,276<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,408,920<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">6,315,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 6,315<span></span>
</td>
<td class="nump">67,937,289<span></span>
</td>
<td class="num">(47,368,359)<span></span>
</td>
<td class="nump">20,651,340<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,834<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
<td class="nump">$ 9,568,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,827,314)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,381,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,382<span></span>
</td>
<td class="nump">68,630,363<span></span>
</td>
<td class="num">(50,632,895)<span></span>
</td>
<td class="nump">18,003,850<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">6,315,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 6,315<span></span>
</td>
<td class="nump">67,937,289<span></span>
</td>
<td class="num">(47,368,359)<span></span>
</td>
<td class="nump">20,651,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">65,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,314,033)<span></span>
</td>
<td class="num">(1,314,033)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,327,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,328<span></span>
</td>
<td class="nump">68,134,402<span></span>
</td>
<td class="num">(48,682,392)<span></span>
</td>
<td class="nump">19,458,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,950,503)<span></span>
</td>
<td class="num">(1,950,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock upon warrant exercise</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">229,946<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,381,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,382<span></span>
</td>
<td class="nump">$ 68,630,363<span></span>
</td>
<td class="num">$ (50,632,895)<span></span>
</td>
<td class="nump">$ 18,003,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period for the cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesDebentureConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of debenture conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesDebentureConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueDebentureConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon Debenture Conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueDebentureConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in value of shares as a result of reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428130476168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,827,314)<span></span>
</td>
<td class="num">$ (1,621,546)<span></span>
</td>
<td class="num">$ (2,958,068)<span></span>
</td>
<td class="num">$ (2,370,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">26,806<span></span>
</td>
<td class="nump">2,983<span></span>
</td>
<td class="nump">19,656<span></span>
</td>
<td class="nump">8,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">124,185<span></span>
</td>
<td class="nump">124,185<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,463<span></span>
</td>
<td class="nump">327,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Grant funds and other receivables</a></td>
<td class="nump">182,663<span></span>
</td>
<td class="num">(72,551)<span></span>
</td>
<td class="num">(114,060)<span></span>
</td>
<td class="nump">53,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">106,979<span></span>
</td>
<td class="nump">82,274<span></span>
</td>
<td class="num">(24,702)<span></span>
</td>
<td class="num">(56,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(289,477)<span></span>
</td>
<td class="nump">252,036<span></span>
</td>
<td class="nump">137,956<span></span>
</td>
<td class="nump">639,282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">314,043<span></span>
</td>
<td class="nump">412,927<span></span>
</td>
<td class="nump">207,498<span></span>
</td>
<td class="nump">972,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,513,271)<span></span>
</td>
<td class="num">(1,208,619)<span></span>
</td>
<td class="num">(2,750,570)<span></span>
</td>
<td class="num">(1,398,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(47,718)<span></span>
</td>
<td class="num">(2,470)<span></span>
</td>
<td class="num">(156,791)<span></span>
</td>
<td class="num">(7,606)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(47,718)<span></span>
</td>
<td class="num">(2,470)<span></span>
</td>
<td class="num">(156,791)<span></span>
</td>
<td class="num">(7,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from sale of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,440,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Net proceeds from issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">170,200<span></span>
</td>
<td class="nump">170,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from bridge financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">888,500<span></span>
</td>
<td class="nump">888,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from sale of common stock and warrants</a></td>
<td class="nump">9,408,920<span></span>
</td>
<td class="nump">11,158,496<span></span>
</td>
<td class="nump">11,158,496<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from warrant exercises</a></td>
<td class="nump">3,404,156<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal repayment of note payable</a></td>
<td class="num">(27,864)<span></span>
</td>
<td class="num">(8,854)<span></span>
</td>
<td class="num">(11,880)<span></span>
</td>
<td class="num">(10,257)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,784,212<span></span>
</td>
<td class="nump">12,508,342<span></span>
</td>
<td class="nump">12,507,816<span></span>
</td>
<td class="nump">1,429,743<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">8,223,223<span></span>
</td>
<td class="nump">11,297,253<span></span>
</td>
<td class="nump">9,600,455<span></span>
</td>
<td class="nump">23,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">9,883,796<span></span>
</td>
<td class="nump">283,341<span></span>
</td>
<td class="nump">283,341<span></span>
</td>
<td class="nump">259,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 18,107,019<span></span>
</td>
<td class="nump">$ 11,580,594<span></span>
</td>
<td class="nump">$ 9,883,796<span></span>
</td>
<td class="nump">$ 283,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132960728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="nump">36,902<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428213344872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Description of Business </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (&#8220;GeoVax&#8221; or the &#8220;Company&#8221;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax&#8217;s Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) based platform utilizes MVA, a large virus capable of carrying several vaccine antigens, to express proteins that assemble into highly effective virus-like particle (VLP) immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax&#8217;s MVA-VLP development programs are focused primarily on preventive vaccines against the SARS-CoV-<em style="font: inherit;">2</em> virus (COVID-<em style="font: inherit;">19</em>) and immunotherapies for solid tumor cancers. Other development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), Human Immunodeficiency Virus (HIV), and malaria. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 28, 2021, </em>GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc., whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#174;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase <em style="font: inherit;">1/2</em> clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and <em style="font: inherit;">no</em> curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#8217;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but <em style="font: inherit;">not</em> limited to, cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">1.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Description of Business</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (&#8220;GeoVax&#8221; or the &#8220;Company&#8221;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or &#8220;GV-MVA-VLP<sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup>&#8221;). In this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into highly effective VLP immunogens in the person being vaccinated. The MVA-VLP virus replicates to high titers in approved avian cells for manufacturing but cannot productively replicate in mammalian cells. Therefore, the MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live attenuated virus, while providing the safety characteristics of a replication-defective vector.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current development programs are focused on preventive vaccines against novel coronavirus (COVID-<em style="font: inherit;">19</em>), Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as immunotherapies for HIV and solid tumor cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our corporate strategy is to advance, protect and exploit our differentiated vaccine immunotherapy platform leading to the successful development of preventive and therapeutic vaccines against infectious diseases and various cancers. With our design and development capabilities, we are progressing and validating an array of cancer and infectious disease immunotherapy and vaccine product candidates. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage <em style="font: inherit;">third</em> party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <em style="font: inherit;"> may </em>take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with <em style="font: inherit;">one</em> or more potential strategic partners.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132910120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Accounting [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Basis of Presentation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying condensed consolidated financial statements at <em style="font: inherit;"> September 30, 2021 </em>and for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020</em> are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2020. </em>We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results in future periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We enacted reverse stock splits of our common stock on <em style="font: inherit;"> September 25, 2020 (</em><em style="font: inherit;">1</em>-for-20) and on <em style="font: inherit;"> January 21, 2020 (</em><em style="font: inherit;">1</em>-for-2,000). The accompanying financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for at least the <em style="font: inherit;">twelve</em>-month period following the issue date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We <em style="font: inherit;"> may </em>never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we <em style="font: inherit;"> may </em>seek additional capital through arrangements with strategic partners or from other sources. There can be <em style="font: inherit;">no</em> assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132988088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Significant Accounting Policies and Recent Accounting Pronouncements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We disclosed in Note <em style="font: inherit;">2</em> to our consolidated financial statements included in our Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2020 </em>those accounting policies that we consider significant in determining our results of operations and financial position. During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>there have been <em style="font: inherit;">no</em> material changes to, or in the application of, the accounting policies previously identified and described in the Form <em style="font: inherit;">10</em>-K, and there have been <em style="font: inherit;">no</em> other recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Summary of Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note <em style="font: inherit;">8.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the <em style="font: inherit;">twelve</em>-month period following the issue date of these consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from government grants and clinical trial assistance, corporate and academic collaborations, and from sales of our equity securities. We believe that our existing cash resources together with current government funding commitments, will be sufficient to continue our planned operations into <em style="font: inherit;">2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We <em style="font: inherit;"> may </em>never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we <em style="font: inherit;"> may </em>seek additional capital through arrangements with strategic partners or from other sources. There can be <em style="font: inherit;">no</em> assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consider all highly liquid investments with a maturity of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fair Value of Financial Instruments and Concentration of Credit Risk</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:c80220527">three</span> to <span style="-sec-ix-hidden:c80220528">five</span> years. We amortize leasehold improvements using the straight-line method over the term of the related lease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases</i> (ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em>), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or <em style="font: inherit;">not</em> the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than <em style="font: inherit;">12</em> months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than <em style="font: inherit;">12</em> months, we made an accounting policy election to <em style="font: inherit;">not</em> recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Impairment of Long-Lived Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be<b> </b>recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Accrued Expenses</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have <em style="font: inherit;">not</em> yet been billed by our <em style="font: inherit;">third</em>-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Net Loss Per Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 1,001,948 and 558 shares at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize revenue in accordance with FASB Accounting Standards Update <em style="font: inherit;">2014</em>-<em style="font: inherit;">09,</em> <i>Revenue from Contracts with Customers</i> (ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em>), which created a new Topic, Accounting Standards Codification Topic <em style="font: inherit;">606.</em> The standard is principle-based and provides a <em style="font: inherit;">five</em>-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grant revenue</i> &#8211; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research collaborations</i> &#8211; From time to time, we <em style="font: inherit;"> may </em>enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive <em style="font: inherit;">third</em>-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em> and revenue is recognized accordingly.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expense</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to <em style="font: inherit;">third</em>-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Patent Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.<b> </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Period-to-Period Comparisons</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results for future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#8217;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note <em style="font: inherit;">8</em> for additional stock-based compensation information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Except as discussed above, there have been <em style="font: inherit;">no</em> recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standards if currently adopted would have a material effect on our financial statements.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132990648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Basic and Diluted Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Basic and Diluted Loss Per Common Share</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share totaled 2,965,451 and 2,550,184 shares for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>respectively, as compared to 204,553 and 78,754 shares for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2020, </em>respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132905928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;"> December 31, 2020:</em></p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and furnishings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">591,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">543,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">707,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">659,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(538,506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(511,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">168,653</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">532,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">534,577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other furniture, fixtures &amp; equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">659,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">661,918</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(511,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(651,312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation expense was $19,656&#160;and $8,350 during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132780024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Accrued Expenses</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;"> December 31, 2020:</em></p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">11,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">279,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">35,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">79,585</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">46,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">359,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Accrued Expenses</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries and directors&#8217; fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">279,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,732,702</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">118,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">359,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,851,040</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132986648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GRA Note</i> &#8211; On <em style="font: inherit;"> February 28, 2018, </em>we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a <span style="-sec-ix-hidden:c80220395">five</span>-year Senior Promissory Note (the &#8220;GRA Note&#8221;) to GRA in exchange for $50,000. The GRA Note bore an annual interest rate of <span style="-sec-ix-hidden:c80220397">five</span> percent. Interest expense related to the GRA Note for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021 </em>was $-0- and $633, respectively, as compared to $411 and $1,344, respectively, for the same periods of <em style="font: inherit;">2020.</em> During <em style="font: inherit;"> May 2021, </em>we repaid the remaining principal balance of $22,737 and retired the GRA Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>CARES Act Paycheck Protection Program Loan </i>&#8211;<i> </i>On <em style="font: inherit;"> April 17, 2020, </em>we received a $170,200 bank loan backed by the United States Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bore an annual interest rate of <em style="font: inherit;">one</em> percent. We recorded accrued interest expense related to the PPP Loan of $-0- and $653 for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>respectively, as compared to $429 and $774, respectively, for the same periods of <em style="font: inherit;">2020.</em> During <em style="font: inherit;"> May 2021, </em>upon receiving payment from the SBA, the lender forgave the full principal balance of $170,200 together with $1,856 of accrued interest and extinguished the PPP Loan.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GRA Note</i> &#8211; On <em style="font: inherit;"> February 28, 2018, </em>we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a <span style="-sec-ix-hidden:c80220569">five</span>-year Senior Promissory Note (the &#8220;GRA Note&#8221;) to GRA in exchange for $50,000. The GRA Note bears an annual interest rate of 5%, payable monthly, with principal repayments beginning in the <em style="font: inherit;">second</em> year. Future principal repayments are expected to be $12,487 in <em style="font: inherit;">2021,</em> $13,126 <em style="font: inherit;">in2022,</em> and $2,252 in <em style="font: inherit;">2023.</em> Interest expense related to the GRA Note was $1,727 and $2,097 for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>CARES Act Paycheck Protection Program Loan </i>&#8211;<i> </i>On <em style="font: inherit;"> April 17, 2020, </em>we received a $170,200 bank loan backed by the United States Small Business Administration pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bears an annual interest rate of <em style="font: inherit;">one</em> percent and is due <em style="font: inherit;"> April 17, 2022. </em>We have accrued interest expense associated with the PPP Loan of $1,203. In <em style="font: inherit;"> October 2020, </em>we applied to the lender to have the loan forgiven, based upon our submission of qualifying information regarding eligible expenses; as of the date of this report our forgiveness application has <em style="font: inherit;">not</em> been processed.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132903912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on <em style="font: inherit;"> December 31, 2022. </em>Rent expense for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021 </em>was $42,803 and $128,410, respectively, as compared to $41,539 and $124,617, respectively, for the same periods of <em style="font: inherit;">2020.</em> Future minimum lease payments total $42,803 for the remainder of <em style="font: inherit;">2021</em> and $176,356 in <em style="font: inherit;">2022,</em> although the lease <em style="font: inherit;"> may </em>be terminated at any time by either party with <em style="font: inherit;">ninety</em> days&#8217; written notice.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of <em style="font: inherit;"> September 30, 2021, </em>there are approximately $607,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in <em style="font: inherit;">2021.</em></p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on <em style="font: inherit;"> December 31, 2022. </em>Rent expense for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $166,577 and $161,673, respectively. Future minimum lease payments total $171,213 in <em style="font: inherit;">2021</em> and $176,356 in <em style="font: inherit;">2022,</em> although the lease <em style="font: inherit;"> may </em>be terminated at any time by either party with <em style="font: inherit;">ninety</em> days written notice.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of <em style="font: inherit;"> December 31, 2020, </em>we had approximately $190,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in <em style="font: inherit;">2021.</em> We expect $165,500 of this amount to be reimbursable to us pursuant to currently outstanding government grants.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132920472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Stockholders</b>&#8217;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Preferred Stock </i>&#8211;<i> </i>On <em style="font: inherit;"> June 7, 2021, </em>we repurchased the remaining 100 shares of our Series B Convertible Preferred Stock for a total price of $1,000. As of <em style="font: inherit;"> September 30, 2021, </em>there are no shares of our preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Public Offering </i>&#8211;<i> </i>On <em style="font: inherit;"> February 11, 2021, </em>we closed an underwritten public offering of 1,644,000 shares of our common stock, including 204,000 shares sold pursuant to the full exercise of the underwriter&#8217;s option to purchase additional shares, at a price to the public of $6.25 per share. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $9.4 million. Additionally, we issued to the underwriter, as a portion of the underwriting compensation, warrants to purchase 72,000 shares of our common stock at an exercise price of $6.875 per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Options </i>&#8211;<i> </i>We have a stock-based incentive plan (the <em style="font: inherit;">&#8220;2020</em> Plan&#8221;) pursuant to which our Board of Directors <em style="font: inherit;"> may </em>grant stock options and other stock-based awards to our employees, directors and consultants. A total of 1,500,000 shares of our common stock are reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan. During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>there were <span style="-sec-ix-hidden:c80220447">no</span> stock option transactions related to the <em style="font: inherit;">2020</em> Plan. As of <em style="font: inherit;"> September 30, 2021, </em>there were 602,000 stock options outstanding, with a weighted-average exercise price of $2.79 per share and a weighted-average remaining term of 9.2 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Purchase Warrants </i>&#8211;<i> </i>During <em style="font: inherit;"> January </em>and <em style="font: inherit;"> February 2021, </em>188,688 stock purchase warrants were exercised on a cashless basis, resulting in the issuance of 145,866 shares of our common stock, and 690,034 stock purchase warrants were exercised for cash, resulting in the issuance of 690,034 shares of our common stock for net proceeds to us of $3,174,156.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During <em style="font: inherit;"> August 2021, </em>27,004 stock purchase warrants were exercised on a cashless basis, resulting in the issuance of 3,839 shares of our common stock, and 50,000 stock purchase warrants were exercised for cash, resulting in the issuance of 50,000 shares of our common stock for net proceeds to us of $230,000.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 28, 2021, </em>in connection with our entering into an Assignment and License Agreement with PNP Therapeutics, Inc. (PNP) we issued a <span style="-sec-ix-hidden:c80220462">five</span>-year stock purchase warrant to PNP for 100,000 shares of our common stock at an exercise price of $13.00 per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> September 30, 2021, </em>there are 2,816,631 stock purchase warrants outstanding, with a weighted-average exercise price of $5.35 per share and a weighted-average remaining term of 3.9 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Common Stock Transactions</i> &#8211; During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>we issued 13,707 shares of our common stock pursuant to consulting agreements.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Stockholders</b>&#8217;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Convertible Preferred Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are authorized to issue up to 10,000,000 shares of our Preferred Stock, <span style="-sec-ix-hidden:c80220646">$.01</span> par value, which <em style="font: inherit;"> may </em>be issued in <em style="font: inherit;">one</em> or more series. The table below presents our issued and outstanding series of preferred stock as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019.</em> Each series of our outstanding preferred stock has a stated value of $1,000 per share. Further details concerning each series of preferred stock, and the changes in each series during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> are discussed in the sections that follow the table.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Carrying</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Carrying</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series B Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">76,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">76,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series H Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,686</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,156,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series I Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">700,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,486</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,932,433</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series B Convertible Preferred Stock </i>&#8211;<i> </i>Our Series B Convertible Preferred Stock, $1,000 stated value (&#8220;Series B Preferred Stock&#8221;), has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series B Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. As of <em style="font: inherit;"> December 31, 2020, </em>there were 100 shares of Series B Preferred Stock outstanding, convertible at any time at the option of the holder into shares of common stock at a fixed conversion price of $7,000,000 per common share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series C Convertible Preferred Stock </i>&#8211;<i> </i>Our Series C Convertible Preferred Stock, $1,000 stated value (&#8220;Series C Preferred Stock&#8221;), has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series C Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> 587 shares of our Series C Preferred Stock were converted into 2 shares of our common stock and the remaining 1,563 shares of Series C Preferred Stock were exchanged for Series F Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series C Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series E Convertible Preferred Stock </i>&#8211; Our Series E Convertible Preferred Stock, $1,000 stated value, (&#8220;Series E Preferred Stock&#8221;) has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series E Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> all outstanding shares of Series E Preferred Stock (1,200 shares) were exchanged for Series F Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series E Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series F Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> February 2019, </em>we entered into Exchange Agreements with holders of our Series C and Series E Preferred Stock, pursuant to which the holders exchanged all shares of Series C and Series E Preferred Stock held by them for an aggregate of 2,763 shares of Series F Convertible Preferred Stock (&#8220;Series F Preferred Stock&#8221;). Our Series F Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series F Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> 507 shares of Series F Preferred Stock were converted into 9 shares of our common stock and all remaining outstanding shares of Series F Preferred Stock (2,256 shares) were exchanged for Series H Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series F Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series G Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> February 2019, </em>we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#8220;Purchasers&#8221;) providing for sale to the Purchasers of an aggregate of up to 1,000 shares of our Series G Convertible Preferred Stock (&#8220;Series G Preferred Stock&#8221;) and related warrants for gross proceeds of up to $1.0 million, which was funded at <em style="font: inherit;">three</em> different closings. Our Series G Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series G Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. At the <em style="font: inherit;">first</em> closing, which occurred in <em style="font: inherit;"> February 2019, </em>we issued 500 shares of Series G Preferred Stock in exchange for the payment by the Purchasers of $250,000 in the aggregate, plus the cancellation of Term Notes held by the Purchasers in the amount of <em style="font: inherit;">$250,000.</em> At the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> closings, which occurred in <em style="font: inherit;"> April </em>and <em style="font: inherit;"> June 2019, </em>we issued an aggregate of 500 additional shares of Series G Preferred Stock in exchange for the payment by the Purchasers of a total of $500,000. During <em style="font: inherit;"> July 2019, </em>all outstanding shares of Series G Preferred Stock (1,000 shares) were exchanged for Series H Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series G Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series H Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> July 2019, </em>we entered into Exchange Agreements with holders of our Series F and Series G Preferred Stock, pursuant to which the holders exchanged all shares of Series F and Series G Preferred Stock held by them for an aggregate of 3,256 shares of Series H Convertible Preferred Stock (&#8220;Series H Preferred Stock&#8221;). Our Series H Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series H Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> 1,570 shares of Series H Preferred Stock were converted into 14,808 shares of our common stock. During <em style="font: inherit;">2020,</em> 1,686 shares of our Series H Convertible Preferred Stock were converted into 469,697 shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series H Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series I Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> July 2019, </em>we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#8220;Purchasers&#8221;) providing for sale to the Purchasers of an aggregate of 700 shares of our Series I Convertible Preferred Stock (&#8220;Series I Preferred Stock&#8221;) for gross proceeds of $700,000. Our Series I Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series I Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2020,</em> 700 shares of our Series I Convertible Preferred Stock were converted into 204,371 shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series I Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series J Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> January 2020, </em>we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#8220;Purchasers&#8221;) providing for sale to the Purchasers of an aggregate of 300 shares of our Series J Convertible Preferred Stock (&#8220;Series J Preferred Stock&#8221;) for gross proceeds of $300,000. Our Series J Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series J Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2020,</em> 300 shares of Series J Preferred Stock were converted into 42,723 shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series J Preferred Stock outstanding</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Common Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Reverse Stock Splits </i>&#8211; On <em style="font: inherit;"> April 30, 2019, </em>we effected a <em style="font: inherit;">1</em>-for-500 reverse stock split of our common stock, on <em style="font: inherit;"> January 21, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-2000 reverse split of our common stock and on <em style="font: inherit;"> September 25, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-20 reverse split of our common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Conversions of Preferred Stock</i> &#8211; During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> we issued an aggregate of 716,790 and 14,819 shares of our common stock, respectively, pursuant to the conversion of several series of our convertible preferred stock as discussed above.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Public Offering </i>&#8211;<i> </i>On <em style="font: inherit;"> September 24, 2020, </em>we entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Maxim Group LLC, as representative of the underwriters (the &#8220;Representative&#8221;), for an underwritten public offering (the &#8220;Offering&#8221;) of an aggregate of 2,560,000 units of our equity securities (the &#8220;Units&#8221;). The Offering closed on <em style="font: inherit;"> September 29, 2020, </em>with gross proceeds to us of approximately $12.8 million; net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $11.2 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Of the 2,560,000 Units sold in the Offering: (a) 2,310,000 Units consist of <span style="-sec-ix-hidden:c80220735">one</span> share of our common stock, and a Warrant to purchase <span style="-sec-ix-hidden:c80220736">one</span> share of common stock (each, a &#8220;Unit Warrant&#8221;); and (b) 250,000 Units consisting of a Pre-Funded Warrant to purchase <span style="-sec-ix-hidden:c80220738">one</span> share of common stock and a Unit Warrant. The Pre-Funded Warrants provided the holder the right to purchase <span style="-sec-ix-hidden:c80220739">one</span> share of common stock at an exercise price of $0.01 per share and were exercised in full during <em style="font: inherit;"> October 2020. </em>The Unit Warrants provide the holder the right to purchase <span style="-sec-ix-hidden:c80220741">one</span> share of common stock, are immediately exercisable at an exercise price of $5.00 per share and expire <span style="-sec-ix-hidden:c80220743">five</span> years after the issuance date. The public offering price was $5.00 per Unit ($4.99 for each Unit including a Pre-Funded Warrant).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the Underwriting Agreement, we issued to the Representative, as a portion of the underwriting compensation, warrants to purchase up to a total of 128,000 shares of common stock (the &#8220;Representative Warrants&#8221;). The Representative Warrants have an exercise price of $5.50 per share, are initially exercisable 180 days after the effective date of the Offering and have a term of <span style="-sec-ix-hidden:c80220749">three</span> years from their initial exercise date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Conversion of Deferred Compensation to Equity </i>&#8211;<i> </i>From <em style="font: inherit;">2016</em> through <em style="font: inherit;"> August 2020, </em>to help conserve the Company&#8217;s cash resources, our executive officers and non-employee directors agreed to defer receipt of all or a portion (at varying levels) of their respective cash compensation. On <em style="font: inherit;"> September 29, 2020, </em>upon our consummation of the Offering, $1,500,000 of the accumulated deferrals were converted at the $5.00 offering price, resulting in the issuance of 300,001 units substantially similar to the units sold in the public offering, with each unit consisting of <span style="-sec-ix-hidden:c80220755">one</span> share of our common stock and <span style="-sec-ix-hidden:c80220756">one</span> warrant substantially similar to a Unit Warrant (a &#8220;Management Warrant&#8221;).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Conversion of Convertible Debentures to Equity</i> &#8211; As discussed in Note <em style="font: inherit;">6,</em> upon our consummation of the Offering, we issued an aggregate of 177,626 shares of our common stock, 126,042 Pre-Funded Warrants and 303,668 Conversion Warrants upon the mandatory conversion of $1,214,667 of Convertible Debentures and accrued interest.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Common Stock Transactions</i> &#8211; During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> we issued 26,581 and 162 shares, respectively, of our common stock pursuant to consulting agreements. During <em style="font: inherit;">2020,</em> certain warrants were exercised using the &#8220;cashless&#8221; exercise feature of the warrants, resulting in the issuance of an aggregate of 36,902 shares of our common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Options</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have a stock-based incentive plan (the <em style="font: inherit;">&#8220;2020</em> Plan&#8221;) pursuant to which our Board of Directors <em style="font: inherit;"> may </em>grant stock options to our employees. A total of 1,000,000 shares of our common stock are reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan. The exercise price for any option granted <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be less than fair value (110% of fair value for ISO&#8217;s granted to certain employees). Options have a maximum <span style="-sec-ix-hidden:c80220773">ten</span>-year term and generally vest over <span style="-sec-ix-hidden:c80220774">three</span> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of option (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">7.0</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">38.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of stock option activity under the <em style="font: inherit;">2020</em> Plan as of <em style="font: inherit;"> December 31, 2020, </em>and changes during the year then ended is presented below.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Term (yrs)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">602,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2.79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">602,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2.79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">355,180</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted-average grant date fair value of options granted during <em style="font: inherit;">2020</em> was $1.12. <span style="-sec-ix-hidden:c80220778">No</span> stock options were granted during <em style="font: inherit;">2019.</em> Total employee and director stock-based compensation expense recognized in the consolidated statement of operations for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $18,730 and $104,420, respectively. As of <em style="font: inherit;"> December 31, 2020, </em>there is $655,510 of unrecognized compensation expense related to employee and director stock-based compensation arrangements that will be recognized over a weighted-average period of 2.9 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Purchase Warrants</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Summary of Warrants Outstanding </i>&#8211; The table below presents summary information about our warrants outstanding as of <em style="font: inherit;"> December 31, 2020. </em>Additional information concerning the warrants follows the table.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55.6%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant Description</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expiration</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series I Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">62,626</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Oct-Dec 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">June 2020 Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">120,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Jun 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Pre-Funded Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">126,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Perpetual</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unit, Conversion and Management Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,163,669</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">128,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Mar 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Warrants Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,600,337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Exercise Price</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">4.7</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series I Warrants</i> &#8211; During <em style="font: inherit;"> July 2020, </em>Series I Warrants were exercised using the &#8220;cashless&#8221; exercise feature of the warrants, resulting in the issuance of 29,755 shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were 62,626 Series I Warrants outstanding, with an exercise price of $5.00 per share, reflective of anti-dilution adjustments resulting from the Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;"> June 2020 </em>Warrants</i> &#8211; As discussed in Note <em style="font: inherit;">6,</em> on <em style="font: inherit;"> June 26, 2020, </em>in connection with the issuance of the Convertible Debentures, we issued warrants to purchase 120,000 shares of common stock, with a <span style="-sec-ix-hidden:c80220791">five</span>-year term and an exercise price of $10.00. As a result of the Offering, on <em style="font: inherit;"> September 29, 2020 </em>the exercise price was reduced to $5.00.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrants Issued Upon Conversion of Convertible Debentures</i> &#8211; As discussed in Note <em style="font: inherit;">6,</em> on <em style="font: inherit;"> September 29, 2020, </em>upon the conversion of the Convertible Debentures into our equity securities, we issued 126,042 Pre-Funded Warrants and 303,668 Conversion Warrants to purchase our common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrants Issued Upon Conversion of Deferred Compensation</i> &#8211; As discussed above under &#8220;<i>Common Stock </i>&#8211;<i> Conversion of Deferred Compensation to Equity</i>&#8221;, on <em style="font: inherit;"> September&#160;</em><em style="font: inherit;">29,</em> <em style="font: inherit;">2020,</em> upon the conversion of amounts owed to current and former executive officers and directors, we issued Management Warrants to purchase 300,001 shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrants Issued in Connection with Public Offering</i> &#8211; As discussed above under &#8220;<i>Common Stock </i>&#8211;<i> Public Offering</i>&#8221;, on <em style="font: inherit;"> September 29, 2020, </em>in connection with the Offering, we issued Unit Warrants to purchase 2,560,000 shares of common stock, Pre-Funded Warrants to purchase 250,000 shares of common stock (fully exercised in <em style="font: inherit;"> October 2020), </em>and Representative Warrants to purchase 128,000 shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Additional Stock-Based Compensation Expense</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to stock-based compensation expense related to the <em style="font: inherit;">2020</em> Plan (see <i>Stock Options</i> above), during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> we recognized $45,733 and $223,080, respectively, of expense related to the issuance of our common stock pursuant to consulting and investment banking agreements. As of <em style="font: inherit;"> December 31, 2020, </em>there is $48,667 recorded as a prepaid expense for <em style="font: inherit;">one</em> of these arrangements, which will be recognized as expense during <em style="font: inherit;">2021</em> over the term of the related agreement.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132929096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Expense<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Stock-Based Expense</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock-based compensation expense related to employee and director stock options was $56,190 and $168,570 during the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>respectively; there was no stock-based compensation expense related to employee stock options during the comparable periods of <em style="font: inherit;">2020.</em> Stock-based compensation expense related to stock options is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the related employee classification. As of <em style="font: inherit;"> September&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2021,</em> there is $486,940 of unrecognized compensation expense that we expect to recognize over a weighted-average period of 2.2 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>we recorded stock-based compensation expense of $29,560 and $80,733, respectively, associated with common stock issued for consulting services, as compared to $6,000 and $24,000, respectively, during the comparable periods of <em style="font: inherit;">2020.</em> As of <em style="font: inherit;"> September 30, 2021, </em>there is $39,773 recorded as a prepaid expense for these arrangements, which will be recognized as expense over the remaining terms of the related agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During <em style="font: inherit;"> September 2021, </em>we recorded $209,825 of expense associated with the issuance of a stock purchase warrant to PNP in connection with our entering into a technology licensing agreement; such amount was recorded as research and development expense.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132955848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because of our historically significant net operating losses, we have <span style="-sec-ix-hidden:c80220491">not</span> paid income taxes since inception. We maintain deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets are comprised primarily of net operating loss carryforwards and also include amounts relating to nonqualified stock options and research and development credits. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of our future profitability and our ability to utilize the deferred tax assets. Utilization of operating losses and credits will be subject to substantial annual limitations due to ownership change provisions of Section <em style="font: inherit;">382</em> of the Internal Revenue Code. The annual limitation <em style="font: inherit;"> may </em>result in the expiration of net operating losses and credits before utilization.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At <em style="font: inherit;"> December 31, 2020, </em>we have a consolidated federal net operating loss (&#8220;NOL&#8221;) carryforward of approximately $61.8 million available to offset against future taxable income of which approximately $53.6 million expires in varying amounts in <em style="font: inherit;">2021</em> through <em style="font: inherit;">2037.</em> Additionally, we have approximately $1.2 million in research and development (&#8220;R&amp;D&#8221;) tax credits that expire in <em style="font: inherit;">2022</em> through <em style="font: inherit;">2040</em> unless utilized earlier. No income taxes have been paid to date. Section <em style="font: inherit;">382</em> of the Internal Revenue Code contains provisions that <em style="font: inherit;"> may </em>limit our utilization of our NOL and R&amp;D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or <em style="font: inherit;"> may </em>occur in future periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 64.1%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">14,737,240</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,328,336</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research and development tax credit carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,189,110</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,122,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,870</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,877,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued salaries and directors&#8217; fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">72,721</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">450,503</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,571</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">16,003,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Deferred tax liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">28,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(15,975,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset after reduction for valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. federal statutory rate applied to pretax loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(621,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(497,833</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,574</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(47,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance, net of expired items and other adjustments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">687,703</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">544,308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reported income tax expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132881592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Grants and Collaboration Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_GovernmentGrantsandContractsTextBlock', window );">Government Grants and Contracts [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Grants and Collaboration Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>we recorded $30,414 and $220,539, respectively, of revenues associated with these grants, as compared to $231,330 and $1,186,844, respectively, for the comparable periods of <em style="font: inherit;">2020.</em> During the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2020, </em>we also recorded $184,128 and $385,193, respectively, of revenues associated with research collaboration agreements with <em style="font: inherit;">third</em> parties. As of <em style="font: inherit;"> September 30, 2021, </em>there is an aggregate of $244,888 in approved grant funds available for use through mid-<em style="font: inherit;">2022.</em></p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Grants and Collaboration Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> we recorded $1,438,465 and $983,682, respectively, of revenue associated with these grants. As of <em style="font: inherit;"> December 31, 2020, </em>there is an aggregate of $165,500 in remaining grant funds available for use during <em style="font: inherit;">2021.</em> During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> we recorded $385,193 and $192,214, respectively, of revenues associated with research collaboration agreements with several <em style="font: inherit;">third</em> parties.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_GovernmentGrantsandContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_GovernmentGrantsandContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132772024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">13.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Subsequent Event</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> November 9, 2021, </em>we entered into an Exclusive License Agreement the (&#8220;License Agreement&#8221;) with City of Hope (&#8220;COH&#8221;) under which we obtained exclusive worldwide rights to key patents, know-how, regulatory filings and clinical materials related to COH&#8217;s COVID-<em style="font: inherit;">19</em> vaccine program, currently undergoing human clinical trials. We will pay an upfront fee to COH of $5,000,000 within <em style="font: inherit;">30</em> days of the effective date of the License Agreement and are obligated to pay additional fees of $3,000,000 and $2,000,000 on the <em style="font: inherit;">first</em> and <em style="font: inherit;">second</em> anniversaries, respectively, of the effective date of the License Agreement. We will also pay COH milestone fees based on achievement of success-based development and regulatory milestones, and annual royalties on net sales of products covered by the License Agreement.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>SBIR Grant</i> &#8211; In <em style="font: inherit;"> January 2021, </em>NIAID awarded us a Small Business Innovative Research (SBIR) grant in support of our development of a vaccine against SARS-CoV-<em style="font: inherit;">2,</em> the virus that causes COVID-<em style="font: inherit;">19.</em> The $299,927 Phase <em style="font: inherit;">1</em> grant, titled, &#8220;<i>Preclinical Development of GV-MVA-VLP Vaccines Against COVID-<em style="font: inherit;">19,</em></i>&#8221; will support the ongoing design, construction and preclinical testing of our vaccine candidates in preparation for human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Warrant Exercises</i> &#8211; During <em style="font: inherit;"> January </em>and <em style="font: inherit;"> February 2021, </em>holders of our warrants exercised 62,626 Series I Warrants, 126,042 Pre-Funded Warrants and 690,034 Unit Warrants, resulting in the issuance of 835,900 shares of our common stock for aggregate net proceeds to us of $3,174,156.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Bought Deal Public Offering -- </i>On <em style="font: inherit;"> February 11, 2021, </em>we closed an underwritten bought deal public offering of 1,644,000 shares of our common stock, including 204,000 shares sold pursuant to the full exercise of the underwriter&#8217;s option to purchase additional shares, at a price to the public of $6.25 per share. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $9.4 million.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131973608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Description of Business </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (&#8220;GeoVax&#8221; or the &#8220;Company&#8221;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax&#8217;s Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) based platform utilizes MVA, a large virus capable of carrying several vaccine antigens, to express proteins that assemble into highly effective virus-like particle (VLP) immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax&#8217;s MVA-VLP development programs are focused primarily on preventive vaccines against the SARS-CoV-<em style="font: inherit;">2</em> virus (COVID-<em style="font: inherit;">19</em>) and immunotherapies for solid tumor cancers. Other development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), Human Immunodeficiency Virus (HIV), and malaria. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 28, 2021, </em>GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc., whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#174;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase <em style="font: inherit;">1/2</em> clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and <em style="font: inherit;">no</em> curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#8217;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but <em style="font: inherit;">not</em> limited to, cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">1.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Description of Business</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (&#8220;GeoVax&#8221; or the &#8220;Company&#8221;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or &#8220;GV-MVA-VLP<sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup>&#8221;). In this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into highly effective VLP immunogens in the person being vaccinated. The MVA-VLP virus replicates to high titers in approved avian cells for manufacturing but cannot productively replicate in mammalian cells. Therefore, the MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live attenuated virus, while providing the safety characteristics of a replication-defective vector.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current development programs are focused on preventive vaccines against novel coronavirus (COVID-<em style="font: inherit;">19</em>), Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as immunotherapies for HIV and solid tumor cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our corporate strategy is to advance, protect and exploit our differentiated vaccine immunotherapy platform leading to the successful development of preventive and therapeutic vaccines against infectious diseases and various cancers. With our design and development capabilities, we are progressing and validating an array of cancer and infectious disease immunotherapy and vaccine product candidates. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage <em style="font: inherit;">third</em> party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <em style="font: inherit;"> may </em>take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with <em style="font: inherit;">one</em> or more potential strategic partners.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131979176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Significant Accounting Policies and Recent Accounting Pronouncements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We disclosed in Note <em style="font: inherit;">2</em> to our consolidated financial statements included in our Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2020 </em>those accounting policies that we consider significant in determining our results of operations and financial position. During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>there have been <em style="font: inherit;">no</em> material changes to, or in the application of, the accounting policies previously identified and described in the Form <em style="font: inherit;">10</em>-K, and there have been <em style="font: inherit;">no</em> other recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Summary of Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note <em style="font: inherit;">8.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the <em style="font: inherit;">twelve</em>-month period following the issue date of these consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from government grants and clinical trial assistance, corporate and academic collaborations, and from sales of our equity securities. We believe that our existing cash resources together with current government funding commitments, will be sufficient to continue our planned operations into <em style="font: inherit;">2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We <em style="font: inherit;"> may </em>never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we <em style="font: inherit;"> may </em>seek additional capital through arrangements with strategic partners or from other sources. There can be <em style="font: inherit;">no</em> assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consider all highly liquid investments with a maturity of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fair Value of Financial Instruments and Concentration of Credit Risk</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:c80220527">three</span> to <span style="-sec-ix-hidden:c80220528">five</span> years. We amortize leasehold improvements using the straight-line method over the term of the related lease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases</i> (ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em>), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or <em style="font: inherit;">not</em> the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than <em style="font: inherit;">12</em> months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than <em style="font: inherit;">12</em> months, we made an accounting policy election to <em style="font: inherit;">not</em> recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Impairment of Long-Lived Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be<b> </b>recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Accrued Expenses</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have <em style="font: inherit;">not</em> yet been billed by our <em style="font: inherit;">third</em>-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Net Loss Per Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 1,001,948 and 558 shares at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize revenue in accordance with FASB Accounting Standards Update <em style="font: inherit;">2014</em>-<em style="font: inherit;">09,</em> <i>Revenue from Contracts with Customers</i> (ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em>), which created a new Topic, Accounting Standards Codification Topic <em style="font: inherit;">606.</em> The standard is principle-based and provides a <em style="font: inherit;">five</em>-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grant revenue</i> &#8211; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research collaborations</i> &#8211; From time to time, we <em style="font: inherit;"> may </em>enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive <em style="font: inherit;">third</em>-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em> and revenue is recognized accordingly.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expense</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to <em style="font: inherit;">third</em>-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Patent Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.<b> </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Period-to-Period Comparisons</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results for future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#8217;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note <em style="font: inherit;">8</em> for additional stock-based compensation information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Except as discussed above, there have been <em style="font: inherit;">no</em> recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standards if currently adopted would have a material effect on our financial statements.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131976392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;"> December 31, 2020:</em></p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and furnishings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">591,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">543,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">707,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">659,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(538,506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(511,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">168,653</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">532,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">534,577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other furniture, fixtures &amp; equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">659,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">661,918</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(511,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(651,312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation expense was $19,656&#160;and $8,350 during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131979176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Accrued Expenses</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;"> December 31, 2020:</em></p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">11,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">279,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">35,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">79,585</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">46,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">359,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Accrued Expenses</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries and directors&#8217; fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">279,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,732,702</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">118,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">359,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,851,040</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131977784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GRA Note</i> &#8211; On <em style="font: inherit;"> February 28, 2018, </em>we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a <span style="-sec-ix-hidden:c80220395">five</span>-year Senior Promissory Note (the &#8220;GRA Note&#8221;) to GRA in exchange for $50,000. The GRA Note bore an annual interest rate of <span style="-sec-ix-hidden:c80220397">five</span> percent. Interest expense related to the GRA Note for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021 </em>was $-0- and $633, respectively, as compared to $411 and $1,344, respectively, for the same periods of <em style="font: inherit;">2020.</em> During <em style="font: inherit;"> May 2021, </em>we repaid the remaining principal balance of $22,737 and retired the GRA Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>CARES Act Paycheck Protection Program Loan </i>&#8211;<i> </i>On <em style="font: inherit;"> April 17, 2020, </em>we received a $170,200 bank loan backed by the United States Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bore an annual interest rate of <em style="font: inherit;">one</em> percent. We recorded accrued interest expense related to the PPP Loan of $-0- and $653 for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>respectively, as compared to $429 and $774, respectively, for the same periods of <em style="font: inherit;">2020.</em> During <em style="font: inherit;"> May 2021, </em>upon receiving payment from the SBA, the lender forgave the full principal balance of $170,200 together with $1,856 of accrued interest and extinguished the PPP Loan.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GRA Note</i> &#8211; On <em style="font: inherit;"> February 28, 2018, </em>we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a <span style="-sec-ix-hidden:c80220569">five</span>-year Senior Promissory Note (the &#8220;GRA Note&#8221;) to GRA in exchange for $50,000. The GRA Note bears an annual interest rate of 5%, payable monthly, with principal repayments beginning in the <em style="font: inherit;">second</em> year. Future principal repayments are expected to be $12,487 in <em style="font: inherit;">2021,</em> $13,126 <em style="font: inherit;">in2022,</em> and $2,252 in <em style="font: inherit;">2023.</em> Interest expense related to the GRA Note was $1,727 and $2,097 for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>CARES Act Paycheck Protection Program Loan </i>&#8211;<i> </i>On <em style="font: inherit;"> April 17, 2020, </em>we received a $170,200 bank loan backed by the United States Small Business Administration pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bears an annual interest rate of <em style="font: inherit;">one</em> percent and is due <em style="font: inherit;"> April 17, 2022. </em>We have accrued interest expense associated with the PPP Loan of $1,203. In <em style="font: inherit;"> October 2020, </em>we applied to the lender to have the loan forgiven, based upon our submission of qualifying information regarding eligible expenses; as of the date of this report our forgiveness application has <em style="font: inherit;">not</em> been processed.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132870088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Convertible Debentures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-term Debt [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Convertible Debentures</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> June 26 2020, </em>we entered into a Securities Purchase Agreement with <span style="-sec-ix-hidden:c80220587">two</span> institutional investors, pursuant to which we received gross proceeds of $1,050,000 in exchange for the issuance of: (i) 5% Original Issue Discount Senior Secured Convertible Debentures (the &#8220;Convertible Debentures&#8221;) in the aggregate principal amount of <span style="-sec-ix-hidden:c80220590">$1,200,000;</span> and (ii) <span style="-sec-ix-hidden:c80220591">five</span>-year warrants (the <em style="font: inherit;"> &#8220;June 2020 </em>Warrants&#8221;) to purchase an aggregate of 120,000 shares of our common stock at an exercise price of $10.00 per share. Net proceeds after deducting the original issue discount, finder&#8217;s fee and other debt issuance costs were $888,500. As a result of the public offering of our securities described in Note <em style="font: inherit;">8,</em> on <em style="font: inherit;"> September 29, 2020 </em>the exercise price of the <em style="font: inherit;"> June 2020 </em>Warrants was reduced to $5.00. The Convertible Debentures had an original maturity of <span style="-sec-ix-hidden:c80220597">twelve</span> months, bore interest at a rate of 5% per annum, and were secured by substantially all of the Company&#8217;s assets until such time as they were paid or converted in full.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Convertible Debentures were mandatorily convertible upon our consummation of a public offering of common stock with gross proceeds of $6,000,000 or more, and which resulted in the listing of our common stock on a national securities exchange (a &#8220;Qualified Offering&#8221;). The conversion price upon the occurrence of a Qualified Offering was equal to the lower of (i) $10.00 per share or (ii) 80% of the offering price. The conversion provisions of the Convertible Debentures were subject to a &#8220;conversion blocker&#8221; such that each of the purchasers could <em style="font: inherit;">not</em> convert the Convertible Debentures to the extent that the conversion would result in the purchaser and its affiliates holding more than 4.99% of our outstanding common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 29, 2020, </em>upon our consummation of the public offering discussed in Note <em style="font: inherit;">8,</em> the $1,200,000 maturity value of the Convertible Debentures and $14,667 of accrued interest were automatically converted at $4.00, the Qualified Offering discounted price, resulting in the issuance of 303,668 conversion units. Of the <em style="font: inherit;">303,668</em> conversion units: (a) 177,626 consist of <span style="-sec-ix-hidden:c80220611">one</span> share of common stock and a warrant to purchase <span style="-sec-ix-hidden:c80220612">one</span> share of common stock (a &#8220;Conversion Warrant&#8221;), and (b) 126,042 consist of <span style="-sec-ix-hidden:c80220614">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c80220615">one</span> share of common stock (a &#8220;Pre-Funded Warrant&#8221;) and a Conversion Warrant. The Pre-Funded Warrants provide the holder the right to purchase <span style="-sec-ix-hidden:c80220616">one</span> share of Common Stock at an exercise price of $0.01 per share, are immediately exercisable and will <em style="font: inherit;">not</em> expire until exercised in full. The Conversion Warrants provide the holder the right to purchase <span style="-sec-ix-hidden:c80220619">one</span> share of common stock, are immediately exercisable at an exercise price of $5.00 per share and expire <span style="-sec-ix-hidden:c80220621">five</span> years after the issuance date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon the issuance of the Convertible Debentures, we recorded a debt discount of $769,334, including the $150,000 original issue discount, $457,833 of fair value allocated to the warrants (recorded as Additional Paid-in Capital), and $161,500 of direct transaction costs incurred. The debt discount was amortized to interest expense over the <em style="font: inherit;">12</em>-month term of the Debentures using the effective interest rate method, up to the date of conversion. As a result of the mandatory conversion of the Convertible Debentures on <em style="font: inherit;"> September 29, 2020, </em>the remaining unamortized debt discount ($645,150) was recorded as Additional Paid-in Capital. Interest expense associated with the Convertible Debentures recorded during <em style="font: inherit;">2020</em> was $138,851, including $124,185 of debt discount amortization.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132828360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on <em style="font: inherit;"> December 31, 2022. </em>Rent expense for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021 </em>was $42,803 and $128,410, respectively, as compared to $41,539 and $124,617, respectively, for the same periods of <em style="font: inherit;">2020.</em> Future minimum lease payments total $42,803 for the remainder of <em style="font: inherit;">2021</em> and $176,356 in <em style="font: inherit;">2022,</em> although the lease <em style="font: inherit;"> may </em>be terminated at any time by either party with <em style="font: inherit;">ninety</em> days&#8217; written notice.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of <em style="font: inherit;"> September 30, 2021, </em>there are approximately $607,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in <em style="font: inherit;">2021.</em></p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on <em style="font: inherit;"> December 31, 2022. </em>Rent expense for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $166,577 and $161,673, respectively. Future minimum lease payments total $171,213 in <em style="font: inherit;">2021</em> and $176,356 in <em style="font: inherit;">2022,</em> although the lease <em style="font: inherit;"> may </em>be terminated at any time by either party with <em style="font: inherit;">ninety</em> days written notice.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of <em style="font: inherit;"> December 31, 2020, </em>we had approximately $190,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in <em style="font: inherit;">2021.</em> We expect $165,500 of this amount to be reimbursable to us pursuant to currently outstanding government grants.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131970824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Stockholders</b>&#8217;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Preferred Stock </i>&#8211;<i> </i>On <em style="font: inherit;"> June 7, 2021, </em>we repurchased the remaining 100 shares of our Series B Convertible Preferred Stock for a total price of $1,000. As of <em style="font: inherit;"> September 30, 2021, </em>there are no shares of our preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Public Offering </i>&#8211;<i> </i>On <em style="font: inherit;"> February 11, 2021, </em>we closed an underwritten public offering of 1,644,000 shares of our common stock, including 204,000 shares sold pursuant to the full exercise of the underwriter&#8217;s option to purchase additional shares, at a price to the public of $6.25 per share. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $9.4 million. Additionally, we issued to the underwriter, as a portion of the underwriting compensation, warrants to purchase 72,000 shares of our common stock at an exercise price of $6.875 per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Options </i>&#8211;<i> </i>We have a stock-based incentive plan (the <em style="font: inherit;">&#8220;2020</em> Plan&#8221;) pursuant to which our Board of Directors <em style="font: inherit;"> may </em>grant stock options and other stock-based awards to our employees, directors and consultants. A total of 1,500,000 shares of our common stock are reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan. During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>there were <span style="-sec-ix-hidden:c80220447">no</span> stock option transactions related to the <em style="font: inherit;">2020</em> Plan. As of <em style="font: inherit;"> September 30, 2021, </em>there were 602,000 stock options outstanding, with a weighted-average exercise price of $2.79 per share and a weighted-average remaining term of 9.2 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Purchase Warrants </i>&#8211;<i> </i>During <em style="font: inherit;"> January </em>and <em style="font: inherit;"> February 2021, </em>188,688 stock purchase warrants were exercised on a cashless basis, resulting in the issuance of 145,866 shares of our common stock, and 690,034 stock purchase warrants were exercised for cash, resulting in the issuance of 690,034 shares of our common stock for net proceeds to us of $3,174,156.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During <em style="font: inherit;"> August 2021, </em>27,004 stock purchase warrants were exercised on a cashless basis, resulting in the issuance of 3,839 shares of our common stock, and 50,000 stock purchase warrants were exercised for cash, resulting in the issuance of 50,000 shares of our common stock for net proceeds to us of $230,000.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 28, 2021, </em>in connection with our entering into an Assignment and License Agreement with PNP Therapeutics, Inc. (PNP) we issued a <span style="-sec-ix-hidden:c80220462">five</span>-year stock purchase warrant to PNP for 100,000 shares of our common stock at an exercise price of $13.00 per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> September 30, 2021, </em>there are 2,816,631 stock purchase warrants outstanding, with a weighted-average exercise price of $5.35 per share and a weighted-average remaining term of 3.9 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Common Stock Transactions</i> &#8211; During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>we issued 13,707 shares of our common stock pursuant to consulting agreements.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Stockholders</b>&#8217;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Convertible Preferred Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are authorized to issue up to 10,000,000 shares of our Preferred Stock, <span style="-sec-ix-hidden:c80220646">$.01</span> par value, which <em style="font: inherit;"> may </em>be issued in <em style="font: inherit;">one</em> or more series. The table below presents our issued and outstanding series of preferred stock as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019.</em> Each series of our outstanding preferred stock has a stated value of $1,000 per share. Further details concerning each series of preferred stock, and the changes in each series during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> are discussed in the sections that follow the table.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Carrying</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Carrying</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series B Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">76,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">76,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series H Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,686</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,156,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series I Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">700,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,486</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,932,433</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series B Convertible Preferred Stock </i>&#8211;<i> </i>Our Series B Convertible Preferred Stock, $1,000 stated value (&#8220;Series B Preferred Stock&#8221;), has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series B Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. As of <em style="font: inherit;"> December 31, 2020, </em>there were 100 shares of Series B Preferred Stock outstanding, convertible at any time at the option of the holder into shares of common stock at a fixed conversion price of $7,000,000 per common share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series C Convertible Preferred Stock </i>&#8211;<i> </i>Our Series C Convertible Preferred Stock, $1,000 stated value (&#8220;Series C Preferred Stock&#8221;), has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series C Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> 587 shares of our Series C Preferred Stock were converted into 2 shares of our common stock and the remaining 1,563 shares of Series C Preferred Stock were exchanged for Series F Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series C Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series E Convertible Preferred Stock </i>&#8211; Our Series E Convertible Preferred Stock, $1,000 stated value, (&#8220;Series E Preferred Stock&#8221;) has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series E Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> all outstanding shares of Series E Preferred Stock (1,200 shares) were exchanged for Series F Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series E Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series F Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> February 2019, </em>we entered into Exchange Agreements with holders of our Series C and Series E Preferred Stock, pursuant to which the holders exchanged all shares of Series C and Series E Preferred Stock held by them for an aggregate of 2,763 shares of Series F Convertible Preferred Stock (&#8220;Series F Preferred Stock&#8221;). Our Series F Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series F Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> 507 shares of Series F Preferred Stock were converted into 9 shares of our common stock and all remaining outstanding shares of Series F Preferred Stock (2,256 shares) were exchanged for Series H Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series F Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series G Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> February 2019, </em>we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#8220;Purchasers&#8221;) providing for sale to the Purchasers of an aggregate of up to 1,000 shares of our Series G Convertible Preferred Stock (&#8220;Series G Preferred Stock&#8221;) and related warrants for gross proceeds of up to $1.0 million, which was funded at <em style="font: inherit;">three</em> different closings. Our Series G Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series G Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. At the <em style="font: inherit;">first</em> closing, which occurred in <em style="font: inherit;"> February 2019, </em>we issued 500 shares of Series G Preferred Stock in exchange for the payment by the Purchasers of $250,000 in the aggregate, plus the cancellation of Term Notes held by the Purchasers in the amount of <em style="font: inherit;">$250,000.</em> At the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> closings, which occurred in <em style="font: inherit;"> April </em>and <em style="font: inherit;"> June 2019, </em>we issued an aggregate of 500 additional shares of Series G Preferred Stock in exchange for the payment by the Purchasers of a total of $500,000. During <em style="font: inherit;"> July 2019, </em>all outstanding shares of Series G Preferred Stock (1,000 shares) were exchanged for Series H Preferred Stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series G Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series H Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> July 2019, </em>we entered into Exchange Agreements with holders of our Series F and Series G Preferred Stock, pursuant to which the holders exchanged all shares of Series F and Series G Preferred Stock held by them for an aggregate of 3,256 shares of Series H Convertible Preferred Stock (&#8220;Series H Preferred Stock&#8221;). Our Series H Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series H Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2019,</em> 1,570 shares of Series H Preferred Stock were converted into 14,808 shares of our common stock. During <em style="font: inherit;">2020,</em> 1,686 shares of our Series H Convertible Preferred Stock were converted into 469,697 shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series H Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series I Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> July 2019, </em>we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#8220;Purchasers&#8221;) providing for sale to the Purchasers of an aggregate of 700 shares of our Series I Convertible Preferred Stock (&#8220;Series I Preferred Stock&#8221;) for gross proceeds of $700,000. Our Series I Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series I Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2020,</em> 700 shares of our Series I Convertible Preferred Stock were converted into 204,371 shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series I Preferred Stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series J Preferred Stock </i>&#8211;<i> </i>In <em style="font: inherit;"> January 2020, </em>we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#8220;Purchasers&#8221;) providing for sale to the Purchasers of an aggregate of 300 shares of our Series J Convertible Preferred Stock (&#8220;Series J Preferred Stock&#8221;) for gross proceeds of $300,000. Our Series J Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series J Preferred Stock has <em style="font: inherit;">no</em> voting rights and is <em style="font: inherit;">not</em> entitled to a dividend. During <em style="font: inherit;">2020,</em> 300 shares of Series J Preferred Stock were converted into 42,723 shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were no shares of Series J Preferred Stock outstanding</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Common Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Reverse Stock Splits </i>&#8211; On <em style="font: inherit;"> April 30, 2019, </em>we effected a <em style="font: inherit;">1</em>-for-500 reverse stock split of our common stock, on <em style="font: inherit;"> January 21, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-2000 reverse split of our common stock and on <em style="font: inherit;"> September 25, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-20 reverse split of our common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Conversions of Preferred Stock</i> &#8211; During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> we issued an aggregate of 716,790 and 14,819 shares of our common stock, respectively, pursuant to the conversion of several series of our convertible preferred stock as discussed above.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Public Offering </i>&#8211;<i> </i>On <em style="font: inherit;"> September 24, 2020, </em>we entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Maxim Group LLC, as representative of the underwriters (the &#8220;Representative&#8221;), for an underwritten public offering (the &#8220;Offering&#8221;) of an aggregate of 2,560,000 units of our equity securities (the &#8220;Units&#8221;). The Offering closed on <em style="font: inherit;"> September 29, 2020, </em>with gross proceeds to us of approximately $12.8 million; net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $11.2 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Of the 2,560,000 Units sold in the Offering: (a) 2,310,000 Units consist of <span style="-sec-ix-hidden:c80220735">one</span> share of our common stock, and a Warrant to purchase <span style="-sec-ix-hidden:c80220736">one</span> share of common stock (each, a &#8220;Unit Warrant&#8221;); and (b) 250,000 Units consisting of a Pre-Funded Warrant to purchase <span style="-sec-ix-hidden:c80220738">one</span> share of common stock and a Unit Warrant. The Pre-Funded Warrants provided the holder the right to purchase <span style="-sec-ix-hidden:c80220739">one</span> share of common stock at an exercise price of $0.01 per share and were exercised in full during <em style="font: inherit;"> October 2020. </em>The Unit Warrants provide the holder the right to purchase <span style="-sec-ix-hidden:c80220741">one</span> share of common stock, are immediately exercisable at an exercise price of $5.00 per share and expire <span style="-sec-ix-hidden:c80220743">five</span> years after the issuance date. The public offering price was $5.00 per Unit ($4.99 for each Unit including a Pre-Funded Warrant).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the Underwriting Agreement, we issued to the Representative, as a portion of the underwriting compensation, warrants to purchase up to a total of 128,000 shares of common stock (the &#8220;Representative Warrants&#8221;). The Representative Warrants have an exercise price of $5.50 per share, are initially exercisable 180 days after the effective date of the Offering and have a term of <span style="-sec-ix-hidden:c80220749">three</span> years from their initial exercise date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Conversion of Deferred Compensation to Equity </i>&#8211;<i> </i>From <em style="font: inherit;">2016</em> through <em style="font: inherit;"> August 2020, </em>to help conserve the Company&#8217;s cash resources, our executive officers and non-employee directors agreed to defer receipt of all or a portion (at varying levels) of their respective cash compensation. On <em style="font: inherit;"> September 29, 2020, </em>upon our consummation of the Offering, $1,500,000 of the accumulated deferrals were converted at the $5.00 offering price, resulting in the issuance of 300,001 units substantially similar to the units sold in the public offering, with each unit consisting of <span style="-sec-ix-hidden:c80220755">one</span> share of our common stock and <span style="-sec-ix-hidden:c80220756">one</span> warrant substantially similar to a Unit Warrant (a &#8220;Management Warrant&#8221;).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Conversion of Convertible Debentures to Equity</i> &#8211; As discussed in Note <em style="font: inherit;">6,</em> upon our consummation of the Offering, we issued an aggregate of 177,626 shares of our common stock, 126,042 Pre-Funded Warrants and 303,668 Conversion Warrants upon the mandatory conversion of $1,214,667 of Convertible Debentures and accrued interest.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Common Stock Transactions</i> &#8211; During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> we issued 26,581 and 162 shares, respectively, of our common stock pursuant to consulting agreements. During <em style="font: inherit;">2020,</em> certain warrants were exercised using the &#8220;cashless&#8221; exercise feature of the warrants, resulting in the issuance of an aggregate of 36,902 shares of our common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Options</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have a stock-based incentive plan (the <em style="font: inherit;">&#8220;2020</em> Plan&#8221;) pursuant to which our Board of Directors <em style="font: inherit;"> may </em>grant stock options to our employees. A total of 1,000,000 shares of our common stock are reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan. The exercise price for any option granted <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be less than fair value (110% of fair value for ISO&#8217;s granted to certain employees). Options have a maximum <span style="-sec-ix-hidden:c80220773">ten</span>-year term and generally vest over <span style="-sec-ix-hidden:c80220774">three</span> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of option (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">7.0</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">38.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of stock option activity under the <em style="font: inherit;">2020</em> Plan as of <em style="font: inherit;"> December 31, 2020, </em>and changes during the year then ended is presented below.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Term (yrs)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">602,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2.79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">602,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2.79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">355,180</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted-average grant date fair value of options granted during <em style="font: inherit;">2020</em> was $1.12. <span style="-sec-ix-hidden:c80220778">No</span> stock options were granted during <em style="font: inherit;">2019.</em> Total employee and director stock-based compensation expense recognized in the consolidated statement of operations for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $18,730 and $104,420, respectively. As of <em style="font: inherit;"> December 31, 2020, </em>there is $655,510 of unrecognized compensation expense related to employee and director stock-based compensation arrangements that will be recognized over a weighted-average period of 2.9 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Purchase Warrants</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Summary of Warrants Outstanding </i>&#8211; The table below presents summary information about our warrants outstanding as of <em style="font: inherit;"> December 31, 2020. </em>Additional information concerning the warrants follows the table.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55.6%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant Description</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expiration</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series I Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">62,626</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Oct-Dec 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">June 2020 Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">120,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Jun 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Pre-Funded Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">126,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Perpetual</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unit, Conversion and Management Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,163,669</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">128,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Mar 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Warrants Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,600,337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Exercise Price</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">4.7</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series I Warrants</i> &#8211; During <em style="font: inherit;"> July 2020, </em>Series I Warrants were exercised using the &#8220;cashless&#8221; exercise feature of the warrants, resulting in the issuance of 29,755 shares of our common stock. As of <em style="font: inherit;"> December 31, 2020, </em>there were 62,626 Series I Warrants outstanding, with an exercise price of $5.00 per share, reflective of anti-dilution adjustments resulting from the Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;"> June 2020 </em>Warrants</i> &#8211; As discussed in Note <em style="font: inherit;">6,</em> on <em style="font: inherit;"> June 26, 2020, </em>in connection with the issuance of the Convertible Debentures, we issued warrants to purchase 120,000 shares of common stock, with a <span style="-sec-ix-hidden:c80220791">five</span>-year term and an exercise price of $10.00. As a result of the Offering, on <em style="font: inherit;"> September 29, 2020 </em>the exercise price was reduced to $5.00.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrants Issued Upon Conversion of Convertible Debentures</i> &#8211; As discussed in Note <em style="font: inherit;">6,</em> on <em style="font: inherit;"> September 29, 2020, </em>upon the conversion of the Convertible Debentures into our equity securities, we issued 126,042 Pre-Funded Warrants and 303,668 Conversion Warrants to purchase our common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrants Issued Upon Conversion of Deferred Compensation</i> &#8211; As discussed above under &#8220;<i>Common Stock </i>&#8211;<i> Conversion of Deferred Compensation to Equity</i>&#8221;, on <em style="font: inherit;"> September&#160;</em><em style="font: inherit;">29,</em> <em style="font: inherit;">2020,</em> upon the conversion of amounts owed to current and former executive officers and directors, we issued Management Warrants to purchase 300,001 shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrants Issued in Connection with Public Offering</i> &#8211; As discussed above under &#8220;<i>Common Stock </i>&#8211;<i> Public Offering</i>&#8221;, on <em style="font: inherit;"> September 29, 2020, </em>in connection with the Offering, we issued Unit Warrants to purchase 2,560,000 shares of common stock, Pre-Funded Warrants to purchase 250,000 shares of common stock (fully exercised in <em style="font: inherit;"> October 2020), </em>and Representative Warrants to purchase 128,000 shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Additional Stock-Based Compensation Expense</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to stock-based compensation expense related to the <em style="font: inherit;">2020</em> Plan (see <i>Stock Options</i> above), during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> we recognized $45,733 and $223,080, respectively, of expense related to the issuance of our common stock pursuant to consulting and investment banking agreements. As of <em style="font: inherit;"> December 31, 2020, </em>there is $48,667 recorded as a prepaid expense for <em style="font: inherit;">one</em> of these arrangements, which will be recognized as expense during <em style="font: inherit;">2021</em> over the term of the related agreement.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131604232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Retirement Plan</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We participate in a multi-employer defined contribution retirement plan (the <em style="font: inherit;">&#8220;401k</em> Plan&#8221;) administered by a <em style="font: inherit;">third</em>-party service provider, and the Company contributes to the <em style="font: inherit;">401k</em> Plan on behalf of its employees based upon a matching formula. During the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> our contributions to the <em style="font: inherit;">401k</em> Plan were $27,511 and $25,876, respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132828360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because of our historically significant net operating losses, we have <span style="-sec-ix-hidden:c80220491">not</span> paid income taxes since inception. We maintain deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets are comprised primarily of net operating loss carryforwards and also include amounts relating to nonqualified stock options and research and development credits. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of our future profitability and our ability to utilize the deferred tax assets. Utilization of operating losses and credits will be subject to substantial annual limitations due to ownership change provisions of Section <em style="font: inherit;">382</em> of the Internal Revenue Code. The annual limitation <em style="font: inherit;"> may </em>result in the expiration of net operating losses and credits before utilization.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At <em style="font: inherit;"> December 31, 2020, </em>we have a consolidated federal net operating loss (&#8220;NOL&#8221;) carryforward of approximately $61.8 million available to offset against future taxable income of which approximately $53.6 million expires in varying amounts in <em style="font: inherit;">2021</em> through <em style="font: inherit;">2037.</em> Additionally, we have approximately $1.2 million in research and development (&#8220;R&amp;D&#8221;) tax credits that expire in <em style="font: inherit;">2022</em> through <em style="font: inherit;">2040</em> unless utilized earlier. No income taxes have been paid to date. Section <em style="font: inherit;">382</em> of the Internal Revenue Code contains provisions that <em style="font: inherit;"> may </em>limit our utilization of our NOL and R&amp;D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or <em style="font: inherit;"> may </em>occur in future periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 64.1%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">14,737,240</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,328,336</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research and development tax credit carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,189,110</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,122,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,870</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,877,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued salaries and directors&#8217; fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">72,721</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">450,503</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,571</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">16,003,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Deferred tax liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">28,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(15,975,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset after reduction for valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. federal statutory rate applied to pretax loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(621,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(497,833</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,574</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(47,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance, net of expired items and other adjustments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">687,703</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">544,308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reported income tax expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131976392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Grants and Collaboration Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_GovernmentGrantsandContractsTextBlock', window );">Government Grants and Contracts [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Grants and Collaboration Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021, </em>we recorded $30,414 and $220,539, respectively, of revenues associated with these grants, as compared to $231,330 and $1,186,844, respectively, for the comparable periods of <em style="font: inherit;">2020.</em> During the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2020, </em>we also recorded $184,128 and $385,193, respectively, of revenues associated with research collaboration agreements with <em style="font: inherit;">third</em> parties. As of <em style="font: inherit;"> September 30, 2021, </em>there is an aggregate of $244,888 in approved grant funds available for use through mid-<em style="font: inherit;">2022.</em></p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Grants and Collaboration Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> we recorded $1,438,465 and $983,682, respectively, of revenue associated with these grants. As of <em style="font: inherit;"> December 31, 2020, </em>there is an aggregate of $165,500 in remaining grant funds available for use during <em style="font: inherit;">2021.</em> During <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> we recorded $385,193 and $192,214, respectively, of revenues associated with research collaboration agreements with several <em style="font: inherit;">third</em> parties.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_GovernmentGrantsandContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_GovernmentGrantsandContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131979176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">13.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Subsequent Event</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> November 9, 2021, </em>we entered into an Exclusive License Agreement the (&#8220;License Agreement&#8221;) with City of Hope (&#8220;COH&#8221;) under which we obtained exclusive worldwide rights to key patents, know-how, regulatory filings and clinical materials related to COH&#8217;s COVID-<em style="font: inherit;">19</em> vaccine program, currently undergoing human clinical trials. We will pay an upfront fee to COH of $5,000,000 within <em style="font: inherit;">30</em> days of the effective date of the License Agreement and are obligated to pay additional fees of $3,000,000 and $2,000,000 on the <em style="font: inherit;">first</em> and <em style="font: inherit;">second</em> anniversaries, respectively, of the effective date of the License Agreement. We will also pay COH milestone fees based on achievement of success-based development and regulatory milestones, and annual royalties on net sales of products covered by the License Agreement.</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>SBIR Grant</i> &#8211; In <em style="font: inherit;"> January 2021, </em>NIAID awarded us a Small Business Innovative Research (SBIR) grant in support of our development of a vaccine against SARS-CoV-<em style="font: inherit;">2,</em> the virus that causes COVID-<em style="font: inherit;">19.</em> The $299,927 Phase <em style="font: inherit;">1</em> grant, titled, &#8220;<i>Preclinical Development of GV-MVA-VLP Vaccines Against COVID-<em style="font: inherit;">19,</em></i>&#8221; will support the ongoing design, construction and preclinical testing of our vaccine candidates in preparation for human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Warrant Exercises</i> &#8211; During <em style="font: inherit;"> January </em>and <em style="font: inherit;"> February 2021, </em>holders of our warrants exercised 62,626 Series I Warrants, 126,042 Pre-Funded Warrants and 690,034 Unit Warrants, resulting in the issuance of 835,900 shares of our common stock for aggregate net proceeds to us of $3,174,156.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Bought Deal Public Offering -- </i>On <em style="font: inherit;"> February 11, 2021, </em>we closed an underwritten bought deal public offering of 1,644,000 shares of our common stock, including 204,000 shares sold pursuant to the full exercise of the underwriter&#8217;s option to purchase additional shares, at a price to the public of $6.25 per share. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $9.4 million.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132928536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SCHEDULE II </b>&#8211;<b> VALUATION AND QUALIFYING ACCOUNTS</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the Years Ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Additions (Reductions)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Description</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Costs and</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expenses</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Other</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accounts</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deductions</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for Deferred Tax Assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,811,563</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,879,954</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,092,724</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428133810840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note <em style="font: inherit;">8.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the <em style="font: inherit;">twelve</em>-month period following the issue date of these consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from government grants and clinical trial assistance, corporate and academic collaborations, and from sales of our equity securities. We believe that our existing cash resources together with current government funding commitments, will be sufficient to continue our planned operations into <em style="font: inherit;">2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We <em style="font: inherit;"> may </em>never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we <em style="font: inherit;"> may </em>seek additional capital through arrangements with strategic partners or from other sources. There can be <em style="font: inherit;">no</em> assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consider all highly liquid investments with a maturity of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fair Value of Financial Instruments and Concentration of Credit Risk</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:c80220527">three</span> to <span style="-sec-ix-hidden:c80220528">five</span> years. We amortize leasehold improvements using the straight-line method over the term of the related lease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases</i> (ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em>), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or <em style="font: inherit;">not</em> the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than <em style="font: inherit;">12</em> months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than <em style="font: inherit;">12</em> months, we made an accounting policy election to <em style="font: inherit;">not</em> recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Impairment of Long-Lived Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be<b> </b>recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_AccruedLiabilitiesPolicyTextBlock', window );">Accrued Liabilities [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Accrued Expenses</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have <em style="font: inherit;">not</em> yet been billed by our <em style="font: inherit;">third</em>-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Net Loss Per Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 1,001,948 and 558 shares at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from Contract with Customer [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize revenue in accordance with FASB Accounting Standards Update <em style="font: inherit;">2014</em>-<em style="font: inherit;">09,</em> <i>Revenue from Contracts with Customers</i> (ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em>), which created a new Topic, Accounting Standards Codification Topic <em style="font: inherit;">606.</em> The standard is principle-based and provides a <em style="font: inherit;">five</em>-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grant revenue</i> &#8211; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research collaborations</i> &#8211; From time to time, we <em style="font: inherit;"> may </em>enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive <em style="font: inherit;">third</em>-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em> and revenue is recognized accordingly.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expense</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to <em style="font: inherit;">third</em>-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Patent Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.<b> </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Comparability Adjustment [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Period-to-Period Comparisons</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results for future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#8217;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note <em style="font: inherit;">8</em> for additional stock-based compensation information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Except as discussed above, there have been <em style="font: inherit;">no</em> recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standards if currently adopted would have a material effect on our financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_AccruedLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_AccruedLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132884168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and furnishings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">591,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">543,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">707,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">659,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(538,506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(511,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">168,653</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">532,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">534,577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other furniture, fixtures &amp; equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">659,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">661,918</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(511,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(651,312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131639144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">11,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">279,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">35,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">79,585</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">46,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">359,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries and directors&#8217; fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">279,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,732,702</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">118,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">359,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,851,040</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132928536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and furnishings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">591,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">543,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">707,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">659,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(538,506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(511,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">168,653</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">532,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">534,577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other furniture, fixtures &amp; equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">659,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">661,918</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(511,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(651,312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132911800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30, 2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">11,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">279,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">35,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">79,585</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">46,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">359,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries and directors&#8217; fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">279,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,732,702</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">118,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">359,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,851,040</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428133051080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ScheduleOfPreferredStockTableTextBlock', window );">Schedule of Preferred Stock [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Carrying</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Carrying</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series B Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">76,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">76,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series H Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,686</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,156,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series I Convertible Preferred Stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">700,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,486</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,932,433</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of option (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">7.0</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">38.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Term (yrs)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">602,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2.79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">602,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2.79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">355,180</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55.6%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant Description</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expiration</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Series I Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">62,626</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Oct-Dec 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">June 2020 Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">120,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Jun 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Pre-Funded Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">126,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Perpetual</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unit, Conversion and Management Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,163,669</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">128,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Mar 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Warrants Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,600,337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Exercise Price</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">4.7</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ScheduleOfPreferredStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ScheduleOfPreferredStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131622392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 64.1%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">14,737,240</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,328,336</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research and development tax credit carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,189,110</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,122,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,870</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,877,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued salaries and directors&#8217; fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">72,721</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">450,503</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,571</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">16,003,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Deferred tax liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">28,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(15,975,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset after reduction for valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. federal statutory rate applied to pretax loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(621,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(497,833</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,574</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(47,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance, net of expired items and other adjustments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">687,703</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">544,308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reported income tax expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132901368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Additions (Reductions)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Description</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Costs and</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expenses</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Other</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accounts</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deductions</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for Deferred Tax Assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,811,563</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,879,954</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,092,724</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428134774216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Basis of Presentation (Details Textual)<br></strong></div></th>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th"><div>Jan. 21, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428129106696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">2,965,451<span></span>
</td>
<td class="nump">204,553<span></span>
</td>
<td class="nump">2,550,184<span></span>
</td>
<td class="nump">78,754<span></span>
</td>
<td class="nump">1,001,948<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131540392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 707,159<span></span>
</td>
<td class="nump">$ 659,441<span></span>
</td>
<td class="nump">$ 661,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(538,506)<span></span>
</td>
<td class="num">(511,700)<span></span>
</td>
<td class="num">(651,312)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">168,653<span></span>
</td>
<td class="nump">147,741<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_EquipmentAndFurnishingsMember', window );">Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">591,554<span></span>
</td>
<td class="nump">543,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 115,605<span></span>
</td>
<td class="nump">$ 115,605<span></span>
</td>
<td class="nump">$ 115,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_EquipmentAndFurnishingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_EquipmentAndFurnishingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131528984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries</a></td>
<td class="nump">$ 11,212<span></span>
</td>
<td class="nump">$ 279,696<span></span>
</td>
<td class="nump">$ 1,732,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">79,585<span></span>
</td>
<td class="nump">118,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 46,212<span></span>
</td>
<td class="nump">$ 359,281<span></span>
</td>
<td class="nump">$ 1,851,040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428130649192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Notes Payable (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 170,200<span></span>
</td>
<td class="nump">$ 170,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,864<span></span>
</td>
<td class="nump">8,854<span></span>
</td>
<td class="nump">11,880<span></span>
</td>
<td class="nump">$ 10,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember', window );">Paycheck Protection Program CARES Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="nump">$ 170,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">653<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="nump">$ 1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_GainLossFromInterestForgiven', window );">Gain (Loss) from Interest Forgiven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_GainLossFromInterestForgiven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents gain (loss) from interest forgiven.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_GainLossFromInterestForgiven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428134019240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, to be Paid, Year One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Unrecorded Unconditional Purchase Obligation, Total</a></td>
<td class="nump">$ 607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=govx_OfficeAndLaboratoryLeaseAgreementMember', window );">Office and Laboratory Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 42,803<span></span>
</td>
<td class="nump">$ 41,539<span></span>
</td>
<td class="nump">$ 128,410<span></span>
</td>
<td class="nump">$ 124,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</a></td>
<td class="nump">42,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, to be Paid, Year One</a></td>
<td class="nump">$ 176,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=govx_OfficeAndLaboratoryLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=govx_OfficeAndLaboratoryLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428125208728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2021</div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 28, 2021</div></th>
<th class="th"><div>Sep. 29, 2020</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock Repurchased During Period, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="nump">$ 3,174,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,404,156<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,581<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member', window );">Stock Incentive Plan 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrantsMember', window );">Representative Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsFirstIssuanceMember', window );">Stock Purchase Warrants First Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,004<span></span>
</td>
<td class="nump">188,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,839<span></span>
</td>
<td class="nump">145,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsSecondIssuanceMember', window );">Stock Purchase Warrants Second Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">690,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">690,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantToPnpMember', window );">Stock Purchase Warrant to PNP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsMember', window );">Stock Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,816,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock Repurchased During Period, Shares (in shares)</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock Repurchased During Period, Value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsFirstIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsFirstIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsSecondIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsSecondIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantToPnpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantToPnpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428130488376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Expense (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 486,940<span></span>
</td>
<td class="nump">$ 486,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices', window );">Stock Issued During Period, Value Expensed During the Period, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,560<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">80,733<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod', window );">Prepaid Expense, Value of Stock Issued for Services During Period</a></td>
<td class="nump">39,773<span></span>
</td>
<td class="nump">39,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_WarrantIssuanceExpense', window );">Warrant Issuance Expense</a></td>
<td class="nump">$ 209,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,190<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 168,570<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,730<span></span>
</td>
<td class="nump">$ 104,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of stock issued for services during period recorded as prepaid expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_WarrantIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs associated with the issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_WarrantIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132960728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428133952328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 30,414<span></span>
</td>
<td class="nump">$ 415,458<span></span>
</td>
<td class="nump">$ 220,539<span></span>
</td>
<td class="nump">$ 1,572,037<span></span>
</td>
<td class="nump">$ 1,823,658<span></span>
</td>
<td class="nump">$ 1,175,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_UnusedGrantFunds', window );">Unused Grant Funds</a></td>
<td class="nump">244,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=govx_NIHGrantsMember', window );">NIH Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 30,414<span></span>
</td>
<td class="nump">231,330<span></span>
</td>
<td class="nump">$ 220,539<span></span>
</td>
<td class="nump">1,186,844<span></span>
</td>
<td class="nump">$ 1,438,465<span></span>
</td>
<td class="nump">$ 983,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=govx_LeidosIncResearchCollaborativeAgreementMember', window );">Leidos, Inc. Research Collaborative Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_UnusedGrantFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of grant funds available for use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_UnusedGrantFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=govx_NIHGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=govx_NIHGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=govx_LeidosIncResearchCollaborativeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=govx_LeidosIncResearchCollaborativeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131965960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 13 - Subsequent Event (Details Textual) - City of Hope [Member] - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Nov. 09, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_UpfrontFee', window );">Upfront Fee</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=govx_CityOfHopeMember', window );">License First Anniversary Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_LicenseFees', window );">License Fees</a></td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=govx_CityOfHopeMember', window );">License Second Anniversary Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_LicenseFees', window );">License Fees</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_LicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense associated with license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_LicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fee paid at the beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=govx_CityOfHopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=govx_CityOfHopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=govx_LicenseFirstAnniversaryPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=govx_LicenseFirstAnniversaryPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=govx_LicenseSecondAnniversaryPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=govx_LicenseSecondAnniversaryPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428220430968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">2,965,451<span></span>
</td>
<td class="nump">204,553<span></span>
</td>
<td class="nump">2,550,184<span></span>
</td>
<td class="nump">78,754<span></span>
</td>
<td class="nump">1,001,948<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132986040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation, Depletion and Amortization, Nonproduction, Total</a></td>
<td class="nump">$ 19,656<span></span>
</td>
<td class="nump">$ 8,350<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428129199912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 707,159<span></span>
</td>
<td class="nump">$ 659,441<span></span>
</td>
<td class="nump">$ 661,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(538,506)<span></span>
</td>
<td class="num">(511,700)<span></span>
</td>
<td class="num">(651,312)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">168,653<span></span>
</td>
<td class="nump">147,741<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,100<span></span>
</td>
<td class="nump">534,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 115,605<span></span>
</td>
<td class="nump">115,605<span></span>
</td>
<td class="nump">115,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_OtherFurnitureFixturesAndEquipmentMember', window );">Other Furniture Fixtures And Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,736<span></span>
</td>
<td class="nump">$ 11,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_OtherFurnitureFixturesAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_OtherFurnitureFixturesAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428118248936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries</a></td>
<td class="nump">$ 11,212<span></span>
</td>
<td class="nump">$ 279,696<span></span>
</td>
<td class="nump">$ 1,732,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">79,585<span></span>
</td>
<td class="nump">118,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 46,212<span></span>
</td>
<td class="nump">$ 359,281<span></span>
</td>
<td class="nump">$ 1,851,040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428125048024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Notes Payable (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 170,200<span></span>
</td>
<td class="nump">$ 170,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ 134,427<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">142,722<span></span>
</td>
<td class="nump">143,524<span></span>
</td>
<td class="nump">4,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember', window );">Paycheck Protection Program CARES Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="nump">$ 170,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">653<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Long-Term Debt, Maturity, Year One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long-Term Debt, Maturity, Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long-Term Debt, Maturity, Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,727<span></span>
</td>
<td class="nump">$ 2,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428117456728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Convertible Debentures (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 29, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 24, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 888,500<span></span>
</td>
<td class="nump">$ 888,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfCommonStockSecuritiesCalledByEachUnit', window );">Number of Common Stock Securities Called by Each Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 124,185<span></span>
</td>
<td class="nump">$ 124,185<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember', window );">Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DebtConversionAccruedInterestAmount', window );">Debt Conversion, Accrued Interest Amount</a></td>
<td class="nump">$ 14,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="nump">303,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember', window );">Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="nump">177,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfCommonStockSecuritiesCalledByEachUnit', window );">Number of Common Stock Securities Called by Each Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember', window );">Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="nump">126,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember', window );">June 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 457,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantMember', window );">Conversion Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfWarrantsCalledByEachUnit', window );">Number of Warrants Called by Each Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember', window );">Unit Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=govx_ConvertibleDebenturesMember', window );">Convertible Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfInstitutionalInvestors', window );">Number of Institutional Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromConvertibleDebtGross', window );">Proceeds from Convertible Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 888,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering', window );">Gross Proceeds from Issuance of Common Stock, Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_PercentageOfOfferingPrice', window );">Percentage of Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage', window );">Debt Instrument, Convertible, Maximum Allowed Ownership of Common Stock Outstanding, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount, Total</a></td>
<td class="nump">$ 645,150<span></span>
</td>
<td class="nump">$ 769,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DebtConversionOriginalDebtDiscount', window );">Debt Conversion, Original Debt Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DebtConversionAccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the debt accrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DebtConversionAccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DebtConversionOriginalDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents original debt discount of debt conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DebtConversionOriginalDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum ownership percentage of common stock outstanding allowed for the conversion feature embedded in the debt instrument to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents gross proceeds from issuance of common stock for public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_NumberOfCommonStockSecuritiesCalledByEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock securities into which each unit may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_NumberOfCommonStockSecuritiesCalledByEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_NumberOfInstitutionalInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to number of institutional investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_NumberOfInstitutionalInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_NumberOfWarrantsCalledByEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants into which each unit may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_NumberOfWarrantsCalledByEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_PercentageOfOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_PercentageOfOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ProceedsFromConvertibleDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to gross proceeds from convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ProceedsFromConvertibleDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_ConversionUnitsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_ConversionUnitsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_ConversionUnitsTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_ConversionUnitsTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=govx_ConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=govx_ConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132283864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Commitments (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense, Total</a></td>
<td class="nump">$ 166,577<span></span>
</td>
<td class="nump">$ 161,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, to be Paid, Year One</a></td>
<td class="nump">171,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, to be Paid, Year Two</a></td>
<td class="nump">176,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Unrecorded Unconditional Purchase Obligation, Total</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 607,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount', window );">Unrecorded Unconditional Purchase Obligation Reimbursable, Amount</a></td>
<td class="nump">$ 165,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of reimbursable purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428112828296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 11, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 29, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th">
<div>Sep. 24, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 21, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th">
<div>Apr. 26, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 26, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">1,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromIssuanceOrSaleOfEquityGross', window );">Proceeds from Issuance or Sale of Equity, Gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfCommonStockSecuritiesCalledByEachUnit', window );">Number of Common Stock Securities Called by Each Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredCompensationLiabilityConversionToEquityAmount', window );">Deferred Compensation Liability Conversion to Equity, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredCompensationLiabilityConversionToEquityConversionPrice', window );">Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation', window );">Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,581<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 655,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod', window );">Prepaid Expense, Value of Stock Issued for Services During Period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember', window );">Expense Related To Consulting And Investment Banking Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,733<span></span>
</td>
<td class="nump">$ 223,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,190<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 168,570<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,730<span></span>
</td>
<td class="nump">$ 104,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member', window );">Stock Incentive Plan 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember', window );">Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount', window );">Debt Conversion, Converted Instrument, Principal and Interest, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,214,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantsMember', window );">Conversion Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class Of Warrant Or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantsMember', window );">Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantMember', window );">Unit Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrantsMember', window );">Representative Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable', window );">Class of Warrant or Right, Period for Warrants or Rights Exercisable (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ManagementWarrantMember', window );">Management Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfWarrantsCalledByEachUnit', window );">Number of Warrants Called by Each Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_SeriesIWarrantsMember', window );">Series I Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember', window );">June 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember', window );">Unit Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember', window );">Series G Convertible Preferred Stock and Related Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized', window );">Convertible Preferred Stock and Related Warrants, Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum', window );">Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ConvertiblePreferredStockAndRelatedWarrantsIssued', window );">Convertible Preferred Stock and Related Warrants Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=govx_SeriesGConvertiblePreferredStockMember', window );">Series G Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum', window );">Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CapitalUnitsMember', window );">Capital Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember', window );">Conversion of Series C Preferred Stock Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember', window );">Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember', window );">Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember', window );">Conversion of Series F Preferred Stock Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember', window );">Conversion from Series F Preferred Stock to Series H Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember', window );">Conversion of Series H Preferred Stock Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,697<span></span>
</td>
<td class="nump">14,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember', window );">Conversion of Series I Preferred Stock Into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember', window );">Conversion of Series J Preferred Stock into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember', window );">Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,790<span></span>
</td>
<td class="nump">14,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ConvertiblePreferredStockConversionPrice1', window );">Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesFConvertiblePreferredStockMember', window );">Series F Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock', window );">Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesGConvertiblePreferredStockMember', window );">Series G Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesHConvertiblePreferredStockMember', window );">Series H Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesIConvertiblePreferredStockMember', window );">Series I Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesJConvertiblePreferredStockMember', window );">Series J Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_CapitalUnitsTrancheOneMember', window );">Capital Units Tranche One [Member] | Capital Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfCommonStockSecuritiesCalledByEachUnit', window );">Number of Common Stock Securities Called by Each Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_CapitalUnitsTrancheTwoMember', window );">Capital Units Tranche Two [Member] | Capital Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_UnitsIncludingPrefundedWarrantsMember', window );">Units Including Pre-Funded Warrants [Member] | Capital Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time for warrants to be exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of convertible preferred stock and related warrants authorized for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ConvertiblePreferredStockAndRelatedWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of convertible preferred stock and related warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ConvertiblePreferredStockAndRelatedWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ConvertiblePreferredStockConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion price related to convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ConvertiblePreferredStockConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt and interest is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredCompensationLiabilityConversionToEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred compensation liability being converted into equity in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredCompensationLiabilityConversionToEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredCompensationLiabilityConversionToEquityConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share for the conversion of deferred compensation liability to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredCompensationLiabilityConversionToEquityConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_NumberOfCommonStockSecuritiesCalledByEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock securities into which each unit may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_NumberOfCommonStockSecuritiesCalledByEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of series C and series E preferred stock exchanged for series F convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_NumberOfWarrantsCalledByEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants into which each unit may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_NumberOfWarrantsCalledByEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of stock issued for services during period recorded as prepaid expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount of proceeds from issuance of convertible preferred stock and related warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ProceedsFromIssuanceOrSaleOfEquityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ProceedsFromIssuanceOrSaleOfEquityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period for the cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ManagementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_ManagementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_SeriesIWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_SeriesIWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=govx_SeriesGConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=govx_SeriesGConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CapitalUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CapitalUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesFConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesFConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesGConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesGConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesHConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesHConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesIConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesIConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesJConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesJConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_CapitalUnitsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_CapitalUnitsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_CapitalUnitsTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_CapitalUnitsTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_UnitsIncludingPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_UnitsIncludingPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428129203000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity - Preferred Stock Summary (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 1,932,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesHConvertiblePreferredStockMember', window );">Series H Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,156,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesIConvertiblePreferredStockMember', window );">Series I Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesHConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesHConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesIConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesIConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428128783784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rates</a></td>
<td class="nump">0.69%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (Year)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">38.16%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428130286504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity- Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">602,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">9 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 355,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428117418248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity - Summary of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 29, 2020</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
<th class="th"><div>Jun. 26, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_SeriesIWarrantsMember', window );">Series I Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember', window );">June 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitConversionAndManagementWarrantsMember', window );">Unit, Conversion and Management Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,163,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrantsMember', window );">Representative Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.875<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_OutstandingWarrantsExcludingPreFundedWarrantsMember', window );">Outstanding Warrants Excluding Pre-Funded Warrants [Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_SeriesIWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_SeriesIWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitConversionAndManagementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_UnitConversionAndManagementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_OutstandingWarrantsExcludingPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_OutstandingWarrantsExcludingPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131638584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Retirement Plan (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 27,511<span></span>
</td>
<td class="nump">$ 25,876<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428131901928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428220440920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 14,737,240<span></span>
</td>
<td class="nump">$ 15,328,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforward</a></td>
<td class="nump">1,189,110<span></span>
</td>
<td class="nump">1,122,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">4,870<span></span>
</td>
<td class="nump">1,877,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees', window );">Accrued salaries and directors&#8217; fees</a></td>
<td class="nump">72,721<span></span>
</td>
<td class="nump">450,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">16,003,941<span></span>
</td>
<td class="nump">18,787,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">28,274<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredTaxAssetsBeforeValuationAllowanceNet', window );">Net deferred tax assets</a></td>
<td class="nump">15,975,667<span></span>
</td>
<td class="nump">18,787,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(15,975,667)<span></span>
</td>
<td class="num">(18,787,230)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset after reduction for valuation allowance</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued salaries and directors' fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredTaxAssetsBeforeValuationAllowanceNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances and after deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredTaxAssetsBeforeValuationAllowanceNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428132267656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Taxes - Reconciliation of Income Tax Benefit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate applied to pretax loss</a></td>
<td class="num">$ (621,194)<span></span>
</td>
<td class="num">$ (497,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(66,574)<span></span>
</td>
<td class="num">(47,053)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, net of expired items and other adjustments</a></td>
<td class="nump">687,703<span></span>
</td>
<td class="nump">544,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Reported income tax expense</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428130415736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Grants and Collaboration Revenue (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 30,414<span></span>
</td>
<td class="nump">$ 415,458<span></span>
</td>
<td class="nump">$ 220,539<span></span>
</td>
<td class="nump">$ 1,572,037<span></span>
</td>
<td class="nump">$ 1,823,658<span></span>
</td>
<td class="nump">$ 1,175,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_UnusedGrantFunds', window );">Unused Grant Funds</a></td>
<td class="nump">244,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=govx_NIHGrantsMember', window );">NIH Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 30,414<span></span>
</td>
<td class="nump">$ 231,330<span></span>
</td>
<td class="nump">$ 220,539<span></span>
</td>
<td class="nump">$ 1,186,844<span></span>
</td>
<td class="nump">1,438,465<span></span>
</td>
<td class="nump">983,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=govx_ResearchAgreementsMember', window );">Research Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,193<span></span>
</td>
<td class="nump">$ 192,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_UnusedGrantFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of grant funds available for use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_UnusedGrantFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=govx_NIHGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=govx_NIHGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=govx_ResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=govx_ResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428116846264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Subsequent Events (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,414<span></span>
</td>
<td class="nump">$ 415,458<span></span>
</td>
<td class="nump">$ 220,539<span></span>
</td>
<td class="nump">$ 1,572,037<span></span>
</td>
<td class="nump">$ 1,823,658<span></span>
</td>
<td class="nump">$ 1,175,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="nump">$ 3,174,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,404,156<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">1,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_SeriesIWarrantsMember', window );">Series I Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,174,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">1,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series I Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Unit Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=govx_SBIRGrantMember', window );">SBIR Grant [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_SeriesIWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_SeriesIWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=govx_SBIRGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=govx_SBIRGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140428133846856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning Of Period</a></td>
<td class="nump">$ 18,787,230<span></span>
</td>
<td class="nump">$ 19,879,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions Charged to Costs and Expenses</a></td>
<td class="num">(2,811,563)<span></span>
</td>
<td class="num">(1,092,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Additions Charged to Other Accounts</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End Of Period</a></td>
<td class="nump">$ 15,975,667<span></span>
</td>
<td class="nump">$ 18,787,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>govx-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:govx="http://geovax.com/20210930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="govx-20210930.xsd" xlink:type="simple"/>
    <context id="d_2021-01-01_2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i_2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-04-01_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInBridgeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">govx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">govx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_TitleOfIndividualAxis-ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">govx:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_TitleOfIndividualAxis-ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">govx:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-21</startDate>
            <endDate>2020-01-21</endDate>
        </period>
    </context>
    <context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:EquipmentAndFurnishingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:EquipmentAndFurnishingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-05-01_2021-05-31_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-06-07_2021-06-07_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-07</startDate>
            <endDate>2021-06-07</endDate>
        </period>
    </context>
    <context id="d_2021-02-11_2021-02-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="d_2021-02-11_2021-02-11_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="i_2021-02-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="i_2021-09-30_PlanNameAxis-StockIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">govx:StockIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsFirstIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsSecondIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="d_2021-02-01_2021-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsFirstIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsSecondIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="d_2021-08-01_2021-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i_2021-09-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantToPnpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantToPnpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-28</instant>
        </period>
    </context>
    <context id="i_2021-09-30_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-09-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_ProductOrServiceAxis-NIHGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_ProductOrServiceAxis-NIHGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_ProductOrServiceAxis-NIHGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_ProductOrServiceAxis-NIHGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_ProductOrServiceAxis-LeidosIncResearchCollaborativeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:LeidosIncResearchCollaborativeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_ProductOrServiceAxis-LeidosIncResearchCollaborativeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:LeidosIncResearchCollaborativeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">govx:CityOfHopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_ProductOrServiceAxis-LicenseFirstAnniversaryPaymentMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">govx:CityOfHopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:LicenseFirstAnniversaryPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_ProductOrServiceAxis-LicenseSecondAnniversaryPaymentMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">govx:CityOfHopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:LicenseSecondAnniversaryPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OtherFurnitureFixturesAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:OtherFurnitureFixturesAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-OtherFurnitureFixturesAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:OtherFurnitureFixturesAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-26</instant>
        </period>
    </context>
    <context id="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-26</startDate>
            <endDate>2020-06-26</endDate>
        </period>
    </context>
    <context id="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-26</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="i_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:ConversionUnitsTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="i_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:ConversionUnitsTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:ConversionUnitsTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:ConversionUnitsTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="d_2020-06-26_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-26</startDate>
            <endDate>2020-06-26</endDate>
        </period>
    </context>
    <context id="i_2020-09-29_ShortTermDebtTypeAxis-ConvertibleDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ShortTermDebtTypeAxis-ConvertibleDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesHConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesHConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesIConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesIConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementClassOfStockAxis-SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesCPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementClassOfStockAxis-SeriesEConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-02-01_2019-02-28_StatementClassOfStockAxis-SeriesFConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesFPreferredStockIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesFPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementClassOfStockAxis-SeriesFConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2019-02-01_2019-02-28_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="d_2019-02-25_2019-02-25_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-25</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="d_2019-02-26_2019-02-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-26</startDate>
            <endDate>2019-02-26</endDate>
        </period>
    </context>
    <context id="d_2019-04-26_2019-04-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-26</startDate>
            <endDate>2019-04-26</endDate>
        </period>
    </context>
    <context id="d_2019-04-26_2019-04-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-26</startDate>
            <endDate>2019-04-26</endDate>
        </period>
    </context>
    <context id="i_2019-07-31_StatementClassOfStockAxis-SeriesGConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementClassOfStockAxis-SeriesGConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesGConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesHConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesIConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesIPreferredStockIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesIPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-01-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesJConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesJPreferredStockIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesJPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesJConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2019-04-30_2019-04-30_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-30</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-09-24_2020-09-24_ClassOfWarrantOrRightAxis-ConversionWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="d_2020-09-24_2020-09-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="d_2020-09-24_2020-09-24_StatementEquityComponentsAxis-CapitalUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="d_2020-09-24_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CapitalUnitsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="i_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CapitalUnitsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="d_2020-09-24_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheTwoMember_StatementEquityComponentsAxis-CapitalUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CapitalUnitsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="i_2020-09-24_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="i_2020-09-24_StatementEquityComponentsAxis-CapitalUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="i_2020-09-24_StatementClassOfStockAxis-UnitsIncludingPrefundedWarrantsMember_StatementEquityComponentsAxis-CapitalUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:UnitsIncludingPrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="d_2020-09-24_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="i_2020-09-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ManagementWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_PlanNameAxis-StockIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">govx:StockIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:SeriesIWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-June2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-UnitConversionAndManagementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitConversionAndManagementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_RangeAxis-WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-OutstandingWarrantsExcludingPreFundedWarrantsMember_RangeAxis-WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:OutstandingWarrantsExcludingPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-07-01_2020-07-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:SeriesIWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NIHGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-NIHGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ResearchAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:ResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ResearchAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:ResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-01-31_ProductOrServiceAxis-SBIRGrantMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:SBIRGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:SeriesIWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-UnitWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-CommonStockWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="i_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2021-01-01_2021-09-30"
      id="thunderdome-EntityCentralIndexKey">0000832489</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2021-01-01_2021-09-30"
      id="thunderdome-EntityRegistrantName">GeoVax Labs, Inc.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2021-01-01_2021-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2021-01-01_2021-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2021-01-01_2021-09-30">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2021-09-30"
      id="c80220915"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2020-12-31"
      id="c80220916"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220863"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220864"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220867"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220868"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220865"
      unitRef="USDPerShare">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220866"
      unitRef="USDPerShare">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220869"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220871"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220870"
      unitRef="Share">100</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220872"
      unitRef="Share">100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220873"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220874"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220875"
      unitRef="Share">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220876"
      unitRef="Share">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220877"
      unitRef="Share">6381541</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220879"
      unitRef="Share">6381541</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220878"
      unitRef="Share">3834095</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220880"
      unitRef="Share">3834095</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"
      id="c80220395">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="2"
      id="c80220397"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c80220447"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantToPnpMember"
      id="c80220462">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c80220914"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxesPaid
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c80220491"
      unitRef="USD">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2020-12-31"
      id="c80220933"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2019-12-31"
      id="c80220934"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220917"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220918"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220919"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220920"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220921"
      unitRef="Share">100</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220923"
      unitRef="Share">100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220922"
      unitRef="Share">2486</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220924"
      unitRef="Share">2486</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220925"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220926"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220927"
      unitRef="Share">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220928"
      unitRef="Share">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220929"
      unitRef="Share">3834095</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220931"
      unitRef="Share">3834095</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220930"
      unitRef="Share">14992</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220932"
      unitRef="Share">14992</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember"
      id="c80220527">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember"
      id="c80220528">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"
      id="c80220569">P5Y</us-gaap:DebtInstrumentTerm>
    <govx:NumberOfInstitutionalInvestors
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220587"
      unitRef="Pure">2</govx:NumberOfInstitutionalInvestors>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220590"
      unitRef="USD">1200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      id="c80220591">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      id="c80220597">P12M</us-gaap:DebtInstrumentTerm>
    <govx:NumberOfCommonStockSecuritiesCalledByEachUnit
      contextRef="i_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheOneMember"
      decimals="INF"
      id="c80220611"
      unitRef="Share">1</govx:NumberOfCommonStockSecuritiesCalledByEachUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantMember"
      decimals="INF"
      id="c80220612"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <govx:NumberOfWarrantsCalledByEachUnit
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheTwoMember"
      decimals="INF"
      id="c80220614"
      unitRef="Share">1</govx:NumberOfWarrantsCalledByEachUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="INF"
      id="c80220615"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="INF"
      id="c80220616"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember"
      decimals="INF"
      id="c80220619"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember"
      id="c80220621">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220646"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <govx:NumberOfCommonStockSecuritiesCalledByEachUnit
      contextRef="i_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember"
      decimals="INF"
      id="c80220735"
      unitRef="Share">1</govx:NumberOfCommonStockSecuritiesCalledByEachUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c80220736"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="INF"
      id="c80220738"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="INF"
      id="c80220739"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c80220741"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      id="c80220743">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"
      id="c80220749">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <govx:NumberOfCommonStockSecuritiesCalledByEachUnit
      contextRef="i_2020-09-29"
      decimals="INF"
      id="c80220755"
      unitRef="Share">1</govx:NumberOfCommonStockSecuritiesCalledByEachUnit>
    <govx:NumberOfWarrantsCalledByEachUnit
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember"
      decimals="INF"
      id="c80220756"
      unitRef="Share">1</govx:NumberOfWarrantsCalledByEachUnit>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2020-01-01_2020-12-31" id="c80220773">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2020-01-01_2020-12-31" id="c80220774">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c80220778"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      id="c80220791">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType contextRef="d_2021-01-01_2021-09-30">S-1</dei:DocumentType>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2021-01-01_2021-09-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2021-01-01_2021-09-30">87-0455038</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2021-01-01_2021-09-30">1900 Lake Park Drive, Suite 380</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2021-01-01_2021-09-30">Smyrna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2021-01-01_2021-09-30">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2021-01-01_2021-09-30">30080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2021-01-01_2021-09-30">678</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2021-01-01_2021-09-30">384-7220</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="d_2021-01-01_2021-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2021-01-01_2021-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2021-01-01_2021-09-30">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219557"
      unitRef="USD">18107019</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219558"
      unitRef="USD">9883796</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivable
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219559"
      unitRef="USD">0</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219560"
      unitRef="USD">182663</us-gaap:GrantsReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219561"
      unitRef="USD">52818</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219562"
      unitRef="USD">168689</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219563"
      unitRef="USD">18159837</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219564"
      unitRef="USD">10235148</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219565"
      unitRef="USD">168653</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219566"
      unitRef="USD">147741</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssets
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219567"
      unitRef="USD">11010</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219568"
      unitRef="USD">11010</us-gaap:DepositsAssets>
    <us-gaap:Assets
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219569"
      unitRef="USD">18339500</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219570"
      unitRef="USD">10393899</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219571"
      unitRef="USD">289438</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219572"
      unitRef="USD">267702</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219573"
      unitRef="USD">46212</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219574"
      unitRef="USD">359281</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219575"
      unitRef="USD">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219576"
      unitRef="USD">183326</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219577"
      unitRef="USD">335650</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219578"
      unitRef="USD">810309</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219579"
      unitRef="USD">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219580"
      unitRef="USD">14738</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219581"
      unitRef="USD">335650</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219582"
      unitRef="USD">825047</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219583"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219584"
      unitRef="USD">76095</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219585"
      unitRef="USD">6382</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219586"
      unitRef="USD">3834</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219587"
      unitRef="USD">68630363</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219588"
      unitRef="USD">55294504</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219589"
      unitRef="USD">-50632895</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219590"
      unitRef="USD">-45805581</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219591"
      unitRef="USD">18003850</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219592"
      unitRef="USD">9568852</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219593"
      unitRef="USD">18339500</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219594"
      unitRef="USD">10393899</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219603"
      unitRef="USD">30414</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219604"
      unitRef="USD">415458</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219605"
      unitRef="USD">220539</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219606"
      unitRef="USD">1572037</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219607"
      unitRef="USD">1224362</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219608"
      unitRef="USD">416756</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219609"
      unitRef="USD">2659980</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219610"
      unitRef="USD">1687113</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219611"
      unitRef="USD">757432</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219612"
      unitRef="USD">435013</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219613"
      unitRef="USD">2562641</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219614"
      unitRef="USD">1364650</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219615"
      unitRef="USD">1981794</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219616"
      unitRef="USD">851769</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219617"
      unitRef="USD">5222621</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219618"
      unitRef="USD">3051763</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219619"
      unitRef="USD">-1951380</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219620"
      unitRef="USD">-436311</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219621"
      unitRef="USD">-5002082</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219622"
      unitRef="USD">-1479726</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219623"
      unitRef="USD">877</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219624"
      unitRef="USD">90</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219625"
      unitRef="USD">3998</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219626"
      unitRef="USD">902</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219627"
      unitRef="USD">-0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219628"
      unitRef="USD">134427</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219629"
      unitRef="USD">1286</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219630"
      unitRef="USD">142722</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219631"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219632"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219633"
      unitRef="USD">172056</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219634"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219635"
      unitRef="USD">877</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219636"
      unitRef="USD">-134337</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219637"
      unitRef="USD">174768</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219638"
      unitRef="USD">-141820</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219639"
      unitRef="USD">-1950503</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219640"
      unitRef="USD">-570648</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219641"
      unitRef="USD">-4827314</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219642"
      unitRef="USD">-1621546</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219643"
      unitRef="USDPerShare">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219644"
      unitRef="USDPerShare">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219645"
      unitRef="USDPerShare">-0.80</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219646"
      unitRef="USDPerShare">-2.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219647"
      unitRef="Share">6349297</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219648"
      unitRef="Share">782978</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219649"
      unitRef="Share">6005032</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219650"
      unitRef="Share">569955</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219654"
      unitRef="Share">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219655"
      unitRef="USD">76095</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219656"
      unitRef="Share">3834095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219657"
      unitRef="USD">3834</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219658"
      unitRef="USD">55294504</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219659"
      unitRef="USD">-45805581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219660"
      unitRef="USD">9568852</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219661"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219662"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219663"
      unitRef="Share">1644000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219664"
      unitRef="USD">1644</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219665"
      unitRef="USD">9407276</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219666"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c80219667"
      unitRef="USD">9408920</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219668"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219669"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219670"
      unitRef="Share">835900</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219671"
      unitRef="USD">836</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219672"
      unitRef="USD">3173320</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219673"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c80219674"
      unitRef="USD">3174156</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219675"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219676"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219677"
      unitRef="Share">1472</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219678"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219679"
      unitRef="USD">5999</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219680"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c80219681"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219686"
      unitRef="USD">56190</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c80219688"
      unitRef="USD">56190</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219694"
      unitRef="USD">-1562778</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c80219695"
      unitRef="USD">-1562778</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219696"
      unitRef="Share">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219697"
      unitRef="USD">76095</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219698"
      unitRef="Share">6315467</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219699"
      unitRef="USD">6315</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219700"
      unitRef="USD">67937289</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219701"
      unitRef="USD">-47368359</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31"
      decimals="INF"
      id="c80219702"
      unitRef="USD">20651340</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219703"
      unitRef="Share">100</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219704"
      unitRef="USD">76095</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219705"
      unitRef="Share">-0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219706"
      unitRef="USD">-0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219707"
      unitRef="USD">-75095</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219708"
      unitRef="USD">-0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-04-01_2021-06-30"
      decimals="INF"
      id="c80219709"
      unitRef="USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219710"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219711"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219712"
      unitRef="Share">12235</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219713"
      unitRef="USD">13</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219714"
      unitRef="USD">65828</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219715"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-04-01_2021-06-30"
      decimals="INF"
      id="c80219716"
      unitRef="USD">65841</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219718"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219720"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219721"
      unitRef="USD">56190</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219722"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-04-01_2021-06-30"
      decimals="INF"
      id="c80219723"
      unitRef="USD">56190</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219725"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219727"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219728"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219729"
      unitRef="USD">-1314033</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-04-01_2021-06-30"
      decimals="INF"
      id="c80219730"
      unitRef="USD">-1314033</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219731"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219732"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219733"
      unitRef="Share">6327702</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219734"
      unitRef="USD">6328</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219735"
      unitRef="USD">68134402</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219736"
      unitRef="USD">-48682392</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-06-30"
      decimals="INF"
      id="c80219737"
      unitRef="USD">19458338</us-gaap:StockholdersEquity>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219738"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219739"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219740"
      unitRef="Share">53839</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219741"
      unitRef="USD">54</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219742"
      unitRef="USD">229946</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219743"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219744"
      unitRef="USD">230000</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219746"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219748"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219749"
      unitRef="USD">56190</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219750"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219751"
      unitRef="USD">56190</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219753"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219755"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219756"
      unitRef="USD">209825</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219757"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-07-01_2021-09-30_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember"
      decimals="INF"
      id="c80219758"
      unitRef="USD">209825</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219760"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219762"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219763"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-07-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219764"
      unitRef="USD">-1950503</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80219765"
      unitRef="USD">-1950503</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219766"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219767"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219768"
      unitRef="Share">6381541</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219769"
      unitRef="USD">6382</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219770"
      unitRef="USD">68630363</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219771"
      unitRef="USD">-50632895</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219772"
      unitRef="USD">18003850</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219773"
      unitRef="Share">2486</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219774"
      unitRef="USD">1932433</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219775"
      unitRef="Share">14992</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219776"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219777"
      unitRef="USD">39340509</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219778"
      unitRef="USD">-42847513</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219779"
      unitRef="USD">-1574556</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219780"
      unitRef="Share">300</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219781"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c80219786"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219787"
      unitRef="Share">-2386</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219788"
      unitRef="USD">-1856338</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219789"
      unitRef="Share">674067</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219790"
      unitRef="USD">674</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219791"
      unitRef="USD">1855664</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219794"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219795"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219796"
      unitRef="Share">521</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219797"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219798"
      unitRef="USD">5999</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219799"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c80219800"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219806"
      unitRef="USD">-595694</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c80219807"
      unitRef="USD">-595694</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219808"
      unitRef="Share">400</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219809"
      unitRef="USD">376095</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219810"
      unitRef="Share">689580</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219811"
      unitRef="USD">690</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219812"
      unitRef="USD">41202172</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219813"
      unitRef="USD">-43443207</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31"
      decimals="INF"
      id="c80219814"
      unitRef="USD">-1864250</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219815"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219816"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219817"
      unitRef="Share">2124</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219818"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219819"
      unitRef="USD">11998</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219820"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-04-01_2020-06-30"
      decimals="INF"
      id="c80219821"
      unitRef="USD">12000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219823"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219825"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219826"
      unitRef="USD">457833</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219827"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember"
      decimals="INF"
      id="c80219828"
      unitRef="USD">457833</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219830"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219832"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219833"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219834"
      unitRef="USD">-455204</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30"
      decimals="INF"
      id="c80219835"
      unitRef="USD">-455204</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219836"
      unitRef="Share">400</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219837"
      unitRef="USD">376095</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219838"
      unitRef="Share">691704</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219839"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219840"
      unitRef="USD">41672003</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219841"
      unitRef="USD">-43898411</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30"
      decimals="INF"
      id="c80219842"
      unitRef="USD">-1849621</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219843"
      unitRef="Share">-300</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219844"
      unitRef="USD">-300000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219845"
      unitRef="Share">42723</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219846"
      unitRef="USD">43</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219847"
      unitRef="USD">299957</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219848"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219849"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219850"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219851"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantsExercised>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219852"
      unitRef="Share">36902</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219853"
      unitRef="USD">37</govx:StockIssuedDuringPeriodValueWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219854"
      unitRef="USD">-37</govx:StockIssuedDuringPeriodValueWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219855"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219856"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219857"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219858"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219859"
      unitRef="Share">177626</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219860"
      unitRef="USD">177</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219861"
      unitRef="USD">569340</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219862"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-07-01_2020-09-30_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80219863"
      unitRef="USD">569517</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219864"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219865"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219866"
      unitRef="Share">300001</govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219867"
      unitRef="USD">300</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219868"
      unitRef="USD">1499700</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219869"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219870"
      unitRef="USD">1500000</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219871"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219872"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219873"
      unitRef="Share">2310000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219874"
      unitRef="USD">2310</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219875"
      unitRef="USD">11156186</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219876"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219877"
      unitRef="USD">11158496</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219878"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219879"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219880"
      unitRef="Share">517</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219881"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219882"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219883"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219884"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219886"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219888"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219889"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-07-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219890"
      unitRef="USD">-570648</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80219891"
      unitRef="USD">-570648</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219892"
      unitRef="Share">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80219893"
      unitRef="USD">76095</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219894"
      unitRef="Share">3559473</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80219895"
      unitRef="USD">3559</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80219896"
      unitRef="USD">55203149</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80219897"
      unitRef="USD">-44469059</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-09-30"
      decimals="INF"
      id="c80219898"
      unitRef="USD">10813744</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219899"
      unitRef="USD">-4827314</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219900"
      unitRef="USD">-1621546</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219901"
      unitRef="USD">26806</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219902"
      unitRef="USD">2983</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-09-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember"
      decimals="INF"
      id="c80219903"
      unitRef="USD">168570</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-09-30_TitleOfIndividualAxis-EmployeesAndDirectorsMember"
      decimals="INF"
      id="c80219904"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-09-30_TitleOfIndividualAxis-ConsultantsMember"
      decimals="INF"
      id="c80219905"
      unitRef="USD">80733</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-09-30_TitleOfIndividualAxis-ConsultantsMember"
      decimals="INF"
      id="c80219906"
      unitRef="USD">24000</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219907"
      unitRef="USD">209825</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219908"
      unitRef="USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219909"
      unitRef="USD">172056</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219910"
      unitRef="USD">-0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219911"
      unitRef="USD">-182663</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219912"
      unitRef="USD">72551</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219913"
      unitRef="USD">-106979</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219914"
      unitRef="USD">-82274</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219915"
      unitRef="USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219916"
      unitRef="USD">124185</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219917"
      unitRef="USD">-289477</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219918"
      unitRef="USD">252036</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219919"
      unitRef="USD">314043</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219920"
      unitRef="USD">412927</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219921"
      unitRef="USD">-4513271</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219922"
      unitRef="USD">-1208619</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219923"
      unitRef="USD">47718</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219924"
      unitRef="USD">2470</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219925"
      unitRef="USD">-47718</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219926"
      unitRef="USD">-2470</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <govx:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219927"
      unitRef="USD">9408920</govx:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <govx:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219928"
      unitRef="USD">11158496</govx:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219929"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219930"
      unitRef="USD">300000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219931"
      unitRef="USD">3404156</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219932"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219933"
      unitRef="USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219934"
      unitRef="USD">888500</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219935"
      unitRef="USD">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219936"
      unitRef="USD">170200</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219937"
      unitRef="USD">1000</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219938"
      unitRef="USD">-0</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219939"
      unitRef="USD">27864</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219940"
      unitRef="USD">8854</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219941"
      unitRef="USD">12784212</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219942"
      unitRef="USD">12508342</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80219943"
      unitRef="USD">8223223</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80219944"
      unitRef="USD">11297253</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219945"
      unitRef="USD">9883796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219946"
      unitRef="USD">283341</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80219947"
      unitRef="USD">18107019</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-09-30"
      decimals="INF"
      id="c80219948"
      unitRef="USD">11580594</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations contextRef="d_2021-01-01_2021-09-30" id="c2016481">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Description of Business &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax&#x2019;s Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) based platform utilizes MVA, a large virus capable of carrying several vaccine antigens, to express proteins that assemble into highly effective virus-like particle (VLP) immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;GeoVax&#x2019;s MVA-VLP development programs are focused primarily on preventive vaccines against the SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; virus (COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt;) and immunotherapies for solid tumor cancers. Other development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), Human Immunodeficiency Virus (HIV), and malaria. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; September 28, 2021, &lt;/em&gt;GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc., whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#xae;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase &lt;em style="font: inherit;"&gt;1/2&lt;/em&gt; clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#x2019;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, cancers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.&lt;/p&gt;
  </us-gaap:NatureOfOperations>
    <us-gaap:BasisOfAccounting contextRef="d_2021-01-01_2021-09-30" id="c2016482">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying condensed consolidated financial statements at &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;and for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be relied upon as predictive of the results in future periods.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We enacted reverse stock splits of our common stock on &lt;em style="font: inherit;"&gt; September 25, 2020 (&lt;/em&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-20) and on &lt;em style="font: inherit;"&gt; January 21, 2020 (&lt;/em&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-2,000). The accompanying financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for at least the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;-month period following the issue date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek additional capital through arrangements with strategic partners or from other sources. There can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;&lt;/p&gt;
  </us-gaap:BasisOfAccounting>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c80220371"
      unitRef="Pure">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c80220373"
      unitRef="Pure">2000</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016483">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Significant Accounting Policies and Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We disclosed in Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; to our consolidated financial statements included in our Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;those accounting policies that we consider significant in determining our results of operations and financial position. During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; material changes to, or in the application of, the accounting policies previously identified and described in the Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K, and there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; other recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements.&lt;/p&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016484">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Basic and Diluted Loss Per Common Share&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share totaled 2,965,451 and 2,550,184 shares for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;respectively, as compared to 204,553 and 78,754 shares for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2020, &lt;/em&gt;respectively.&lt;/p&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80220384"
      unitRef="Share">2965451</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80220385"
      unitRef="Share">2550184</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80220388"
      unitRef="Share">204553</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80220389"
      unitRef="Share">78754</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016485">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2020:&lt;/em&gt;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;September 30, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Equipment and furnishings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;591,554&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;543,836&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;707,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;659,441&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(538,506&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(511,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;168,653&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;147,741&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016486">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;September 30, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Equipment and furnishings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;591,554&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;543,836&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;707,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;659,441&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(538,506&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(511,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;168,653&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;147,741&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember"
      decimals="INF"
      id="c80220207"
      unitRef="USD">591554</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember"
      decimals="INF"
      id="c80220208"
      unitRef="USD">543836</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="INF"
      id="c80220209"
      unitRef="USD">115605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="INF"
      id="c80220210"
      unitRef="USD">115605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220211"
      unitRef="USD">707159</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220212"
      unitRef="USD">659441</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220213"
      unitRef="USD">538506</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220214"
      unitRef="USD">511700</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220215"
      unitRef="USD">168653</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220216"
      unitRef="USD">147741</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016487">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2020:&lt;/em&gt;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;September 30, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued salaries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;11,212&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;279,696&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;35,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;79,585&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;46,212&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;359,281&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016488">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;September 30, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued salaries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;11,212&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;279,696&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;35,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;79,585&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;46,212&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;359,281&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220217"
      unitRef="USD">11212</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220218"
      unitRef="USD">279696</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220219"
      unitRef="USD">35000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220220"
      unitRef="USD">79585</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220221"
      unitRef="USD">46212</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220222"
      unitRef="USD">359281</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016489">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Notes Payable&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;GRA Note&lt;/i&gt; &#x2013; On &lt;em style="font: inherit;"&gt; February 28, 2018, &lt;/em&gt;we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a &lt;span style="-sec-ix-hidden:c80220395"&gt;five&lt;/span&gt;-year Senior Promissory Note (the &#x201c;GRA Note&#x201d;) to GRA in exchange for $50,000. The GRA Note bore an annual interest rate of &lt;span style="-sec-ix-hidden:c80220397"&gt;five&lt;/span&gt; percent. Interest expense related to the GRA Note for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;was $-0- and $633, respectively, as compared to $411 and $1,344, respectively, for the same periods of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; During &lt;em style="font: inherit;"&gt; May 2021, &lt;/em&gt;we repaid the remaining principal balance of $22,737 and retired the GRA Note.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;CARES Act Paycheck Protection Program Loan &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;On &lt;em style="font: inherit;"&gt; April 17, 2020, &lt;/em&gt;we received a $170,200 bank loan backed by the United States Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bore an annual interest rate of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; percent. We recorded accrued interest expense related to the PPP Loan of $-0- and $653 for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;respectively, as compared to $429 and $774, respectively, for the same periods of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; During &lt;em style="font: inherit;"&gt; May 2021, &lt;/em&gt;upon receiving payment from the SBA, the lender forgave the full principal balance of $170,200 together with $1,856 of accrued interest and extinguished the PPP Loan.&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220396"
      unitRef="USD">50000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2021-07-01_2021-09-30_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="-3"
      id="c80220400"
      unitRef="USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2021-01-01_2021-09-30_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220401"
      unitRef="USD">633</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-07-01_2020-09-30_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220402"
      unitRef="USD">411</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-01-01_2020-09-30_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220403"
      unitRef="USD">1344</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="d_2021-05-01_2021-05-31_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220405"
      unitRef="USD">22737</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c80220406"
      unitRef="USD">170200</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2021-07-01_2021-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="-3"
      id="c80220408"
      unitRef="USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2021-01-01_2021-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c80220409"
      unitRef="USD">653</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-07-01_2020-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c80220412"
      unitRef="USD">429</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-01-01_2020-09-30_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c80220413"
      unitRef="USD">774</us-gaap:InterestExpenseDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c80220415"
      unitRef="USD">170200</us-gaap:ExtinguishmentOfDebtAmount>
    <govx:GainLossFromInterestForgiven
      contextRef="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c80220416"
      unitRef="USD">1856</govx:GainLossFromInterestForgiven>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016490">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Commitments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Lease Agreement&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on &lt;em style="font: inherit;"&gt; December 31, 2022. &lt;/em&gt;Rent expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;was $42,803 and $128,410, respectively, as compared to $41,539 and $124,617, respectively, for the same periods of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; Future minimum lease payments total $42,803 for the remainder of &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and $176,356 in &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; although the lease &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated at any time by either party with &lt;em style="font: inherit;"&gt;ninety&lt;/em&gt; days&#x2019; written notice.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Other Commitments&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;there are approximately $607,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;/p&gt;
  </us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c80220418"
      unitRef="SquareFoot">8400</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2021-07-01_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c80220421"
      unitRef="USD">42803</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2021-01-01_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c80220422"
      unitRef="USD">128410</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2020-07-01_2020-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c80220423"
      unitRef="USD">41539</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2020-01-01_2020-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c80220424"
      unitRef="USD">124617</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c80220426"
      unitRef="USD">42803</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c80220428"
      unitRef="USD">176356</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220431"
      unitRef="USD">607000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:PreferredStockTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016491">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Stockholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Preferred Stock &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;On &lt;em style="font: inherit;"&gt; June 7, 2021, &lt;/em&gt;we repurchased the remaining 100 shares of our Series B Convertible Preferred Stock for a total price of $1,000. As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;there are no shares of our preferred stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Public Offering &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;On &lt;em style="font: inherit;"&gt; February 11, 2021, &lt;/em&gt;we closed an underwritten public offering of 1,644,000 shares of our common stock, including 204,000 shares sold pursuant to the full exercise of the underwriter&#x2019;s option to purchase additional shares, at a price to the public of $6.25 per share. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $9.4 million. Additionally, we issued to the underwriter, as a portion of the underwriting compensation, warrants to purchase 72,000 shares of our common stock at an exercise price of $6.875 per share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock Options &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;We have a stock-based incentive plan (the &lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Plan&#x201d;) pursuant to which our Board of Directors &lt;em style="font: inherit;"&gt; may &lt;/em&gt;grant stock options and other stock-based awards to our employees, directors and consultants. A total of 1,500,000 shares of our common stock are reserved for issuance pursuant to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan. During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;there were &lt;span style="-sec-ix-hidden:c80220447"&gt;no&lt;/span&gt; stock option transactions related to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan. As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;there were 602,000 stock options outstanding, with a weighted-average exercise price of $2.79 per share and a weighted-average remaining term of 9.2 years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock Purchase Warrants &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;During &lt;em style="font: inherit;"&gt; January &lt;/em&gt;and &lt;em style="font: inherit;"&gt; February 2021, &lt;/em&gt;188,688 stock purchase warrants were exercised on a cashless basis, resulting in the issuance of 145,866 shares of our common stock, and 690,034 stock purchase warrants were exercised for cash, resulting in the issuance of 690,034 shares of our common stock for net proceeds to us of $3,174,156.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During &lt;em style="font: inherit;"&gt; August 2021, &lt;/em&gt;27,004 stock purchase warrants were exercised on a cashless basis, resulting in the issuance of 3,839 shares of our common stock, and 50,000 stock purchase warrants were exercised for cash, resulting in the issuance of 50,000 shares of our common stock for net proceeds to us of $230,000.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; September 28, 2021, &lt;/em&gt;in connection with our entering into an Assignment and License Agreement with PNP Therapeutics, Inc. (PNP) we issued a &lt;span style="-sec-ix-hidden:c80220462"&gt;five&lt;/span&gt;-year stock purchase warrant to PNP for 100,000 shares of our common stock at an exercise price of $13.00 per share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;there are 2,816,631 stock purchase warrants outstanding, with a weighted-average exercise price of $5.35 per share and a weighted-average remaining term of 3.9 years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Other Common Stock Transactions&lt;/i&gt; &#x2013; During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;we issued 13,707 shares of our common stock pursuant to consulting agreements.&lt;/p&gt;
  </us-gaap:PreferredStockTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="d_2021-06-07_2021-06-07_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220434"
      unitRef="Share">100</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-06-07_2021-06-07_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220435"
      unitRef="USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220436"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-02-11_2021-02-11"
      decimals="INF"
      id="c80220437"
      unitRef="Share">1644000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-02-11_2021-02-11_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c80220438"
      unitRef="Share">204000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-02-11"
      decimals="INF"
      id="c80220439"
      unitRef="USDPerShare">6.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-02-11_2021-02-11"
      decimals="-5"
      id="c80220440"
      unitRef="USD">9400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"
      decimals="INF"
      id="c80220441"
      unitRef="Share">72000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"
      decimals="INF"
      id="c80220442"
      unitRef="USDPerShare">6.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2021-09-30_PlanNameAxis-StockIncentivePlan2020Member"
      decimals="INF"
      id="c80220444"
      unitRef="Share">1500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220449"
      unitRef="Share">602000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220450"
      unitRef="USDPerShare">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2021-01-01_2021-09-30" id="c80220451">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"
      decimals="INF"
      id="c80220452"
      unitRef="Share">188688</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"
      decimals="INF"
      id="c80220453"
      unitRef="Share">145866</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember"
      decimals="INF"
      id="c80220454"
      unitRef="Share">690034</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-02-01_2021-02-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember"
      decimals="INF"
      id="c80220455"
      unitRef="Share">690034</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-02-01_2021-02-28"
      decimals="INF"
      id="c80220456"
      unitRef="USD">3174156</us-gaap:ProceedsFromWarrantExercises>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"
      decimals="INF"
      id="c80220457"
      unitRef="Share">27004</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"
      decimals="INF"
      id="c80220458"
      unitRef="Share">3839</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember"
      decimals="INF"
      id="c80220459"
      unitRef="Share">50000</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsSecondIssuanceMember"
      decimals="INF"
      id="c80220460"
      unitRef="Share">50000</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-08-01_2021-08-31"
      decimals="INF"
      id="c80220461"
      unitRef="USD">230000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantToPnpMember"
      decimals="INF"
      id="c80220463"
      unitRef="Share">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-StockPurchaseWarrantToPnpMember"
      decimals="INF"
      id="c80220464"
      unitRef="USDPerShare">13.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-09-30_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"
      decimals="INF"
      id="c80220465"
      unitRef="Share">2816631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-09-30_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"
      decimals="INF"
      id="c80220466"
      unitRef="USDPerShare">5.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2021-09-30_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"
      id="c80220467">P3Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80220469"
      unitRef="Share">13707</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016492">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Stock-Based Expense&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Stock-based compensation expense related to employee and director stock options was $56,190 and $168,570 during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;respectively; there was no stock-based compensation expense related to employee stock options during the comparable periods of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; Stock-based compensation expense related to stock options is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the related employee classification. As of &lt;em style="font: inherit;"&gt; September&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there is $486,940 of unrecognized compensation expense that we expect to recognize over a weighted-average period of 2.2 years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;we recorded stock-based compensation expense of $29,560 and $80,733, respectively, associated with common stock issued for consulting services, as compared to $6,000 and $24,000, respectively, during the comparable periods of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;there is $39,773 recorded as a prepaid expense for these arrangements, which will be recognized as expense over the remaining terms of the related agreements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During &lt;em style="font: inherit;"&gt; September 2021, &lt;/em&gt;we recorded $209,825 of expense associated with the issuance of a stock purchase warrant to PNP in connection with our entering into a technology licensing agreement; such amount was recorded as research and development expense.&lt;/p&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-07-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c80220471"
      unitRef="USD">56190</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c80220472"
      unitRef="USD">168570</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-07-01_2020-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c80220475"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220479"
      unitRef="USD">486940</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2021-01-01_2021-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c80220480">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c80220483"
      unitRef="USD">29560</govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices>
    <govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c80220484"
      unitRef="USD">80733</govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices>
    <govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c80220485"
      unitRef="USD">6000</govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices>
    <govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c80220486"
      unitRef="USD">24000</govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices>
    <govx:PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220488"
      unitRef="USD">39773</govx:PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod>
    <govx:WarrantIssuanceExpense
      contextRef="d_2021-09-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="c80220489"
      unitRef="USD">209825</govx:WarrantIssuanceExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016493">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Because of our historically significant net operating losses, we have &lt;span style="-sec-ix-hidden:c80220491"&gt;not&lt;/span&gt; paid income taxes since inception. We maintain deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets are comprised primarily of net operating loss carryforwards and also include amounts relating to nonqualified stock options and research and development credits. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of our future profitability and our ability to utilize the deferred tax assets. Utilization of operating losses and credits will be subject to substantial annual limitations due to ownership change provisions of Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; of the Internal Revenue Code. The annual limitation &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in the expiration of net operating losses and credits before utilization.&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <govx:GovernmentGrantsandContractsTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016494">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Grants and Collaboration Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;we recorded $30,414 and $220,539, respectively, of revenues associated with these grants, as compared to $231,330 and $1,186,844, respectively, for the comparable periods of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; September 30, 2020, &lt;/em&gt;we also recorded $184,128 and $385,193, respectively, of revenues associated with research collaboration agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties. As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;there is an aggregate of $244,888 in approved grant funds available for use through mid-&lt;em style="font: inherit;"&gt;2022.&lt;/em&gt;&lt;/p&gt;
  </govx:GovernmentGrantsandContractsTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-07-01_2021-09-30_ProductOrServiceAxis-NIHGrantsMember"
      decimals="INF"
      id="c80220496"
      unitRef="USD">30414</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-09-30_ProductOrServiceAxis-NIHGrantsMember"
      decimals="INF"
      id="c80220497"
      unitRef="USD">220539</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-07-01_2020-09-30_ProductOrServiceAxis-NIHGrantsMember"
      decimals="INF"
      id="c80220498"
      unitRef="USD">231330</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-09-30_ProductOrServiceAxis-NIHGrantsMember"
      decimals="INF"
      id="c80220499"
      unitRef="USD">1186844</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-07-01_2020-09-30_ProductOrServiceAxis-LeidosIncResearchCollaborativeAgreementMember"
      decimals="INF"
      id="c80220503"
      unitRef="USD">184128</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-09-30_ProductOrServiceAxis-LeidosIncResearchCollaborativeAgreementMember"
      decimals="INF"
      id="c80220504"
      unitRef="USD">385193</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <govx:UnusedGrantFunds
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c80220506"
      unitRef="USD">244888</govx:UnusedGrantFunds>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2016495">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Subsequent Event&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; November 9, 2021, &lt;/em&gt;we entered into an Exclusive License Agreement the (&#x201c;License Agreement&#x201d;) with City of Hope (&#x201c;COH&#x201d;) under which we obtained exclusive worldwide rights to key patents, know-how, regulatory filings and clinical materials related to COH&#x2019;s COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; vaccine program, currently undergoing human clinical trials. We will pay an upfront fee to COH of $5,000,000 within &lt;em style="font: inherit;"&gt;30&lt;/em&gt; days of the effective date of the License Agreement and are obligated to pay additional fees of $3,000,000 and $2,000,000 on the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; and &lt;em style="font: inherit;"&gt;second&lt;/em&gt; anniversaries, respectively, of the effective date of the License Agreement. We will also pay COH milestone fees based on achievement of success-based development and regulatory milestones, and annual royalties on net sales of products covered by the License Agreement.&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <govx:UpfrontFee
      contextRef="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220510"
      unitRef="USD">5000000</govx:UpfrontFee>
    <govx:LicenseFees
      contextRef="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_ProductOrServiceAxis-LicenseFirstAnniversaryPaymentMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220512"
      unitRef="USD">3000000</govx:LicenseFees>
    <govx:LicenseFees
      contextRef="d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_ProductOrServiceAxis-LicenseSecondAnniversaryPaymentMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220513"
      unitRef="USD">2000000</govx:LicenseFees>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219954"
      unitRef="USD">9883796</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219955"
      unitRef="USD">283341</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivable
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219956"
      unitRef="USD">182663</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219957"
      unitRef="USD">68603</us-gaap:GrantsReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219958"
      unitRef="USD">168689</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219959"
      unitRef="USD">95320</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219960"
      unitRef="USD">10235148</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219961"
      unitRef="USD">447264</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219962"
      unitRef="USD">147741</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219963"
      unitRef="USD">10606</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219964"
      unitRef="USD">11010</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219965"
      unitRef="USD">11010</us-gaap:DepositsAssets>
    <us-gaap:Assets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219966"
      unitRef="USD">10393899</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219967"
      unitRef="USD">468880</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219968"
      unitRef="USD">267702</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219969"
      unitRef="USD">152653</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219970"
      unitRef="USD">359281</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219971"
      unitRef="USD">1851040</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219972"
      unitRef="USD">183326</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219973"
      unitRef="USD">12500</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219974"
      unitRef="USD">810309</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219975"
      unitRef="USD">2016193</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219976"
      unitRef="USD">14738</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219977"
      unitRef="USD">27243</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219978"
      unitRef="USD">825047</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219979"
      unitRef="USD">2043436</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219980"
      unitRef="USD">76095</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219981"
      unitRef="USD">1932433</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219982"
      unitRef="USD">3834</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219983"
      unitRef="USD">15</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219984"
      unitRef="USD">55294504</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219985"
      unitRef="USD">39340509</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219986"
      unitRef="USD">-45805581</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219987"
      unitRef="USD">-42847513</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219988"
      unitRef="USD">9568852</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219989"
      unitRef="USD">-1574556</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80219990"
      unitRef="USD">10393899</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80219991"
      unitRef="USD">468880</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220002"
      unitRef="USD">1823658</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220003"
      unitRef="USD">1175896</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220004"
      unitRef="USD">2444459</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220005"
      unitRef="USD">1910715</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220006"
      unitRef="USD">2196014</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220007"
      unitRef="USD">1637674</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220008"
      unitRef="USD">4640473</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220009"
      unitRef="USD">3548389</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220010"
      unitRef="USD">-2816815</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220011"
      unitRef="USD">-2372493</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220012"
      unitRef="USD">2271</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220013"
      unitRef="USD">6359</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220014"
      unitRef="USD">143524</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220015"
      unitRef="USD">4495</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220016"
      unitRef="USD">-141253</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220017"
      unitRef="USD">1864</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220018"
      unitRef="USD">-2958068</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220019"
      unitRef="USD">-2370629</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220020"
      unitRef="USDPerShare">-2.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220021"
      unitRef="USDPerShare">-781.87</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220022"
      unitRef="Share">1383829</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220023"
      unitRef="Share">3032</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220027"
      unitRef="Share">3450</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220028"
      unitRef="USD">1971333</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220029"
      unitRef="Share">11</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220030"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220031"
      unitRef="USD">37483204</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220032"
      unitRef="USD">-40476884</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31"
      decimals="INF"
      id="c80220033"
      unitRef="USD">-1022347</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220034"
      unitRef="Share">1700</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220035"
      unitRef="USD">1542950</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220036"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220037"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220038"
      unitRef="USD">147050</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220039"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220040"
      unitRef="USD">1690000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220041"
      unitRef="Share">-2664</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220042"
      unitRef="USD">-1581850</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220043"
      unitRef="Share">14819</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220044"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220045"
      unitRef="USD">1581835</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220046"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220047"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220048"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220049"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220050"
      unitRef="Share">162</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220051"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220052"
      unitRef="USD">24000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220053"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220054"
      unitRef="USD">24000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220056"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220058"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220059"
      unitRef="USD">104420</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220060"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220061"
      unitRef="USD">104420</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220063"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220065"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220066"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220067"
      unitRef="USD">-2370629</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220068"
      unitRef="USD">-2370629</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220069"
      unitRef="Share">2486</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220070"
      unitRef="USD">1932433</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220071"
      unitRef="Share">14992</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220072"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220073"
      unitRef="USD">39340509</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220074"
      unitRef="USD">-42847513</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220075"
      unitRef="USD">-1574556</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220076"
      unitRef="Share">300</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220077"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220078"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220079"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220080"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220081"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220082"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220083"
      unitRef="Share">-2686</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220084"
      unitRef="USD">-2156338</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220085"
      unitRef="Share">716790</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220086"
      unitRef="USD">717</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220087"
      unitRef="USD">2155621</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220088"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220089"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220091"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220093"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220094"
      unitRef="USD">457833</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220095"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220096"
      unitRef="USD">457833</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220097"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220098"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220099"
      unitRef="Share">286902</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220100"
      unitRef="USD">287</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220101"
      unitRef="USD">2213</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220102"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220103"
      unitRef="USD">2500</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodSharesDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220104"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220105"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodSharesDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220106"
      unitRef="Share">177626</govx:StockIssuedDuringPeriodSharesDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220107"
      unitRef="USD">177</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220108"
      unitRef="USD">569340</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220109"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220110"
      unitRef="USD">569517</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220111"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220112"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220113"
      unitRef="Share">300001</govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220114"
      unitRef="USD">300</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220115"
      unitRef="USD">1499700</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220116"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220117"
      unitRef="USD">1500000</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220118"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220119"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220120"
      unitRef="Share">2310000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220121"
      unitRef="USD">2310</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220122"
      unitRef="USD">11156186</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220123"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220124"
      unitRef="USD">11158496</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220125"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220126"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220127"
      unitRef="Share">26581</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220128"
      unitRef="USD">27</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220129"
      unitRef="USD">94373</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220130"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220131"
      unitRef="USD">94400</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220133"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220135"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220136"
      unitRef="USD">18730</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220137"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220138"
      unitRef="USD">18730</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220139"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="0"
      id="c80220140"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220141"
      unitRef="Share">1203</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c80220142"
      unitRef="USD">1</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220143"
      unitRef="USD">-1</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c80220144"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31"
      decimals="0"
      id="c80220145"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220147"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220149"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220150"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220151"
      unitRef="USD">-2958068</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220152"
      unitRef="USD">-2958068</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220153"
      unitRef="Share">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c80220154"
      unitRef="USD">76095</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220155"
      unitRef="Share">3834095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c80220156"
      unitRef="USD">3834</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c80220157"
      unitRef="USD">55294504</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c80220158"
      unitRef="USD">-45805581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220159"
      unitRef="USD">9568852</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220160"
      unitRef="USD">-2958068</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220161"
      unitRef="USD">-2370629</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220162"
      unitRef="USD">19656</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220163"
      unitRef="USD">8350</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220164"
      unitRef="USD">124185</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220165"
      unitRef="USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220166"
      unitRef="USD">64463</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220167"
      unitRef="USD">327500</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220168"
      unitRef="USD">114060</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220169"
      unitRef="USD">-53211</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220170"
      unitRef="USD">24702</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220171"
      unitRef="USD">56211</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220172"
      unitRef="USD">137956</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220173"
      unitRef="USD">639282</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220174"
      unitRef="USD">207498</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220175"
      unitRef="USD">972132</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220176"
      unitRef="USD">-2750570</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220177"
      unitRef="USD">-1398497</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220178"
      unitRef="USD">156791</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220179"
      unitRef="USD">7606</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220180"
      unitRef="USD">-156791</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220181"
      unitRef="USD">-7606</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220182"
      unitRef="USD">300000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220183"
      unitRef="USD">1440000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220184"
      unitRef="USD">170200</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220185"
      unitRef="USD">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220186"
      unitRef="USD">888500</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220187"
      unitRef="USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <govx:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220188"
      unitRef="USD">11158496</govx:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <govx:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220189"
      unitRef="USD">0</govx:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220190"
      unitRef="USD">2500</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220191"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220192"
      unitRef="USD">11880</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220193"
      unitRef="USD">10257</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220194"
      unitRef="USD">12507816</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220195"
      unitRef="USD">1429743</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220196"
      unitRef="USD">9600455</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220197"
      unitRef="USD">23640</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220198"
      unitRef="USD">283341</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2018-12-31"
      decimals="INF"
      id="c80220199"
      unitRef="USD">259701</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220200"
      unitRef="USD">9883796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220201"
      unitRef="USD">283341</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations contextRef="d_2020-01-01_2020-12-31" id="c2016496">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Description of Business&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or &#x201c;GV-MVA-VLP&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;TM&lt;/sup&gt;&#x201d;). In this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into highly effective VLP immunogens in the person being vaccinated. The MVA-VLP virus replicates to high titers in approved avian cells for manufacturing but cannot productively replicate in mammalian cells. Therefore, the MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live attenuated virus, while providing the safety characteristics of a replication-defective vector.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our current development programs are focused on preventive vaccines against novel coronavirus (COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt;), Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as immunotherapies for HIV and solid tumor cancers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our corporate strategy is to advance, protect and exploit our differentiated vaccine immunotherapy platform leading to the successful development of preventive and therapeutic vaccines against infectious diseases and various cancers. With our design and development capabilities, we are progressing and validating an array of cancer and infectious disease immunotherapy and vaccine product candidates. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more potential strategic partners.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.&lt;/p&gt;
  </us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016497">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note &lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;-month period following the issue date of these consolidated financial statements.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from government grants and clinical trial assistance, corporate and academic collaborations, and from sales of our equity securities. We believe that our existing cash resources together with current government funding commitments, will be sufficient to continue our planned operations into &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek additional capital through arrangements with strategic partners or from other sources. There can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from those estimates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We consider all highly liquid investments with a maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Fair Value of Financial Instruments and Concentration of Credit Risk&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from &lt;span style="-sec-ix-hidden:c80220527"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c80220528"&gt;five&lt;/span&gt; years. We amortize leasehold improvements using the straight-line method over the term of the related lease.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02,&lt;/em&gt; &lt;i&gt;Leases&lt;/i&gt; (ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt;), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months, we made an accounting policy election to &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be&lt;b&gt; &lt;/b&gt;recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been billed by our &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 1,001,948 and 558 shares at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize revenue in accordance with FASB Accounting Standards Update &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (ASU &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;), which created a new Topic, Accounting Standards Codification Topic &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; The standard is principle-based and provides a &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Grant revenue&lt;/i&gt; &#x2013; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Research collaborations&lt;/i&gt; &#x2013; From time to time, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; and revenue is recognized accordingly.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Research and Development Expense&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.&lt;b&gt; &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Period-to-Period Comparisons&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be relied upon as predictive of the results for future periods.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of the deferred tax assets will be realized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#x2019;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; for additional stock-based compensation information.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Other Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Except as discussed above, there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet effective, accounting standards if currently adopted would have a material effect on our financial statements.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222139">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222140">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note &lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;-month period following the issue date of these consolidated financial statements.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from government grants and clinical trial assistance, corporate and academic collaborations, and from sales of our equity securities. We believe that our existing cash resources together with current government funding commitments, will be sufficient to continue our planned operations into &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek additional capital through arrangements with strategic partners or from other sources. There can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2020-01-01_2020-12-31" id="c80222141">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from those estimates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222142">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We consider all highly liquid investments with a maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2020-01-01_2020-12-31" id="c80222143">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Fair Value of Financial Instruments and Concentration of Credit Risk&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222144">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from &lt;span style="-sec-ix-hidden:c80220527"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c80220528"&gt;five&lt;/span&gt; years. We amortize leasehold improvements using the straight-line method over the term of the related lease.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02,&lt;/em&gt; &lt;i&gt;Leases&lt;/i&gt; (ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt;), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months, we made an accounting policy election to &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222145">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be&lt;b&gt; &lt;/b&gt;recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <govx:AccruedLiabilitiesPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222146">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been billed by our &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</govx:AccruedLiabilitiesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222147">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 1,001,948 and 558 shares at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220542"
      unitRef="Share">1001948</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220543"
      unitRef="Share">558</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222150">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize revenue in accordance with FASB Accounting Standards Update &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (ASU &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;), which created a new Topic, Accounting Standards Codification Topic &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; The standard is principle-based and provides a &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Grant revenue&lt;/i&gt; &#x2013; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Research collaborations&lt;/i&gt; &#x2013; From time to time, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; and revenue is recognized accordingly.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2020-01-01_2020-12-31" id="c80222151">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Research and Development Expense&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2020-01-01_2020-12-31" id="c80222152">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.&lt;b&gt; &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2020-01-01_2020-12-31" id="c80222153">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Period-to-Period Comparisons&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be relied upon as predictive of the results for future periods.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222154">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of the deferred tax assets will be realized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2020-01-01_2020-12-31" id="c80222155">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#x2019;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; for additional stock-based compensation information.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c80222156">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Other Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Except as discussed above, there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet effective, accounting standards if currently adopted would have a material effect on our financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016498">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;532,100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;534,577&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other furniture, fixtures &amp;amp; equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,736&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,736&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;659,441&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;661,918&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(511,700&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(651,312&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;147,741&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,606&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Depreciation expense was $19,656&#160;and $8,350 during the years ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively.&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016499">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;532,100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;534,577&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other furniture, fixtures &amp;amp; equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,736&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,736&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;659,441&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;661,918&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(511,700&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(651,312&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;147,741&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,606&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="INF"
      id="c80220223"
      unitRef="USD">532100</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="INF"
      id="c80220224"
      unitRef="USD">534577</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="INF"
      id="c80220225"
      unitRef="USD">115605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="INF"
      id="c80220226"
      unitRef="USD">115605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OtherFurnitureFixturesAndEquipmentMember"
      decimals="INF"
      id="c80220227"
      unitRef="USD">11736</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-OtherFurnitureFixturesAndEquipmentMember"
      decimals="INF"
      id="c80220228"
      unitRef="USD">11736</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220229"
      unitRef="USD">659441</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220230"
      unitRef="USD">661918</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220231"
      unitRef="USD">511700</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220232"
      unitRef="USD">651312</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220233"
      unitRef="USD">147741</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220234"
      unitRef="USD">10606</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220563"
      unitRef="USD">19656</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220564"
      unitRef="USD">8350</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016500">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued salaries and directors&#x2019; fees&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;279,696&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,732,702&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;79,585&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;118,338&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;359,281&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,851,040&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016501">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued salaries and directors&#x2019; fees&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;279,696&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,732,702&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;79,585&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;118,338&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;359,281&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,851,040&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220235"
      unitRef="USD">279696</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220236"
      unitRef="USD">1732702</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220237"
      unitRef="USD">79585</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220238"
      unitRef="USD">118338</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220239"
      unitRef="USD">359281</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220240"
      unitRef="USD">1851040</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016502">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Notes Payable&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;GRA Note&lt;/i&gt; &#x2013; On &lt;em style="font: inherit;"&gt; February 28, 2018, &lt;/em&gt;we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a &lt;span style="-sec-ix-hidden:c80220569"&gt;five&lt;/span&gt;-year Senior Promissory Note (the &#x201c;GRA Note&#x201d;) to GRA in exchange for $50,000. The GRA Note bears an annual interest rate of 5%, payable monthly, with principal repayments beginning in the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; year. Future principal repayments are expected to be $12,487 in &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; $13,126 &lt;em style="font: inherit;"&gt;in2022,&lt;/em&gt; and $2,252 in &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; Interest expense related to the GRA Note was $1,727 and $2,097 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;CARES Act Paycheck Protection Program Loan &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;On &lt;em style="font: inherit;"&gt; April 17, 2020, &lt;/em&gt;we received a $170,200 bank loan backed by the United States Small Business Administration pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bears an annual interest rate of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; percent and is due &lt;em style="font: inherit;"&gt; April 17, 2022. &lt;/em&gt;We have accrued interest expense associated with the PPP Loan of $1,203. In &lt;em style="font: inherit;"&gt; October 2020, &lt;/em&gt;we applied to the lender to have the loan forgiven, based upon our submission of qualifying information regarding eligible expenses; as of the date of this report our forgiveness application has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been processed.&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220570"
      unitRef="USD">50000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="2"
      id="c80220571"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220573"
      unitRef="USD">12487</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220575"
      unitRef="USD">13126</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220577"
      unitRef="USD">2252</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220579"
      unitRef="USD">1727</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2019-01-01_2019-12-31_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c80220580"
      unitRef="USD">2097</us-gaap:InterestExpense>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c80220582"
      unitRef="USD">170200</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c80220584"
      unitRef="USD">1203</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermDebtTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016503">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Convertible Debentures&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; June 26 2020, &lt;/em&gt;we entered into a Securities Purchase Agreement with &lt;span style="-sec-ix-hidden:c80220587"&gt;two&lt;/span&gt; institutional investors, pursuant to which we received gross proceeds of $1,050,000 in exchange for the issuance of: (i) 5% Original Issue Discount Senior Secured Convertible Debentures (the &#x201c;Convertible Debentures&#x201d;) in the aggregate principal amount of &lt;span style="-sec-ix-hidden:c80220590"&gt;$1,200,000;&lt;/span&gt; and (ii) &lt;span style="-sec-ix-hidden:c80220591"&gt;five&lt;/span&gt;-year warrants (the &lt;em style="font: inherit;"&gt; &#x201c;June 2020 &lt;/em&gt;Warrants&#x201d;) to purchase an aggregate of 120,000 shares of our common stock at an exercise price of $10.00 per share. Net proceeds after deducting the original issue discount, finder&#x2019;s fee and other debt issuance costs were $888,500. As a result of the public offering of our securities described in Note &lt;em style="font: inherit;"&gt;8,&lt;/em&gt; on &lt;em style="font: inherit;"&gt; September 29, 2020 &lt;/em&gt;the exercise price of the &lt;em style="font: inherit;"&gt; June 2020 &lt;/em&gt;Warrants was reduced to $5.00. The Convertible Debentures had an original maturity of &lt;span style="-sec-ix-hidden:c80220597"&gt;twelve&lt;/span&gt; months, bore interest at a rate of 5% per annum, and were secured by substantially all of the Company&#x2019;s assets until such time as they were paid or converted in full.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Convertible Debentures were mandatorily convertible upon our consummation of a public offering of common stock with gross proceeds of $6,000,000 or more, and which resulted in the listing of our common stock on a national securities exchange (a &#x201c;Qualified Offering&#x201d;). The conversion price upon the occurrence of a Qualified Offering was equal to the lower of (i) $10.00 per share or (ii) 80% of the offering price. The conversion provisions of the Convertible Debentures were subject to a &#x201c;conversion blocker&#x201d; such that each of the purchasers could &lt;em style="font: inherit;"&gt;not&lt;/em&gt; convert the Convertible Debentures to the extent that the conversion would result in the purchaser and its affiliates holding more than 4.99% of our outstanding common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; September 29, 2020, &lt;/em&gt;upon our consummation of the public offering discussed in Note &lt;em style="font: inherit;"&gt;8,&lt;/em&gt; the $1,200,000 maturity value of the Convertible Debentures and $14,667 of accrued interest were automatically converted at $4.00, the Qualified Offering discounted price, resulting in the issuance of 303,668 conversion units. Of the &lt;em style="font: inherit;"&gt;303,668&lt;/em&gt; conversion units: (a) 177,626 consist of &lt;span style="-sec-ix-hidden:c80220611"&gt;one&lt;/span&gt; share of common stock and a warrant to purchase &lt;span style="-sec-ix-hidden:c80220612"&gt;one&lt;/span&gt; share of common stock (a &#x201c;Conversion Warrant&#x201d;), and (b) 126,042 consist of &lt;span style="-sec-ix-hidden:c80220614"&gt;one&lt;/span&gt; pre-funded warrant to purchase &lt;span style="-sec-ix-hidden:c80220615"&gt;one&lt;/span&gt; share of common stock (a &#x201c;Pre-Funded Warrant&#x201d;) and a Conversion Warrant. The Pre-Funded Warrants provide the holder the right to purchase &lt;span style="-sec-ix-hidden:c80220616"&gt;one&lt;/span&gt; share of Common Stock at an exercise price of $0.01 per share, are immediately exercisable and will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expire until exercised in full. The Conversion Warrants provide the holder the right to purchase &lt;span style="-sec-ix-hidden:c80220619"&gt;one&lt;/span&gt; share of common stock, are immediately exercisable at an exercise price of $5.00 per share and expire &lt;span style="-sec-ix-hidden:c80220621"&gt;five&lt;/span&gt; years after the issuance date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Upon the issuance of the Convertible Debentures, we recorded a debt discount of $769,334, including the $150,000 original issue discount, $457,833 of fair value allocated to the warrants (recorded as Additional Paid-in Capital), and $161,500 of direct transaction costs incurred. The debt discount was amortized to interest expense over the &lt;em style="font: inherit;"&gt;12&lt;/em&gt;-month term of the Debentures using the effective interest rate method, up to the date of conversion. As a result of the mandatory conversion of the Convertible Debentures on &lt;em style="font: inherit;"&gt; September 29, 2020, &lt;/em&gt;the remaining unamortized debt discount ($645,150) was recorded as Additional Paid-in Capital. Interest expense associated with the Convertible Debentures recorded during &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was $138,851, including $124,185 of debt discount amortization.&lt;/p&gt;
  </us-gaap:ShortTermDebtTextBlock>
    <govx:ProceedsFromConvertibleDebtGross
      contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220588"
      unitRef="USD">1050000</govx:ProceedsFromConvertibleDebtGross>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="2"
      id="c80220589"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220592"
      unitRef="Share">120000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220593"
      unitRef="USDPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220594"
      unitRef="USD">888500</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220596"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="2"
      id="c80220598"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <govx:GrossProceedsFromIssuanceOfCommonStockPublicOffering
      contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220599"
      unitRef="USD">6000000</govx:GrossProceedsFromIssuanceOfCommonStockPublicOffering>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220600"
      unitRef="USDPerShare">10.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <govx:PercentageOfOfferingPrice
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="1"
      id="c80220601"
      unitRef="Pure">0.80</govx:PercentageOfOfferingPrice>
    <govx:DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="4"
      id="c80220603"
      unitRef="Pure">0.0499</govx:DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80220605"
      unitRef="USD">1200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <govx:DebtConversionAccruedInterestAmount
      contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80220606"
      unitRef="USD">14667</govx:DebtConversionAccruedInterestAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80220607"
      unitRef="USDPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80220608"
      unitRef="Share">303668</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheOneMember"
      decimals="INF"
      id="c80220610"
      unitRef="Share">177626</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember_StatementClassOfStockAxis-ConversionUnitsTrancheTwoMember"
      decimals="INF"
      id="c80220613"
      unitRef="Share">126042</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="INF"
      id="c80220617"
      unitRef="USDPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember"
      decimals="INF"
      id="c80220620"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220622"
      unitRef="USD">769334</us-gaap:DebtInstrumentUnamortizedDiscount>
    <govx:DebtConversionOriginalDebtDiscount
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220623"
      unitRef="USD">150000</govx:DebtConversionOriginalDebtDiscount>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220624"
      unitRef="USD">457833</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="d_2020-06-26_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220625"
      unitRef="USD">161500</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2020-09-29_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220627"
      unitRef="USD">645150</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-01-01_2020-12-31_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220629"
      unitRef="USD">138851</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2020-01-01_2020-12-31_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c80220630"
      unitRef="USD">124185</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016504">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Commitments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Lease Agreement&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on &lt;em style="font: inherit;"&gt; December 31, 2022. &lt;/em&gt;Rent expense for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $166,577 and $161,673, respectively. Future minimum lease payments total $171,213 in &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and $176,356 in &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; although the lease &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated at any time by either party with &lt;em style="font: inherit;"&gt;ninety&lt;/em&gt; days written notice.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Other Commitments&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;we had approximately $190,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; We expect $165,500 of this amount to be reimbursable to us pursuant to currently outstanding government grants.&lt;/p&gt;
  </us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220632"
      unitRef="SquareFoot">8400</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseAndRentalExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220634"
      unitRef="USD">166577</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220635"
      unitRef="USD">161673</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220636"
      unitRef="USD">171213</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220638"
      unitRef="USD">176356</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220641"
      unitRef="USD">190000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <govx:UnrecordedUnconditionalPurchaseObligationReimbursableAmount
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220643"
      unitRef="USD">165500</govx:UnrecordedUnconditionalPurchaseObligationReimbursableAmount>
    <us-gaap:PreferredStockTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016505">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Stockholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Convertible Preferred Stock&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We are authorized to issue up to 10,000,000 shares of our Preferred Stock, &lt;span style="-sec-ix-hidden:c80220646"&gt;$.01&lt;/span&gt; par value, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be issued in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more series. The table below presents our issued and outstanding series of preferred stock as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt; Each series of our outstanding preferred stock has a stated value of $1,000 per share. Further details concerning each series of preferred stock, and the changes in each series during the years ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; are discussed in the sections that follow the table.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Carrying&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Carrying&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series B Convertible Preferred Stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;76,095&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;76,095&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series H Convertible Preferred Stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,686&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,156,338&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series I Convertible Preferred Stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;700&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;700,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;76,095&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,486&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,932,433&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Series B Convertible Preferred Stock &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;Our Series B Convertible Preferred Stock, $1,000 stated value (&#x201c;Series B Preferred Stock&#x201d;), has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series B Preferred Stock has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to a dividend. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there were 100 shares of Series B Preferred Stock outstanding, convertible at any time at the option of the holder into shares of common stock at a fixed conversion price of $7,000,000 per common share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Series C Convertible Preferred Stock &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;Our Series C Convertible Preferred Stock, $1,000 stated value (&#x201c;Series C Preferred Stock&#x201d;), has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series C Preferred Stock has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to a dividend. During &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; 587 shares of our Series C Preferred Stock were converted into 2 shares of our common stock and the remaining 1,563 shares of Series C Preferred Stock were exchanged for Series F Preferred Stock. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there were no shares of Series C Preferred Stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Series E Convertible Preferred Stock &lt;/i&gt;&#x2013; Our Series E Convertible Preferred Stock, $1,000 stated value, (&#x201c;Series E Preferred Stock&#x201d;) has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series E Preferred Stock has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to a dividend. During &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; all outstanding shares of Series E Preferred Stock (1,200 shares) were exchanged for Series F Preferred Stock. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there were no shares of Series E Preferred Stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Series F Preferred Stock &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;In &lt;em style="font: inherit;"&gt; February 2019, &lt;/em&gt;we entered into Exchange Agreements with holders of our Series C and Series E Preferred Stock, pursuant to which the holders exchanged all shares of Series C and Series E Preferred Stock held by them for an aggregate of 2,763 shares of Series F Convertible Preferred Stock (&#x201c;Series F Preferred Stock&#x201d;). Our Series F Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series F Preferred Stock has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to a dividend. During &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; 507 shares of Series F Preferred Stock were converted into 9 shares of our common stock and all remaining outstanding shares of Series F Preferred Stock (2,256 shares) were exchanged for Series H Preferred Stock. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there were no shares of Series F Preferred Stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Series G Preferred Stock &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;In &lt;em style="font: inherit;"&gt; February 2019, &lt;/em&gt;we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#x201c;Purchasers&#x201d;) providing for sale to the Purchasers of an aggregate of up to 1,000 shares of our Series G Convertible Preferred Stock (&#x201c;Series G Preferred Stock&#x201d;) and related warrants for gross proceeds of up to $1.0 million, which was funded at &lt;em style="font: inherit;"&gt;three&lt;/em&gt; different closings. Our Series G Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series G Preferred Stock has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to a dividend. At the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; closing, which occurred in &lt;em style="font: inherit;"&gt; February 2019, &lt;/em&gt;we issued 500 shares of Series G Preferred Stock in exchange for the payment by the Purchasers of $250,000 in the aggregate, plus the cancellation of Term Notes held by the Purchasers in the amount of &lt;em style="font: inherit;"&gt;$250,000.&lt;/em&gt; At the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; closings, which occurred in &lt;em style="font: inherit;"&gt; April &lt;/em&gt;and &lt;em style="font: inherit;"&gt; June 2019, &lt;/em&gt;we issued an aggregate of 500 additional shares of Series G Preferred Stock in exchange for the payment by the Purchasers of a total of $500,000. During &lt;em style="font: inherit;"&gt; July 2019, &lt;/em&gt;all outstanding shares of Series G Preferred Stock (1,000 shares) were exchanged for Series H Preferred Stock. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there were no shares of Series G Preferred Stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Series H Preferred Stock &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;In &lt;em style="font: inherit;"&gt; July 2019, &lt;/em&gt;we entered into Exchange Agreements with holders of our Series F and Series G Preferred Stock, pursuant to which the holders exchanged all shares of Series F and Series G Preferred Stock held by them for an aggregate of 3,256 shares of Series H Convertible Preferred Stock (&#x201c;Series H Preferred Stock&#x201d;). Our Series H Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series H Preferred Stock has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to a dividend. During &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; 1,570 shares of Series H Preferred Stock were converted into 14,808 shares of our common stock. During &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; 1,686 shares of our Series H Convertible Preferred Stock were converted into 469,697 shares of our common stock. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there were no shares of Series H Preferred Stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Series I Preferred Stock &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;In &lt;em style="font: inherit;"&gt; July 2019, &lt;/em&gt;we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#x201c;Purchasers&#x201d;) providing for sale to the Purchasers of an aggregate of 700 shares of our Series I Convertible Preferred Stock (&#x201c;Series I Preferred Stock&#x201d;) for gross proceeds of $700,000. Our Series I Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series I Preferred Stock has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to a dividend. During &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; 700 shares of our Series I Convertible Preferred Stock were converted into 204,371 shares of our common stock. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there were no shares of Series I Preferred Stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Series J Preferred Stock &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;In &lt;em style="font: inherit;"&gt; January 2020, &lt;/em&gt;we entered into a Securities Purchase Agreement with the purchasers identified therein (the &#x201c;Purchasers&#x201d;) providing for sale to the Purchasers of an aggregate of 300 shares of our Series J Convertible Preferred Stock (&#x201c;Series J Preferred Stock&#x201d;) for gross proceeds of $300,000. Our Series J Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series J Preferred Stock has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to a dividend. During &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; 300 shares of Series J Preferred Stock were converted into 42,723 shares of our common stock. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there were no shares of Series J Preferred Stock outstanding&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Reverse Stock Splits &lt;/i&gt;&#x2013; On &lt;em style="font: inherit;"&gt; April 30, 2019, &lt;/em&gt;we effected a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-500 reverse stock split of our common stock, on &lt;em style="font: inherit;"&gt; January 21, 2020, &lt;/em&gt;we effected a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-2000 reverse split of our common stock and on &lt;em style="font: inherit;"&gt; September 25, 2020, &lt;/em&gt;we effected a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-20 reverse split of our common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Conversions of Preferred Stock&lt;/i&gt; &#x2013; During &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; we issued an aggregate of 716,790 and 14,819 shares of our common stock, respectively, pursuant to the conversion of several series of our convertible preferred stock as discussed above.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Public Offering &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;On &lt;em style="font: inherit;"&gt; September 24, 2020, &lt;/em&gt;we entered into an Underwriting Agreement (the &#x201c;Underwriting Agreement&#x201d;) with Maxim Group LLC, as representative of the underwriters (the &#x201c;Representative&#x201d;), for an underwritten public offering (the &#x201c;Offering&#x201d;) of an aggregate of 2,560,000 units of our equity securities (the &#x201c;Units&#x201d;). The Offering closed on &lt;em style="font: inherit;"&gt; September 29, 2020, &lt;/em&gt;with gross proceeds to us of approximately $12.8 million; net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $11.2 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Of the 2,560,000 Units sold in the Offering: (a) 2,310,000 Units consist of &lt;span style="-sec-ix-hidden:c80220735"&gt;one&lt;/span&gt; share of our common stock, and a Warrant to purchase &lt;span style="-sec-ix-hidden:c80220736"&gt;one&lt;/span&gt; share of common stock (each, a &#x201c;Unit Warrant&#x201d;); and (b) 250,000 Units consisting of a Pre-Funded Warrant to purchase &lt;span style="-sec-ix-hidden:c80220738"&gt;one&lt;/span&gt; share of common stock and a Unit Warrant. The Pre-Funded Warrants provided the holder the right to purchase &lt;span style="-sec-ix-hidden:c80220739"&gt;one&lt;/span&gt; share of common stock at an exercise price of $0.01 per share and were exercised in full during &lt;em style="font: inherit;"&gt; October 2020. &lt;/em&gt;The Unit Warrants provide the holder the right to purchase &lt;span style="-sec-ix-hidden:c80220741"&gt;one&lt;/span&gt; share of common stock, are immediately exercisable at an exercise price of $5.00 per share and expire &lt;span style="-sec-ix-hidden:c80220743"&gt;five&lt;/span&gt; years after the issuance date. The public offering price was $5.00 per Unit ($4.99 for each Unit including a Pre-Funded Warrant).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Pursuant to the Underwriting Agreement, we issued to the Representative, as a portion of the underwriting compensation, warrants to purchase up to a total of 128,000 shares of common stock (the &#x201c;Representative Warrants&#x201d;). The Representative Warrants have an exercise price of $5.50 per share, are initially exercisable 180 days after the effective date of the Offering and have a term of &lt;span style="-sec-ix-hidden:c80220749"&gt;three&lt;/span&gt; years from their initial exercise date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Conversion of Deferred Compensation to Equity &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;From &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; through &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;to help conserve the Company&#x2019;s cash resources, our executive officers and non-employee directors agreed to defer receipt of all or a portion (at varying levels) of their respective cash compensation. On &lt;em style="font: inherit;"&gt; September 29, 2020, &lt;/em&gt;upon our consummation of the Offering, $1,500,000 of the accumulated deferrals were converted at the $5.00 offering price, resulting in the issuance of 300,001 units substantially similar to the units sold in the public offering, with each unit consisting of &lt;span style="-sec-ix-hidden:c80220755"&gt;one&lt;/span&gt; share of our common stock and &lt;span style="-sec-ix-hidden:c80220756"&gt;one&lt;/span&gt; warrant substantially similar to a Unit Warrant (a &#x201c;Management Warrant&#x201d;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Conversion of Convertible Debentures to Equity&lt;/i&gt; &#x2013; As discussed in Note &lt;em style="font: inherit;"&gt;6,&lt;/em&gt; upon our consummation of the Offering, we issued an aggregate of 177,626 shares of our common stock, 126,042 Pre-Funded Warrants and 303,668 Conversion Warrants upon the mandatory conversion of $1,214,667 of Convertible Debentures and accrued interest.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Other Common Stock Transactions&lt;/i&gt; &#x2013; During &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; we issued 26,581 and 162 shares, respectively, of our common stock pursuant to consulting agreements. During &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; certain warrants were exercised using the &#x201c;cashless&#x201d; exercise feature of the warrants, resulting in the issuance of an aggregate of 36,902 shares of our common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We have a stock-based incentive plan (the &lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Plan&#x201d;) pursuant to which our Board of Directors &lt;em style="font: inherit;"&gt; may &lt;/em&gt;grant stock options to our employees. A total of 1,000,000 shares of our common stock are reserved for issuance pursuant to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan. The exercise price for any option granted &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be less than fair value (110% of fair value for ISO&#x2019;s granted to certain employees). Options have a maximum &lt;span style="-sec-ix-hidden:c80220773"&gt;ten&lt;/span&gt;-year term and generally vest over &lt;span style="-sec-ix-hidden:c80220774"&gt;three&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average risk-free interest rates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;0.69&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected life of option (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"&gt;7.0&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;38.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;A summary of stock option activity under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan as of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;and changes during the year then ended is presented below.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Number&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;of Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Weighted-&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Weighted-&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Remaining&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Contractual&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Term (yrs)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Aggregate&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Intrinsic&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;602,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2.79&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited or expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;602,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;2.79&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;9.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;355,180&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The weighted-average grant date fair value of options granted during &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was $1.12. &lt;span style="-sec-ix-hidden:c80220778"&gt;No&lt;/span&gt; stock options were granted during &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt; Total employee and director stock-based compensation expense recognized in the consolidated statement of operations for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $18,730 and $104,420, respectively. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there is $655,510 of unrecognized compensation expense related to employee and director stock-based compensation arrangements that will be recognized over a weighted-average period of 2.9 years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock Purchase Warrants&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Summary of Warrants Outstanding &lt;/i&gt;&#x2013; The table below presents summary information about our warrants outstanding as of &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;Additional information concerning the warrants follows the table.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55.6%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant Description&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Number&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;of Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Expiration&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series I Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;62,626&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Oct-Dec 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;June 2020 Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;120,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Jun 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Pre-Funded Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;126,042&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Perpetual&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unit, Conversion and Management Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,163,669&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Sep 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;128,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.50&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Mar 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total Warrants Outstanding at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;3,600,337&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-Average Exercise Price&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4.84&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"&gt;4.7&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Series I Warrants&lt;/i&gt; &#x2013; During &lt;em style="font: inherit;"&gt; July 2020, &lt;/em&gt;Series I Warrants were exercised using the &#x201c;cashless&#x201d; exercise feature of the warrants, resulting in the issuance of 29,755 shares of our common stock. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there were 62,626 Series I Warrants outstanding, with an exercise price of $5.00 per share, reflective of anti-dilution adjustments resulting from the Offering.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt; June 2020 &lt;/em&gt;Warrants&lt;/i&gt; &#x2013; As discussed in Note &lt;em style="font: inherit;"&gt;6,&lt;/em&gt; on &lt;em style="font: inherit;"&gt; June 26, 2020, &lt;/em&gt;in connection with the issuance of the Convertible Debentures, we issued warrants to purchase 120,000 shares of common stock, with a &lt;span style="-sec-ix-hidden:c80220791"&gt;five&lt;/span&gt;-year term and an exercise price of $10.00. As a result of the Offering, on &lt;em style="font: inherit;"&gt; September 29, 2020 &lt;/em&gt;the exercise price was reduced to $5.00.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Warrants Issued Upon Conversion of Convertible Debentures&lt;/i&gt; &#x2013; As discussed in Note &lt;em style="font: inherit;"&gt;6,&lt;/em&gt; on &lt;em style="font: inherit;"&gt; September 29, 2020, &lt;/em&gt;upon the conversion of the Convertible Debentures into our equity securities, we issued 126,042 Pre-Funded Warrants and 303,668 Conversion Warrants to purchase our common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Warrants Issued Upon Conversion of Deferred Compensation&lt;/i&gt; &#x2013; As discussed above under &#x201c;&lt;i&gt;Common Stock &lt;/i&gt;&#x2013;&lt;i&gt; Conversion of Deferred Compensation to Equity&lt;/i&gt;&#x201d;, on &lt;em style="font: inherit;"&gt; September&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;29,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; upon the conversion of amounts owed to current and former executive officers and directors, we issued Management Warrants to purchase 300,001 shares of common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Warrants Issued in Connection with Public Offering&lt;/i&gt; &#x2013; As discussed above under &#x201c;&lt;i&gt;Common Stock &lt;/i&gt;&#x2013;&lt;i&gt; Public Offering&lt;/i&gt;&#x201d;, on &lt;em style="font: inherit;"&gt; September 29, 2020, &lt;/em&gt;in connection with the Offering, we issued Unit Warrants to purchase 2,560,000 shares of common stock, Pre-Funded Warrants to purchase 250,000 shares of common stock (fully exercised in &lt;em style="font: inherit;"&gt; October 2020), &lt;/em&gt;and Representative Warrants to purchase 128,000 shares of common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Additional Stock-Based Compensation Expense&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In addition to stock-based compensation expense related to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan (see &lt;i&gt;Stock Options&lt;/i&gt; above), during the years ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; we recognized $45,733 and $223,080, respectively, of expense related to the issuance of our common stock pursuant to consulting and investment banking agreements. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there is $48,667 recorded as a prepaid expense for &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of these arrangements, which will be recognized as expense during &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; over the term of the related agreement.&lt;/p&gt;
  </us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220645"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220649"
      unitRef="USDPerShare">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <govx:ScheduleOfPreferredStockTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016506">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Carrying&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Carrying&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series B Convertible Preferred Stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;76,095&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;76,095&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series H Convertible Preferred Stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,686&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,156,338&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series I Convertible Preferred Stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;700&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;700,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;76,095&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,486&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,932,433&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </govx:ScheduleOfPreferredStockTableTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220241"
      unitRef="Share">100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220242"
      unitRef="USD">76095</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220243"
      unitRef="Share">100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220244"
      unitRef="USD">76095</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220245"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220246"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220247"
      unitRef="Share">1686</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220248"
      unitRef="USD">1156338</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220249"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220250"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220251"
      unitRef="Share">700</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i_2019-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220252"
      unitRef="USD">700000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220253"
      unitRef="Share">100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220254"
      unitRef="USD">76095</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220255"
      unitRef="Share">2486</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220256"
      unitRef="USD">1932433</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220651"
      unitRef="USDPerShare">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220654"
      unitRef="Share">100</us-gaap:PreferredStockSharesOutstanding>
    <govx:ConvertiblePreferredStockConversionPrice1
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220655"
      unitRef="USDPerShare">7000000</govx:ConvertiblePreferredStockConversionPrice1>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesCConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220656"
      unitRef="USDPerShare">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220660"
      unitRef="Share">587</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220661"
      unitRef="Share">2</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember"
      decimals="INF"
      id="c80220662"
      unitRef="Share">1563</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesCConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220663"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesEConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220664"
      unitRef="USDPerShare">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember"
      decimals="INF"
      id="c80220668"
      unitRef="Share">1200</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesEConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220669"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <govx:NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock
      contextRef="d_2019-02-01_2019-02-28_StatementClassOfStockAxis-SeriesFConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220670"
      unitRef="Share">2763</govx:NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesFPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220674"
      unitRef="Share">507</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesFPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220675"
      unitRef="Share">9</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember"
      decimals="INF"
      id="c80220676"
      unitRef="Share">2256</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesFConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220677"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <govx:ConvertiblePreferredStockAndRelatedWarrantsAuthorized
      contextRef="d_2019-02-01_2019-02-28_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember"
      decimals="INF"
      id="c80220678"
      unitRef="Share">1000</govx:ConvertiblePreferredStockAndRelatedWarrantsAuthorized>
    <govx:ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum
      contextRef="d_2019-02-25_2019-02-25_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember"
      decimals="-6"
      id="c80220679"
      unitRef="USD">1000000.0</govx:ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum>
    <govx:ConvertiblePreferredStockAndRelatedWarrantsIssued
      contextRef="d_2019-02-01_2019-02-28_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember"
      decimals="INF"
      id="c80220684"
      unitRef="Share">500</govx:ConvertiblePreferredStockAndRelatedWarrantsIssued>
    <govx:ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum
      contextRef="d_2019-02-26_2019-02-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember"
      decimals="INF"
      id="c80220685"
      unitRef="USD">250000</govx:ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum>
    <govx:ConvertiblePreferredStockAndRelatedWarrantsIssued
      contextRef="d_2019-04-26_2019-04-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockAndRelatedWarrantsMember"
      decimals="INF"
      id="c80220689"
      unitRef="Share">500</govx:ConvertiblePreferredStockAndRelatedWarrantsIssued>
    <govx:ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum
      contextRef="d_2019-04-26_2019-04-26_StatementEquityComponentsAxis-SeriesGConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220690"
      unitRef="USD">500000</govx:ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2019-07-31_StatementClassOfStockAxis-SeriesGConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220691"
      unitRef="Share">1000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesGConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220692"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220694"
      unitRef="Share">3256</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220698"
      unitRef="Share">1570</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220699"
      unitRef="Share">14808</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220701"
      unitRef="Share">1686</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220702"
      unitRef="Share">469697</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesHConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220703"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220704"
      unitRef="Share">700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="d_2019-07-01_2019-07-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220705"
      unitRef="USD">700000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesIPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220709"
      unitRef="Share">700</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesIPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220710"
      unitRef="Share">204371</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesIConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220711"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-01-01_2020-01-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220712"
      unitRef="Share">300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="d_2020-01-01_2020-01-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember"
      decimals="INF"
      id="c80220713"
      unitRef="USD">300000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesJPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220717"
      unitRef="Share">300</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesJPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220718"
      unitRef="Share">42723</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesJConvertiblePreferredStockMember"
      decimals="-3"
      id="c80220719"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2019-04-30_2019-04-30_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c80220721"
      unitRef="Pure">500</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c80220723"
      unitRef="Pure">2000</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c80220725"
      unitRef="Pure">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220728"
      unitRef="Share">716790</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2019-01-01_2019-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c80220729"
      unitRef="Share">14819</us-gaap:ConversionOfStockSharesIssued1>
    <govx:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2020-09-24_2020-09-24_ClassOfWarrantOrRightAxis-ConversionWarrantsMember"
      decimals="INF"
      id="c80220730"
      unitRef="Share">2560000</govx:ClassOfWarrantOrRightIssuedDuringPeriod>
    <govx:ProceedsFromIssuanceOrSaleOfEquityGross
      contextRef="d_2020-09-24_2020-09-24"
      decimals="-5"
      id="c80220731"
      unitRef="USD">12800000</govx:ProceedsFromIssuanceOrSaleOfEquityGross>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2020-09-24_2020-09-24"
      decimals="-5"
      id="c80220732"
      unitRef="USD">11200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-09-24_2020-09-24_StatementEquityComponentsAxis-CapitalUnitsMember"
      decimals="INF"
      id="c80220733"
      unitRef="Share">2560000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-09-24_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember"
      decimals="INF"
      id="c80220734"
      unitRef="Share">2310000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-09-24_2020-09-24_StatementClassOfStockAxis-CapitalUnitsTrancheTwoMember_StatementEquityComponentsAxis-CapitalUnitsMember"
      decimals="INF"
      id="c80220737"
      unitRef="Share">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="INF"
      id="c80220740"
      unitRef="USDPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c80220742"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2020-09-24_StatementEquityComponentsAxis-CapitalUnitsMember"
      decimals="INF"
      id="c80220744"
      unitRef="USDPerShare">5.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2020-09-24_StatementClassOfStockAxis-UnitsIncludingPrefundedWarrantsMember_StatementEquityComponentsAxis-CapitalUnitsMember"
      decimals="INF"
      id="c80220745"
      unitRef="USDPerShare">4.99</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"
      decimals="INF"
      id="c80220746"
      unitRef="Share">128000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"
      decimals="INF"
      id="c80220747"
      unitRef="USDPerShare">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <govx:ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable
      contextRef="d_2020-09-24_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"
      id="c80220748">P180D</govx:ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable>
    <govx:DeferredCompensationLiabilityConversionToEquityAmount
      contextRef="d_2020-09-29_2020-09-29"
      decimals="INF"
      id="c80220752"
      unitRef="USD">1500000</govx:DeferredCompensationLiabilityConversionToEquityAmount>
    <govx:DeferredCompensationLiabilityConversionToEquityConversionPrice
      contextRef="i_2020-09-29"
      decimals="INF"
      id="c80220753"
      unitRef="USDPerShare">5.00</govx:DeferredCompensationLiabilityConversionToEquityConversionPrice>
    <govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation
      contextRef="d_2020-09-29_2020-09-29"
      decimals="INF"
      id="c80220754"
      unitRef="Share">300001</govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-09-29_2020-09-29"
      decimals="INF"
      id="c80220758"
      unitRef="Share">177626</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80220759"
      unitRef="Share">126042</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80220760"
      unitRef="Share">303668</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <govx:DebtConversionConvertedInstrumentPrincipalAndInterestAmount
      contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80220761"
      unitRef="USD">1214667</govx:DebtConversionConvertedInstrumentPrincipalAndInterestAmount>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220764"
      unitRef="Share">26581</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220765"
      unitRef="Share">162</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220767"
      unitRef="Share">36902</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2020-12-31_PlanNameAxis-StockIncentivePlan2020Member"
      decimals="INF"
      id="c80220769"
      unitRef="Share">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="d_2020-01-01_2020-12-31"
      decimals="1"
      id="c80220772"
      unitRef="Pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016507">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average risk-free interest rates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;0.69&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected life of option (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"&gt;7.0&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;38.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="4"
      id="c80220257"
      unitRef="Pure">0.0069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c80220259"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2020-01-01_2020-12-31" id="c80220261">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="4"
      id="c80220263"
      unitRef="Pure">0.3816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016508">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 9pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Number&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;of Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Weighted-&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Weighted-&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Remaining&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Contractual&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Term (yrs)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Aggregate&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Intrinsic&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;602,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2.79&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited or expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;602,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;2.79&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;9.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;355,180&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220265"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220266"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220269"
      unitRef="Share">602000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220270"
      unitRef="USDPerShare">2.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220273"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220274"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220277"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220278"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220281"
      unitRef="Share">602000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220282"
      unitRef="USDPerShare">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2020-01-01_2020-12-31" id="c80220283">P9Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220284"
      unitRef="USD">355180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c80220285"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220286"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220288"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220777"
      unitRef="USDPerShare">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c80220781"
      unitRef="USD">18730</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c80220782"
      unitRef="USD">104420</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220783"
      unitRef="USD">655510</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c80220784">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016509">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55.6%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant Description&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Number&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;of Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Expiration&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series I Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;62,626&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Oct-Dec 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;June 2020 Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;120,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Jun 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Pre-Funded Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;126,042&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Perpetual&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unit, Conversion and Management Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,163,669&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Sep 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;128,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.50&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Mar 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total Warrants Outstanding at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;3,600,337&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-Average Exercise Price&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4.84&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;"&gt;4.7&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember"
      decimals="INF"
      id="c80220289"
      unitRef="Share">62626</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember"
      decimals="INF"
      id="c80220290"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220292"
      unitRef="Share">120000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220293"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="INF"
      id="c80220295"
      unitRef="Share">126042</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="2"
      id="c80220296"
      unitRef="USDPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-UnitConversionAndManagementWarrantsMember"
      decimals="INF"
      id="c80220298"
      unitRef="Share">3163669</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-UnitConversionAndManagementWarrantsMember"
      decimals="0"
      id="c80220299"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"
      decimals="INF"
      id="c80220301"
      unitRef="Share">128000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"
      decimals="1"
      id="c80220302"
      unitRef="USDPerShare">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220304"
      unitRef="Share">3600337</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-12-31_RangeAxis-WeightedAverageMember"
      decimals="INF"
      id="c80220307"
      unitRef="USDPerShare">4.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-OutstandingWarrantsExcludingPreFundedWarrantsMember_RangeAxis-WeightedAverageMember"
      id="c80220310">P4Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-07-01_2020-07-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember"
      decimals="INF"
      id="c80220786"
      unitRef="Share">29755</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember"
      decimals="INF"
      id="c80220787"
      unitRef="Share">62626</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember"
      decimals="INF"
      id="c80220788"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220790"
      unitRef="Share">120000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220792"
      unitRef="USDPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c80220793"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80220795"
      unitRef="Share">126042</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c80220796"
      unitRef="Share">303668</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember"
      decimals="INF"
      id="c80220799"
      unitRef="Share">300001</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember"
      decimals="INF"
      id="c80220800"
      unitRef="Share">2560000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="INF"
      id="c80220801"
      unitRef="Share">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrantsMember"
      decimals="INF"
      id="c80220802"
      unitRef="Share">128000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember"
      decimals="INF"
      id="c80220805"
      unitRef="USD">45733</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember"
      decimals="INF"
      id="c80220806"
      unitRef="USD">223080</us-gaap:AllocatedShareBasedCompensationExpense>
    <govx:PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220807"
      unitRef="USD">48667</govx:PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016510">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;b&gt;Retirement Plan&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We participate in a multi-employer defined contribution retirement plan (the &lt;em style="font: inherit;"&gt;&#x201c;401k&lt;/em&gt; Plan&#x201d;) administered by a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service provider, and the Company contributes to the &lt;em style="font: inherit;"&gt;401k&lt;/em&gt; Plan on behalf of its employees based upon a matching formula. During the years ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; our contributions to the &lt;em style="font: inherit;"&gt;401k&lt;/em&gt; Plan were $27,511 and $25,876, respectively.&lt;/p&gt;
  </us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220816"
      unitRef="USD">27511</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220817"
      unitRef="USD">25876</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016511">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;we have a consolidated federal net operating loss (&#x201c;NOL&#x201d;) carryforward of approximately $61.8 million available to offset against future taxable income of which approximately $53.6 million expires in varying amounts in &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2037.&lt;/em&gt; Additionally, we have approximately $1.2 million in research and development (&#x201c;R&amp;amp;D&#x201d;) tax credits that expire in &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2040&lt;/em&gt; unless utilized earlier. No income taxes have been paid to date. Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; of the Internal Revenue Code contains provisions that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;limit our utilization of our NOL and R&amp;amp;D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or &lt;em style="font: inherit;"&gt; may &lt;/em&gt;occur in future periods.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 64.1%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Net operating loss carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;14,737,240&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,328,336&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Research and development tax credit carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,189,110&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,122,536&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,870&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,877,284&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Accrued salaries and directors&#x2019; fees&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;72,721&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;450,503&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,571&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,003,941&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;"&gt;Deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;28,274&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net deferred tax asset after reduction for valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. federal statutory rate applied to pretax loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(621,194&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(497,833&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Permanent differences&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;65&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(66,574&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(47,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance, net of expired items and other adjustments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;687,703&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;544,308&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reported income tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c80220819"
      unitRef="USD">61800000</us-gaap:OperatingLossCarryforwards>
    <govx:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c80220820"
      unitRef="USD">53600000</govx:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-5"
      id="c80220823"
      unitRef="USD">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxesPaid
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c80220826"
      unitRef="USD">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016512">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 64.1%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Net operating loss carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;14,737,240&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,328,336&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Research and development tax credit carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,189,110&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,122,536&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,870&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,877,284&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Accrued salaries and directors&#x2019; fees&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;72,721&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;450,503&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,571&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,003,941&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;"&gt;Deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;28,274&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net deferred tax asset after reduction for valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220313"
      unitRef="USD">14737240</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220314"
      unitRef="USD">15328336</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220315"
      unitRef="USD">1189110</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220316"
      unitRef="USD">1122536</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220317"
      unitRef="USD">4870</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220318"
      unitRef="USD">1877284</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <govx:DeferredTaxAssetsAccruedSalariesAndDirectorsFees
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220319"
      unitRef="USD">72721</govx:DeferredTaxAssetsAccruedSalariesAndDirectorsFees>
    <govx:DeferredTaxAssetsAccruedSalariesAndDirectorsFees
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220320"
      unitRef="USD">450503</govx:DeferredTaxAssetsAccruedSalariesAndDirectorsFees>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220321"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220322"
      unitRef="USD">8571</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220323"
      unitRef="USD">16003941</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220324"
      unitRef="USD">18787230</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220325"
      unitRef="USD">28274</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220326"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <govx:DeferredTaxAssetsBeforeValuationAllowanceNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220327"
      unitRef="USD">15975667</govx:DeferredTaxAssetsBeforeValuationAllowanceNet>
    <govx:DeferredTaxAssetsBeforeValuationAllowanceNet
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220328"
      unitRef="USD">18787230</govx:DeferredTaxAssetsBeforeValuationAllowanceNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220329"
      unitRef="USD">15975667</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c80220330"
      unitRef="USD">18787230</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c80220331"
      unitRef="USD">-0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c80220332"
      unitRef="USD">-0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016513">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2019&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. federal statutory rate applied to pretax loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(621,194&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(497,833&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Permanent differences&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;65&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(66,574&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(47,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance, net of expired items and other adjustments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;687,703&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;544,308&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reported income tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220335"
      unitRef="USD">-621194</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220336"
      unitRef="USD">-497833</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220337"
      unitRef="USD">65</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220338"
      unitRef="USD">278</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220339"
      unitRef="USD">66574</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220340"
      unitRef="USD">47053</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c80220341"
      unitRef="USD">687703</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c80220342"
      unitRef="USD">544308</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c80220343"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c80220344"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <govx:GovernmentGrantsandContractsTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016514">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Grants and Collaboration Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; we recorded $1,438,465 and $983,682, respectively, of revenue associated with these grants. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there is an aggregate of $165,500 in remaining grant funds available for use during &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; During &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; we recorded $385,193 and $192,214, respectively, of revenues associated with research collaboration agreements with several &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties.&lt;/p&gt;
  </govx:GovernmentGrantsandContractsTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NIHGrantsMember"
      decimals="INF"
      id="c80220832"
      unitRef="USD">1438465</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-NIHGrantsMember"
      decimals="INF"
      id="c80220833"
      unitRef="USD">983682</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <govx:UnusedGrantFunds
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c80220834"
      unitRef="USD">165500</govx:UnusedGrantFunds>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ResearchAgreementsMember"
      decimals="INF"
      id="c80220838"
      unitRef="USD">385193</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ResearchAgreementsMember"
      decimals="INF"
      id="c80220839"
      unitRef="USD">192214</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016515">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;SBIR Grant&lt;/i&gt; &#x2013; In &lt;em style="font: inherit;"&gt; January 2021, &lt;/em&gt;NIAID awarded us a Small Business Innovative Research (SBIR) grant in support of our development of a vaccine against SARS-CoV-&lt;em style="font: inherit;"&gt;2,&lt;/em&gt; the virus that causes COVID-&lt;em style="font: inherit;"&gt;19.&lt;/em&gt; The $299,927 Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; grant, titled, &#x201c;&lt;i&gt;Preclinical Development of GV-MVA-VLP Vaccines Against COVID-&lt;em style="font: inherit;"&gt;19,&lt;/em&gt;&lt;/i&gt;&#x201d; will support the ongoing design, construction and preclinical testing of our vaccine candidates in preparation for human clinical trials.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Warrant Exercises&lt;/i&gt; &#x2013; During &lt;em style="font: inherit;"&gt; January &lt;/em&gt;and &lt;em style="font: inherit;"&gt; February 2021, &lt;/em&gt;holders of our warrants exercised 62,626 Series I Warrants, 126,042 Pre-Funded Warrants and 690,034 Unit Warrants, resulting in the issuance of 835,900 shares of our common stock for aggregate net proceeds to us of $3,174,156.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Bought Deal Public Offering -- &lt;/i&gt;On &lt;em style="font: inherit;"&gt; February 11, 2021, &lt;/em&gt;we closed an underwritten bought deal public offering of 1,644,000 shares of our common stock, including 204,000 shares sold pursuant to the full exercise of the underwriter&#x2019;s option to purchase additional shares, at a price to the public of $6.25 per share. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $9.4 million.&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-01-31_ProductOrServiceAxis-SBIRGrantMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220844"
      unitRef="USD">299927</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-SeriesIWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220847"
      unitRef="Share">62626</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220848"
      unitRef="Share">126042</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-UnitWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220849"
      unitRef="Share">690034</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-02-28_ClassOfWarrantOrRightAxis-CommonStockWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220850"
      unitRef="Share">835900</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-01-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220851"
      unitRef="USD">3174156</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220852"
      unitRef="Share">1644000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c80220853"
      unitRef="Share">204000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c80220854"
      unitRef="USDPerShare">6.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-02-11_2021-02-11_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c80220855"
      unitRef="USD">9400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016516">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;GEOVAX LABS, INC.&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;SCHEDULE II &lt;/b&gt;&#x2013;&lt;b&gt; VALUATION AND QUALIFYING ACCOUNTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;For the Years Ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Additions (Reductions)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Description&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Balance at&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Beginning&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Of Period&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Charged to&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Costs and&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Charged to&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Other&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Accounts&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Deductions&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Balance at&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;End&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Of Period&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Allowance for Deferred Tax Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Year ended December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,811,563&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Year ended December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;19,879,954&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,092,724&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="d_2020-01-01_2020-12-31" id="c2016517">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Additions (Reductions)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Description&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Balance at&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Beginning&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Of Period&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Charged to&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Costs and&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Charged to&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Other&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Accounts&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Deductions&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Balance at&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;End&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Of Period&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Allowance for Deferred Tax Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Year ended December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,811,563&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Year ended December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;19,879,954&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,092,724&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c80220345"
      unitRef="USD">18787230</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c80220346"
      unitRef="USD">-2811563</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="c80220347"
      unitRef="USD">-0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="c80220348"
      unitRef="USD">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c80220349"
      unitRef="USD">15975667</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2018-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c80220350"
      unitRef="USD">19879954</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="d_2019-01-01_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c80220351"
      unitRef="USD">-1092724</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="d_2019-01-01_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="c80220352"
      unitRef="USD">-0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="d_2019-01-01_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="c80220353"
      unitRef="USD">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c80220354"
      unitRef="USD">18787230</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!\H"<'XGI7GKV(M_\V6X^!=02P,$%     @ +HA$5(83B%(-!@  -!D  !@
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MGH3.85HR0B2QV"=W6,I/>%283)J!_-BC$NRB$)DB4IE08QQ!\A1!?F?LD\-
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MQ8X(GIID-E4?D0B[20N\$-$X C-Q OO^V*E)OS85D0A_>VD0>*+&<#\PCNC
M/8M4Q<('EL91F$F\\*OK&IT&K;1D@$C0-3K]4&6RIG9_'+QE-4YUT34Z#6YI
MR< D@6R(2'K$B%SXB:FC+DKO':F'+TF-\]MQ^=;_WE4;Z82?.V@^8!J:&TV]
M->^7#I7]VJ$RKY\.7L":'_5NLN36?E=O[*;"--$H1/.]:<[PSJ\GZV!L,H^J
MCVF02 0JPT,1F#04B\"T@6#$^<%W,37?26=WZC?3Q2J;E=>V:/Y#<XZQW'S+
MV^9#7=VMOY[I<U77U7S]XVU93,IE([!_OZZJ>O>A^<:G_9?MO?X_4$L#!!0
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MM*Q%Q0S<W!GX@F@9C>0:73.]11\@XAJ]^=RR?27 YBTZ09_O;M";G]Z>+0U
ML1TNRV'8JWY8,C-L@3[*UFPU>@_#5\_;+\&%@Q_DR8\K$NSPCN_>(1K]C$A$
ML ?/]>N;1P$X]$ K[?JC<[1:QM8=8VLE&P333C$CVDV?M\((KD\#X\2'<>)N
MG'AFG-]AHM=2:U\$^I9)U]+.YON+DS@G&<7QV?+^F!J/(4X)3N+T8/@,7'(
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MEXO\W[W8S55O[,K'"60@SJ<,>>Q(G,V4<#QJ#0Z+C1/<E_D9@'MTQPO<8Q<
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MSH@$E549[LGKHH@=N'12.^O" L$HAN5Y6WE>K[ROF0F3 4H\( 5$!+:T'#$
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MD^<%>%XX#)3^@C<8?[(Y^P]02P,$%     @ +HA$5-,G@H/P @  6P8  !D
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M;"]W;W)K<VAE971S+W-H965T,38N>&ULK5G;;ALY$OT5P@LL$D"693G762>
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MPO@[&5;++?]#![E.!?$60:NYV*CP4_WVDNZ!<?()@5,R!E%=*HL8<*5 U8:
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M#X1//W6F+]$U_&OAPD40)OZX4A+Y1@OPOG*P/W^A _K?FU__#U!+ P04
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M.??#]LGHH,W.%H@.'DJI[#@JG*NNXMCR DMF>[I"15\VVI3,D6FVL:T,LCR
M2AFG2?(Z+IE0T604]A9F,M)[)X7"A0&[+TMF'F<H]6$<]:.GC:78%LYOQ)-1
MQ;:X0O>Y6ABRXI8E%R4J*[0"@YMQ-.U?S0?>/SA\$7BP1VOPE:RUWGGC73Z.
M$I\02N3.,S":[G&.4GHB2N-'PQFU(3WP>/W$?AMJIUK6S.)<RZ\B=\4XNH@@
MQPW;2[?4A[?8U'/N^;B6-HQPJ'VS) *^MTZ7#9@R*(6J9_;0].$(</$2(&T
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MA#;_9-=_YM*^G78L1!!A)R[@+CQ<=PO<,?NF,CLS[#I+1-+ ?[F;/^KN .C
MMLK ;FG@17<GXJ-8M%DO#%@W[$9-"NUFOQ(QV"/''NY0IU?YN^?P>CO\;9A5
M[$9F/(LE3^%Y;@4VAC4[\/L5?M_A][?@WV,7"*U%X@/*_OTD7BV[2/'\GZ9P
M[D2C$G)B%CP69RW4""/TBVB='[?7DJ7(%?9>\M<\$^S(^SU@" .,?!:ZBD7
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M9X*C$Q(!OD^4LN4+":C^S\+Y_P!02P,$%     @ +HA$5+=54^EW @  G 4
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ML-H+"'UNE<3A?!>[\L53IW3$(((578G]H942= ]X3PYP2X]H>;%;[IC<X5_
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MQA%GE0(E*1)WY\P'0SV$:BH^8B'CC>;,Q/F-=Y6.*3NWO6VE D\M:7?;.!2
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MX,)3M]Q5/]1PV _3 9^?;7"F+7RDDEUW9=YHIF,R?TDHR Q'AU["LG$,<6X
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M+E,\_Z<IG#O1J(2<F#F/Q5D+-<((_2I:Y\?ME60I<H6M2_Z:9X(=>;\'#&&
MD2]"5[$(V$/^DLJ8W8_!)[,)NQ4O.D<I85%4L3FH^SEM></^\;=1MQO^1J'
M'GAW,6$9=&Z$SY0G:/KF<1]R'4]1 ]A/KC5' -A7GCD-*E4\^77N%+S()]B1
MQ=I]5D/NCDKD,:H2NS!,C1L%W]LIWJ_4;(8:YK5XAFC#8V_B5FN:4G=W*HR:
MXW2ELE>AK7Q)Q4;,?@K&-?YR.U5:_A?KR%1I3"Y8/J?G* S"T/TQ,P6ILU/E
M>ATI8'OM,')!4C (NZBPI]A)^(F01\WK#<MK*Z"Y0LC>*2C5PY-7Z ^>0MW5
M%^077BYWVA[!ICUV- S"X\'J2\'^92?[(?Z+@N%HB-]H, QZO5')>/<AXQ'$
M'15^?58616%%@6[0!^X>D(][>.[U/F<1-D"F[*8W@Y+]ZC/LY.U@!\C-_P/D
M=H.QM@.)]9,XOW^$8Z=:B!)M+#6V\QK%7G?@ M%F1L0JPQ:82IVPB[F6J2]J
MGNYKGKY_J,^7AK*8-MKDV;8CW7T*:3?&UTV,HMYYLH]@5LK6HT#043O]V],\
ME:B?WDN^:I%BT5)"A1+5Z^9@N>K3R+@RB*JRKNJR/*SWC1I<?VEQM58Y]WZ,
M6")\P6#HM]J/C'0VJ(],9NY;B7G"]OD!*'M1G1+I8"0RAFH>\J#^=Q];Y:1!
M4MNMN$: #F-R=!:JG83_ U.-7FAI73N9(!>I\0=L(7R934K"1^$:;H;9 #@!
MXX9Q-E?:S;[*&Y+7P6(UPV1O.!$ KVQH@)N77<Z7<(X?JC  B="V5DMY["-L
MG,?W24C1<U?UJ1JF^QK]=M!FSQM*+[OJE..-9TR\"1U+:((LB07)VQNT!R&;
MPW%.A\"U'PEG8S!"=A<,G"I+- I9PM_AA[$%/>DF$"UW#, '*TJW5'G!L7F]
M: :.F?].VW^9:;1V7>;95<V%Y*FB82+GAK76OR6YRD18Q:Z7QFOQ M?DVL]_
M!?CPXY%@F?B%])69""V[L-$%[9#.-)3.,6219^8I'%^/Y.KT1 ^TYZW("N<
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M10(  .D$   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;'V47V_30 S
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M+^<!Z,K/JHE5A;>$N;)D,'ZXHE\ :A= ^ZFBBUI/7(+FIS+X!U!+ P04
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M.^6RY1IO9?6G*$RY\N8>%+CC764^R<.O..236KY<5MI]X="?318>Y)TVLA[
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M/B,H;8)YOQ+FEK>!+=!]F&9_ %!+ P04    "  NB$142X,-)B #  "W!P
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MXUUE/LG#KSCDDUJ^7%;:?>'0GTT6'N2=-K(>P!1!+9I^Y$^##B> >?@"(!H
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MZ65%90_0_D[2E1\FUL'X5J^_ 5!+ P04    "  NB$14E8NR[K4"  "D!@
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MM-?\<44?$JB= KUO%(WFK> <[#Y-YO\!4$L#!!0    ( "Z(1%0H7HO"[P(
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MGR6-=-3.@?8+17=A;SB"]D]B_@]02P,$%     @ +HA$5,UQ<MPI @  $P4
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M2460NK)I>]A6->OV[,)-L&HPLYVF^_O9AK(TI%5>P-<^Y_B>:WS)=E(]Z!K
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M49="1V%2%6'25EO8;J"Q%$S4<A'R[]1&_4Y".2K%#8=N5*5"HY8;#&5Q ,'
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ME!9@WN?"=,)F8PVTL^#T/U!+ P04    "  NB$1486X/;S<"  #9!   &0
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M?:VH.XH75:&=<J7+=M5<Z*L8" /0\S.NBVW3,;6[O=R-_@)02P,$%     @
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M;;L]* >PZVMI+_00N/XP_C_R?U!+ P04    "  NB$147@ +P.0#  "S#P
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MB(>)9)OL^C!G4EU&LN%:W:J!:X#ZOF1J5\HG^D92W-,'_P-02P,$%     @
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MV ZZJDG-$'C82QO5['M$DR,TLV-+*M9&9UQM8ISA".-Z+$B3'C*3WHP\)^5
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M?EQ3LJ0\&:"^7S$F=P_)2RK%FUAG_P%02P,$%     @ +HA$5"2Q<Z,@ P
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M+55S2W\+J-T$^KZF6^6EXQ9H_S\F/P!02P,$%     @ +HA$5$9 23JB#P
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MWOT+1CE?7G)J@&F\HJZRP )0_ 9R -_!TJHOQN^P**FZRE8G)\A6+X["/M#
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MSLHQQ1N HGK#7M3N2S.KVR97K'9,F0>@J//0OMIQER-ZY]"X3F'KS>&F]S^
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MM,6* XD-*4MMUW%".R,TMX9]LS?APSY;RY3F,.%(K+.,\-<1I&P[L+#UMO%
MEXG4&_:POR)+F()\7$VX6ME5E)AFD O*<L1A,;"^XYL(NYI@$+\I;,7>,]*E
MS!A[THN[>& Y6A&D,)<Z!%%_&QA#FNI(2L=S&=2J<FKB_O-;])^F>%7,C @8
ML_0/C64RL+H6BF%!UJE\8-M;* L*=+PY2X7Y1=L"VPDM-%\+R;*2K!1D-"_^
MR4O9B#T"]H\0W)+@MB5X)<%K2_!+@F\Z4Y1B^A 1289]SK:(:[2*IA],,PU;
ME4]S[?M4<O66*IX<_F(24!=]0U/)YD\)2V/@XBOZ\;RF\E5M3Y0-P#G$!0!-
MB^\#740@"4W%I<(\3B-T\>6R;TLE2(>UYV7R49'</9)\"JMKY#E7R'5<W$ ?
MGZ9',%=T;.A. SUJ3<>]0[JMNEBUTJU:Z9IX_I%XNU8)W:HK)!+"02!UVH0D
M>4SS);J@>;G=U*YQD2 T"?2)W0RQHRK;[!=5Q[A^-ZQ !]*]2KK74KIQN<G)
M(D"PE_:=L'$=T0F=7O!.?AV%>Y[K>UYS!7Y5@7^R@BEPJGH]0F.6;X!+.DNA
M]O'^O8=L!OS?";.#*E_PR6:/@IJ1[SM:1]0_A].8@]K"JK;PS*]A'+;R^B/4
M@;I.I:[3QNG;<YWN5OFZGWVLNQ\Y'=41.#QVJ'N5\-ZY-O8^.M11'8%Q$'I>
MMUD;=G;WCM/&QKMS;<1[-QW^;"/+#*><;(!TCAU(O+M:<-N[Y:B798139C9
ME#:G)L_>FR?T]'=/^)+F J6P4$3GNJ,B\&*@*A:2K<R(,6-2#2SF,5%#*' -
M4.\73(T9Y4)/+=58._P/4$L#!!0    ( "Z(1%3.N<,5< (   4&   9
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M2^K3:+P![1>:'GLW\0?TG7_^%U!+ P04    "  NB$14Y--!IYD#  !R#@
M&0   'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6RM5UUSFS@4_2L:9F>:SK3A
MPP;;'=LSB4FW?>@V$S?I]%&!:Z.)0%02<?+O5Q(8VPDFZJY?;!#W')US+^)*
MTPWC#R(#D.@IIX68.9F4Y2?7%4D&.1;GK(1"/5DQGF.I;OG:%24'G!I03MW
M\R(WQZ1PYE,S=LWG4U9)2@JXYDA4>8[Y\R50MIDYOK,=N"'K3.H!=SXM\1J6
M(&_+:Z[NW)8E)3D4@K "<5C-G O_4^Q'&F B[@ALQ-XUTE;N&7O0-U_3F>-I
M14 AD9H"J[]'6 "EFDGI^-V0.NV<&KA_O67_;,PK,_=8P(+1GR25V<P9.RB%
M%:ZHO&&;+] 8"C5?PJ@POVA3QXY&#DHJ(5G>@)6"G!3U/WYJ$K$'",(C@* !
M!"\!T1' H $,7@#\X1' L $,369J*R8/,99X/N5L@[B.5FSZPB33H)5]4NBZ
M+R573XG"R?D_3 (:HX]H*5GRD#&: A?OT-7OBLCG9A1]+TV-+G2-U# ZBT%B
M0L5[A;M=QNCLK_=35RHUFM--FIDOZYF#(S-/T#=6R$R@JR*%M ._Z,?[00^!
MJ]+0YB+8YN(RZ&5<0GF.!MX'%'B!WR6H'QY#HN"^@7L=\-@:[D]ZW S:R@X,
MW_ (W_=*"HF+E!3K#TADF(- 9Z1H+CL+5A-&AE!_,![GD;+B*3./^VEX';:+
M.) Z;*4.[:7^-$L54G3Q"%Q]>M#5$_"$"$#7G"1@/*2,4LP%*H'7?CKMU)..
M]G0&YZ/)"S,V07$=%+[M.&P=A[V._^:X4!YM"Q/V9+RV\3JBJW1Q']&!D:@U
M$MD9.5G9%E%_10YDCEJ9HUZ96S&V&5^,;!,U;A6,;16<+E5CV_=RTJJ<]*I4
MO70%1&MC',%32;A]RB:V*?.]77/R_H.<T^6OF=XB@?Y>0_5/_=UM&-_\\%K&
MQ1UQQVP%.UO!__A&WX#>8ZIG:*%Z,E>[N0I3] -XCLY^ >;=MOMGG*!GT"4,
M4%[W>=7Q4_PL.@MI1^5[6ZY@V,%UF)I=H_7_H--^5?:)VA8GZ [3"CK%#EZ]
M=8,P],?':K1KHWY_'VW6 ;ZG8+MH&T:;5V77V_S^YG8@XX2+-;1>K+ONY?>W
MKP.I-J6+WM3@[FW&<^!K<Z@1*&%5(>N]:#O:'IPNS''AQ?A"'ZC,)G]'4Y_&
MOF&^5D(1A96B],Y'2@^O#SCUC62EV?+?,ZD.$.8R4X="X#I /5\QM>UO;O0$
M[3%S_B]02P,$%     @ +HA$5"[<\V\*!   F!$  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S N>&ULQ5C];Z,V&/Y7+#1I5^D:,%])3DFD:YIH=UIO5:-;
M-4W[P8$WB57 .=LTK;0__FR@0%L@=&HT10H8WN?A_?*#S>3 ^)W8 4CT$$>)
MF!H[*?>?3%,$.XB)&+ ]).K.AO&82#7D6U/L.9 P \61:5N6;\:$)L9LDEV[
MYK,)2V5$$[CF2*1Q3/CC!43L,#6P\73AAFYW4E\P9Y,]V<(*Y/?]-5<CLV0)
M:0R)H"Q!'#93XS/^M+0=#<@L_J1P$+5SI$-9,W:G!U_"J6%ICR""0&H*H@[W
M,(<HTDS*CQ\%J5$^4P/KYT_LRRQX%<R:")BSZ):&<C<U1@8*84/22-ZPPV]0
M!.1IOH!%(OM'A\+6,E"0"LGB JP\B&F2'\E#D8@: +LM +L V"\ MM<"< J
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MIIYYEQXIH:)K;A[D]C/T?E++5TBNW9-L^]C (\5:&]GT8%30,-&]Z4N?AQU
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M3&6 N#\GA&]/Y YF]C^*WO]02P,$%     @ +HA$5.CY-R+E @  M <  !D
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MHNX</#B/@LTY%6S__3#[!5!+ P04    "  NB$14EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( "Z(1%10@ O J@4
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M/IO_:WS]&U!+ 0(4 Q0    ( "Z(1%0'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ +HA$5)MIY/GN
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ +HA$5)E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  NB$14&6\<!LT#  #K#0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ +HA$5+;[^69\!@  XAH  !@              ("!$ P  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "Z(1%3IH*F8; ,
M "4.   8              " @<(2  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  NB$14AA.(4@T&   T&0  &               @(%D
M%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ +HA$5$9Q
M9 S##P  >&\  !@              ("!IQP  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( "Z(1%1_;7?[<P8  -P9   8
M  " @: L  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  N
MB$14#,BOD6 #  "?"@  &               @(%),P  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ +HA$5%*DQE]D!@  O1H  !@
M         ("!WS8  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( "Z(1%0\)OCMU@(  &P*   8              " @7D]  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  NB$144H*<N,P%   M&
M&0              @(&%0   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( "Z(1%08Z K[<@X  -IB   9              " @8A&  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ +HA$5!F_P#W.
M!@  G!P  !D              ("!,54  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  NB$14'TSY8_P!   .!   &0
M@($V7   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "Z(
M1%3D67RO. <  +X1   9              " @6E>  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ +HA$5-,G@H/P @  6P8  !D
M         ("!V&4  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  NB$14S8>[^P$,  !['@  &0              @('_:   >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "Z(1%3*@RI]&P,  #H'
M   9              " @3=U  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ +HA$5#50&G"D P  :PD  !D              ("!B7@
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  NB$14&(JQ
M$Q\#   %"   &0              @(%D?   >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( "Z(1%296))#KP(  . &   9
M  " @;I_  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M+HA$5-05O3<9 P  P@@  !D              ("!H((  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  NB$14RGA ^7P(  !E&   &0
M            @('PA0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( "Z(1%2W55/I=P(  )P%   9              " @:..  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ +HA$5):O>'\=!0
M"0P  !D              ("!49$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  NB$14*7"-:2(#  #4"   &0              @(&E
ME@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "Z(1%1G
MOPW(N0(  %\&   9              " @?Z9  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ +HA$5.19?*\X!P  OA$  !D
M     ("![IP  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "Z(1%2,/ \>$00  ,H(   9              "
M@:NZ  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ +HA$
M5+H +Y<8 P  P@@  !D              ("!\[X  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  NB$14B,5:Q'P(  !E&   &0
M        @(%"P@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( "Z(1%2Q^(D.10(  .D$   9              " @?7*  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ +HA$5*LXE; >!0  "0P
M !D              ("!<<T  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  NB$14:B1/?"$#  #4"   &0              @('&T@
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "Z(1%0)E2QA
MN@(  & &   9              " @1[6  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ +HA$5')3S<U( P  S 8  !D
M ("!#]D  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  N
MB$14P55_DE8-   (*   &0              @(&.W   >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "Z(1%05*8//( ,  +<'   9
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M970T-2YX;6Q02P$"% ,4    "  NB$14%<9O7.8#  "F"   &0
M    @(%D^P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M "Z(1%0H7HO"[P(  # &   9              " @8'_  !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ +HA$5,UQ<MPI @  $P4  !D
M             ("!IP(! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    "  NB$14;I=.GL4"   4"   &0              @($'!0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( "Z(1%38?]K\VP(
M ,H(   9              " @0,( 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ +HA$5+[(N<!= @  2P8  !D              ("!
M%0L! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  NB$14
M3:2S >P#   J#P  &0              @(&I#0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( "Z(1%2R?W06E ,  -$+   9
M      " @<P1 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ +HA$5 E2-2A'!P  D"4  !D              ("!EQ4! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  NB$148D3L2_8#  !R#@
M&0              @($5'0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( "Z(1%22,T#V%P(  -,$   9              " @4(A 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ +HA$5+3",4MJ
M P  P L  !D              ("!D",! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    "  NB$1438@?JBX"  !C!0  &0
M@($Q)P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( "Z(
M1%3MLA7],P,  !<*   9              " @98I 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ +HA$5&%N#V\W @  V00  !D
M         ("! "T! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    "  NB$14[@*Q1 X#  #H"0  &0              @(%N+P$ >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( "Z(1%3Z@2X67 (  $L&
M   9              " @;,R 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
M4$L! A0#%     @ +HA$5%X "\#D P  LP\  !D              ("!1C4!
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  NB$147.OE
M8Q\'  "5)0  &0              @(%A.0$ >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;%!+ 0(4 Q0    ( "Z(1%0DL7.C( ,  (L(   9
M  " @;=  0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
M+HA$5$9 23JB#P  F&H  !D              ("!#D0! 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    "  NB$14-TUTH>0"  #B"@  &0
M            @('G4P$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( "Z(1%3.N<,5< (   4&   9              " @0)7 0!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ +HA$5.330:>9 P
M<@X  !D              ("!J5D! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    "  NB$14+MSS;PH$  "8$0  &0              @(%Y
M70$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( "Z(1%3=
M8IX4,P(  -H$   9              " @;IA 0!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ +HA$5!"-$9.S @  4 <  !D
M     ("!)&0! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "Z(1%3H^3<BY0(  +0'   9              "
M@:AV 0!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ +HA$
M5 -CM*L, P  BQ    T              ( !Q'D! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  NB$14EXJ[',     3 @  "P              @ '[? $
M7W)E;',O+G)E;'-02P$"% ,4    "  NB$144( +P*H%  !?,P  #P
M        @ 'D?0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ +HA$5'KM
M3FU6 @  CBT  !H              ( !NX,! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ +HA$5%6HN6<2 @  <RP  !,
M     ( !288! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %4 50!*%P
&C(@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>270</ContextCount>
  <ElementCount>363</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Statement - Consolidated Statements of Stockholders' Equity (Deficiency)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficiency)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Statement - Consolidated Statements of Cash Flows (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 1 - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-1-description-of-business-</Role>
      <ShortName>Note 1 - Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 2 - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-2-basis-of-presentation</Role>
      <ShortName>Note 2 - Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-</Role>
      <ShortName>Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 4 - Basic and Diluted Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share</Role>
      <ShortName>Note 4 - Basic and Diluted Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 5 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-5-property-and-equipment</Role>
      <ShortName>Note 5 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 6 - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-6-accrued-expenses-</Role>
      <ShortName>Note 6 - Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 7 - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-7-notes-payable</Role>
      <ShortName>Note 7 - Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 8 - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-8-commitments</Role>
      <ShortName>Note 8 - Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 9 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-9-stockholders-equity</Role>
      <ShortName>Note 9 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 10 - Stock-based Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-10-stockbased-expense</Role>
      <ShortName>Note 10 - Stock-based Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 11 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-11-income-taxes</Role>
      <ShortName>Note 11 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 12 - Grants and Collaboration Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue</Role>
      <ShortName>Note 12 - Grants and Collaboration Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 13 - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-13-subsequent-event</Role>
      <ShortName>Note 13 - Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 1 - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF</Role>
      <ShortName>Note 1 - Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 3 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-3-property-and-equipment</Role>
      <ShortName>Note 3 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 4 - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-4-accrued-expenses-</Role>
      <ShortName>Note 4 - Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 5 - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-5-notes-payable</Role>
      <ShortName>Note 5 - Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 6 - Convertible Debentures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-6-convertible-debentures-</Role>
      <ShortName>Note 6 - Convertible Debentures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 7 - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-7-commitments</Role>
      <ShortName>Note 7 - Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 8 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-8-stockholders-equity</Role>
      <ShortName>Note 8 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 9 - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-9-retirement-plan</Role>
      <ShortName>Note 9 - Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 10 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-10-income-taxes</Role>
      <ShortName>Note 10 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 11 - Grants and Collaboration Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue</Role>
      <ShortName>Note 11 - Grants and Collaboration Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 12 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-12-subsequent-events-</Role>
      <ShortName>Note 12 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 5 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables</Role>
      <ShortName>Note 5 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-5-property-and-equipment</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 6 - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables</Role>
      <ShortName>Note 6 - Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-6-accrued-expenses-</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 3 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables</Role>
      <ShortName>Note 3 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-3-property-and-equipment</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 4 - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables</Role>
      <ShortName>Note 4 - Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-4-accrued-expenses-</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 8 - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables</Role>
      <ShortName>Note 8 - Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-8-stockholders-equity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 10 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-10-income-taxes-tables</Role>
      <ShortName>Note 10 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-10-income-taxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 2 - Basis of Presentation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual</Role>
      <ShortName>Note 2 - Basis of Presentation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-2-basis-of-presentation</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 4 - Basic and Diluted Loss Per Common Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual</Role>
      <ShortName>Note 4 - Basic and Diluted Loss Per Common Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details</Role>
      <ShortName>Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details</Role>
      <ShortName>Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 7 - Notes Payable (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual</Role>
      <ShortName>Note 7 - Notes Payable (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-7-notes-payable</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 8 - Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-8-commitments-details-textual</Role>
      <ShortName>Note 8 - Commitments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-8-commitments</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual</Role>
      <ShortName>Note 9 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-9-stockholders-equity</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 10 - Stock-based Expense (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual</Role>
      <ShortName>Note 10 - Stock-based Expense (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-10-stockbased-expense</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 11 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual</Role>
      <ShortName>Note 11 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-11-income-taxes</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 12 - Grants and Collaboration Revenue (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual</Role>
      <ShortName>Note 12 - Grants and Collaboration Revenue (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note 13 - Subsequent Event (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual</Role>
      <ShortName>Note 13 - Subsequent Event (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-13-subsequent-event</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note 3 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual</Role>
      <ShortName>Note 3 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details</Role>
      <ShortName>Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details</Role>
      <ShortName>Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Note 5 - Notes Payable (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual</Role>
      <ShortName>Note 5 - Notes Payable (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-5-notes-payable</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Note 6 - Convertible Debentures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual</Role>
      <ShortName>Note 6 - Convertible Debentures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-6-convertible-debentures-</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Note 7 - Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-7-commitments-details-textual</Role>
      <ShortName>Note 7 - Commitments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-7-commitments</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual</Role>
      <ShortName>Note 8 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Note 8 - Stockholders' Equity - Preferred Stock Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details</Role>
      <ShortName>Note 8 - Stockholders' Equity - Preferred Stock Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Note 8 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details</Role>
      <ShortName>Note 8 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Note 8 - Stockholders' Equity- Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details</Role>
      <ShortName>Note 8 - Stockholders' Equity- Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Note 8 - Stockholders' Equity - Summary of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details</Role>
      <ShortName>Note 8 - Stockholders' Equity - Summary of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Note 9 - Retirement Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual</Role>
      <ShortName>Note 9 - Retirement Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-9-retirement-plan</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Note 10 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual</Role>
      <ShortName>Note 10 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-10-income-taxes-tables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Note 10 - Income Taxes - Reconciliation of Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details</Role>
      <ShortName>Note 10 - Income Taxes - Reconciliation of Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Note 11 - Grants and Collaboration Revenue (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual</Role>
      <ShortName>Note 11 - Grants and Collaboration Revenue (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Note 12 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual</Role>
      <ShortName>Note 12 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-note-12-subsequent-events-</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="govx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" original="govx-20210930.htm">govx-20210930.htm</File>
    <File>ex_331601.htm</File>
    <File>ex_331664.htm</File>
    <File>ex_331720.htm</File>
    <File>govx-20210930.xsd</File>
    <File>govx-20210930_cal.xml</File>
    <File>govx-20210930_def.xml</File>
    <File>govx-20210930_lab.xml</File>
    <File>govx-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>a02.jpg</File>
    <File>a03.jpg</File>
    <File>govx20220202_s1img001.gif</File>
    <File>govx20220202_s1img002.gif</File>
    <File>govx20220202_s1img005.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="929">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="17">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "govx-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 270,
   "dts": {
    "calculationLink": {
     "local": [
      "govx-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "govx-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "govx-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "govx-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "govx-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "govx-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 436,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 66,
    "http://geovax.com/20210930": 6,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 77
   },
   "keyCustom": 44,
   "keyStandard": 319,
   "memberCustom": 60,
   "memberStandard": 17,
   "nsprefix": "govx",
   "nsuri": "http://geovax.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://geovax.com/20210930/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "009 - Statement - Consolidated Statements of Operations",
     "role": "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010 - Statement - Consolidated Statements of Stockholders' Equity (Deficiency)",
     "role": "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficiency)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "govx:StockIssuedDuringPeriodSharesDebentureConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "011 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "govx:StockIssuedDuringPeriodSharesWarrantsExercised",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "012 - Statement - Consolidated Statements of Cash Flows (Parentheticals)",
     "role": "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
     "shortName": "Consolidated Statements of Cash Flows (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 1 - Description of Business",
     "role": "http://geovax.com/20210930/role/statement-note-1-description-of-business-",
     "shortName": "Note 1 - Description of Business",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 2 - Basis of Presentation",
     "role": "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation",
     "shortName": "Note 2 - Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements",
     "role": "http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-",
     "shortName": "Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 4 - Basic and Diluted Loss Per Common Share",
     "role": "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share",
     "shortName": "Note 4 - Basic and Diluted Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 5 - Property and Equipment",
     "role": "http://geovax.com/20210930/role/statement-note-5-property-and-equipment",
     "shortName": "Note 5 - Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 6 - Accrued Expenses",
     "role": "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-",
     "shortName": "Note 6 - Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "role": "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 7 - Notes Payable",
     "role": "http://geovax.com/20210930/role/statement-note-7-notes-payable",
     "shortName": "Note 7 - Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 8 - Commitments",
     "role": "http://geovax.com/20210930/role/statement-note-8-commitments",
     "shortName": "Note 8 - Commitments",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 9 - Stockholders' Equity",
     "role": "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
     "shortName": "Note 9 - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 10 - Stock-based Expense",
     "role": "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
     "shortName": "Note 10 - Stock-based Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 11 - Income Taxes",
     "role": "http://geovax.com/20210930/role/statement-note-11-income-taxes",
     "shortName": "Note 11 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "govx:GovernmentGrantsandContractsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 12 - Grants and Collaboration Revenue",
     "role": "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
     "shortName": "Note 12 - Grants and Collaboration Revenue",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 13 - Subsequent Event",
     "role": "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
     "shortName": "Note 13 - Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 1 - Description of Business",
     "role": "http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF",
     "shortName": "Note 1 - Description of Business",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "role": "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 3 - Property and Equipment",
     "role": "http://geovax.com/20210930/role/statement-note-3-property-and-equipment",
     "shortName": "Note 3 - Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "govx:ScheduleOfPreferredStockTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2019-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "role": "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 4 - Accrued Expenses",
     "role": "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-",
     "shortName": "Note 4 - Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 5 - Notes Payable",
     "role": "http://geovax.com/20210930/role/statement-note-5-notes-payable",
     "shortName": "Note 5 - Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 6 - Convertible Debentures",
     "role": "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
     "shortName": "Note 6 - Convertible Debentures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 7 - Commitments",
     "role": "http://geovax.com/20210930/role/statement-note-7-commitments",
     "shortName": "Note 7 - Commitments",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 8 - Stockholders' Equity",
     "role": "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
     "shortName": "Note 8 - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 9 - Retirement Plan",
     "role": "http://geovax.com/20210930/role/statement-note-9-retirement-plan",
     "shortName": "Note 9 - Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 10 - Income Taxes",
     "role": "http://geovax.com/20210930/role/statement-note-10-income-taxes",
     "shortName": "Note 10 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "govx:GovernmentGrantsandContractsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note 11 - Grants and Collaboration Revenue",
     "role": "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
     "shortName": "Note 11 - Grants and Collaboration Revenue",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note 12 - Subsequent Events",
     "role": "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
     "shortName": "Note 12 - Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "role": "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note 5 - Property and Equipment (Tables)",
     "role": "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables",
     "shortName": "Note 5 - Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note 6 - Accrued Expenses (Tables)",
     "role": "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables",
     "shortName": "Note 6 - Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Note 3 - Property and Equipment (Tables)",
     "role": "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables",
     "shortName": "Note 3 - Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Note 4 - Accrued Expenses (Tables)",
     "role": "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables",
     "shortName": "Note 4 - Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "govx:ScheduleOfPreferredStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Note 8 - Stockholders' Equity (Tables)",
     "role": "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables",
     "shortName": "Note 8 - Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "govx:ScheduleOfPreferredStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Note 10 - Income Taxes (Tables)",
     "role": "http://geovax.com/20210930/role/statement-note-10-income-taxes-tables",
     "shortName": "Note 10 - Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SummaryOfValuationAllowanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)",
     "role": "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SummaryOfValuationAllowanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Note 2 - Basis of Presentation (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual",
     "shortName": "Note 2 - Basis of Presentation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Note 4 - Basic and Diluted Loss Per Common Share (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual",
     "shortName": "Note 4 - Basic and Diluted Loss Per Common Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited)",
     "role": "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-04-01_2020-06-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInBridgeFinancingMember_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
     "shortName": "Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
     "shortName": "Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromNotesPayable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Note 7 - Notes Payable (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual",
     "shortName": "Note 7 - Notes Payable (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ExtinguishmentOfDebtAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unitRef": "SquareFoot",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Note 8 - Commitments (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual",
     "shortName": "Note 8 - Commitments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-04-01_2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual",
     "shortName": "Note 9 - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-08-01_2021-08-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember",
      "decimals": "INF",
      "lang": null,
      "name": "govx:ClassOfWarrantOrRightExercisedDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Note 10 - Stock-based Expense (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
     "shortName": "Note 10 - Stock-based Expense (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "lang": null,
      "name": "govx:StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Note 11 - Income Taxes (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual",
     "shortName": "Note 11 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Note 12 - Grants and Collaboration Revenue (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual",
     "shortName": "Note 12 - Grants and Collaboration Revenue (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "govx:GovernmentGrantsandContractsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-07-01_2020-09-30_ProductOrServiceAxis-LeidosIncResearchCollaborativeAgreementMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "govx:UpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Note 13 - Subsequent Event (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual",
     "shortName": "Note 13 - Subsequent Event (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-11-09_2021-11-09_CounterpartyNameAxis-CityOfHopeMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "govx:UpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Note 3 - Property and Equipment (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual",
     "shortName": "Note 3 - Property and Equipment (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
     "shortName": "Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
     "shortName": "Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromNotesPayable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Note 5 - Notes Payable (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
     "shortName": "Note 5 - Notes Payable (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Note 6 - Convertible Debentures (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
     "shortName": "Note 6 - Convertible Debentures (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unitRef": "SquareFoot",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Note 7 - Commitments (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual",
     "shortName": "Note 7 - Commitments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-02-11_2021-02-11",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
     "shortName": "Note 8 - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-09-24_2020-09-24",
      "decimals": "-5",
      "lang": null,
      "name": "govx:ProceedsFromIssuanceOrSaleOfEquityGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Note 8 - Stockholders' Equity - Preferred Stock Summary (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details",
     "shortName": "Note 8 - Stockholders' Equity - Preferred Stock Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "govx:ScheduleOfPreferredStockTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Note 8 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
     "shortName": "Note 8 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Note 8 - Stockholders' Equity- Stock Option Activity (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details",
     "shortName": "Note 8 - Stockholders' Equity- Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "govx:StockIssuedDuringPeriodSharesWarrantsExercised",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)",
     "role": "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Note 8 - Stockholders' Equity - Summary of Warrants (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
     "shortName": "Note 8 - Stockholders' Equity - Summary of Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31_RangeAxis-WeightedAverageMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Note 9 - Retirement Plan (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual",
     "shortName": "Note 9 - Retirement Plan (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Note 10 - Income Taxes (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual",
     "shortName": "Note 10 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details",
     "shortName": "Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Note 10 - Income Taxes - Reconciliation of Income Tax Benefit (Details)",
     "role": "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details",
     "shortName": "Note 10 - Income Taxes - Reconciliation of Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Note 11 - Grants and Collaboration Revenue (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
     "shortName": "Note 11 - Grants and Collaboration Revenue (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "govx:GovernmentGrantsandContractsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2020-01-01_2020-12-31_ProductOrServiceAxis-ResearchAgreementsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Note 12 - Subsequent Events (Details Textual)",
     "role": "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
     "shortName": "Note 12 - Subsequent Events (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "d_2021-01-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "076 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)",
     "role": "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2018-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx-20210930.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "007 - Statement - Consolidated Balance Sheets",
     "role": "http://geovax.com/20210930/role/statement-consolidated-balance-sheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "008 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 78,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20210930/role/statement-document-and-entity-information",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-tables",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-commitments",
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-commitments",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables",
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan",
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20210930/role/statement-document-and-entity-information",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-tables",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-commitments",
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-commitments",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables",
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan",
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geovax.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "govx_AccruedLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding accrued liabilities.",
        "label": "Accrued Liabilities [Policy Text Block]"
       }
      }
     },
     "localname": "AccruedLiabilitiesPolicyTextBlock",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "govx_CapitalUnitsTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the tranche one capital units.",
        "label": "Capital Units Tranche One [Member]"
       }
      }
     },
     "localname": "CapitalUnitsTrancheOneMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_CapitalUnitsTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the tranche two capital units.",
        "label": "Capital Units Tranche Two [Member]"
       }
      }
     },
     "localname": "CapitalUnitsTrancheTwoMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_CityOfHopeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents City of Hope.",
        "label": "City of Hope [Member]"
       }
      }
     },
     "localname": "CityOfHopeMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during period.",
        "label": "govx_ClassOfWarrantOrRightExercisedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights issued during period.",
        "label": "govx_ClassOfWarrantOrRightIssuedDuringPeriod",
        "terseLabel": "Class Of Warrant Or Right, Issued During Period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time for warrants to be exercisable.",
        "label": "govx_ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable",
        "terseLabel": "Class of Warrant or Right, Period for Warrants or Rights Exercisable (Day)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "govx_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents warrants to purchase common stock.",
        "label": "Common Stock Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents consultants.",
        "label": "Consultants [Member]"
       }
      }
     },
     "localname": "ConsultantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionFromConvertibleDebenturesToConversionUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of convertible debentures to conversion units.",
        "label": "Conversion from Convertible Debentures to Conversion Units [Member]"
       }
      }
     },
     "localname": "ConversionFromConvertibleDebenturesToConversionUnitsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionFromNotesPayableToConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents conversion of notes payable to convertible preferred stock.",
        "label": "Conversion from Notes Payable to Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConversionFromNotesPayableToConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the conversion from Series F Preferred Stock to Series H Preferred Stock.",
        "label": "Conversion from Series F Preferred Stock to Series H Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConversionFromSeriesFPreferredStockToSeriesHPreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfPreferredStockIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the conversion of preferred stock into common stock.",
        "label": "Conversion of Preferred Stock into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfPreferredStockIntoCommonStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfSeriesCPreferredStockIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the conversion of series C preferred stock into common stock.",
        "label": "Conversion of Series C Preferred Stock Into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesCPreferredStockIntoCommonStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to a conversion.",
        "label": "Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to a conversion.",
        "label": "Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfSeriesFPreferredStockIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about conversion of series F preferred stock into common stock.",
        "label": "Conversion of Series F Preferred Stock Into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesFPreferredStockIntoCommonStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfSeriesHPreferredStockIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about conversion of series H preferred stock into common stock.",
        "label": "Conversion of Series H Preferred Stock Into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesHPreferredStockIntoCommonStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about conversion of series H, Series I, and Series J preferred stock into common stock.",
        "label": "Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfSeriesIPreferredStockIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about conversion of series I preferred stock into common stock.",
        "label": "Conversion of Series I Preferred Stock Into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesIPreferredStockIntoCommonStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfSeriesJPreferredStockIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about conversion of series J preferred stock into common stock.",
        "label": "Conversion of Series J Preferred Stock into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesJPreferredStockIntoCommonStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionUnitsTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the tranche one conversion units.",
        "label": "Conversion Units Tranche One [Member]"
       }
      }
     },
     "localname": "ConversionUnitsTrancheOneMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionUnitsTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the tranche two conversion units.",
        "label": "Conversion Units Tranche Two [Member]"
       }
      }
     },
     "localname": "ConversionUnitsTrancheTwoMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion warrant.",
        "label": "Conversion Warrant [Member]"
       }
      }
     },
     "localname": "ConversionWarrantMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion warrants.",
        "label": "Conversion Warrants [Member]"
       }
      }
     },
     "localname": "ConversionWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConvertibleDebenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to convertible debenture.",
        "label": "Convertible Debentures [Member]"
       }
      }
     },
     "localname": "ConvertibleDebenturesMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of convertible preferred stock and related warrants authorized for issuance.",
        "label": "govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized",
        "terseLabel": "Convertible Preferred Stock and Related Warrants, Authorized (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockAndRelatedWarrantsAuthorized",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_ConvertiblePreferredStockAndRelatedWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of convertible preferred stock and related warrants issued during the period.",
        "label": "govx_ConvertiblePreferredStockAndRelatedWarrantsIssued",
        "terseLabel": "Convertible Preferred Stock and Related Warrants Issued (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockAndRelatedWarrantsIssued",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_ConvertiblePreferredStockConversionPrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion price related to convertible preferred stock.",
        "label": "govx_ConvertiblePreferredStockConversionPrice1",
        "terseLabel": "Convertible Preferred Stock, Conversion Price1 (in dollars per share)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockConversionPrice1",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "govx_DebtConversionAccruedInterestAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the debt accrued interest being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Related accrued interest",
        "terseLabel": "Debt Conversion, Accrued Interest Amount"
       }
      }
     },
     "localname": "DebtConversionAccruedInterestAmount",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt and interest is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount",
        "terseLabel": "Debt Conversion, Converted Instrument, Principal and Interest, Amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentPrincipalAndInterestAmount",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_DebtConversionOriginalDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents original debt discount of debt conversion.",
        "label": "govx_DebtConversionOriginalDebtDiscount",
        "terseLabel": "Debt Conversion, Original Debt Discount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtDiscount",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum ownership percentage of common stock outstanding allowed for the conversion feature embedded in the debt instrument to become effective.",
        "label": "govx_DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage",
        "terseLabel": "Debt Instrument, Convertible, Maximum Allowed Ownership of Common Stock Outstanding, Percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleMaximumAllowedOwnershipOfCommonStockOutstandingPercentage",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "govx_DeferredCompensationLiabilityConversionToEquityAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred compensation liability being converted into equity in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Deferred compensation",
        "terseLabel": "Deferred Compensation Liability Conversion to Equity, Amount"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityConversionToEquityAmount",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_DeferredCompensationLiabilityConversionToEquityConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share for the conversion of deferred compensation liability to equity.",
        "label": "govx_DeferredCompensationLiabilityConversionToEquityConversionPrice",
        "terseLabel": "Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share)"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityConversionToEquityConversionPrice",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued salaries and directors' fees.",
        "label": "govx_DeferredTaxAssetsAccruedSalariesAndDirectorsFees",
        "terseLabel": "Accrued salaries and directors\u2019 fees"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccruedSalariesAndDirectorsFees",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_DeferredTaxAssetsBeforeValuationAllowanceNet": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances and after deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "govx_DeferredTaxAssetsBeforeValuationAllowanceNet",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsBeforeValuationAllowanceNet",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents employees and directors.",
        "label": "Employees and Directors [Member]"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_EquipmentAndFurnishingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents equipment and furnishings.",
        "label": "Equipment and Furnishings [Member]"
       }
      }
     },
     "localname": "EquipmentAndFurnishingsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expense related to consulting and investment banking agreements.",
        "label": "Expense Related To Consulting And Investment Banking Agreements [Member]"
       }
      }
     },
     "localname": "ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ExtinguishmentOfDebtIncludingInterestAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount extinguishment of debt including interest amount.",
        "label": "Extinguishment of debt"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtIncludingInterestAmount",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_GainLossFromInterestForgiven": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents gain (loss) from interest forgiven.",
        "label": "govx_GainLossFromInterestForgiven",
        "terseLabel": "Gain (Loss) from Interest Forgiven"
       }
      }
     },
     "localname": "GainLossFromInterestForgiven",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_GovernmentGrantsandContractsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.",
        "label": "Government Grants and Contracts [Text Block]"
       }
      }
     },
     "localname": "GovernmentGrantsandContractsTextBlock",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents gross proceeds from issuance of common stock for public offering.",
        "label": "govx_GrossProceedsFromIssuanceOfCommonStockPublicOffering",
        "terseLabel": "Gross Proceeds from Issuance of Common Stock, Public Offering"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStockPublicOffering",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_June2020WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to June 2020 warrants.",
        "label": "June 2020 Warrants [Member]"
       }
      }
     },
     "localname": "June2020WarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_LeidosIncResearchCollaborativeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Leidos research collaborative agreement.",
        "label": "Leidos, Inc. Research Collaborative Agreement [Member]"
       }
      }
     },
     "localname": "LeidosIncResearchCollaborativeAgreementMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_LicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense associated with license.",
        "label": "govx_LicenseFees",
        "terseLabel": "License Fees"
       }
      }
     },
     "localname": "LicenseFees",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_LicenseFirstAnniversaryPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents first anniversary payment for license.",
        "label": "License First Anniversary Payment [Member]"
       }
      }
     },
     "localname": "LicenseFirstAnniversaryPaymentMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_LicenseSecondAnniversaryPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents second anniversary payment for license.",
        "label": "License Second Anniversary Payment [Member]"
       }
      }
     },
     "localname": "LicenseSecondAnniversaryPaymentMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ManagementWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the management warrant.",
        "label": "Management Warrant [Member]"
       }
      }
     },
     "localname": "ManagementWarrantMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_NIHGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants from the National Institutes of Health (NIH).",
        "label": "NIH Grants [Member]"
       }
      }
     },
     "localname": "NIHGrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_NumberOfCommonStockSecuritiesCalledByEachUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock securities into which each unit may be converted.",
        "label": "govx_NumberOfCommonStockSecuritiesCalledByEachUnit",
        "terseLabel": "Number of Common Stock Securities Called by Each Unit (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockSecuritiesCalledByEachUnit",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_NumberOfInstitutionalInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to number of institutional investors.",
        "label": "govx_NumberOfInstitutionalInvestors",
        "terseLabel": "Number of Institutional Investors"
       }
      }
     },
     "localname": "NumberOfInstitutionalInvestors",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of series C and series E preferred stock exchanged for series F convertible preferred stock.",
        "label": "govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock",
        "terseLabel": "Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock (in shares)"
       }
      }
     },
     "localname": "NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_NumberOfWarrantsCalledByEachUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants into which each unit may be converted.",
        "label": "govx_NumberOfWarrantsCalledByEachUnit",
        "terseLabel": "Number of Warrants Called by Each Unit (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsCalledByEachUnit",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_OfficeAndLaboratoryLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to office and laboratory lease agreement.",
        "label": "Office and Laboratory Lease Agreement [Member]"
       }
      }
     },
     "localname": "OfficeAndLaboratoryLeaseAgreementMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-commitments",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "govx_OperatingLossCarryforwardsSubjectToExpiration",
        "terseLabel": "Operating Loss Carryforwards, Subject to Expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_OtherFurnitureFixturesAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Furniture Fixtures And Equipment [Member]"
       }
      }
     },
     "localname": "OtherFurnitureFixturesAndEquipmentMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_OutstandingWarrantsExcludingPreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to outstanding warrants excluding pre-funded warrants.",
        "label": "Outstanding Warrants Excluding Pre-Funded Warrants [Member]"
       }
      }
     },
     "localname": "OutstandingWarrantsExcludingPreFundedWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_PaycheckProtectionProgramCaresActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents loan designed to provide funds for small businesses to keep their employees on the payroll.",
        "label": "Paycheck Protection Program CARES Act [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCaresActMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_PercentageOfOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of offering price.",
        "label": "govx_PercentageOfOfferingPrice",
        "terseLabel": "Percentage of Offering Price"
       }
      }
     },
     "localname": "PercentageOfOfferingPrice",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "govx_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the pre-funded warrants.",
        "label": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of stock issued for services during period recorded as prepaid expense.",
        "label": "govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod",
        "terseLabel": "Prepaid Expense, Value of Stock Issued for Services During Period"
       }
      }
     },
     "localname": "PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_ProceedsFromConvertibleDebtGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to gross proceeds from convertible debt.",
        "label": "govx_ProceedsFromConvertibleDebtGross",
        "terseLabel": "Proceeds from Convertible Debt, Gross"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebtGross",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of common stock and warrants.",
        "label": "Net proceeds from sale of common stock and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum amount of proceeds from issuance of convertible preferred stock and related warrants during the period.",
        "label": "govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum",
        "terseLabel": "Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_ProceedsFromIssuanceOrSaleOfEquityGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "govx_ProceedsFromIssuanceOrSaleOfEquityGross",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityGross",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_RepresentativeWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the representative warrants.",
        "label": "Representative Warrants [Member]"
       }
      }
     },
     "localname": "RepresentativeWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ResearchAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Agreements [Member]",
        "label": "Research Agreements [Member]"
       }
      }
     },
     "localname": "ResearchAgreementsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ReverseStockSplitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding.",
        "label": "Reverse Stock Split [Member]"
       }
      }
     },
     "localname": "ReverseStockSplitMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SBIRGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Small Business Innovative Research (SBIR) grant.",
        "label": "SBIR Grant [Member]"
       }
      }
     },
     "localname": "SBIRGrantMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ScheduleOfPreferredStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of preferred stock.",
        "label": "Schedule of Preferred Stock [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfPreferredStockTableTextBlock",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "govx_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Series B Convertible Preferred Stock.",
        "label": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents series C convertible stock as per the securities purchase agreement.",
        "label": "Series C Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesEConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Series E Convertible Preferred Stock.",
        "label": "Series E Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesFConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about Series F Convertible Preferred Stock.",
        "label": "Series F Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesFConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesGConvertiblePreferredStockAndRelatedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about series G convertible preferred stock and related warrants.",
        "label": "Series G Convertible Preferred Stock and Related Warrants [Member]"
       }
      }
     },
     "localname": "SeriesGConvertiblePreferredStockAndRelatedWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesGConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Series G Preferred Stock.",
        "label": "Series G Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesGConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesHConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Series H Convertible Preferred Stock.",
        "label": "Series H Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesHConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesIConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Series I Convertible Preferred Stock.",
        "label": "Series I Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesIConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesIWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Series I Warrants.",
        "label": "Series I Warrants [Member]"
       }
      }
     },
     "localname": "SeriesIWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesJConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Series J Convertible Preferred Stock.",
        "label": "Series J Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesJConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_StockIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to 2020 stock incentive plan.",
        "label": "Stock Incentive Plan 2020 [Member]"
       }
      }
     },
     "localname": "StockIncentivePlan2020Member",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period for the cancellation of accrued compensation.",
        "label": "Common stock issued for cancellation of accrued compensation (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_StockIssuedDuringPeriodSharesDebentureConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of debenture conversion.",
        "label": "Issuance of common stock upon debenture conversion (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesDebentureConversion",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares of common stock issued during the period upon exercise of warrants.",
        "label": "Common stock issued (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cancellation of accrued compensation.",
        "label": "Issuance of common stock upon cancellation of accrued compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCancellationOfAccruedCompensation",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockIssuedDuringPeriodValueDebentureConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon Debenture Conversion.",
        "label": "Issuance of common stock upon debenture conversion"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueDebentureConversion",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices",
        "terseLabel": "Stock Issued During Period, Value Expensed During the Period, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockIssuedDuringPeriodValueReverseStockSplits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in value of shares as a result of reverse stock split.",
        "label": "Roundup of shares following reverse stock split"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueReverseStockSplits",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockIssuedDuringPeriodValueWarrantExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the exercise of warrants.",
        "label": "Issuance of common stock upon warrant exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantExercise",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Warrants exercised for common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockPurchaseWarrantToPnpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock purchase warrant to PNP.",
        "label": "Stock Purchase Warrant to PNP [Member]"
       }
      }
     },
     "localname": "StockPurchaseWarrantToPnpMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_StockPurchaseWarrantsFirstIssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock purchase warrants, first issuance.",
        "label": "Stock Purchase Warrants First Issuance [Member]"
       }
      }
     },
     "localname": "StockPurchaseWarrantsFirstIssuanceMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_StockPurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock purchase warrants.",
        "label": "Stock Purchase Warrants [Member]"
       }
      }
     },
     "localname": "StockPurchaseWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_StockPurchaseWarrantsSecondIssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock purchase warrants second issuance.",
        "label": "Stock Purchase Warrants Second Issuance [Member]"
       }
      }
     },
     "localname": "StockPurchaseWarrantsSecondIssuanceMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_UnitConversionAndManagementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the unit, conversion and management warrants.",
        "label": "Unit, Conversion and Management Warrants [Member]"
       }
      }
     },
     "localname": "UnitConversionAndManagementWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_UnitWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the unit warrant.",
        "label": "Unit Warrant [Member]"
       }
      }
     },
     "localname": "UnitWarrantMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_UnitWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the unit warrants.",
        "label": "Unit Warrants [Member]"
       }
      }
     },
     "localname": "UnitWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_UnitsIncludingPrefundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the capital units that include pre-funded warrants.",
        "label": "Units Including Pre-Funded Warrants [Member]"
       }
      }
     },
     "localname": "UnitsIncludingPrefundedWarrantsMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of reimbursable purchase obligations.",
        "label": "govx_UnrecordedUnconditionalPurchaseObligationReimbursableAmount",
        "terseLabel": "Unrecorded Unconditional Purchase Obligation Reimbursable, Amount"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationReimbursableAmount",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_UnusedGrantFunds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant funds available for use.",
        "label": "govx_UnusedGrantFunds",
        "terseLabel": "Unused Grant Funds"
       }
      }
     },
     "localname": "UnusedGrantFunds",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_UpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fee paid at the beginning.",
        "label": "govx_UpfrontFee",
        "terseLabel": "Upfront Fee"
       }
      }
     },
     "localname": "UpfrontFee",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_WarrantIssuanceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs associated with the issuance of warrants.",
        "label": "govx_WarrantIssuanceExpense",
        "terseLabel": "Warrant Issuance Expense"
       }
      }
     },
     "localname": "WarrantIssuanceExpense",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_WarrantIssuedForTechnologyLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents warrant issued for technology license.",
        "label": "Warrant Issued for Technology License[Member]"
       }
      }
     },
     "localname": "WarrantIssuedForTechnologyLicenseMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_WarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in noncash financing activities.",
        "label": "Warrant issued (in shares)"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_WarrantsIssuedInBridgeFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents warrants issued in bridge financing.",
        "label": "Warrants Issued in Bridge Financing [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInBridgeFinancingMember",
     "nsuri": "http://geovax.com/20210930",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Income Taxes - Reconciliation of Income Tax Benefit (Details)"
       }
      }
     },
     "localname": "statement-statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-10-income-taxes-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Income Taxes"
       }
      }
     },
     "localname": "statement-statement-note-10-income-taxes-tables",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-3-property-and-equipment-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Property and Equipment"
       }
      }
     },
     "localname": "statement-statement-note-3-property-and-equipment-tables",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-4-accrued-expenses-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Accrued Expenses"
       }
      }
     },
     "localname": "statement-statement-note-4-accrued-expenses-tables",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-5-property-and-equipment-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment"
       }
      }
     },
     "localname": "statement-statement-note-5-property-and-equipment-tables",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)"
       }
      }
     },
     "localname": "statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-6-accrued-expenses-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Accrued Expenses"
       }
      }
     },
     "localname": "statement-statement-note-6-accrued-expenses-tables",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-8-stockholders-equity-preferred-stock-summary-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stockholders' Equity - Preferred Stock Summary (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockholders-equity-preferred-stock-summary-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-8-stockholders-equity-stock-option-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stockholders' Equity- Stock Option Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockholders-equity-stock-option-activity-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-8-stockholders-equity-summary-of-warrants-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stockholders' Equity - Summary of Warrants (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockholders-equity-summary-of-warrants-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-8-stockholders-equity-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stockholders' Equity"
       }
      }
     },
     "localname": "statement-statement-note-8-stockholders-equity-tables",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule II - Valuation and Qualifying Accounts (Details)"
       }
      }
     },
     "localname": "statement-statement-schedule-ii-valuation-and-qualifying-accounts-details",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://geovax.com/20210930",
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r45",
      "r47",
      "r89",
      "r90",
      "r193",
      "r228",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r192",
      "r227",
      "r262",
      "r263",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r404",
      "r406",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r192",
      "r227",
      "r262",
      "r263",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r404",
      "r406",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r155",
      "r246",
      "r247",
      "r385",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r155",
      "r246",
      "r247",
      "r385",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r192",
      "r227",
      "r249",
      "r262",
      "r263",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r404",
      "r406",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r192",
      "r227",
      "r249",
      "r262",
      "r263",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r404",
      "r406",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r46",
      "r47",
      "r89",
      "r90",
      "r193",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r158",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r374",
      "r376",
      "r379",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance.",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r370"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses (Note 4)",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r35"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued salaries"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r166"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      },
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r292",
      "r293",
      "r294",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r265",
      "r267",
      "r298",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock option expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r188",
      "r231",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Warrants issued in bridge financing"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r267",
      "r289",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r59",
      "r70",
      "r212",
      "r349"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt discount",
        "terseLabel": "Amortization of Debt Discount (Premium)"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "us-gaap_AreaOfRealEstateProperty",
        "terseLabel": "Area of Real Estate Property (Square Foot)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r86",
      "r144",
      "r147",
      "r153",
      "r160",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r329",
      "r332",
      "r339",
      "r368",
      "r370",
      "r387",
      "r396"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r44",
      "r86",
      "r160",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r329",
      "r332",
      "r339",
      "r368",
      "r370"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r268",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalUnitsMember": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares.",
        "label": "Capital Units [Member]"
       }
      }
     },
     "localname": "CapitalUnitsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r25",
      "r72"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r66",
      "r72",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r340"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r84",
      "r86",
      "r113",
      "r114",
      "r115",
      "r117",
      "r119",
      "r126",
      "r127",
      "r128",
      "r160",
      "r177",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r225",
      "r226",
      "r229",
      "r230",
      "r339",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r235",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price (in dollars per share)",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Number of warrants (in shares)",
        "terseLabel": "Class of Warrant or Right, Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r174",
      "r391",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-7-commitments",
      "http://geovax.com/20210930/role/statement-note-8-commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, authorized (in shares)",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r370"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $.001 par value: Authorized shares \u2013 600,000,000 Issued and outstanding shares \u2013 3,834,095 and 14,992 at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Preferred stock converted (in shares)",
        "terseLabel": "Conversion of Stock, Shares Converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Shares issued (in shares)",
        "terseLabel": "Conversion of Stock, Shares Issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Shares issued upon conversion (in shares)",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Pre-funded stock purchase warrants (in shares)",
        "terseLabel": "Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Convertible debentures",
        "terseLabel": "Debt Conversion, Original Debt, Amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r206",
      "r213",
      "r214",
      "r215",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r85",
      "r91",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r218",
      "r219",
      "r220",
      "r221",
      "r352",
      "r388",
      "r389",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r191",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r189",
      "r218",
      "r219",
      "r350",
      "r352",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r37",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38",
      "r85",
      "r91",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r218",
      "r219",
      "r220",
      "r221",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_DebtInstrumentTerm",
        "terseLabel": "Debt Instrument, Term (Year)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r202",
      "r349",
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "us-gaap_DebtInstrumentUnamortizedDiscount",
        "terseLabel": "Debt Instrument, Unamortized Discount, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "govx_DeferredTaxAssetsBeforeValuationAllowanceNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred tax asset after reduction for valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r315",
      "r317",
      "r318"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development tax credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "govx_DeferredTaxAssetsBeforeValuationAllowanceNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssets": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r70",
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "us-gaap_DepreciationAndAmortization",
        "terseLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r70",
      "r142"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-7-commitments",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-8-commitments",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r51",
      "r52",
      "r53",
      "r101",
      "r102",
      "r103",
      "r105",
      "r110",
      "r112",
      "r125",
      "r161",
      "r231",
      "r233",
      "r292",
      "r293",
      "r294",
      "r320",
      "r321",
      "r334",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r407",
      "r408",
      "r409",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "us-gaap_ExtinguishmentOfDebtAmount",
        "terseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r70",
      "r222",
      "r223"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on debt extinguishment",
        "negatedLabel": "Gain on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grant funds and other receivables"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r168",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r306",
      "r308",
      "r314",
      "r322",
      "r324",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r111",
      "r112",
      "r143",
      "r304",
      "r323",
      "r325",
      "r402"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "totalLabel": "Reported income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r302",
      "r303",
      "r308",
      "r309",
      "r313",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance, net of expired items and other adjustments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "U.S. federal statutory rate applied to pretax loss"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch",
        "negatedLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r67",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "us-gaap_IncomeTaxesPaid",
        "terseLabel": "Income Taxes Paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInReceivables",
        "negatedLabel": "Grant funds and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r81",
      "r162",
      "r382",
      "r383",
      "r384",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r54",
      "r141",
      "r348",
      "r351",
      "r393"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "us-gaap_InterestExpense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r59",
      "r210",
      "r217",
      "r220",
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "us-gaap_InterestExpenseDebt",
        "terseLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Domain]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r57",
      "r140"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Warrant issued for technology license fee"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "us-gaap_LeaseAndRentalExpense",
        "terseLabel": "Operating Leases, Rent Expense, Total"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-commitments",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-commitments",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year One"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year Two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r86",
      "r148",
      "r160",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r330",
      "r332",
      "r333",
      "r339",
      "r368",
      "r369"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r86",
      "r160",
      "r339",
      "r370",
      "r390",
      "r398"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficiency)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r86",
      "r160",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r330",
      "r332",
      "r333",
      "r339",
      "r368",
      "r369",
      "r370"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r91",
      "r175",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
        "terseLabel": "Long-Term Debt, Maturity, Year One"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r91",
      "r175",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
        "terseLabel": "Long-Term Debt, Maturity, Year Three"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r91",
      "r175",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
        "terseLabel": "Long-Term Debt, Maturity, Year Two"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Note payable, net of current portion"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r38",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature of Expense [Axis]"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r129",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r48",
      "r49",
      "r53",
      "r55",
      "r71",
      "r86",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r116",
      "r144",
      "r146",
      "r149",
      "r152",
      "r154",
      "r160",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r335",
      "r339",
      "r392",
      "r401"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonmonetaryTransactionTypeAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.",
        "label": "Nonmonetary Transaction Type [Axis]"
       }
      }
     },
     "localname": "NonmonetaryTransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonmonetaryTransactionTypeDomain": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.",
        "label": "Nonmonetary Transaction Type [Domain]"
       }
      }
     },
     "localname": "NonmonetaryTransactionTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r144",
      "r146",
      "r149",
      "r152",
      "r154"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r35"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.",
        "label": "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock",
        "negatedLabel": "Repurchase of preferred stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "us-gaap_PaymentsOfDebtIssuanceCosts",
        "terseLabel": "Payments of Debt Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r268",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)",
        "terseLabel": "Preferred Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)",
        "terseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r370"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $.01 par value (Note 8): Authorized shares \u2013 10,000,000 Issued and outstanding shares \u2013 100 and 2,486 at December 31, 2020 and 2019, respectively",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Net proceeds from bridge financing",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "us-gaap_ProceedsFromIssuanceOfCommonStock",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Net proceeds from sale of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
        "terseLabel": "Proceeds from Issuance of Preferred Stock and Preference Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Net proceeds from issuance of note payable",
        "terseLabel": "Proceeds from Notes Payable, Total"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Net proceeds from warrant exercises",
        "terseLabel": "Proceeds from Warrant Exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r165"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r167",
      "r370",
      "r394",
      "r399"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net (Note 3)",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r26",
      "r167",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "us-gaap_RepaymentsOfNotesPayable",
        "negatedLabel": "Principal repayment of note payable",
        "terseLabel": "Repayments of Notes Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r301",
      "r381",
      "r418"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r233",
      "r295",
      "r370",
      "r397",
      "r410",
      "r411"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r101",
      "r102",
      "r103",
      "r105",
      "r110",
      "r112",
      "r161",
      "r292",
      "r293",
      "r294",
      "r320",
      "r321",
      "r334",
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r138",
      "r139",
      "r145",
      "r150",
      "r151",
      "r155",
      "r156",
      "r157",
      "r245",
      "r246",
      "r385"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Grant and collaboration revenue",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r273",
      "r279",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r235",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Weighted average risk-free interest rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable, shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Exercisable, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Forfeited or expired, shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Forfeited or expired, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted, shares (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Outstanding, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r275",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Outstanding, shares (in shares)",
        "periodStartLabel": "Outstanding, shares (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Outstanding, Weighted Average Exercise Price (in dollars per share)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r266",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r268",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r284",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of option (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Outstanding, Weighted Average Remaining Contractual Term (Year)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term debt.",
        "label": "Short-term Debt [Text Block]"
       }
      }
     },
     "localname": "ShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r79",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r84",
      "r86",
      "r113",
      "r114",
      "r115",
      "r117",
      "r119",
      "r126",
      "r127",
      "r128",
      "r160",
      "r177",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r225",
      "r226",
      "r229",
      "r230",
      "r231",
      "r339",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r51",
      "r52",
      "r53",
      "r101",
      "r102",
      "r103",
      "r105",
      "r110",
      "r112",
      "r125",
      "r161",
      "r231",
      "r233",
      "r292",
      "r293",
      "r294",
      "r320",
      "r321",
      "r334",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r407",
      "r408",
      "r409",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-tables",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-commitments",
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-commitments",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables",
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan",
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r125",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-",
      "http://geovax.com/20210930/role/statement-note-1-description-of-business-A4C5FB3F-C458-441B-B6E3-FD9D8B4591BF",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-reconciliation-of-income-tax-benefit-details",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-tables",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense",
      "http://geovax.com/20210930/role/statement-note-10-stockbased-expense-details-textual",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-11-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes",
      "http://geovax.com/20210930/role/statement-note-11-income-taxes-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue",
      "http://geovax.com/20210930/role/statement-note-12-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation",
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-details-textual",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements-",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share",
      "http://geovax.com/20210930/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable",
      "http://geovax.com/20210930/role/statement-note-5-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-",
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-commitments",
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable",
      "http://geovax.com/20210930/role/statement-note-7-notes-payable-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-commitments",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-preferred-stock-summary-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables",
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan",
      "http://geovax.com/20210930/role/statement-note-9-retirement-plan-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r41",
      "r207",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Conversion of preferred stock to common stock (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Issuance of common stock for services (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r231",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Sale of common stock for cash (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Sale of convertible preferred stock for cash and cancellation of note payable (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Roundup of shares following reverse stock split (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r231",
      "r233",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercised, shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r42",
      "r231",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r231",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Sale of common stock for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Sale of convertible preferred stock for cash and cancellation of note payable"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r16",
      "r17",
      "r231",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "us-gaap_StockRepurchasedDuringPeriodShares",
        "negatedLabel": "Repurchase of preferred stock (in shares)",
        "terseLabel": "Stock Repurchased During Period, Shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r16",
      "r17",
      "r231",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "us-gaap_StockRepurchasedDuringPeriodValue",
        "negatedLabel": "Repurchase of preferred stock",
        "terseLabel": "Stock Repurchased During Period, Value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r20",
      "r21",
      "r86",
      "r159",
      "r160",
      "r339",
      "r370"
     ],
     "calculation": {
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity (deficiency)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-deficiency-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity (deficiency):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1",
        "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-2-basis-of-presentation-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r347",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r347",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r347",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r371",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-13-subsequent-event"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-",
      "http://geovax.com/20210930/role/statement-note-12-subsequent-events-details-textual",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-tables",
      "http://geovax.com/20210930/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-5-property-and-equipment-tables",
      "http://geovax.com/20210930/role/statement-note-6-accrued-expenses-tables",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-tables",
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-10-income-taxes",
      "http://geovax.com/20210930/role/statement-note-10-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).",
        "label": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
        "terseLabel": "Unrecorded Unconditional Purchase Obligation, Total"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-7-commitments-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r92",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "us-gaap_ValuationAllowancesAndReservesBalance",
        "periodEndLabel": "Balance at End Of Period",
        "periodStartLabel": "Balance at Beginning Of Period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "Additions Charged to Costs and Expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts",
        "terseLabel": "Additions Charged to Other Accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "us-gaap_ValuationAllowancesAndReservesDeductions",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "us-gaap_WarrantsAndRightsOutstanding",
        "terseLabel": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) (Year)",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-note-6-convertible-debentures-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-details-textual",
      "http://geovax.com/20210930/role/statement-note-8-stockholders-equity-summary-of-warrants-details",
      "http://geovax.com/20210930/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20210930/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://geovax.com/20210930/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e639-108305"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29502-108402"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123385986&loc=d3e32049-108421"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=6457341&loc=d3e32102-108422"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r419": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r421": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r422": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001437749-22-002516-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-002516-xbrl.zip
M4$L#!!0    ( "Z(1%2+NWO??0P  &$-   '    83 R+FIP9YV69U@3V[K'
M)X00""6T +*!H#05@4V1;*4$E"(J(DA1@B "0H2 (-V8T*4C<$!%:0***$T(
MH AL6E Y"DH)184D;)6>(,1H0G+"WOO<\^5\N/?^9_UGO<^:M6;>WZSWF6?X
M4_QY0/JXG8,=  *!@ N" ^!3@2NVL=A+ .#H".P' $ 4$ $9 D*""":P.Q@$
M0 0]2. +8/"?_8X!9^F_XIV3LPP@_->X5+^S['_BG7GV$0$!H5>#PB(%8VD5
M -"<QY\%C@)"(-!.^UM@"'A'(L+"8 A4! K=L:B8N)BH*$P4"H5)PF#B$@)!
MQ:3@DA)2._'.37:6[ZP2- E1J*C$_UG\WP$944 ?* >#]@!",B"P#(@_ " %
MF4) ?PKX6R AL#!$1) 23%PP@20M2!\,%A(D"Q$6P(*N"ZX#PC(0V=V&UB)R
MSK[0/>'R1HGYE:(:1YI[$2[O&)K&%R.2Q& *BDJ[E+6T=?;NVV]RT!3UVZ'#
M1VUL[>R/.1P_X^KF[G'VG*>??\"EP"#LY:N14=$QL7'QR2FI:3?2,S(+"O]1
M5'SK]IV2^U75-0\>UCZJ>]K22FIK[WCVO*]_8) \]/+5Z_=CXQ.3E*GI&2J-
MOO#'YR]?%Y>8&]\VMUC?V3]^[G"! ##HW_JO7#("+B'!'@A#=[A 0C$[$V2$
M(;L-162MG:&^X7)[C!)%Y8_D5S;WBFD8NS 0%R/>P10T3:A:S!VT/\G^=V!)
M_R^R_P'[#]<,("$H42$9L R !K:Y#1YT%!D'G3=(K&9"TQN\/PUXS4[;Y.\N
M"'Z<E5&@Y)L#U5_7J 6NE264+#W^8YO0SU-NY\$, _S?VZ.2>P)_TQC7O\\9
MCJ%AV&*)HF3TNY"[;]Y&*+,TIN;!2Y!#/DZ7;:+R(ZI_W1)Y >7!4CE>3AP9
M7G^9&7/M#G+&W#'LDLFZY$PZE]PY$7K;.BBS?"CCO%=CE!TBAB?VB'%B@-C2
MLZ++H/01?NT>)\$5SRWZ!$]^[BD?Z5"D&%E,]!DO?/$O/'PE?F^%>'E[XVI5
M-:\7W=+U94#2QYK"=53Q:)O!M9568^YH=724LNR[> N&7Y[D6KV5#[CCUE4@
M)C&J@0@:WJN%J>,H_^ #K(6Q4,O]L>549+^N3QE:/K:/<G[R5A#NN7ON<.VQ
M4]:_>*]96,H>SK\2/DK_*G8?D^YI^I8".24E!>\"#F?2>'#\WE'B)9]44Y[:
M6)3D&0[4 ?L@%Q?F5LS"1!;8W7Q4=DFO^81TY>W5TU KW:?G$'2))T^>&"FI
MB6Y50)VM#B'ZN0K;5>:JG*..M!H&H5FA'9FT-<U%U;V!H0HEN; <D_T+OJPP
MV* #*%EB01E8V]N ID_VT TD\=J3^MUJ;*(3$Y7]HE*AT*_66]S,V+C)67,C
M2GJH=$U._W7*W@.V.+8B)R16QYX/I-SB&/!D#9J/;M=&?N0#?B@,].["^@]N
M%Z=M[8O2B GHL2V"#,_YZ<H'6N%<W;NQH6NDVR8B3,G-=WM-?X;H76G"5+^Y
M]Z2PJ<,P6Z6^>H .5E<ME7=#,"W+/FGA5+PQI6ZX5+HG5.UR'^;"S<;S-1TC
MM17BX\Y>\%4$QPK+!UIZ$HBDAV,'PV0N4\;T<G,JL<YB49(1S-Z-5:K+D>SY
MXIC]Z95W;N_53C!;TJ7U9!,5+<WQ2FPF0YONQ2Q.J&>>&1JF+I<#V!)_6<_I
M1;N^)1J6,+7,NM.@QTV-SI<(QT]-9\NQ:@"/B:C?(G%&M WJB\YKQTJP&$Y=
M10%QMX\%L?< 5^\/WFMWWJ'GNR:[C98H<]);.IK%'VM?![1GE?^@!^GY@BND
MF8D^ULLS-@3UT?4#VGS@S'7P[*M$KGZ-T]=@^GJJ#YB(;93 *S*^]'9:'/V=
M &$,I>!HHWFY*PTUXP=SG$XDXCNJVUIB)\V"VS-<C8]M' @Y6]<&5, MM^_S
MC!ZN9O$!2#I['Z/L_0SM&W6H;[G>:>!G%^M]Y+;'@*G[XL)T\G?-:]97GC9]
M\<^M4G^$^,X'TKGV#]GH?LI,6_WUX >+\>=?W(JY%>.27DE*E6]YN38%$_ Y
M_ Y01KS-MQ-\&>C>1O!B#R2L=4Z8W4*-^O"=I]8]H7Z-<VU:WZUXRX#G>Z!O
M^9IY@<C<9PC^WH7Y&1X9B4!?/K2[?;O&W)>J&MS+<AD\S-;I;4,IQ+LWFH2J
M(D^7!!I[V3VIZ_N R[XIOKYHI1;<0)BPW/.4$9C5$Y3E*/69X\7.B,,RUN<?
MWEB3J;IN)_8@3)MEBXX*]?^F/W53E$0Z65:T%99P8)7HMS[M.?$BG&ZV>ADN
M_'7#>_F3UF3HB>&(E\J8C(^W&9U9N)/<QR1[:^\X3A!7G?EF:+ GF2C] DRU
M0)*7&4_IKEB\<?AC2:UJ5'0P#O'F17:.= 'BVVG=!%,O2]&#/^H%KS>;W<@Y
M19@6%')87_DTZC2)T=._[).%,=AR1/9[MI84+;AC==>"ETN;\[1D=VGO4UX-
MTQ$N@P#QQ%PT+I@/L/>UKX33X!DS<ZF$$:IJC%L8!*_-4!T<*45FDYY5QUX<
M#[L5I-]<;)^KYH[6=I#ZUAXVBFZ-KHHS2+)4X@WR0$S(>)D)Q<3,C+AKJ;C=
MQ>$JM5P20\Z(B=P(C!B.M)^F09*1A^[>SV082!%[Y?#6?$!XY>D-FAMEU9>F
MZP/!(T?79AUP9_I8E*%^]R<I;W$7"X["3LX7R88$FB6L>SMQ(%RA[;J> .(L
M\@B;%!!7Q?5DMJ]:4(,[.SGP74LNB]\)R-:V8C'U$MJQ?/)$RFQ%CC3P7EZ)
MEI37P@?F!29-=G*07!$&NM\G;4,5/8"67BBT(96(H984HG_%I.H&U0]_/+XJ
M+#JD=;*FZ9C25OG4"19QE#A?7,XXI0JW82)6Z^]9BK\+-;>FO3E97K3VP6)B
MI297//7BZR=SAF?'S"F9^$ ^D!3"&RUOO4$> 7']F:B!D313I'2WTIP3*@U_
M2#'M03=C(N6,N@=6,T[A\XE["3;W($,PXY(U@BZQ5X_KR,%RC<9;D3._T'72
MN6>PCS .P#MSC9!NU='Z#TD*'NF[M)Y'FIW#+\)$3D?'5!0V"!YWEC!&E.L)
M:4R8>3@PE^[]2RN#D$/KNAB<!_G*.VI_321;*-W_V<4!\P+5-S?E_2K4DWT<
M/5)Y9#[0_/89Q^"K:5N9.IM$#\MPK)FVKUG,7\*&^04\F"%G9BAC9O<\;G)U
M_GS\?,=\]CU.#1#([AR,)R::ZSX*CB?],SK>.R]8;_7#^G??M(/Z*X1,L491
M03Y103$$ _;5!OP%RH%/(P/EOQ@,I7ONN_KY'/9RF?N=X!&KXDJ5Q,3N."DC
M<BVQUY6 X'JR?W!,&A.Z91=YJL^?,2]523Y,#YR,$FEM3W;P>F5^H:ZEQ9'D
M:V9WY-C"U<PJ*CR'V#J7M/DULM2#%<<X5:$W>A2'OF$>I]J5[=R \!CN:/>P
M$OE5Y(H\1PBTI87O$A0:AZDUM"K&W/D#>'"NIPGOUC!$#8,9WW2_KF/_[0+*
MD'FSQ7L8WZ]3Y&IAZ%EFF,S*8A=R$'B[-/H)!BJ5H!L<?<N4MZOI/<DA5'W,
M+]+5Y_":S6F*RLO>?*%]^RC"E#*\?B'K =N6T=AO*<5 ]B*3>8J,N=3-ER:S
M9M?]R-\5C4-R$';XK!#_^0('S8)30> 5N *[KO_W;OGQK2YW*LZD2^T]9OG5
ME.SN-$W]-:LOJ2ZQFXVOB5-R/%@18XY5*OB,[L='<- #>1EJ^L\F'C*&$LQU
M[L=&KVUM.LHBL@]DSMJV&GD[/+?':KK#*AWHB,VY5?MYXDP[*UVP)<38L5X^
M,$V4Y**8NF3*H_LV,_K-5R;C[?)T(<\ZXFJL1O9EQ:_8JCCTOFRLZ;G$!Q+4
M5+>+"<)L)^IZ*DZC=92K43.[&%VQY_'Q9O4S&JO +I6DE6LM<I\2S&^P_-B[
MZ6&91&4,/8]L<7C.AFD2[8(EP!DI5VO&O<6;BA*+';3 LCX?(-:ZC:_3LY0+
M4'*;]?*G0;9_VQO.(++DWG%!G$OX8^P_ZGT,,O X>D#;6&1G1KT[FFVW6;O'
M%?/;(?/.M)C"I!]@)17.H#R(P0>X"G?I(ZD$M44BE*M*K\=&HH78PX-Z1)J[
M86O.H[/8IKN-3>1,L9@R^DJMM$33!\-7C:[;F98JL87D,GT*#\5>FG$T]F)^
M+.K*NV&./MA3I)-BHO2J0-<#FA]NW%02/FHT4+XQK//QA?V\!9R,^GE^LKX*
M&U\SF1'.ZCJ,Z;0I.2'6Y/$FO4D;U:L1,3\_20+DG6W_JXG\Z7\!4$L#!!0
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MNW[50=]S0&]\]J4TTKBC76?2+>0(;Q<?O<0ZR*"7[)V!'[F8<6'94.G),]9
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MMLDU+Z\X''KE,G58F_J 5T)L=L3Q!A"D/$9<(*?ZMS0'%7);*UU8R#(+C\H
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M ]6]NAW/>N,YW/9A.+[N37KT1<-I;S"<S7O3WC5,[BY'PROH7EW=WHWGP_$
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M%9OY>1*C>XD6^7-,OUDQ$?E(PBOQ^,#)MRLV^:?0_G$K\&0[#HW-P%^.U?-
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M](.AZY<]5NTW.H"?]=S<(][G1S]S+^0G_-#7WKL=GEYUN61>4S.5?1PC_^G
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M!*P8ST67"E09V,NH=^($S0K*@:?,=HE2&F2R4GTLF)U-ZYJ 3CR/<]G!9AF
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M,O:4H#)Y?)<$3V$@AV"?C0(7.9#JG!#ZQ(]&GB"/PD=0/O06T4F;>3/!U V
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M)9Z.Q_UYG:'K Q^'7&.10LR (1. D,0YT[-Q_ 8DOO6[,79!)^!:2()AW[2
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M,AQ&&F-5;1EVHC#\YGEZ]Z'8PYV5BCXDO6I-;@#,Z7?10-Q\HS>4<"2T5?9
MV;;$MRJOS?)0<2"M:"S\%S^XB).L% ';OJD@F$!2]@AU3W%"% -K,!+>!'?
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MC%"@BN,Y]!CM4Z>86H9SH1Z -2;V0#H)YE-@Z$]A1%R4>0$4C:8GIDACG#Y
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MT&58>'QCFG#*/DR&+IE6.</;5*%H$:^>0(MU#-'-N7,1@MK>:B0\U N4/&3
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M 7860=M$P9$;E2]X\$B!X"Y%K"A#BAH+@ %-6#!QUGE4Q9;0?[IQY:TZ!LB
M];%6Y98Q:;(@E+D869V=BF[IHVZ*&QL6AKH.5]QA%QLBT+=#&0\"1U<FX&(J
M(T4O(7@,?TM\B:;BA^S\WHVBA-IW4D&LB4'18:.5D@(F+:BIYA#H55@:4"6B
MKZ-V*:H%9L!2\H%K6QB)T(%R>>=RJEIAM-18I[57,MJO;A"I<)T:YP6,LY$;
MJ+J!8B/HM>4+Z8HF7=?E$A+5$J";ON 56VTG*6:-CNN6>MFF!4<9>5F? ?07
M^[Q#R3D$)H]4_X$LR#HK=&;NS30+HN JX.\U^3)K.]N1IFV/23U!MM?R>\CF
M<SB7*K0)*2FAC\4C&6U@Z3>I3A@9O AS?D1-:FPOB'2%?$YX#&&)L/R'*IAA
M#PA< BH^SGK79IOU -%@@M!W!2^[U8E@U!A<2<]]K[[BS2QKT[R<66%V/T F
MT'B]VELK>C3J,AU/<1\_ 3/;;5H.!B2[W'V>[$J5+Y(=ZJ<,HX1#FO.45>^K
M"G!Y9V,^:FOWSZP_A!7?!AO4^YAC^ZH-8Q*JT^JYCA'N8-!J!#@>?8A(!K >
MXZ9UE%:BP;VPXKL-ZS<98C=A8E<2.!CBS5ZJ&2"OS(R\?.5=L)ZA.G/:;^GL
M&;)=+=+K%3"%5FT4@S+/)PP_7>E!O6DLLXVD<()1/-E%,@_SS/6);C]0=;%H
M0&!1:^A2E0&?^Y%NRPD%!<> ^+&W_BU"6J+:B%1Y3LK;:6!>'Y\01H%O[$[%
M\GR4'DI*>Z#4Q8(0(O7S@R('H2P[9]S %@;\0#X%R\]3:,67?\E(C/E(BNM0
M5(2&@Z<<8TE%<)H 12),12R5D:%6/QW6!(5X.#K^G&AU2H=HN@RWB!38("QO
M%JA&K^H@+$E00%L#T]@QGE 2U#:P,M;[).KW7(&SD9D*RYAK5%MH:&_4[.9J
MT61:6IM;\T;NM*\TO]\(^9/.I/S0%(>KF%TGS6C8ZSI4RO69I]4NH4VQ@')J
M=F()$7/RCS=U#+) .1O<*%@5M^?>G /14U)-!:Y4 H0NS^!6'R9X>#%AAQ-?
M<V5&?-*>Q<N$'CN'H/<_1:5Y3ZKFOQQ+CAJ@@&T92G72KB )% 1F?HQ:%D\L
M6<,$O*#S<K(S4<#R(H ^#^>D!QD590=JU+3.N]&'908R 1G.*E],5^<'F/(;
M!31K_;5IF!9:$5/4R*).I*) U'1Q5(_2\NI<,655E&K-%H6K][!_)2K2%-!Z
MH!J,"7^LQ7EDUN1RK@TJ@X0!#I3LIT@I92KDH;8R#PVSN&"3I.(==):("Z0M
MI*1'LK@&9C=G#O<3,!)O"-CS&[BTR5 %^7W9#V)79WT[@4U-1=/6I:7"UNSU
MDTM=*6SN5&6"PF2@JV*WZ:ELFJ$EW>J*[#G%_30@#"HH(*!NV&*>ACPHV]F%
M[&K=QX'DV&L!CPVRW5KH\:X 0T+#%,F*-E^C@C/7RBA?S?E*O'+2\^B#N7B4
M4)QA7QD-!;-:^R+BI^&#Z62OQGUP="G"LFJQ8^0MNWXOQ(8T28IK]SXP&V:P
M!DQOSPL8GZL40,)1+TTN\C#L(ZX:DKDF&%F77PZUF:ANB)"@D7QPCHR+FJ'T
MD)SE^DU=5FU6,>7W,VG(VP%8XTHF<#ZK?1]HP(KR9RD$_"2^C!:._2SOQ"A4
M?W5;.+=:L]=&1<HS[("&#JMA3R8CM4V,=52)3@74H3ANHL2'C9&O)E9L3AZW
M9%!N:N!=**;.@SJ-L'BI &='R0$?GYEN;'WR\=E?WS3?6'@,-<)$>+^?_AV-
MA*W_SAU?T@G; RC.YUJ?XV[@C/F(ZW,<JK.NS[&3?[@BL!YP[$S>2%W5@3:*
M8^)@]$D-;(]^N\Q5;._8/5['N<<V=4"/V"BYX:BS>G9#&!>,W)-"!5-QN/ )
M5I\/$5.:P$?DB9H):R9\.!,2E 2#T(.94 ";U3&OF@UK-EP>&Q9/R%387/5-
MUUUOLV.7##_H_[/W[LUM6TG:^%=!;66VI%U0D>1+DDEVJF39CK43VRK+<7X[
M__P*)$$*8Q+@X"*9\^G??OIR+B H.XF=V!+?=W=CD01P<$Z?/GUY^NG/52YW
M$*)A"-'1X0Y#=.LP1#LE?!N4L$\S2OBY:4>.T[ ,VN/X2 ?7I"HEF[  9T:[
M4<:$P\Z:Q;T_4Y6]D^+;(L5!, R\O)+US5K%M6FEQ,%G*H9_2H9W[$I*>?M.
M\QFR="CY[ HI1%Z!N3E;<J.\,+V[*&RVZ4@KEG<OX7J^,1'H9*552UQ^']#D
MQ>BM<5'%O,/;N$5=<DAR64'#C,UEX))S8<R]H2%AQ*IML!*IH)NU/:8.5QW'
M+3E BK/Y5&^E:_K1)Z%=I8(D+[4=<]":<9LHI5J,N-##1X&[9+*T3/<$L(!"
MNK1BCQ.&#*N#R@EX#WP2F!M]&V'$%K!!G:^ZUL,&I_G2IBPB.[V5$N[;&84N
MV93.>4'2,NC,1_^U,-+7 I<#!< Q&KD?_482VM5$2I=+A,4&H)/]%; .-2P@
MV@7$,%YK%\*E8Q!?H#')G5-.SX=(<4,B:P>A<;V N#E.#-6(5\$W5-<B<(3)
M?;WF,+A=V92V8^T.DA\'22XTI-^7N%2T2=8XE-D0P%0_8R,@+^7]PPZ%*0OV
M- ]J!YI >)0Q!G@1EW!7B!O)'$U<U*9H[.NV6 CC67,)!<?(T,O$>S4<-$DX
M2$X6316V\[GY*6YM'#,YX_-R!668'N.$J+?W5UDQH-X$'!+>7?>G?P7PSC3A
MW\PEKJ@-;=@SC V(\BC#T"U/3Z=S<2LW[7 K;F3(SDAFN=2V8]I"I'#;]:U5
M7H%!J@T2*N5K(XGF#D5"BZCM*P DK>K62N?=/*UTGN)FQPI!43)J24CCUR'H
M1.\K3ZOJNV?(,E>DF^,0, 7%ZT!X@<5ZS>V^#)_DN909NL6+-K76>"&W(MM=
MO98/VAB9(5F_>^62U\'M:-C#$J+O*MGZ@"[;Y"W _?6!J4$M:\Q%P;I63.O6
MK$FO4#'#X< [U_%EX)G6CR*B^O%'Q%OZ/VA6U(*IS^&N^U/A6_9EDTMP>1HB
MS_D$?=CA$+N;>Q!,\FIM;#Z-\QEBCNV@UU%\?L#V$#><UM0;A/YP%@8]YDFZ
MY"F_SJW<9YR5;^MNU<8=,SQ6\P,$)>W-C:RJ[\E=11L F/U^:QB/OX=!N7IO
MJ?(7JAP<JD7XFP(B5W;,W#0 QE1(1SAX9L/;3'8#&1IYRUU,E-PV1'Q+YXQ.
MFT&  #'4/B84(=&J0?X5X'5WX=Y0*=:^/+3:.>)5._JE0$L)%$RHO4!NJXMH
MC#^R07UQ:[QN#OQE4B$ \ @>A[6T/F=,?T@3X,Z&H+K6:_\HH"$*0A\'CN%Y
M9DC=&YAGK)>/"UDI_S23RBZT0 K7DSXKIL:I; (<:Z=F6&8'WOTLO#X<:\.2
M2A/ EG_,WSA4G.KFQQ,5^<40/\06:%QCY&6V].AGX1XM!//H>7? B51("8N&
MX[5H3:J:V#.TP00# %>/;.CP;##T<16T>M1.NRLMDI/).TC.MU3+I;V 5_!%
M5Q8\'4+WY#JF15WF';:YW>"79JD"CG]J4T9GEV\@H[2=7O;F-(>M^[%K;7(5
MEQ!$1DU5QZ>'192" V^@6,*/.>P[=6=+\9Y*%( K4:T:6Y= JZYYE_:7U_A6
M;3MP=- 6K9PMN#FPD&&QTS#KV5U13<PX,CPC#: W%I,5J!B,IE@Z8F-FAX="
MF'"Y!1YD5":ICU.XH:O5V#2(10X]R%IY=KVJF@V5$4)Y0XGL_^ZF4 *W71$S
M\R#YR>NJ2@[N>H;V:L)[B9 JPC9&]8CR##F>=U#'74[NU^?DR'=8>99 !\J/
MP/KXOFM"6TZ$F ZPJEX!7BX\Q]S:,YOF^F,N"S/*INFP";K#"'UA&*&C'49H
MAQ'::?+/4),'*(#O21M_IHIU)VNW0=:"JF.Q6]5*D CD.HR5.IX.RS)%&2E)
M?G*<$-7I8?/#SU2 _S0'#;0ABP_R#8;!&577(EJ;:G-5S<F+W2<UZ)O19>V@
MDG)JLVJ8_M?WE(I"@:Y4P:$XS-E[FZ_#-A="14 NM\!H\KJIRC)?W.YP+1:/
M_-,H(<%9B!OS'ULYK3<Z\6QT+H]P=D%'Z5JR G<V*/N+U@]RF@#YEQH.2Y-/
MZKSE8)<$,O(XPHJVL*/+ZCHUQ!3[-RYN)-'.DK:, 9.8QJM!<F0"AJ=T$^-H
M!'1Y?95;)UZ/R:T:H5OEO%08]W7)NS@8JU@/[VYA !Q/1=HZ=2&.*9/J%/6D
M6U[Q:UIPQ.5P+?[&LH>0C3W==+BV1(SF)WBM*GZ3;'I%]\N4PK;3%H?:?-CG
M>P9@"!8;D>?SIW%T,S@\-A&DCC$A#DPQGS::;./-A;>$/[?G<Z@K;-JC-/HS
M_@:)L#1F@G!PJ&!/]U*QU74IC& ^RC.UR3CS@>V &3Z<0.D[Q($T_LJ_QY:P
M7,C>H3D9R_6&8 Z75/#MV*ZXO<E8"8*#@/L #%6+]"L7B7:T%N&[]]I 51M)
MJVDGL>#<2#CIS>#6R0JX0OB%#Y49N545$VGL@KBJW09VDF^!&(9 M8++99A<
MD(<A'$/'DM<5T3U"2@%+E@\?:[]_;'BXVT.##V$%XS-,L$:6*P=V!7NDJ%$<
ME,K;R*RO^F9AMRW:]FG4!-((83S^5"4Z4(5%R6P,HH0>Y\VJ\$RSL9*0#G5#
M%^(<4IS=O_,XWJ[[COL)\3R[BZ+ LAB @L%SCZ#39&,#WKS)[-PS)< ][FP(
M-GE*O+/;@=;Z 8E.9H3"^;]IJBE\Q@1ABPPXQG=D$Y7%/1-F);O_0 ,0)14.
M4XK:BHN?SPH^@@_5%6W$I?5_:L3HM'-4-ERQ5<#UD&P&WO+N2L"+O-!4J#:V
M.->T)\WP:UB;2.\F+V$XY"0(\D-DK2P%[P"M3#S*C<>:UB%(;6_[G'.>3=M+
M 0Z);2#V#2]DKV;!TL"04OZ9X8['=94!\!280ZXQ*YY"?X#=-"A "Q!#6W-4
MWK1LW@K8:S G3WI)DWA"*<GV<]L?HK1JC,<H:ERQ UV87NP!!&ZQ=SD(4#WE
MAMND%JK)VUOKWIES+3 7QDPHP?/,/"I,0H-) !#CDD2!#KFK"MS2B[O'[?-!
M\V1=GY3WMM'TO"?@#CN:]6<T.57\^R9950*,/'J3:/], 1\%,!:N7^D"7$:
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M_C-XN,CE\-$4U!%QD-!-F_0K9]N3P_Q7**YQF%"[I[;?]1/.+9A]-6O6*(G
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MIMP8^19?AF1CU@P%QG2UKR>XZ2%R=U3-D305TU'6O.44"%!6K6N7AN7J5OP
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MPDCCV=*1(^/PN.QH5,E5-IF PT?ZG2^77<DF7+;B1AWSK"@;N!@S[M[>-7"
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MS_M]3T5[D?<.1;']98=SA+\U%_C%[H/3JB;;BJV>Y(WJ]8^T(WY;S.H/%Z]
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M:;& .K7&7-JR2UJW,HE.L*PS7E;2 *5 Y?FHZ%;"G8ZF3;,,WACI*CXZ+3U
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MC9M*&V<&9CM4:X'!:IN0G57H&3JG S:[VVET;K>ZGIO5]3Q;X(ZQX?6C-FA
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MFR3)J4%Z0"1"XOMO%V=R\GO#+C#.JGC[?$B)?ER):8\ 8?0B:Y"DZY:D:1;
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M4S>9. ?6XE6?&X99]2@UV(%0\"ZXLYY%JKG7T-Q11A3E5;6XRAL'Z>;T/Q>
MDQ4.Y!(@ &R?TF?O[W%RB\7A;&"=TV1:=PKP'3N "YSW()%?%_.*LZIV8C%\
M%-<'2R&1  <8R6KW900;,9/A:5619?>8'JX!G&;)E6?D0"9[3Q__9[9<?7^*
MOZ3117(NX&U--6N"&=_[TR<4"]!W=8MY_/"&H^PX>Q1/) *^^5;VJQ"+Y- H
M#5A"KQO=3W2C)>J6*RU0$\B@(.K8/(SR"*GRG*7.6TI!<)(O^(=:Z9ER_X1Z
MFKS-\Q5_80".%+Q]+-C6;D9(&(V<,S<B%TTNZME+>Q#9^ -S&3>\)@<0<5V(
MBB:"0M+AFH-]!2H S P%&F)H:QIZ!FSU["V*N+7]I0"M9)/K_N0".K<)V<PG
MCW45L%XJ14RFIZH=[L:HDM5O\X P-U97FG39D1GN:E]_?>UKZ%0&=$/8P WG
M@=&B)+(.S2P,>\,Q%ZY\WG^QSZ4$=">NMT%<GT>1,#[]?"1"<\2LYN7@:\AX
M0ULB6%(%PHIB2FF)4?(C'<1)?,MS9 )PO.XAG+8?GH [R=Y)]J>3[(MNK'6;
MYK,"OBJU8&?E%:1\GFD4!4\1\S% 87/SRYY/KGM#4!1+LI3)FIB@*-278ZGE
M,>S-<T<_0#]HZ^S$?R?^GT[\3ZQ+";,7THJ-M!\CTD/#PHEF 4:((3 B84>.
M$C+QL;"3X9T,?SH99K_.JW%.!]U<.>,U/;FW(!#VH$3G&G8-^^ED64.R/U,!
MWL'=ML#=OMG!W6X=W&VGK6^#MNY7AT'I/OKIQ!?% 9#O<<]<[L])L\O"Y=T#
MT^+C*.9;'()_)(Z&Q#+%>U]S!%ZK\?B8#+P8;=$V$+8/_7SFR.3N<^3<2*5\
M5/<7H:"T%5$,IW$V)"^J.DGP^T%Q5H<-LOB^B"WC-VCA)NC_D9.BHA3FB\IQ
M?H=MH832]GKSG1FL'D@:>A_7Q;CCU,*M3%INJ<A^0C,P9UHY5.>=2)Y.B8_V
MGOQ\LN]R=VO!R?C^7KPVOF,S_D0%0+[ "]7<N5VA"5+]$50D2';E4K(K7&,P
MT3R"(FBLU@J%U*"I'#O@@.\"F%UEQ2(D#M1J:,M#<"8QKT%=CF:9S!D+Z)U"
MNJ(QY#H-!?(60E-@;8H?/+QO>B=,%*7NI4])C,3^S(60G2<EZ4H1TMQG1ERZ
M"G6^_FN&)%5*9SCX>^&-,D9J5/FZ94,)29'-RXJSCY@M)B!4,  ?O\BET4>+
M8I:/9$)S;@TW-0R$D+K+AFT$(Z40 <ZBH+ G(+]"TJ3F1N;6YS)U0U>:&UD9
M%$8ON @488]&006.[GZQYME2) %M[)F "E%,>9WQFXGF<@@'!S##WYP!*SRB
M0]]F"!@E#P;,E.7&=(<]*&3=/I_1'JM'Y$.\>)UK4OEY-<5+&)RCJ .^G8VB
MG/?!L&[U<<.B8U5/CC\Y3+E'_>+\J:.90,[K7Y>VUYG;"!QJT/[DR>$&06"9
M<9W!58I,MGRDGF1H^T2_ +ZU5T[I?BX(&]K+(Y]#ON'$:I(]?O2T6B+:-^E_
MJVD:;DC8^THZR;P3&HE@=V\<N?O]K+@_Z%S[F.APY'E91R=GP!, G&J8L)Y5
M/GD>)N4M=WMG9?BUSNLT%Q8!AGK$J0R- $.];<O<.W#=M)ITC($1,@(&I"/'
M%P27%1P0K.]!<J&)[;RDA9H(QGY)ZB@KBV:IU0Y.QX81#:#UF%4$M3I SZ ?
M(]J@<=X&)D\-E):TBD3?@]QX9$7=EE-)1M*/2$$S&Q'3#.)X"C<E!_S0AF!2
M%TLFA:#!U?/<ES5SD8:=/E=D=V4?PH]UBR7K"??&G;%T!6"'R2+/:@B7+*LQ
M3S%SGV$0S/)FM*$GO*B871AT+"I7S&7&O,$@B 1@9&U5_5@&YO<#^51IO6+X
MZ)^1(&&)Q2*.E$@@ZL&0-4XF&@U'N'07YA8RN>3_I">M(:[,_=#BW<K D'C.
MM,ZNO3?H:).LUDPM@ "9OZK(UL*()L55L6#;Q62PH7F\XU+VRV7.AA%S4+?N
MF&"B*S,O\2%4?MJC:G%<.>N(O"_&[MG!YG%ZYK\YTC3GS@OV57)9YK_WW'M7
M+<XN&H/]F55&;R[(G4C@! AE3H"#ULXVDA5\GFG*CM\2"%[T=2)K<[$6$3/6
M()9]_J<'>#&4+VJ2ZZ9+04(('\M<-Y= ]7-S6BV6CBZ,W..[*YNYU#?U+!O<
M-H#[I8J*8V56"4CFNDG#XS75\U9D:ZIG+C>X8KFH."_%#;SPM_=MTA!PLTFP
ML5(D@@8\?%\?&H0U_F"@=N.EA E)(6E%0YI)MM)E]N^LGJK;%?H[_@NFBQ>U
M;VX=#;-4G]/Q"ANX5?8!LYBPK'MT;3 O(GA+!*5-)8L=4)*T=VQ^+Q!CT5]S
M]Q1TC&;>>@;_3[0%?0G=,<8'DZX6=GV%WN73CR^_?X2P]N';V)&OZVHEI3WJ
M.IY#<2&:()6#R9N*E!'M:JWS^R3H[L]RIUY8[.-X,/9A9P):I >A'Z[I$NV/
M212K)+F226Q0;/F&_!JF7N,(8AST:&TUS)&WXRA 7*@#M<QS'R*BTY_)26B+
M5"#K6]#KB;9.Z(&PH_1QWAT*,1QV>LD5_4"A#\(XP];*+&0'14Q[F:L=Z[],
MZJK )&J*,_H:+&WA@'LSEX;.G=31(.8B88<"-:I3+O?9\URCV.FD@]BXRCF8
M(FB6C8OV92)=.8=;!0XOK:UM=S!/@NYR@G'X8&^\OW>T/R@>E8^>W7MP9#\9
MQ%0WN.# [SP5FF6>V6([3[=8LJM<YUKH.LTG1:,=VA^2OU&VEW?8\,/Y0/)N
MIDE3+:8'R5/(P;L,3B!OA"5Z,4Z4^4@.BFNLN&U2Z84G<&V6)]D0LC?*?&[\
MF;I#M;/F0JHL]19,H[2 ,^B>9,3=RMD81MUQ'SG<'%]A>+-IOF+>KDJJ0!=K
MC5+ 4Y7+])=^<Y.)U<'E1:/-QAP)T'%*^4CS5Z239JUT 6=.ZJQ>%'F=FCGG
M@5K*G(/ *1.+ OXB/Q;.F]2(>E;DWRBTB]G>];G1C]4^N7*.%JX! 2SIK=4(
MT\BVB^D308*MN5'QN* OI?S$C9FL9,#>T7& GLJ+Y<+'O!7<T[5M(%E#M.TN
M:1^3#F#5N[3;HITQJ@!K%XO263U(+@K$/?"1<)#;PG!JCH9#DW[?TD.;Z]>P
MAN$20J4?_NKAM_9</.NK>P\.[>\_?>_N$!5;$!7?[A 5MPY1\:<=5)H=0!52
M?I5;T^!VH[R6M1TS0J8)4T(Z_L?4\T= ;3\7WD?6Q5R1S+U?H"!)Z]%3YAPM
M<A:APAV9N%V"HAD?+,$/6I\GDNYB' O@\Z;.39_"%FN:CF-W:7)97<MH^'6N
ME4[7K#M8E+E7T.Y1M\.7BN#\=\=)>LU)6>6EGW6+-"HF=8Y%O[E<8/_\"Y0U
M+K+6SS-LB[ARAK45LWZ2KP0:-:F:ECV@*>=CK0LQ_/B(2'#*YKU/_2 )P+^\
MYC0!$U!(FW"58TA[F, ;'GY<21L2D18\3%+Y[WVQ@^1LID_L9PW=I'* L)!7
M#AZOZ;X;'H1@RQ144:EU]ZN"Q&$=L"$8,Y4&P0NXM*".A.HM6E8N4[+DUOUX
M8]SQQ(4<)<ID$7"CDYTQ%<#D,J@]OL"??&>DG+K%5*HO&P1?,B'CQGA#:W-5
M*0\25Y?BRTL)*<'K8^Y[):^9%=9A\2#Y)0\"/)S;V;+4OVNFHI=C<6413:1^
M.U@Z?G@6"1:]\!5Z,]Z=YE:T)M-*-JMKQ<2[D@UOEW>3V5-:;5=TKIF[@#S4
M8?"=B$:-S<25TFVKOPYV[T'R*L.ZBSX3?3"7/ASPOA=K2>S0<H^PW&LG">$H
MQ)60.P99?\7@0/RCNOV-]E)&;[))0.(%;=U[H$5HU%/4MWK\0K+D: D:H0\4
M[<9OOJ =D0\,0PJP=;X0L&+,0!Y6F(=Y]ANJVQIM*2$YL4DFX>0G'3K&Q/NN
M;O83X\D/<\JZINX2YCI1WB'N!(I)P[Z:%"NV631Z$KT FR6P131S;.B;IM..
MHJUGL#(IL<1@#A85:!DGHUOG[8W&]$TT$.S#)O<D*3Y_O9400MZ4UZK'VA"M
M8_SP)$< 0/NL.:M,%3>]>%1/7N?T!A,$UK416#A>OK<&&9=;BR![+!,3I@V>
M":**;P4:,(MU80SD4-<</=$4@*8&"C[[&A)Q]"*J'!N&&\]!\E3:OBVK6EKD
M .S8!*N121H*?3H"(K)XZ)-L99 YC6@H.& 6IBHV44V^WP.?3/X\LKL!^H<-
M.\Q-%5E!=T:M(SX%M8/=0\YNN<%Q&2W?AJ$(2'MP/I+,\E<26N(NQ"6;:OE\
M+AH3/Z-C@7QC"=Z5'=,^6I2=3 +9S>1%2X,2=$DN;VI3K+X.+N XZ[@@X=/]
M 3GTUM@L.F)&Z&O<D[T[M>QU=MUC39<-[96JK:NE_P+X TPZHQSL,1LVFG@4
MBRTXPOQQ&BBD+1I7T4%>/#9M ^73N,[-47<^;7!X*/@[.#MBEX"-P'@6W/NS
M#[S@GJ8T\ER<&-/D,4#J=GC)IV:X?PA-U.W9#"^'W4+2"MH3DX5*51!+E7S%
MX9DF]_X.ZJTAMY):6%UF-)X)-R;)+*<AG@?Z.G'3R-YOE'0HZ"[@K@KQ1=D$
M??:*B6(,=%<5RB,G^+Q?;%RYXK'IG6DV "3A:%;#<#@<_C7[W$#49"MNCJ4/
MEU%?PK;]GDR6:L&NFKN-<U>_%ZBWV"9N)K[7?E[7'AJF50\ZP%.?7Y!CV5DX
MWB<KP^&81M+5D'=S,(15L0)I4'2B;UPOGN[ZAGYY8?O33S6,@\1@R#I?.G.Z
MSH*T=$O) ^8)8L(@9, <YQVM/>.&&T'U=((*69LAV;>@QW3 2MV &GM!)S(Y
M4K_7*7KKGR:*3KP;@<\-<IG%"RHU!DT5#SQD67)67F&COV8/4WH>7O5M3[N%
M %Z UL)@V,=I,X;0A$UJ8G_-<X'XH)*<"T+.MC4DTC>H?9"DMV]]B.2U3?_F
MVY<9@[4FU;ST(9%QWN([WQE#>H3E=ZCKXB\</W!F@.$I-[2J46E!,'*Q[RR5
M-T#B/4-:,FQRRDHY%<[WTC@SMNGHX+J+K*QF19K\>/'WE!S:>O(V!5UPT^0(
M]Q<M#:=H+HOD=59F8WK :]H\TTP.#BG5D/ZNWR?+8LISM_VIC%DV9;KM(/!#
M>[PNR6)ZEX+*&O_@YZ16#)(F5B(B@WE656_)[98M'ATA944+7M4C;0MNTVE;
MW2PMG5[\Z<> ^7]Q]DPRW>YP0"1FO9*V-W2R,"J,N\I$S>V#WO:*)$')4*T#
M]!SJF7&H3_-F5;02<QHX?7?M7#Z3;.QWNVSL+AO[L<Z'YY4D ,C_O*:/UYN1
M'PT^N""30?^F41"UY$)M#@EX9'C&\L$*A=MGIY%J R9G,/:WQR>2J/>OO9IU
MFA<:3 ^)?2G=DBAG-.)Q!K]:2Q N7",K/=2"5E;:3'#<M2ZXC1AA7O>*;@2A
MQXW;''Z6#";M%.%NS!'8.8XO_Z[7E]6"71K6M1RST:=.<\,:T8E15LHSK0?P
MGLR1'PUI?52&8:)?O3@Y2/Z>QT>71+]7F>6_4 LR:C@@&&8"H@+J@5B=LENZ
MDR_5H^\$N8!_D"$QR9+SGT[3Y+2K\S?9)'EQ\ 8G(U>MSBO]-1_I<KXG%P<G
M](D[4;& ;[)%F5]ER<63.V.+G<01%S-+ZCR$W!D:GM=:I<IUX'02[@M@HP:0
M<9B/L62^X;-)(]I]O$,SY#-I;/=8NP^\+"=THW6=PW9XE,G;D@S4M*PI&-V!
M,(R,JT9MMH2QG^2CT'4U^9G5(GF^AB5S06;&>"P+'DK/:C&Y,ZO^VE5,>R5:
M5@QI%0,MGVZZRM.(PCV-F/8;+O!^#TD]:0_C",Z$J(ZA-/N;>1?6S.H7N"@R
MH-RY]$P7OR"P_E6CL#EMU:V(0L.J6='R<Z+<2=LR^R=4SOM",;."^SE+DH%'
MP&IQ@0:=\VPN(=*^[;Q!^2VOU.36FO7I]HG2(@\^OJ3K/(D!+(CD1Y+1EGFI
MD354GZ2Z+!O2\B+H^E>D($EWBW_]XR)[5UTL2?_^'5Z_#()6L_\XY_K$O]?C
M;>AY!XGTP8C8_3.FO.#*)H:T8FU8;]@DI3Y5M9EHC0[D2C.%TJ!$BXS13MK:
M][BN"J>\V$$KJ>=,S0!$[-G)F[,T3E3:Y6=PS1D"Z\MG+BJR)Y*360V*]^3D
M[/'%P,]E#K$'WK=FMA+.F7S4(<S!A([6" */QEOM<=\":=KT.)^X%EG?>6J'
MJ&1. ; ZNKTGK]X\>?026B;_?M^L U<9,#/HFOEU/*$\J#\=Y_H9J$+7.1M%
M]T$)B ,_SVS3<(^FNF#D=UO4>8MP&S22G'D<\G6%LC3%-X>'#V"SB!*V%*IQ
M601++?=U> +ZVYC.N?_XV1O6DXB6H8*-*U*&M)P_XR67%F3ZI*AUZ(4\.,L?
M\KT;]2P&J(.!"#OB9$V>OPV:S/I;W_!J.^F,#^K>N>P4K]#1,\G*4A&HQD9"
MFOI$U,4HZ&/FOAV-%]7DK1R.<J'>E*RLUQ=D-*<(\0C$),+*H32&U)4K+FV2
M^\FT:C2VY8IY7&&DU^*_/'LI*JI85'1, LSA:0F41MR#_8LFS% [3PI\ N5\
MD9N+XYZ*_FE-ZQE ]^X=CNX?_B75\@V.#XNQH=@$K?YLM-L"1H?[@(T <)*,
M5CD#D&:U49""HE +:^%.):UCV"RN-Z,.PA.=E[)S\ZE5T3/"P]I5ZLLUVI5+
M?L4K9H0CNHQRAM7DB/X_]KZ\N6TDR?>K(/IU;T@1$)OW,>[M"%F^U&-;6LOM
M?OO^ \FBB#8(L'%(YGSZEU<5"B"HPQ8E2L+&SHPL 84ZLO+.7UKPD_K[C!21
M@K7O)9C\-NC]DN\/IA ]5OVW'-;$^-XQ: ,!U@8A&,$I2OTX73VW(&<AACZ1
M=H%<O03DQ0TFPW+*C$30.?[A,R7:K=!S;*RU1 !;R<;?;^J$SCW0#S;U0.?;
MG0_*GF)0!KE&**]OS!+]I1KIZ"_%HE4*Q*Q3@O^GTH-20G3)4$'EH!#"1,N'
MI(\!W'!Q**"IL<13)/M1&W6Y3\#CAO7"MO 7YR9-'(0#&05@ND^S0$G_7$V>
M%$6S*NS*M"FYCOA=T-*1\6&PSN+F-J5*>WE<=VJ"&I:,E-^2:\\>B3>I-(QT
M]XE@+W3BJ59E9*_77C2YT.-5L4F.$+,+ IDJ[,A>D8,KE!87CT&7?K@&\:+J
M'0)9J5I';MHRW$]H0_TL2-6T$*'(B%N@X67UL"VWS2E);:&P,=Y+.$TVW?%$
M38HNZ'9(IQ/0,>'+"/QR,(\N79UL049?(1_!#\%X\O+NDR8=$$,LN=0E"S$+
M);H<%0+^AHMM.A]0C4P6 "KAE[DB'>GRR>ICH# E 2X5F@15=Q1SQ?RT.R_E
MCFG:]!QX#J/>T;2 (4)=9=4W8+ )1\=TT6:8X)W0^O,Z1DA%Q/N[6W;6)8\/
M%63K-.L@6QUDNT-UP8!UH2,C24C\4GX96CS$'7Q;B5Z*$JW++TR.FF&VF/RU
MEGZU[@8@L8!I^I19YP?%)*P*B6:LO1O-J8)/VV$O_..E,K);!!_++2\!7<46
MD][46Z9V<3PE,3"2E'Y32[NB$#*I\21."JNM6*+T^38M' N%GGEAQ\2/)]E"
M0'I<6_58VWJ=CBMG(]H+?UFT#E-&@YD;$\[X9Q]F0MM#>4]KVN2FT@@1D'Y8
MWGK[='-Q9PY"Y_+JZBSSG02LZJ^*F[<RTNPL>\9(58>DR!JG<*?E8O/RIJOK
MX"1D8]0B!#WCPU,$7N6RNX1"*Y>4' C4;BPVF'ZK:]"4+7T4GFCU'>TRV:2H
MOG"Z'?-V43G% 3IF@"L45U:+6F 0TI^.(@.&ZGQ&BV_E[)T>?=XO(, DH,I[
MP!HPA-(:&?K&4S%(;0B:B5L'VPEJTS0S3"8WAK.E6 _4UE(7JN5=7T,) E&N
MI0V)2([Z#0]?VDX[O/B"2<%SI%D!C;>;TBK2P LR1D:24MDL@5SR=24P'Y#6
M!Z0D)IO8I7P=4SZ907LYB(_U6 D1W>)1MA5)L_2F2*$+/DM$4Y1L+CXQ-/3L
MIR7UBZS#DOUX79_=O[/83Z:^3A@N(,7D;CMS6"E"+)Z[B)XMV664S8^YUC.,
ME44SIXSN;ZN\>6YH@KVPY*\VZ>NTVE+!?N5J+2Y-/;E."7K$2K#G_$!^]3.^
M^BG?248HF@$)#[LN>6VB,$#OZDS%,7O[!"A:@SF]\]+)_. O[QNB%1^B8Y7/
MQV Z<?A6W"_P<J='2SMJD((T>.&T>OU&Y6_1]%@@^(%UU 8+TUHZ_"I;LE #
M]BW]3I/<(M$.(ON= .MM-=KYAE:L)3!205^2VI.&WD(:SIJA55@GI<1T-+HO
M[D*2?_7,S2F.U2K"[$-82,HT GRP="-EI@6P+B8IO*("%50]+6W'P4W/JUXP
M,PF[J.?FVEBEETJ0Z7.L'\T ,%3X\96)3UK-A<P3UW08VGOY_G#?A2N>)=4?
MK1[S_:'Y:+%'AE=@.2Y:I6J9YN!8^M#,XH&*LPG[_K&ZE[XO=&!8JQZ2.+@?
M,-VK;^C 3!CL: J<$.M*8<]/0MG((@>4!'C/@@\KW7><3>%"D^*!^/7F*EMK
M+O352S7>86*CM-'6I6D99%1]6_I5EX?)Y<^ST\\GKE2Z(2RBEX,LI@8YF791
MT!5X.4GEQ @_H9(K<5&SID:, >DR7E#OR+V@E03]BEMF.YYSA@52[.:!"WF:
MZVA'6.V- 032]))B(@<[.QK.>W4.9&/Y1BB5@D W[<=U66N%*& Z,+>Y?(>Y
M]L6(VAQ$94V26;(I"JTR<U+ID?MK[PJJG5J-PI4EF5&G$HU'9T\Q5V>Y0ERC
MK%@JM":J_&SL#7MAH[5(%6T8.>>91TI57CF] ?_80L0M9C1RTD"U.XHJ6KQS
M3.@S]2QL"&KTP$N![J4[8NU>,J>:6RK#)*7/@M_V9_DO2:>BMANF]BX?Q3*1
M](M1;J3@-:4SU^/P[\NKT\\X:'NM7397B_ Y8I;Y(3 P?\JM+@3'G)LXK0@+
M(HM3UK=0LRH<;Z7B0LI $7MX]7SMDY.\"M]8C7 DLRCPH]S(Z)5U=.#IL0E\
MZD1#CW#G#82+!9=PP+Z 8B9:2@TPSCG?!FNI%.*9Z$18C&GK0*KD)5#:K:F
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M)\H*)B!VG2-T*7@4QWR*I_V*L"+PB(O7_[/ZYB7.!]&&7V+=U=QJI4QEZH0
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M%_/=$-3 J:L^:T*Y 3R+4V,*U'1R,SK9%L# TR@5W@6)?$3Q&U)2X0>T!B[
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MUBO-E3?E>3:<OS@Q84+L*3%11I"ER!N ,7!)VIAYO]ZWO)9.[UQL$YG)X,0
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MV-9&>R 7<OY_Z+>N[>7+[0DV2_)R3TI%5\0/A162MU-IM<9UQEE*FA#F=P7
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M&^(O)F5'=QW+.UW:)@-UQ<RCFZ]#N"5*H@5RVA(B,9R0F*.!%C@%JDI+@\.
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M HH"B@)*R8%2'G.C!$,HA<53K=;U1@;*M=TS>=3)NK"3->_)USNEMGQ:)C:
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M=/D+N$>RHDS6V(&*2ET ,?>2*P#?DPJ6+ O4KWQK2#0%+JD+@#&>8%TV?IP
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M#T8BFIO,QN=#+X_TP7IHQ(V=%\,2M@3:PC'1"ZP [*-#,DHN1?D(>C3[B3@
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M\?U[HN3Z2+$L,3-F69(KQ;IY,L\K-C^="]H(QW0T'8E.U!Z% 8/HC8I#YQD
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M02?I>=[(U8A%6DCA+?J.R/DTW?YTC,Z&",-#GSPCT5F 5058NO,2&XV!B+6
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M(X^B84^E<.+5!I5M@_*<H4&N[=E)QNF/*5)ACH63_1#2D/3Z04^;4*$3-;'
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MF !)QP48MF6X8L[Q.T<FS&^D2U!D4D.&>IK515:_D].(N)4D#+7HR4DP<=!
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M:)DH3SHG[Q\P;'R(WX\<Y,3Q753G$NN,Z8YU09^+)[$ ^J:+#9PP:!HWQG&
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MZ=,6QG%V>W-^<?-P<:[!JX?;ZZOSWB/\\? (__EZ<?/XH-U>:F>_]FZ^7#S
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M.;J8<L*J0NK>(367P%1!#J6\-*S>[:JRM;U#;BZ1J+5KUI3QJI":#:F=2K:
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MSCN%4X7369QV<N$*SM>)EQFG2RHLRE)=H>":'UQS"=OEZ,93.G6_01HY JR
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MFST3"YHV*A,T;100-(T1@,PH0$(2,*WW0)$QYSYV'1M>ZUSX'T^,%92S:%?
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M6$6]'?M\V3=5<D1)'-$NW/',SQ'-CM+9F=M9Z,3JQ +;7578)M7VEEIU*\[
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MG;D-PEYW.IM2?AU>3!C=..<M'*CDQQ=1[09\H@CA5?/(3RE#NIJU6J;^IH5
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M\U7@3AB!'C53]:G';&*TI0,7+J7K< \%&1^_AN^[86V;YP>&B:X^_M 1Q^I
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MIV&E[)I?104 A!4 ;%7]S1T_IKC7'VEM-CO<9^('6N,8)#[ TN-T\Q;/0FQ
M@:U]6/XH*=#-UC]LM;WV!7GK/*:T^RB5GRF?=CK[BDA)]9$)A0B*^:M<7^8-
M':]2AG-"(>:J*CQ7I %U4'-0XP2$GJL]TPW58RNI]51B?#W5Y"V&A'^*9^GS
M1YE3ECG=D=-.0IX_4HQ\TMPR#6>A/DS<Q43G-HW5\8;#]70:;DRGAW"U"YG:
M^H>YG5:7XRA&X&*3 ;2.ZTL) /S$.S;3(6KQ$)I>B49$AO,-_T>S670D4]O^
M63N*F7!+8\H514GU&<)8*X;5YBM[V/!9PT>]-%W/#S5KNL)F%?NI%NQ<Z""G
MFNYVE7:WNTKJ1<Y2Y$$Q31#*-P.K^32B:][8PM.+P#>FQPI7P/3!W3-Y@C72
MXND&4"NIR&GW-$^-S807C?8@[Y2:EM)M)U1"I 6U&,13R+<B[[$E^<#Y=&RC
M0IAM]\"P;"2$$C)B%NU*A.P60%V1"-DUI7>!U-747FW&(X7M>%@,3-; 6VL'
MK3@:M4#5[)$K08&0 #F#) U%[305-:%LZ4@4<P9-VP^> \_/JCI79!6ZLWWL
MXA&W U>==2PUR2^%BM6<*S(9.R;Y+N110^DFU0UOHS=7G)??DGB5TYLK>G3M
M3FVV5Z0F=DWH7<!T);&+UIKM%<=(%HBZ:ZU9;ZSH"'<<.G--XGX63N/-#R.U
M"0P#FV6+IBTL?L3"R%ACRAF*GZ'J>Y[Y;+/S^2B];DR='7Q::(IX?WN/S5E<
M;4H#W]2]L!<BO/]IP\Z'S78]H?-ALFA 8.*M$;!IR%PYC'YCT_C)N;>G%4ZD
MJ7EBW3DR:>V5*8*"2%J-9)K:.$TBYK$ET\HN+6NG#*K>5,ENP7SK"\K6Z1*E
MJ[:5=B.AH> JVZ6$,'T[K5!O6VI6@^]:IXVT''8AH?HBR#9/H/#3OFWPIX\!
M#F/P<R'X=B<E!-\X[1U;"#[6!^+?X,*;H[>4 SX >!ZB?XKE'>>;/N\^F3JS
M8]*8,UO/LZW*\OC[EX[[2-T78+N\MD)#Z=02NE*FF KQY+<H+& SCD-KT#OZ
M]CGK6MO,W217GYO+D]Z1-+/YVWPSFNP]9P[K5-&LL0RK3(S2N0^\3.+<\7QO
M*>OM)9\^JE?F])%:*^KXT0E[[G"8_/&<-WJ,%6/%RSR3>H:&Y5G,<@D+M!8J
M.M;UZ>AD[-/!"@6BQL<#<6>VVA65X4G34BS )JX^N:1CJTX#K;:B]A+<JG7'
MTSL9^W-4G@!JNZNT.@D4,#(9-15K*_J9B-HLP&_:[B7E*A,ZA^Q_]_(<*\HC
M"^;9/[;WO!D+MH+>O,'&)E)I?@&FQ_H@/]L@ D5:"/L_H^UP8@&$>&Z(..!L
MB3.0?P6F9_H4&\&A'2H6&S6H8!6J#)SP,RW<$;QQ=,"<B4,**'*FDWAC);C"
M,[7!J[.XKQ?K1OU"HV_QIV3M1/F"^)-%!&9&BSDR=4:!C<H/0PV"&G#U]X$K
M.-77'*\6W^)\8JX1\[E'H$:\PK<C&?JW>%#/PX(Q5C_,Y@3&/T=SY=;Q_T7A
M-B$88LR7T]=H=MM*KYEV'E[ +A&R_ECS8T?;&8#$+S@<$V(! HNYRO6RRZ =
M;0#W_L#C$V_A]]2Y<$(W081%X83ZD5?T98L%5$!MOL9:S:]5&6O"@-T516J=
ME9&&Q2Z\*X(,[.RRT)#B@Z<QY9\5%'JH]Y16.X<%V%U16;8ZNE*=9^[6E$ZF
M<3R>HYM,C[%P\5S\1<2?6 9\%GX1ZM?;J)%;-YLY5DE2MI-S7&O1LV+>AWH
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M-@MN@N$#1N/0!/M(']N@WY[?B+";P U]H98S1?O)G$P"L*%@S[0IN#R,75_
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M+L/6 @Z)X\*N^;%E@6UFXBTC5,&5"87KF#XQ I>1E#TQA>M[X%4BS<1SCQU
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M/-!L>58"K^2BBG$RE(.D(<I]Z.31=P1W+>4)+\-*!EQ)P;K%@0WBZ4'^(N*
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MJ$DD?,W$5NT9'Y,@BIO*UC5%O0KTY!G\*&G.&LF6X]BKPG2I*2G/II\_AC!
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MS)M>3LQNF^8-V3!)>7,K1.3=Z(J.0[/8[^FP=^*L*_9T0_5)K4(!YDU<'!1
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MNC(/OCV?"BT&CA>"1=TH0 $+Y7SO)6$2?T(ZU2;-U[053TD)H4W&@P@<1 Z
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M@J7N>K.Y],,B54@UH%YU9SN\@*P*N@#VH%8Y0VMJV'T'/L7L/S]83Q&MUYH
M?T5[JWPY0G%:KM=@ZB%MXG1$Z1VE6B4KF[1$IK^_TT3Q(FS.T6/G$L/7DI#\
M<SZ\\P6T[E6S#=IZJZO07!?QV')S! _AA+6V0JQP>3^?/JW2B9,IU:1,<</&
MB%KV+EF"/ 2B-4"3BP(I<T'X$&=,:,E@ -KR-O,C[W_L$!TQ ZE>ZG5RR04&
MV!*J7KM<4?3J!IF4'M+=OV+&;:.M]ZJYUWS:M3.<#0IQ?SJ%GG\Q&52@^ZH,
M#&X"H<<;/5Q3VQ"M1PKH3I)0S.COX6N)SB29EMF()Y]<PS/)*QGYZ(H\9Q-C
MQCUES]P,YA7%_#YP8?(("K<?<(M^J3!IX?QU/,0WH#!>C<UK6 1<\$_X9-DJ
MEJCL143X.5D^,/)X(O.]"9'%R%SB-290E!F5E_9& &?SQ$8HQA\QL?DREU(B
M'B'#XZ9S<5%>\S 35Z;1+;+B.3W1E9?I7#%@&K)OV"E@[,BP/-%9HV *2:=3
MKJ?KHMI%!"X13M+'U4>6R[TNGV;Q(_=\NDT?I(@I^_*(Z&L"38!Y(Z9%>%"I
MET2$&F:19Q'@9[SZ!%#P,FX?[V+_NKP.%+]"=$;$A.W0!9T)7C'A8VG*>+$Z
MC7<? ^8(+U8%PX\\?HFJSS-SL%3*GFDO#'-S0=4NM693%=0\$5D#'#GT>13D
MDVT 2WX<CEW ;&WBFLRFFS,90I#/2\;G.$>DJ''BC@6Q)QDE?])'^K3D@F%@
MV; [/[IWR^&81HDH?@C<VN#CQ:2AHWFDTH!^HWF6_W=E!#<ARVMFW(TJ8M3Q
M_6(1#FR+Q=P$"SBH=-FV1I%N);8Y8'@T.H8I!G'"][W$)GDUB &L:C(5_7>2
M6XT6CR>;!7 OJ)2)5[Q:MHT\(SG3")ZT; V3F_R$JHAI3Y2C9^I$'H8]I*@$
MO2@-[[10$C3%N2'V$Z(&0[";Q+;1T@F%UQ%O*[&>?)%X#-,%<0"I;;NO_J];
M1D)%='Y!5D:&9<[QR.&8F2'6QQ K_#3/"HGK"2[S)QR?L] 83D^8;?$$+_UD
M4TLI8N(8>FQ507EFP":G&!8&@UR&>'\+**%$A'A'EO/$$S8$M/AQ*QZ/4+=^
M_J")3S"<_*O6F\8QY1[^=;G0OT8!:LO!-FZ_:M7I#XSN,]L&=C4$3"/!CK]/
M<5R:^)T'TO''C[\% ]><P;^B^#LY(0 C9-![X :!.T'5-#!5")#=T?P!XDL.
MS VN,G3QD,[_>U=?G$E1^BWINZ%/.+0J' [PV/0'1G<L8!7/@XNJKN$_[U&)
MV!B!)(XA3I$B&:X"33%HO@Y 2Q]L$[>WZLO>\"6CAVK]2Q9TGSS9')1_";R/
M_[&8 2C2:! VV%55JS>Z\'^MUOMUV(1D@NWNS_F +K%,"MB:@+:\\L"=BAL7
M'TBX2)6(9S%I!E;6/[.$VI'227SEU<C,H)^71<@\&MO:@HVE5U303)(02;J1
M_R+/!*JWEO8]Y9I GQ:;0!FY?P/Z#LI[EI#U#W"[-W"YTKO_ %>[O"74Q.*<
M=C:/?6.WF87]NX\_GY$OBWSYQONW7_K<OM_FG6R0J[9:Q%#7YZK[XJ37TBZ2
MG3VUF<5L\\PWE^>;Y?KD[Y)ORLO]+.YV-;Z)_1VKEUD7TIEOGOGFWK71O?--
MZ:P27J0+\CR^WX!)4,;&6O].MP.])!)+GT=O 4]=QY>TJK^]B&D^,6]22Y;S
MU#%91E'.@S?^[F/G,E//LPTD.'/#$^2&IZ-%OKCHG[8IG_:L02ZI0;87SG38
MFP;Y9W2O*]O>C>YE+9L!?%8BWSS;_$7$-GZA^$RB:"Y9&GOT4=R^1O4 WFP^
M+*@A);Q@H)1*.I=+K, (X(JC"JBE'HVF]V7G&7PUC\>/F:,QROZVL)\,U4S#
M+P-FNZ^+PNI'$6I,\L9DJ+$O+J,@O-@]AQ?/X<7]1YYX(PVN9NWHE3C*@_+&
MSF'-$T<N&6"K[!2_^CR:M]-WR@SHG;Z4\OO.1'0FHA,AH@<V,2C[<*=OO8*O
MH!T9&O9.WXN>0>UBMADW[YF$#YF$^[)@9Z<(=@MX;3F^-=SI6\GW\S9SF9I[
MS&5*S-[#YB5SYGI.=MGQ.+*J^W"D*AIVEBZ-7-5]*AP(B>OD%EI>Z<[_,<\U
M#7^<J=JI[-9)>N@!)M6>?SHH;%-TUE1@VZ)NK9O!.:ES"BTPU<[Q.#'Q(+Q,
M*ZY27"))+U#XVX_YQ,<*M[<>P?W"2Y/.RL;R['_IO+^MR "Z0/_6X57^Z>%-
M2Q4-MZMU9<GPFU9"#A'Q.CG]EO(1;QT5Q%\*_U910Q8T3+GL[#AU_Y $XK&*
MU=-8Y>C4D1-(KQ7%UF>%9'FYL'0:V?(]HI(I$PM["!VV?7E&ID)D6KJEVC:5
M#(EJ:^D9AXV.9SEY3"<^5KB]=7?'C>N-F!6DFKD<N*JQ9J!XHT*DW%:6EC7K
M=3W<E"=%X :V=>T[YC4BA\%[^CK%T\GW(EA*7L7VU:$-X>>9+K)TD=/X?3LZ
MV+K4<30JF2I-8?&=!F/+.;P$G1-ZV2Z4H<,\^>F^;"=W>CQI1X>9:I33K>QP
M-> &H)OIAEAULW=1G[>7965]MY;??_A@4I?V'4 L"_O=*[VKHN0.,7+;V5/;
M(@SU2/CCR;+::WCS3#$G)SWVT2]E(25$A2")V@PLEZBG&JET&P6-5'J7O6PC
ME3,=G"7'RI*C659R;%%B1"4=5&6QXK255DM/C W?@4NDH72)G$,)BE0%*OX_
M&U7[XP"5(A:@* C9E565P(\5K:H*B$N<%@ _O?N8)?_*63R>Q>,:XE%1OK);
MPRI!(4<3/#A3RNE(C@+O=&7##;'.:/,&&6QW+?MC#3L]P5C3]D?N7.*#",26
MMSK>1NLXG!;U*GN)R(D7^2.^TL.F9&^W4BWE7@V_<%ST\ADZ6U0;"BM.Z(^?
M 3I15\L51RA>UK+S32]+S:3KOOOXS94#Z=*#P&AXUS(75.M=\AMZHAF6<A(?
MC4(SQ;1,+3FP<Y@ *0T_<WR<ZCATGQU /%/.I\7)NABP-7 C?@#_0BAS-&(B
ML0.A%;4&]$5;P*4Z#L8-!\O->EZ A?,QLAPL_!<AR]-LRN=U7@N8)5+7BV:/
M2RSMV[8[1/"HT?6:@W9%Y.KJG89B."="JA  BBF5BBG01P" :E-OUK,02 ^(
MOM3Z*W>YQ*F .(:Y&)Z-525T!%,^*EL-HF\X,MY'WH3WX1,))_]^Y?K!-S?X
M'P:OD02Z8NBUU=);BFF?"+W029!_#GNP#3'R<TD&8R12^''>:A!-4TR\DX9Y
M&EE)-B7^G9C+NT1DHSR*[^C>N#"Z<3WQ$3Z7ZB+?07=T;O"CG@U^[&N6*>R"
M_1C:H<ED@U/3>I'M3>^_?/O^1V$OJ$@SCU3SC,,U3T-\]Y'>IVDW%?[F0K'1
MY$*#;_$7V*/\>1RYI._[7ZXKGQZN^_^L]&^>KA]^U0S[U9CY4N5'EZ_#YO8\
M9KQ5:QVU4>&Q_L\J_4?ES!9_>J?]H@37/SX_*,&%^FWJQ='A^7UDSD7HD;J8
MY$W)2\P\L]TIZ')NL2;GRI_./'0\8]RX69Y/2Z92X6'YX.3&!QKMRCL!4[-D
MV3S9C]H_)Z;I:L; #0,:\_HJ%TZ.GUVAN?,E%WM]L*CP#: K)M\'''7(O&A,
M</12,426/J3-[X7=;*S+,^+DV+6!LOWK?X=6, ,NS>35W7D/2-B^NKES;Z7F
MSFLPNR/HW"S94ZMUV?YYB83H/<V&Y/<,I.$//8MT@"VT:2R=!OYF6R<>>W]J
M97G 7HL!SCAWVLV<MX%Q6[EW*>Z:E\T-R(-MH(&L2DI<RUM/_@=3UX+E;Q,Z
M^D$GIBQ:L+Z';@C=7KZCZ%]7J!S>C01XA9I);@D.^EL)^(S73>D>5RZ7,#M6
M]!#5]79]QV.8#KWOQE(=1O>!=KWJ5M"N(#:C7#25C1'],3*H<H.*Q1C9NCR,
M9G/;D)0[E'D%7H*[85#YS(;H'VB*?(9-2<6CS][\/708CU&=Q>+J_*F@-J>
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M;S^_I[]'2U%6R&<V-3SR%. ZJ$53XJ.C^>$452R9&_IB#(>6P_*G8;,1\*3
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M?;&\$%5= T<;AJB97]W]>?NYZ.NUGA!W3_#](MZK<CW4:S%5T8]YO!?A0/?
M6>Z_YFCM:385SZ4_/R@&7>_U]%X]VSM"NQ^#$52$4#4.84(#70.SRF:F+K!Q
M^ 'P]!Y4 AL4&-@5:&PII/CR9^6//_N5/[_>:W]R[/"UOD"/$I>K"Q9A?>2O
M,[%@ -!68B)BC>L\NZCIF R].3K>L@^\C6, BN1I8GL!\VEJ\IS=-H3G+!,D
M$=77P1= :AA1D?LX! +6XC6 :.U8H!P=FTEX[3 .;HUF&<[SE^$1T5__8-X0
MS&0_S8 6ZY81$Z(+7*!?:C=LX,VSK+%K@Y7ORYMZY3OR-2:V9&I%U*[*(TU3
M>[U2[_[K"FOS[D;BN'?> SHQ.2DSG,AR*_[BKTGX-+DK954HWRS!;7( W\,>
M7'/%T'1=;]>S Q\U?B[M5I,GTPOAJ%+CEX(C\ :TFIAYM)"LU=MZM9DU>S4X
M6H6?+0(FMZ0*X*E*CUL*GM\!$$<+RG:OJE<;62-!PU,E,!(,@= F/BVJG2W?
M#ZD^&_T%^>!M*;+&E@/OE3N9N Z-YMP:E&GU6SA1&J3TH"_?&D%]Q0$;C9;>
M4[D;?'J+Y*I#.B[P9=@1B;K8F8(Y5%//'3)F^E3?[B_RK[14J3P*Z&]0>[H7
M&T3U24 N$EDK&O=ZK=/4:ZTLZSQI@?_)#8$$0'L#_>8^'-A@@]YA(0O28*6"
M1O/'NV*K(Y+A->ZJDW+\%2O@7937H$.1Y_X5OA$P1QOP=YKXSBE_IRO?N8#.
M5:YF0J]:+?GC1F@V,K"+R!;N@_ZTJG=0;S>;>G4Y@M71]<^M@T)@J1(,U@46
M/6V9%ESXHX$M% @Z]/S="_,PJXC")G=3W,[^ 8PY/47@]4';!"3T4,P$LOD%
M=0F1^J9LK!&A,//D+$ZX'3HF50F'8#FC084Q7Q&,XN_0L>V& 3P5K$KYA@CM
MBQFKRG&]+HX#-P7XJB^"]LMOXAZW&S^XDM2_K"L"*%/F<<!<:M^2HH9W&1/U
M-8#9$;S)QK/\(?9DX8H6$@-H!K!<,KLWXB$BX\G77C%88$SA%3]@7P&S9\7@
M5A4G;Y"[+)!CMT+7N1LEE)$(\NVRV0VM=Q][EPI5"X2(#3\<B#]4=D>Y__+I
MG^K.*-GL%/$))9S01]*+F5KOV_<_"KM'K-%^Y1UY<;6;2KW-$S*D%U?[;1SE
M'-[WOUQ7/CU<]_]9Z=\\73_\JAGVJS'S978-YO0Y;&X?8\8/5<<,$9&2^)]5
M^H\J6U'\Z9WVBPH"__C\H(0 @C+U7G&>R"V=]$O'/QVQC]SW@D2WGSCWU3'_
M.P2@C&;H8!MRSO(96 SH*Z&7T^RGO5T/^H(.(9@4<GWW9___T[[V/SWJVNVW
MJ\L2/N^M;.3QZA_7G[]_O=9N;S7AQ2?W$/Q)^[/_]7O_Z?;NF];_]EG[[^_]
MK[<W_W/[[8O6O[JZ^_[MZ?&H'?6+87,#MA0*^/]AAN=KU^0D6"K07<IQQOO%
MB"#*$3;@"B?P@EF2(F4VNIKV.N=&6Z53L ]IE?6[-VVH(=4RDY9V4Z<2];IJ
MO[%>5WUA'_G:Q8-L*>R_WTWWJS.5'/LJAP*KS;5:VT 3M28*N#E"#\88N%^"
MTK=<FO09!+AG37.GZ*W'=?-/>VXQR.'_R; ID&($'/R[>BV#GS'%<:=OO1MI
MW(=X[IQYXFA]-8;?J$_C3A'LBF?A.^9.WRH*GS8QX/>,U6>LSK)-]*/O](W2
M^7;&Z!/'Z,^1J7>^ZA._ZCUIFM<[%L8;U3&/IW'W/IOV>2],XXR$6ER0HUUB
MV^.8L4"[D56<U.T$H^U_C:WA6+,"K4\=O<6\BD-V<9Q7.:]R7N6\RNFNLODN
MAG.;//]:]M>WKE9$@6?*@I;MTK0GXP=7(39AKAPN(9Y7.:]R7N6\RF&O\K:;
M'J==/CW:!V:7:8R2RS()9$?7Z#&_J5UO#_,CFJW\6;+_RN:K^7W'%*X)/TH$
MSSYV-\IT8BV3'E[\/N'Z.*;QZX<_T^0@\+.P0[YB?I6JP\YAX:J(:#VY&#F%
MS]>9GA)W;ZSKW5I-;[7WTXS_C+XYZ%O8"K3<I*=#15\*D<JHY0&W'CUSWBV@
M;LG>9H>%NG'D=15T/6/I(6)I$9+V\IL='AAFKJ>_MO1>IZ6WV]G.1CO#S[?M
M/%W.,,T9<'TXA+U@P7W0\GQ;$[)%NR=(RSV]V^GIO=:.A[,=NJS9%TH6F9^J
M9B^J7J:'A9[;,3]K>K57USOU\TS!?6-LD=JN:AIS1!A[MCC?%K:6[!]_6-AZ
M-C)/ C&+\%+1B^A D?'HXR)'-0-H>YU\;I[4?6P4G7RBCA")!<:CBN>^RK_,
M_PF[-VB+NP6I[>6\FQ8-=:A%4$>\-FX2E&H8=/R]@U:"^-/=U5?+^3L"5-Q[
MJ 2H%C4ETC(XK_,KTC7@#-8HEQ(5+!$/O%23HJT2H7CCH6PGVL&.WY(MR=CL
M>W^S)L] <@%OV%I'P0?__9=?@\^KU=;ELS4"ZO"&Q7]/LL!&J_=!$&BMVOZ
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M"&Q&0\>-81 :MCVCYSQF !R !F<X*S&DGCZ#&8<Z!Y$B7F$X&L_TTC4_M.B
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M#?S<H\AS38JM4'9!*7)?,5++NY-RK1]EER^<:"2O3,L4>NJ+:Z,II3TSL M
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M)J6J]X\B54_G2T;K9?6>GVA]O=5HGF7"0<N$O=-;O7F0ME GSP:Z+;2!U%;
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MI3C3)ZH2-%6IM I*=3WO5.\UFSI2O=/+#=7U3D3U=D&I;N22ZEK3Z'2:/<T
M^G=UK<$?C:/]DEL T#J1VU JG8*2NYEK<H.HPR^]_9.;@&BAT5M*I5M08J\>
MC+AO8K=5P^CI^OZ)+<[ABU-F;2P>6DKN9T<YIDL(#KZJI5E6M1Q<54L9X+Y<
MW;9SK6X[X+=T]<[^U:UTI82^[8"^U0MJ7CNYIG=/5;N&T01Z_Z4UM6ZWO?]H
MR5#%26Z@>5&#Y&Z>::Y3O*SI1/-VK]?N[-6MBI(FLBX1J%[4J*F7<ZK#]G8P
M:OI+5UN::NR3ZJF:@&9$=[U92+KG&!!;#%GKZQ#^1$SI*"0XW<PI-)U(HM;M
MJ"TAB5JKV5R'()]=4;\HZK[2<N=Q[,*,96"R<?1<\8Q,ELN>.Q/FR0HQ/+>7
M/K@',K@\JLTUO7-/<1Q:H0F*-SOKZ=Z(XFGJ)94Q4>5#12^HB.94<::$M&=T
M#$$R U3H)B2[B422QK2MJGBNZ$6,:YIY3PG,DL]8*ZZ)R)>0B1\(L7(-Z,\1
M:ZV 9)98R>F,J#CMCZ03RBF=0L;#Q\6E8:YQ>J1A4Y5!94]K:QOIRY4FKJ:(
M.0#97A(572TH'7,- .H:^"HM7259U%O=9G<3.BXZ@)S2GX*.<Z>L@)9%#/F;
M>0?W@):ZWFV23.K=CM';R BN)9/S)QB F+V"$C/?J!UJ6$-O(S$-O=4VUD+G
M(V(N*+=.N35&4:.^?"-NLQ1;"WB9$;\XS"LDC5IU[<==D AWV-#:ZEHR\269
M?/7-'6,B\P1;\Y]9@^^6@R/;*E]OJ\KEY77Q]EM3ZYKRXTZV_,49IZZJM3L:
M.?N:;K1:ZCHT.Z=ANN-L.-;GP10'1<V#S%AA?\8>+%,YKBMGKFDJ%:V(, G0
M4\\K/9.22UW7C';C7M<A ."/#YJZ'L2\!DU3Y,3>%,JW>CR15:D4,5V !,V_
MB!IHMUI8!*"I1VMAE4EBZ,JM*QI&X2\0V7D:%[&F#FC<RCF%,3)HZ[TNN28J
M?+06D>>)MO0DNNB&@4PAS^SAH7:*&*(>#7'LIQ4Q7$ :YUZ.,99O]U1R0'6C
MV>GT-G% KUSGZ,^0V6*JL"#RE]F>/Q6]H!*:4Q!&[2'!X'^JIG5ZC7ON/K#'
M[G>L=U;;I([7,JV7LB- BE!+Y+&ZW.*>CUWO"?N64@O3X E;.!22UOD&:<!_
MTMHM =*HW79[K1CFF@51]X<3R[7=>VO ;+"?V"@"1U3/,T!\?OZ*R8XG%XX?
M6$$H*SMLFWOWXD3XA4.'H]W0AZ#(Y\S'%Q9XSY=!X!+:H\<P;!%KM( I\@WV
M %,T6S(CHK6Z^EJ:>W.FP&/<%UCYC?QPPX'6V,?CJ\]?B5V2AFRMF%^*> 0*
M^"7?4!/\V%9U*N[2.EVMTUH+"*$AY$1#\.FP:@L5_B52,+8*7T]/4B8A8R,J
M6D%MOZ;FFI8S7EMW+8#D-AR/4_TMYEWU,SE\GJJ#XOZTU#6JL$Z<EN^JGVSZ
MI;D>.GF<[>TTK[/[0NLN==N6]'8ZL'P-4C_?!4088FM=M0'?>,2-UL"Y_ZO[
M?2UD['%@AS[&TIN3_Q0]== "O[D3/F>&>Q'-C2(FSY'F^:XZFLGXK.>VK>Q[
M%1<_S#30*FA""$F8[UJDV:3=6M8WTS'J!H\A^@=+0CWGQ;9:#S1<K],1QUOT
MMKY6)1+VM+9,B]% N;@=F* JPB=:$<,6W4",<H<)V/9:>XV-Q>5XLF_69&A;
MQ4RVPN[J.]W=]1S(].ZN3&\K%3GFB!I#1WVV6O5"*J4=G?GXQ\1ES\(P[E3T
ME#P.(-YR^%-VHZFI'KCX#&=;*1-VS^,1=HL;#U;KQ:.'!KQZ<77[AB2Y<&S+
MX<J_3FXN"9JB9I]G[B!,AIC.?VRZ<&?L1L@F$^SU+,E!$!@3_2#/P*@HGRT;
M+NSS 0O!&<.>??2<@-W+?IK@39LTCBJ"R=++B1Y7!;-1+1[=;D]_VQ'=[MBC
MZ[CC)U ^ 80YQ/6#$1^S%"&+N(.GQY?[V\%39@^B)I_88J*/\42Q]_/L_//^
M]O.,#VDXP.%LY^7QR?ZV\Y+UN7TH.WE]<[Z_G;R.CYAMRIIOM2&='7K#'7VM
MR!PL.;4%Y^!E8=.:%_=L2J_[U9OO)IV/YGL-16V-M(W:&J5:Y/PPVS4IZO5C
M3, 1"G&(*O:WC1HA+6Y3M3;=YGL+O5WWH$S[IW1?7ECRX\\K^P+1F-D!LZ.]
M#MS)"D4AV_RNW)O,&_](+[M2&G#G-[KG9^J<@)V]T>NLSSSA>59^Z;;G99?G
M16,;GOQQ>Q*][H(N')/.\^,(F'%R<A';\Z-.4UPO&2"%>=H)INYPC T>$! 7
MESRQ'0G(9.:**<3\8RL5GR+H24U4?#GT ,/9/GR.8+,IVZL@6V"?!T*!6':T
M@!_WFW=I<(8_X8,@%!W^)Z$W<7V!@,J9 KZB:7BEIB^90P"?:CW#2%=\UA0Q
MTYN>IW47?/$\FJ>>W*$Y=P<7QQA,<7!$:IJ8;;$^V/3@24ZB"&B'?+G84@*V
ME  ];Q*0M!02HR[ !00+B*C.W.2,:!8=M3P)/0]Y_(;C1#Z<ND%UK=VCWZ6(
M1)5LE(Q1VYLSSIN[26_^@$/K--J2UY:=1LM.HP>JGHWWHIY%LP>#E'.WM.I;
MLDWS0-CFV'%"JE3.<(VFQFPC!A%VQ;B%DFVV9)O6@;#-L]I&#F=IEGSS*GS3
M?E]\HY?ZYG7XIO-N^"8S)Z;DFRWYIOM>^"8^?F>4G/,JG-/+&^?\SY4;X $\
M\W]+TFZ)Y:MYH^U;:04:0R5\UU:I$;9EF]SE@-X48M':8J!5R3?;\LV[R9QD
M)_.4C+,MX[P;3#<Y?"KFH9:X[M:\\\Z 7=']6>N5C+,MX[PS:#>:*5;RS99\
M<RC0[I\A\P+NV4\+=,Z?DG7B8_.=4NN\#O>\&X!W=JI=R3K;LLZA8+SK>CK-
MDG%>AW%R!_'NPF)IHC^?5K+/MO6P[P9%SHS7*?EF6[XI(HR<[>*M8[G](E9:
MW*8@9JG;(TVIX&$ENHMA&$>ZT>NUNM69Y'?):J_$:D5$GK.L9KP1JR6(H^AV
MIY:\MB6O%1&LSO):\\UY351GE)IM>VX[%'A[@]1(U"FY9)YMF>?=0-QQ55CD
M46$?23_$OG6@ZBZ L92VJE7Z5:R)$>.)[Z,.,;='O]?B@:D#UQE:2'J+V0H^
MC,Y_TNE-RU=D4P5EQ!ZP/S1W%'=L!?@NS$_/'8<+?,7D$*N.+0?^6K&J].?H
M:LL98D<$>KPEVC&-98]RZF!:L59\8>J&MJG8UG<.@;!HST2GH@.+3L>.&.P,
MM=-*EF,-E4G8MZT!?,.T_('M^MPLQ6M;\3J43,"SXA6#*B*)5,I7*5^[D*]W
MDRN9FP=<\LZVO//>DB5&R3BOPSB'DBS9)."23?'W8=4CT[W$LK_(JD?W&H1^
M 'OKP:[3!6P0@"S!+X''6> OO3DL8>)9#PP'_7B9ERO%:]O3^^\FF90D(M52
MNDKIVHUT%3'EMEUUD1 N?8OF1>G7>_6VEGM\RLQ#UGE&BO9_@W1;PZ?L8S_V
M/Y'>TCIUY2OV'@O8=Y L_V.C_VG'KYQ[R=<[LY*?D:/EU%'6VX\*>Y&LO^XB
M[D!^J0D=MO,'L4S-"\$NG7W9H@[8A/L_Y51$<\])6O>-.>EE5F/K13RG;>Y<
M4O8UQ0P][&",3L<$'!*7ADA,1Q;$O>X0[(F/CH3/L"$DCB;H<[QZS$SX*@.'
MR0^.^) &=(*'Q.),:#1R8G%KR));\\.MSS$*>+EY96 Y]D3P;M)IU./_"2U/
MN$1^U"54!95>,:JKFXS^_#I=&@^^$V);7EMV0BP[(1ZV[LNO\H-@S\:>Q7+&
M4$K_H3H<LD% EIL_ "W0=%L^F?EA()H:*XG5-ID8NIV.%V=:.5=<\:4QV'NX
M!E6+L/W*0N./[JD[K HWH@9+!-ZV3 %@N/%8)'9_#X^#1]3@EA,Q;0)\BB$(
M--XK8+8BNSC++Z2!#I_3>/%@%/UQ\<KKRI4;8#]['-6$K$S7PA?YO0N_U6BS
MP(YX-)4:UF9R^3/<]L&UPS%MC9^8"W***"TJ=BQP<:&F:]O,4QZ8'2[[@DA]
M(O3#'P>< "(62$]KRB)7"2^M"L@'5F;R!TN\41S1V^X4USD"Q:C AD>$X\ E
M8P("QNS1&H=C\5Q\8^K?#A\_81]OR3;)K##<4KQ)NE4WH0#Q[*E3=SRV?)H)
M,DF!;#<AZ(NFWJSTJXHUK"V@*OXJ*.BGMA/?;>+A9/"$ZHX+K 7>)6R)H^CJ
M#S.$CUXIOG?R<N).<]P@T([!S^EI10(%3)CD,^?B,O-GH0N%"I1W2!A[,6>]
ME:]0ZN&%>CB_BCCMA<:@;J;F 04)&'TB6\R3NJ;I"D,L: @\JQ_2A:@;0"(>
M+#?TT\4.JU4<=>-//UO*#CS)#P>C+/:\ZD9;</3N ;C-L%(E\TQ%/C3C%$7D
M3;M-\;^2YZ\]%^P8C@\8N5.PK%Y-*/$)\]B]QR8C7\$P0ZM"T%2+?[2$/H]_
MQ=_[+AI>-QH6:%.9RZR-BP,9(&6?1XQ&[+ B](:H)Q@!VZ17!9$X#OI@E)BP
M\,X(_68T/7#1,/0<RQ^)!U*4='XJ;I<&DC-&()["8- 0AU;%7!1B+1K'('8.
M(05K*8R]VK27H.B.H:R7'01Y>QV,C#24'JH<,4*Z5>;B(GAKP6B/I<-&. /-
M2>ISJ9R)\2C):!0AI$QQX.66:&J/HRN"3JB0KP5>(OG.EE,CE4$06NSJH%N)
M*TI]BP5"C,#WXTL6))2*1?G-ONO@<!<SY3])7WUYBF=K?HS$Z.5,LYFJ7^I=
MO<G;O9VTO>PHS&Y"SS&:+PI),IP.RGO,F<B?K[!0*(S22*1X62#+210D0R-X
M&.;I0\=W(7PBA@>F)L&.W7K*ADN.+CDY=YS\LF,V.[$;M><,Q_I& _4M(=&A
M!]Z.S[WE68Z2$_?$B3F-(L_1VY@#8%9[WBGX!?,:%21*1P(9NJ'6DS]%Q4S
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M/>L))M4@ZT9';VAA2OMY6'$X\NS0XUS!T$94Y60#B$6,"$P.KJ#PF(&S,7W
M(608/L/8<"D9'/@O^=D1*S^M^%)>*QL.K2ZX4]8%EW7!A^<HY%7MX@$Q>60Y
M]HH10-E<%\OB((%2+BAA8WTW#)[1RE;@ISWA&$W;2+V7"8!\BL!#/B7@.&;Y
M3/27X*\2?I_#@@E>6NDSS,6$>3T%72KH?CZ9<_;\;BJ1.W=^ESA68%#I#,/6
M)6P0WDE :%DW "9Z((F*T"6UG91$\I(/-BGSK(!"KRE3?&.J= 6^Z>.YTYGE
M@:3R\<1VGSB>,77XT JH2'JCA6ZPKFJL(UY8?KJ;^K]=Y5M*DYLWI3;(IU*[
M<'QWR#Q,/:&Y&#O6,#*ZZ42IP'7%F;-G\7)Y-&F"JHXZV@#KFI8'4NUZ$,<
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M&R='VCQH,"] OD$V>9-FA@W##I"9X$WL-XYF5O\H5-0"Z*<"2@JA<4R\-FS
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M,5F$19*WG^27XT@)WE-[2NJ2T,?PZ2\17?,O?7C_[N/W[[XK2>5'0$[X5_)
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M*P!LH!'G;;R9 PM";Q<K-]"H=$M.6R#Z[C-WMD&O=1U"I0LL126;Q=SV]?Q
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MB]J\)4;R\L?0:HR.7]WDB'^#]?=PUG&S60T,9[TS2WGQ<98  _KG^\5H608
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MII9A3;N-!Y&UK>EU2-0Z9&W(P_/Q,Z6I.) X:]R*V^V]%$^S89QI:V-1;=1
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M4X'[GN2Z;[N<VV=RE,E;M.T=8+A*N41'GH5L\6TAZ\O/$4 //#B4V1) ?<:
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M7)+Z=^\U?[;X49'+>Y*F7-+)6)AM=U'*"D.>03][9%;YMQO0">MHP]:WX9<
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MW34QDB?7WOUHO/>\^[%K]Z/:ACG0.#F8T@@$AZVR<U./!A NEJK,'5A'@3.
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M_O'D:I$JKHT'\AY<[\'U'ESOP;7E5H)I;V_-8]M&$QNRW[9+R]-8';9=Z3[
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MEMT*\A2U)K3ML6!09OH']!@Z#@25"FJI>Z&;'?[(=G]ELA"85F-AP7XD\)C
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MF_;G1!WV@$[BM#\!RI C=.*"??SRB!%TUX(E\*U"!H&3\M/ )@460P0$__/
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MW604[\GVU=.\+]?[<KTOMW>+7V,I%)VENB%>$QD-G<VZ.6:[(MC S-T6+!9
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M.CYD"!X/J\F\YP0I7EN:=?;IFGL)KC!<%-IF,_:+WV(09A/.11>-:;1>2O!
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MEO0/15OQ $,VK!1MJ(H=Q(NMV5TA*D]\0RXVA#,NX0"A;_)]4I$TVVQHT[1
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M7#^,)L&YG!=OOMK!#Q*6Z0)1I#4<FCH809<W 0&;2(R(Q&=%!+:MI'>_A8+
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M#@+8'IH S@_9AI)7]&F=[U)QS^82 Z4[N<BT6']-7CW3I(0__XO_B5(U[BF
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ML?=DJ@XR:4'SRW8#/%(>U3R5F3GI0L>M9W=%MLG6T #@",/9AC%&'V,CV;6
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MS%9S56;%.MLF.61S2$1@65RW4- <\ZORUK5D1@J8*0F#2[WLGZ+5'L=I)YS
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M1^%#Z1PN_ /_&_]A^R/^G]NDHOPG_S]02P,$%     @ +HA$5+TOD!I@9
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M-8D981Y<5=.MT+56!OL^*F!GKH 9"Y#;DWKG;\3]QT_Q1<%B7T+_*8S"-"0
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M)8,!@7H9ZF6HEXQ;+[DKS_E=Y,<IOV2OMT<=KA[760(U,-3 4 -##0PU,-3
M4 ,;I@96_UWO4^UZ[[%P$8?S,.!0;JM<B((7:QJ% 5<2<PTF(0$Y^CFA,?_W
MH'A"3'UF+7^U%Z6N$YA1!T0=$'7 <>N #_MKX6)W[._*2T&G_9E-1KT/]3[4
M^U#O0[T/]3[4^X:I]]5YT8>1C&:HQ.D7LIQ$AJH6JEJ#45%<P0,3Q%"%0A4*
M52A4H5"%0A4*52B'$\1F-,CR?\F#^')F]<)X3I-5_B&XN@1<J&MUR0B,3M2E
M"_[YF0#A)O(7%>I)Y>\=*DP3<?\DQ)_0V;&$(_NY0VBNROVYX:?%C^Y($M+9
M#?];E2*G'=L;G/\B?@*#\F1D#S#>[OE;)GU#A_<+;974#1G: Y2/_!,*R Y_
M[A":4GJ8S?CER,I_B#U[*[7#*,;V!:>X4:;)(_TFMQ9)1_8%XQWE3T;T_X=K
MR:VH']P7I+GX-$WN$OH<%HUVE+!*AG<.[80?BL2/;OES^O*_R48*IF1<Y_ -
MQ7Q9?.YZ19)%&"\^)_1;NIS0U=J/Y313CNX<UILP(LF$<]6")G(8*T=U#MMM
M'-!D30L!.F?]B7!&)!OEL0;-ZASV>[((A7H0IU_]E1S8ZF&=0_>P\J/HLO0R
M2(&K'-4Y;(_^R^U,R/;" R7V\&NV>B*)%$K-^+$[*TQAHD*87M*82,DF&^*.
MS?.LS5<@$?L<C%@FA(!K3XZRQRFV%"S8.<HH&I*HGFXP1=ZY01&%U0M,B@]N
MD )HU@*3Y4<7R2*QHX&)\I-;1#FU-X$I\;,;E#!6W< $^N@2@4"Z#I@TGUPB
MC=8T"I=2G)+<-,98.%6<$MX@]E0X:1R1XJ!F<3AAWKM!&+D7%4X*1\1;M?$(
M3@Y'Q%JM>1Q.$4=D6JWI&$X1IV1;@)NGIZ"@@,8S465Y)OZ-T2B<\5]FWI,?
M^?P-]-B2D)1Y09;D!%CG&JR7Q7XV"\6X@C!+DG(1--HAJP\AZN2S70<<=0@T
M9G-TFLWQP/>"L,L)C9])DH9/$;G;WB4/*0W^^)54N$=JS+00USZ)?,:F\QR8
MRJW6#[0!-5VMA%;/8;GSDVF2R]XST8R:W)'D8<F/B@P-^$R[>.6@L(LL7=(D
M_ ^9Z?$YGF$U-^4$KEO&,C@6KT</ ?YIEO*K/)[Q9Q>*1,44*T7Y#B\<P^-B
M-MDZ=L!# YLT$&R4!T<_82!8Z(\/<);-W*_#-[!"" &/QZP[4ZBG\UV^V1UE
M8:[=J9,V3:9B/N% 4H,@>V4]J1#CCOIG#.E-2N$:BG-$T2?2J1^@L<?:&'%)
M;77<.2IU&+TW4.<5IJ#6RU*OH_TY=UP,**36))T[1<:4J=),P509J/^W.56D
M2N[8PQW-2&-LF>TN['&P94,,K+UCCW]L2)A&5\U G<4-20*X9VSXBG<#F"A7
M%_ALZ<TC^HUUYR:N_45+'N*&\*)SN%/G<*%,,K[S-_R4'JB65^2)[TF6B&I9
M^T&_Q6'*Y [CYJNU@!+_5KK_1MDJ[S;FSR)AZ<5*Q%%7P6XPK14@BPM:A+_P
M0U.>O:*=WV8/QB,5K2;XKBO ;K!0"XA<OXB:J%G(EH4)5)#Q-@ZB3-S4>JK7
MF-X"T'?^)E@2+JHE-"6!(!G_MT7BKR:Y6!*D<A8WG-H&L FYR<05^+N?B"0K
MQ?G3#&TCF$2\R(5X<I4EHAIN'NE3O-$3$0H413D/3N?E$3IDS,H@DU96[!JU
M+4&O7T@2A.S$I=E@A;9 O\N28.DSLOW039BP5$ C:*@(\C&<VP*XXM[7,[-\
M5 L@;!>N]$\K1M@+<BKAF2;WX6*9*ARXVO%#P0$2L:6:826P9ON@EH;Z0WWM
MN%J1V20;Q81?B3R7&W[B_LRXK+8KP:W@,J.YUG$K15$AT#&NV I9 [)S]189
M(K;;VVR:3//=:8JX;CWK-!"IZ,H+1C?<.@;3)%R$L1^)OQ82,&RW%/,LX;1G
M&\V%4CW0.M0@7E(-QY I\Y"IB<^6-\)0! ^5DD[!$*F!V'Q5>X2A4><3&J6X
M[*GIM>H23> 2-3659%PADUZ]/8VJTVN1KE!''R0$- ^X$@D#8I<&AC!7XF+@
M=-+9Y5SA'/U1JF$#<84XQH]5J_Y!5PX=C,546K%+_"07".M[WEP)T(-?SR ?
MH"MDZ2,L?"SQB1@6KHPL:^RA=>6JA0;@P9U6SCW'<@92>86=NU1KGB/#H WG
M+F(YV5H(UNHN;GQ(U&K# 7L>,>3-HNC.*ZB\):\VF&@#K;C;A&A:YS*8. .M
MN6MTFQM&#/>7JB MT-8@&<%PS1[2#6I!A D%';3CP6)HG19#&Q(>6 K-$B98
M"@U+H=G'PHE2:"<RW4ABXK",& 3:D5NOL8Q8C+%R/?NXQN*R0!\7EC[J@$)8
M^@A+'V'IHYJD&5#IHX&3IZ5K9M3^*B-+T7FYIX98\PA0QZ<5EX+AZKTZ%VK!
MAFZ&'NL6?:4I87?^1F@'VP!BHTXW+2S7*E+3^>M/W<8I/;@>((@8+7$FY5.Z
MJ@)A5CK!=/H0,-2F0 -F# &/,D)M&_IA6++C=-YP<,(:)(,[15B18H@5*4;O
M!<+*"$YZ?; R GI[L H -!_.5(96I;:X3BQ 48!:*HDK+J,ZS-1<VW:%>I@G
MWW&>? -SE'.NRPYC(,;BI\08B"8)K#(3CBL7#F;W#C/=:2RW2R5Q6LR=[]1A
M&?.7TGOG/?DLS'UUAU^!.R8AJW3M@(3#@([&3AV-N?#U2'<AN;N#(K.^&<YJ
M <1[(FXK4MSCZRA4=*_0#+5@#;P4')Y7"1"WJSRK0#K.AE4\9.(^SA+RR$_?
M920:MJI-L8 98\?CN(5;KYA\I3%7M4GJ)YM'_@XQ/Z\/]<@!4;B/8),&A8W2
M?P2=ACX7]%3 )433]\RZLV*P_2\-+L^QJ^KHRH&_+[3N#>X*G?26+9.7VA5#
M#IQ[X)*]*[3IPQP\%FO6V9N#(;H5!2N2?5JJ/N3VG<#SXYDW"Z-,!)MS3)BW
M)HD7Y-Y#CQWFSP!M5\;K]F+-J@D5VK?.QKXU1+.&*WA8-<]<^TG,;UJVS0?<
M02?!0SL>31AHPD 3!IHPT(0Q?D5KM+HF*EI*10OXB/>I</V<_T,D[FX.-Q.H
M5DEF]Z(\*;^-*M+9J$@2$ U[XQS"6:NM3N]):!5WCTP'4H^V!#^V0!ZY_NP*
M'E;M %]HO."ZS4HPBR8X0S5T ) KSX)ZL TK (E#FN0O4N5#H!V']A:TMZ"]
M!>TM:&_!ONA]TT0I"5"S5]<5FNB-4GKYR14#'90_-,*-*^3 GL*PR[2'GL*C
M#2'"I%HT[JN-^R K6Y^F_8]Y"%&8YAJ&H6&_<FXO9GW%E]&H?^Y&_>E\'@;D
M(A;7!4W$.ILOQ&?D8I&0_*-RH[[A5"M5#'=\#[?MPR:-W43K"AYV3<V"W2<T
MSB')_.B1:P@J<[-F^$ P4)N=M1/0C(MF7#3CHAD7S;@=FZ1TKPDUO[5=H0W
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MCESM-N21[@?]%H>JWE;-5VL5I7S]QX0KYTLRC54ED&%3.@/N\1LU!>YD2JO
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M)!/9JD]=Z:/'A,5L22-.=)87X$XWACJ3<HU>="< !*A#=9ONYJ_#U(_@B6&
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M)HR?O(2D85+\9<UEZBTHP :,TOD%*ATW7]1\'1LO8O-ZLSI 6.-S:#4^[[@
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MV)_/^;;P79G0.#\V3&;,,Y_8AC?D]I?/%?'KKUP?U4,<<\5(0-P^^+(H[4/
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M90N</DK/=,6N8_;JP8,1?)U&\%T$ 3^-LR^A_Q1&8<K)?R>V8:-,NP5/:@'
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M2RECR6$SF]D:J)/:H$)GM@;J=6U0H3-; U7^7.I A<YL#=3/)I>@!OCZ:_6
M3GW@.P+UE]J@0F>V!NIM;5"A,]L#%<JLDH&M ?*/VC2#SFP#U,((*PK&\#?Z
M+O)CH=DJ  2,;PVL$P]Z46)C(H2=*"JS),N")8?&$3G@=5=L58Y2@K)ERFUQ
MNTIIW6R%5H$_*,HLYQ+IH'8!4!QQ7>WHQB P?@BB+*^WQ(<"54*CB382^J+\
M<Z3@I$N?O3X%ZNPXV&2["8O?_&1VW)'G&(VJ,19@/0Q[JN0H_4 ;4$M[R1U#
MK6DZ9P-J>4WZ:N!UC8KLXP#9 GV7,OMXZ$J]FF!H6C;6/O8F5:!,*-&DNM20
MJ7*\I>W01%>6V3Y%]+U_==/LXK3WNI1O6B'0WA-&DN?<!GV3B<#-K<%3AJ3I
M.I:Q/@B1$3!KNGJ=(&LV?0@8GO8*U2$EZRYJ%X]2>=Q&34A?(=V\8?'?JSJ6
M9BA)BE_VBH]1B[PCM&IT%K2(6T6XSOZ-FN;P:K:Q]GH#VF'M90+K4]PK!M>K
M=40WA)0NU6J%^2O-HU_(+-=(V2/E#]GA[Z*8W%>:_HND]R2@B[@B5+#S[UGE
M@\ZPVF6^E'\2XV1'J%\@AD'OO.!X?A\H#1/:\39P*$/D5FL:BU DU<6A'&L!
M]CS^,EP5C)&7DN0\4UC=1%J3"A63J18P^^H+<7PZ+VV$BA=:,=(&W#3FF@9)
M_60C,A.9'P@FUQ@889,&A8V2MZ#3+& D_%/BP5?L1M40BY J*5T]R :TKYR2
M=WXR38JF<7G@&+]E\F=0A@5HLM67[C6(A6XCS<> 31H</GICD6:698RJXOE.
M8DZ*/Q!11J,B)+;98L/#_U7\GPFNKR;:+6U8*3]?""VT"'._W.R'E/5E<J$Z
M_W__Y$+VSALND]C;_,0X:57J\I^+O*JXP*4JU+3#+SE$N=^)L*)SY>Z9)/Z"
MY#]>\0?MQ@^3_$WKA:I:*(9-<:8\=;ETS&]@B)34Y:=L4>Y)SR5/Q]AP%2E,
M\L&58?^MKV^?O^I@L2T>57J##[L<%GW4VB:;]H/VZ5A:>7,(-<*\=+Q=++:I
M9H=1)@HE4#O>)@Y'9B@&P4,U!PM6.UFP6AW@>N"O.P@NW@<Y2+%KLJCE.T !
M^DE26QW\3Q89+KY?R;?\IUIX[B;;QZ^L+EA<;R*_>)_*M>?&>_$42[4_PV6L
MXJSJLB7:54MPU$V#X32NLN%U,LZQG/P9EI.7BGBGO3BEP<G.$44I+U(CEZ@K
MM*G. Z!]VAE<(:596)6TY[+K9#(.Y:2*N<X32YN"H>NM[#)U5&$2QVTXC<)"
MG"$0+ B#0F:X3*?*\ AZ^KO+-#!HPZ.V'SK7ET@E2]<N:M)= YIA4\FLGHIS
MO"0]7/4R7%RA3QVA4%)ZU[RBNBM'L5LB@DN<=]<?:M@WFUGY)5>HU"+3-:FK
MWUV+K6$SG5DA+5>HU"+3F?<]Z*X?V>B(V$9K%E=>7P/]21^WX(I<!S:]MUA>
MSSF&:H5V+M]DIH]F1U3ZR2TJF95?=(5*+8H6YGV(P$3\>=A$-&4UL_*9KE"I
M158S;YT$)N+'81/1E-7,JHZZ0J466<V\M94KI@Z]A&^2].R*B _W,<*+TX-I
M\VG8M&E3F&C>^,\5ZP_ F0*K7.G*$01%B1@T_W/NPH8&_NF*S+IR+\&%)GBW
M=%?,+O##I*G_#;]=QA(94H=;)$WL7;EBX-QR!VF4!>>9@3])<)ZI42W>%4$&
MSCSP)E.NV'3AM $UAW2%+'K9MT9U3U?D8.,(_ IWYH%YB"_'/YAQ4N0-6\M!
MS87#@5O ]2PFKR;F"B?) H(-NP.Y8JG6LX2BGX@K/*%-E0)6 G7EGH"_T(!.
M9*Z<%#A1(/VUG7$_U-&IG:8(P)>@JP'KRKVJR>+*V:+\K8S^R<4QED6B1-U%
M/+O-RT[GU8C\^ _QMT5"BMS4LS#BG;"0*A7>4=.4/NCN2W6M'3 IC"F1"C_7
M%SOD.$7V4'PW*N':W34S$@)!:_=V9P ?":&TM7.[,_H.CD('EH6*4).]-2&O
M)G=2?J<[ ^?@""5UE>O:!W5GT1L;C23=:KK3,P='H*(LTJZG79[!M@N4.$HK
MNGX)EJ)V25G23)E#4YNDQEKJ,$EJ$(G?@@!AK+(-DVC5==9-DAK\EW"5G=0O
MZTYO&28=#2A6W(#U)5=W9/MZ)0X[=#L/EE+MM$. 4\X=J;]I<4DXS5S1 ZK,
MGZ>'M#Z=QJ\&R%_.5UT[*ILJP.GDCBI@WN $3B7'](&#J.CJ%N#"YU"?6N,7
M]95>FB;=T^%$'+_HKR3B]0M)@G#7#>&XQWJ#%W+\LG[=<LYP<ZM#TCVT#P6<
M..X(](;7U_$AK$_"\4OV<BEUUY_WF%SEE2;<;O4IYXA\?U6B<%@A^4OH/X51
MGG6RU88>:2&97:QH=MH !TXU1Z1]0ZH=^4SJDV_\2L!!%**L:8G0!Z(HQWTZ
MOP@"#N<K0M<GGV/:P?9>:TTA>.>.0M!N7QPX!=W1!EY'I.^<F;<QXW =I"SP
M9[5L=]C4F?=N_!I!^3IH*,=?@3@(UWZ41X!Q) A+&[ZL[QW2%!JU=()3;/SJ
M@_XQW9[1K19?WU#[?ORJPCX686=5*[,^"V+=<\23YYR[;C(1V+FU3M8GVOBU
MA%?Z>R_M-.'4';\VT9BZNAZO<&*.7[< ]_UIT#\<3L_Q*QN-Z=E.&VPXR1U2
M7[KOYPXGJSLZ3=$YAS-?-7W+5(WZE!J_ G.2$%B(V=7T^DKS]!527)SLD7)1
MZO!WT;#H*TW_1=)[$M!%W"C$[H,[&DYGQ-V9O,L_B7$-(K3'KR$I'2QMA/M_
M&+]:M"WQLO;#67D#YN]P&:A]HG'#XG[^]L,)V?C7_RA^RW\2P-^3^7?BG[_=
MW^XP71#Z[+_\):"K'T37W3>?WK\I*,>V:'@Q38GWR4M(&B;%7]:1'WNSHHNL
ME[YN(UMT_!5H>ML%\R:^==<K4&4A/\5DBVTELN7X5_O8.G8%-/QO1-2>^1[>
M]9B1X"^<*#_,2)B#(OXE)U!.'%G3V:C@<75/VAH]F/702-("#P!2)@["8#KE
MDAI]BTN0ZG0\[K^%]169\UN!/SUQFH1/6:Y*<G8KWZCD*F2!X$0:^\GF<%!A
ML#Q"N9U%+;<QEUV61SCJTC/M0/TJFU0&<44/;6PQCBW&SZ;%>)=IYV,E 6:=
M*URA;;YF?<K(;]]X8<Q'$2_U7PAK*"$#5^M%/C:"!:7CLY..):!.UT2X2^+%
M%\K8Q$^2S9PFN8'E(7OZ;Q*DCW3O4JF"V&@!JX(L9SWAR@@FXA)*-J_KR1S+
MZZJQ%F"_S8_VH_]2YN96,C5L\""@K[PEH,-M8D#8G1_.=( 7HZQRN_Q<2H"7
M3["*APA"X!+"4GE<JP>ALFQ76>X(6GZ^)ER$#M-#)E5:7Q0SK/)V-5SRBUT[
M?B@XB'JKRBL>. M-,6B*.0]3C$9FHZ;2D2MTT5]YM.:MX@J%]!8LB#[@BCT/
M?HX *IXK1-&S"%"R<(4@1K>*2KF YW(,FR!]> (&WOX'/0$U/ %PHT%W5\?@
MB-/<+MK=M3(X8M70T;N[<09+'8UEL5<7VEMOD4=3>WX\\P(:\6N:EFR<D&<2
M9Z2I6ZW^%_IQM36%#]UOW;K?;G_Y7-%UXI6?K7K(>?G^MH*MK,?"(7"ZL2V
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MB-W#E6>V+YHV\*9WD*=E,ZVM+XJ;!U:YPM/@;*Y:@4D=O%<VV;$&&91$5,4
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MQK6*55LFP$&!<C">JJ+F0VBD75&O0X);_1)! \6S7L-P<+',(6!=40'5#%M
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M-(97=T*<#.EBX)9Q)\#)D$80RZ8K$=O&Q %X!IR[= :8S5U4O>7?3]*^P[Q
M4<DZ&WMW/#)TRFB%=^?>)CT]#$Q%SKU*=:@CTU>=>Y7JLXZA%<J5;.CF;-45
MX0:>C-0"RVF,?V!*&;?P&!&E(%92,*'@_3L&3*A^(\/ M#5N^3%$VBI"@N "
MZ%BL1HVY3!%<!Z?66'2Z2FHU#DZ'TVG4PGNSV&4XD48MP[>0I@&GU*@%^N;I
M!W!"C5I^;SV-"4ZW48OO;:?JP,GFLBRO#%2"D\@)*;Y&P 2<0D[(XHT"IN V
MT5%+ZXUSV>!TJFE7OXX'V?U2&QT/)XRQ8#YLPFAC;GK*K(]I2KR/E?GC.W(7
MOWHL6ZW\1.25IWX8[=#29]8W_T;7F?5M08AM+=MI:RG+ZB6B"?KE@?D;D-15
M8V9KH/Y2&U3HS-9 O:T-*G1F"Z#N3VR;9_<0I6Z^8",5-O(9*V,<E3FE\H'6
MDS2A27C 6=;Q,6QP==QLWDZRUR%_0-((9>,QA=!NFMVX@F^[O(S/)*@;N]^
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M\P46+,DLBX@7AMXSY^Q\>8]OEO=GYD?A?",VS0\"FHF*3\9]%QHMWW6%JQ:
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M"!B@(**^^_@_Y\-9W]:UKNNY[_6[UV-D8JBF[N9-X0?\!/Y?@0   0 ,  @
MH  . ' @@(, ' S@$ "' G@ P(, '@+P,(!' #P*$ "   ($""#   $!""A
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M*$("$!*(D""$!",D!"&A" H@*(B@$(+""(H@*/J_0_B7QC\D_WS]&_X[!1R
MXD 4!Z$X&,4A* Y%\0"*!U$\A.)A%(^@>!0E "@!1 D02H!1 H(24)0(H$00
M)4(H$4:)"$I$41* DD"4!*$D&"4A*.E_8O\.[5_:_Y#_V_O_BO__$OE%30$
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MQFG/7UP8$FU\[(EZ9C3JF+R;G,G('6GD;HLV\%\-G^+;;<@W6J7#PB\SP*5
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M\Y@@$9I:/FGT#G3? ?^O8   !@ @ @ 4 ( &@ ( 4!@ B@% B0 H!0"E 5
M  H&0&$ *"( 10&@:( D " )!DC" )*(@"0*((D&( $ )!B A &0B  2!4"B
M :@  !4&H&( 5"* 2@%0:7]W V@P  T#H!$!- J ]K?YBPV# 3 P !$&H/R=
MP:  &!0&@V)@4"(,2H%!:3 4 (:"P5 8&(H(0U%@*!HL"0!+@L&2,+ D(BR)
M DNBP4@ & D&(V%@)"*,1(&1:# J $:%P:@8&)4(HU)@5!J,!H#18# :!D8C
MPF@4&.TOC[]GPS  # 9 Q  H?VEAH  ,%(:!8C!0(@9*P4!I&!0 @X)A4!@,
MBHA!43 H&B8)@$F"89(PF"0B)HF"2:)A2  ,"88A83 D(H9$P9!H&"H 0X5A
MJ!@,E8BA4C!4&H8&P-!@&!H&0R-B:!0,[:\$?Q6'$0$8(H!(!%#^*D*$ HA0
M&!&*(4*)1"B%"*4140 B"D9$88@H(A%%(:)HQ"0 ,0E&3,(0DXC$) HQB48D
M 8@D&)&$(9*(1!*%2*(1J0 B%4:D8HA4(I%*(5)I1!J 2(,1:1@BC4BD48BT
MO^K_-1M& 6 H "(%0/EK!@4*H$!A%"B& B52H!0*E$9! 2@H& 6%H:"(%!2%
M@J)1D@"4)!@E"4-)(E*2*)0D&H4$H)!@%!*&0B)22!0*B4:A BA4&(6*H5")
M%"J%0J51:  *#4:A82@T(H5&H=!H_PO"7S?^2O*7U]_AWRA  30HC ;%T*!$
M&I1"@])H*  -!:.A,#04D8:BT% T6A* E@2C)6%H241:$H661*.1 #02C$;"
MT$A$&HE"(]%H5 "-"J-1,30JD4:ET*C_ _L;M+]N_Y7\[]W_%_S_E\1/1CH
MX#= X7_-_]X$@(4&^,XJ9MI3-Y[*PBOO/MM3/YD!EC2K,NUMF,H6@@7MSO8V
MSN2)&V:)(1\TS17)VI/<YQXT+Y0I^<Y7(?M:%BLU(]_MSO6U+M?JI[)=,NMO
M6VTT+9+WF.]O7V^U:32K-AL@48M653"C\P,=S[J]\ZYU.-_N&._\-D'R6!CL
M>H[#L$X;:\8<;/5RO=])7'C8_>*I5V,)?YN3_^90+!W4DS+T>78"6-\L71Y[
MY2@Y17@Z'4<\\!O.-<R^;+GCLT-AN;G0+%CP5?]9#;O5M86=B)/G0Y&O-DW*
M(^ ;OLS6?(\MMO4>]]SXMZBJ_.&8_]+RY7^['HU\>X^X;M*AF__=,7ZU6/&=
M.6?B-_>#7SF"@FVNZ.VY^)M>TU9/GR0681M%'P>#[WW^QD;U%8-?%#=S)0TJ
M/LP/>]K,[.&X&WCG11J?8QM/U$+2C*?[2\57A_"27N9%Y]4#-:+?LF(?O^>J
M\2MW#)A-JN8V,\>0M>[C0[7:=)WSMZ_@1 +>U5%" %)#8.64>@'O5)85"F>3
M1APE[WDX'N0Y8XC2N%_8\E*<AKQD34S@2<#S?\2L H3+-02:)&.FTF/<<="=
M<[_0U]O&T@2IH),WM9LGFD)!H_Z0%@@YR<"BX. PMNQ>^+RS2^U39:'Z6&PX
MQ#M.XDG,9@"&1B__KJU>*T8Z.*.9J5:%C'TIW^# (_\*7S#RLZH\UG@H[QXH
MI<W"$28_7!*S'&WRKG<V"UA;L3"_%02I\*,_35@8J@APG4]Z6:]7;^3:$'YX
MF"[E?Y%F8I'!F/SK:NI2.O9#[MPT]%_[#.1#*+S.J&-.:F4P)A^R<^UK".3*
MO.-NAXE5@./08:!='J1<H*,EY,/<EE?(5TQGN(,F&F%= Y3C/94* UN4Y52,
M'0:IKOJI($2F2Z 'PQR3/GV0A2-H0\;]ALH:_3+M6%_'UW<<E_%UH9UG:V;4
M:/1X>?/KP^&1CV4/1-2ORZN0R7)%T\^(_6PF(D'BI CT].L;!XY/:>=5LLK!
MN(#&LM)$X /].>6N[_M:*,LCPOO+%]!*EDO$+\_<V=O"XM$'29-".T]<&R"L
MK)!CO4HP@^+XY3_R _%1+[LJ* EEM^+OG-PJ[!Y .@Y;+U-;0.&]J_J@&LCU
M#-T&0OQ>,ZA_M:;+PL7DC[;D_8F48;_*5HU_=<R_;N\%#9+]IE_&^R_6O PW
M:LWHT[_ @P;#7IF1\B"!.1(M\R8J[ES56W;3V\YW=W[]_N]'AL, &5FJ&=7T
M>D=0!$*7E2=Q=).SHY2@(H$3.AC3)-B90L+$@1E,P=KTE5[Q?XZ)#!S+"JMR
M]GU?3"9X$'[04]:2>^ZJU?W8AG#-?#J1"MI49>YGA8CB/O=^4DR587*#DR]Q
M_Q\Q*>+>MC\"RK=>S@(SB"5^RK2NLAPV*,EGL,3H@YH.7N5($H7KE_TDZ;F4
M'3;E8P(-.()B&7X?-5UU(N C=#=L_7$FO;059;6#U(;+WS45WN%ES7;MEU0@
MJYK*26@KZYT9QJE/M;3'=,%UY>;AG$P:"X^#='IY\_PF8*S?$D+2F83MW[+Q
ME34HW\YKVWWU1Y5WO/92:*$^+VCM\7FJF&N+ZX<.J1)W7*IJ&U9\\^+2F+94
MRX?QWEN9C.[H?:-REI+VZ/8<S!^V5]VCGSXF1ESPX?8%>SP(4ZB'"J4JTP>:
MRB"6HFYT]>#+V">T+\@@'<[P!M4W6I;I8GBC;\Z7EAR/GCI5I,<N5VT5D;\"
M(UKJXY_R"(GE)/4EOI0.V&9G\OBXW8J:!RJ>463_ %]=?Y39:7C_ 7%>5K#*
M<MY?25Z^7,5@M>E&I@)O)1ZHK%[0M37E<'=!KOQIT);AYQZ$Q1M;RRN6!G/L
M\>14]NW<1_UH_70^>\3'#U;A>L?VC#Y2/E;&^2B9M:ELT'72"=U[P\$+[B9$
MH'[97:1MS-?JD1S3:.:[)?,'-KKJ!&8]AW@Y92S3DQVM8J,'7[T<EP:ZM@+1
M1G4_4%YERFU+W($*A$+JG#X/P:=I/%QSB([)<K/ 7X&G<QZ<JJ7;D(,\P(OS
MLDD@KDL7X=A:!'#I375":V/;68][PDM +A*'ICG;=JL2J63X+;FUH1V>H_3
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MO9+D<72DJ11IC+4)'$L#:@N$J^3'GAP&A@@D6TVAQ8526))<4\:#R].!/\K
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MA%+<^4!?BVOC0&T;BDL 6K=@,J7B[27>,N:1PL!I@Y2*K> )?T XT?\6UC+
MS='"/U ^T,&ZVSM;\4CC"\'M,,QOD P>[%@$]FX//TW;"=30]S<2J)7O&/.$
M!8X=:UX7>FA.5?%M0=>C8E0F^DX.T3]E@1P]]W^8!Q=:#/($/4;/3SV;*?&;
M+M%0<DWKX/^^IBU6:"$98,WTV2T7G>7GPQ/ YIJW$\OIEIC%A)ZHK/N\,^7R
M6UL97-N+\$F0O<S9)L*I@>'"^O8=#W0GQUYRBL ^IX'1:ZZ<8+1W^J/2PT!J
M9.F!0?$<L!4NFJ(!2'<];FP2:#=QU1-.$&O4 I=EQG](!H(AP!45@2E9\ ]*
MQ,+?<"8_4F7MM,9#M;(64:SH]QVFN!$06/V:U=LB4_;;6R65-RR6N_A1IJ*N
MSRQ KH["^@(4E\K+1?&F'(6M.<2_[IDP)Q#. @772QOK97A&(Z7-&A)=WI2E
M%\PC[1[(G(E%W."Y0@HV(<TU5G:35QI+!5?-*WPO#M)",(V!8$'IC$CE*KUV
MW.(3UME7ZJL-P@QN9N 5;X?1;Q/Q=+V_ .B$'T2'W\1^5A=3S.3['.$*X+33
M^6:FDZNE!;AF,XE+@]:NHN1\^*B)3BED%CAC^K)S+:1(^%(<^_B*.;:#(;G7
M(^?)AOEL3(R(PV9=^F0:BVULFNW 64[SAYP<TXM47ZAD45+8S>VY1 7!5\.;
MN8;BS9LK/S$\F(ELEE448Z_9.SK!R7KN,'-N\?/DX!GO,77QE+*\,N/0!=&B
M=5$S;H'ZVG%?YXXV(>=<2;E-SMY:?J/(7\GHH41W;>&G7S(9.*JW[@FMV2'@
M7B"]HA:T>>*2<HX4?^)C9^<:QA\U$QW3K2(/K[R!5)3."LQOR+5/)LL87LIN
M33M<@!\WFG3L<X8W3ZBUF%^LE%K4%-^I>UA*#+R#8:P$5YQO_5-]\ S$]NL=
M[7#A76Z&<"OR1@MA&F-^&FFN2_D7N8H+RM5>X!GE,;TGG)NO?,17I#I2BN7=
MY1[ U7L^D[_V,TFGI93C^*"YW2M P1>D4<HLSHJ0'UY>];/@\./,C9\S'W"]
ML\CP/NC^FGR%$@B?4K0_"E9^2T"/F@E_OVHM1\ZO"*%M3:E\6%RN#Z14/]"!
MI T)OV&1Z-T8+08ME&-G2F(_9[!6['!PDL@"Z"KI8\,1,/%$7R6_8^9;QQ:"
M\,^BL.<KBDM]PHS4\:!4J$6<UM7&R>#)^UG&(/^[PVD7VM<R'+]Z7)9][/=$
M3 %'K!L;].N=GI+M2*;[H"][RG,MQ>YP%JQ?+6AN2W/E/SE13O,E94FAK>!'
M9V'[Q_GW*RL;S9M>!*\$_%13.NL@BY.,A=X6"RQO9!]\PA3:"3-P' 1R>N](
MFVS?_.W=][IP;=CGDKKP!0#=H?M"+K#V(.+]G\2=A;K\^7/OSHY/ZR.QS..-
MKX>@+_?'RHT?@T31@9^4KUD)RS_[\*FE[0N+#U;I% GM>%T4OFQ;XI>8_T4S
MO]NQW4[+K3P@ITW AUO=1_M1>1YL4G/E<F_IO\M;FI])89Q'(UR(UE_Z:*ZR
M$ Z$#Y]?ON;2/G*A]A\1'W]/GIN>6A)5/#0-[CN5W.2>:6T=MX]->3NO7?U&
MIX%$UJ=,+QN?JUSIQG<9*_$VT4HEG.&\.E9\MV+N/OWNC&_C.'0Y(>VCJ6YY
M0F_OL+V\[7RFP3,\F>Y^I!72XA]JF.TR'0U>'(CL0L*_W??(B[Q6AD*N]$R7
MWYE]1>_'#Q$,>*M9?[W&C.2V"G%]'3G+<9*I$#,[%^MJ</SKVK$F2^R%YH%O
M??,=BU*2 ,NO'_2&LURB(-QO9]7?QZKPDC.#-(N!$_GO,.5S_L-UEH)S>"(/
MJ=3YJX1*MIA*!^3T7MDU\J<_;QAWN9+)3*O&_WY% 6RMM_52?@$WH>4V/G#_
M>54U]R&E'?WT%3#$O>6V\&0:'V_01FN^9W_*ZEMCJ=)"/Z/TA;K>71/K;3.<
MG*Z(PY;M)_0T7M5E4_(<?+R2*&"($(N-@EADS*L+C#KG7U:V(>.O4HU"Y,RK
M&64>N+=8!(^WLJ7RW!WN@1KVNND&B>V<GZ)&HMD1J%B'^N7"J,\[3&(TYT_>
M$^D<5Q!5SI_1TX1+-W%B+E_\YDM8:_W:8^HQ"]6Z_P ON9YAUYHM:Q'5KM^"
M-KL\GN(NN9V'[-32-J>KW;[?VA]-I $ON_\(>SE%N/)]4?!GQ/%B]<T92Y[Z
ML\2-KG\K<T?CO;I92[C^XRSJ,YI.F+QK]<CZ15Q*A>$#&>L>S_Y\T</I$*__
MWOXYE\J[>-9]\QOIQEP;]IT+%_P=D,(U]CO>;EF/GC6>=9Q9JY'K$=OZ1,B-
M#RKN<J.-5@VWGWP+,RAH: )/?*@K0[#)=?47SK=-YSLX+#<UJ#:!)49_3.:9
MI*GORC0R/(/:C$L]RU:>D5),>5 CV]ATNS'Y/GGN*JTH=Q?;5.28@+S"1(79
MWI3SW5E;4'W(]W6*9R^$%UZ#S0$C"X$I/(O7Z^,S$3>H:>&2V757H\SDN-3Z
MK:ON\]G7"F8'G1E#?!1Z5I/?TIV8YX/)#]:-/W]5=:@*Z?]LDPA0D[-U<%*3
ML\):?8F8=^9NCIYO*$X&.GE$4@>>X>Z%XIT\DZ4'G7WSF.YL>:8;#[H$U#*I
M"_LWA>)W O\9<'0-[6X>?![TE*G9S:;%$B=TNWM4W=T?5W!>%+SH$>-J62C\
M;"]B(#UF)_SAI1:)&%KZLSV?Z4M#+RPV4=\/0OF!S2^L*:'.1(NFZO)RZ\M_
M_-"6JG_\#G+WJG]X$XJ0&$]:@;G5L5^1]&5$D8\5IY8_T;<E#E-I>/GX597A
M'\TC"^VEHS<6GG^(;\N2$15OBQ/UM-_6I]_1?EO=V#(2U-$]K1W<]?!8&VLQ
M GP>3'J:6_'!@H*X^^$!]?Y.2.N>P*_0X6<M-SX.+^<^/_5/3FRI?])\^NA?
M]U]_U,/\03*_;V,+77Y_"J1MEAY-(EO<(^;G+*?WK166'W\-T_A7)VI%0V;T
MZZJE2?59+>R)YIOBZYX>V,V8)??SAH#E(>SSR(!+[_9AGA<QSZL%]&(Z"'DB
M/RUT)/2P1R4!SV\-'4X_NGCW=%KO=F_?F\NW/[Q8^?-!XXG,35X-\HQ?PM=5
MIQ>$LQ=>5XIH7_<TKO#^_+?6Z\_%WANO>\@?,:E2GS)857>Y_F'ZX$7/''N3
MD2<LB>7W%3H&33BSU:=_F'1215<.<*"&>@[LIP/@Z@J<)R@_34)GD@55;@!N
M64F'IAVR^PL9@@=MTM7]#CFBRR<%=\ 9:E42'.E;DY<$E#,0C U<V9IU^:J]
MXE5T/*FY$_7@Z%;XO]O<B:8-4Q\=E/6A6@7W?C24E8BU::_#347F?I!+O%L4
M/L<UW!$ZJM=DDS5QHN3Q?ILU4M96EM->\RVYQ2>9J,EF=Y8,E*#R0B#P>?%T
MBZ;&LWH0$K)6:&%PE.OY &D8H5+@ZK<&T6 U<^?W+X*Y+%O4^4AA:48,(JT)
M1_)><M*VBVF7;>CYKME'FR<+I945^SD@[CM(7O= BHO4,RLCF0K]<\CE\YH;
M,*9""Z(-;P5'0>;U<&E>_UF_PA<A+)I> Y815E_LBG6.%4\DI"W4(JMF$UJ5
M?-*@KE9VI4<4JN+#.86[']=KSQ\W*YVZ+/_ST;YZB$+5Y[U8SL0>H3JJ_$CW
M&:6]]8H+KZVV&D(K;-VNG=5/]+?IUL/L"DLWFF2, \U0(W:E@QO-U],#+?RU
M[2LV-UJ&N-<M+T6*5I]OJ-X^.[&(,RMN T6WA*[..Q?&\6.!)= I,VXSF$_)
MK(6:!)EEQ[**S;[9B.DJ,-PL@]2(JK:B?\41F,_HJM:;IVI3(E<DWF$O#0'V
M-<!!+G-DO13<&O*(7^7;+%D*FX*K#_W6@@WK4#D8R7L"+(7,YQNY!V?AD E!
M5[!"T_4?(Z[XX\<EF94_U*L<;B/?J?%N'W)&RG8(=*JC%!S56!QY*U&/HQR-
M:ZAI^N0O8))!JI!A89</,NAY"M@0=)U[<D''+7^,GMKR3?R#@:SH5BJW5$^B
M&HL(.(6*;)(0GMC+"/\JKSQMA2[,YNB4$G@D]L$S>@0]^SYJ%6 YD2M0T<BA
MD'#C*BL)Z'AEYE1!1*H@4S4M3>CK'G."R7N:XR=UF1'&$P6#E4_Y5%+K*+R:
M,<'_!OB15?0 \SV6A- .T,02=5A;NM>+\"C/YW&RT)9TKR-EODKUQP#$F$B6
MX@SA[](W!#DFSP9R\#BG^WU[\-18(5SB48&_N/-3KU"E2.WGSY[L\ \[SJ7=
MF<P&]K[;F$D+_: OU.LX.L'?!_[36]JMM7.M47.&:951Y$P>^!_:Q"D0S! )
MK"IZGS7.D<-4GV]BOJW'M'D_XB->B/%JP)4%J64WG)(D4&5'M5-CGL)M6+<X
MLJL+5>\VVG]7&6F6KPIB6,R7ANF"L[W[SJ.'X2B%E%6= +#!$+4P5C5BORI?
M(?@U1XY01VQW4V8_;:UQVI4NVJ!-P6_YSKG5@G1O%EZ"U<A+1(LL/9O%:W%<
MI^;R0#TQS."RF+/_1KEXN%X/&1RR>S8DW,LJC!"9[\Q!'$5/1SJ>CM]CVON\
MQO^@"/<^ C;N13Z67V?74DII7 U1>_K\"5DZK+)+MRJF]N)!"^>_29&G#NZW
M%;".]1T97[5/,T"QY)L0G.@],0?T;EVORR5$36;(<\^9N%?3PJ="*V-X53S3
MD\02L@IPWT.AXV'7ZM#':$F[PT13 _&2@5NN,MQG*M_C7SZ[-P#/?72:<D <
MU_, QI0MHO,>J6&WF!3N5.%0PW9E\X\)I_$7TKUYSW]HVC!!2\=(96$\:;3*
M=YG!]A(ZL8-ULH-. 5;1$@IOEZT:]IS*8HVNYOUX9+/_15GMG<FUIW%+,?M?
M:YD3WQI;BUPI(>M6=+]*=;AILIDGHTET(KPWN7EWQZTE)[#8NH#E0<%/[!NY
MIR_^R]!+0^R]?_*]0JW1^T%DPDGY:LY8@-[G^A<))\RUN:Q:?X2[:O\[NIG^
MZT9!7O38]82-M0+(PZ=/?II'<)^_\<P]_>?IKVQMOJW;K7\R/R/__/=$'+KY
M^O<^W=@&#^>/I$S:Y!,&*2X%DF[J+)OE5GE=V!B0#&7582\+UV<)(0*K2.P4
M1E:*/@LHJ_W=&"%\C%MUG$4'SNXP7KJMSRT%%Q0;!_G!:7EWQYG[QP5 \(<C
M^&=7QT$?QJZ023Q2X^)I<)[^,<ZJ\2LZ$R(Z<&G&"1D_ XDJ^)4< YF<"7GR
MA((4-,-T@D!DM'P+5?HP=ATD8B8[64=GR ,RA(; F:O@_%7ZTB #R02XNL(X
M^&A,1,I04@RN_6'RIA%<84,^L_Z!F/F(OR&YSYYLY&?T,)*,2#-Z9V?4FFED
MI&!D2"8;Z!C)/R?A9O,_8@OE&L!Z[0UE .G"65[E'6Y+^HZ>H9:MH.QF$5:M
MY!Z;;1[W\*E!V1N^X_+*0JG](A6=6):R_$*1N!+L2EK!6[R&$(-J2/:8&2DC
M5C$Q&(_E@U?&=HGI/'I"8J.U<F=?%P-^G""-N4YLBIA8=-Y@!V4%-+%U@:<E
MCPQX& 4ZM0=_:P\R\STRN_&H$X]7;E+0F80IC]&)S:JF4/J5Z_J2^Z':Y@RJ
M*UIB>#KE-M5$/D2UT'2V3A$QC"T[+&MO+2N[BC%-:O+)52 QS'B/+4OYN:KV
M>F_0[Q(,&]2'C7W/ *GV&UZHRLX-JCC)$HG\79)79=*TH]]4R!XC5MYT,5?[
M0;"+Q213PJQ)00"-)3;%$\/=:R^R*LHJR0J_!HE7@?L+8!Z)[%W18L9,WAN\
M^/A/A=9:K*YI$#\>6?31K%<<KZK6@NM:5R!%]=V%:5!"EV%1!4FHU3@3HO(>
M3P.)]I .C>M^EZ2>+'C%X>NYS;!59GZ^X^T/R@7=YNOG*#@EU<+='DX=@2[9
MLNB?XRTZY6$?!/?E+3-^5"#+'PT_GU/"=HPY9"N/I2%C4T<:U,584BT:80>,
M]0<6IH=-?:*SJHV-]W,?%_IIEV2^E0YRY8N,0,;C84HP*'L3+Z&X7(2] F>A
M4M16H #G9IPKZ2E?R"LJ#S^:Z2#=((TCT)DMC_G88R1*AT47 WPLA@$"F$+6
M"Z/REG*$895\;\^\_Z/IH*]R>!;6EZ)J.I^Y]R=9\NOR,14L79K%\JR%T!/3
MY)4L%#'/18P?<]7"C31M(92J%*;UC=0-6C=9YDNEO=B8*55&^O%8#TMFNKGJ
M).XJ5<K:K/\V);:9+EN0-G85W1-*-"<9 U47XP*[;LEKS$;AZ?D?<5(HWA_*
MT",0]SB[[<+I/ 5A[L?+!"VS5??ECR2SC#I2)7;:\I=EBOOL03]4S!1Z>&9Y
M(+5DT=$[?6'Z,"KK*K&)>,2_-V_\.+[+W[Z'7KI%\?5ZWBO3U#!CPEMI?!*D
M*&PN1'5ECS[]R0_&*"D3 8MY\\4;?W:M[48WO#X7NAN5_Q=%]+& .%3C;4+G
M RU8GU#D&=*7Z^9&:B[L]]P:&X=88.]X[7M7;KGBAN^N&7*W, S/AI"F417&
MF'DYP?HI!^,6WH$.47TK6D9_!SXG.93:LSJ1++J5DB\ZK3E>&"_>U^V*<US7
M\+L[C0-/?B*Q!2'E?T6-%W/K/.4UG$VHB%8H]$F"AKB6.>H:1-:OA6L]$^F=
M;:=GNLU(W7LY)\G!EAQM,9-@)W6&>(]F^<%FFO)[,PW$<$5V:43;*OFW)=A@
MJ;:H@I",5V7-1E[==.=FP9O-%TJ878[:4MPS)<9:=[&P5\523QD=RG4<TQ4%
MS)M9$@^4:XJ[FCNG\]*>->U:I]99MS$*&$AOV;VV'IZ]P?ZZ):]X.B405?UX
MNM.,=5O[4:5A;PLIS_*SKI1P/D;>]L^1XLZ$M%/4!O(2JC7?$9J,<OW)GZ&M
M1"LFT*7J+ G]V,3OJKZ;&% :2[Y88R,H.>9N,->#=7@6^BDOIP(ILW$.RW4*
M<Z!AO'N@6>=+9&)'AE7S@D2PR]Q15YU1J^U>3]COU18I=>W*^]/NCZ8_6+2+
M#9G],D@9TTP9H]/X]C<(+N2]33$WTR/5V72=CI,(8:@B$OK3^C.HHUQ\.EC%
MK$RZ-#.6&+!X(YF%O:T8&?!%&KJ:[Z18B%;V"AFQ.=;N'@E6A$@+A!2[/CUR
MZ<66D["E]:.S>6E(7V76KA5/=-RSC)_CWYK( [[>HQ_,B/$N/UXU5*E(BIUL
M.S*9*:>W#/^>3F7E$VV&\)0B>VWXRXI[16UV!3 ^$P*W#O%^/EJ+;,I#="\V
ME(-RMM$>3EG@$1#,GH.;98:QG@N!S]V=:QIQZ@>,!?G9(4&6$7VSD:"]>F%!
M4@*+3U"V2NA,]N*\9K.=&,@L@T-!^_7\.]G]);O](\5G-W151:?7;^BZ)%-4
MYX,<VONM\<Y <VH!BF>Y)Y2E06*%U_+Y5C/2?7[')+&E08WEL\YTR)HK)@52
MK_DP47Q]:]$+N_W0Z*-KMJK7&P?(NS.($^-\(!M[T1&$7V">Y.!FXN FO41[
MT,5VHQN0R3.>1WCKJS7W8F]W.L1_3@GH.43_G!XWI_C3AE?-T4'7*\,4ZGYC
M5\G&_2CM6.A)\AL/%U59864;]P/0I N5]>D%:9BGE[YYM_1$T#"J*[K=;IO#
M=9^W2/_/7%^TD6]UDX(D$B@PWEPL(#/ XJ3ZICV^/"+.B3V!F.Y@G3Z\YAHM
M\OP4JK:H7I%D^G8OY2A]-PMB.DOP+>%8*EE4I>=?!/\VZ ^#?/^O$&TQ(?_H
M6B)Y_A]I@?E+V4ZJ:#,.:%0\Y'2*4]28SW_+(>7'_4W0O(. =R[%/-B.:K-G
M5_7#+</,W"UBR@%2^N3TQ07?\RJMF0U^X:3C^ZRYM/;N=_G[-QK[.@M\ZA0B
M$:GX_D.A4I^#74=5,9P3W7/V9ID>GD7D5)MC"$5G-#F0TPJ?0R?$XG+P>[.D
M2[F7TT4S].T5E ++C2S_%7N_45[2EAE^RYIK\V%J;[Z#]HOKT?.\'DOTQ_?S
M/*WC"(*1<2>\_WF---H!;W7!)14B/6>N?K-XET4I;<9;OW4.W?00+:7+0;@D
M/\9HZ2ZE-]GG2<X]6E+MESTHLS!K9U4X7'R@Z6_J_5N3?K/+69H_'@(I= 9*
M9K98]TJ;#ZP4>U\SK[D!"&WY^!IRH?#.87HED=TA8-$F>/ZD(I':,PE15'_7
MIOK<Q&)DI1/!=-I.W.7T=Z>9JZX6X5AFX>O'MT\WIT9]CMQW0P=-G5 [K&5F
M\2-\&$6>6W9AH;K!4]\L0PETLZ-T.K\6F6X?*F$[0=G'N_L+KDSN;NQ[MU3P
M97,]/^<W:BVF?14'.()1.6<N2U)K[<?>L[]G79H1[<6(5?<-4I)_5]/]]IP(
M"*'\PHC$ +VE)]WWLBLC?&_S5KKO@,!V.).5CJB5INY'N1+7D]?N=K?\8[X-
M&<(ZDA)>'9QA%W)Y@M8\FY\87T]FEVPI+,2YR(IV=^?PI QL.%I &I/F?IRN
MMV*6/C(Y7($;+XK@B1\@+Q[,?FW9:<-12EW".PO8%5/5LL2YV7V.7"C\G0V#
MH_=HAT(']$*(8*&6;YA(LX[$+G0<_N/QBIO*_3<EAWNET2\3]O&(]Y,$.K*(
MHH"CK6!WM^NNKK$.N]M:6JZ>8FOG_; *EM_:SUW\_ZU6LYQ1%5*^YJSV'R/1
MVZ)IT?A"9SZ%"?5J@JY@+KK-:' D^TV[/+'T)[_J-98K"_9X2B@X:( \BI%G
MD'!_W]-N' 9^-YS=<.-Z\3Z_B>G\ V@1QVQ0C>>;/Z:?-VQT$<^,3PH5?QZY
M\>T^AK+8WQ BZIY]WK@1+ UY^'$G\,%&#.)=@S$X3;8DF]YG^_5/"_4W[TK>
M"-[5^OB.?%.WD$N"VPF.?)'[B?MFL.O-<Q894V3LV.]%\W8C6K;OA>]G]SO,
M7LB"KM[^!H50O7"7V_%EAA.:J+N9Y/VIKZO#7[>5(O?8#9& 6VNIPFMQ@2B)
M*5*,DU+0>HP.AB+!82<;6AJ<<WHEV@*B:+?!]!*W^O 6GUM*SVE*[.PNT&FR
M)797P.I185JF]2P.:.:HT=&]$0[GG-7U>-[G.A>J-NO(J_3O[O=;9F<YY7G!
M._'$%6X?D1+=G]ZXZ Y+?G9];CXM837_JMPB;^>VE@U;9;:]/N[#8!O9Y+GF
MD:C6R^@?BR\2:/!?'N2\H@&FUYD?3-D'<JC3%*6^C-U0S^U\W5]\-]\O-E._
M'K6$][K&[*RM-L#Z/F('F/%((M"*AY8*),"5-=!XVZ$P'Q ."^194)7CF!#E
M$/WXO-7"9<:?H83[E^F7QBD+LK:\I//:D9+_A6G*A7/XEGZ6=HEQ([,\1A4]
M9X8QD SC$4&OR =-(#O;D97*H7;_F?XKU6O-+]TNE;E^;-DU+S6*W+;S7LKZ
M9IK[F"WB14_N9=&KJEE*A"E1M[<O%=NXZU^DH</2;#5/CF;\96&)[L$/KDZ/
M<'S&#&![O"=%?5BRD9)RBU.-'F6K]ITAVQ8;\^_@;L_[9-[%=YM#H5VW78*W
M^K\'QC^ZOOZDL._&VG/!+L\9[.4;[[);K,^_UER^U&T5<F,P?/-7UD+T$VOU
MT5==]8K/GXE(T>+7J-S=S9XEBKT^9/F)Y4"OG-W?%]^__OLO[682'9NF>!*A
MMW\O9JG$Q,[XWA3 U@AMN@;F)&9RVX+2X8P2.*ZL^C7]"O?7!<A3>*0HTMQ_
M8HJ#Q58VTY88.[V50)0EVP2P^>,V$,(\+:L9EJ_3#SDTZY@M3;'^#4B\+75S
M/=[V&Z)2Y0O<MQ!2)-;LY\NG->=L7ZQ;NGG77&5(BF";JP7T=>;\NJY?5Z\U
MYR1=8I17/;K(6*)2T<E7''')1W4:7M.<7$1(E2;[ID?9OFWSCHUF>JYT3S[R
M=4( _QE1J%+9H!&"Y7-T:F!3BU^QC7CB9Q_<5B# $?\V+DTT.%B1%N,:_+#B
M33DD0OJKJ/6L8DR5^\51AEC$*G7=O>L-RH0K[A"9[9HBH?N]NG?-1[0R9F#_
M3G"TU).80LC<&<+7"8_:J+O-./+KVN//\Y6UZ&EAJ&@*B0JS,>2&8[=$Z27X
MZC'\Z#;9C%1=61ODTE7!_=!!?V(9XO)FNL"DUK?*0RG>6ZK<=@R\$$,AT&O5
M3 37Z11/S+RI2*WQ]6V2>ZW]]L]5/9(N50@YQY?>:V:T_;VP>J[?#U-B?M5L
M3:9Y2N;(Q*O^X;418ABJT0;;+'%H9/3PQ&^C%=44=?O2U%1A0!(=9G53$1*5
MGZZYP123'FF>XI@0,G#B;!E^[SC&Y5(KC1L'XDF?:X=C5=$#A8'-T*Z(J2[U
MO;C.T1&Q%,+XG4H]?U%!)^0O5:<0D^'CUMWP>6'1Y[&#+1I=O2_T N+KR"*"
M^X.L AK/CW6(1YN+NAK1'\U/'-7F'L]!GS[^(M7+6).R[&%&(8!QX0RN0)?$
M>@3P-LM)*O/USA+?SFI(AV7#K?[\W)@9[)4\#04'#020(Z\HX$]\VSI"TRAM
M,F6_02Y%UE>VU\#1?+\/6M[482<>!/9]K'K%7.Z53.D($EG>U!2=3-"SEB.8
MV*&OB'SCL "#"MR:(IZ$&W?)U3G/Z>D5U"XE',-,VVNSU>GEEMPM3'+?L1<Y
M-(S+6"Y>5;>@99:6GPVR$9'>^I5&+C41$P55>1%9AY<^\'U5S%]A$QG4RK4\
MNCJY(O'>[46]8&2I<=6KA Y'G>'Y#D1QS;_EUYRZE 521B;%&)',\6'D(LO?
MJH-@PB>LP8EE:(,*JY1R=T%N0M,]/0.%ZS7*NF1]PXD(/V&3.6N)NS\%#;S)
MNBR]MZ6D7$M%@_T;V4*/$44N;LVY#PKR)<A!L>%U^=,VY2R9/CQWY-F^7TZK
M6I=B]>7U69,KB*JT. W5[=!VO>WYH+BLCDFY>L&-_J;=_63-=+D2 Y#9A9^J
M+,I/DH@E*X>^E&[7#PUX[ /*Q'\N:N#G"GA:D+U@D%HLHLXHEU90R45C;S1,
M3J!<,YUC;$B)%?IF8X+ MM4'7&6R%>*6\C6T;\7>.9^I&5(.&*%'QE:\'MDB
ML_%%T"W)[$1KKY8PYR4;< KXEA@4D3_KMZV6WJ-'5;W<,-/J+-KLO PSE1)9
MA<4R%-EWKO/XP!^T6Y4XC;8P]0(:<B0$8+->!W?JV7]F=RB/T3DIO&P0[<&7
ML?N CO;?RA?[M9F*7)1C@>CBSOE"J.O\W%Z_G_P_U$)QAF#I0K\)'F$D-MB,
M82X.^*M<ON!([7)<EG'+@^(\?/K5LP)W)EAY>S3R<S#2O*@6; 8?5;NFQR$)
MG&PQ*"E46- JRK:CKIP5YX[9V%PJXL[3@]$*3K>9?"(,3=.Q1/GD-$=3=0-H
MITT*\5&8O.05<SYXWMS@H_-,<7.#!?;&E_+RZ6<Z61($D[[9SKJ-.]+USY='
MSU(5OH:8:&>&V[78R>[#WEV[D6!AU;LA>_E9DQ)$IBC'&R,W$5USFR<Y7CZ%
M%R1^V$2-GF\+FM/ALQ5K[C0$"^?(9D(W[_]AO_L&NHAR-ES\$ZXF(7)HYA5[
M)$N6;I:>' I^J9.9FB5'EA44>2^$DQNK_?P^N6..W\+1'[([+"VSZE"F7=U4
MT0$B!RPKB"O;2KE62157XJ7,6OI_EEN3YZQN_F0IC *IKXG<EE[YP6^^'U"P
M0F9143<RA7I$@7=I%QR2>O?8[ 38'J=REM=1(_E\?LT]YQ+N'?)M_&ANRC=Z
M>GZ4VV.P&L'GJQ<?:W5EC-7C?DC9"UWMF?&6=@(?M+SE^S7FB"K)/7,M&=&$
MWJ6$#O^UM V!@ZO17T*S#4%%PXT''E\KI,7AN1T8@T+2'?S=74F+C,)3=9FK
M_55_^H)^7#U3"^N=<FA<\T&(O Y()PLC:N!-.0JIN'$.R(3C?_FY!SFI8T_\
MA>GI%I701SI%46E.OEFL@0^>%Z-TB[ 0N@)MWR]^?+;!Y0R]WE9@XP%.1/-V
M?2&Y&1UQ=*4['?NTZ:J>Y7SE[P/I?GH8V_0U=)D8)Y"#\[$H%G/"US4[0!/W
M<IM6.B(K37TR][D<Q/(T2TKX<0*+G&ROBU4;S]JI4KSK.M*"C.ES?#&[4M,T
M>?U>YH#CC+MQC5%[1.DS!EV?_RH(.W-YO7=(44 BNZT;K\7M2-F"AZQ2CZ[
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MVP":D+'LW7G(A"C]\&H0)MEL! W,DEK(^Z1;XFB)$!J*L,<K0,0P$",&C!@
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M1APK1$2Z#X$V[/V@RROT0=24(K98BV>F\"OHB)SBKR1 H6;4YLJ29;MDSRT
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MMN". +ZMDB=+[\UP5L+ 5S:*#S&ZTCM@71^A%H5OX".*G@*G A]U)GRJ_NE
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M#58*HY;&=?S=J592!N4' OW-KS8,*-PT:(0!*5+/_YZ:61^9.+)WS]JW>]\
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M"U@BC[?NZ(VN;2"\0PPFH7TZAX[8*<;JQVY.1!^BCY00)9PRJ7X<QO:\4*G
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M)$O2"SL-3''SA,Z5.%5R+?#L;Y51VESHT+UU>ZZ'PU>(:!#+=[JD;[ CN<6
M=(BA<.B,F(F[N0FU\2[GW01#$R0!;L:@[>STS W/(K([,9+ERPU5_ZJS?+>Z
MJ'$JSCL)(E2.NW.ZA2T%J1OERL*,N'F Y&5G;U6_Q-KCZ0UT:&/PQ4S4$5$
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M96<\ET$]N=-5RIY6Z/YA&6*,UIRXH[&+$%7;'?91OV5/#:K?C%*Y[@@@Q #
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MR7':_Q'..V%X(<;-1[/D;):$E!7/^>BP<\(BW("$Q;B&1,A9[H&AYX0U"1Q
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M^1F3< ./Q2Y/26K#XB[R,PS7T9\/00PW8)C/\Q 9XA!,<7:B 4P^$A)+43Q
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M6+"T$.\VN[#M'PU1K\N!Q/.4@7,I*]4IR=A'5\@;N3MS%&]0)^:E4E)GA.X
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M$\3)!'VV\YMD58DU89$04$22GR(9_^8LD F## HG%:[-C#IW2MICXB0&+MP
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M114L_(@S(YGC+W(9@6M5!&,P8K6P9"@*!4IB%[(-/#J=3$F4J!UIE@8>1"'
M="R0*LPQ"<ZZ!@@#M-E2RP08MYK@B@@0AUFK>^M1]*G'&PL]6@HF"HZ8<(,W
M;]40=..\CQC_!O^CF3 -9L#&U3R3$&R:FA0Z9M5""CQLBK&@E"*&N.M4Q>12
M4[SVU#Q<6$M97L'9TRUA'Z3@(B[QK"ZAK3,L.0)2H\?"Q-\Q*(N<P^<5H44C
MFCB1&6:QCPY\(I\34+&Y<$'TFX$F$QG0((\2(3.!H75!"2V&V@(K7]"F\>4
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M)YMXRBXS2P-)2:&*"W\,JKB+*6:Y(8$/*5JZL6LBEM,9K?"BF^F4F)Y?J2-
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MJ*2@$"/YT9#*B"AF>^;!&B!-UUW(!7]9EF:KA/,YN1'%0GW4UD*@&+71J<I
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M0 5:4)3$:0:]H..^Q0 D#D915!CBB1ZLQ-0-#!1=O,FE')EL :=Y"%$F-$(
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MQ4@,"%7,<$I4EDDAD:8KC!Q<:([0J\"@I_^\V^;=73X^ZU(,0Z @R2<TA<P
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M"[V-Q!%*K(A!\('*IS046MQI[(J)-[68+47,/O_A2:,*9<3XR^>>: &B:4C
MG2&!TM_@F0.WQ T BD,X)0AN4<I\E/'2U*DE&PI*!*4ES&A$9);(U):AA,#L
M9D3HC#$*".T4!S'"AN9X]-3M67%(+:MATTWTVS<.5K&6"SWH)IJ::T8YA&*2
MS._X2S=^JW\(IE9.!AG.-"*]6XX6[X@8E@'1%1>%2-)4<-_H#R[C<MWV#RPJ
MJ0^N()+6L7MD(^>Q(X^$". P4V,,#NL!2_" D52ORW[88$^I:L*>GLM@WVAY
MC)A1YW32S0H-@^BT;B1>A*-$<<75B24^!G4H4\5$S").G#O]113/,_ID"#%(
M@K2A'%((+W5,"ZP\8>+_^02\O."I0.]3@!>.!3,U(2CU"-%Y-$]I1Z2):=1T
M_-N"D-?E! PG_6+8!0?5K65W3!U*&>,9V=H#^M\JFP=)?JWC#HUQ4Q-H>(GC
M>-' /J$)\L[X2$>!]G*PE6U<A1X'56G$7*F*H5_O2E'H/;4'8UZ2?I&JDDVX
M($K#J""BE!-"# T0ZM+=7C,ZZ>:4/.B^P*#R!=-]K(304EEXM)9BQ:9!EDK6
M**=%:(HY6\1B:(50!6JA"!]!-=^FU,DDSAMA)%EZLM.FT,W,<4C(]-5E,54B
MODJ8VDSXD&P=!Q G+EFF"IU93Y%%\:*_I2B!M>=60E7]EI5]\=GW+O16TE18
M_X('9=C1ML" J$VM&""YU#G@E#"+M-%&2\$$%_3?I$Z3\OD:7IX+DS2)Y!GW
MBS[)J0+<&*9-CXW,-/ONJ "MDZ!FF_>5D=QG0@AUEC%$YVWPP>&9(D5J!XNW
MNK*@W:IC"7+MNZ*$C_0OD+H'Q40CX C$6[/,1BA-)M"7_![ %O#1?CNT82H2
ME<F@).Q(.14D;"Y6#&N"'&YS$1]&82 &Q>9*V0 V$?4)H!W7JL\-:#T&PZ%D
M0UF$G'Y<NW%(@:(?C?SG/W]11D32>X@'2; %=CV%=I%R_>U/"1*L5DH[VN:$
MK5#)'E5(9)9J!$F(_IU:ZS0=[96TDRG''9&.;:R[9/_QGP8)#<-@\CY DGL3
MI$]P'KC@!W4M3Z6&XC3E.X(%J(]YJ=TN[CAI6T$HR:$$BD:8JX=TEO?>LI_;
M8U(TJZI,;]IXHX8\D+>1:YZ[FT\<>V=@<!'*,M^:AVPPRZCIFGR$RPASDO80
M^3C=$#05B:A_R&@1,>SN[J7,A<T958;L=:;0.F SU%Y3RMP$MG=RL5<,!M70
M# ?-N?^>*'U$A*[-<GO\1&6O! O*BV5 VJ7E2[[YIG0SVB"/#*OLG5IY);W<
ME]7QSB0IR-IQI;F#QVSQRH6,V/4BZG6T5/7A8@:.C.),@K%*A3Y(&KXMC0*]
M3\G$RTY0UTX "MWJ^6=T+W7_G$[PS)WR@6(8R4L3.OJ.KJ"]DP1@ANNY?6IG
M3KQG>@0XC<LPK[>G<F-$8)X&9[!F(61GA*92\*@TT70.K8!83L?I")&.6\^
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M]E9UEB&V&&-C(2;86H)]YN6;8C""1F&-/;663W).TE,TF9BFSY>9#+A:,L2
M,EM2]ADE)V)% @<;7FI!)=M236E5&6A"H96I;I3PY1Q3<RIZWZI3T?DG8II.
MLDQYMMZ*:ZZW9A?4F&#2AU]1K;4VR53Y#;B;4D YZJA][CF;3$'+%C13)C<Y
M"FDR%Q:$(87=6@CNMQ5B*"&&7HED6D$-U<C0C!I]5*.)"\4K4HT)\?@0C XE
M]-)$,>++[H4YTE-A4%C=MQ-2.JFU):G&TO4<9\BIZA-!IM%SW)/I^3255E-1
MHJE06CKW&UZ?,DG5)&\0&E9=3?5$YV1F2988;CPQ2G;96117)Q:1C.G<YW1#
MB8KN0-&P?!^F4QG;VF&9J27K3\I<9^R?/D4I7%7$?3H44,,>IQ0Q0]5\L&OM
M'?GG4FVA@<889]TW9)6Z_\Y-=]VV@J(DJ&D5!?9K+;-V791^$Z-)>ZL%U9HF
M_1'('WP ?D+M39!R.Y,FV!*3#*2@8"MYY0R6:R$H4S<(J8"C8YA)/11I5Y!#
M!F4D\, >N2XP[:X[1'OL,5Z((XF[Z_Z@4&L16YAQO(ULG<EIS:5)&#C0>:YV
MG1':9T^%C6%]&M83RKUFUF<6=/;4:T]H]MYC?UG;?5:OO?GJ!Y895-BK'[_W
M]=^_OO:!!=:V]O3[WY:UF4\SU9O$/@XUD$092#8H(]SR" 45C6D)<YKHA=]4
M=:E.'25A;#,0DS)H'ZEX:CA024RGPL8;OZE-3'0AQFYJ9;<8RG"& YE:X1"G
MN/_"$6Z'@-,AX AW0Z_=$(A"?)0F)@?$1R7QA@7)80Z!Z,-' >6).J1B>ZX(
M129J$7!3=.(.M3B3[DSMBU3\XA*?:,8=FK&*8T1C&<LX1E"\<8U9/.-KK+A&
M]C!QB4"\8Q:?>,?"=4ANM5*=ZO2ANF4()!JJV\>&'$D/2!IMD8>,1G8$TDBN
M# 0AB#K-0.J!R7V DBOUV! BM?/(1Z+RDYUTI'8RF1U&)E!U&V+D*5\)#5+>
MTC0=(HAR?@FQ+8T)F,H99I:6ATQB!K.8S/S;Q)"I)-G0<)K4I)O<JJF=:VJ2
M.]KT3C>K!$[QA'.;WN0F-L^)S6Z*LY7=&><TW8G.79G_LSSJ)&<\[XG/?.IS
MG_SLIS]C6,]_"G2@WU'E*J?92(.>,Y.J#*C=%$K0B$ITHA2MJ$4OND^'8G2?
MF;QG1TW32%B:!H:B- U$R:/1C:ITI2QM::Y4F4M7XFH8O?2F(GFYG9HF<)[:
MX217E!$->E@RJ!N:"$)<M,E(<C([N42(0(Y*D2HYE:CZ8&0N)]*0F.YCJI%,
MH"('F4"=VJHK7?V.4$UBRYMZ5:AB_6AX[ ,>HH:()344ZW8,2A)$*20[$V%D
MA_S%U]/H R.K$R6\0&))M49$=15)B$L?"]G(2G8?Q-#'30BGCS#&CD.6?8A
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M_ 3^7X$   $ #  ( *  #@!P(("# !P,X!  AP)X ,"# !X"\#" 1P \"A
M@  "! @@P  ! 0@H0 0 (@@0(8 ( T0$(*( "0!(($"" !(,D!" A/Y[&T!!
M (4 % 90!$#_-?^T01" 0  & >3?#,0!( X$<1"(@T$< N)0$ ^ >!#$0R >
M!O$(B$=! @ 20)  @008)" @ 06) $@$02($$F&0B(!$%"0!( D$21!(@D$2
M I)0$ 5 % 11"$1A$$5 ])^/?VN#$ !!  P!R#];$ Z <""$@R <#.$0"(="
M> #"@Q >@O PA$<@/ H1 (@ 0@0((L 0 8$(*$0$("(($2&("$-$!"*B$ F
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MC@[509ZN1:(N'"^ZS97/RM=D14QS@&**TS[58HHEW_H\[FHDC-3<U67#KN>
MT_3K8;-RTN0(EG<J5Y2/-P']</4A\OM4$<K&TXY"IMLOO=VS5>RU7CHV,+AI
M[!0S2,"-^Q!OWEP3K7MW7<C'\NBC]-?<MRA/&N[GS\&T90'_]3%+@=A?U7D<
MV+XL[)(;3*N84_C*M6BY/$W41?Y"D4=I9EU5^OW;_]U[3^2S_.C7W!:(2NT^
MZ'KIM-O<YZX^T<HKB&TL\QWL=[@[[9\KGN54SEM^BEA/%FH8,@ K$G_''HG6
M7_!3FFJ*W^%U;6T[(@H5.N1:2P>>6-CS1>STW Q\M!J#>W=K\3/=;O-!Q\W7
M?.$'AILIO)8-#'ESD8[5+DHG?0[E3UHS@VZU$4NH'K/1F9\=_&Y:E-C/N=XL
MTB\T(+,_6.#7N#.^<TOSX'%A[BXQD*3S4S'BU9:4V/#G,_YX%_F.IJFRF!,9
MW)C<P'GY1P3W\QUCW+TQ[?/FWBNAT[R=&;L+<O==.EIQ3/PL4KS7^["O4\^4
M;.=P0COS]1JX'[)Z;"-2'J41J[Z'#PC957J\-R^A@U6\ZL"IXW&*=:WVR4+3
M5.[[?N8'*67!V]PWJO-M+^RU!9JV,O"''&3Z+9S-&^A(<5^[YJ><WQ7CA92L
M"0=5A#^I6L\*B^/E66[:7#WR/:WC>T6YT^(DK.KV"Z?C ?TBS13>T\U[H9UQ
M(^URFZ4$&W.I[(GC#UGSP:?_. PMRU_X%E5PMVU%F7/4YU[ZD^'@_<<C4JV/
M#MYO:42T7I3=KM)\XB,:>R@\5T2_4)HV&*!<R9J=YE";9?WX+M[0#$X))_ I
M-3+2FY3R##G1#JA>LV2O?*U?LG&@]8L_./Z4(E,<ASCV(,O*4)?28"M?I^Y/
MN;]%B^T*;4V*4IQ*8"AH.J>-7M 33@A.CUIC8+V:T9?E.R[A=G&=?4S89[C%
MU80N?IEWZ:CWX3B&BL/(E+W;ZK6PR)//6G)(!N9,_@BW+WWP#^<4M\B"4OZ5
M>O>O&OPMUQI2_E-GT#4Y3__ET4&!F.&&\?F,O-$OSUK_^M GVBL5G5KC+E_?
M;+!/'>97U&UGODYQD"<Y=LJ8EJ'W@9TO_N^-4]EL-*FC&T-T/2;VSRA3J-*]
MMA1"%W(B+A1T'M]3$J=YP'#UW"$GXR]SG].[SJ>DT@S"/@4D@+^YL5]KQ3S&
M&Y/%2N[JEX5AF$(^Z;DLI(HDVO*JR"?F/EZ@AAW2:L^)I+CP+3C=*GXIHQTP
MX^!-Z>GR9*&@4.P_&Z5X?E$^_'%9_[X)J/>]=.K<$173EX (Y( [XL<25J*)
M7NR-2=JUP::2$*6--$&#:JF/-5F?@!<NL!HY;VD#>VO\H'!RP+,YN&G&."<Y
MGUR6$;)3I=V+W'&FC\,';!OH"-\;KEI=F L "LTPG%2.]Y>@N)[<!U[]?M>J
MF.]F&9),'4);?!]-;^S1ZE6\G=>+<D1=,]2$J&4X&1Y:1N9?.]_>2*7DPA \
M\;VT;D%XX*R39(N_78W>B)W<$2&,^/Y7O8[NSKVV)7D=B<.7?)5VEKT&C8*J
M"_.:Z?4RC N,5OW,U=H3)F\;N6WD\KVLW5:!1R$!C8T>;94TAQ-S;UXL):K0
MR%ZDTK 92Y%LHY9@C56:%M[,.E*A4)EA;?)<N-S2I&RP$9 P(:T:Q6AACRP7
MM (J US=W@1*$SE[NV-;^XF#X/)-OL"VOO:G>+_Z>N(G?>![R;934L!8RX/P
M(+J5_T23M*5E^'G\P@3VB3G%3+G64LKD?JVM>?S^F8!K85R<0SOZY[V2K+._
M<+QJDOM.Q[%R%_4?[[;38KE>A&'89'SUVL'BKT0?>_O7*-GS;K;8YS:J*A;!
MLX\<XI6,=7P7'DB4UKU;#BY27/W[V2#!-X^JG:&UW:6Q?ZE-U?N*B0<Y0\'Y
MT/'RP9@<D=X\_>(PU1TT?NJ9H;A7AM2XU0[S ^&L,_[2BXE8P>&J;KZQ,P:*
M!D7)?SJ?Q52!6=%=K2$6W^"]@C,2J9'<XE?% P+DA/+$+3[-\WX3?ZG+7?+R
M1LZD ^T54KS5Y4O<WFP%]LSF3&]2 DW2__M1/RN0$V*6;R8A]90KV&&#+^W9
MM:440W:KG._R=[S%B/JNV78%,_QW6$?FD\LF^RX$]K@H*::;#YI$4C'E&9FA
M 2W\3C(%A=CNNMLK'Z@O$0MT/O,.]4B0IPLU)%/*S+(9[[3*NJ=/,[/L<T@S
M9CP[1]WM19Y?SRWD"3WS9Y!FEKE2H[8,NRK..R9<WBHUK]M=V7!_P'6NX0:+
M M7#,>TD7Z_)#77EB:1+6MGX.RY+!U^L=XK,PN>G!W<-OA_MO'5Q'%/BY7T7
M"/VN?Q,,__2J[ZOZ(\%A9CW TN=V\. A9N+<63,]"MM5#!->[4,,_VC8\/>/
M=\=H/EPL?7.PM@FY$QC60E..++!XOAK[:1<6UZUP!1^)M/VS4X-)],M,G[M,
M%;]Z8ME?O33_R/.N.ZF-:HH\;L,0IM9K6'I(&!78]3I"?=:I#97"ZW;%ZXG,
MUJ)I;5_2_6GI:VP9"C00_;BZ_!LFMO-MB\$BX?/C>+6;3?]Y!/._F=L79!]&
M(-<%NU)RN8"CZS"%::SC.6-/EQ/S0=/KK=?#_;[?)(^H[=$)E1ZD^%]W'E>/
MJ:3*4:$8G;FF:4CW<"KS3 OCJ6;F"'I$V;JP=77PM.! L5;L#96ZW'JB*NZ^
MQ+BXGJ9W^*D\JDR1V'.LEM(CD1VZ=H[4SDBMCB_&WW-38)(B?,->;;[V++:>
M-DB;X8N8EBBW;/V!I-JW&"V*D.\>!*Y-_T>=(?:7!=1?.LNXN718&XZ =H=L
M\O"U:Q^H^80HKQC:L07,:S6$7D1W.E0UK.RZQV\DC' SMO,*XMW\HRYBJ=QR
M1K7.BJNZ'-LKNG/_^!@B$Q^R.0SAE6DK%1*3O:(5&F0?=D2,TK%?EL23ZYA;
M\H5Z:!1F)5*41;@.C(PB):*XE\SU]*+J%Q+N1KD\'H4&4W##6T&TM<R#K*FI
MDJ8R?7'S[>$S==9D%88;D(S7OIE6LC6#M1]OI'<3;43#.B=?'=OY'HAF4O9S
M\G5S*;6M5XF^^OSC=;)]#:FQ:;I0._./;[?S*'R"AZ$%NQOQRG)T\1$O\B7<
MT^+)-&RI7JQ*H<DQ' +WO1WR&Z\*DGV-^F)\@:@M2A/+=9F@(6^WRQ$'(5P'
MWO(ONK#HV+;WX][L6]P"*=NWUPT%1_5%H@HC?O0Z+WPP,U^(6*MUYE#D9&Y4
MSB.DU7.SG3GB/P[A2YQ4_7PF*IC#.C(\EHXCZ#>WH%ZO.07HZ,61+)0,T>]G
MBL8[/3@C_^$PD-O=!UX(91JV?;8I]%0_SU&'^4_"W;,UM%+%^M^C69E@H>-(
M'^&MO"=J2=>-O4^34T/K(B;M<R=)K*Z2K/EN@JN&9RN_F?C8IQ"*T_V>N4O;
M9:$OA15T&=A4:+7H;[>3^8S4HKJ\<O!CB@6BM,UI;JM]F'DOD4KA:,J:7)5?
M.>[UG$<?_9/UM2G69?S60L1L3K^R-WLL<H6*QS2AB57:ID Y.@M]',WS)\=)
MHY_5BE) G<O$D2,J),K$O(=56I?AG+) ,,:<QSXWT*3TE(A$AAHKR;BP4T<Z
M6Q_T>YWO'V[Z(MFM>_&2#CG8QS=F-8'683/,G(<M[X.,:73)3$).*E4^3,D]
MO,E%)<U=*&+K^\UN,QPNZSO-92^G6WQ/OB_;OU: +U4BF-LR9<SEZR%5D_CU
M?H=XWIS8-4E777%+UO[3TQU"/]A*1?%L2EP*2'5<S&@(_D= "SG'%,(\E,KY
MEG _2*?J?:-P=QC70]IRSQ^:%1RJ+J)&O11&55L)3CK,2TTB >F0N'*6]PCH
M1<M2_H,3K#[],K[&0CF/04?8>X'[HI\ NMMTU5N_DD)/HU(MGV?_K'%>S%::
MW4)[.)=UTBH%3%:B_:!BOHX-<#M*I ^Y+%W-_$94SYCS0N$YP5$I3&HZJ)PK
MI4<9LV\MH?9,:-M7B(HMD$;FONZ25/@B5DU7)#E$'8KBFK/B)A6J:WPPN<K&
MJ2UCE.47D,5:,L+ <M!;VR1Q2ZR=N:)1E9"H4UY@D-(GHNB4%=@GY X$_CFL
M6/41"=#@9;''/-O S2WZ3/LX?N:.)"S(LA<D-]4Q!V'D@RI=LKFN\?^(X522
MB>WU>_W*2%\F)/!RJE%C<#%%QKPCANQ[JVZT\(X;9U!,[NQ^$[BIB94NMWEY
MI:W;_,A0X.$K;W1+/="OD?.WJI)K$\8\Y5Z"G2!(=RE+V3;3#4O#VLKVYH$
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MOB UT54T84S%X:YK#>5Q4+FD%/]Z:V9<^Y)0'*RS3FGFPS,1JATDUEG(^F6
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M;![F&QOF7QH6V!BNH:<'-/\/4$L! A0#%     @ +HA$5(N[>]]]#   80T
M  <              ( !     &$P,BYJ<&=02P$"% ,4    "  NB$14]Y8Z
MR9H+  "##   !P              @ &B#   83 S+FIP9U!+ 0(4 Q0    (
M "Z(1%3;E^,AB@L  '@V   -              "  6$8  !E>%\S,S$V,#$N
M:'1M4$L! A0#%     @ +HA$5')29@:K P  E18   T              ( !
M%B0  &5X7S,S,38V-"YH=&U02P$"% ,4    "  NB$14J32Z CD'   :3P
M#0              @ 'L)P  97A?,S,Q-S(P+FAT;5!+ 0(4 Q0    ( "Z(
M1%0(P;1_)L "  -Y'0 1              "  5 O  !G;W9X+3(P,C$P.3,P
M+FAT;5!+ 0(4 Q0    ( "Z(1%1,BR.$SQ4  &<K 0 1              "
M :7O @!G;W9X+3(P,C$P.3,P+GAS9%!+ 0(4 Q0    ( "Z(1%1&O#NO"0P
M "WE   5              "  :,% P!G;W9X+3(P,C$P.3,P7V-A;"YX;6Q0
M2P$"% ,4    "  NB$14-$RH64AA  "!XP@ %0              @ '?$0,
M9V]V>"TR,#(Q,#DS,%]D968N>&UL4$L! A0#%     @ +HA$5.HHG6O<8P
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>9S P-2YG:6902P4&      X #@!Z P  1HH%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
